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Barbara McClintock
1902-1992
"Private Residence. Do Not Enter." These words, written in a plain hand on a small, aged,
brown card thumbtacked to the door of Barbara McClintock's Hooper apartment, must have
dissuaded many would-be proselytes. Others were intimidated by her presence. Although
nearly everyone at the Laboratory in the last 50 years saw Barbara somewhere, in her
laboratory, strolling the grounds, or at Laboratory functions, not everyone spoke to her. Strik-
ing up a conversation with the legendary scientist required either courage or nerve. Small in
size, of the minority gender in science, and averse to publicity, Barbara protected herself from
outsiders with a reputation of reclusiveness. But those who raised a feather to this wall found it
easily toppled. Behind it was a woman of great warmth, boundless intellectual energy, and
open mind. She was willing to talk to anyone who really had something to say; her only in-
tolerances were of stupidity and zealotry.
Barbara was born on the 16th of June, 1902, in Hartford, Connecticut. Her parents, Sara
Handy McClintock and Thomas Henry McClintock, were both from New England, but they had
very different backgrounds. Barbara's mother came from one of the best familes in Hyannis,
Massachusetts, and could trace her lineage on both sides back to the Mayflower. Her father
was the son of British emigrants, a newcomer by his future in-laws' standards. When they
were married, Thomas was still in medical school, and so the young couple had little money.
They soon began having children, however, and Barbara was the third of four children.
When Barbara was six, the family moved to Brooklyn. Barbara attended Erasmus Hall
High School, and at age 17, she entered Cornell University's School of Agriculture in Ithaca,
New York. She majored in botany, receiving her B.A. degree in 1923. Advanced degrees fol-
lowed in quick succession: She earned an M.A. in 1925 and a Ph.D. in 1927. In the mid
1920s, genes were still abstract units of heredity. Geneticists widely accepted that genes
were carried on the chromosomes, but the bricks and mortar of a gene, its physical basis,
was not known. Barbara's dissertation was on cytogenetics, a new field that sought to link pat-
terns of inheritance to the behavior and structure of chromosomes. Her organism of choice
was Zea mays, or maize, the colorful "Indian corn" familiar in Thanksgiving table settings.
Maize was one of two primary organisms used in genetics at that time, the other being the
fruit fly Drosophila, whose use was pioneered by Thomas Hunt Morgan. Maize was useful be-
cause of the pigments that make its ears so appealing. The color patterns these pigments
produce can be easily tracked, both through the development of a particular ear and from
generation to generation. The problem with maize, however, was that identification of the indi-
vidual chromosomes had so far been impossible. Barbara's thesis described a technique for
staining and distinguishing each of the ten maize chromosomes, thus making possible
studies linking the inheritance of specific traits to a given chromosome. Barbara's studies in
maize, carried out with Harriet Creighton, were among the first in biology to show that genes
are carried on chromosomes. This paralleled the famous Drosophila work in Thomas Hunt
Morgan's laboratory that resulted in the "chromosomal theory of inheritance."
Barbara's Ph.D. adviser was R.A. Emerson, one of the leading cytogeneticists of the day.
Her colleagues at that time included Marcus Rhoades, who became one of the foremost
maize geneticists of the last 50 years, and George Beadle. Beadle later left maize genetics to
study Drosophila with Morgan and then switched to the mold Neurospora. In 1958, Beadle
won the Nobel prize for his role in developing the "one gene-one enzyme hypothesis" that
helped usher in the new field of molecular biology. Emerson thus has the unusual distinction
of having trained two future Nobelists simultaneously.
Barbara remained at Cornell for several years after completing her Ph.D., working as
Emerson's research assistant and pursuing her studies in maize. Always a bright student, it
was during this time that she began her long series of uncanny insights into the behavior of
genes and chromosomes. From the behavior of certain traits of pigmentation, Barbara in-
ferred the existence of small ring chromosomes. Throughout the cell division cycle, these
rings would break and replicate, randomly losing certain pigment genes in the process. She
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became convinced of the existence of ring chromosomes
based on her reasoning, and only
then did she actually see them in her histological preparations.
It was this ability to think
through her data, rule out all possibilities but one, and "know"
how the chromosomes must be
acting-even when they were acting in ways contrary to everything then known about
them-that distinguished Barbara's science.
In 1936, Barbara was appointed assistant professor at the
University of Missouri, Colum-
bia. There, she generalized her work on broken chromosomes
and described the "breakage-
fusion-bridge" cycle. Barbara noticed that under certain conditions, her chromosomes would
break, forming loose ends that could fuse with like or unlike chromosomes. Two of these mix-
and-match chromosomes sometimes formed a bridge, which stimulated another breakage
and ref usion, beginning the cycle again. By repeatedly cutting and pasting pieces of
chromosomes to each other, the breakage-fusion-bridge cycle shuffled the pigment genes,
producing new patterns in the maize kernels. This was the first of several major contributions
Barbara made to understanding how the genome introduces variety within itself. In genetics,
variety is not the spice of life, it is the stuff of evolution.
The prejudices of the day created not a "glass ceiling" for women scientists, but a con-
crete one. Barbara was told outright that her chances of being promoted at Missouri were
minimal, even though she had become a well-respected scientist and had served as the vice
president of the Genetics Society of America. At the end of 1941, she accepted an invitation
from the Carnegie Institution of Washington to join its Department of Genetics at Cold Spring
Harbor. At the turn of the year, she was made a staff member of the Carnegie, a position she
held until 1967, when she became a Distinguished Service Member.
It was at Cold Spring Harbor that Barbara made her most famous contribution to science.
Using the same skills she had used in identifying ring chromosomes 20 years before, Barbara
reasoned the existence of a brand-new phenomenon in chromosome behavior. To set the
scene, the prevailing view of the genome at that time was a static one. A chromosome was a
string of genes, each fixed in position relative to every other. When Barbara announced, in
1951, that she had found genes that seemed to move around, it was as surprising as if the big
pearl in the center of a necklace spontaneously jumped to a position near the clasp. These
movable genes, called transposable elements or transposons by scientists and "jumping
genes" by the popular press, shook the foundation of the prevailing view of the genome.
This story has been told so many times that it has become a myth. Barbara has been
canonized as a martyr of scientific dogmatism and narrow-mindedness. Her image in the
public eye is that of a diminutive underdog vainly trying to speak the truth to the entrenched
old-boy network of scientists, a woman ignored for 30 years until more objective and en-
lightened young minds gave her the credit she deserved. In fact, Barbara was already a giant
in the field when she discovered transposons. She had been a member of the National Acad-
emy of Sciences for seven years. She had published many important papers. Although it is
true that the significance of her work was not widely appreciated for a long time, the reasons
are more subtle.
First of all, Barbara's work was hard to understand. She thought in such leaps that even
many first-rate minds had trouble following all of her arguments. The brilliant Drosophila
geneticist Alfred Sturtevant reportedly said of this work, "I don't understand a word of it, but if
Barbara says it is so, it must be so!" Barbara, after all, had never actually seen a transposon.
She had again inferred their existence from careful study of her crosses. Few could follow the
intricate lines of reasoning that led her from splotches of color on corn kernels to bits of genes
hopping around the chromosomes. Second, its applicability to other organisms was not clear.
Many people thought that Barbara was probably right, but so what? It was likely a genetic
curiosity, restricted to maize. Plants were, after all, rather strange organisms. Few people ex-
pected to find transposons in bacteria or yeast, let alone humans.
It took the advent of molecular biology to make clear the existence and importance of
transposable elements. In the late 1970s, science had advanced far enough that we could
isolate the actual DNA that jumped from site to site in the genome. Nina Fedoroff studied the
molecular biology of maize transposons, at last isolating the genes Barbara could see only in
her mind. Also, transposons were found in other organisms. David Botstein found transposons
in bacteria. Gerald Fink found them in yeast. It was the generality of transposition that won
Barbara McClintock the Nobel prize, and it took time for that generality to be established.
Following her transposon work, Barbara took maize research into yet another new arena.
She undertook a sort of agricultural anthropology, using maize genetics to trace the ancient,
sophisticated Indian cultures of Mexico. For this work, she traveled to Mexico, learned
Spanish, and discovered a new meaning for the term "field work."
Barbara lived and worked at Cold Spring Harbor for more than 50 years-nearly half the
Laboratory's history. During that time, she had a significant influence on Cold Spring Harbor
science. She may have influenced younger generations of scientists even more than her con-
temporaries. She exerted a direct influence, of course, on the plant geneticists here. Some
are exploring the molecular biology of Barbara's famous Ac/Ds system. Others are using
transposons as vehicles for inserting "reporter" genes into an otherwise unwilling host, the
chromosomes of the small plant Arabidopsis. When a transposon ferries a reporter into an
Arabidopsis gene, scientists can identify both the location and the function of the Arabidopsis
gene. Barbara spoke with Laboratory scientists often, giving her advice, visiting the cornfields
at Uplands Farm. Her work of the 1950s and 1960s was important to the yeast group here
during the 1970s, as they worked on mating-type switching. Barbara's early work on the
breakage-fusion-bridge cycle identified the structures at the chromosome tips now called
telomeres, sparking a field of research that has implications for both aging and cancer.
A striking feature of Barbara's research is that it continues to generate new ideas. In
molecular biology, knowledge advances so quickly that a paper becomes "old" (i.e., ir-
relevant) in 5 years or less. Yet Barbara's papers from the 1960s, 1950s, 1940s, even the
1930s continue to be cited. The reason is that she sought "molecular" explanations for her ob-
servations even though the actual molecules had not yet been identified. She saw a level of
abstraction deeper than her data could take her. As the science catches up with her thinking,
the relevance of her interpretations becomes clear.
Barbara's main influence on Cold Spring Harbor, however, was on a one-to-one level.
People from all sectors of the Laboratory-Rolling Five scientists, postdocs, administrators,
and groundskeepers-had ongoing conversations with her. They talked about science, wild-
flowers, politics, the weather, where to find a good sweater. With the younger scientists, she
often talked about motivation and the life of a researcher. Barbara had a reputation for being
a mystic. She wasn't a mystic, she was just thoughtful. She was interested in what a person
had to say. She would ask questions until she understood the problem and then draw on her
experience to give a fresh perspective. If she saw things the rest of us did not, it was simply
because she thought more clearly and deeply than most of us.
Since Barbara's death on September 2, 1992, the Laboratory has not been the same. For
many of our community neighbors, Barbara McClintock symbolized Cold Spring Harbor
Laboratory. People with no idea of what an oncogene or a receptor protein is knew about "the
corn lady" who somehow beat the system and eventually got the recognition she deserved.
She has become a local legend. Ironically, Barbara would just as soon not have been a
legend, not a Nobel laureate, not famous. It was fame that forced her to hang that sign on her
apartment door. Those who cared about who she was, rather than what she did, knew that
below the words "Do not enter" was an implicit "Please knock."
Nathaniel C. Comfort
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Taggart Whipple
1912-1992
The Laboratory has three overlapping types of supporters: those who contribute scientifically,
those who contribute monetarily, and those who contribute with their spirit. Had Taggart Whip-
ple been a scientist, he would have been all three. As it was, Tag, who passed away on No-
vember 26, 1992, was a long-time friend and adviser who left an indelible mark on Cold
Spring Harbor Laboratory.
Born in Manchester, New Hampshire, in 1912, to Stanley Cornell Whipple and Ruth Storey
Whipple (née Taggart), Tag was raised in the Massachusetts town of Cohasset, near Boston.
His father sold advertising for major magazines such as The Saturday Evening Post. He at-
tended the small, private Noble and Greenough School, where he did well and graduated
young. His parents thought it would be best if he attended a somewhat larger prep school be-
fore he went on to college, so he attended Exeter for a year after graduating from Noble and
Greenough, an experience he thoroughly enjoyed.
In 1929, Taggart matriculated at Harvard. He did well academically and also took part in
sports and social activities. After injuring his knee playing football, he became a member of
the rowing team. He graduated in 1934 with a bachelor's degree in English.
After graduation, Arthur Chase, a rowing buddy, invited Tag to spend time with him at his
Adirondack mountain camp. As it happened, a young woman from New York City named
Katherine Brewster was summering with her family at their nearby camp. She was learning to
sail, to the chagrin of her father, who worried about her out on the water in a tippy boat. When
the crewman she had working the mainsheet of her boat had to leave, she began scouring
the nearby camps for a suitable crew member. She wandered into the camp of a family friend,
Arthur Chase, who said he had staying with him a young man who was about six-foot-two, 170
pounds. Katherine thought, "Hmmm, that sounds about right." Taggart was willing, so she had
herself a full crew.
At the end of the summer, Katherine and Tag went their separate ways and did not see
each other for several years. Taggart went to New York to begin work and school. He had
hoped to attend Harvard Law School, but the Depression had sapped his father's resources
so badly that he could not afford to send his son to the prestigious and pricey institution. So
Taggart set out on his own to put himself through school. His friend Arthur Chase introduced
him to Judge Barrett, at the Lehigh Valley Railroad, who put Tag to work as a law clerk. Tag
also attended law school at night at New York University, and by 1938, he had four years ex-
perience in a law office, as well as a fresh J.D. degree. That year, he passed the New Ycrk
State Bar exam.
Judge Barrett was sufficiently impressed with this young man that upon Taggart's gradua-
tion, he arranged an interview for Tag with the New York firm of Davis, Polk, and Wardwell.
This first-rank firm drew its members from the best law schools, not from night school. Around
the halls of Davis, Polk, and Wardwell some people wondered what things were coming to if
they were beginning to hire NYU night school graduates. Nevertheless, Taggart got the job.
He proved to be an intelligent, thorough, and extremely hard worker, and over the next four
years, he rose through the ranks. He developed a reputation for leaving no stone unturned
when he was preparing a case. He was meticulous and well-prepared-a formidable op-
ponent in the courtroom.
After several years, Taggart and Katherine met again through mutual friends, and in 1941,
they married. In the spring of 1942, Taggart was called up for service. He wanted to join the
Navy but was turned down because of his college knee injury. He wound up in the Army, in
Ordnance, repairing equipment as it returned from the Pacific. But Taggart wanted to go to
the Pacific. After pestering his commanding officer repeatedly about a transfer, the CO finally
exploded, "If you're not quiet, I'll have you transferred all right-to the Aleutian Islands!" Tag-
gart was finally transferred into Field Artillery. He and Katherine moved to Fort Sill, Oklahoma,
and then to Texas; then at last, Taggart went overseas, to Italy. Upon his return in 1945, he
and Katherine moved to Washington, D.C., where Taggart worked in Intelligence. The Whip-
pies' first child, Christine, was born in Washington in 1946.
Like a lot of young men, Taggart was not quite sure what he wanted to do after the war.
He thought about going back to Boston, and he considered moving to Philadelphia. He finally
decided he didn't like the way law was practiced in those cities, and so he returned to New
York and Davis, Polk, and Wardwell. He spent the rest of his career there and in 1950 he
made partner. He distinguished himself through his intelligence, skill, and hard work, as well
as through his mentoring ability. Younger lawyers who worked with Tag later wrote that he
was tough, fair, thorough, and a role model they kept throughout their careers. He argued be-
fore the U.S. Supreme Court on two occasions, and he won one of those cases.
Although he remained with the same law firm for the rest of his career, Taggart's life was
far from static. He and Katherine, known to all as "Sinka," adopted two boys, Hugh and
George (called Steve). Tag was devoted to his children, and although he may have been
strict, he loved them dearly. He was always there to help them out of a scrape when neces-
sary. Like all lawyers in the fast-track world of New York corporations, Taggart worked ex-
tremely long and hard hours, yet he was always able to separate his work life from his home
life. He didn't bring the office home with him; when he was with his family, he was all theirs.
Since his college days, he loved anything to do with boats and the water (this native bent
was undoubtedly reinforced by the way he met his wife). Tag took his family on sailing vaca-
tions to Nantucket, Maine, and Shelter Island. The Whipples were friends with Laboratory
patrons Walter and Jane Page, and once they vacationed together in the Caribbean, sailing
from island to island. He also cultivated an appreciation for the arts. His introduction to art
came through a feisty oilman named Charlie Wrightson. Wrightson turned barrels of oil into
barrels of money and accordingly had a retinue of attorneys. These lawyers were apparently
more eager to keep the Wrightson account than to give him sound advice; so Wrightson fired
them and approached Taggart Whipple. Never a yes-man, Tag said that if Wrightson wanted
to do something that Tag thought was ill-advised, he would tell him so. Wrightson liked this;
he hired Tag and also befriended him. Wrightson had an art collection at the Metropolitan Mu-
seum of Art and introduced Tag to the arts. Tag later became very interested in the theater.
He became associated with the Lincoln Center for the Performing Arts. He also served on the
Board of Directors of the Repertory Theater of Lincoln Center and was a member of the Board
of the Lincoln Center for many years.
Walter Page, whose family has been associated with the Laboratory for more than 65
years, introduced Tag to the Laboratory in the early 1980s. Tag quickly took to the way we live
and joined our Board of Trustees in 1983, just before his 1984 retirement from Davis, Polk,
and Wardwell would provide him much time to work in the Laboratory's behalf. From 1986 to
1992, he was vice chairman of our Board, serving also as chairman of the Nominating Com-
mittee and member of the Executive and Development Committees. During our Second
Century Campaign, he and Sinka took great pleasure in making possible the construction of
the Whipple Room in the Beckman Building, later providing us with a collection of paintings
and drawings to decorate its walls.
Always he was the consummate friend and adviser. In particular, I valued Tag's love for
the English language and the happiness that came from the use of a word or phrase ap-
propriate to the occasion. Upon becoming a member of our Board, he made a point of read-
ing my past Director's Reports and made me feel good by telling me how interesting they still
were years removed from the occasion of the writing. In his last months, when he no longer
was effectively mobile, I took much pleasure in bringing him the first drafts of a still not yet
completed book on how my family and teachers formed the values that have shaped my later
life. Even in his last days, Tag could still spot awkward language while at the same time reas-
suring me that those who knew me less well would also enjoy reading my new book.
Tag's résumé of memberships reads like a laundry list of the Renaissance Man. Besides
his Lincoln Center affiliation, he was a member of the Phoenix Theater, the New York Univer-
sity Institute for Fine Arts, Distillers (USA) Inc., the Council on Foreign Relations, and the
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Society of St. Johns land. In addition to the Laboratory, he was a member of the Woods Hole
Oceanographic Institution and the Community Hospital of Glen Cove. Tag also served on
numerous educational boards, including those of NYU, the NYU Law Center Foundation, Vas-
sar College, East Woods School (which his children attended), Salisbury School, the Harvard
Alumni Association, and the British-American Educational Foundation. His professional asso-
ciations included the American Bar Association, where he served on the council section on
antitrust law from 1966 to 1970; the New York State Bar, where he chaired the antitrust law
section in 1962 to 1963; and the New York City Bar, for which he chaired the committee on
trade regulation and trademarks. He also served on the Federal Bar Council, the American
Judicature Society, and others. In addition, he was a member of the Century, Piping Rock,
Union, Pilgrims, and Anglers Clubs.
His many accomplishments by themselves, even a complete catalog, could never sum up
Taggart Whipple. His greatest contributions to the Laboratory, to his business, and to his fam-
ily by their essence are not documentable. At their heart was always his awesome integrity.
He made us expect more of both ourselves and the organizations we believe in. Most impor-
tantly, he knew how to behave when the inappropriate decision might lead to real trouble. On
such occasions, I invariably went to Tag.
Without him, I grieve.
James D. Watson
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DIRECTOR'S
REPORT
Forty years ago, in Cambridge, England, Francis Crick and I proposed the
double-helical structure for DNA, the molecule that carries genetic information.
Before we found it, we feared that the structure might be uninformative, still leav-
ing us in the dark as to the essence of the gene. But as soon as we saw the pos-
sibility that the structure of DNA could be double-helical, we became enormously
excited. The double helix, with complementary sequences of the four bases on
its two chains, suggested a simple way for the genetic information of our
chromosomes to be exactly copied when our cells divide to form new cells. From
the moment we saw the A-T (adenine-thymine), G-C (guanine-cytosine) base
pairs, we knew that our double-helical structure, if later validated, would change
the way we think of life. By providing a logical starting point to understanding
heredity in terms of molecules, Francis and I also suspected that we would go
down in history as two of the major names of science. But we knew that the
science behind our discovery was not that difficult and that it was the elegant
simplicity of the double helix that might make us household names to biology stu-
dents of the future. So we were not surprised that many scientists in Cambridge
who did not think we deserved the resulting fame took pleasure in calling the
double helix the WC structure.
Our discovery was not all luck, however, since independently we had made
two decisions that gave us great advantages over other scientists who also
hoped to discover the real secret of life. First of all, both Francis and I thought
that DNA had to be the most important molecule of life since it was the molecule
of the gene. This opinion was then a minority viewpoint among our peers, and the
vehemence with which we held to this belief led many around us to regard us as
unsound yet arrogant. If we were right, they might be devoting their lives to minor
objectives. Our second conviction was that to understand functions, one had to
understand molecular structure at the three-dimensional level. To many others,
this was reductionism at its worst, taking away from life the grandeur that they
thought it deserved.
Fortunately, both of us could test our beliefs in a then tiny research unit for the
study of molecular structure supported by the Medical Research Council (MRC)
at the Cavendish Laboratory. The Cavendish Professor at that time was Sir
Lawrence Bragg, who early in his youth had discovered how to use X-ray crystal-
lographic diffraction techniques to solve the first three-dimensional structures of
simple molecules. For this work, Bragg had received the Nobel prize when he
was only 25, and now at 61, he was keen to see his technique used to solve the
structure of the key macromolecules of life, the proteins and DNA. At his sugges-
tion, the MRC had set up a small unit, headed by Max Perutz, to work out tech-
niques for solving, in particular, the structure of proteins.
When I arrived in the fall of 1951, there were fewer than ten scientists so sup-
ported, but what a powerhouse of brains and common sense. We could think for
the long term and not worry about justifying our ideas before scientists who had
more pedantic objectives and who would be bound to object that we were wast-
1
ing government money on projects unlikely to come to fruition in the foreseeable
future. To many, Sir Lawrence Bragg was taking a dangerous course in not
devoting all of the Cavendish Laboratory to the nuclear physics that had made
the Cavendish the most famous of all scientific laboratories in the history of
science. But in retrospect, we now can take pleasure that his term as Cavendish
Professor had just as great an impact on science as the glorious reign of his im-
mediate predecessor Ernest Rutherford. Not only did Francis and I find the dou-
ble helix, but it was Bragg's patronage that made possible the 1959 elucidation
of the three-dimensional structures of proteins by Max Perutz and John Kendrew.
To follow up these discoveries, the MRC unit required more space than could
be provided by the Cavendish Laboratory. At first, a now-famous Quonset but
gave the unit needed breathing space for Francis Crick and Sydney Brenner to
tackle the Genetic Code. But soon the decision was made to create, in 1962, a
major new MRC Laboratory of Molecular Biology (LMB) on the new Addenbrooks
Hospital site. Happily, by continuing to have grand objectives and long-term sup-
port, this laboratory, although much larger, is still at the forefront of biology. Four
Nobel prizes (Fred Sanger, Aaron Klug, Cesar Milstein, and George Kohler) have
already recognized the stellar science accomplished over the interval, and we
can confidently expect more to be awarded for research now ongoing. Although
daily life no longer has the wonderfully unhurried pace of 40 years ago, the con-
stant preoccupation with writing grants to obtain research monies that now so
drags down the American scientific scene is not a part of the LMB scene. One
large grant from the MRC keeps it on its grand path.
Now the Cold Spring Harbor Laboratory is roughly the same size as the LMB,
and judged from the number of literature citations that our scientific papers
receive, we have been almost equally influential in the development of molecular
biology over the past several years. Ratings published last year showed that
Cold Spring Harbor Laboratory and the MRC Laboratory of Molecular Biology are
the two most productive molecular biology laboratories in the world, despite the
very different ways our respective science is funded. LMB has had the comfort of
stable, long-term government funding, whereas Cold Spring Harbor Laboratory
has been almost totally dependent on the receipt of short-term research grants,
whose future receipt would quickly be threatened if the quality of our science
were to decline.
Such soft money, however, was not always the way of life at Cold Spring Har-
bor. From 1904 to 1962, genetics programs here were maintained by funds pro-
vided from the large endowment of the Carnegie Institution of Washington, a
body for the support of science created in 1902 by Andrew Carnegie with some
of the monies that he obtained from selling his steel mills to the U.S. Steel Com-
pany. When the Carnegie Institution of Washington was funded, there existed vir-
tually no federal monies for the support of pure science, a situation that con-
tinued to exist until the end of World War II. The firSt scientists that Carnegie sup-
ported here thus had very privileged positiOns, which they used to make Cold
Spring Harbor one of the world's leading centers for genetics, a situation that still
existed when I first came here in 1948 as a graduate student of Salvador Luria.
Soon afterward, government monies for support of pure science rapidly grew,
and by the early 1960s, private universities and research institutions no longer re-
quired large endowments to play important roles in science. Even more important
for an institution's scientific future was the entrepreneurial spirit that sought out
government funds not only for direct research support, but also for construction
grants that led to major increases in the facilities available to do high-level
science.
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The 1962 decision by the Carnegie Institution of Washington to close down its
Genetics Department at Cold Spring Harbor Laboratory thus did not immediately
threaten the perpetuation of science here. As long as excellent scientists chose
to work here, government monies were available to cover not only their research
costs, but also their salaries. But it was then more difficult to foresee that Cold
Spring Harbor could retain its commanding presence in the field of genetics
which had come to it by having on its staff scientists such as Alfred Hershey and
Barbara McClintock. Recruiting future intellectual giants would be much more dif-
ficult than it had been in the Carnegie years, since the better young molecular
geneticists would inevitably be tempted to start their scientific careers in institu-
tions that had federal, state, or endowment funds to cover their salaries. The first
several years following the Carnegie pullout were thus rocky years for Cold
Spring Harbor Laboratory, and great doubts existed among even its closest sup-
porters as to whether it had a future worth saving.
When I became the director in 1968, I decided to give the Laboratory more
stability by focusing its research on the genetic basis of cancer, a field that had
long intrigued me dating back to my beginning days as a scientist in Salvador
Luria's laboratory at Indiana University. In particular, I wanted to attack cancer
through the study of several small animal viruses that were capable of changing
normal cells into their cancerous equivalents. I had known how to think in terms
of viruses ever since my Ph.D. research, and increasingly, I wanted to follow up
my 1959 hunch that tumor viruses possessed genes that upset the normal
regulatory pathways which kept cells from multiplying out of control. Happily,
there was no shortage of National Cancer Institute monies for such research, and
we obtained a sizable grant that allowed me to recruit several very talented
young scientists who had already begun research on tumor viruses. Here, Cold
Spring Harbor had the advantage in that attacking cancer was not yet a major
objective of most of our better intellectual competitors who remained absorbed in
working out how genes function in the more simple bacterial systems. We thus
stood out as one of few intellectual centers that was moving DNA-based thinking
into the world of cancer. Led by Joe Sambrook, whom I recruited from tumor
virus research at the then newly formed Salk Institute, this effort quickly yielded
results and Cold Spring Harbor soon again displayed the intellectual eclat that
dominated the 20-year era led by Miraslov Demerec which had begun in 1941.
Our full potential as a center for biology, however, needed more than the
abundance of targeted federal cancer monies. As the director, I needed un-
restricted monies so that I could staff other areas of research both through the
creation of new research facilities and through the recruitment of new staff mem-
bers. This freedom to extend our intellectual horizons happily came soon when
suddenly in 1973 our neighbor Charles S. Robertson conveyed to us an ex-
traordinary 8 million dollar gift to endow the Robertson Research Fund. From its
inception, we decided to focus this fund virtually exclusively toward ensuring the
success of the careers of our younger scientists as opposed to providing tenure-
like support for those whose research had already taken off. Even though this de-
cision has meant an inevitable loss of key scientists in the 35-40-age bracket to
more secure positions at major universities, in the long term, we have benefited
from the renewed vigor brought to us by their more youthful replacements.
For almost 10 years, the availability of Robertson funds meant that as director
I had the freedom to focus on the doing of science as opposed to worrying about
how to fund it. But by 1981, as a result of the newly developed recombinant DNA
procedures, the pace of our science suddenly quickened, with it becoming more
apparent each year that DNA methodologies were increasingly going to domi-
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nate more and more of biology. As a premier institution, we had to accomplish
each year even more good science just to stay intellectually even with our better
competing institutions. Luckily, the emergence of the first gene cloning com-
panies encouraged moves toward biotechnology by many major industrial com-
panies, and we greatly benefited in the mid 1980s from short-term partnerships
with Pioneer Hybrid International, Monsanto, and Exxon. On our side, we helped
train their scientists for the biotechnology future while they provided the funds
needed to let us move into new areas of recombinant DNA research at full speed.
Similar agreements with other companies were made by many other leading in-
stitutions, and we began to witness the transformation of the more than 30-year-
old bipartite academic-governmental partnership into a troika of academia, gov-
ernment, and industry partners. Crucial to the emergence of this new triumvirate
was the 1980 Bayh-Dole legislation, which allowed academic institutions to hold
the commercialization rights to their federally funded research. Before this bill
was passed, these rights were held by the federal government itself, thereby
greatly diminishing the incentives for academic institutions to find industrial part-
ners for their discoveries. Under this new law, academic institutions became free
to make deals that gave industrial partners rights to the commercial development
of research that had been partially funded with government monies.
In witnessing the emergence of industrial monies as major factors in today's
biomedical sciences, we should make clear that this change has not been the
result of a real decrease in government support. Instead, the actual driving force
is the increased number of highly qualified scientists applying for federal grants.
As a result, not only has the size of individual federal grants been going down,
but also more and more good grant applications are at best delayed in their
funding and at worst turned down. In the past, young scientists who were suc-
cessful during their postdoctoral period could realistically expect to be funded as
soon as they commenced their first academic appointment. Now such individuals
have more uncertain futures unless their academic institutions can provide inter-
im funding until their first grants are approved. Until very recently, most high-
quality institutions thought that they could effectively house first-class science as
long as they provided the necessary research facilities. Today, however, we are
entering an era in which to maintain high-quality science on university campuses
or within nonprofit research laboratories, these respective institutions must have
substantial, internally controlled funds to plug the increasing leaks in our re-
search fabric.
The sums now required are far beyond those that previously could be ob-
tained from private individuals, who in the past have largely been approached for
funds to build new buildings or to renovate out-of-date facilities into virtually new
laboratory space. Nonetheless, we are bound to increasingly witness more
solicitation of private citizens for direct support of science, particularly for those
fields such as cancer research where the general public has a strong vested in-
terest in success. Correspondingly, we have also become more dependent on
help from the foundation world. But unfortunately, there exist relatively few sizable
foundations that are still strongly oriented toward basic science, and, to our dis-
may, we are witnessing the increasing tendency of peer-review groups to fund
most scientists at the same level, independent of whether there are large dif-
ferences in their relative potential for true innovation. Thus, those science-
dominated foundations that do exist, such as the Keck, Markey, Mathers, and
Sloan, are finding themselves more and more called upon to maintain the high in-
tellectual goals of our major research institutions.
Almost paradoxically, it may be the elite research-dominated institutions that
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have their way of life most threatened by these years of increasing fiscal
stringency. Until recently, their major scientists routinely received the multiple re-
search grants needed to support their 10-30-member research groups that have
become facts of life for many leaders of this recombinant-DNA-dominated re-
search era. That the largest of such research groups are cost-effective, however,
is far from clear, and the money consumed might be more wisely expended if
distributed to two independent research groups. But even granted that such ex-
cesses do exist, there is no doubt that many of our best scientists need multiple
grants to generate the science that our nations expect from them. Vital help for a
small fraction of our best scientists now comes from the Howard Hughes Medical
Institute, which provides major support for some 200 highly talented structural
biologists, molecular geneticists, cell biologists, neurobiologists, and im-
munologists. But for every well-supported Hughes investigator, there exist some
5-10 other scientists of equal future potential whose productivity remains
hostage to the effective crapshoot atmosphere now pervading peer-review group
decisions. Fortunately, an increasing number of foundations, such as the Pew
Charitable Trusts and the McKnight Foundation, provide career development
awards to help highly talented younger scientists get started. But once such
awards have expired, their research could easily falter even when their objectives
don't deviate too much from conventional wisdom.
So those of us who oversee our major research-oriented institutions are more
and more becoming engaged in seeking large-scale industrial funds to keep our
science moving forward. But in seeking much more sizable help than we have
ever asked for before from the pharmaceutical and biotechnology worlds, we will
be asking for more money than can fit under the rubric of charitable contribu-
tions. Such transfers of money to us must in return make commercial sense to in-
dustry by providing research that otherwise would be carried out in the com-
panies themselves. Conceivably, by placing such research in university-like at-
mospheres, it can be done faster and cost less than if industries themselves
carried out these tasks. Until recently, in general, neither the academic nor the
commercial worlds thought that such arrangements were good for either side.
Too many years, if not decades, might pass, for example, before the pure re-
search carried out at institutions like Cold Spring Harbor would ever affect the
market place. Moreover, those companies that could have so funded us might
not be the right ones to develop our prospective products commercially. Today,
however, many academic research objectives are indistinguishable from what in-
dustry sees it has to accomplish. For example, both worlds wish to know more
about how life-threatening cancers develop. Conceivably, such
research has a
better chance of success if carried out in more academic
atmospheres where re-
search goes on all through the night and where weekends are indistinguishable
from ordinary days of work.
The pharmaceutical and biotechnology industries now
want such partner-
ships, although it is far from clear that the sums of money they can devote to
academic-sited research will ever be even close to the
amount needed to correct
the deep malaise developing throughout the biomedical
world of our country.
Enough industrial funds are available, however, to
stabilize fiscally a few key in-
stitutions, as shown by the recent proposed
agreement between the Scripps Re-
search Institute of La Jolla and the Swiss
pharmaceutical giant Sandoz. To obtain
the right of first refusal for all discoveries
made at Scripps, Sandoz was willing to
provide 30 million dollars a year to Scripps,
whose current budget for science is
now approaching 90 million dollars,
much of that coming from federal research
grants. Key to Sandoz's interest in Scripps was
not only the general excellence of
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its wide-ranging program in biomedical research, but also, in particular, its
recently developed School of Chemistry and its companion drug-discovery
group.
The breathtaking size of this proposed agreement, announced early this year,
soon brought into the public gaze the question of how deals between industry
and academia should be structured, particularly as to whether the proposed deal
was for the public good as well as for that of Scripps and Sandoz. Among the
concerns raised was whether the presence of Sandoz members on the Scripps
Board of Trustees would effectively give Sandoz control over one of our nation's
leading research institutions. Equally troubling to many was the possibility that
this agreement, if allowed to go forward, would lead other major institutions to
similar pacts, thereby making many of the choice fruits of our publicly supported
research unavailable to competitive bidding by newly emerging biotechnology
companies. By now both NIH and congressional voices have expressed their dis-
pleasure, and it is likely that the arrangement will be revised so that Sandoz has
less apparent control over Scripps' future and, in particular, its intellectual prop-
erty rights.
If the finally revised and governmentally smiled upon deal still has the mega-
dollar properties guaranteed to insulate Scripps from the financial restraint so ap-
parent elsewhere, their scientists may soon find that they have struck a Faustian-
like pact. The knowledge that it is cash-rich will not escape the notice of the NIH
peer-review group members, who will invariably come from institutions under
siege. Members of its talented Chemistry School are likely to be the first to expe-
rience standing last among their peers as priorities are made for the distribution
of scarce monies. And even those scientists distant from the world of drug dis-
covery are likely to find themselves disadvantaged when applying for funds. They
will belong to an institution that clearly has more than enough funds to tide over
grant delays, particularly if it restricts further growth of its facilities and uses
restraint in setting scientific salaries. Scripps thus could find itself progressively
more dependent on Sandoz support and have to move their research progress
increasingly in the directions that are attractive to its industrial partner.
So if a Scripps-Sandoz-like deal were to be offered to Cold Spring Harbor
Laboratory, it might not be in our long-term interests to accept it. Much better
would be the arranging of much more restricted agreements with a number of
companies, each targeted to the needs of specific staff members who have com-
mon interests with their specific corporate partner. Thus, while individuals of our
staff might have the good fortune of being research-money-rich, their good for-
tune need not handicap those of our staff whose research is unlikely to appeal to
industry and so badly need NIH and/or NSF support. As implied earlier, these lat-
ter scientists are likely to be under constant anxiety over the foreseeable future,
and we must take on the institutional responsibility to find the funds that will allow
their careers to blossom while with us. In this way, we can remain a laboratory
that has important, long-term basic research objectives like how our brain func-
tions to let us perceive, memorize, and think.
Only with time will we know whether the acceptance of more and more corpo-
rate support will seriously move us away from seeking profound explanations for
fundamental cellular and molecular processes that underlie living systems.
Certainly, if we move too far, we will face demise as an intellectually alive institu-
tion. But at the same time, we must not fall into the all too often academic trap of
believing that because a research objective is purer than pure, it is more
worthwhile to do than projects with obvious practical objectives. Instead, there
are often very good reasons to seek out research goals that are simultaneously
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pure as well as applied and so clearly fundable. This was until recently most
certainly the case for cancer research, where the uniqueness of cancer cells can
only be understood when related to the comparative behavior of normal cells.
Unfortunately, during the last several years, the increasing number of scientists
interested in cancer genes began to put pressures on the money available for so-
called untargeted cancer research. But those competent scientists interested
specifically say in breast cancer still have no funding dilemmas.
There should thus be no undue pessimism about the immediate future of Cold
Spring Harbor Laboratory as long as we keep a strong sense of what both we
and the public want from science. Increasing connections to industry need not
hurt us as long as the companies we work with also see the need to understand
life ever deeper at the molecular and cellular levels. So institutions that have the
apparent good fortune to remain totally governmentally funded, such as the
MRC-supported Laboratory of Molecular Biology at Cambridge or the vast in-
tramural program of NIH at Bethesda, will not necessarily do more inspired
science than those of us who have multiple masters controlling our fates. Con-
ceivably, they may suffer more from the lack of need to constantly reappraise
their courses than we will suffer from the anxiety that comes from simultaneously
displaying both pure and applied faces.
Our next years obviously will not be carefree, but neither were the great years
of our past.
HIGHLIGHTS OF THE YEAR
An Exciting Year Scientifically
This has been an active and exciting year for Cold Spring Harbor science. New
developments in the biology of the cell cycle, the cytoskeleton, aging, plant biol-
ogy, and neurobiology convey some of the diversity of Laboratory research in
1992.
David Helfman and Jim Lees-Miller, in collaboration with Trina Schroer of
Johns Hopkins University, found a major piece of an intracellular "motor." This
protein, related to the molecule actin, which helps muscles contract, is called
actin-RPV. It appears to be involved in moving organelles
around the inside of
the cell. Actin-RPV may therefore be an important
piece of the machinery that
ensures a molecule is in the right place at the right time. In addition,
because it is
associated with the spindle poles that form during
mitosis, actin-RPV may turn
out to play a role in cell division.
Staff investigator Xiaodong Cheng has solved the
structure of the first DNA
methylase. Working with enzymes from the bacterium
Hemophilus, Xiaodong
solved the structure to a resolution of 2.5 A. In
bacteria, methylases act in con-
cert with restriction enzymes to regulate the
cutting of DNA. In eukaryotes, how-
ever, they serve a more complex function as
part of a group of enzymes
responsible for DNA replication and in the
regulation of gene expression.
Grisha Enikolopov works on Science
magazine's "Molecule of the Year." Nitric
oxide (NO) is a gas that functions in transmitting signals between nerve
cells.
NO seems to act in concert with other
messengers, such as calcium, to enhance
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their effects. It thus acts as a sort of molecular volume knob, modulating the im-
pact of a given neurotransmitter. NO first made science headlines because it is a
"retrograde" messenger. It exerts its effects backward with respect to the electri-
cal nerve signal, from the receiving cell to the sending cell. NO thus closes a
feedback loop; the sending cell signals to a receiver, and the receiver, via NO,
"responds" with a signal back to the sender that changes gene transcription.
Postdoc Steven Bell and senior staff scientist Bruce Stillman discovered what
some refer to as the "Holy Grail of DNA replication." The grail in this case is a
cluster of proteins that bind to a specific site on the DNA to begin replication.
When a cell divides, complete replication of the DNA must occur to ensure that
each new "daughter cell" gets a full set of genes. The finding is important be-
cause it links research on the signals that trigger cell division with research on
how cell division actually happens.
Senior staff investigator Carol Greider and colleagues at McMaster University
found a new potential link between the chromosomes and cancer. Telomeres, the
ends of chromosomes, consist of many repeats of a simple DNA base sequence.
In 1991, Greider along with Bruce Futcher showed that telomeres shorten with
age. This is the result of an enzyme Greider discovered called telomerase, which
chops off telomere sequences each time a cell divides. In this latest work, she
showed that telomerase is not active in cultured cancer cells that become "im-
mortal"; thus, the telomeres of immortal cells do not shorten like those of normal
cells. The next question in this research is whether telomere shortening is a
cause or an effect of immortalization.
Mike Gilman's laboratory developed a "cell-free" system for studying signal
transduction, the mechanism of bringing chemical signals from the outside of the
cell, such as hormonal signals, into the cell and into the nucleus, where they
change the cell's behavior. What Gilman has done in essence is to reproduce
certain aspects of signal transduction in a test tube. This allows a more direct ex-
amination of the mechanisms of signal transduction. From a practical standpoint,
the system may provide an exceptionally simple assay for novel compounds that
either interfere with or augment signal transduction; these could have significant
therapeutic potential.
Proteins called G1 cyclins are key controllers of cell division in yeast. Bruce
Futcher and David Beach looked for similar proteins in human cells and found
one they called cyclin D. Importantly, this cyclin turned out to be aberrantly ex-
pressed in many cancers. These findings indicate that (1) the most basic controls
on cell division are conserved from yeast to humans and (2) at least some can-
cers may result from disturbances of the cyclins that control cell division.
Niko lai Lisitsyn, Natalya Lisitsyn, and Michael Wig ler have developed a rapid
new way to identify disease-related genes in human DNA. Called the "representa-
tional difference method," this technique enables researchers to compare the
DNA of normal individuals with the DNA of afflicted individuals to isolate the DNA
regions gained or lost in disease carriers. Although a similar technique had been
developed for bacteriophage and yeast, until now, no one had succeeded in
using it on human DNA. Wig ler and Lisitsyn's method uses some clever applica-
tions of the polymerase chain reaction to circumvent problems posed by the
large size of the human genome. Preliminary data indicate that this technique
may provide a powerful way to identify genes underlying hereditary diseases and
certain types of mutations involved in cancer.
Using one of the transposable elements first discovered by Barbara
McClintock, senior staff investigator Tom Peterson is firmly rooted in classical
maize genetics. Modern techniques of molecular biology, however, allow Peter-
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Dr. Michael Brown at Dorcas Cummings Lecture
son and his group to explain in molecular detail how the Ac element jumps in and
out of the maize P gene. In addition, the Ac element creates "mutations" within the
P gene; each Ac insertion site produces a different pigmentation pattern in the
mature ear. By comparing these insertion sites with the resulting pigment pat-
terns, Peterson learns about the function of different regions of the gene.
Symposium
This year marked the 57th Cold Spring Harbor Symposium on Quantitative Biol-
ogy. The topic was The Cell Surface," and the meeting was organized by
Richard Axel of Columbia University, Corey Goodman of Berkeley, Richard
Hynes of MIT, and our own Bruce Stillman. The diversity of research interests
represented by this group of organizers reflects the breadth of the topic for this
year's meeting. The Symposium featured talks on a wide range of subjects, in-
cluding immunology, neurobiology, developmental biology, and cellular commu-
nication. This year's Dorcas Cummings Lecture was given by Michael Brown,
M.D., of Southwestern Medical School in Dallas. Presented on the Sunday of the
Symposium, the Dorcas Cummings lecture features a prominent scientist speak-
ing to the public, rather than to an audience of specialists. Dr. Brown, who
shared the 1985 Nobel prize in Physiology or Medicine with his collaborator Joe
Goldstein, discussed that fatty molecule so often talked about in the popular
press: cholesterol. In his lively talk, Brown explained the difference between
HDLs and LDLs, what cholesterol counts really mean, and how much genes may
influence the risk of heart disease.
Banbury Meetings Pushing the Envelope
The Lloyd Harbor estate donated to the Laboratory in 1976 by Charles Robertson
is the setting for an ongoing series of small, in-depth conferences assembled by
Director Jan Witkowski. These meetings, typically 3 days in length and attended
by about 40 people, run the gamut from highly technical presentations of new
9
Dr. Barney Clarkson
laboratory results and techniques to scientific topics
with a strong social
relevance. Over the course of a year, Banbury attendees
include leading
scientists, congressional staffers, corporate heads of
biotechnology corporations,
and journalists. This year's schedule contained meetings on the control of gene
expression in the AIDS virus and mechanisms of neuronal
survival, as well as
workshops on the commercialization of biology, the human
genome, and the im-
pact of indirect costs on independent research
institutions. The Banbury meet-
ings continue to push the envelope of knowledge within and between pressing
topics in biomedical research.
Baring Brothers Executive Meeting
A highlight of the annual Banbury schedule is the meeting sponsored by Baring
Brothers & Co., Ltd., the celebrated English merchant bank. The conference is
founded on the idea that the industries affected by science benefit from first-
hand interactions with the people, ideas, and techniques of science. Each Octo-
ber, business executives from the biotechnology, pharmaceutical, and financial
communities convene to hear leading researchers discuss their latest findings.
This year's topic was aging; the conference featured talks on the longevity revo-
lution, neurodegenerative diseases, and prions, the controversial disease-
causing mini-proteins. In addition, Mark Bloom and David Mick los of the DNA
Learning Center led the executives through a laboratory exercise in DNA finger-
printing.
A Vigorous Board of Trustees
Our board of trustees helps shape Laboratory decisions on a wide range of is-
sues, including new construction, hiring of scientists, and raising money. Of the
30 trustees, 10 are working scientists; the remaining 20 public members bring
expertise in business, the law, or public service. They live primarily on Long Is-
land or in New York City and join us because of their interest in promoting
biomedical research. Without a strong board of trustees, the Laboratory would
not be the success it is. Each member is limited to two 3-year terms on the
board, and each year some members are required to relinquish their seats. This
year saw the retirement of six board members, including two officers. We have a
brand new set of officers and six new members who I am sure will be valuable
additions to our board.
Special mention must be given to Barney Clarkson, M.D., our retiring
chairman. Barney and I have worked together for many years, and his advice has
guided me and the Laboratory through many mazes. Barney is a valued friend as
well, and I hope that he will continue as a member of the Laboratory community
in his new role as honorary trustee. In recognition of Barney's service to the
Laboratory over the years, we dedicated the new air-conditioned downstairs
dining room in Blackford Hall the Clarkson Dining Room.
Vice chairman Taggart Whipple also retired at our November trustees meet-
ing. Enough cannot be said about Tag. He was a long-time friend and adviser
who helped with, among other things, many legal aspects of running an institu-
tion such as this. Sadly, shortly after the November meeting, Tag passed away.
Everyone who knew him will miss his sharp mind and kind heart.
Bill Everdell retired from our board as well. He has been an important and
generous supporter of the Laboratory. At our November meeting, Bill was pre-
sented with a Steuben crystal vase etched with his name and the CSHL logo. Our
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other retiring trustees were Tom Maniatis, David Sabatini, and Jonathan Warner.
Tom is best known in Laboratory circles as the author of the lab-bench bible
Molecular Cloning. He was a scientist at Cold Spring Harbor Laboratory from
1974 to 1976, and from 1985 to 1992, he was chairman of Harvard's Department
of Biochemistry and Molecular Biology. While on our board, Tom served on the
Banbury Meetings Program committee and as chairman of the Tenure and Ap-
pointments committee. David Sabatini, chairman of the Department of Cell Biol-
ogy at New York University, also served on the Banbury and Tenure and Appoint-
ments committees and on the DNA Learning Center committee as well. Jonathan
Warner, director of the Division of Biological Sciences and chairman of the De-
partment of Cell Biology at the Albert Einstein College of Medicine, first came to
the Laboratory in 1963 to attend the Symposium on Synthesis and Structure of
Macromolecules. He was an active member of the Banbury committee.
Our new members are an excellent group of scientific and business leaders.
Joan Steitz is a Howard Hughes Medical Institute Investigator and the Henry Ford
II Professor of Molecular Biophysics at Yale. She is a leading researcher in the
field of RNA processing. J. Anthony Movshon is an American-born, British-trained
neuroscientist. Director of New York University's Center for Neural Science and a
Howard Hughes Medical Investigator, Tony studies the visual system. We look
forward especially to his input on our neuroscience program. Don Wiley, also a
Howard Hughes Medical Investigator, became chairman of Harvard's Depart-
ment of Biochemistry and Molecular Biology in 1992 and is a member of the Na-
tional Academy of Sciences.
Edwin Marks studied at Princeton and the U.S. Military Academy, where he
received a B.S. in engineering. Since 1961, he has been president of the New
York investment firm Carl Marks & Co., founded by his father. He is also a mem-
ber of a number of cultural, educational, and charitable organizations, including
the Lincoln Center for the Performing Arts and the Chief Executives Forum. John
J. Phelan, Jr. is a retired chairman and Chief Executive Officer of the New York
Stock Exchange. A magna cum laude graduate of Ade 1phi University, he holds
honorary doctor of laws degrees from seven universities. He is a member of the
Council on Foreign Relations, president of the International Federation of Stock
Exchanges, and a member of numerous corporate, charitable, and philanthropic
boards. Thomas A. Saunders III is a graduate of the Virginia Military Institute and
the University of Virginia's Colgate Darden Graduate School of Business Adminis-
tration. A 22-year veteran of the New York firm of Morgan Stanley, Saunders is
now a general partner of Saunders, Garonzik & Karp. He and his wife Jordan live
in Locust Valley.
This large turnover in our board of trustees has led to a new group of officers.
The new chairman of the board is David Luke, who so ably chaired the Second
Century Campaign. His vice chairman is Mary Lindsay, a long-time and
enthusiastic Laboratory supporter. John Reese has taken over the job of
treasurer. Wendy Hatch is now serving as secretary of the board, with Townsend
Knight serving as assistant secretary.
Second Century Campaign Concludes
Mounted in preparation for the Laboratory's 100th birthday in 1990, the Second
Century Campaign drew to a close at the end of 1992. Under the steady hand of
chairman David Luke, the Campaign met and surpassed what initially was
thought to be an optimistic goal. Originally set at $40 million, the goal of the
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Second Century Campaign volunteers David Luke, Wendy Vander Poel Hatch,
Townsend J. Knight, and George W. Cutting
Campaign was raised to $44 million. By the end of this year, $51 million had been
raised to support Laboratory programs. We are grateful to David Luke and the
large cadre of volunteers who made this campaign so successful.
Robertson Research Fund
The Robertson Research Fund, established in 1973, is a mainstay of the
Laboratory's endowment. It supports plant genetics and other research, contrib-
utes to meetings, courses, and travel and relocation expenses for Laboratory
scientists, and provides backup support for underfunded research projects and
meetings. The Fund supports the Outstanding Junior Fellow Award, which this
year went to David Barford, a crystallographer who studies a class of enzymes
called protein phosphatases. The Fund also supported several postdoctoral fel-
lows and staff scientists.
Major Gifts
Without the support of generous individuals and corporations, the Laboratory
could not continue to carry out basic research. In 1992, we received substantial
gifts of many types that will support scientists, help provide researchers with
modern facilities, and contribute to DNA education of children and teachers. Our
infrastructure fund received pledges totaling $650,000-a crucial form of support
that is not always easy to find. We received major new gifts for infrastructure from
the Baxter Foundation, Marion Merrell Dow Inc., and Pfizer Inc. The Westvaco
Corporation this year doubled their gift from 1991.
The cancer fund supports all aspects of cancer biology research at the
Laboratory, still the backbone of Cold Spring Harbor research. Our cancer fund
received pledges totaling nearly $2.0 million in 1992. Major gifts received from
Eleanore and William Everdell, Robert Gardner, the estate of Charles Leach II,
George and Mary Lindsay, Thomas and Jordan Saunders, the Pritchard Trust,
the Farish Fund, J.P. Morgan & Co., the Marks Family Foundation, the Bodman
Foundation, the Ache lis Foundation, and the Hyde and Watson Foundation will
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help ensure progress in our basic understanding of cancer. Our education fund
received major support at a crucial time from Cablevision and the Harris Trust,
totaling $300,000. This fund supports the DNA Learning Center, which is growing
rapidly and in 1993 will expand to include a new theater and more laboratory and
exhibit space.
We received four major contributions to our endowment, which is now
stronger than ever. The W.M. Keck Foundation pledged $1.5 million to found the
Keck Chair in Structural Biology. $1.5 million was received from the estate of the
late Maxine Harrison to establish a chair in memory of her mother Al le Davis Har-
rison for the study of molecular neuroscience. The Fort Hill Foundation, estab-
lished by the family of William J. Matheson, successor to Eugene Blackford as
president of the Biological Laboratory in 1904, pledged $500,000 to found the
William Matheson Chair. The Banbury Fund, administered by the Robertson fam-
ily, added to the endowment that supports the Robertson Chair for Neuroscience.
As a contribution to Planned Giving, the four daughters of Sara D. Redmond
donated a house previously owned by the family in Oyster Bay.
Finally, the Annual Fund reached an all-time high total of $560,334 in 1992.
The Annual Fund comprises gifts intended to be used in the year they are given
and goes to support many aspects of the Laboratory, including startup money for
young investigators, support for postdoctoral fellows, renovations, and equip-
ment.
Blackford Hall Remodeling Finished
In 1992, renovations to Blackford Hall were completed. Bill Grover and Jim Chil
dress of Centerbrook Architects, with Jack Richards' able staff, have executed an
architectural version of the proverbial 50 clowns in a circus car. They managed to
double Blackford's dining capacity, enlarge the bar, expand the deck, add a
J.D. Watson, Dr. Franziska Racker, and Ann Racker Costello
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Racker Reading Room in renovated Blackford Hall
game room, modernize the kitchen, and provide a formal dining room, while only
minimally changing the outward appearance of the building. The aspect from
Bungtown Road is scarcely changed, and the harbor side of the building seems
merely to have the area under the deck enclosed. Updating the 1907 building
enables us to accommodate the ever-swelling number of meetings attendees.
Blackford can now serve 400 people at one sitting, which, not coincidentally, is
about how many attended our larger meetings last year.
Although much modernized, the building retains its historical feel; old-timers
returning to Blackford will still recognize it, inside and out. Thanks for this go not
only to Centerbrook, but also to Liz Watson and Laura Hyman, who arranged the
decor, particularly of the Racker Reading Room (formerly the fireplace room).
Four oversized "mission" style chairs-two originals bought from A&S in 1906 and
two replicas-preside over the room, and portraits of scientists who worked and
lived here in the 1940s, 1950s, and 1960s hang on the walls. The portraits were
drawn or painted by Ef Racker, a scientist and "artist-in-residence" here in the
late 1940s and early 1950s, and were generously donated by Franzie Racker.
Other Rackers grace the two upstairs dining rooms, which were named the Mayr
Dining Room, for Ernst Mayr, and the Hotchkiss Dining Room, for Rollin
Hotchkiss. The new downstairs dining room, which is the only room in Blackford
that is air-conditioned, was recently named the Clarkson Dining Room, for Dr.
Bayard Clarkson, our just-retired chairman of the board of trustees.
McClintock Renovation Continues Apace
Renovation of McClintock laboratory will be completed in 1993. The most
dramatic change to the 1914 structure will be the third story being added to the
top. With lots of glass and a copper roof, the addition should blend with the
original feel of the building while providing much-needed space for offices and
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conference rooms. Below, the exterior is intact, but the former "animal house" will
receive an all-new circulatory system and digestive tract, bringing it up to mod-
ern standards for a molecular biology laboratory. Once completed, David Beach
will set up shop on the second floor and continue his investigations into the
genes and proteins of the cell cycle. Dick McCombie will move to the first floor
and set up a gene-sequencing laboratory there. Working in collaboration with
Beach and Tom Marr, McCombie is mounting a "pombe genome project," which
seeks to sequence the entire genome of the model yeast Schizosaccharomyces
pombe.
DNA Learning Center
The DNA Learning Center greatly extended its reach this year in its continuing ef-
fort to bring DNA education to the public. A major step was the hiring of Robert
Willis as special programs manager. Bob is responsible for teaching in the
Bio2000 Laboratory, ordering supplies and other aspects of keeping the teaching
program up and running. One of his goals is to recruit disadvantaged minority
students from the New York City area to come to the Learning Center to partici-
pate in laboratory workshops. Bob is also involved with the Fun With DNA sum-
mer workshops. Three of these workshops this coming summer will be targeted
especially at minority students.
Late in the year, the Learning Center staff began dismantling the Smithsonian
Institution "Search for Life" exhibit that had been up since the Learning Center
opened in 1987, in order to make space for a new 100-seat auditorium. The DNA
Learning Center will provide the venue for Cablevision's forthcoming multimedia
presentation on Long Island, which in turn will feature a segment on Cold Spring
Harbor Laboratory. In addition to using the auditorium for its own presentations,
the Learning Center will make the new hall available to other small museums
the area.
The Learning Center's ground-breaking teaching programs reached new
corners of the globe this year, with collaborations with new science museums in
Sardinia, Italy, and Svalof, Sweden. In these collaborations, the Learning Center
staff helped set up new DNA exhibits and had an opportunity to field test experi-
mental interactive computer exhibits. These include "DNA Detective," which takes
students through the process of DNA fingerprinting and gives them a chance to
solve a crime using DNA evidence.
Carol Greider Honored for Research on Aging
Senior staff investigator Carol Greider was named the first recipient of the Allied
Signal Outstanding Project Award for Biomedical Research. Carol's research
proposal was selected from a pool of more than 50 applicants in the field of re-
search on aging. The award consists of a check for $200,000, which goes to the
Laboratory in support of Carol's research. Allied Signal is an advanced technol-
ogy company with businesses in aerospace, automotive products, and
engineered materials. The research, carried out jointly by Carol and her col-
league Calvin Harley, focuses on telomeres, the ends of chromosomes. Carol
previously showed that telomeres shorten with age. An enzyme called telomerase
is responsible for the shortening; each time a cell divides, telomerase snips off a
portion of the telomere region. Although it is not yet known whether aging causes
telomere shortening or vice versa, shrinking telomeres may serve as a molecular
clock, indicating the age of the cell.
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Carol Greider
Jacek Skowronski
Jacek Skowronski Wins Johnson
& Johnson Award
Staff investigator Jacek Skowronski
was awarded a 3-year, $270,000 grant from
Johnson & Johnson. The award supports
Jacek 's work on the AIDS virus and w
asaccompanied by a luncheon and presentation in
his honor. Jacek works on the
gene nef, an AIDS virus gene that seems
to play a role in disrupting the immune
system of the host animal. To study
this gene, he inserts it into the immune cellsi
of mice, making a lineage of transgenic
animals that have this single AIDS virus
gene only in the cells where the gene acts.
CSHL Press
The Cold Spring Harbor Laboratory Press continued
to grow this year, publishing
15 new books in 1992. A showpiece of the 1992 catalog is The Dynamic
Genome, a Festschrift honoring Barbara McClintock's 90th birthday in June.
Edited by Nina Fedoroff and David Botstein, this collection of essays includes
hard science, history, reminiscence, and anecdote, putting Barbara's life and
ideas in context with the development of modern genetics. The Press also
reissued the 1966 classic Festschrift for Max DelbrOck, Phage and the Origins of
Molecular Biology, edited by John Cairns, James Watson, and Gunther Stent.
The new edition is expanded to include Stent's obituary of Delbruck, two com-
mentaries, reprinted from Scientific American and Science, on issues raised in
the book, and a new preface by John Cairns. Other new titles this year include
The Cell Cycle, the proceedings of Symposium 56; A Short Course in Bacterial
Genetics, an instantly successful laboratory manual; DNA on Trial, now becoming
popular among lawyers who need to grasp the significance of genetic evidence
for the courtroom; and Transcriptional Regulation, a major monograph in the Cold
Spring Harbor tradition, edited by Keith Yamamoto and Steve McKnight.
One of the bread-and-butter titles for the Press, the second edition of
Molecular Cloning: A Laboratory Manual, sold briskly in 1992, with sales surpass-
ing even those of the first edition. Antibodies: A Laboratory Manual, written by for-
mer Cold Spring Harbor scientist Ed Harlow, also sold extremely well this year.
The Press's journals are also doing well. Genes & Development increased its cir-
culation and was named for the third year in a row the journal with the highest im-
pact factor in the fields of genetics and developmental biology by the Institute for
Scientific Information. Manuscript submissions also increased, making it likely the
journal will publish more issues in 1993. PCR Methods and Applications com-
pleted its rookie year and began its second volume in the black-no mean feat,
given today's economic climate in publishing. Increases in advertising sales and
manuscript submissions, as well as sponsorship from Perkin-Elmer, will enable
the journal to go from four to six issues per year in 1993.
The coming year promises to bring further growth for the Press. Twenty-five
new titles are planned, including lab manuals on techniques for fission yeast,
plant molecular biology, protein chemistry, and the biology of nerve cells. Several
monographs are also planned, including works on RNA, reverse transcriptase,
and a definitive reference on Drosophila development.
Special Events
The Laboratory calendar featured a number of unusual lectures and cultural
_Ad events. Pianist Mikhail Yanovitsky performed a program of Bach, Beethoven, and
Mikhail Yanovitsky Schubert. Michael Novacek, vice president and Dean of Science at the American
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Drs. Mark Lippman (left) and Mary-Claire King (right) at Cold Spring Harbor
Laboratory seminar on breast cancer
Museum of Natural History, presented an interesting talk on paleontology in
Mongolia, complete with slides of new species of fossil dinosaurs and of fossil
dinosaur eggs. Breast cancer specialists Mary-Claire King and Mark Lippman
returned to give an update on the search for a breast cancer gene. The two
scientists also helped allay fears about the infamously high rate of incidence of
breast cancer on Long Island. Rounding out the schedule was Ron Davis' Lloyd
Harbor Seminar on learning and memory research. The Lloyd Harbor series, held
at the Banbury Center, is organized by George Toumanoff for the benefit of Ban-
bury neighbors.
Undergraduate Research Program
Each summer since 1959, approximately 20 undergraduates from around the
country and overseas have come to the Laboratory to carry out research projects
with our scientists. This year, 23 students participated in the 10-week program,
coming from Berkeley, Harvard, Tuskegee, Cambridge, and Glasgow Univer-
sities, among others. The students learned new techniques and carried out re-
search projects, working on such topics as learning and memory in Drosophila,
the maize P gene, the ras oncogene, protein structure, and pattern recognition in
DNA sequences. Each student has a sponsor, with support coming from Baring
Brothers & Co., Ltd., the Burroughs Wellcome Fund, Theodore N. Danforth,
Hanson Industries, the National Science Foundation, the Robert P. Olney Fund,
and the Phillips Petroleum Foundation, Inc.
Partners for the Future
In 1990, the Laboratory extended the idea of the Undergraduate Research Pro-
gram to high school students through the Partners for the Future program. It has
proved successful in attracting some of Long Island's best and brightest high
school seniors into the laboratory to give them a taste of cutting-edge molecular
biology research. Sponsored by area businesses, students receive a stipend as
well as hands-on experience unattainable in a classroom. Five students were
selected from 150 Long Island schools to spend 10 hours per week after school,
from October to March, under the tutelage of a Cold Spring Harbor mentor. This
year's Partners, with their school and mentor, were Tara Adamovich, Garden City
High School (Dr. Robert Franza); Jason Altman, Herricks High School (Dr.
Elizabeth Moran); Rafaz Hogue, Commack High School (Drs. Tim Tully and
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Richard Roberts
Michael Regulski); Munfarah Hossain, Walt Whitman
High School (Dr. Yi Zhong);
and Jayson Mystkowski, Kings Park High
School (Dr. Venkatesan Sundaresan).
Long-term Service
In 1992, three employees completed 20 years
of service to the Laboratory. Senior
Staff Scientist Richard Roberts, who obtained his
Ph.D. in organic chemistry at
Sheffield, England, came here after postdoctoral
research at Harvard University
to lead our efforts in nucleic acid chemistry. Susan
Cooper came to the
Laboratory from the University of California library
system at Irvine to head our li-
brary. Today, she ably directs both the Library
and the Public Affairs Office. Terri
Grodzicker, whose Ph.D. was from Columbia University, came to James
Laboratory to work on tumor viruses after postdoctoral research at Harvard Medi-
cal School. Now she is Assistant Director for Academic Affairs for the Laboratory
as well as editor of our journal Genes and Development.
Changes in Scientific Staff
Senior Staff Scientist and Assistant Director for Research Richard Roberts ended
a distinguished tenure of research and administration at Cold Spring Harbor this
year. Although temporarily still on the rolls quarter-time, Roberts has moved on to
New England Bio-Labs, in Beverly, Massachusetts, near Boston, to become
director of research. His important scientific contributions here have included
leading the world in the discovery of important new restriction enzymes and or-
chestrating the Cold Spring Harbor role in the seminal discovery of RNA splicing.
Rich also played a major role in the day to day life of the Laboratory, in particular
through his role as Assistant Director of Research that commenced in 1986. In
bringing computers to Cold Spring Harbor, in attracting the Core Facility, and in
advising younger colleagues on their grant proposals, Rich was an important part
of the growth and success of the Laboratory from 1972 to 1992, and we shall al-
ways remain indebted to him for his devotion to our purposes.
Staff investigator Eric Richards has moved on to Washington University's De-
partment of Biology, in St. Louis, where he landed an assistant professorship. He
will be continuing his work on chromosome structure. Three staff associates have
also left the Laboratory. Tamar Michaeli, from Mike Wigler's lab, is now an as-
sistant professor at the Albert Einstein College of Medicine, in the Bronx. Will
Phares, from Winship Herr's lab, has moved to Vienna, to the Sandoz Research
Institute, where he is a laboratory leader. Jim Lees-Miller has left David Helfman's
lab to take a position in Calgary, Alberta.
New Staff Members
The Laboratory boosted its programs in neuroscience and genome research this
year with the hiring of three new staff scientists. Senior staff investigator Richard
McCombie comes to us from the National Institutes of Health in Bethesda,
Maryland. He is establishing a "pombe genome project" here in collaboration with
David Beach and Tom Marr. He will be working on the first floor of the remodeled
McClintock laboratory when renovations are completed. Senior staff investigator
Alcino Silva arrived from the Massachusetts Institute of Technology this fall. His
exciting work with genetic "knockout" mice promises new insights into mam-
malian learning and memory. Staff investigator Yi Zhong, coming to us from the
University of Iowa, further strengthens our research efforts in Drosophila learning
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and memory. Four visiting scientists joined us this year. Nicholas Muzyczka, of
Stony Brook Medical School's Department of Microbiology, is spending a sab-
batical in Bruce Stillman's laboratory. Robert W. West, Jr., from the SUNY Health
Science Center in Syracuse, is working with Ron Davis. Frederick Schachat, of
Duke Medical School, is working in David Helfman's lab. and Roussoudan
Bourtchouladze has joined Alcino Silva's lab from the Anokhin Institute of Normal
Physiologie, in Moscow.
Staff Promotions
With the approval of our Board of Trustees, David Spector was promoted to
Senior Staff Scientist in the fall of 1992. David came to us from Baylor in 1985. His
research focuses on RNA splicing and nuclear structure. David also runs the
Laboratory's electron microscope facility in Cairns lab. Hong Ma was promoted
to Senior Staff Investigator. He continues his research on the molecular biology of
the model plant Arabidopsis. Several scientists became Staff Investigators, in-
cluding Masafumi Tanaka, Roymarie Ballester, Nikolai Lisitsyn, and Gilbert
Morris; Ann Sutton, from Kim Arndt's lab, and Mark Pittenger, from David
Helfman's lab, became Staff Associates. Carmelita Bautista was promoted to Re-
search Associate.
Postdoctoral Fellows
A number of Cold Spring Harbor postdoctoral fellows have moved on to other
positions and locales. Gary Otto, from Rich Robert's lab, is now a research asso-
ciate at the Courant Institute of Mathematical Science at New York University.
Saulius Kulakauskas, also from Roberts' lab, is now at the INRA in France. Anoth-
er Roberts, postdoc, Denise Roberts, is now a project leader at Oncogene
Science, in Uniondale, New York. Maria Jose-Frenandez Sarabia, a postdoc with
Kim Arndt, has moved to Onyx Pharmaceuticals in Richmond, California. Sushma
Abraham-Ogram, a postdoc with Betty Moran, is now at Washington State Uni-
versity, in Pullman. Yasuji Rikitake, also from Betty Moran's lab, is now at Medical
Environment Co., in Tokyo. Steven Brill, from Bruce Stillman's lab, has taken a job
as assistant professor at Rutgers. Also from Stillman's lab, Glenn Bauer has
moved to St. Michael's College, in Colchester, Vermont, as assistant professor.
Anindya Dutta, also from Bruce Stillman's lab, is now an instructor at Brigham
and Women's Hospital, Harvard Medical School. Chiu K. Cheung, from John
Anderson's lab, has gone back to school full-time at Touro Law Center. Chitra
Kannabiran, a postdoc with Mike Mathews, is now at Rutgers. Mark Kessler, also
from Mathews' lab, is now a senior scientist at Biotechnology General in Nes
Ziona, Israel. Kwang-Ai Won has left Mike Gilman's lab for the Scripps Research
Institute in La Jolla, California. Toru Mizukami, a postdoc with David Beach, is
now at the Kyowa Hakko Tokyo Research Laboratories.
Two graduate students working at the Laboratory have moved on to postdoc-
toral fellowships. Lisa Molz, from David Beach's lab, is now at the Cardiovascular
Research Institute at the University of California at San Francisco. Laura
Berkowitz, from Mike Gilman's lab, is now at Indiana University's Department of
Biology in Bloomingdale. Two other graduate students are pursuing medical de-
grees. Fred Bunz, from Bruce Stillman's lab, is now at the University at Stony
Brook's medical school, and Yuhong Qiu, from Ron Davis' lab, is at the Anderson
Cancer Center at the University of Texas, Houston.
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David Spector
J.D. Watson and Bruce Stillman
Appointment of Bruce Stillman as Director to Commence January 1, 1994
This year marks my 25th year as the director, having formally assumed the posi-
tion in February of 1968 while remaining a professor at Harvard. Then I was not
quite 40 years old and still a very active participant in science, running with
of theGilbert a major laboratory at Harvard and on a first name basis wit most
active players in the world who worked with DNA. After Charles S. Robertson's
1973 gift of the Robertson Research Fund, the Laboratory had the means to bring
me on as a full-time director. So in the fall of 1974, my family and I moved into the
director's house, which had just been totally renovated, using plans prepared by
the noted architect, Charles Moore. Long-called "Airslie", this 1806 wooden dwell-
ing, located above the sand spit at the end of Bungtown Road, has been a per-
fect home for me and my family, and we have been very privileged to live among
the beauty of its great lawns and trees that date from its period as part of the
once grand Henry DeForest Estate. Now we will soon leave Airslie, for the time
has come for me to step down as director. At 65, I know that I am no longer the
active participant in science that the Laboratory needs to oversee its research
and recruit the talented young brains that will keep us at the forefront of science.
But if I were to stay on as director much longer, I might all too soon lose this
clarity of vision.
Happily in Bruce Stillman, who first came to work at Cold Spring Harbor in
1979, we have the perfect future director. This change will formally occur on Jan-
uary 1, 1994, although Bruce has effectively acted in his new role since our Feb-
ruary 27, 1993 Board meeting when he was formally selected by the Board of
Trustees as the new director.
Bruce, Australian by birth, was born in 1953 and educated at the University of
Sydney and the Australian National University where he took his Ph.D. in 1979.
From there, he came directly here as a postdoctoral fellow for two years, at the
conclusion of which he joined our staff in 1981. Rapidly rising through our ranks,
his appointment as a Senior Staff Scientist occurred in 1985. Beginning already
as a Ph.D. student, his research has been on DNA replication, initially focusing
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on adenovirus DNA. Now regarded as one of the world's leading scientists inter-
ested in DNA replication, Bruce most appropriately was elected to be a Fellow of
the Royal Society in March of this year.
Bruce's high intelligence combined with his common sense approach to life
and the ease with which he works effectively on behalf of others here led to his
appointment as Assistant Director in 1990. In that capacity, he has shown great
leadership capabilities, and everyone here looks forward to assisting him in his
new role.
Creation of the Position of President
Happily for me, our Board of Trustees at the same time created the new position
of President that will continue to allow me to retain a major role at the Laboratory.
As President, I will report to the Board of Trustees, and in addition to overseeing
the Laboratory's ever-continuing quest for funds, I will have reporting to me the
directors of the DNA Learning Center, the Cold Spring Harbor Laboratory Press,
and the Banbury Center, with Bruce taking on the additional responsibility for our
advanced courses and the meetings held in Grace Auditorium. To let us remain
on the Laboratory grounds, the Trustees have authorized the construction of a
new President's House that will be built on the site where the Henry De Forest
house stood until 1943. Centerbrook of Essex, Connecticut, the distinguished ar-
chitectural firm that the Laboratory has used for all its major building projects
since 1973, has provided plans for a beautiful house into which my wife and I will
move in the summer of 1994.
I have every reason still to look forward to the future.
August 4, 1993 James D. Watson
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ADMINISTRATION
1992 was a year of extraordinary science at the Laboratory, marked also by con-
cern that there may not be adequate funding from traditional sources for the un-
precedented opportunities ahead. Federal support of biomedical research is in
danger of being overwhelmed by the national deficit. For the first time in recent
years, the President's budget request for the National Institutes of Health did not
match the projected rate of inflation and represented an actual decline for many
of the individual institutes. Moreover, the Administration seems determined to
shift the emphasis from basic toward more applied research.
During the past decade, the present system of peer-reviewed Federal fund-
ing, augmented by support from foundations, corporations, and individuals, has
played an important role in making American biomedical science the best in the
world. Most likely there will now be increased reliance on industrial support at in-
stitutions such as ourselves. This will involve important issues concerning in-
tellectual property, conflict-of-interest for scientists and institutions, and just what
is an approximate balance between applied and basic research.
Despite such worries, the Laboratory's financial results were very good in
1992. Revenues reached a new high of more than $36 million. For the fourth con-
secutive year, there was a surplus from operations after adding to reserves for fu-
ture contingencies and fully providing for depreciation, which in 1992 totaled
nearly $2.4 million. The year ended with the Laboratory in strong financial condi-
tion.
The past 5 years have been a period of very rapid growth. The number of
Ph.D.s here has about doubled, and the academic program now extends from
early spring until late fall, with already a few incursions into the winter months.
Laboratory scientists have excelled in the competition for Federal and private
grant support and so the good financial results are not surprising. Close attention
has been directed to controlling operating costs and carefully limiting the growth
of support personnel. As a result, the Laboratory has generated a positive cash
flow from operations of nearly $10 million before reserves and depreciation over
the period. This has been invested in new and improved facilities and programs.
At year-end, the Laboratory's endowment, consisting of the Robertson and
Cold Spring Harbor Funds, stood at nearly $65 million, a gain of some $8 million
from the previous year. As in the past, the funds have enjoyed excellent invest-
ment management by Miller Anderson and Sherrerd and last year also benefited
from the addition of over $4 million of new donations to the Cold Spring Harbor
Fund. The new money included two new fully endowed chairs of $1.5 million
each, which were donated by the W.M. Keck Foundation for the study of struc-
tural biology and by the late Maxine Harrison in memory of her mother Al le Davis
Harrison for the study of molecular neuroscience. A major factor in the remark-
able growth of the endowment has been a conservative drawdown policy, which
over the life of the funds has averaged a bit less than 3.5% of income each year.
This policy has balanced strong support for science with protecting the funds
against inflation and allowing for the support of new programs.
The Laboratory's endowment has been used primarily to fund young
scientists who so often produce the most innovative new ideas but have difficulty
obtaining early grant support. So it is important that the endowment continue to
grow in future years. We cannot realistically expect the recent high rates of in-
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vestment return to continue and so adding new funds
from new sources must be
a high priority.
An important new source of funds is emerging from the Laboratory's technol-
ogy transfer activities. Federal granting agencies recognize
the desirability of
technology transfer to the commercial sector for
the general public good and
therefore encourage grantee institutions to license
research results in keeping
with the institutions' own policies. As a result, the
Laboratory has become more
active in commercializing its technology and has
received both cash payments
and stock ownership in growing amounts as a result
of these efforts. The cash
and whatever proceeds may be derived from the
eventual sale of stock can pro-
vide important future support for research. The Laboratory's
Board of Trustees
has therefore established the "Science Fund" in which to accumulate the pro-
ceeds received from such activities. The Science Fund will be an integral part of
the endowment intended to be used solely for the long-term support of the direct
and indirect costs of the science program.
December 31 of last year marked the formal conclusion of the Second
Century Campaign, the Laboratory's enormously successful first ever capital
campaign. The total raised of nearly $51 million for facilities, endowment, and
programs stands as a remarkable tribute to all involved and as a challenge to
those who will be asked to help in future years.
The growing activities of the Cold Spring Harbor Laboratory Press, Banbury
Center, and the DNA Learning Center play an important role in the overall suc-
cess of the Laboratory. They are led impressively by John Inglis, Jan Witkowski,
and Dave Mick los, respectively. Each operates as an individual profit center.
Last year, after a difficult 1991, the CSHL Press made a positive financial con-
tribution to the Laboratory in addition to its always positive intellectual contribu-
tion. Total revenues exceeded $3.7 million, ahead 20% from 1991. Fifteen new
book titles were published, including The Dynamic Genome, a remarkable tribute
to the late Barbara McClintock, and Jeffrey Miller's eagerly awaited A Short
Course in Bacterial Genetics.
Revenues of the Journal Department exceeded $1 million for the first time.
Genes & Development, now in its 5th volume, again earned "most cited" status in
its field. It passed the 2600 mark in subscriptions and maintained good
profitability. In only its second year, PCR Methods and Applications already has
over 2000 subscriptions and has been profitable since inception. The success of
the journal program is also spawning new journal concepts, one of which, a new
journal dealing with the subjects of learning and memory, is already well ad-
vanced.
Banbury Center marked its 15th anniversary last year and continues to gain in
the esteem of scientists and other professionals in academia, biotechnology, and
policy making throughout the world. Sixteen meetings and workshops were held
in 1992, covering such diverse subjects as the commercialization of biology, in-
direct costs, new techniques in molecular biology, human genetics, science
policy and funding for the decade of the brain. Of particular significance was a
year-end major grant from the Charles A. Dana Foundation for a program to pro-
mote research on manic-depressive disease encompassing work here and at
Johns Hopkins Medical School and Stanford University Medical School.
The DNA Learning Center (DNALC) had another very productive year, ex-
tending its hands-on laboratory workshops on DNA science to increasing num-
bers of minority and disadvantaged youths. A very successful new program
taught genetics to 5th graders at a series of Fun With DNA summer camp ses-
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sions. The DNALC mobile laboratory vans continued to tour the nation, conduct-
ing DNA science workshops for students and teachers.
At year-end, the Laboratory exercised its option to purchase the previously
leased DNALC building in Cold Spring Harbor Village from the Cold Spring Har-
bor School District, and the Learning Center embarked on a two-phase expan-
sion program. Phase I involves a major renovation of the building. It includes the
construction of a new 104-seat auditorium with state-of-the-art multimedia
audiovisual capability and the installation of a computer teaching laboratory.
Phase II will begin a year from now and will include a second DNA science
laboratory, a library, and lunchroom facilities.
Of major importance over the past 2 years has been the formation of a Corpo-
rate Advisory Committee, now chaired by Doug Fox of Newsday. The Committee
is composed of representatives of key Long Island companies who are assisting
the DNALC in planning a variety of public and professional education programs
designed to build support for biotechnology on Long Island and to benefit the
economy here. The Committee also seeks to raise badly needed unrestricted
funds for the Learning Center from Long Island businesses.
The accomplishments of the past year would not have been possible without
the outstanding support of the Laboratory's administrative departments, often op-
erating under difficult financial constraints. Jack Richards and the Buildings and
Grounds staff have once again managed a major project, the McClintock
Laboratory renovation and expansion, within the budget and on schedule. Art
Brings and the Environmental Safety staff have dealt successfully with the
seemingly intractable problems of low-level radioactive and medical waste dis-
posal with an innovative program that has sharply reduced the quantity of the
materials generated without affecting laboratory efficiency and has saved sub-
stantial money. Susan Cooper and her Public Affairs staff have managed an al-
most endless series of events consistently reflecting distinction on the
Laboratory. John Maroney, Bill Keen, Susan Schultz, Sande Chmelev, Cheryl Sin-
clair, and Barbara Ward also lead their departments with great skill and energy.
Roberta Salant assists me immeasurably and tends carefully to the needs of the
Board of Trustees.
Now as the calendar turns again we look forward to another of those
watershed events that mark the Laboratory's more than 100 years. The Board of
Trustees at its February 1993 meeting created the new position of President
which Jim Watson will assume as of January 1, 1994. Bruce Stillman, now
Assistant Director, will become the Laboratory's new Director at that time.
Already Jim and Bruce have been functioning in this way for some time, and it is
clear that the leadership of the Laboratory will continue with the vision and
strength to which we have all become accustomed.
G. Morgan Browne
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BUILDINGS AND GROUNDS
Growth and refinement marked the year of 1992 for the Buildings and Grounds
Department as we strove to add more space to our buildings and to refine the
facilities of Cold Spring Harbor Laboratory. As 1992 began, the Blackford Hall
addition was coming to completion while the McClintock Laboratory renovation
stepped up to top speed. Throughout the year, many other projects were started
and completed, increasing the Laboratory's usable area and improving its infra-
structures.
Blackford Hall
Blackford Hall had already seen 12 months of construction as 1992 began and
the deadline for the spring meetings was fast approaching. Renovation of the hot
kitchen, the final phase, began in January. This work included the installation of
new appliances in their new location, completion of new cold storage rooms,
removal of the old hot kitchen, and installation of the new cold kitchen and serv-
ing lines. At the same time, finish work was being completed in all other areas of
Blackford Hall; all surfaces received a final coat of paint, carpet was put down,
new furniture was put in place, and the area surrounding the building was
landscaped. Because the project posed significant challenges, it was decided to
use as much laboratory labor as possible to facilitate timing and coordination. For
example, during the entire renovation, the construction crews did their best to
work in areas that would be least disruptive to the food service staff while they
continued to prepare and serve many meals. Our electricians, plumbers, car-
penters, painters, and HVAC (Heating, Ventilating, and Air Conditioning) staff all
worked extremely hard to meet the construction deadline and produce a top
quality building. To the delight of all, the work at Blackford Hall was completed
and the spring meetings season of 1992 had a new and expanded dining hall.
McClintock Laboratory
1992 found the McClintock Laboratory building very empty and in the initial
stages of demolition. To provide a first-hand look at the physical construction of
this very old building, some of the walls and ceilings were removed so that the ar-
chitects and engineers could proceed with their design work. Once all the design
problems were solved, demolition proceeded rapidly and the entire building was
gutted. Slowly, some of the walls were put in, and the elevator pit and shaft were
installed. Once again, Blackford lawn was dug up so that a the new water line
could be run to McClintock. As the year came to a close, McClintock Laboratory
had a new third floor, and much of the mechanical equipment and new windows
had been installed. The building is well on its way to being completed in the
spring of 1993.
Alterations and Renovations
Jones Laboratory: Jones had always been used as a summer course laboratory,
with limited winter use. However, because of increased space requirements forboth laboratories and courses, Jones Laboratory was converted into a full-
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fledged lab by the Buildings and Grounds staff in only 4 months. Included in this
project was the relocation of the cold room, complete overhaul of the HVAC sys-
tems, installation of vacuum and compressed air, the addition of a glassware
kitchen, installation of office space, complete repainting, and extensive work on
the electrical systems.
Bassett House: Located on the Uplands Farms facility, Bassett House was trans-
formed from a dorm type of residence to a single-family dwelling for one of our
scientists. The entire interior was repainted, and all of the floors were refinished
or carpeted.
Doubleday House: Renovation of this house on Moore's Hill Road included con-
struction of a new deck to replace the old one. In addition, the exterior of the
house was painted and the surrounding areas were relandscaped. Doubleday
House will also provide quality living space for Laboratory staff.
Energy Projects
Two Buildings and Grounds projects that have had significant impact on our
facilities are the replacement of the James emergency generator and the ongo-
ing installation of Building Energy Management. It was decided in the spring of
1992 that the James generator had come to the end of its usefulness. The unit
needed extensive repairs and the building was demanding more power than the
generator could produce. A larger unit was thus purchased and installed in a
new location. All of the trades contributed to the installation of the new unit, in-
cluding the electrical crews who spent long hard hours rewiring the emergency
circuits. All of our crews are to be congratulated for a fine job.
The HVAC Department has undertaken a long-term modernization project that
is starting to show favorable impact on the management of our energy consump-
tion. During the year, the old controls on many of the mechanical systems were
replaced with computer-driven controls. This replacement included complete
rewiring of the HVAC systems, installation of new controls, and programming for
maximum efficiency. These technological enhancements have made it easier to
monitor and correct problems before they become major difficulties. As the year
closed, the HVAC crew completed work on Grace Auditorium, Bush Lecture Hall,
Blackford Hall, Jones Laboratory, Beckman, and much of Demerec Laboratory.
Many years of work will be required to complete this project, but the benefits of
lower energy costs and less mechanical wear are already very significant.
Core Facilities
Some of the core facilities under the Buildings and Grounds Department will see
some changes in 1993. We started in 1992 with the purchase of a golf cart for the
Equipment Repair Department to help with the many trips up and down to the
Beckman Building. Bob Borruso of this department retired after 18 years of ser-
vice to the Laboratory. We wish him well in his retirement. We transferred George
Newell from the Grounds Department to the open position created by Bob's
retirement, and we added a new position, Equipment Maintenance Technician,
filled by Danielle Strano. With two new people to train and the increasing work
load, Cliff Sutkevich will have his hands full.
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Next on the list for an overhaul
is the Receiving Department, whose work
load has become overwhelming. We
will look for ways to improve the operation of
this department in 1993.
Thanks to All
The Buildings and Grounds Departmentha
has
wcorked very
ompleted another
hard to keep up with the
year. The
talented people in all our departments ve
Laboratory's increasing work load, and I
want to thank them all for a job well
done. Special thanks also go to the office staff; Pege,
Charlie, Leslie, and Peter.
Finally, Peter Stahl is doing a great job as our new Facilities Manager; he is a
most valuable employee and a great help to me.
Jack Richards
DEVELOPMENT
1992 and Beyond
1992 was another very successful year for development at the Laboratory. The
highly successful Second Century Campaign raised $5,139,689 in 1992 and to-
taled $51,092,883 at the end of the year (with prospects of more to come in 1993
from solicitations currently outstanding). This amount included, in part, gifts of
$2,034,418 to the Endowment Fund (which stood at $32,396,431 on December
31), $1,500,000 to the Cancer Research Fund, $650,000 to the Infrastructure
Fund, and $350,000 to the Education Fund.
The Annual Fund of the Cold Spring Harbor Laboratory Association (CSHLA)
contributed $531,263 in 1992, exceeding $500,000 for the first time. Even without
an organized effort, the laboratory received Planned Gifts totaling $567,278.
This is a very healthy growth pattern not only because of the actual amount of
the contributions received, but also because of the diversity of giving sources.
The Laboratory's continuing reputation for excellence in the field of basic re-
search in genetics attracts important support from Trustees, Directors of the
CSHLA, other individuals, foundations, and corporations; this breadth of support
from a variety of sources outside the federal government is very desirable.
As we look to 1993, the Laboratory's needs will be concentrated in four areas:
increasing the Endowment, organizing a comprehensive Planned Giving Pro-
gram, building the Annual Fund, and, on a rifle shot basis, raising funds for
specific capital projects. As our operating budget grows and Federal funding be-
comes ever more fickle, we want to strenghten our financial foundation by
making a concerted effort to increase the Endowment and develop an effective
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Planned Giving program; at the same time, and with equal enthusiasm, we want
to increase the level of Annual Giving in order to provide additional funding for
our science program. Finally, we will probably need to raise some capital funds
from time to time, but only for specific projects and at a lower level of intensity
than in the past.
The Laboratory is fortunate to have so many good friends and loyal sup-
porters. We are most appreciative of the breadth and depth of this support and
thank each of you for what you have done for the Laboratory over the years; we
hope you will continue to be firm in your support as we embark on these new
directions in development.
Second Century Campaign
As part of the Laboratory's Centennial celebration in 1990, a major fund-raising
campaign-the Second Century Campaign-was organized with a goal of raising
$44 million in support of capital construction projects and the establishment of
endowment funds to support the programs of the Laboratory. At the end of 1992,
gifts and pledges totaling $51,092,883 had been raised, exceeding the goal by
$7,092,883. In addition, we think there will be additional contributions coming in
during 1993, in response to currently outstanding solicitations.
This has certainly been a tremendously successful effort, with broad support
from individuals, foundations, corporations, and Trustees. However, it is fair to
say that the Trustees contributed more than their fair share to this effort not only
with their gifts and pledges, but also with their leadership. David L. Luke III, now
Chairman of the Board of Trustees, was Chairman of the Second Century
Campaign. He was blessed with an outstanding Steering Committee consisting
of George W. Cutting, Jr., Oliver R. Grace, Mrs. Sinclair Hatch, Townsend J.
Knight, William R. Miller, and Taggart Whipple.
During 1992, the Second Century Campaign received gifts and pledges total-
ing $5,139,689 from a broad base of donors. The Trustees again showed their
strong support for the work being done at the Laboratory, with Bill and Ellie Ever-
dell, George and Mary Lindsay, Edwin and Nancy Marks, and Tom and Jordan
Saunders making wonderfully generous gifts to the Cancer Research Fund.
The Laboratory enjoys an excellent reputation with foundations, and they con-
tinue to provide very substantial support for our activities. We received a spec-
tacular gift for our Endowment from the W.M. Keck Foundation, which enabled us
to establish a Chair in Structural Biology; the William Stamps Farish Fund made a
most generous grant to the Cancer Research Fund, as did the Bodman and
Achelis Foundations and the Hyde and Watson Foundation. Our Endowment
received another wonderful boost from the Ft. Hill Foundation which made it pos-
sible to start the William T. Matheson Chair. The Robertson family, with Bill
Robertson serving as a Trustee of the Laboratory and Anne Meier as a Director of
the Association, demonstrated their generosity again in 1992 with an additional
contribution to the Charles Robertson Chair in Neuroscience; Bob Gardner also
made an additional contribution to the Second Century Campaign, as did the
William and Maude Pritchard Charitable Trust. Early in the year, we received a
very significant bequest from the estate of Charles Henry Leach II.
Corporations again gave wonderful support to the Laboratory in 1992 with
grants received from the Baxter Foundation, Marion Merrell Dow Inc., J.P.
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Morgan and Co., Incorporated, and Pfizer Inc.
and an additional contribution
from Westvaco Corporation.
Mary Jeanne and Henry Harris are
two individuals who have done much for
Cold Spring Harbor Laboratory over
the years, with particular emphasis on the
DNA Learning Center. In 1992, they made another
generous contribution to the
Education Fund, which supports the programs
of the DNA Learning Center.
Cablevision also made a very generous
contribution to the Education Fund.
Our heartfelt thanks for all of this support
and for the very effective effort of all
the volunteers. The Laboratory is certainly the
richer for the success of the Sec-
ond Century Campaign not only because of
the additional laboratories, visitor
facilities, and increased endowment, but also
because of the deep involvement
of the Trustees, the Directors of the CSHLA,
and the broad base of wonderful
volunteers, all of whom worked so hard on this campaign.
Annual Giving
Annual Giving at Cold Spring Harbor Laboratory really consists of four parts: the
CSHL Association Annual Fund, the Corporate Sponsor Program, the Un-
dergraduate Research Program, and the DNA Learning Center Annual Fund.
These four entities contributed a total of $1,443,440 to the Laboratory in 1992, a
handsome sum in and of itself and a significant increase over 1991.
The CSHLA Annual Fund, the major source of unrestricted giving to the
Laboratory, contributed a total of $531,263 in 1992, of which $436,540 was in un-
restricted funds. This was the first time the Annual Fund exceeded the $500,000
level, an important milestone for the Laboratory and a particular tribute to the ef-
forts of the CSHLA and George Cutting, who has led the Association since 1986.
The Annual Fund, which is devoted to science, was up by almost $100,000 in
1992 compared to 1991, a tremendous vote of confidence in the work of the
Laboratory and of great importance to the continuation of the important work
done here.
The Corporate Sponsors Program, which supports the meetings program at
the Laboratory and at the Banbury Center, generated $741,000 from 38 com-
panies in 1992. This represented an increase from 1991 not only in total support,
but also in number of companies participating.
Undergraduate Research Program, a highly selective 10-week summer pro-
gram for college students interested in basic scientific research, is supported
from a wide variety of sources and raised $128,404 in 1992. Each student-the
group usually numbers about 20 and is selected from applications from around
the world-is assigned a research project by a staff scientist, who becomes that
student's mentor. This is an extraordinary opportunity for the students selected to
work with a top scientist here at the Laboratory.
The DNA Learning Center Annual Fund, an initiative begun in 1991, is
designed to create a base of unrestricted annual support for the DNA Learning
Center from the Long Island business community. This effort, which is organized
by the Corporate Advisory Board, was originally headed by Robert McMillan of
McMillan, Rather, Bennett & Rigano, P.C. and his efforts got the DNA Learning
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Center Annual Fund off to an excellent start. Douglas B. Fox, Vice President of
Marketing, Times Mirror Group, took over the chairmanship early in 1992 and
devoted considerable effort working on a mission statement to make the DNA
Learning Center more meaningful to the business community. The DNA Learning
Center Annual Fund generated $29,100 in 1992 and is positioned to grow sig-
nificantly in 1993.
Planned Giving
Planned Gifts are of great benefit to the Laboratory. This method of giving fre-
quently enables donors to make a larger gift than they had thought possible and,
at the same time, can provide them with significant economic and tax ad-
vantages. These can be benefits of increased income, elimination of capital gain
taxes, and/or current tax deductions. Planned Gifts typically go to the Endow-
ment which, as the Laboratory grows in size and scope, becomes an ever more
important part of our financial foundation. Planned Gifts can be made to take ef-
fect immediately or be deferred to take effect at a later date. Planned Gifts fall
into three basic categories:
Bequests: Perhaps the easiest and best known method of planned giving in
which donors make a provision in their will for Cold Spring Harbor Laboratory.
Life Income Plans: Perhaps the most popular planned gifts are the various life
income plans that benefit both the donor and CSHL during the donor's lifetime. In
a typical life income plan, the donor transfers cash, securities, or other
marketable assets in return for a life income for self, spouse, and/or others, with
the remainder principal passing to the Laboratory at the death of the last surviv-
ing beneficiary. The donor gains a current income tax deduction for the present
value of the projected remainder interest. If appreciated assets are used to fund
the life income plan, the donor avoids capital gains tax on the transfer.
There are three basic kinds of Life Income Plans: The CSHL Pooled Income
Fund (managed by U.S. Trust Company); a Gift Annuity or Deferred Gift Annuity;
and a Charitable Remainder Trust.
Other Planned Gifts: These include Charitable Lead Trusts, Life Insurance, and
Retained Life Estate.
If you are interested in discussing a Planned Gift to the Cold Spring Harbor
Laboratory, please call Gordon S. Hargraves in the Development Office (phone:
(516) 367-8842). We can help you get started.
Staff
The staff of the Development Department is quite small in relation to the amount
of money raised for the Laboratory, but our efforts are leveraged enormously by
the number and excellence of the volunteers who contribute their time and ex-
pertise to make things happen.
The Development Committee of the Board of Trustees helps to keep our ef-
forts and priorities focused, so that staff resources are well utilized. The Directors
of the CSHLA assist us by shouldering many burdens in helping to fulfill the mis-
sion of the Association.
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We are lucky to have such a
hard-working and effective staff in the Develop-
ment Department, and the staff, in
turn, is fortunate in having such an ex-
traordinarY cadre of volunteers with
which to work. Particular thanks go to Joan
Pesek, now Associate Director of
Annuals iving; Claire Fa
ieirs, of whom churn
an, Events Coor-
dinator; and Debra Mullen and Gisela Jeings,
out an enormous amount of good
work with a high degree of cheerfulness.
Gordon S. Hargraves
LIBRARY SERVICES
Staff Changes
Genemary Falvey, head of library services, resigned in July to relocate to An-
chorage, Alaska, where her husband, John, will be teaching at the university
there. Genemary had been with the library for more than 10 years, first as a
volunteer, then as trainee and acting librarian. After completing her MLS in
1981 at Long Island University, C.W. Post campus, Genemary became the li-
brarian. During her tenure at the Laboratory, she began the task of com-
puterizing the library's technical and reference services. Working closely with
the scientists and computer center, Genemary installed several reference
databases, including the CD-ROM which uses compact disks to impart in-
formation to users. These disks hold huge amounts of data and have excellent
graphic resolution. By using a tower that holds several CDs, information can
be accessed concurrently. Beginning February 1993, Genemary will become
science/medicine librarian for the Anchorage Municipal Libraries. She will be
headquartered in the Z.J. Loussac Central Library.
Margaret Henderson, the new head of library services, came to us from the
DNA Learning Center where she taught science classes. Prior to coming to the
Laboratory, Margaret was the reference/on-line services librarian at the Univer-
sity of Western Ontario, London, where she received her MLIS in 1986. Mrs.
Henderson will continue to bring the library's catalogs on line and to stream-
line public services.
Lynn Kasso, archives assistant, left in June and relocated to Arizona. Lynn
was largely responsible for the move from the archives room to an archives
floor in 1988. She provided accurate, secure access to this repository of
Laboratory history. Lynn cataloged the archival holdings, putting many of the
manual records into the computer.
Our new archives assistant, Clare Bunce, was promoted from the library
clerk position, where her experience in the library and public affairs made her
an excellent candidate. Replacing Clare is Kelly Kasso, a recent graduate of
SUNY College at Oswego. Kelly's education and her interest and energy have
already made her a valuable asset to this small hard-working staff.
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Continued Active Archives
1992 was a busy year for the archives. With the death in September of Bar-
bara McClintock, requests for information about her life increased twofold. Dr.
McClintock touched the lives of so many people; requests have come from the
press, students, teachers, scientists, and artists, all with a common interest in
her life.
There has also been heightened interest in Dr. Watson and his relationship
to the Human Genome Project as well as the approaching 40th anniversary of
the discovery of the structure of the DNA double helix. Requests for reprints,
biographical information, and photographs have increased.
The subject of the 1992 Archives Conference held at Brookhaven National
Laboratory in October was "Discovery." We exhibited important reprints of
books by Alfred Hershey, James D. Watson, and Barbara McClintock, as well
as books detailing the Laboratory's history. A montage of photographs of Dr.
McClintock from her youth through her last days here was displayed, sur-
rounded by corn and her published works. This exhibit drew interest from all
who attended.
Reference Services
An additional computer has been added for bibliographic searching. Having
two computers in the reference room allows more patrons to access Med line,
Entrez-Sequences, and Current Contents. These computers also provide ac-
cess to the Laboratory network and word processing and also have the full
text of the Journal of Biological Chemistry available. We will continue to ac-
quire bibliographic and text CDs as the budget
The library staff answered more than 200 reference questions per month in
1992. The tables of contents of 87 journals continue to be sent to 60 scientists.
In September, Margaret Henderson began the Library Newsletter, whose pur-
pose is to inform the staff of new books, new journals, and new and changing
library policies.
The on-line serials system has been installed and includes the use of Inter-
net to claim missing and damaged issues of journals. This provides needed
assistance to Leigh Johnson whose considerable talent as library assistant
can be utilized in other areas. More than 5000 books have already been en-
tered into the on-line database and will be available to the scientists in 1993.
The catalog will be accessible directly from scientific offices, laboratories, and
branch libraries.
Whatever the medium-whether it be paper, compact disk, electronic,
audio, or video cassette-the mission of the library continues to support the in-
formation needs of the scientific staff, quickly and accurately.
Space and Water Damage
Since the need for additional space has not yet been addressed, we must
continue sending older journals to off-premises storage in order to provide
space for the current journal collection. The need for study space has become
extremely critical. Quiet study areas are in short supply.
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Water damage plagues the lower level, especially the Watson archives,
where puddles contribute to an alarming increase
in mold and staining. The time
has come to address the future plans for the
Laboratory's information center. It is
no longer acceptable to ignore and postpone
decisions that affect the library's
future. I urge the administration to address this issue immediately.
Susan Cooper
PUBLIC AFFAIRS
Events
A sizable number of events were planned and organized this year by the Public
Affairs Department. On January 25,1992, concert pianist Peter Orth performed a
second benefit for Cold Spring Harbor Laboratory. The capacity audience was
thrilled with Orth's performance of Chopin, Schumann, and Brahms. The net in-
come from this benefit was $8000.
The official end of the Second Century Campaign was discussed on April
12,1992, when Chairman David Luke III announced that the campaign had suc-
cessfully raised $6 million over the goal of $44 million. The dinner held in the new
dining room in Blackford Hall was a celebration of the committee's achievement
and the announcement of the fact that the deadline was being extended until De-
cember 31,1992, with the exception of solicitations outstanding.
The Samuel Freeman Cancer Center in the newly renovated Jones Laboratory
was dedicated on July 19, 1992. Dr. Robert Franza spoke about the new re-
search that is being done in the Center and remarked on the joys of being in a
building with such historical importance. Elizabeth Watson, Architectural Histori-
an, presented a brief history of the Jones building, and Dr. Watson's talk
centered on the recognition of the Samuel Freeman Charitable Trust and its
Chairman, William E. Murray. Dr. Watson praised Mr. Murray for his continuous
support of special Laboratory projects and thanked him on behalf of the Board of
Trustees. The afternoon concluded with a dinner at Airs lie.
A special dinner was held on June 6,1992, to recognize George Cahill's as-
sistance with the Neuroscience Center during his tenure at the Howard Hughes
Medical Institute. Dr. Cahill, his wife Sally, members of his family, and personal
friends had dinner with Dr. and Mrs. Watson at Airs lie house.
Barbara McClintock delighted in her 90th birthday party held at Airs lie house.
Thirty close friends from all phases of Dr. McClintock's life came to Cold Spring
Harbor on June 13 to share stories and laughter and to unveil The Dynamic
Genome, a book with contributions from many more of her friends and col-
leagues and produced by Cold Spring Harbor Laboratory Press. She told us that
she was surprised to have enjoyed the celebration. "The food was good; I had
some wine and probably talked too much. It was fun, but I'm very tired," she said.
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Sadly, Dr. McClintock died on September 2, and on November 17 a celebra-
tion of her life was held in Grace Auditorium. Many of her friends gathered to hear
Howard Green (Harvard University), James Shapiro (University of Chicago),
Evelyn Witkin (Rutgers University), and Oliver Nelson (University of Wisconsin,
Madison) speak on the many aspects of Barbara's life. A small program was
prepared for the occasion with an elegant essay by Nathaniel Comfort entitled
"Small in size, but great in stature." Waclaw Szabalski (University of Wisconsin,
Madison), Jochim Messing (Rutgers University), and Tom Broker (University of
Rochester) made special comments at the end. A collection of these talks is
being prepared for distribution in late spring 1993.
On October 4,1992, the Racker Reading Room in Blackford Hall was dedi-
cated. Mrs. Franzie Racker presented the Laboratory with 22 of her husband's
drawings. In the 1940s and 1950s, Dr. Efraim Racker sketched the scientists who
worked and studied at Cold Spring Harbor Laboratory. Their likenesses now
adorn the walls of Blackford Hall. Scientists from that period were invited back to
reminisce, and so they did: Rollin Hotchkiss, Ernst Mayr, Bruce Wallace, and Jim
Watson imparted interesting tales of times past. The decoration of this room,
made easier by its rich history, would not have been possible without the
aesthetic and artistic choices made by Laura Hyman and Liz Watson.
In addition to these major events, four Lloyd Harbor Seminars were planned
and presented with the help of George Toumanoff, a Lloyd Harbor Trustee. These
seminars are held at the Banbury Center in February, March, October, and No-
vember. The 1992 seminars were The Living Will and New York's Proxy Law;
Science in Russia after Glasnost; Myths and Realities of the Soviet Union; and
Understanding Learning and Memory.
All four regularly scheduled public walking tours were given to a total of 106
new faces. Special talks and tours were arranged for Svalovskommun, Svalov,
Sweden; C.W. Post University Club, Greenvale; The Japanese Exchange Team,
Syosset Rotary; Alternative Culture Exchange, Jericho; C.W. Post Special Library
class, Lawrence Road Jr. High School; Northport Girl Scouts, Commack Middle
School; Aspect ILS (international students); Ethical Humanists Society of Long Is-
land; Cedar Swamp Historical Society; C.W. Post Library Association; Polytechnic
University Alumni Association; Independent School Exchange, Greenvale; and
Kiwanis Club of Huntington. I am grateful to the many laboratory scientists and
other staff members who made these tours and talks a rich resource for our com-
munity.
Several holiday parties were organized by the staff Activities Committee co-
chaired by Art Brings and David Helfman. The new tree-lighting and caroling
event on December 9 was a special success and will continue annually. Santa
Claus distributed presents to 102 Laboratory kids at the first Lab-wide children's
holiday party held on December 16. The gifts were purchased by Joan Pesek,
Lesley Inglis, Candy Davis, and Grace Stillman and wrapped by a dozen
volunteers from the staff. The party included holiday goodies and well-deserved
wine and cheese for the parents in attendance. Plans for other parties included
Super Bowl Sunday, Valentine's Day, St. Patrick's Day, Halloween, and Crazy Hat
Day, all arranged by Rob Gensel. The annual Thanksgiving Day feast, organized
with good help from Margaret Henderson, returned in 1992 after a 3-year hiatus
while Blackford Hall was being renovated.
As a member of the newly convened Events and Benefits committee under
the leadership of board vice-chairman Mary Lindsay, I now include among my
responsibilites the generation of a monthly Laboratory-wide calendar. To this
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end, I installed Calendar Creator Plus
software on my personal computer to pro-
duce the calendar. This speeds up the process
of informing staff and volunteers
of the wide variety of changing activities
at the Laboratory.
New Printed Materials Produced by Veteran
Staff
Harbor Transcript has a new look and new
colors. Margot Bennett, using her new
Mac Ilci and Quark Express design software,
fashioned a new masthead and
format beginning with volume 10, and our first
century burgundy has given way
to a second century blue. The 12-page design
has some standard features: The
front page stories always share the limelight
equally between scientific research
and non-science Laboratory-related information;
alternate issues trade trustee
profiles with historical highlights; and a new feature,
the book review, appears in
each issue on page 11. This design lends itself to easier preplanning while
retaining the flexibility necessary to meet the changing
information demands of
this institution. Margot's artistic talent and special
nurturing of the Harbor Tran-
script as well as all the other printed pieces create a visual image that equals the
quality of the institution.
Nathaniel Comfort has brought new substance to the writing of the Harbor
Transcript and the other pieces produced for the Laboratory. He has the tenacity
and ability to capture the essence of a scientific project and interpret that to our
audience. Nathan's research skills and the sheer volume of work he produces
are overwhelming. One of his major contributions to the press package this year
was the conceptualization and creation of the Experts Book. This small volume
details and indexes the work of individual researchers and encourages the press
to seek answers to questions in molecular biology from our Laboratory scientists.
The cover is a terrific cartoon drawn by CSHL artist Jim Duffy.
In addition to the 1992 issues of the Transcript, Public Affairs produced three
meetings and course posters; Take a Look at Us, a handout for the general pub-
lic, and the Annual Fund brochure with its accompanying solicitation cards and
envelopes. Two pieces that accompany our public handout, the Trustee Card
and the Fact Sheet, were each updated twice in 1992. Four event invitations,
three programs, and five fliers were produced and widely distributed. F A.0 E S. .
the Laboratory photographic yearbook, will skip a season and be issued in April,
1993, and annually thereafter.
Events Challenge Audiovisual Department
In 1992, the Laboratory held more than 30 scientific meetings either in Grace
Auditorium or at Banbury, more than 15 Association and public events, three
concerts, and two dedications, as well as in-house events too numerous to count.
Herb Parsons and Ed Campodonico, with the help of some excellent part-time
support in the summer, manage to handle the audiovisual (AV) needs of this
complex organization. They juggle individual course-site requests for VCRs,
projectors, and microphones and provide light and sound for special events from
the end of summer party, through the small group of folk dancers who meet on
Mondays, to the needs of a world-class concert pianist. The ever-increasing
number of events has stretched the AV staff and facilities to the farthest point.
We are no longer assured that Banbury meetings will not run concurrently
with an event planned for Grace Auditorium or that one of our AV specialists will
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be able to double as a photographer. The time has come to reorganize the de-
partment and add the staff necessary to support this vital function.
Media Coverage Increases
Media Coverage: 1991-1992
91 92
CSHL
91 92
JDW
91 92
Barbara McClintock
91 92
In Progress
0 Miscellaneous
Tours and Talks
Radio
Television
Books
Magazines
II Newspapers
1111
Comparison of media coverage for 1991 and 1992. CSHL= coverage of the Laboratory; JIM= coverage ofJames Watson and the Human
Genome Project; In Progress= coverage in any of the three preceding categories unpublished as of the end of the year.
As the chart implies, Public Affairs was flooded by requests for information about
the Laboratory and its staff. A memorable press year saw telomeres and origin
recognition complex (ORC) become the focus of the scientific press. The resig-
nation of Jim Watson as Director of the National Center for Human Genome Re-
search and the death of Barbara McClintock created intense peaks in the De-
partment's media work, yet there was still more general coverage of the
Laboratory than in any previous year. Both of these peak events were reminders
of our vulnerability as well as indications of individual strength. Jim Watson's stel-
lar 4-year government career brought worldwide attention and support for the
Human Genome Project, which now reveals daily some clue to our genetic
makeup. Barbara McClintock, friend and colleague for 20 years, Laboratory em-
ployee for more than 50 years, and a lover of life for more than 90 years will be
missed personally, professionally, and scientifically. Her legacy of elegant obser-
vation, keen wit, and scientific clarity will guide many for centuries to come.
With the events calendar already well into 1995, it is clear that this Depart-
ment will not want for work. Plans already include the dedication of Blackford Hall
and McClintock Laboratory and the completion of a new four-color booklet detail-
ing our present scientific program.
Susan Cooper
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TUMOR VIRUSES
Members of the Tumor Virus Section are wedded by an interest in understand-
ing cellular processes in eukaryotes and how they are altered in cancer cells.
When this section began nearly 25 years ago, tumor viruses were the tool
used to probe these mechanisms. Nowadays, the number of tools available is
greatly expanded. In addition to the DNA tumor viruses, SV40, adenovirus,
and papillomavirus, section members use human immunodeficiency virus and
herpes simplex virus as probes. In recent years, we have learned that
eukaryotes as outwardly different as yeast and humans are more similar than
dissimilar. Yeast is therefore becoming an increasingly popular model to study
cell processes relevant to human cells. With these various tools, members of
this section study (1) the structure and replication of viral and cellular
chromosomes (Stendlund, Stillman) and regulation of this process through the
cell cycle (Mathews, Moran, Morris, Stillman); (2) regulation of transcription
(Herr, Laspia, Mathews, Morris, Tanaka) and the processing of the resulting
transcripts (Krainer); (3) translational control (Mathews); and (4) regulation of
these processes by phosphorylation (Marshak). The studies by these investi-
gators are described in this section.
DNA SYNTHESIS
B. Stillman N. Muzyczka
M. Akiyama
G. Bauer
S.P. Bell
S. Brill P. Kaufman F. Bunz H. Rao
S.-U. Din T. Melendy K. Fien L. Borzillo
A. Dutta J.M. Ruppert K. Gavin N. Kessler
C. Hardy S. Waga Y. Marahrens
DNA is the genetic material present in all cells and
needs to be accurately duplicated with each cell divi-
sion. The enzymatic process of replicating the double
helix is conserved from bacteria to human cells. In
particular, the general process of initiation of replica-
tion is much the same for the bacterial chromosome
of Escherichia coli, the bacteriophage X. chromo-
some, and the chromosome of the small DNA virus,
SV40. Although we know that eukaryotic cells have
specific DNA sequences that specify the initiation of
DNA replication, the mechanism and control of this
process are not understood. It is commonly expected
that initiation of DNA replication within eukaryotic
chromosome replicons will follow the paradigm es-
tablished for other well-studied replicons, but we
simply do not know how eukaryotic chromosomes in-
itiate DNA replication. Our recent work has in-
creasingly focused on this latter problem.
SV40 DNA Replication
F. Bunz, L. Borzillo, S.-U. Din, A. Dutta, T. Melendy
N. Muzyczka, J.M. Ruppert, S. Waga, B. Stillman
As an entrée into the study of DNA replication in
eukaryotic cells, we have for many years studied the
replication of the small chromosome of simian virus
40 (SV40). This is because the SV40 chromosome
has a single replicator that determines the site of in-
itiation of DNA replication, called the SV40 origin
(ori) sequence. Moreover, only one virus-encoded
protein, the SV40 large (T) tumor antigen, is required
for the replication of the small chromosome. Thus,
DNA replication relies heavily on the cellular replica-
tion apparatus. For some years, we have purified
proteins from human cell extracts that are required,
with T antigen, for the replication of SV40 ori-
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containing plasmids. We previously have reconsti-
tuted with purified proteins the initiation of DNA
replication, the replication of both leading and lag-
ging strands, and the segregation of the daughter
chromosomes. In this purified system, however, the
lagging-strand Okazaki fragments remained as short,
discontinuous strands because they were not ligated
together. We have therefore focused our attention on
reconstituting the complete replication of SV40 ori-
containing plasm ids and the production of a covalent-
ly closed, circular product in which the lagging-
strand Okazaki fragments become ligated during
DNA replication.
Two new DNA replication factors, maturation fac-
tor 1 (MF1), a 5' to 3' exonuclease, and DNA ligase
1, have been identified as essential components re-
quired for the complete reconstitution of SV40 DNA
replication. These two proteins are required along
with the previously identified DNA replication fac-
tors summarized in Table 1, and all of these purified
DNA replication factors are necessary and sufficient
in the reconstituted replication reaction. It has there-
fore been possible to determine the role of each factor
in complete DNA replication by systematically omit-
ting single factors from the reconstituted reaction and
examining the corresponding "phenotype" by deter-
mining the structure of the resulting replication pro-
ducts. Utilizing this approach, we have demonstrated
TABLE 1 DNA Replication Factors
Protein Functions
T antigen
Replication protein
A (RPA)
DNA polymerase
a/primase
DNA polymerase 8
Replication factor
C (RFC)
Proliferating cell nuclear
antigen (PCNA)
Topoisiomerase I
Topoisiomerase II
Maturation factor 1 (MF1)
DNA ligase I
initiator; DNA helicase;
primosome loading protein
single-strand-binding
protein; polymerase acces-
sory protein; initiation cofactor
DNA polymerase and DNA
primase for lagging strand
DNA polymerase for leading
and lagging strand
primer-template-binding
protein; ATPase; polymerase
accessory factor
polymerase 8 accessory
factor; RFC cofactor
removes tortional strain;
chromosome segregation
5' to 3' exonuclease
required for lagging-strand
synthesis
DNA ligase required for lag-
ging-strand synthesis
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that RPA, polymerase
a/primase, and T antigen are
essential for the initiation of DNA replication. Sepa-
rate omission of RFC, PCNA, and DNA polymerase
8 eliminated leading-strand synthesis, as we have
demonstrated before, but allowed the synthesis of
Okazaki fragments on the lagging-strand template.
Surprisingly, in the presence of MF1 and DNA
ligase, these Okazaki fragments were not ligated to-
gether, suggesting that PCNA, RFC, and DNA
polymerase 8 are required for complete synthesis of
the lagging-strand product. We are currently investi-
gating how these three DNA replication components
are required for lagging-strand synthesis, but the
simplest hypothesis is that they are required to extend
short nascent DNA chains that are synthesized by
DNA polymerase a/primase so that DNA ligase and
MF1 can cooperate to ligate the nascent Okazaki
fragment to the growing lagging strand. This and
other possible explanations are under further investi-
gation.
As a part of our effort to understand the mechan-
ism and regulation of cellular DNA replication, we
have been systematically cloning cDNAs encoding
the human DNA replication proteins. In collaboration
with Dr. Ryuji Kobayashi (see Protein Chemistry,
this section), protein sequence has been obtained
from the five subunits of the human RFC protein, and
a full-length encoding the 140-kD large sub-
unit of RFC has been obtained. In addition, a panel of
monoclonal antibodies raised against the 140-kD
RFC subunit has been prepared, and these reagents
are currently in use to determine the precise functions
of the polypeptide.
As indicated above, T antigen, RPA, and DNA
polymerase a/primase are essential for the initation
of DNA replication, and in their absence, no nucleic
acid synthesis occurs. In the last year, results from a
number of laboratories have established that specific
protein-protein interactions between these replication
proteins play a critical role in establishing a func-
tional initiation complex at the SV40 origin of DNA
replication. T antigen interacts with DNA polymerase
a/primase (composed of four polypeptides) and with
RPA (composed of three polypeptides). Moreover,
both RPA and DNA polymerase a/primase interact
with each other.
We have investigated the functional consequences
of these protein-protein interactions by testing the
ability of DNA polymerase a /primase to initiate
DNA replication on unprimed, single-stranded DNA
templates. When the single-stranded DNA is coated
with RPA, DNA polymerase a/primase is unable to
initiate DNA synthesis. Addition of T antigen, how-
ever, allows DNA polymerase a/DNA primase to in-
itiate DNA replication on this template DNA. On the
basis of our results and the results from other
laboratories, we have proposed that T antigen, a
DNA helicase and initiator protein, also functions to
load DNA polymerase a/primase on to the RPA-
coated template DNA much like the primosome load-
ing proteins found in prokaryotes. For example, the
E. coli dnaC protein is required to load the dnaB
helicase on to single-stranded DNA-binding protein
coated DNA, thereby allowing E. coli primase to
bind to the template DNA and prime DNA synthesis.
We imagine that T antigen functions like dnaC as a
primosome loading protein. Therefore, T antigen has
combined the function of three separate E. coli
replication proteins: the initiator function (dnaA), a
DNA helicase function (dnaB), and a primosome
loading function (dnaC).
Because initiation of replication from the SV40 on
relies so heavily on T antigen, it is not possible to ex-
trapolate these studies on SV40 DNA replication to
reveal details about the initiation of the replication of
cellular chromosomes. Therefore, we have in-
creasingly turned our attention to studying the
replication of chromosomes in the yeast Sac-
charomyces cerevisiae. Furthermore, to address more
directly the role in chromosome duplication of the
cellular replication factors described in Table 1, we
have systematically purified the functional homologs
of these human cell proteins from S. cerevisiae and
have cloned the genes encoding them so that a genet-
ic approach may yield insight into their function.
Cell Chromosome Replication
M. Akiyama, S.P. Bell, S. Brill, K. Fien, K. Gavin
C. Hardy, Y. Marahrens, H. Rao, B. Stillman
As discussed above, we have begun to identify from
S. cerevisiae the functional homologs of the human
DNA replication factors that are required for SV40
DNA replication in vitro. To date, all of the replica-
tion factors (except MF1) have been identified, and
many of the genes encoding subunits of these
proteins have been cloned by us or others. Most
recently, RFC from S. cerevisiae (scRFC) has been
purified, and in collaboration with Dr. Ryuji
Kobayashi, protein sequence has been obtained to
clone the genes encoding each subunit. These studies,
and similar studies with scRPA reported previously,
will allow a genetic approach toward an understand-
ing of the roles of these proteins in cellular DNA me-
tabolism.
One of our central goals is to understand how cel-
lular DNA replication begins and how this process is
controlled. To this end, we have previously studied
the structure and DNA sequence requirements for a
chromosomal replicator or origin of DNA replication
called ARS1, located on chromosome IV in S.
cerevisiae. Linker scan mutagenesis of the locus
revealed that ARS1 contains one essential (A) and
three important (B1, B2, B3) DNA sequence ele-
ments. The individual B elements are not essential,
but combined, the B elements are necessary for ARS
function. The B3 element binds the cellular transcrip-
tion factor ABF1 and the A element is responsible for
sequence-specific recognition by the origin recogni-
tion complex (ORC), a multisubunit DNA-binding
protein that binds to all yeast origins of DNA replica-
tion in an ATP-dependent manner. The arrangement
of an essential sequence combined with redundant,
nonessential DNA sequence elements within the
ARS1 replicator represents an unusual structure for a
replicator because such a structure has not been de-
scribed in either bacteria, phage, or eukaryotic virus
origins of DNA replication.
To test the generality of the unusual structure of
this yeast chromosomal replicator, we have now
completed a systematic analysis of another cellular
replicator, the ARS307 locus located on chromosome
III in S. cerevisiae. Linker scan mutagenesis revealed
an essential DNA element (A) containing, like the
ARS1 A element, a perfect match to the degenerate
11-base-pair ARS consensus sequence. Additionally,
two other important elements were detected and have
been designated b1 and b2 (see Fig. 1). Mutations in
either of the b1 or b2 elements of ARS307 reduced
origin function, and when mutations were introduced
into both elements, origin function was eliminated.
Because the general characteristics of the ARS307
replicator structure resembled the ARS1 structure, but
there was little sequence similarity between them, we
have mixed and matched these elements (see Fig. 1).
This analysis has revealed that the A and B elements
from ARS307 can substitute for their counterparts in
ARS1, and vice versa. Moreover, the B1 and B2 ele-
ments cannot substitute for each other. Surprisingly,
little sequence similarity exists between the B1 ele-
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A
ARS 307 SWAP
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b2
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STABILITY (%)
27.8 f 2.8
31.7 ± 2.0
4.2 ± 1.3
26.7 ± 1.1
5.0 ± 1.9
12.6 ± 2.2
22.7 ± 2.7
20.4 ± 1.0
6.3 ± 1.6
0.4 ± 0.02
27.7 ± 2.7
4.0 ± 1.1
A Imwi 7.0 ± 1.2
bl 22.5 ± 2.4
FIGURE 1 Multiple elements in yeast replicator sequences. (Stippled boxes) The four elements A,
Bl, B2, and B3 from ARS1; (open boxes) the three elements A, b1, and b2 from ARS307. The top
line in each group shows the wild-type organization for either ARS1 or AR307and the corresponding
plasmid stability. The lines below these show the plasmid stability of linker scan mutations (wavy
line) or substitutions with heterologous DNA elements.
ments of ARS1 and ARS307, and the only common
feature of the B2 elements is a match of 9 bases out
of 11 to the degenerate ARS consensus sequence.
These studies have been very informative because
they focus attention on the function of each of these
elements, and this clearly presents an immediate
challenge.
To understand further the initiation of chromoso-
mal DNA replication, we have focused our attention
on the proteins that interact with the ARS replicator
elements. In last year's Annual Report, we described
the purification and characterization of a putative in-
itiator protein, ORC. In collaboration with Ryuji
Kobayashi, we have obtained protein sequence from
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the six core polypeptides that consistently cofrac-
tionate with ORC DNA-binding activity and a
seventh protein that is variably associated with ac-
tivity. Using this protein sequence information, the
genes for the six core ORC subunits have been
cloned from S. cerevisiae, and the sequences for most
of these genes have been obtained. All are novel
proteins that have not been described previously.
Most interestingly, one of the genes called ORC2, en-
coding the 72-kD second largest subunit of ORC, is
identical to a gene isolated in Jasper Rine's
laboratory at University of California, Berkeley, that
has not yet been reported in the literature. Margit
Foss in Rine's laboratory cloned ORC2 by corn-
plementation of mutants that were defective in silenc-
ing a modified silent mating-type gene, HMR. The
HMR gene is part of the complex regulatory appara-
tus that controls the mating type of yeast. Further-
more, the orc2 mutants were also temperature-
sensitive and arrest with a cell-division-cycle-arrest
phenotype consistent with ORC2 playing an impor-
tant role in S phase. These observations provide ge-
netic evidence for ORC as a key protein required for
cell cycle progression through S phase. Moreover,
they suggest that the putative replication initiator
protein plays a key role in regulation of gene expres-
sion. It is worth noting that studies at Cold Spring
Harbor Laboratory approximately 10 years ago by
Hicks, Strathern, Klar, and Nasmyth helped elucidate
the role of transcriptional silencing in regulation of
yeast mating type. In the future, it will be of consid-
erable interest to determine whether these studies on
transcriptional silencing and our studies on DNA
replication might point to a more general link be-
tween DNA replication, transcription control, and
chromatin structure.
Chromatin Assembly
G. Bauer, P. Kaufman, N. Kessler, B. Stillman
During S phase in the cell cycle, the DNA present in
chromosomes is duplicated along with the chromoso-
mal proteins. Under certain conditions, this process
can be duplicated in vitro, with plasmids containing
the SV40 origin of DNA replication replicating and
being assembled into a chromatin structure that
resembles the structure of chromatin in the cell. We
have reported previously that a multisubunit protein,
chromatin assembly factor-1 (CAF-1), is required for
the replication-dependent assembly of histones onto
the daughter DNA helices at the replication fork.
CAF-1 consists of protein subunits with a relative
mass of 150 kD, 60 kD, and 50 kD. In the last year,
we have obtained, in collaboration with Ryuji
Kobayashi, partial amino acid sequences of these
proteins and used this information to clone human
cellular cDNAs encoding each protein. Although
each protein sequence is novel, the two smaller sub-
units are related to each other because they contain
multiple copies of an approximately 40-amino-acid
repeat found in the 13 subunits of receptor-linked G
proteins and a number of other proteins. Interestingly,
some of these other proteins are transcription factors
that may influence gene expression by altering
chromatin structure. Although the function of the
repeats is not known, we should be in a strong posi-
tion to investigate further the individual CAF-1 sub-
units and the role of the repeats in chromatin assemb-
ly by expressing the protein using expression vectors.
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MOLECULAR BIOLOGY OF BOVINE PAPILLOMAVIRUS
A. Stenlund M. Ustav
P. Szymanski
J. Sedman
R. Kluttig
E. Ustav
L. Gandhi
T. Sedman
The papillomaviruses infect and transform the basal
epithelium in their hosts, inducing abnormal prolif-
eration of the cells at the site of infection. The result-
ing tumors (warts) are in most cases benign and will
usually regress after some time, but certain types of
human papillomaviruses (HPVs 16, 18, 31, 33, and
39) give rise to tumors that are prone to progress
toward malignancy, especially frequently cervical
carcinoma. In total, HPV DNA can now be found in
approximately 80% of the biopsies from cervical car-
cinomas. Interestingly, in this type of lesion, the
papillomavirus DNA is generally found integrated in
the host genome, which indicates that viral DNA
replication might have some special significance in
tumorigenesis, since in normal nonmalignant lesions,
the viral DNA is maintained as a freely replicating
plasmid in the nucleus of the infected cell.
The correlation between papillomavirus infections
and human carcinomas has spurred a great deal of re-
search on the biology of these viruses over the past
decade. One of the key impediments to this work has
been the inability to define an in vitro cell culture
system for any human papillomavirus, largely due to
the fact that these viruses normally require special-
ized differentiating cells that only with great dif-
ficulty can be generated in tissue culture. The answer
to this problem has been to turn to study of related
viruses. Study of the animal papillomaviruses
generally does not carry the same restrictions. In par-
ticular, a bovine papillomavirus (BPV-1) has become
the prototype virus for the papillomavirus group,
solely for the reason that a convenient cell culture
system is available where oncogenic transformation,
gene expression, and viral DNA replication can be
studied. To date, more than 60 different papil-
lomavirus genomes have been characterized and
cloned, and all of these show a remarkable degree of
similarity in their genome organization. This original-
ly formed the basis for the assumption that what was
learned from one virus could be applied to another.
This assumption has largely been verified; most of
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the phenomena that were originally defined in the
BPV system have subsequently been found also in
human papillomaviruses. This includes a consider-
able degree of conservation concerning the replica-
tion apparatus.
In previous years, we have reported the develop-
ment of a short-term replication assay that was
designed and used to define the replication apparatus
of BPV. This assay has allowed us to initiate a
detailed study of the requirements for BPV DNA
replication. The two viral polypeptides, El (the in-
itiator) and E2 (a viral transcription factor), that are
required for replication and also the necessary cis-
acting elements have been defined using this assay.
During the past 2 years, we have concentrated our
work on the functional role of these two polypeptides
and their interaction with the on sequence. This year,
we have taken the first step into an in vitro system to
try to explain at the molecular level the events that
are required for initiation of DNA replication of
papillomaviruses.
One important characteristic of the papillomavi-
ruses is their ability to maintain the viral DNA in a
latent state as a low-copy-number nuclear plasmid.
This property is likely to require a number of features
in addition to DNA replication, including copy num-
ber control and an active partitioning system. During
the past year, we have begun to develop systems to
study these features.
Role of the E2 Polypeptide
in DNA Replication
E Ustav, M. Ustav, P. Szymanski, A. Stenlund
Our previous studies had demonstrated that the viral
transcription factor E2 was essential for replication in
vivo. Since the minimal Ori contains a low-affinity
binding site for E2, it seemed likely that E2 would
function through binding to this site. To determine if
the DNA-binding activity of the protein was required
for replication, point mutants were generated in con-
served motifs in the carboxy-terminal part of E2, and
the resulting mutants were tested for their ability to
bind to DNA, and subsequently tested also for their
ability to dimerize in an in vivo dimerization assay,
since dimerization is a prerequisite for DNA binding.
Mutants that were capable of dimerization but were
defective in their ability to bind DNA were chosen
and tested for their ability to support replication. A
perfect correlation was observed between DNA-
binding ability and ability to support replication.
These results indicated clearly the that DNA-binding
capacity of E2 was required for DNA replication and
that the E2 polypeptide probably was required to bind
to the Ori region.
Mutational analysis of the E2-binding site in Ori,
with mutations that either increased or decreased the
affinity of E2 for the site or deletions of the entire
E2-binding site, demonstrated that the binding site
was absolutely required for a functional Ori but that
E2-binding sites that were severely crippled for bind-
ing of E2 in vitro were still functional for replication.
Furthermore, replication activity could be restored to
a mutant where the entire E2-binding site had been
deleted, by insertion of an unrelated high-affinity E2-
binding site at a different position in the plasmid.
These results indicated that the position and distance
of the E2-binding site relative to the El-binding site
were not critical, at least when a high-affinity E2-
binding site was used.
We also generated a series of on constructs where
we inserted spacer sequences between the E2-binding
site and the recognition sequence for El. Insertion of
a 10-bp spacer resulted in loss of on function with a
low-affinity E2-binding site, whereas with a high-
affinity E2-binding site, replication activity was
retained; in fact, the distance between the El- and
E2-binding sites could be increased to at least 1 kb
when multimerized high-affinity E2-binding sites
were used. Thus, low-affinity sites could function
only when located close to the El-binding site, and
high-affinity sites could function at greater distances.
These results were consistent with an interaction be-
tween the E2 polypeptide and some other component
of the replication machinery, resulting in a stabiliza-
tion of the E2 interaction with a low-affinity binding
site.
Interaction between El and E2
Proteins at the Origin of
Replication
L. Gandhi, A. Stenlund
A simple model to explain the relationship between
affinity of the E2-binding site and distance depen-
dence would be that E2 can participate in an interac-
tion with El that would serve to stabilize the binding
to a low-affinity site. To explore this possibility
directly, we expressed and purified both El and E2
proteins from Escherichia coli to determine if an in-
teraction between the two proteins could be detected
at the origin of replication. By using DNase footprint
assays, we could determine that the two proteins bind
cooperatively to the origin when the binding sites
for both proteins are present (Fig. 1). Furthermore, by
27 (wt) Msp/15
E 1 I - 1 0 2 0 4 0 8 0 1 - 10 20 40 801
E2 30 30 30 30 30 30 30 30 30 30
T
FIGURE 1 El and E2 proteins bind cooperatively to the Ori
when binding sites for both proteins are present. DNase
footprint reactions were carried out on the wild-type Ori (27)
and on a mutant Ori that lacks the E2-binding site (Msp/15)
using purified El and E2 proteins. At the low level of E2
used (30 ng), no footprint is detectable on either template in
the absence of El. The bar indicates the combined El and
E2 footprints that appear on the wild-type template.
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Relationship between El and E2 at the origin
A/T CDO
A/T
FIGURE 2 A schematic figure illustrating possible arrange-
ments of viral proteins and cis-acting sequences for replica-
tion of the minimal Ori in vivo.
Replication
using a so-called McKay DNA precipitation assay,
we could demonstrate that the ability of El to bind to
its site at the Ori in the presence of E2 was propor-
tional to the affinity of the adjacent E2-binding site
for E2. These experiments also demonstrated that E2
could stimulate specific binding of El even when the
E2-binding site was located at a distance from the
El-binding site, provided a high-affinity E2-binding
site was used. These results, which indicated a direct
interaction between the El and E2 when both
proteins are bound to DNA, thus showed a very good
correlation between the requirements for in vitro
binding and in vivo replication activity. Taken to-
gether, these results indicate that a specific ternary
complex composed of El, E2, and the Ori DNA is re-
quired for functional initiation of replication in vivo
(Fig. 2).
Replication In Vitro
J. Sedman, A. Stenlund
To further investigate the molecular events that are
required for replication of BPV DNA, we have
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started experiments to characterize
the initiation of
DNA replication using a cell-free
system. An in vitro
replication system for BPV has
recently been devel-
oped by M. Botchan and colleagues (University of
California, Berkeley). Using this system (which is
based on a crude nuclear extract
from mouse FM 3A
cells), we can achieve replication of the BPV Ori if
the El protein, which is expressed
and purified from
E. coli, is added. Interestingly,
this system shows dis-
tinctive differences
compared to replication in vivo.
Although replication in vivo shows an absolute re-
quirement for the E2 protein and E2-binding sites in
cis, in the in vitro replication system, E2 is not ab-
solutely required but has a stimulatory effect on
replication. However, this stimulatory effect does not
appear to be dependent on the presence of binding
sites for E2. We are presently trying to determine the
basis for this difference between in vivo and in vitro
replication.
Maintenance Replication
M. Ustav, A. Stenlund
A unique and interesting aspect of BPV replication is
the ability of the viral genome to persist in BPV-
transformed cells by replicating as a nuclear plasmid
with a constant copy number under cell cycle control.
Last year, we described a system to study this partic-
ular aspect of BPV replication which has been termed
maintenance. Our strategy has been to develop cell
lines that express the El and E2 polypeptides con-
stitutively and allow replication from the BPV origin
of replication (these cells are the functional equi-
valent of COS cells for SV40). To assay for mainten-
ance, a vector containing a neo resistance marker and
an origin-containing fragment of the BPV genome is
transfected into this cell line. After selection for
G418-resistant colonies and further passage for
several weeks, DNA can be prepared and analyzed
for the presence of episomal vector sequences. These
experiments demonstrated that the El and E2 gene
products were the only viral proteins required for
maintenance. The next question that we addressed
was whether the cis-acting sequences that were suffi-
cient for short-term replication (i.e., the minimal Ori)
were also sufficient for maintenance. These experi-
ments were carried out by inserting fragments from
the BPV genome of increasing size all containing the
minimal Ori into the neo plasmid. The Ori constructs
were tested initially in a short-term replication assay
in which all constructs replicated to similar levels.
After G418 selection and passaging, however, the
minimal Ori constructs could not be recovered as
episomal DNA. These results indicated that addi-
tional sequences were required for stable mainten-
ance of BPV. Further mapping of these sequences in-
dicates that they are located within the E2-dependent
transcriptional enhancer.
Regulation of Viral
DNA Replication
P. Szymanski, A. Stenlund
The E2 open reading frame of BPV encodes, in addi-
tion to the full-length polypeptide that functions as a
trans-activator, two shorter polypeptides that contain
the same carboxy-terminal DNA-binding/dimeri-
zation domain as the full-length protein. These two
polypeptides have been shown to act as competitive
repressors of transcription from E2 responsive
promoters; however, the mechanism of action has not
been determined. Two obvious possibilities are either
competition for DNA binding, since these three
proteins have the same DNA-binding specificity, or
formation of inactive heterodimers, since the
dimerization domain is also shared. Since the full-
length E2 is also involved directly in DNA replica-
tion, we were interested in determining if the short
forms of E2 could affect DNA replication directly,
and what relative contributions heterodimerization
versus competition for binding make to this repres-
sion.
To distinguish between these two mechanisms, we
utilized several point mutants in the carboxyl termin-
us of E2 that are deficient for DNA binding but are
still capable of dimerization. If either of the short
forms of E2 is included in an E2-dependent replica-
tion assay, a low-level repression of replication is ob-
served. If instead a DNA-binding-deficient mutant
version of the short E2 is used, repression is in-
creased considerably. In contrast, repression of tran-
scription behaves differently: The wild-type version
of the short E2 is a considerably better repressor than
the DNA-binding-deficient mutant of the same
protein. In both assays, however, the most effective
repressor is a DNA-binding-deficient form of full-
length E2 that can efficiently repress both replication
and transcription. The conclusion from these experi-
ments is that hybrid dimers, formed between the
wild-type activator and the DNA-binding-deficient
mutant, are incapable of activating transcription due
to a lack of DNA-binding activity of the hybrid. In
contrast, hybrid dimers, consisting of the wild-type
activator and the short form of E2 which are com-
petent for DNA binding, appear to be capable of sup-
porting replication to some extent but are not func-
tional for transcription. Taken together, these results
indicate that the naturally occurring repressor forms
of E2 function largely through competition for DNA
binding with the full-length E2 polypeptide.
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ADENOVIRUS TRANSFORMING FUNCTIONS
E. Moran S. Abraham
A. Ebrahim
Y. Rikitake
H.-G.H. Wang A. Pepe
P. Yaciuk N. Dawkins
F. Chadrin J. Altman
The adenovirus ElA gene products continue to serve
as extremely sensitive genetic probes for dissecting
the pathways regulating cell growth. Within the past
few years, the recognition that one host-cell growth-
regulating function in ElA is genetically linked with
activation of the cellular E2F transcription factor, and
with binding of a family of cellular products includ-
ing the growth suppressor gene, pRB, has led to the
understanding that E2F is an important regulator of
cell-cycle-specific transcription and that pRB, its
homologs, and their associated cyclins are cellular
modulators of E2F activity.
Our interest in understanding the means by which
cell growth control pathways can be overridden leads
us to study not just the growth-regulating mechan-
isms linked with the pRB-binding function of ElA,
but also the control points at which the ElA products
can influence cell growth independently of the pRB-
binding function. In our laboratory during the past
year, we have continued to characterize another
major cell-growth-regulating region of ElA and a
cellular protein, p300, that is bound by ETA at this
site. Residues important for p300 binding are re-
quired for the transformation function of E1A and are
involved in other E1A-mediated gene-regulating
functions, including activation of cell-cycle-regulated
products and repression of tissue-specific enhancer
activity. In the past year, we have significantly
refined our understanding of the E1A active sites and
the distinction between the binding sites for p300 and
the pRB-related proteins. We have also discovered
that these associations occur in the same ElA com-
plexes, and probably on the same E1A molecule,
bringing pRB and the pRB-related proteins and their
associated cyclins and kinases into close proximity
with p300. Interestingly, the ElA products of the on-
cogenic serotype, adenovirus 12 (Ad12), are able to
inactivate the p300-binding site via a posttransla-
tional modification, leaving a stable ElA product
able to bind pRB, but not p300. In the past year, we
have also increased significantly our understanding
of the nature and function of p300 itself. We have
succeeded in developing a series of p300-specific
monoclonal antibodies, which have served to reveal
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two distinct forms of p300, and the existence of a
number of p300-associated cellular proteins. Genetic
analysis now suggests that p300 may have specific
interactions with the basal transcription assemblage:
The ability of the E1A products to activate the hsp70
promoter through specific TATA box sequences has
been linked with E1A sequences required for p300
binding, and we have obtained physical evidence of
an interaction between p300 and the basal transcrip-
tion factor, TBP (the TATA-box-binding protein).
These results are described in more detail in the sec-
tions below.
Analysis by Mutation and Monoclonal
Antibody Competition Reveals
the Independence of the
E1A-binding Sites for p300 and
the pRB-related Proteins
H.-G.H. Wang, Y. Rikitake, P. Yaciuk, S. Abraham,
F. Chadrin, N. Dawkins, J. Altman, E. Moran
Our current understanding of the E1A regions in-
volved in cell growth control is illustrated in Figure
1. Although conserved region 1 has been known for
some time to be required for the binding of most
E1A-associated proteins, our recent analysis has indi-
cated that region 1 probably is composed of two sub-
regions with distinct binding activities. Through a
combination of site-specific mutation and analysis of
monoclonal antibody competition for cellular protein-
binding sites on E1A, we have obtained strong evi-
dence that p300 and the pRB-related proteins bind
within conserved region 1 at nonoverlapping sites.
This study has also revealed specific amino acid
residues in the amino-terminal region that are re-
quired for p300 binding and E1A-mediated changes
in cell growth patterns. We have also found that the
rat and human pRB molecules have distinguishable
requirements for binding sites on the E1A proteins.
This increasingly clear knowledge of the structure of
the E1A-binding sites has significantly expanded our
ability to design and interpret E1A mutant studies.
p300
p130
p107
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FIGURE 1 Schematic model of E1A functional regions directed at cell cycle control mechanisms and
of the cellular proteins bound by each. Adenovirus E1A oncogene-encoded sequences essential for
transformation and cell-cycle-regulating activities are localized at the amino(N)-terminus and in
regions of highly conserved amino acid sequence designated conserved regions 1 and 2. These
regions interact to form the binding sites for two classes of cellular proteins: the 105-kD retinoblas-
toma gene product and its possible homologs, whose association with the E1A products is specifi-
cally dependent on region 2, and another class that so far in vivo is known to include only a large
cellular DNA-binding protein, p300, whose association with the E1A products is specifically depen-
dent on the amino-terminal region. Association between the E1A products and either class of cellular
proteins can be disrupted by mutations in conserved region 1. A combination of site-directed point
mutagenesis and monoclonal antibody competition experiments now suggests that p300 and pRB
bind to distinct, nonoverlapping subregions within conserved region 1.
The Binding Sites for p300 and
the pRB-related Proteins Are
Apparently Occupied on the
Same E1A Molecule
P. Yaciuk, H.-G.H. Wang, F. Chadrin, A. Pepe,
N. Dawkins, E. Moran
Our ongoing studies of the E1A-binding sites have
also resulted in the surprising discovery that p300
and the region-2-associated proteins are in the same
El A complex and can probably occupy the same
E1A molecule. The availability of a strong panel of
p300-specific antibodies, reported in more detail be-
low, has permitted us to examine E1A complexes
from the viewpoint of p300. p300-specific im-
munocomplexes clearly contain protein species that
comigrate with the E1A region-2-associated proteins,
p130, p107, and p105-RB (Fig. 2). Comparison by
partial proteolytic peptide mapping confirms that
these are indeed the same protein species. Several
lines of evidence suggest that the amino-terminal and
region-2-binding sites are occupied on the same
molecule as opposed to different molecules within
El A oligomeric complexes: First, p300-specific
antibodies cannot bring down any of the region -2-
associated proteins in a mixed infection where
region-2 and the amino-terminal binding site are each
present, but on separate molecules. Second, all at-
tempts to show co-immunoprecipitation between dif-
ferent E1A molecules in these complexes have
proved negative. Third, although the amino-terminal
and region-2-binding sites can function independent-
ly, there is some evidence that binding at one site sta-
bilizes binding at the other. (Binding of p107 is lost if
specific single residues within region 1 and region 2
are altered simultaneously but appears unaffected
when only one is altered. Nevertheless, disruption of
the p300-binding site in combination with just the
region-2 substitution abrogates p107 binding, sug-
gesting that when p107 binding is accomplished
through just a single site, binding of p300 serves to
stabilize the association.) Together, these observa-
tions suggest strongly that the region-2-binding site
and the p300-binding site are generally both occupied
on the same E1A molecule.
The ability of the E1A products to bring the
region-2-associated proteins into close proximity to
p300 may have important implications for the func-
tion of the El A complexes. A major part of the E1A
population appears to be bound to p300 in E1A-
expressing cells, and our preliminary studies have
suggested that a large part of p300 is bound to cel-
lular DNA, even in the presence of E1A. The
presence among the region-2-associated proteins of
species that are themselves associated with cellular
cyclins and kinases raises the possibility that these
species may have important interactions not pre-
viously recognized. Thus, it will be important to
determine the cellular location of the E1A complex
and the functional consequences of the structure of
the El A complexes.
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FIGURE 2 p300 and the pRB-related proteins are present in the same
complexes. (A) Components of specific im
munocomplexes, separated on SDS-polyacrylamide gels.
E1A-specific antibodies (lane 2) will precipitate the E1A
products and the E1A-associated proteins, p300, p130, p107, and p105-RB
positions of each of these proteins in
the gel is indicated at the right). p300-specific antibodies (lane 3) will precipitate the same group
of proteins, indicat-
ing that p300-bound E1A complexes are not distinct from E1A
complexes containing any of the pRB-related proteins.
In the absence of E1A expression, the p300-specific antibodies (lane 4) do not coprecipitate the pRB-related proteins,
indicating that the p300-specific antibodies do not recognize these species
directly, and only pull them down when
they are in association with the E1A products. Although these results are compatible
with either of the models shown in
panel B, additional evidence cited in the text favors model number 1, the situation where both binding sites are oc-
cupied on the same E1A molecule, as opposed to model 2, where the cellular proteins bind to different El A
molecules, which are themselves associated in oligomeric complexes (indicated by the dashed line).
The Oncogenic Serotype, Ad12,
Generates Stable, Prominent
Forms Able to Bind pRB
but Not p300
H.-G.H. Wang, P. Yaciuk, E. Moran [in collaboration with
R.P. Ricciardi, University of Pennsylvania, M. Green,
St. Louis University Medical Center, and K. Yokoyama,
Tsukuba Life Science Center, Japan
The RB product binds to E1A sequences that are
highly conserved among the EIA products of various
serotypes, whereas p300 binding requires sequences
at the El A amino terminus, a region not highly con-
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served. To help evaluate the roles of the E1A-
associated proteins in cell growth control, we com-
pared the p300-binding abilities of the E1A products
of Ad5 and the more oncogenic Ad12 serotypes. We
have found that in spite of encoding a sequence that
varies somewhat from the p300-binding sequences of
Ad5 E1A, the Ad12 ElA products associate with
p300 with an affinity similar to that of the Ad5 E1A
products. Both the 12S and 13S splice products of
Ad12 E1A, like those of Ad5 E1A, encode proteins
able to associate with p300. In addition, like Ad5
El A, Ad12 E1A can bind p300 and the region -2-
associated proteins, such as pRB, in the same com-
plex. Interestingly, though, the proteins translated
from both Ad12 E1A splice products also give rise to
prominent amino-terminally modified forms that are
unable to associate with p300. This modification, at
least in the 13S product, does not appear to diminish
the affinity of this product for pRB. The generation in
this serotype of a stable modified E1A form that spe-
cifically sheds the p300-binding site adds strong sup-
port to our hypothesis that there are functional con-
sequences to binding p300 and the region -2-
associated proteins in the same complex.
Development of p300-specific
Monoclonal Antibodies Reveals the
Presence of Two Prominent
p300-related Species and Two
Distinct Categories of
Monoclonal Antibodies
P. Yaciuk, A. Pepe, E. Moran
The targeting of p300 by E1A implies strongly that
p300 plays a significant role in cell-growth-regulat-
ing processes. However, our previous analysis of
p300 expression and phosphorylation revealed little
difference in p300 as visualized from cells at various
different stages of cell growth. An analogy with the
most characterized E1A-associated protein, pRB,
suggests that p300 may participate in regulated pro-
cesses via specific protein-protein associations. Since
these kinds of interactions are often excluded from
polyclonal serum-derived immunocomplexes, we set
out to generate monoclonal antibodies that might be
more useful in visualizing E1A-associated proteins.
This endeavor resulted in the generation of 11
monoclonal lines, designated NM1 through NM11.
One of the earliest observations to arise from anal-
ysis of p300 with these antibodies is that a subset of
them also immunoprecipitate a prominent product of
about 270 kD that shows a strong relationship to
p300. The antibodies can be separated into two cate-
gories distinguished by whether or not they im-
munoprecipitate the 270-kD form (Fig. 3A). The
close relationship between the 270-kD species and
p300 itself is indicated by the fact that both species
are recognized directly by the monoclonal antibodies.
In addition, these species show closely related partial
proteolytic peptide patterns. The prominent ap-
pearance of the 270-kD species was a bit surprising
because, although the species seen in association with
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FIGURE 3 Development of p300-specific monoclonal
antibodies reveals the presence of two prominent p300-
related species and two distinct categories of monoclonal
antibodies. Eleven p300-specific monoclonal antibody lines
(NM1 through NM11) were generated in this project. Inter-
estingly, these fall into two categories, shown in panel A.
Category I, which includes 7 of the 11, recognizes predomi-
nantly a single form of p300 that comigrates with the major
form seen in E1A-specific immunocomplexes (see panel 8).
Category II consistently immunoprecipitates two p300-
related forms, of approximately 300 and 270 kD. In panel B,
E1A-specific immunocomplexes are compared with im-
munocomplexes from a category II monoclonal line, in tripli-
cate. It is clear that the E1A products associate preferential-
ly with the p300 form. The p270 form is recognized directly
by the antibodies, and its partial proteolytic digest pattern is
very similar to that of the p300 form, indicating that these
are closely related species. It will be important to determine
whether they are differentially modified forms of the same
gene product or the distinct products of two closely related
genes.
E1A often appear to be heterogeneous, forms co-
migrating with the 270-kD species have not appeared
prominently. Thus, this form, although apparently
abundant in cells, does not seem to associate readily
with the E1A products. This distinction is readily ap-
parent when E1A-specific immunoprecipitations are
compared side-by-side with immunoprecipitations
done with a monoclonal line that recognizes both the
p300 and p270 forms (Fig. 3B). Both the p300 and
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p270 forms are highly phosphorylated, so one does
not appear to be an unmodified precursor of the
other. Of course, other modifications may distinguish
these species, and it will be important to determine
whether these are the products of related, but distinct,
genes or differentially modified forms of the same
gene product.
Development of the p300
Monoclonal Antibodies
Reveals a Number of
p300-associated Proteins
P. Yaciuk, A. Pepe, S. Abraham, H.-G.H. Wang,
F. Chadrin, E. Moran
The p300 and p270 forms described immediately
above are both recognized directly by the monoclonal
antibodies. However, when all components of p300/
p270 immunocomplexes are examined, more than ten
cellular proteins that are not recognized directly by
the antibodies are revealed. Curiously, these addi-
tional species appear only in immunocomplexes with
the category of antibody that recognizes the p270
form in addition to the p300 form. The evidence that
these are not cross-reactive species and that they are
lost from the immunocomplexes under conditions
that disrupt protein-protein associations indicates
strongly that these are specific p300/p270-associated
proteins. Most of the associated species, like the
region-2-associated proteins and p300/p270 and the
El A products themselves, appear to be phosphopro-
teins. The phosphoprotein forms are shown in Figure
4. The selective appearance of the associated prod-
ucts only in immunoprecipitations that contain p270
in addition to p300 could be interpreted to indicate
that these factors are associated specifically with
p270. Alternatively, both p300 and p270 may associ-
ate with cellular factors, but the epitope specificity of
the first antibody category may be such that it is in-
compatible with the binding of the associated
proteins; this epitope may be less accessible on the
p270 form. Work is in progress to distinguish these
possibilities, which will be important in understand-
ing the functional consequences of p300/p270 cel-
lular complex formation and the effect of El A ex-
pression on these complexes. The ability to visualize
these proteins will now enable us to go on to
determine whether there are associations that are
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FIGURE 4 The p300/p270 products associate with a num-
ber of cellular proteins, many of which appear to be
phosphoproteins. When the total components of the
p300/p270 immunocomplexes are examined, a far more
dramatic difference becomes apparent between the two
categories of antibodies distinguished above. The category
I antibodies coprecipitate few if any cellular proteins (a rep-
resentative is shown in lane 2), whereas the category II
antibodies coprecipitate a number of cellular proteins
(shown in lane 3). Shown here are the species visible via
32P labeling. We consistently see three relatively high-
molecular-mass species of approximately 190, 170, and 160
kD, and five lower-molecular-mass species of approximately
64, 59, 50, 45, and 44 kD. These are indicated by arrows to
the right of lane 3. 35S labeling reveals a similar pattern,
with two additional prominent species of about 75 and 71
kD. None of the proteins designated as associated species
are recognized directly by these antibodies. When the im-
munocomplexes (lane 4) are denatured to disrupt protein-
protein associations, then probed again with the same
antibody, only the p300 and p270 forms reappear (lane 5).
specific to individual stages of cell growth, such as
phases of the cell cycle, transformed versus normal
cells, or aging and terminally differentiated cells.
An important property already revealed from our
study of these complexes is that p300 and at least two
of the p300-associated phosphoprotein species are
also present in specific complexes with the general
transcription factor, TBP (the TATA-box-binding
protein). These results are described further below.
Genetic Data Implicate the
Amino-terminal E1A Function
in trans-Activation via
Specific TATA Box
Sequences
E. Moran, F. Chadrin [in collaboration with V. Krauss
and J. Nevins, Duke University]
Several years ago, it was observed by J. Nevins and
others that the 12S E1A splice product can activate
the hsp70 promoter dependent on specific TATA box
sequences. The E1A 12S product can activate a wild-
type hsp70 promoter with its cognate TATA box ele-
ment, TATAA, but cannot activate a mutant hsp70
promoter in which the SV40 TAITIAT sequence
has been substituted for the normal hsp70 TATAA
element, even though the heterologous element is still
activated in response to heat shock. In the past year,
in a continuing collaboration with the Nevins labora-
tory, we have supplied newly generated E1A mutants
with amino-terminal alterations that have helped to
map this activity in E1A. These mutants indicate that
the ability of ElA to trans-activate via the hsp70
TATA element is dependent on E1A sequences also
involved in p300 binding and independent of region-
2-specific associations.
Our previous results have indicated that p300 is a
sequence-specific DNA-binding protein and thus is
likely to be involved in transcription. However, p300
shows no affinity for sequences related to TATA box
elements, showing instead a specific preference for
GC-rich sequences related to certain tissue-specific
enhancer elements known to be targeted by E1A in a
manner dependent on the p300-binding region (de-
scribed in 1991 Annual Report). These properties of
p300 and the E1A products appear to be linked to the
ability of the E1A products to repress many forms of
tissue-specific gene expression. Whether they are
also linked to the ability of the E1A amino-terminal
active site to activate hsp70 and cell-cycle-specific
gene expression remains to be determined. However,
the link revealed by E1A mutant anaylsis between
p300 association and TATA box responsiveness
raises the possibility that p300, even if bound to up-
stream GC-rich elements, may have specific interac-
tions with the protein complexes formed at the TATA
box. Evidence that this indeed is so is described in
the following section.
p300 and p300-associated
Proteins Are Components of
Specific TATA-binding Protein
Complexes
S. Abraham, P. Yaciuk, H.-G.H. Wang, A. Pepe,
E. Moran [in collaboration with S. Lobo,
Cold Spring Harbor Laboratory]
Last year, we reported evidence that p300 is a DNA-
binding protein with specific affinity for known en-
hancer motifs, suggesting that p300 may be a com-
ponent of transcription factor complexes. The pos-
sibility that upstream element binding factors might
interact with basal transcription factors, coupled with
the evidence described above indicating that the E1A
products, dependent on p300-binding sequences, can
activate the hsp70 promoter dependent on a specific
TATA box sequence, led us to investigate whether
p300 interacts, directly or indirectly, with the TATA-
binding protein (TBP). The availability of the panel
of p300-specific monoclonal antibodies developed in
our laboratory, together with a panel of TBP-specific
monoclonal antibodies developed by S. Lobo in the
Hernandez laboratory (see Genetics Section), enabled
us to investigate this possibility through the analysis
of specific immunocomplexes. We found indeed that
TBP-specific immunoprecipitations show a 300-kD
protein copre-cipitating with TBP. This protein is lost
from the precipitated material if the lysates are boiled
in SDS prior to immunoprecipitation, implying that
its presence does not result from nonspecific antibody
cross-reactivity but is dependent on specific associa-
tion with TBP (these interactions are shown in Fig.
5). The TBP-associated 300-kD protein and p300
originally defined by ElA association show in-
distinguishable partial proteolytic digest patterns, in-
dicating that these are identical or closely related
species. Moreover, p300-specific complexes and
TBP-specific complexes include at least two addi-
tional common polypeptide species, phosphoproteins
of 64 kD and 59 kD.
These results suggest that p300 interacts with TBP,
probably through intermediate protein-protein associ-
ations. Additionally, the observation that the TBP-
specific immunocomplexes examined here include
both the p270 and p300 forms indicates that both of
these forms can participate in cellular complex
formation.
57
A00
I
IMP
0
00
a_
p300
p270
11"644 p59
B
p64 p59 Control
p300 TBP p300 TBP{ 1
in 0 0 ic) ° r) 0 in
Lc)
IR 11 41040
0
to
I 2 3 4 5 6 7 8 9 10
1 2 3
FIGURE 5 Evidence for specific physical interactions between p300 and TBP (TATA-
binding protein) complexes. A subset of TBP-specific monoclonal antibodies will
coprecipitate p300 in immunocomplexes. One of these is shown in panel A, lane 3, where
the TBP-specific immunocomplex is compared with a p300-specific immunocomplex (lane
1). (These lysates are labeled with 32P to facilitate detection of the p300-associated
phosphoproteins and thus do not reveal TBP, which is not known to be phosphorylated.)
The suggestion that these immunocomplexes represent authentic in vivo protein associa-
tions is supported strongly by the observation that other p300-associated proteins, the
phosphoprotein species, p64 and p59 (marked with arrows in panel A), appear in im-
munocomplexes with the same subset of TBP-specific monoclonal antibody lines that
coprecipitate p300. That these are indeed the same species is indicated by their essen-
tially identical peptide digest patterns, shown in panel B. The p64 species, derived from
either p300-specific or TBP-specific immunocomplexes, show the same pattern (lanes 1
and 2 compared with lanes 3 and 4), as do the p59 species from either immunocomplex
(lanes 5 through 8). A control protein of similar size shows a very different pattern (lanes 9
and 10).
Conclusions and
Future Plans
P. Yaciuk, H.-G.H. Wang, A. Ebrahim, F. Chadrin,
J. Altman, E. Moran
This year has seen considerable progress both in
characterizing the intracellular interactions of p300
and in understanding the molecular formation of cel-
lular protein complexes on the El A molecule. The
observation that p300 and p300-associated proteins
are present in TBP-specific complexes strongly sup-
58
ports previous indications that p300 plays a sig-
nificant role in cellular transcription. The visualiza-
tion of p300-associated cellular factors is an impor-
tant step toward identifying and understanding the
cellular role of p300 and the regulatory pathways in
which it functions. Increased understanding of the na-
ture of E1A complex formation has revealed a poten-
tial for direct interaction between p300 and the
region-2-associated proteins that may be very impor-
tant in understanding the means by which the E1A
products override cell growth control mechanisms,
thus revealing vulnerable cell growth control points.
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F. Sun
M. Vandenberg
I.J. Yu
The Protein Chemistry laboratory conducts research
on signal transduction and cell growth using ad-
vanced methods of analytical and preparative
biochemistry. These methods include automated
protein sequence analysis, high-performance liquid
chromatography (HPLC), amino acid analysis, prepa-
rative electrophoresis, mass spectrometry, and pep-
tide synthesis. Using such procedures allows us to
deduce chemical structures of proteins and to
synthesize structural and functional domains. In addi-
tion, physical analysis of proteins by mass spec-
trometry, in conjunction with chemical studies,
permits the determination of posttranslational modifi-
cations of proteins, such as phosphorylation and
acylation. Our goal is to attack biological problems of
the control of cell growth by using an arsenal of
state-of-the-art biochemical methods. Often, this re-
quires the development of new methods when exist-
ing procedures are not adequate to solve the cell
biological question. This chemical approach to cell
biology is highly complementary to genetic ap-
proaches in many other laboratories at Cold Spring
Harbor, and analytical biochemistry is an essential
part of a multidisciplinary approach to problems of
normal and abnormal cell growth, as in cancer.
Synthetic Peptide Substrates
for Protein Kinases
D.R. Marshak, M. Vandenberg, I.J. Yu, F. Sun,
M. Meneilly, G. Binns
Protein kinases are enzymes that catalyze the transfer
of phosphates from the y-phosphate position of ATP
to a hydroxyl moiety (serine, threonine, or tyrosine)
on proteins. The recognition sequences for protein
kinases are surprisingly short; usually only four to six
amino acid residues in linear sequence are required
for specifying the substrate. Therefore, synthetic pep-
tide substrates have been quite useful as model sub-
strates for protein kinases. Such peptides, usually
10-20 residues in length, can be synthesized by
solid-phase methods using automated instrumenta-
tion. They are constructed as protected molecules on
polystyrene supports and then deprotected and
cleaved from the support by treatment with acid. In
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our laboratory, rigorous purification and characteriza-
tion are carried out to assure purity and identity of the
material. We have documented evidence that prod-
ucts of the side reactions of peptide synthesis can
alter the measured kinetic properties of the substrate
(Marshak and Carroll, Methods Enzymol. 200: 134
[1991]). Therefore, we use mass spectrometric
measurements to assess the molecular weight of the
product to eliminate unwanted modified side prod-
ucts that arise from incomplete removal of protecting
groups or other modifications. Combined with HPLC
and amino acid analysis, mass spectrometry has al-
lowed us to prepare peptides with excellent character-
istics as kinase substrates, including low KM values.
During the past year, we have examined the sub-
strate specificity of p34cdc2 isolated from He La cells
arrested during mitosis by the drug nocodazole. This
compound disrupts microtubules and thus does not
allow a cell to pass metaphase because there is not a
functional mitotic spindle apparatus for chromosome
segregation. These mitotic human cells have very
high levels of p34cdc2 complexed with cyclin B. This
enzyme has been thought to have the substrate
specificity Ser/Thr-Pro-(X)n-Z, where the phosphory-
lated residue can be either a serine or threonine that is
always followed by proline. The residues marked X
are usually polar, where n = 1-3, and Z represents a
basic residue. We tested the requirement for the basic
residues downstream in a series of synthetic sub-
strates based on the p34cdc2 phosphorylation site
found in SV40 T antigen. By changing basic residues
to leucine hydrophobic residues, we were able to alter
the KM, the Vmax, or both, depending on the positions
of the residues substituted. Furthermore, we altered
the polar uncharged residue X to a negatively
charged residue, glutamic acid, and observed in-
creased phosphorylation of that substrate. These data
are significant because new, putative sites of phos-
phorylation by p34cdc2 might be due to a related en-
zyme with slightly altered substrate specificity, such
p33cdk2 p34cdc2as or bound to a different cyclin
molecule.
Molecular Cloning and Expression
of Casein Kinase II Subunits
N. Chester, I.J. Yu, M.T. Vandenberg, D.R. Marshak
The enzyme casein kinase II (CKII) is a protein
serine/threonine kinase found in all eukaryotic cells.
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Its ubiquitous distribution among species and tissues
implies a function central to all nucleated cells. The
enzyme consists of two subunits, a and 11, With
molecular mass ranges of 37-44 kD and 24-28 kD,
respectively, and an apparent subunit composition of
a2[32. The a subunit is found in two different forms,
known as a and a' , that arise from separate genes.
To answer questions about the mechanism of enzyme
regulation, we have cloned and expressed DNA
molecules coding for the full-length forms of the a
and 13 subunits. To do this, a novel method using the
polymerase chain reaction was developed (N. Chester
and D.R. Marshak, in press).
We have also obtained a clone of the a' subunit
from Dr. Ed Krebs in Seattle. We built these clones
into a T7 expression vector (a gift from W. Studier,
Brookhaven, and J. Kuret, CSHL) for production of
the subunits of the protein. In addition, the a' sub-
unit was expressed as a fusion protein with the bac-
terial maltose-binding protein. This construction
permits rapid purification of the fusion protein on af-
finity columns, followed by cleavage of the enzyme
from the binding protein. M. Vandenberg has shown
that the purified recombinant a' subunit can be ac-
tivated in vitro by the recombinant 13 subunit. We
plan to go on with large-scale expression of various
forms of the enzyme for structural analysis by X-ray
diffraction.
Cell Cycle Regulation of
Casein Kinase II
G.L. Russo, I.J. Yu, G. Binns, M. Vandenberg,
D.R. Marshak
A set of studies has been conducted by Gian Luigi
Russo to investigate the cell cycle regulation of the
phosphorylation of p34cdc2. This enzyme has major
phosphorylation sites at threonine and tyrosine
residues that regulate its activity positively and nega-
tively, respectively. Previous reports of serine
phosphorylation have led us to attempt to identify
these minor sites of phosphate attachment. We dis-
covered that the p34cdc2 kinase, which is central to
growth control in eukaryotic organisms, is phosphor-
ylated on Ser-39 during the G1 phase of the HeLa cell
division cycle (Russo et al. 1992). This site was
mapped on protein labeled in vivo and in vitro. We
utilized our new phosphoprotein sequencing methods
to identify the exact site of phosphorylation. The en-
zyme responsible for this phosphorylation event is
casein kinase II, which was previously shown by us
to be activated during middle to late G1. This
phosphorylation was demonstrated using purified na-
tive p34cdc2, recombinant protein from Escherichia
coli, and representative synthetic peptides. Different
phosphorylated forms of p34cdc2 were identified on
two-dimensional gels (in collaboration with R.
Franza).
Subcellular Localization
of Casein Kinase II
N. Chester, I.J. Yu, D.R. Marshak
The CKII enzyme activity is found both in cytosol
and in nuclei, and there are substrates identified in
both locations. Cytosolic substrates include proteins
involved in translational control (eIF-2, -3, -4B, -5),
metabolic regulation (glycogen synthase), and the
cytoskeleton (nonmuscle myosin heavy chain, (3-
tubulin). Substrates found in the nucleus include
DNA topoisomerase II, RNA polymerases I and II,
oncoproteins such as Myc, Myb, and SV40 large T
antigen, and transcription factors such as serum
response factor. The extraordinary range of substrates
for this enzyme supports the contention that CKII
plays a significant role in cell physiology. We have
developed a large set of specific antibodies to
synthetic peptide antigens that react with the individ-
ual subunits of CKII. These antibodies allowed us to
continue our studies of the subcellular localization of
the subunits of the enzyme during the cell division
cycle of He La cells. Using immunofluorescence mi-
croscopy, we examined asynchronous populations of
cells, as well as cells arrested and released from the
Gi/S transition by the chemical hydroxyurea. The
results indicated that the a and 13 subunits are local-
ized to the cytoplasm during interphase and through-
out the cell during mitosis. However, using an
antibody with different specificities, it appears that a
pool of a subunit does exist in the nucleus. The reac-
tivities of the epitope or the physical localization of
the enzyme itself changes at the G1 /S -phase transi-
tion. These dynamics suggest that CKII may affect
cell division cycle control by altering its conforma-
tion or localization to different subcellular compart-
ments.
Structural Analysis and
Phosphorylation of
Nuclear Proteins
D.R. Marshak, M. Vandenberg, G. Binns [in collaboration
with T. Curran, Roche Institute; M. Mathews and A. Krainer,
Cold Spring Harbor Laboratory; and E. Harlow,
Massachusetts General Hospital]
DAI KINASE
Significant progress has been made on mapping the
autophosphorylation sites on the double-stranded
RNA-activated protein kinase, DAI, done in col-
laboration with M. Mathews. The kinase is phosphor-
ylated and immunoprecipitated on a large scale. The
protein is eluted from the precipitate in formic acid,
digested with cyanogen bromide, and subjected to
reverse-phase chromatography. At least three pep-
tides have been recovered from these digests. Using
phosphoprotein sequencing methods, we have tenta-
tively identified one site. Further subdigestion of the
other fragments using proteases has enabled us to
recover other phosphorylated peptides for analysis.
SPLICING FACTOR 2
We have been trying to determine the in vivo
phosphorylation sites of human pre-mRNA splicing
factor 2 (SF2) to study the relationship between
structure and function in RNA processing. Following
electrophoresis and digestion in situ with lysyl
endoproteinase, the fragments recovered by reverse-
phase chromatography were located and sequenced.
We are now in a position to determine the phosphor-
ylation sites by similar maps after 32P-phosphate
labeling in vivo and in vitro. Interestingly, as we se-
quenced all of the fragments, we found several pep-
tides derived from an unknown protein that corn-
igrated with SF2 on electrophoresis. Sequence analy-
sis revealed that this protein is another putative RNA
splicing factor.
TRANSCRIPTION FACTORS
The phosphorylation of the c-Fos and c-Jun proteins
was done in collaboration with T. Curran's group at
the Roche Institute (Abate et al., Oncogene 6: 2179
[1991]; Baker et al. 1992). Sites on c-Fos and c-Jun
proteins were analyzed by phosphorylating in vitro
the proteins produced in bacteria as recombinants.
Purified proteins as well as truncated versions with
various domains deleted were used. Phosphorylation
sites on c-Fos occur in regions that have been linked
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genetically to the regulation of transcriptional con-
trol. Notably, sites for the cell-cycle-regulated protein
kinase, p34cdc2, were identified, suggesting that there
might be significant cell cycle regulation of the tran-
scriptional control by c-Fos. Sites of phosphorylation
by p34cdc2 were also found on c-Jun protein. One of
these sites overlaps a carboxy-terminal site reported
to have negative regulatory effects. A second site for
p34cdc2 was found in the amino-terminal domain
close to the region that is different in the v-Jun
protein.
RETINOBLASTOMA
The recessive oncogene, retinoblastoma (Rb), was
analyzed in collaboration with E. Harlow at the Mas-
sachusetts General Hospital (Lees et al., EMBO J. 10:
4279 [1991]). Rb protein is quite large (105 kD), but
it is found in only minute quantities in cells. It is
therefore very difficult to identify phosphorylation
sites directly from in vivo metabolically labeled
proteins. We took a novel approach of using synthetic
peptide model substrates to map phosphorylation
sites in vitro and then compared these to maps of im-
munoprecipitated, in-vivo-labeled Rb protein. This
approach required that we survey the Rb protein se-
quence, inferred from the cDNA structure, for poten-
tial sites of p34cdc2 phosphorylation. We identified
clusters of potential sites and synthesized moderately
long peptides (30-40 residues) covering these sites.
Determination of the stoichiometry and positions of
the phosphates was accomplished by a combination
of mass spectrometry and protein sequencing. The
final compilation of data allowed the assignment of
five sites of phosphorylation of Rb by p34cdc2 and
excluded several sites from phosphorylation in vivo.
Protein Chemistry
Core Facility
G. Binns, M. Meneilly, N. Poppito, M. Vandenberg,
R. Kobayashi, D.R. Marshak
The Protein Chemistry Core facility provides high
technology methods, equipment, and expertise for
use by all scientists at Cold Spring Harbor Labor-
atory. The services provided include protein sequenc-
ing, peptide mapping by HPLC, peptide synthesis,
HPLC and electrophoretic purification of proteins,
mass spectrometry, and amino acid analysis. These
methods can be used for structural analysis of the
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amino acid sequence and composition of a protein, as
well as for determining posttranslational modifica-
tions. Although peptide synthesis remained approxi-
mately constant, amino acid analysis returned to 1990
levels. Protein sequencing and peptide mapping have
been aided by the addition of new equipment to the
laboratory. We have obtained an Applied Biosystems
473 protein sequencer and have adapted it for either
standard Edman or phosphopeptide sequencing. In
addition, we have been awarded a large shared in-
strumentation grant that provides funds for a new
HPLC and another protein sequencer. The new
HPLC is a Hewlett Packard 1090M, with the new
workstation based on DOS operating software. This
instrument is networked to our existing HPLC,
providing a comprehensive system for chromato-
graphy. Now we can do peptide maps and carry out
amino acid analysis at the same time.
Structural Analysis of Proteins
R. Kobayashi
Amino acid sequence information of protein has an
important role in studying the structure and function
of proteins. This year, I introduced a new technique
to isolate and separate peptide fragments after digest-
ion of protein with protease while still embedded in
polyacrylamide gels. In this way, internal amino acid
sequences can be obtained in a minute amount of pro-
tein having biological importance. With this new
technique, the procedure for obtaining internal amino
acid sequences of proteins at a level of 2-10 lig, with
a molecular mass of up to 150 kD, became relatively
simpler and routine: separate proteins by SDS-PAGE,
stain the proteins with Coomassie blue, destain the
background of the gel, excise the protein bands,
digest the protein in the gel by Achromobacter
protease I (lysylendopeptidase), extract the peptides,
and separate them by reverse-phase high-perform-
ance liquid chromatography (RP-HPLC), using an
anion exchange pre-column of diethylaminoethyl
(DEAE)-derivatized silica. The eluted peptide frag-
ments are then analyzed on an automated protein se-
quencer. When proteins radioactively labeled with
32P were analyzed, I calculated more than 97%
recovery with this technique.
In collaboration with B. Stillman (Cold Spring
Harbor Laboratory), I have obtained a partial amino
acid sequence of the origin recognition complexes
(ORC; subunits: 50, 53, 56, 62, 65, 72, and 120 kD)
and replication factor C (RFC; subunits: 36, 40, 41,
and 103 kD) from the yeast Saccharomyces
cerevisiae and chromatin assembly factor (CAF-1;
subunits: 55, 60, and 150 kD) from human. We ob-
tained enough information to isolate these genes for
further studies; the sequence analysis is currently un-
der way for human maturation factor (MF- 1)
In collaboration with A. Krainer (Cold Spring Har-
bor Laboratory), I have obtained sufficient sequence
information of mRNA splicing factor p52 to isolate
its gene. We also made peptide maps to determine the
in vivo phosphorylation sites of human mRNA splic-
ing factor 2 (SF2).
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Methodological Study of Protein
Sequence Analysis
R. Kobayashi
One of my research interests is to develop a new,
highly sensitive method for protein sequence analy-
sis. Protein sequence analysis has played a major role
in studies on the relationship of protein structure and
function. Proteins of biological importance, however,
are not easily obtained in sufficient amounts for
structure analysis, and this has caused delays in
biological discoveries. As the technology for identi-
fying and purifying proteins continues to develop,
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FIGURE 1 Sequence analysis of insulin B-chain (Sequence: FVNQHL ) by the
modified Edman degradation.
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more sensitive techniques will be required for protein
structural analysis. Although the technique that I
employed this year allows us to obtain internal se-
quence information in the amount of a few micro-
grams of protein, which can only be purified by
polyacrylamide gel electrophoresis, we still require
more than 1 p.g of protein. This amount is still some-
times difficult to obtain for many biologically sig-
nificant proteins. At this time, there are proteins that
are detectable when separated by HPLC after frag-
mentation of the proteins, but we cannot sequence
them. Therefore, I have been trying to improve the
sensitivity of protein sequencing by modifying the
Edman degradation. This year, I employed amino-
lytic conversion instead of acid conversion to intro-
duce a fluorescence tag, and I gave up using a new
Edman-type reagent for sequencing. I decided to stay
with the well-studied phenylisothiocyanate. The Ed-
man chemistry is the same as the original until the
extraction step of 2-anilinothiazolinone of amino
acids. Here, a fluorescence tag is introduced into
these molecules through aminolytic conversion. The
sequencing products are detectable by both their fluo-
rescence and their chemiluminescence. To test
whether the chemistry worked, 60 pmoles of insulin
B-chain was sequenced. The results of the first six
cycles from the amino terminus are shown in Figure
1. One fifth of the sequencing products were sepa-
rated by HPLC and monitored by their fluorescence.
Although I did not use very small amounts of starting
protein, these results clearly show that it is feasible to
use this chemistry to sequence proteins. I am current-
ly synthesizing and purifying all of the standard
amino acid derivatives to optimize HPLC separation.
Finally, I will apply chemiluminescence detection,
which is much more sensitive than fluorescence
detection, to the new method in order to study sub-
picomole levels of peptides.
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Research in this laboratory continues to focus on the
regulation of gene expression in human cells. We are
investigating three systems that function at different
levels. The first operates at the level of protein syn-
thesis, where we are studying a protein kinase that
controls the rate of translational initiation. The kinase
is part of the interferon-induced antiviral defense
mechanism and is influenced by viral products that
serve to neutralize its action. The second project is
concerned with the regulation of a cellular gene at the
transcriptional level by a viral oncogene. Expression
of the essential DNA replication protein known as
proliferating cell nuclear antigen (PCNA) is activated
by one of the transforming proteins encoded by
adenovirus, as well as by various other stimuli in the
normal cell. We are trying to understand how these
stimuli impinge on the activity of PCNA in the cell's
nucleus. Finally, the AIDS virus HIV-1 (human im-
munodeficiency virus type 1) exploits a range of
regulatory devices, some of them sophisticated and
unprecedented. We are interested in controls that
govern viral gene expression at both the transcrip-
tional and translational levels, and which may also
link viral gene activation to the proliferative status of
the cell. During 1992, Piruz Nahreini joined the
laboratory as a postdoctoral fellow, Chitra Kan-
nabiran and Mark Kessler moved on to other appoint-
ments, and Christian Schmedt worked for several
productive months as an exchange student.
Translational Control
P. Clarke, Y. Ma, C. Schmedt, D. Taylor, S. Green,
L. Manche, M.B. Mathews
The protein kinase DAI, an acronym for the double-
stranded RNA activated inhibitor of translation, is an
important element in the host antiviral response that
is induced by interferon. The kinase is associated
with ribosomes in a wide range of tissues and
normally exists in an inactive or latent state. As im-
plied by its name, DAI is specifically activated by
double-stranded (ds)RNA, probably of viral origin,
but not by single-stranded RNA, DNA, or RNA-
DNA hybrids. In some situations, activation of DAI
by dsRNA results in a complete inhibition of protein
synthesis, whereas under other circumstances, there
is selective inhibition of the translation of certain
mRNAs. This inhibition of protein synthesis is due to
the phosphorylation of the initiation factor eIF-2,
which is involved in ternary complex formation dur-
ing the initiation of translation. The kinase was ini-
tially discovered as part of an antiviral pathway, but
more recently, it has been implicated in cellular dif-
ferentiation, inhibition of cellular proliferation, the
heat-shock response, and perhaps also the transcrip-
tional induction of gene expression by dsRNA. Our
laboratory is endeavoring to understand the molecu-
lar mechanism by which DAI is activated and how
small RNAs, such as adenovirus VA RNAI, can
block this activation. Recent work has concentrated
on identifying the nature of the contacts made be-
tween DAI and RNA and on elucidating the pro-
cesses of enzyme activation and inactivation by these
ligands.
To explore the complex interactions between DAI
and RNAs, we synthesized the enzyme in vitro and
examined its RNA-binding domain. Our findings lo-
cated the domain at the amino terminus of the protein
and revealed that it consists of two copies of a novel
RNA-binding motif. The motif is characterized by a
high density of basic amino acids, by the presence of
conserved amino acid residues, and by a probable a-
helical structure (Fig. 1). Deletion of either of the two
motifs prevents the binding of RNA, but their relative
positions can be exchanged, suggesting that they
cooperate to interact with RNA. Mutations within the
RNA-binding motifs and duplications of the individ-
ual motifs indicated that the first (amino-terminal)
copy of the motif plays the more important role. Sur-
prisingly, mutations that impair binding have similar
effects on the binding of dsRNAs of various lengths
and of adenovirus VA RNAI, implying that the dis-
crimination between activators and inhibitors takes
place subsequent to RNA binding.
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FIGURE 1 Structure of DAI. (Top) Map of DAI showing the basic regions (1-3), putative substrate
determinant (S), and kinase
subdomains (1-X1). (Bottom) RNA-binding motifs from DAI and consensus
sequence from human and mouse DAI, vaccinia
E3L, rotavirus N534, and TAR RNA-binding protein. Similar or identical
amino acids present in the same position in four or
more of the sequences are shown in bold type as lowercase or uppercase
letters, respectively. Motifs 1 and 2 correspond to
basic regions 1 and 2, respectively. The amino-terminal part of each motif
is predicted to form an a-helix. (From Green and
Mathews 1992.)
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On the basis of these results, we produced a trun-
cated form of DAI (p20) that encodes just the first
184 amino acids of DAI, representing the entire
RNA-binding domain. This protein was overex-
pressed in Escherichia coli and purified to more than
95% homogeneity. In RNA-binding assays, p20 func-
tions identically to the full-length protein, and gel
shift analysis suggests that each copy of the motif in-
teracts with a single turn of the RNA helix. These ob-
servations lead us to speculate that kinase activation
involves the interaction of the two motifs with suit-
ably spaced helical regions on the activator dsRNA.
DAI is a serine/threonine kinase and its activation
as an eIF-2 kinase is correlated with its autophos-
phorylation. We have begun to identify the location
of the autophosphorylation sites and the mechanism
of autophosphorylation of DAI. In collaboration with
Dan Marshak and Georgia Binns (see Protein
Chemistry in this section), the locations of several
autophosphorylated sites have been found through
peptide mapping and sequencing. These sites may
define an auto-regulatory region, separating the en-
zyme's RNA-binding and kinase domains. Once the
phosphorylation sites have been characterized, we
will determine which of these phosphorylated serines
and threonines are important to the function of the
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kinase and study the mechanism of autophosphoryla-
tion. Preliminary data indicate that some sites on
truncated forms of DAI can be phosphorylated inter-
molecularly, consistent with the view that such a
mechanism is used by full-length DAI, but further
studies are required to prove the point with the intact
protein.
Many viruses have the potential to activate DAI
during infection, so it is not surprising that they have
evolved mechanisms to inhibit DAI activation and
maintain viral replication (sometimes at the expense
of host translation). One mechanism involves the ac-
cumulation of high concentrations of small, highly
structured RNAs that can specifically block the ac-
tivation of DAI by dsRNA. At late times during
adenovirus infection, VA RNA' plays this role. Ear-
lier work indicated that the function of VA RNA is
dependent on its secondary structure and that this
consists of a terminal base-paired stem separated
from an apical stem-loop by a complex system of
stems and loops referred to as the central domain.
To understand this structure in more detail, we
have conducted a phylogenetic analysis using six
species of VA RNA drawn from three classes of hu-
man adenovirus and one simian adenovirus. The VA
RNA of the avian adenovirus CELO proved to be too
distantly related to be useful in this study. All the
mammalian VA RNAs are built on the same plan,
and the comparison served to reveal several interest-
ing features. Although there is little sequence conser-
vation outside regions containing transcription se-
quences, and the relative proportions of the structural
elements also vary, there is a GC-rich sequence in the
apical stem that is located in a suitable position to
suggest a role in DAI binding. Furthermore, in the 3'
part of the central domain, there is a conserved
tetranucleotide (ACCC) that is insensitive to single-
strand-specific nucleases but is flanked by two highly
sensitive regions and can pair with another conserved
tetranucleotide (GGGU) located farther upstream.
Support for the view that this structure contributes to
the conformation and function of VA RNA comes
from mutagenesis of these sequences and from func-
tional assays. Comparing the overall secondary struc-
tures of the VA RNAs, it transpires that the most ac-
tive species have a long apical stem-loop and a
trident-structured stem in the central domain. The
two moderately active species differ somewhat in the
central domain but have a very similar apical stem-
loop structure. The VA RNA,' forms display only
weak translational function and do not appear to pos-
sess the same secondary structure in the central
domain, presumably accounting for their weak trans-
lational function; on the other hand, they are striking-
ly closely related to one another at the primary se-
quence level, suggesting that they may play a dif-
ferent role in viral infection.
Previous work indicated that DAI binds primarily
to the apical stem of VA RNA/ and that the blocking
activity of VA RNA/ resides in the central domain.
We have studied the interaction of a large number of
VA RNA mutants with DAI in vitro, using a binding
assay. The results largely confirm earlier observa-
tions: Mutations that disrupt pairing within the apical
stem also disrupt binding and function, whereas most
mutants within the central domain that lack function
nevertheless retain significant binding activity. We
have now applied direct approaches to examine the
RNA-protein interaction in more detail. Ribonuclease
footprinting experiments indicate that DAI protects
the base of the apical stem, the complementary con-
served tetranucleotides, and other regions in the cen-
tral domain. The truncated form of DAI, p20, dis-
plays somewhat reduced protection of the central
domain. Exposure of the complex to chemical probes
suggests that the protein does not make sequence-
specific interactions with the bases, but more likely
interacts with the backbone of the RNA duplex.
Moreover, these footprints showed protection of ap-
proximately half a turn of the apical stem, in the
minor groove of the duplex, consistent with close
contacts between the amino terminus of DAI and the
backbone of the apical stem. At an altogether dif-
ferent level of resolution, we have collaborated with
Luis Jimenez-Garcia and David Spector (Molecular
Genetics of Eukaryotic Cells Section) to examine the
intracellular distribution of VA RNA and DAI. These
two moieties colocalized in the cytoplasm, as
anticipated from their function, and both were also
found in the nucleus. VA RNA displayed a dotted
pattern in the nucleoplasm, consistent with its site of
synthesis. Less expectedly, DAI was found in the
nucleolus and, to a lesser extent, in the nucleoplasm.
Its nucleolar site of distribution might be related to its
assembly onto ribosomal particles, but alternative ex-
planations cannot be ruled out at present.
Regulation of PCNA
G.F. Morris, C. Labrie, C. Kannabiran,
R. Packer, M.B. Mathews
Activation of the DNA replication machinery is cen-
tral to the process of neoplastic transformation. The
proliferating cell nuclear antigen, PCNA, plays an es-
sential part in leading-strand DNA replication. It is
the auxiliary factor of DNA polymerase 8 and func-
tions in leading-strand DNA synthesis during DNA
replication. In accord with this function, cellular
PCNA levels increase during the oncogenic trans-
formation of rodent cells by the adenovirus E1A
gene. The goal of this project is to explore the rela-
tionship between transformation and gene activation
by elucidating the mechanism of E1A-mediated in-
duction of PCNA gene expression.
The E1A 243R protein (243 residues long), trans-
lated from the E1A 12S mRNA, is able to stimulate
PCNA transcription and to activate the PCNA
promoter in the absence of other viral genes. To
define the E1A sequences needed, we assayed 13 dif-
ferent El A mutants for their ability to trans-activate
a cotransfected PCNA promoter construct in He La
cells. Large deletions that in combination span the
entire protein severely impair the ability of E1A to
induce PCNA expression, whereas smaller deletions
and point mutations that target specific cellular
protein-binding properties of El A 243R are less
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deleterious to PCNA induction. The results suggest
that E1A can activate transcription of the PCNA gene
by multiple mechanisms and that, of the known E1A-
associated proteins, p300 and p107/cyclin A can
mediate the response, whereas p105-Rb and p130 can
probably be excluded. However, two ElA mutants
that separately bind p300 and p107/cyclin A do not
complement each other in the cotransfection assay,
implying that the two proteins must be bound to the
same E1A molecule or that an as yet unidentified
ElA- associated protein is involved.
To define the cis-acting sequences involved in the
induction of PCNA by ElA 243R, we conducted
linker-scanning and site-directed mutagenesis of the
promoter. The required promoter region lies between
nucleotides -59 and -45 upstream of the transcrip-
tion initiation site and includes the sequence
AGCGTGG immediately upstream of the ATF-
binding site previously shown to be important for ac-
tivation of PCNA by ElA 243R. This PCNA E1A-
responsive element (PERE) appears to constitute a
complex promoter element as mutation of either the
upstream component or the ATF site within the
PERE diminishes basal promoter activity and
abrogates trans-activation by ElA 243R. The PERE
is also essential for both basal and E1A-induced ex-
pression in the context of the full-length PCNA
promoter and is sufficient to confer responsivity to
ElA upon a heterologous promoter. Furthermore, the
importance of the PERE to PCNA gene expression is
highlighted by the occurrence of a similarly posi-
tioned homologous sequence in the rat and mouse
PCNA promoters and in the promoter for another hu-
man DNA replication protein, DNA polymerase p.
We have begun to characterize the proteins that in-
teract with the PERE using biochemical techniques.
The PERE is protected from DNase I digestion by
nuclear extracts from 293 cells, and gel retardation
assays with the PERE have revealed the existence of
multiple PERE-associated complexes in 293 cell
nuclear extracts. We will now attempt to identify the
cellular proteins that compose these complexes. In a
complementary genetic approach, we have replaced
the PERE with five GAL4 sites and tested the ability
of various effectors, expressed as fusions with the
GAL4 protein, to mediate activation by E1A. It ap-
pears that weak effectors can mediate induction by
243R, whereas ElA reduces activation by strong ef-
fectors (Fig. 2). Thus, the PCNA basal promoter is
configured in a manner that permits the response of
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FIGURE 2 Activation of the PERE. The model shown il-
lustrates a possible mechanism for the E1A response of
G5PCNA-CAT to effectors of varying strengths. In the ab-
sence of effector, a stable initiation complex is not formed
on the PCNA promoter and there is no response to ElA.
Weak effectors support the stable association of the initia-
tion complex with the promoter, and E1A interacts with the
initiation complex in a manner that complements the weak
effector. In contrast, strong effectors interact with the initia-
tion complex more productively than the weak effectors.
E1A represses transcriptional activation by the strong effec-
tors because it interferes with the interaction of the strong
effector with the initiation complex.
transcriptional activators to be modulated by E1A,
perhaps by favoring protein-protein interactions that
recruit further factors such as TFIID to this TATA-
less promoter.
Most of these experiments were conducted in
HeLa cells, a transformed cell line derived from a hu-
man cervical carcinoma. To extend our analysis of
ElA activation of the PCNA promoter to more
normal cell types, we employed two kinds of rodent
cells, primary baby rat kidney (BRK) cells and
cloned rat embryo fibroblasts (CREF). These two cell
types display more regulated growth control than
HeLa cells and they can be transformed by
adenovirus infection. Surprisingly, the PCNA
promoter is repressed by E1A in both cell types. As
with other promoters repressed by E1A, repression of
the PCNA promoter mapped to the p300-binding
region of ElA. The cis-acting sequences of the
PCNA promoter required for repression by E1A
reside between nucleotides 234 and 213 upstream of
the transcriptional initiation site of the PCNA
promoter. Within this sequence is an 18 out of 20
match to a p53-responsive element. Gel mobility shift
experiments conducted in collaboration with J. Bis-
choff (Genetics Section) indicated that this sequence
is bound by wild-type, but not mutant, human p53 ex-
pressed in yeast. Presumably, the HPV E6-induced
loss of p53 function in He La cells precludes repres-
sion of PCNA-CAT by E1A in these cells. Consistent
with our observations in He La cells, constructs lack-
ing sequences upstream of -213 are activated by E1A
243R in both CREF and mouse 3T3 cells. Future ex-
periments will address the relationship between E1A
repression of PCNA-CAT and p53 function in other
cell types.
Regulation of HIV Gene Expression
S. Gunnery, P. Nahreini, M. Kessler, B. Hofmann,
M.B. Mathews
Expression of the genes encoded by the human im-
munodeficiency virus (HIV-1) is critically dependent
on a viral protein called Tat which functions in con-
junction with a viral RNA sequence known as TAR.
These elements cooperate to increase the rate of tran-
scriptional initiation and the efficiency of transcrip-
tional elongation (for a discussion of the mechanisms
involved, see below). Previous work, using transient
expression assays, indicated that the action of Tat can
be influenced by the origin of SV40 DNA replication
in such a way as to suggest that transcription from the
viral long terminal repeat (LTR) might be linked to
replication. Since the activation of HIV transcription
is indispensable for the virus to exit from latency and
initiate a productive infection, we reasoned that the
proximity of the integrated HIV provirus to a DNA
replication origin may affect the viral promoter ac-
tivity and its subsequent pathogenicity. To address
this, as well as to extend our previous studies, we are
exploiting the ability of recombinant adeno-
associated virus (AAV-1) to transfer and stably in-
tegrate the reporter gene cassette into human
chromosome 19 in a site-specific fashion. In pursuit
of this goal, we have recently constructed several
chimeric AAV vectors containing the LTR-CAT
reporter cassette. In some of these chimeric AAV
vectors, a selectable marker gene was inserted to fa-
cilitate the isolation of clones containing the in-
tegrated HIV gene cassette. Such recombinant AAVs
were used to infect He La cells, and the process of
isolating clones is currently under way. In the near
future, the site of LTR-CAT gene integration will be
determined using the cloned chromosome-19-specific
AAV junction DNA fragment as a probe, and the
HIV promoter activity will be monitored in the ab-
sence or presence of the Tat protein. We hope that
this strategy will provide insights into the effects of
host DNA replication on HIV gene expression and
perhaps disclose a link between HIV pathobiology
and the proximity of the integrated provirus to a cel-
lular replication origin.
The TAR sequence is also capable of influencing
HIV gene expression at the translational level. The
5' -untranslated region of all HIV-1 mRNAs contains
this sequence, and TAR RNA also exists as a free
cytoplasmic form of about 58-66 nucleotides. As
reported earlier, this short form of TAR RNA can act
like VA RNA to block the activation and autophos-
phorylation of DAI in a kinase assay in vitro. We
have now extended this observation to a cell-free
translation system where TAR RNA reverses the in-
hibition of protein synthesis mediated by dsRNA.
TAR RNA folds to form a stem, bulge, and loop, and
mutagenic and structural analyses indicate that a stem
of at least 14 by is required for this activity, whereas
the TAR loop and bulge required for trans-activation
by Tat are dispensable. Truncation of the RNA to 68
nucleotides results in the loss of translational rescue
ability, suggesting that the short cytoplasmic TAR
RNA produced by viral transcription in vivo may not
have the capability to suppress activation of the
kinase.
To determine the significance of the inhibitory
property of TAR RNA in vivo, we employed a
transient expression assay. Transfection into 293 cells
of a plasmid containing the chloramphenicol acetyl-
transferase (CAT) gene under the direction of the
mouse 13-globin promoter leads to activation of DAI
and eIF-2 phosphorylation. The resultant poor ex-
pression of CAT is greatly stimulated by cotransfec-
tion of a plasmid producing the VA RNA which
blocks the activation of DAI and consequently im-
proves the expression from the vector. We have now
shown that TAR RNA can function in the same way.
To express TAR RNA in vivo, we constructed the
pVA-TAR plasmid, in which TAR sequences are
placed downstream from the strong VA RNA/ gene
promoter. Because this RNA polymerase III promoter
is intragenic, the transcribed RNA is chimeric: VA-
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TAR RNA is 171 nucleotides long, containing the
TAR sequence (-3 to +82) flanked by 68 nucleotides
of VA RNA sequence on its 5 ' side and 9 nucleotides
on its 3' end. The VA RNA sequences that are pres-
ent in VA-TAR lack both of the features of this RNA
that are required for blocking DAI activation, the
central domain and the apical stem, and when exam-
ined by nuclease sensitivity analysis, the regions
derived from VA RNA were unstructured, as evi-
denced by frequent single-strand cuts. However, the
TAR RNA structure in the VA TAR chimera is es-
sentially identical to that in free TAR RNA. Thus, the
main structure observed in the molecule was the stem
and loop structure of TAR RNA together with a small
3' -terminal stem-loop (Fig. 3C). Cotransfection of
pVA-TAR with the reporter plasmid resulted in a
stimulation of CAT enzyme activity (Fig. 3A), show-
ing that a longer TAR transcript can stimulate expres-
sion in vivo. This finding raises the possibility that
the TAR structure at the 5' end of viral messages ex-
erts its function in cis, thereby conferring a transla-
tional advantage to HIV mRNA over cellular mRNA.
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Transcriptional Regulation by the
HIV-1 Tat Protein
P. Wendel, M.F. Laspia
The genome of HIV-1 contains, in addition to the
structural genes gag, pol, and env, several novel
regulatory genes. One of these, tat, is essential and
encodes a powerful trans-activator that greatly stimu-
lates HIV-1 gene expression. It does so by increasing
transcription directed by the promoter located within
the long terminal repeat (LTR) of the virus. Trans-
activation occurs by a novel mechanism in which Tat
binds to an RNA element, known as TAR RNA, that
is present in the 5' -untranslated region of all HIV
mRNAs. In the absence of Tat, the level of HIV-
directed transcriptional initiation is low and transcrip-
tional elongation is inefficient, such that the number
of transcriptional complexes declines with increasing
distance from the promoter (polarity). The binding of
Tat to TAR RNA produces dual effects on transcrip-
tion, increasing initiation of transcription by RNA
units
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FIGURE 3 Effect of TAR RNA in vivo. (A) CAT enzyme activity in lysates of human 293 cells transfected with carrier
DNA only (lanes 1,2), ppCAT plasmid alone (lanes 3,4), or with pVA (lanes 5,6), or with pVA-TAR (lanes 7,8). CAT as-
says were conducted with two different amounts of lysate. (B) Blot of RNA from transfected cells probed with an RNA
complementary to the 5' end of VA RNA. Cells were transfected with salmon sperm DNA only (lane 1), ppCAT alone(lane 2), pVA (lane 3), or pVA-TAR (lane 4). (C) Secondary-structure model for VA-TAR RNA.
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polymerase II as well as improving the efficiency of
elongation. We are interested in understanding the
mechanism by which Tat acts to stimulate HIV tran-
scription, both as a paradigm for regulation of
eukaryotic gene expression and because approaches
that interfere with trans-activation may have thera-
peutic potential for the treatment of AIDS.
We first began analyzing trans-activation by Tat
several years ago, in vivo, in a recombinant adeno-
virus He La cell model system. The recombinant
adenovirus vector provides an efficient means to
deliver an HIV-1 LTR reporter gene fusion into He La
cells. This enabled us to perform a detailed analysis
of the effects of Tat on HIV transcription rates. These
studies suggested that Tat did not act as an
antiterminator as was thought to be the case at the
time. Rather, we found that Tat stimulates transcrip-
tional initiation and generally improves elongation.
Furthermore, an examination of the basis of the
synergistic stimulation produced by Tat and general
activators indicated that stabilization of transcrip-
tional elongation, rather than increased transcrip-
tional initiation, is responsible for synergy. It is
thought that synergy between Tat and other viral and
cellular activators may contribute to the transition
from low levels of gene expression during latency to
high-level expression during productive infection.
Since a detailed understanding of the mechanism
of Tat action is most likely to emerge from a cell-free
approach, we have also analyzed trans-activation in
vitro. As discussed in last year's Annual Report,
characterization of a cell-free system for trans-
activation indicated that purified, bacterially ex-
pressed Tat specifically stimulates HIV-1 transcrip-
tion in a He La cell nuclear extract. An examination
of the effects of Tat on promoter proximal and
promoter distal transcription has shown that in vitro
Tat regulates transcriptional elongation (Fig. 4). The
effects of Tat on HIV-directed transcription rates
were measured by pulse-labeling transcription and
hybridizing the radioactive RNA to contiguous DNA
fragments extending across the transcription unit.
This provided an estimate of the relative distribution
of transcription complexes along the template. In the
absence of Tat, the number of transcriptional com-
plexes decreased markedly with increasing distance
from the promoter. Although Tat did not significantly
increase the number of promoter proximal com-
plexes, it increased the number of promoter distal
complexes 15-fold. The magnitude of trans-
activation by Tat was found to be greatest when ex-
amined following an interval of pretranscription dur-
ing which the efficiency of transcriptional elongation
in the absence of Tat decreased. Together, these
results suggest that the principal effect of Tat, under
these in vitro conditions, is to stabilize elongation.
The inability to detect an effect on initiation in vitro
may be a consequence of high basal levels of HIV
transcription or inefficient reinitiation.
These findings are consistent with Tat acting to
preserve the activity of a factor required for efficient
elongation or to overcome the action of an inhibitor
of elongation. Analysis of the effects of the detergent
sarkosyl on HIV transcription has suggested a pos-
sible mechanism for how Tat acts to increase HIV-1
transcription. The addition of low concentrations of
sarkosyl to transcription reactions increased HIV
basal transcription to a level similar to that achieved
by Tat alone. Like Tat, sarkosyl stimulated transcrip-
tion by increasing the efficiency of transcriptional
elongation. The combined effects of sarkosyl and Tat
on transcription were not additive, implying that they
may act on HIV transcription in a similar fashion.
Moreover, low basal expression by the HIV promoter
may not be due to the assembly of a deficient tran-
scription complex. Rather, stimulation by sarkosyl
suggests that HIV transcription may be subject to
repression. Since sarkosyl also stimulated transcrip-
tion from heterologous promoters, repression may be
a property shared with other eukaryotic promoters.
This hypothesis is supported by the finding that Tat
stimulated transcription in vitro from the adenovirus
major late promoter with a TAR element cloned
downstream from the transcriptional start site. As a
working model, we propose that Tat is a gene-
specific antirepressor that, when bound to TAR,
enables transcriptional complexes to overcome a gen-
eral inhibitor of elongation.
We have also characterized the function of the
HIV-1 TAR element in trans-activation by Tat. TAR
RNA folds into a structure consisting of a 59-
nucleotide paired stem with a trinucleotide bulge and
an apical pentanucleotide loop. Tat binding to TAR
RNA in vitro is abolished by mutations in the bulge;
however, mutations in the apical loop do not reduce
the binding of Tat to TAR RNA. On the other hand,
mutations that disrupt the stem or change the
nucleotide sequence in either the bulge or the apical
loop greatly reduce trans-activation in vivo. To as-
sess the role of TAR in trans-activation, we have ex-
amined the ability of synthetic wild type and mutant
TAR RNAs to inhibit stimulation by Tat in the cell-
free system. Although the addition of 1 Ilm wild-type
TAR RNA, corresponding to nucleotides +1 to +83,
71
2 minutes
5 minutes
HIV-I LTR
nef U3 R
Scal PvuII
CAT
+To t
HindIa
PvuII EcoRI NcoI Scal Sou 3A
SV40
t intron poly A
Sau3A BamHI
-642 -453 -135-18 +79+229 +329 +630 +743 +867
Probes: U3 I II III 17
I. I I I
+1477 +1714
Transcript 21 38 32 95 31U Content
FIGURE 4 Effect of Tat on HIV-promoted transcription rates in vitro. (Top) Transcrip-
tion reactions contained HIV DNA template, 250 ng of Tat, and HeLa cell nuclear ex-
tract. Transcription was initiated and, after 30 min, pulse-labeled with [a- 32P]UTP for
2 min or 5 min as indicated. RNA was isolated and hybridized to filter-bound,
antisense DNA probes corresponding to portions of the HIV-directed transcription
unit. Following washing, filters were subjected to autoradiography. (Bottom)
Schematic of the HIV-1 DNA template (top line), the DNA probes used to analyze HIV
transcription rates (second line), and the uridine content of each transcript (third line).
The amount of radioactivity, normalized for uridine content, hybridizing to each probe
is an estimate of the relative number of transcription complexes located in that region
of the gene.
strongly inhibited trans-activation by Tat, the addi-
tion of mutant TAR RNA containing a deletion of
nucleotides +35 to +38 failed to compete trans-
activation when added at 8µM. In addition, synthetic
TAR RNA with mutations in either the bulge or the
apical loop also failed to inhibit trans-activation.
These results indicate that the integrity of the stem as
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well as the sequence of both the trinucleotide bulge
and apical loop is essential for TAR RNA to inhibit
trans-activation by Tat. This suggests that Tat may
bind cooperatively with a cellular protein that has
specificity for the apical loop. We are currently
determining whether inhibition of Tat responsiveness
by synthetic TAR RNA is due to competition for the
binding of Tat or the binding of a cellular protein(s)
that increases the affinity of Tat for TAR.
At the present time, little is known about cellular
factors that might be involved in trans-activation.
However, genetic and biochemical evidence supports
the idea that cellular cofactors, either activators
and/or repressors, are required for Tat responsive-
ness. As mentioned above, Tat appears to bind
cooperatively with a cellular cofactor(s) to TAR
RNA. We are attempting to purify and characterize
this cellular factor(s) from fractionated nuclear ex-
tracts using the ability to overcome inhibition of
trans-activation in vitro by competitor TAR RNA or
the ability to bind to TAR RNA as assays. An addi-
tional strategy that is being utilized to purify a cel-
lular cofactor(s) required for Tat responsiveness is to
obtain a "minimal system," through the purification
of transcription factors, that supports basal transcrip-
tion but not Tat-stimulated transcription. At least
eight cellular activities are required for basal tran-
scription of mRNA promoters: TFIIA, IIB, IID, IIE,
IIF, IIH, Ill, and RNA polymerase II. We are
determining whether these factors are necessary and
sufficient for a Tat response in a reconstituted system
with purified factors. Initial studies indicate that a
fractionated system consisting of nuclear extracts that
have been fractionated by chromatography on P11
phosphocellulose is capable of supporting basal tran-
scription but not trans-activation by Tat. We are
utilizing this system to attempt to purify a cellular
protein(s) required for Tat responsiveness by com-
plementation of activity.
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MECHANISMS OF MAMMALIAN PRE-mRNA SPLICING
AND SPLICE SITE SELECTION
RNA splicing is a required step in the expression of
most eukaryotic protein-coding genes. Alternative
pre-mRNA splicing is a widespread mechanism for
generating structurally and functionally distinct
protein isoforms from single genes, often in a tissue-
specific, developmentally regulated, or physiological-
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ly controlled manner. Both types of mechanisms in-
volve multiple protein components as well as RNA
components that are part of small nuclear ribonucleo-
protein (snRNP) particles. RNA-RNA base-pairing
interactions among snRNAs and pre-mRNA are im-
portant determinants of splice site recognition and in
addition probably participate in forming the active
sites for the trans-esterification reactions within the
spliceosome. The role of spliceosomal proteins is less
well understood, although protein-RNA and protein-
protein interactions are also essential for pre-mRNA
splicing. Several required protein-splicing factors are
thought to play important roles in spliceosome as-
sembly, splice site selection, and conformational
rearrangements coupled to ATP hydrolysis. Other
possible roles include regulation of active site acces-
sibility, turnover of snRNPs, and positive and nega-
tive regulation of alternative splice site selection, for
example, through posttranslational modification.
Some protein factors might also contribute chemical
groups to the trans-esterification active sites. Our
laboratory has focused on the identification, purifica-
tion, and molecular characterization of protein factors
that are necessary for the catalysis of splicing and/or
for the regulation of alternative splice site selection in
vitro.
STRUCTURE, FUNCTION, AND EXPRESSION OF
HUMAN SPLICING FACTORS SF2/ASF AND HNRNP Al
We showed previously that human pre-mRNA splic-
ing factor SF2/ASF has an activity required for splic-
ing in vitro and promotes utilization of proximal
alternative 5 ' splice sites in a concentration-de-
pendent manner by opposing heterogeneous nuclear
RNP (hnRNP) Al. J. Caceres introduced selected
mutations in the amino-terminal RNA recognition
motif (RRM) and the carboxy-terminal arginine/
serine (RS) domain of SF2/ASF and assayed the re-
sulting recombinant proteins for constitutive and
alternative splicing in vitro and for binding to pre-
mRNA and mRNA. Mutant proteins inactive in con-
stitutive splicing continued to affect alternative splice
site selection, demonstrating that these activities in-
volve distinct molecular interactions. Specific
protein-RNA contacts mediated by solvent-exposed
Phe-56 and Phe-58 in the RNP-1 submotif of the
SF2/ASF RRM are essential for constitutive splicing,
although they are not required for RRM-mediated
binding to pre-mRNA. The RS domain is also re-
quired for efficient constitutive splicing activity, and
both arginine and serine residues are important for
74
biochemical activity. Analysis of domain deletion
mutants showed that the RRM exhibits strong RNA-
binding cooperativity with a central degenerate RRM
repeat and that these two domains are sufficient for
alternative splicing activity in the absence of an RS
domain.
A related mutagenic analysis of hnRNP Al struc-
ture and function is being carried out by A. Mayeda
in collaboration with Steve Munroe (Marquette Uni-
versity). The ability of hnRNP Al to promote use of
certain distal alternative 5' splice sites appears to re-
quire specific protein-RNA contacts mediated by
pairs of conserved phenylalanine residues (analogous
to those of SF2/ASF) in the RNP-1 submotifs of each
of the two RRMs, although these residues are not re-
quired for general RNA binding. The glycine-rich
carboxyl terminus of hnRNP Al is also essential for
alternative splicing activity. These mutants are cur-
rently being analyzed for their effects on the general
splicing stimulatory activity of Al and on its RNA
annealing activity. Previous work on hnRNP Al has
shown that it binds single-stranded nucleic acids in a
sequence-independent fashion and in a cooperative
manner due to protein-protein interactions between
carboxy-terminal domains. However, in crude ex-
tracts, distinct binding preferences for 3' splice sites,
as well as changes in the ability to cross-link this
protein to pre-mRNA depending on the integrity of
snRNAs, have been shown in other laboratories.
We have proposed that the intracellular ratios of
SF2/ASF and hnRNP Al may control the specificity
of splice site selection and that in vivo regulation of
one or both of these activities may play an important
role in the tissue-specific or developmental regulation
of alternative splicing. A. Hanamura measured the
levels of SF2/ASF and hnRNP Al polypeptides dur-
ing adenovirus and SV40 productive infections by
immunoblotting with a monoclonal anti-SF2/ASF
antibody (generated by D. Kozak with C. Bautista
and M. Falkowski, of the CSHL Monoclonal
Antibody Facility) and a monoclonal anti-hnRNP Al
antibody (provided by G. Dreyfuss). Only minimal
variation in the ratio of SF2/ASF and hnRNP Al was
observed, and altered mobilities that might reflect
differences in posttranslational modifications were
not seen. It remains possible that these viruses control
the alternative splicing patterns of some of their
transcripts by altering the activities, rather than the
total concentration, of SF2/ASF and/or hnRNP Al
through interaction with other components. For ex-
ample, J. Stevenin and colleagues proposed that long
adenovirus transcripts sequester SF2/ASF or similar
factors, leading to a lower effective concentration,
which results in a shift toward late splicing patterns.
We previously showed that increasing the concentra-
tion of hnRNP Al relative to that of SF2/ASF leads
to activation of the late E1A 9S 5 ' splice site and
repression of the 13S and 12S 5 ' splice sites in vitro.
A. Hanamura has documented substantial variation
in the natural ratio of SF2/ASF to hnRNP Al in dif-
ferent rat tissues. In addition, significant changes
were also observed among different cell lines, for ex-
ample, in response to transformation (in collaboration
with J. Caceres and with B.R. Franza), which might
explain some of the alterations of alternative splicing
patterns that are commonly seen in transformed cells.
These studies of variations in the relative levels or ac-
tivities of SF2/ASF and hnRNP Al have to take into
account the existence of complex gene families, as
well as isoforms generated by alternative splicing and
posttranslational modification. Interestingly, a pre-
viously documented but unknown posttranslational
modification of hnRNP Al, termed Alx, appears to
eliminate alternative splicing activity. We have also
shown that SF2/ASF has multiple phosphates, but we
do not know at present the consequence of phosphor-
ylation on activity. In collaboration with R.
Kobayashi, G. Binns, and D. Marshak (see Protein
Chemistry, this section), A. Hanamura and A.
Mayeda are attempting to map the posttranslational
modification sites in SF2/ASF and in hnRNP Alx.
Mapping and identification of these modifications
should allow further studies of their potentially
regulatory roles.
THE SR FAMILY OF NUCLEAR PHOSPHOPROTEINS
A conserved family of nuclear phosphoproteins was
recently identified in the laboratory of M. Roth (Fred
Hutchinson Cancer Research Center, Seattle). In col-
laboration with the Roth laboratory, A. Mayeda
showed that SF2/ASF is one member of this SR fam-
ily and that a different member of the same family
from Drosophila could substitute for SF2/ASF in
general or alternative splicing assays with HeLa ex-
tracts. Other members of the SR family have several
conserved structural features and similar functional
properties. Another example is the human splicing
factor SC35, which shares 31% homology with
SF2/ASF. In collaboration with X.-D. Fu and T.
Maniatis (Harvard University), A. Mayeda found that
either protein can reconstitute the splicing activity of
S100 extracts and of SC35 immunodepleted nuclear
extracts. We found that SC35, like SF2/ASF, can af-
fect alternative 5' splice site selection by antagoniz-
ing hnRNP Al (Fig. 1). In addition, we found that
both SF2/ASF and SC35 also favor the proximal site
in pre-mRNA-containing duplicated 3' splice sites
but that this effect is not modulated by hnRNP Al.
Thus, SF2/ASF and SC35 appear to have essentially
equivalent splicing activities in vitro.
The SR family members so far cloned in several
laboratories include human SF2/ASF, human SC35,
Drosophila SRp55 and its closely related variant
B52, mouse X16 (identical to human SRp20),
5' splice site duplicated pre-mRNA
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FIGURE 1 SC35 and hnRNP Al affect alternative 5' splice
site selection in opposite ways. S100 extract (6 RI) was com-
plemented with 3 RI of human SC35 expressed in baculo-
virus (lanes 2-7) and increasing amounts of human hnRNP
Al expressed in E. coli (lane 2, no addition; lane 3, 0.5 RI;
lane 4, 1 RI; lane 5, 2 RI; lane 6, 4 RI; lane 7, 6 RI) or with 3 RI
of hnRNP Al (lanes 8-12) and increasing amounts of SC35
(lane 8, no addition; lane 9, 0.75 RI; lane 10, 1.5 RI; lane 11,
3 RI; lane 12, 6 RI). Nuclear extract (lane 1, 8 RI) was in-
cluded as a control. The substrate is a model 13-globin pre-
mRNA with duplicated 5' splice sites. The positions of the
mRNA products generated by selection of proximal or distal
5' splice sites are indicated.
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Drosophila rbpl, and an SR protein from
Arabidopsis. Fragmentary protein sequence has been
reported for several other mammalian SR proteins,
and a closely related cDNA fragment is available
from Caenorhabditis elegans. In addition to the ex-
tensive primary structure similarity between different
SR family members from the same or from different
species, actual homologs are extremely conserved
through evolution. Thus, for example, whereas hu-
man SF2/ASF and human SC35 share 31% amino
acid sequence identity, human and mouse SRp20 and
human and mouse SF2/ASF are 100% identical.
Therefore, although individual SR proteins appear to
be functionally equivalent or very similar in the in
vitro assays currently available, it seems certain that
individual family members are not functionally
redundant, but rather have specific properties in vivo.
ALTERNATIVE 3' SPLICE SITE SELECTION AND EXON
SKIPPING
As mentioned above, SF2/ASF and hnRNP Al
modulate alternative splicing in vitro of pre-mRNAs
that contain 5' splice sites of comparable strength
competing for a common 3' splice site. Using natural
and model pre-mRNAs, A. Mayeda (in collaboration
with D. Helfman, see Molecular Genetics of Eukary-
otic Cells Section) examined whether the ratio of
SF2/ASF to hnRNP Al regulates other modes of
alternative splicing in vitro. We found that an excess
of SF2/ASF effectively prevents inappropriate exon
skipping, and also influences the selection of mutual-
ly exclusive tissue-specific exons in natural 13-
tropomyosin pre-mRNA. In contrast, an excess of
hnRNP Al does not cause inappropriate exon skip-
ping in natural constitutively or alternatively spliced
pre-mRNAs. Although hnRNP Al can promote
alternative exon skipping, this effect is not universal
and depends, for example, on the size of the alterna-
tive exon and the strength of the polypyrimidine tract
in the preceding intron (Fig. 2). This was shown with
model substrates, kindly provided by R. Kole (Uni-
versity of North Carolina, Chapel Hill). With ap-
propriate alternative exons, an excess of SF2/ASF
promotes exon inclusion, whereas an excess of
hnRNP Al causes exon skipping. We proposed that
constitutive splice sites have evolved in conjunction
with appropriate sequence and structural contexts to
match exclusively appropriate pairs of 5' and 3'
splice sites so as to avoid exon skipping, regardless
of variations in the levels of SF2/ASF, hnRNP Al,
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FIGURE 2 Effect of upstream polypyrimidine tract composi-
tion on hnRNP Al-promoted exon skipping. The structures
of the model pre-mRNAs and the sequences of the
polypyrimidine tracts and 3' splice sites in each upstream
intron are shown. The five dots indicate the nucleotide dif-
ferences (transversions) between the two substrates. The
exon and intron sizes are indicated in nucleotides. The
structures of the two mRNAs resulting from alternative exon
inclusion or skipping are represented on the right. The reac-
tions contained nuclear extract (NE, 6 [11), or S100 extract (6
[t1) plus SF2/ASF (0.7 til) plus recombinant hnRNP Al (lanes
2 and 6, none; lanes 3 and 7, 1 RI; lanes 4 and 8, 4 14
and similar regulatory factors. In contrast, alternative
splice sites that are in cis-competition have more
balanced relative strengths and are therefore suscep-
tible to variations in the levels of such factors.
Using model substrates containing alternative 3'
splice sites, A. Mayeda has identified and partially
purified activities that stimulate proximal (SF6) or
distal (SF7) 3' splice sites. SF6 activity turned out to
cofractionate with SR proteins, and, for example, ei-
ther SF2/ASF or SC35 can stimulate proximal 3'
splice sites when present in relatively high concentra-
tions. SF7 appears to be distinct from SR proteins
and from hnRNP Al, and its purification is almost
complete. This factor will be used together with
SF2/ASF and hnRNP Al to investigate the molecular
mechanisms of splice site selection in vitro.
OTHER ESSENTIAL PROTEIN SPLICING FACTORS
We are continuing to purify and characterize addi-
tional protein factors that are essential for one or both
RNA cleavage-ligation reactions. Using selective in-
activation and biochemical complementation strate-
gies, G. Joshi-Tope (now at Brookhaven National
Laboratory) and D. Horowitz have identified two
novel activities required for cleavage at the 5 ' splice
*site and lariat formation. These activities have been
chromatographically separated, and their purification
is in progress. B. Dong used immunological and ge-
netic approaches to attempt to identify and isolate
cDNA homologs of the Saccharomyces cerevisiae
PRP18 splicing factor, which is required for 3' splice
site cleavage and exon ligation (in collaboration with
D. Horowitz and with J. Abelson, California Institute
of Technology). Recently, B. Dong purified a 54-kD
HeLa cell polypeptide that reacts strongly with
affinity-purified anti-PRP18 polyclonal antibodies. In
collaboration with R. Kobayashi (see Protein
Chemistry, this section), partial peptide sequence of
p54 was obtained and used to design degenerate
primers for reverse transcriptase-polymerase chain
reaction (RT-PCR). The resulting unique sequence
DNA probe was used to isolate full-length HeLa
cDNAs encoding p54. Although p54 turned out only
to share a fortuitous epitope with yeast PRP18, its
amino acid sequence reveals the presence of two
RRMs and significant sequence similarity to a num-
ber of RNA-binding proteins and mammalian splic-
ing factors. Immunological and biochemical ap-
proaches will be used to study the RNA-binding
properties of p54 and its possible involvement in pre-
mRNA splicing. The fortuitous cross-reactivity of
p54 with PRP18 may explain our previous im-
munocytochemical and biochemical data with anti-
PRP18 antibodies and human cells. Therefore, the ex-
istence of a true PRP18 homolog in human cells
remains uncertain.
CONSERVED MOTIFS IN PROTEIN SPLICING FACTORS
E. Birney (now at Balliol College, Oxford) and S.
Kumar (in R.J. Roberts' laboratory, now at New Eng-
land Bio-Labs) have carried out a detailed sequence
analysis of conserved motifs in metazoan protein-
splicing factors and related RNA-binding proteins.
This analysis, still in progress, includes the character-
ization of RRMs and the construction of a complete
RRM database, as well as statistical analysis of
arginine-serine repeats and other simple repeats
found in RNA-binding proteins. Several proteins in
the databases were found to contain previously un-
noticed RRMs and homologies with known splicing
factors, which strongly suggest that they are RNA-
binding proteins. One example of this analysis is the
finding of significant homology between an open
reading frame in the recently sequenced S. cerevisiae
chromosome III and the large subunit of the human
splicing factor U2AF (Fig. 3). Both proteins contain a
short amino-terminal RS domain followed by three
RRMs, the last of which is atypical. If the YCL11c
open reading frame is a functional homolog of
U2AF65, the similarities in the splicing machinery of
yeast and metazoans would extend to non-snRNP
factors, in addition to the known similarities in
snRNAs and snRNP polypeptides. It is of interest that
U2AF recognizes the conserved polypyrimidine tract
of metazoan 3' splice sites and that such extensive
tracts are generally absent from S. cerevisiae 3'
splice sites. In addition, the above sequence
represents the first example, to our knowledge, of an
RS domain, albeit a short one, in a yeast protein.
The RS domains of Su(wa) and tra have been
shown to be required for targeting of these proteins to
the nucleoplasmic speckle region, where splicing fac-
tors reside. The RS domains of human U2AF65 and
SF2/ASF are required for constitutive splicing in
vitro. It is unclear at present what constitutes a mini-
mal RS domain, both from statistical relevance and
from protein structural standpoints. Sequence analy-
sis of RS domains showed that very few proteins in
the databases contain significant repeats of inter-
spersed arginine and serine residues (Fig. 4). Vir-
tually all of these proteins have been directly or in-
directly implicated in constitutive or regulated splic-
ing. Many of these proteins also contain one or more
RRMs. The proteins of the SR family have character-
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FIGURE 3 Similarity in sequence and domain organization between human U2AF65 and an open reading frame from
chromosome III of S. cerevisiae. The alignment of the YCL11c ORF protein (top line) and U2AF65 (bottom line) was generated
with the GCG program Bestf it, with a gap weight 3.5 and gap extension 0.1. Black boxes represent identical matches;
stippled boxes represent conservative changes (V=L=1, F=Y=W, R=K, Q=N, D=E, S=T). RRMs are shown by horizontal lines;
RNP-1 and RNP-2 submotifs are boxed. The broken line for the carboxy-terminal RRM indicates a weak match to the con-
sensus, particularly for RNP-2 of hU2AF65
istic, highly clustered repeats of consecutive RS or
SR dipeptides at their carboxyl termini, an amino-
terminal RRM, and in some cases a central
degenerate RRM, in addition to other distinctive fea-
tures. In other proteins with RS domains, the arginine
and serine residues are more dispersed and show less
periodicity.
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We use viruses to probe the mechanisms of transcrip-
tional regulation in mammalian cells. Viruses provide
simple regulatory systems in which the cellular tran-
scriptional apparatus is frequently usurped to regulate
viral gene expression in a temporal cascade. The cel-
lular changes undergone during this process can be
more easily compared than during cellular differen-
tiation because initiation of the process by infection
can be rapid and discrete.
During the last decade, we have used three primate
viruses to study transcriptional regulation. Our earlier
studies concentrated on the structure of transcrip-
tional enhancers, which have the ability to activate
transcription even when positioned at a large distance
from the transcriptional start site. Our genetic studies
with the simian DNA tumor virus SV40 showed that
the SV40 enhancer is composed of regulatory mod-
ules that can cooperate with one another or duplicates
of themselves to stimulate transcription. Analysis of
the proteins that bind to these regulatory modules led
to the purification of the octamer motif (ATGC
AAAT)-binding protein Oct-1. This is a cellular pro-
tein that is expressed in a broad array of cells and is a
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close relative of another octamer motif-binding pro-
tein called Oct-2. Unlike Oct-1, Oct-2 is more re-
stricted in its expression pattern, being expressed in B
cells where it is believed to be involved in activation
of immunoglobulin promoters. Both Oct-1 and Oct-2
are members of the POU family of homeodomain
proteins. POU proteins are distinguished from other
homeodomain proteins because they contain two
helix-turn-helix type DNA-binding domains, a
homeodomain and POU-specific domain, fused to-
gether in the form of a bipartite DNA-binding
domain.
Although Oct-1 and Oct-2 recognize the same
transcriptional regulatory motif, they preferentially
activate different types of promoters: Oct-1 is better
able to activate transcription of the U2 small nuclear
RNA gene, a ubiquitously expressed gene involved in
RNA splicing, and Oct-2 is better able to activate a
typical mRNA promoter. This differential promoter
activation is achieved by the use of promoter-
selective transcriptional activation domains that, even
when attached to the same DNA-binding domains,
are able to activate different types of promoters. This
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differential activation probably results from selective
interactions with differing promoter-proximal initia-
tion complexes.
Another mechanism used by Oct-1 and Oct-2 to
elicit different programs of gene expression is
through differential interaction with the herpes
simplex virus (HSV) protein VP16. VP16, also
referred to as Vmw65 and a-TIF, is an HSV virion
protein that upon infection is released into the cell
and forms a multiprotein complex with Oct-1 and a
second cellular protein called HCF (or Cl, VCAF, or
CFF by other investigators), on a class of cis-
regulatory elements called TAATGARAT (R =
purine). VP16 first binds to HCF, which primes
VP16 for association with Oct-1 in a DNA-dependent
complex. VP16 can associate with Oct-1, but not ef-
fectively with Oct-2, by recognizing the Oct-1
homeodomain, which differs from the Oct-2
homeodomain at seven positions that are exposed
when Oct-1 and Oct-2 are bound to DNA. Associa-
tion with VP16 can result in two important changes
in the activity of Oct-1: First, VP16 contains a very
potent acidic mRNA-promoter activation domain that
alters the transcriptional activation properties of Oct-
1, and second, VP16 can recruit Oct-1, but not Oct-2,
to a new cis-regulatory site, thus essentially changing
the DNA-binding specificity of one but not the other
of two proteins that otherwise display the same
DNA-binding specificity. It is in this manner that we
have been using HSV to probe the mechanisms of
transcriptional regulation in mammalian cells.
We use human immunodeficiency virus type 1
(HIV-1) to study promoter variation in infected indi-
viduals. HIV provides an excellent model to study
such variation, because, like other retroviruses, it
mutates rapidly and because unfortunately there are
many known infected individuals from whom
variants can be isolated. Below are descriptions of ac-
complishments we have made during the past year.
The Structure of the Oct-1 POU-specific
Domain Is Strikingly Similar to That
of the Bacteriophage 2 Repressor
DNA-binding Domain
R. Aurora [in collaboration with N. Assa-Munt,
R. Mortishire-Smith, and P. Wright, The Scripps
Research Institute]
We have determined the solution structure of the Oct-
1 POU-specific (POUS) domain by NMR. Figure 1
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FIGURE 1 Model of the Oct-1 POU-specific domain. The
Oct-1 POU-specific domain is shown with ribbons indicating
a helices. The amino terminus is at the bottom left and the
carboxyl terminus is at the upper right. In this view, helix 1 is
at the left, helix 2 is at the right, helix 3 extends horizontally
from right to left at the back, and helix 4 is in the center fore-
ground. Helix 3 is the putative DNA recognition helix and
helix 2 is where the human dwarfism mutation in the Pit-1
POU-specific domain lies.
shows a model of the deduced structure. The struc-
ture is remarkably similar to the bacteriophage A. and
434 repressor DNA-binding domains. These DNA-
binding domains contain the helix-turn-helix (HTH)
motif. The HTH motif is found in a variety of DNA-
binding proteins but is not itself an independently
stable domain; other structural components are re-
quired to form a stable structure. This stabilization
can be achieved in a number of ways. For example,
in the tri-a-helical homeodomain, a single helix
closes off the hydrophobic face of the HTH structure,
whereas in the bacteriophage A. and 434 repressors,
two helices, the first and fourth, serve the same pur-
pose.
The Oct-1 POUs domain has the same tetra-a-
helical HTH-containing structure as the bacterio-
phage X, and 434 repressors. The POUs structure dif-
fers, however, because it contains an unusual HTH
structure, in which the first helix and the turn of the
HTH structure are extended. This extended structure
means that sequence similarity between the POUs
and bacteriophage repressor DNA-binding domains is
not readily detectable. This result explains why the
link between the POUs domain and the two bac-
teriophage repressor DNA-binding domains was not
made prior to elucidation of the POU domain struc-
ture.
The POU domain structure, together with the
known effects of a POU domain mutation, suggests
a further similarity between the human POU domain
proteins and bacteriophage repressors. A human
dwarfism mutation in the pituitary POU domain
protein Pit-1 affects the ability of this protein to ac-
tivate transcription but has little effect on DNA bind-
ing; presumably, this mutation affects protein-protein
interactions important for positive control. This mis-
sense mutation is located within the first of the two
HTH helices, the same region in which mutations
with similar effects lie in the X. repressor. Thus, ap-
parently similar defects in a human and bac-
teriophage transcriptional activator can cause changes
in either human or X bacteriophage development.
The Oct-1-encoding mRNA 5' Leader
Does Not Contain an Expected
AUG Initiation Codon
R. Freiman
Of the many Oct-l-encoding cDNAs we have isola-
ted previously, none extended far enough to contain
the likely translational initiation codon. To extend the
5 ' cDNA sequences further, we have employed the
polymerise chain reaction (PCR) procedure. By this
strategy, the oct-1 mRNA sequences were extended
by 625 nucleotides. Curiously, although the Oct -1-
encoding open reading frame extends for 79 codons
upstream of the previously described AUG initiation
codon, the extended reading frame does not contain
any other prototypical AUG initiation codon. There
is, however, an unusually large and stable RNA
secondary structure. We are currently testing whether
translation of Oct-1 initiates at a non-AUG codon.
Enhanced Activation of the
Human Histone H2B Promoter
by the Oct-1 Variant Oct-1B
G. Das
We have previously described an oct-1 cDNA result-
ing from alternative splicing that has the potential to
encode a carboxy-terminally truncated form of Oct-1.
This variant form is called Oct-1B and carries a
unique carboxy-terminal 12-amino-acid extension.
This 12-amino-acid extension is almost entirely com-
posed of glutamine, proline, and threonine residues;
such residues are typical of mRNA'promoter activa-
tion domains. Previously, we have found that Oct-1
does not activate mRNA promoters effectively. Be-
cause of the Oct-lB carboxy-terminal structure, how-
ever, we tested the ability of Oct-lB to activate the
histone H2B promoter. We found that indeed, in a
transient cotransfection assay, Oct-lB activates the
histone H2B promoter better than does Oct-1. In fact,
Oct-lB is as effective an activator of histone H2B
transcription as the mRNA-promoter activator Oct-2.
Structure of the VP16-associated
Protein HCF
A. Wilson [in collaboration with K. LaMarco
and G. Peterson, Tularik, Inc.]
An important focus of our studies on transcriptional
regulation has been the structure and function of the
VP16-induced complex. It has been known for
several years now that the herpesvirus trans-activator
VP16 does not associate effectively with Oct-1 in the
absence of the second host-cell factor HCF. HCF
binds to VP16 to form a heteromeric complex and
thus primes VP16 for association with Oct-1 in the
presence of an appropriate DNA-binding site. Thus,
HCF serves an unusual function in the assembly of a
multiprotein-DNA complex. Until now, HCF has
been relatively poorly characterized, largely because
its structure has been unknown.
We have now purified HCF, obtained amino acid
sequence, and with this information isolated HCF-
encoding cDNAs. The purified protein is a mixture of
seven distinct polypeptides. When separated on an
SDS-polyacrylamide gel, they form three doublets of
approximately 110, 125, and 150 kD and a singlet of
about 300 kD. These proteins are apparently all re-
lated to one another because the doublet proteins dis-
play very similar peptide fingerprints. Unexpectedly,
however, the cDNAs we have isolated encode a very
large protein of 2035 amino acids, which we believe
corresponds to the 300-kD HCF protein. Thus, the
smaller proteins are probably derivatives of the 300 -
kD protein. They are not an artifact of HCF purifica-
tion, however, because, using HCF antibodies, we
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detect the same pattern of HCF polypeptides in ex-
tracts from cells that have been rapidly lysed with
detergent. We are now focusing on the mechanism by
which these smaller polypeptides arise.
Consistent with its unusual function, the deduced
sequence of HCF is not related to any other proteins
with which we have compared sequences. Within the
middle of the predicted HCF sequence, however,
there is a set of eight 26-amino-acid-long repeats.
These HCF repeats portend the existence of a new
type of functional motif. Now that the last piece of
the puzzle in the VP16-induced complex is cloned,
we can elucidate how it is able to induce VP16 asso-
ciation with Oct-1.
A.
Differential Association of
Mammalian Oct-1 Proteins
with VP16: An Assay for
the Response of Human Oct-1
to VP16 in Murine Cells
M. Cleary
To our surprise, even though the Oct-1 homeodomain
is identical in humans, chickens, and Xenopus, there
is considerable sequence heterogeneity among mam-
mals. For example, as shown in Figure 2A, the
murine Oct-1 homeodomain differs from its human
counterpart at four positions on the homeodomain
VP I 6
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FIGURE 2 Murine Oct-1 associates with VP16 less effectively than human Oct-1. (A)
The positions and identities of Oct-1 amino acids that differ between the human and
murine Oct-1 homeodomains are indicated on an illustration of the engrailed
homeodomain bound to the major groove of DNA (stippled). In the nomenclature sys-
tem used here, the identity of the human Oct-1 residue is given first in single-letter
code, followed by its position in the homeodomain and the identity of the differing
murine Oct-1 residue. (B) Electrophoretic mobility retardation analysis comparing
VP16 association with murine Oct-1 and human Oct-1. Either no in vitro translation ex-
tract (lane 1) or equivalent amounts of unprogrammed (URL; lanes 2,3), or murine Oct-
1 (lanes 4,5), or human Oct-1 (lanes 6,7) programmed in vitro translation extracts were
incubated with a TAATGARAT probe in the absence (-; lanes 1,2,4,6) and presence(+; lanes 3,5, 7) of E. coli- expressed VP16. All binding reactions contained partially
purified human HCF. (VIC) VP16-induced complex. (Reprinted, with permission, from
Cleary et al. 1993 [Copyright held by CSHL Press].)
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surface responsible for interaction with VP16. In-
deed, as shown in Figure 2B, murine Oct-1 does not
form a VP16-induced complex (VIC; see lane 5) as
effectively as human Oct-1 (lane 7).
We used this difference to establish an in vivo as-
say for the involvement of human Oct-1 in activation
of transcription by VP16. In human cells, ever-
present endogenous Oct-1 obscures the activity of
transiently expressed Oct-1 from a transfected ex-
pression vector. In murine NIH-3T3 cells, however,
cotransfection of expression vectors for human Oct-1
and VP16 results in a much larger transcriptional
response than with either vector alone. Using this as-
say, we showed directly that human Oct-1, but not
human Oct-2, can respond to VP16 in vivo. The Oct-
1 DNA-binding POU domain is sufficient and the
Oct-1 homeodomain is critical for this response, be-
cause an Oct-1 POU domain containing the Oct-2
homeodomain fails to respond to VP16.
A Single-amino-acid Exchange
Transfers VP16-induced Positive
Control from the Oct-1 to the
Oct-2 Homeodomain
J.-S.
We have known that the seven differences between
the Oct-1 and Oct-2 homeodomains are responsible
for the different abilities of Oct-1 and Oct-2 to asso-
ciate with VP16 and as described above to respond to
VP16 in vivo. Figure 3 shows the positions and
identities of these seven differences. Now we asked
which of these seven differences are key in determin-
ing the discrimination between Oct-1 and Oct-2 by
VP16. Only two of the differences are important, one
in each of the first two a-helices of the tri-a-helical
homeodomain. The major determinant is a single
glutamic acid residue at position 22 at the top of the
first a-helix (circled in bold in Fig. 3). A less sig-
nificant position is at position 33 (circled with an in-
termediate thickness). Replacement of the alanine
residue found at this position in the Oct-2 homeo-
domain with the Oct-l-derived glutamic acid residue
is sufficient to transfer to Oct-2 the ability to associ-
ate with VP16 and respond to VP16 in vivo. Thus,
the specificity of positive control of transcription by
homeodomains can be conferred by a single-amino-
acid difference. This result means that even as little
FIGURE 3 The positions and identities of Oct-1 amino acids
that differ from the Oct-2 homeodomain are indicated on an
illustration of the engrailed homeodomain bound to the
major groove of DNA (stippled). The three homeodomain a-
helices (1-3) are drawn as bold cylinders. The seven amino
acid differences between Oct-1 and Oct-2 homeodomains
are circled. The identities and positions of Oct-1 residues
are indicated followed by the identities of the amino acids in
the Oct-2 homeodomain at the corresponding positions. (N)
Amino terminus; (C) carboxyl terminus. (Reprinted, with
permission, from Lai et al. 1992 [Copyright held by CSHL
Press].)
as a single-amino-acid difference on the surface of
other homeodomains found in nature can have a sig-
nificant impact on their ability to regulate transcrip-
tion.
A T-cell Factor That Recognizes
HIV-1 Enhancers Containing
Tandem Sequence Duplications
W. Phares
In HIV-1 LTR sequences amplified directly from
peripheral blood cells of infected individuals, we
have found a hot spot for tandem sequence duplica-
tions (TSDs) immediately upstream of the duplicated
KB enhancer sequences. These TSDs vary in size
from 15 to 29 bp, but all encompass a common 12-bp
region. Such duplications in other enhancers, e.g.,
SV40, affect enhancer function. To analyze their pos-
sible significance, we have studied the ability of
nuclear proteins to associate with the TSDs in an
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electrophoretic mobility retardation assay. We have
found an activity in T cells that is absent in the non-
T-cell lines we have analyzed. This activity binds to
the duplicated forms of the HIV-1 LTR but not the
nonduplicated form, and chemical modification inter-
ference analysis shows that both copies of the
tandemly duplicated sequence are important for asso-
ciation with this T-cell factor. This factor may there-
fore be responsible for the activity of the TSDs in
vivo and will therefore be the focus of our future
studies.
Study of Synergism in
Transcriptional Activation
M. Tanaka
Studies of the mammalian POU-domain transcription
factor Oct-2 have revealed that cooperative interac-
tions among modular elements organized at multiple
hierarchical levels are a basis for efficient transcrip-
tional activation. A basic element, an 18-amino-acid
subsegment of the Oct-2 glutamine-rich activation
domain, was identified by a novel multimerization
approach. This 18-amino-acid segment can form a
progressively more potent activation domain when
tandemly reiterated in increasing numbers. Such an
activation domain can cooperatively function with its
duplicate or a heterologous proline-rich activation
domain on the same polypeptide. When bound to the
same promoter, multiples of these activators can
cooperate to activate transcription efficiently.
To analyze further the importance of cooperative
effects among these modular elements and to investi-
gate a biochemical basis for cooperativity in tran-
scriptional activation process, I plan to use the yeast
Saccharomyces cerevisiae as a model system and a
potent acidic activation domain of HSV VP16 as an
activation domain. The multimerization approach
was applied to the VP16 activation domain, and
several subsegments (between 8 and 13 amino acids
in length) were found to activate transcription in
yeast when reiterated and fused to the GAL4-DNA-
binding domain. I will systematically change a vari-
ety of parameters in this model system, including af-
finity and the number of activator binding sites in a
promoter, the number of activation domain subseg-
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ments in an activator, and concentration of an ac-
tivator. Their effects will be examined both in vivo
and in vitro for occupancy of activator binding sites
as well as efficiency of transcription. Biochemical
approaches will further focus on identification and
characterization of protein-protein interactions that
involve activation domains to develop a mechanistic
basis for their synergistic actions.
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MOLECULAR GENETICS OF EUKARYOTIC CELLS
Investigators in this section study diverse biological phenomena, from signal transduction to the
pathogenesis of the human immunodeficiency virus. Some of the highlights of the year include
the following.
M. Gilman and colleagues (Nuclear Signal Transduction) have developed an entirely cell-
free system which reflects signaling from growth factors to transcriptional activation. Such a
system will, in principle, enable the biochemical dissection of an entire signal transduction
pathway. They have also made progress characterizing the interaction between the tran-
scription factor SRF and proteins with the homeodomain motif.
R. Franza and co-workers (Quantitative Regulatory Biology) have continued their studies of
cellular regulatory proteins, focusing on proteins that interact with KB sites, and, in collabora-
tion with N. Tonks, protein phosphatases.
Members of N. Tonks' laboratory (Structure, Function, and Regulation of Protein Tyrosine
Phosphatases) have identified novel members of the protein phosphatase family and have
characterized many of the biochemical interactions involving these phosphatases. Most sig-
nificantly, they have shown that a transmembrane receptor-like phosphatase may serve as
its own ligand when present on an adjacent cell and thereby mediate cell-cell aggregation.
D. Bar-Sagi's laboratory (Transmembrane Signaling) continues to study signal transduction
pathways in mammalian cells that involve the RAS proteins. They have characterized the
proteins upstream of RAS that link its regulation to growth factors. Included among these are
novel guanine nucleotide exchange factors and "adaptor" molecules with SH3/SH2 domains
that link RAS exchange factors with transmembrane protein tyrosine kinases.
M. Wig ler and colleagues Cell Genetics) have continued studies of the RAS sig-
naling pathway. Most significantly, they have identified a protein kinase cascade, conserved
from yeasts to humans, that is regulated by RAS. They have shown that RAF (in vertebrates)
and byr2 (in fission yeast) are two protein kinases that are likely to be immediate downstream
targets of RAS regulation. In addition, the lab has developed a powerful new tool for genomic
analysis, called RDA. RDA allows the discovery of new pathogens, the cloning of loci that un-
dergo rearrangement in cancer and sporadic genetic disease, and the isolation of polymor-
phic probes linked to inherited disease loci. Finally, in collaboration with chemists at Colum-
bia University, the lab has developed a new approach to drug discovery based on com-
binatorial chemical synthesis and combinatorial decoding.
S. Patterson's laboratory (Posttranslational Modifications and Apoptosis) has continued to
refine methods for the chemical analysis of minute amounts of peptides and has begun an
analysis of the changes in protein composition of cells undergoing programmed cell death
(apoptosis).
D. Spector and co-workers (Cell Biology of the Nucleus) have observed changes in protein
localization within the nucleus as a consequence of transcriptional activity. In particular, they
have observed the shuttling of splicing and other nuclear factors to new sites of RNA tran-
scription.
The laboratory of D. Helfman (Molecular Cell Biology) continues to study the function and ex-
pression of cytoskeletal elements. They have identified new tropomyosins and actins essen-
tial for cytokinesis which may work in connection with myosin motors to power cytoplasmic
reorganization. They have also identified RNA-binding proteins that are likely to be involved
in tissue-specific splicing patterns.
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J. Skowronski and his co-workers (Transgenic Mice) have been using transgenic mice to
study the function of proteins encoded by HIV-1, the virus implicated in AIDS. In particular,
they have shown that nef down-regulates CDC4 antigen expression on the surface of T cells
and alters the development and activation of CDC4+ T cells.
J. Garrels and colleagues (Quest Protein Database Center) continue the development of
software for the analysis of 2D gels and, in collaboration with S. Patterson, R. Franza, and
others, the building of databases. A new double amino acid labeling protocol facilitates the
identification of 2D protein spots.
TRANSGENIC MICE
J. Skowronski R. Mariani
S. Salghetti
L. Usher
Human immunodeficiency virus (HIV) infection of
CD4+ T cells and antigen-presenting cells (APCs) is
associated with depletion of CD4+ T cells and dereg-
ulation of the immune system that are the hallmarks
of the immunodeficient state in AIDS. However, the
mechanism(s) by which immunodeficiency viruses
subvert the normal function of infected cells and the
identity of viral genes that mediate these effects in in-
fected CD4+ T cells are not well understood. Besides
the gag, pol, and env genes, found in all retroviruses,
immunodeficiency viruses encode several additional
"accessory" proteins. The function of some of these
accessory genes is not known as they are not required
for the viral life cycle in established cell lines. Re-
markably, some of these "nonessential" genes are re-
quired for efficient viral replication in vivo and for
disease induction and therefore have an essential
function in the viral life cycle in vivo.
We continue to seek a better understanding of the
function and mechanism of action of the nonessential
genes of immunodeficiency viruses. Our studies have
focused on the nef gene of human immunodeficiency
virus type 1 (HIV-1). nef is dispensable for the viral
life cycle in vitro, but although its function is not
known, it is strictly required for disease development
in primate models of AIDS. Our laboratory has been
using approaches in vivo, in transgenic mice, and in
vitro to address the consequences of Nef expression
on normal cellular functions and its interaction with
cellular regulatory mechanisms. In the last year, these
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studies provided novel and important insights into
possible functions of nef, which will remain the focus
of our studies in the future.
HIV-1 Nef Alters Development
and Activation of CD4+
T Cells when Expressed
in Transgenic Mice
J. Skowronski, L. Usher, R. Mariani [in collaboration with
D. Parks, Stanford University, Stanford]
To assess the consequence of Nef expression in pri-
mary cells in vivo, we constructed transgenic mice
that express HIV-1 nef in T cells. Last year, we
reported results of the initial characterization of these
CD3 Nefl transgenic lines. We have shown that CD3
Nefl animals show abnormally low frequencies of
peripheral CD4+ T cells, which is reminiscent of
CD4+ T-cell depletion invariably associated with hu-
man AIDS. Our recent experiments addressed the
mechanism of CD4+ T-cell loss in these transgenic
mouse models and the consequences of Nef expres-
sion on T-cell receptor function in transgenic T cells.
Analysis of transgene expression patterns in devel-
opmental T-cell populations revealed that Nef was
expressed at relatively high levels in the immature
thymic T cells but not in the mature T cells found on
the periphery of transgenic animals. This dichotomy
suggested that Nef may be blocking the normal de-
velopment of T cells in the thymus and, as a result, T
cells that express Nef are depleted from the periphery
of transgenic mice. To test this possibility, we char-
acterized developmental populations of thymic T
cells in CD3 Nefl animals. Flow cytometry analysis
with monoclonal antibodies to a panel of differentia-
tion antigens revealed that Nef preferentially blocks
development of the CD4+ T cells in transgenic
animals. These studies also revealed that CD4
antigen expression on both immature and mature
transgenic thymic T cells was two to three times
lower than that on control thymocytes.
These observations provided an explanation for the
defect in T-cell development in CD3 Nefl mice. CD4
interactions with class II antigens are directly in-
volved in T-cell differentiation. This has been indi-
cated before by findings that development of CD4+ T
cells is defective in mice where MHC class II ligands
were blocked with monoclonal antibodies or in-
activated by a germ-line mutation. Thus, one possible
explanation for the defective CD4+ T-cell develop-
ment in CD3 Nefl animals is that decreased CD4 ex-
pression on immature thymocytes disrupts T-cell
receptor MHC class II interactions and hence positive
selection of CD4+ T cells. Interestingly, our data are
consistent with a rather tight regulation of T-cell de-
velopment by CD4. It is remarkable that in contrast
to previous genetic and antibody-blocking experi-
ments, which virtually eliminated CD4-MHC class II
interactions, in CD3 Nefl mice, the relatively small
decrease in CD4 levels on thymic T cells was suffi-
cient to disrupt differentiation of CD4+ T cells.
HIV-1 NEF PROMOTES T-CELL MITOGENESIS
To assess the functional capability of developing T
cells, thymocytes isolated from transgenic animals
and littermate controls were stimulated with anti-
bodies to CD3 in the presence of phorbol ester.
Strikingly, thymocytes from transgenic animals
showed elevated responses to stimulation when com-
pared to those of littermate controls (Fig. 1). This ef-
fect was remarkable because transgenic thymuses
contain a lower fraction of mature T cells than would
normally be expected to proliferate in response to this
stimulation. In contrast, mitogenic responses to
stimulation with phorbol ester and calcium iono-
phore, which bypasses the T-cell receptor to induce
calcium-dependent responses, were not significantly
different. This suggested that the observed hyper-
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FIGURE 1 Proliferative responses of CD3 Nef1 2.2
thymocytes. Thymic T cells isolated from 2-3-month-old
CD3 Nef1 2.2 or CD3 Nef1 3.2 (T) and littermate controls (C)
were cultured in the presence of anti-CD3 monoclonal
antibody and PMA a-CD3/PMA; 2 µg /ml and 5 ng/ml,
respectively) or ionomycin and PMA (IONO/PMA; 0.3 vg/m1
and 5 ng/ml, respectively). Proliferation was determined by
[3H]thymidine uptake 48 hr after stimulation, and results
from triplicate wells are shown. Shown are representatives
of four independent experiments.
reactivity of transgenic T cells reflects elevated T-cell
receptor signaling.
THYMIC T CELLS ARE HYPER-REACTIVE TO
T-CELL RECEPTOR STIMULATION
Accumulation of intracellular calcium is one of the
early events following T-cell receptor stimulation.
Therefore, to assess T-cell receptor function, we
characterized calcium responses in anti-CD3-stimu-
lated thymic T cells (in collaboration with D. Parks,
Stanford University). As illustrated in Figure 2, cal-
cium accumulation was elevated in transgenic single
positive CD4+ as compared to the control thymo-
cytes. In addition, calcium responses of the immature
CD4+CD8+ T cells were also enhanced. Both the
magnitude of the response, which reflects elevated
mobilization of free calcium in transgenic cells, and
the kinetics of the response were increased. Also, the
frequency of responding T cells was almost twofold
higher in both the double- and single-positive CD4+
transgenic populations (Fig. 2, two rightmost panels).
DOES NEF ENHANCE T-CELL ACTIVATION OR
SURVIVAL ?
What could be the significance of nef for viral in vivo
replication? Our data indicate that nef alters T-cell
activation. We suggest that through this effect, nef
can enhance viral replication in infected T cells. The
first possible mechanism is suggested by previous ob-
servations indicating involvement of CD4 in the neg-
87
1.00
0.75
CD4/CD8 0.50
0 0.25
0.00
1.00
0.75
CD4
0 0.50
0 0.25
C3H
0.0 2.0 4.0 6.0
#3.2
1.00 1.00
0.75- 0.75-
0.50 - 0.50-
0.25- 0.25-
0.00
0.0 2.0 4.0 6.0
#5.2
0.0 2.0 4.0 6.0
0.0 2.0 4.0 6.0 0.0 2.0 4.0 6.0
Time (min)
0.0 2.0 4.0 6.0
Frequency
Time (min)
FIGURE 2 Elevated calcium accumulation in CD3 Nef1 thymic T cells. Kinetics of Ca++ accumulation in control (C3H), CD3
Nef 1 3.2 (3.2) and 5.2 (5.2) thymocytes following stimulation with anti-CD3 monoclonal antibody (145 2C11) was determined
by flow cytometry analysis of Indo-1 loaded cells. The distribution of Ca++ concentrations in stimulated double-positive
(CD4/CD8) and single-positive (CD4) populations is presented as a function of time. Cells were stimulated with 50 [kg/m1145
2C11 monoclonal antibodies at time 0. Each distribution is represented by three curves: The lower curve reflects Ca++ ratio
at the 20th percentile, the upper curve at 80th percentile, and the middle curve reflects the median Ca++ (50th percentile).
Calcium concentration is represented by the violet/green ratio of lndo-1 fluorescence (measured with filters at 395-415 nm
and 515-560 nm, respectively). All values are normalized to the fluorescence ratio of ionomycin-treated cells (saturating high
Ca++ concentration + 1.0).
ative regulation of T-cell receptor signaling and ac-
tivation of mature T cells. Thus, it is conceivable that
nef may counteract inhibitory effects of CD4 and/or
modulate additional signals to promote T-cell activa-
tion and viral replication in infected T cells. The sec-
ond possibility stems from the observation that the
cytopathic effect of HIV-1 in cultured T cells in-
volves interaction between CD4 and envelope
glycoproteins and may involve a ternary complex
with p561ck . Although it is not known at present
whether nef can interact with these complexes, such
interactions could result in improved survival of in-
fected CD4+ T cells and augmented viral replication.
Either of these effects could be critical for viral sur-
vival in the natural setting of immunodeficiency virus
infection. Current experiments address these pos-
sibilities.
Interaction with CD4 Reflects
Conserved Function of Nef
R. Mariani, J. Skowronski
We have observed that NL43 Nef expression results
in a low-level CD4 antigen display on the T-cell sur-
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face, and down-regulation of CD4 antigen expression
on the surface of human T cells has been observed
before by other investigators. However, these obser-
vations were regarded as controversial because they
were observed only with some but not other HIV-1
nef alleles. It is well established that nef is not re-
quired for viral replication in primary T cells nor es-
tablished T cell lines under the commonly used in
vitro conditions, and nef open reading frames from
HIV-1 and SIV isolates that have been propagated in
vitro frequently encode prematurely terminated and
hence nonfunctional Nef proteins. Therefore, the ap-
parently contrasting results from in vitro experiments
may have reflected genetic variation among com-
monly studied nef alleles; this variation may result
from the absence of selection for nef function upon in
vitro propagation of cloned viruses.
In an attempt to circumvent limitations resulting
from the lack of genetic selection for nef under the in
vitro conditions, we isolated a large number of "pri-
mary" HIV-1 nef alleles directly from two patients in-
fected with HIV-1 and analyzed the effect of their
transient expression on CD4 antigen expression on
the surface of human CD4+ CEM T cells. Altogether,
we have characterized 15 new HIV-1 nef alleles from
patient SKI (NA clones) and 3 from patient SK4 (NB
clones). A compilation of results from these experi-
ments is shown in Figure 3. Expression of Nef from
all clones derived from SKI. effected a decrease in
CD4 antigen on the surface of CEM T cells, albeit to
different extents. Interestingly, nef alleles from
several of these clones, including NA3, 7, 10, 13, 14,
18, 11, and 15, were more potent than NL43 nef. The
NA1, 5, 6, 8, and NB1 alleles were as potent as the
NL43 Nef. In contrast, the NA4, NA17, NB5, and
NB9 alleles were exceptional in that they had little
effect on surface CD4 expression; we are currently
mapping the loss-of-function mutations in these al-
leles.
Three lines of evidence from our experiments indi-
cate that CD4 down-regulation reflects a conserved,
selected in vivo function of nef. First, approximately
80% of all nef alleles, including all those that directed
detectable expression of Nef protein, down-regulated
surface CD4 antigen upon transient expression in
CEM T cells. The observation that the remaining
20% of SK1 nef alleles showed a weak effect (or no
effect) on CD4 is not contradictory. A similar fre-
quency of functionally defective alleles (30%) was
observed before with the HIV-1 tat gene, which is es-
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sential for the viral life cycle, in populations isolated
directly from peripheral blood lymphocytes of AIDS
patients. Second, although sequence variation ob-
served among primary isolates of Nef proteins and
the NL43 Nef amounted altogether to more than 40
amino acid substitutions, most reflected conservative
changes with little or no detectable effect on CD4
down-regulation. Third, CD4 down-regulation was
disrupted by mutations in amino acid motifs that are
conserved among human and simian Nef proteins.
Remarkably, an intact amino-terminal myristoylation
site, which is invariantly found in both HIV-1 and
HIV-2/SIV Nef proteins, was required for full Nef
activity. These results provided a stage for current ex-
periments to address the biochemical mechanism(s)
of CD4 down-regulation by Nef.
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FIGURE 3 Primary HIV-1 and SIV Nef isolates down-regulate CD4 in human CD4+ T cells. Compila-
tion of results from flow cytometry analyses of nef alleles from patients SK1 and SK4. Each arrow
represents an individual NA or NB nef clone, which is identified by a number below. Each arrow
reflects the median level of CD4 expression on the surface of CEM cells transfected with the respec-
tive expression vector. Vertical lines represent the wild-type level CD4 expression on CEM T cells
(CEM wt). CD4 expression on CEM cells electroporated with the CD3 NL43 (which is associated with
abnormally low CD4 expression in CD3 Nef 1 transgenic mice) and CD3 HxB3 (which encodes a
nonfunctional Nef protein) are shown for comparison.
89
In Press, Submitted, and In Preparation
Mariani, R. and J. Skowronski. 1993. CD4 downregulation
by nef alleles isolated from I-IIV-1 infected individuals.
Proc. Natl. Acad. Sci. (in press).
Rothstein, J.L., D. Johnson, J. Jessee, J. Skowronski, D.
MAMMALIAN CELL GENETICS
M. Wig ler
Solter, and B. Knowles. 1993. Construction of primary
and subtracted cDNA libraries from early mouse em-
bryos. Methods Enzymol. 225: (in press).
Skowronski, J., D. Parks, and R. Mariani. 1993. Altered T cell
activation and development in transgenic mice express-
ing the HIV-1 nef gene. EMBO J. 12: 703-713.
R. Ballester H.-P. Xu N. Lisitsyn J. Brodsky M. Riggs
E. Chang J. Camonis L. Van Aelst G. Bolger J. Douglas
K. Sen A. Polverino R. Swanson S. Marcus T. Michaeli
K. O'Neill M. Barr L. Rodgers C. Nicolette V. Jung
G. Asouline N. Lisitsyn
This was an extraordinary year. For the 12-month pe-
riod ending as of this writing, three lines of work cul-
minated in extremely important achievements in
diverse areas of molecular biology. First, our studies
of RAS oncogene function have led to the discovery
that RAS activates a protein kinase cascade, con-
served in evolution from yeast to metazoans. This ac-
tivation is probably mediated through a direct interac-
tion with a MAP protein kinase kinase kinase
(MAPKKK). In mammalian cells, one such
MAPKKK upon which RAS acts is likely to be the
RAF oncoprotein. In Schizosaccharomyces pombe, a
fission yeast, it is the byr2 kinase. The methodologies
we have employed in these studies, cross species
complementation and the S. Fields and 0.-K. Song
genetic system to detect protein/protein interactions,
are likely to yield yet additional yeast and mam-
malian elements that operate in this pathway. Second,
we have developed a major new genetic tool that
detects the differences between two like DNA popu-
lations. This tool (RDA) enables us to discover
probes for pathogenic genomes from infected tissues,
to clone probes corresponding to the genetic lesions
from neoplastic cells and from organisms suffering
spontaneous genetic disease, and to clone probes
linked to inherited disease loci. Third, in collabora-
tion with Clark Still and his colleagues in the Depart-
ment of Chemistry at Columbia University, we have
developed the most powerful tool yet for conducting
combinatorial chemistry. This tool allows the
synthesis of extremely large numbers of chemical
compounds, the selection of the few with desirable
characteristics, and the determination of the structure
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of those few. In short, the combinatorial methods we
have developed enable organic chemists to operate
like geneticists. With such methods, the discovery of
small molecular agonists and antagonists to desired
targets may become as easy as raising monoclonal
antibodies.
Regulation of RAS
R. Ballester, L. Van Aelst, J. Camonis, V. Jung
RAS genes encode GTP/GDP-binding proteins, found
in yeasts and metazoans. They were first discovered
as the oncogenes of acutely transforming retroviruses
and then rediscovered as mutated alleles of the first
human oncogenes. Wild-type RAS proteins partici-
pate in physiologically normal signal transduction
pathways that regulate growth and differentiation in a
wide variety of cell types. Signaling from RAS oc-
curs in its GTP-bound state, and normal RAS protein
slowly hydrolyzes GTP. The wild-type proteins are
regulated by at least two types of molecules: factors
that accelerate guanine nucleotide exchange on RAS
and factors that accelerate guanine nucleotide
triphosphate hydrolysis by RAS. CDC25 of the yeast
Saccharomyces cerevisiae was the first protein of the
first class to be discovered (Camonis et al., EMBO J.
5: 375 [1986]; Broek et al., Cell 48: 789 [1987]).
Mammalian GAP was the first protein of the second
class to be discovered (Trahey and McCormick,
Science 238: 542 [1987]). Both CDC25 and GAP are
representatives of large families of proteins, found in
a wide variety of eukaryotic organisms. Mutant, on-
cogenic RAS proteins are frequently abnormal in
their regulation, and in particular in their response to
GAP. The object of this section has been to under-
stand the nature of the components and pathways that
regulate RAS.
Work in S. cerevisiae has indicated the existence
of at least three CDC25-like molecules: CDC25 it-
self, BUDS (Chant et al., Cell 65: 1213 [1991];
Powers et al., Cell 65: 1225 [1991]), and SDC25
(Boy-Marcotte et al., Gene 77: 21 [1989]; Damak et
al., Mol. Cell. Biol. 11: 202 [1991]). Previous genetic
analysis suggested a role only for CDC25 in the
physiological regulation of RAS. The biochemical
role of CDC25 was clarified by the discovery of
dominant interfering forms of RAS2, RASG1Y22, and
RAsAla15, which block CDC25 function (Powers et
al., Mol. Cell. Biol. 9: 390 [1989]). BUDS appears
likely to regulate BUD1, which is a RAS-like protein
(also known as RSR1) involved in polarity selection
during bud formation (Bender and Pringle, Proc.
Natl. Acad. Sci. 86: 9976 [1989]; Chant and
Herskowitz, Cell 65: 1203 [1991]). The true
physiological role of SCD25 is unknown. In high
copy, a truncated SCD25 gene can complement the
loss of CDC25, but the disruption of SCD25 has no
apparent phenotype.
Molecular analysis of CDC25 has revealed clues
about its regulation. The smallest domain of CDC25
needed for viability is a carboxy-terminal portion
(from amino acid 1102 to 1541). The entire molecule
is 1589 amino acids long. Regulatory regions are
found in the amino-terminal domains. A point muta-
tion (S 364 F) activates CDC25, and overexpression
of an amino-terminal domain (from amino acid 1 to
239) blocks wild-type CDC25 function. Cells ex-
pressing only the minimal catalytic region of CDC25
still exhibit glucose-dependent cAMP regulation
(Van Aelst et al., Eur. J. Biochem. 193: 675 [1990];
R. Ballester and L. Van Aelst, unpubl.). Therefore,
either this minimal region contains the regulatory
domains for glucose responsiveness or the pathway
that regulates cAMP in response to glucose does not
pass through CDC25. One interesting possibility is
that glucose regulates adenylyl cyclase through
GPA2, a protein that is in the family of the Ga sub-
units of heterotrimeric G proteins (Nakafuku et al.,
Proc. Natl. Acad. Sci. 85: 1374 [1988]). GPA2 has
been shown to affect cAMP levels and is a homolog
of gpa2, an S. pombe protein that is known to regu-
late adenylyl cyclase (Isshiki et al., Genes Dev. 6:
2455 [1992]). If this hypothesis is correct, then RAS
proteins and GPA2 may codominantly regulate
adenylyl cyclase. The codominance of RAS proteins
and G proteins is a theme to which we will return.
In S. pombe, there is a single known RAS
homolog, rasl (Fukui et al., Cell 44: 329 [1986];
Nadin-Davis et al., EMBO J. 5: 2963 [1986]). It is
regulated by a CDC25-like protein called ste6
(Hughes et al., Nature 344: 355 [1990]). Whereas
rasl is required for cell shape, sporulation, and con-
jugation, ste6 is required only for conjugation. There-
fore, other nucleotide exchange regulators of RAS
may be found in S. pombe. We have obtained direct
evidence for this. Upon testing libraries of mutated
rasl genes, we found several dominant negative rasl
mutants. One of these (rasl Tyr62) induced a rasl null
phenotype when overexpressed in wild-type cells but
had minimal effects when overexpressed in cells con-
taining the activated ras/val 17 gene. We therefore
presume that ras1TYr62 blocks the activation of rasl
by acting upon a regulatory molecule other than ste6.
One candidate for this is ral2. Disruption of ral2 pro-
duces a phenotype that is very similar to the rasl null
phenotype (Fukui et al., Mol. Cell. Biol. 9: 5617
[1989]). However, the primary sequence of ral2 does
not resemble that of CDC25-like molecules. Prelim-
inary data, obtained in collaboration with Dan Broek,
indicate that RAS molecules with the Tyr-62 muta-
tion bind irreversibly to CDC25-like molecules.
Genes with regions homologous to the catalytic
domain of CDC25 have been found in flies (Sos) and
mammals (rasGRF, mSosl, mSos2) (Simon et al.,
Cell 67: 701 [1991]; Botwell et al., Proc. Natl. Acad.
Sci. 89: 6511 [1992]; Shou et al., Nature 358: 351
[1992]). Although rasGRF has been shown to
catalyze guanine nucleotide exchange on RAS (Jac-
quet et al., J. Biol. Chem. 267: 24181 [1992]; Shou et
al., Nature 358: 351 [1992]), this had not been shown
for the Sos proteins. In collaboration with Pierre
Chardin and Dafna Bar-Sagi, we demonstrated that a
fragment (amino acids 707-1059) of hSosl, a human
homolog of Drosophila Sos and of mouse Sosl, com-
plements the loss of CDC25 in S. cerevisiae and
stimulates nucleotide exchange on RAS in vitro. Ex-
tracts from mammalian cells where hSosl is over-
expressed exhibit higher nucleotide exchange activity
on RAS. These data demonstrate that hSosl is a bona
fide nucleotide exchange catalyst for RAS. Larger
fragments of hSosl failed to complement a loss-of-
function mutation of CDC25, suggesting the exis-
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tence of negative regulatory domains. Further studies
will center upon the regulation of hSos1 function.
Recently a gene, SEM5, has been identified in
Caenorhabditis elegans, a simple worm, that encodes
a protein that appears to act upstream of RAS (Clark
et al., Nature 356: 340 [1992]). Homo logs of this
gene have been found in flies and mammals
(Lowenstein et al., Cell 70: 431 [1992]). In mam-
mals, the gene is called GRB2. This gene encodes a
protein composed entirely of SH3 and SH2 domains,
in the order SH3/SH2/SH3. SH2 domains, which are
found on a wide variety of molecules involved in sig-
nal transduction, bind certain peptide motifs contain-
ing phosphotyrosine (Pawson and Gish, Cell 71: 359
[1992]). SH3 domains are also found on a wide vari-
ety of signal transduction molecules, and bind certain
peptide motifs, but these motifs are less well charac-
terized (Ren et al., Science 259: 1157 [1993]). Two
of the human homologs of CDC25, hSosl and hSos2,
contain peptides in their carboxy-terminal domains
that are candidate SH3-binding motifs. We therefore
reasoned that the Sos proteins might bind to GRB2.
To test this, we utilized a genetic assay in S.
cerevisiae for protein/protein interactions, the two
hybrid system of Fields and Song (Nature 340: 245
[1989]). These studies indicated that GRB2 interacts
with the carboxy-terminal domain of hSos1 (amino
acids 1131 to 1333), and this was further demon-
strated by direct coprecipitation. Our genetic studies
indicated that both SH3 domains are required for in-
teraction.
We have continued our investigations of NF1 in an
ongoing collaboration with Francis Collins and his
colleagues at the University of Michigan. NF1 is the
locus for Von Recklinghausen's neurofibromatosis,
an inherited disease affecting the proliferation and
differentiation of neuroepithelium. It encodes a mem-
ber of the GAP family of GTPase-activating proteins
capable of causing the down-regulation of RAS
proteins (Xu et al., Cell 62: 599 [1990]; Wang et al.,
Cell Regul. 2: 453 [1991]). NF1 mRNA comes in two
alternately spliced forms, one with an insertion in the
midst of the region thought to encode the catalytic
domain (Anderson et al., MoL Cell. Biol. 13: 487
[1993]). Both spliced forms are expressed in all tis-
sues examined, although in varying ratios. We
demonstrated that both forms are catalytically active.
Mutational studies of the conserved residues of NF1
have indicated that certain are required for full ac-
tivity, as judged by genetic assays in S. cerevisiae
(Gutmann et al., Oncogene 8: 761 [1993]). Substitu-
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tion at residue 1426 abolishes activity, and substitu-
tions at residues 1423 and 1391 merely diminish ac-
tivity.
Questions remain whether GAP-like molecules
have RAS-effector function. The evidence is clear
that GAP can down-regulate RAS, but evidence is
also accumulating that GAP has some effector ac-
tivity (Yatani et al., Cell 61: 769 [1990]; Martin et
al., Science 255: 192 [1992]; Schweighoffer et al.,
Science 256: 825 [1992]). We have continued to pur-
sue this issue for the IRA genes, which encode GAP-
like molecules in S. cerevisiae (Tanaka et al., MoL
Cell. Biol. 9: 757 [1989]; Tanaka et al., MoL Cell.
Biol. 10: 4303 [1990]). Disruption of both IRA and
IRA2 in S. cerevisiae leads to the same phenotype
seen when RAS2 is activated by mutation. Disruption
of RAS2 in an iral- ira2- background restores a
wild-type phenotype. Thus, the only function we can
detect for the IRA proteins is the down-regulation of
RAS protein (R. Ballester, unpubl.).
A Conserved Cascade of Protein
Kinases: RAS Effector Function
S. Marcus, L. Van Aelst, A. Polverino, H.-P. Xu,
M. Barr, M. White, K. Sen
In the fission yeast S. pombe, ras 1 participates in
pheromone-induced sexual differentiation (Fukui et
al., Cell 44: 329 [1986]; Nadin-Davis, EMBO J. 5:
2963 [1986]; Nielson et al., EMBO J. 11: 1391
[1992]; Neiman et al., MoL Biol. Cell 107: [1993]).
rasl- cells are unable to conjugate, and they sporu-
late inefficiently. gpal, a gene that encodes a protein
homologous to the Ga subunits of heteromeric G
proteins, is also required for conjugation and sporula-
tion (Obara et al., Proc. Natl. Acad. Sci. 88: 5877
[1991]). gpal presumably mediates the signaling
from the pheromone receptors. Studies during the
past few years have indicated that overexpression of
several genes is capable of bypassing the requirement
for rasl for sporulation in S. pombe. Among these
genes are byr2 and byr1, two genes encoding putative
protein kinases and also required for both conjugation
and sporulation (Nadin-Davis and Nasim, EMBO J.
7: 985 [1988]; Wang et al., MoL Cell. Biol. 11: 3554
[1991]). Overexpression of these genes also restored
sporulation to gpal- cells (Neiman et al., MoL Cell.
Biol. 4: 107 [1993]). Epistasis experiments, utilizing
sporulation of diploid cells as the observable
phenotype, placed byrl downstream from byr2, and
both downstream from rasl and gpa1, but these ex-
periments could not order rasl and gpal with respect
to each other.
We have succeeded in ordering gpal and rasl by
examining expression of mam2, the gene encoding
the receptor for P-factor pheromone (H.-P. Xu et al.,
submitted). We have found that mRNA levels for
mam2 depend on components of the pheromone sig-
naling pathway itself. We view this relationship as a
rudiment of a sexual arousal response. Disruption of
rasl, gpal, byrl, or byr2 reduces mam2 expression
10- to 100-fold in wild-type homothallic cells. By
overexpressing these genes, we have confirmed that
byrl and byr2 act downstream from gpal and rasl
but also that gpal acts downstream from rasl, and
rasl downstream from gpal. In other words, rasl and
gpal are codominant. These same studies find no role
for spkl in the regulation of mam2 (see below).
Work continues to find other elements of S. pombe
that participate in the sexual differentiation pathway.
We have found mutants of diploid S. pombe that
sporulate in the absence of rasl and have demon-
strated that one of these mutants is recessive. The
mutant locus encodes a product that appears to act
upstream of byr2. Hence, the mutant locus might en-
code a protein that normally functions to block sexual
differentiation, perhaps by acting on the pathway be-
tween gpal and byr2 or between rasl and byr2. In a
similar approach, we have constructed S. pombe
strains containing a mam2 promoter-reporter gene
(ADE2) that we are using to look for new mutations
in the sexual differentiation pathway.
In collaboration with Aaron Nieman in Ira
Herskowitz's laboratory at the University of Califor-
nia, San Francisco, and Brian Stevenson in the
laboratory of George Sprague, University of Oregon,
we showed that the byr2 and byrl kinases are each
structurally and functionally related to the STEll and
STE7 kinases of S. cerevisiae, respectively (Neiman
et al., Mol. Cell. Biol. 4: 107 [1993]). STE11 and
STE7 are themselves required for the pheromone-
induced sexual differentiation pathways in the bud-
ding yeast, with STE11 acting upstream of STE7
(Teague et al., Proc. Natl. Acad. Sci. 83: 7371
[1986]; Rhodes et al., Genes Dev. 4: 1862 [1990];
Cairns et al., Genes Dev. 6: 1305 [1992]; Gartner et
al., Genes Dev. 6: 1280 [1992]; Stevenson et al.,
Genes Dev. 6: 1293 [1992]). Our studies of cross
species complementation suggest that byrl and byr2
cooperate in S. cerevisiae, and hence probably direct-
ly interact. Furthermore, byr2 appears to restore
pheromone responsiveness to STE11-deficient cells,
indicating that the regulation of byr2 by upstream
elements has been conserved.
A pair of protein kinases, FUS3 and KSS1, found
in S. cerevisiae, also participate in the sexual differ-
entiation pathway, probably downstream from STE11
and STE7 (Gartner et al., Genes Dev. 6: 1280 [1992];
Errede et al., Nature 362: 261 [1993]). They are
homologous to the spkl protein kinase of S. pombe,
likewise required for sexual differentiation in that
organism (Toda et al., Genes Dev. 5: 60 [1991];
Neiman et al., Mol. Cell. Biol. 4: 107 [1993]). In our
collaborative studies, we demonstrated that spkl and
the FUS3/KSS1 kinases share function. Most sig-
nificantly, these kinases are structurally related to the
MAP/ERK protein kinases of vertebrate cells
(Boulton et al., Cell 65: 663 [1991]; Toda et al.,
Genes Dev. 5: 60 [1991]). The latter kinases are ac-
tivated, in a RAS-dependent fashion, by a variety of
extracellular factors (DeVries-Smits et al., Nature
357: 602 [1992]; Robbins et al., Proc. Natl. Acad.
Sci. 89: 1624 [1992]; Thomas et al., Cell 68: 1031
[1992]; Wood et al., Cell 68: 1041 [1992]). This sug-
gested a possible conserved kinase cascade between
yeasts and vertebrates. Consistent with this, we
demonstrated that ERK2, a member of the MAP
kinase family, could partially replace spkl function
in S. pombe (Neiman et al., Mol. Cell. Biol. 4: 107
[1993]). Significantly, a MAP kinase kinase, called
MEK, was found by others that is homologous to
STE7 and byrl (Crews et al., Science 258: 478
[1992]) and, even more recently, a MEK kinase
(MEKK) that is homologous to STE11 and byr2
(Lange-Carter et al., Science 260: 315 [1993]).
The dependence of agonist-induced MAP kinase
activation upon RAS was demonstrated by other in-
vestigators who showed that interfering forms of
RAS block MAP kinase activation (DeVries-Smits et
al., Nature 257: 602 [1992]; Robbins et al., Proc.
Natl. Acad. Sci. 89: 1624 [1992]; Thomas et al., Cell
68: 1031 [1992]; Wood et al., Cell 68: 1041 [1992]).
Moreover, scrape loading cells with mutant, activated
RAS leads to MAP kinase activation (Leevers and
Marshall, EMBO J. 11: 569 [1992]). In collaboration
with Ellen Shibuya of Joan Ruderman's laboratory at
Harvard Medical School, we showed that this interac-
tion could be observed in cell-free Xenopus oocyte
extracts (Shibuya et al., Proc. Natl. Acad. Sci. 89:
9831 [1992]). Addition of activated RAS protein
results in a slow (1-3 hr) activation of MAP kinase.
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Mutant RAS that lacks the site for carboxy-terminal
processing failed to activate MAP kinase. The slow
kinetics of the response to activated RAS probably
reflects the slow processing and maturation of RAS.
In vertebrates, the RAF oncoprotein is a candidate
downstream effector of RAS. RAF can overcome
growth defects in cells in which RAS function is
blocked (Smith et al., Nature 320: 540 [1986]; Cai et
al., Mol. Cell. Biol. 10: 5314 [1990]). Interfering
forms of RAF block RAS function (Kolch et al., Na-
ture 349: 426 [1991]). Moreover, RAF is capable of
phosphorylating MEK, a MAP kinase kinase (Dent et
al., Science 257: 1404 [1992]; Howe et al., Cell 71:
335 [1992]; Kyriakis et al., Nature 358: 417 [1992]),
and RAF becomes hyperphosphorylated in response
to RAS activation (Morrison et al., Proc. Natl. Acad.
Sci. 85: 8855 [1988]; Wood et al., Cell 68: 1041
[1992]). To begin our investigation of the rela-
tionship between RAS and RAF, we expressed RAF
in S. pombe. We observed inhibition of sexual con-
jugation by RAF and partial suppression of the
phenotypes of activated RAS. No phenotype was ob-
served when we expressed an "activated" RAF, lack-
ing the amino-terminal, putative regulatory domain.
These experiments suggested that interactions with
upstream elements regulating RAF may have been
conserved.
We decided to test directly whether RAS and RAF
could interact. To do this, we employed a genetic sys-
tem in S. cerevisiae, Fields and Song's (Nature 340:
245 [1989]) two hybrid system, that detects physical
complex formation between proteins fused to the
separated activating and binding DNA domains of the
transcriptional activator GAL4. These experiments
revealed that RAS forms a complex with RAF (L.
Van Aelst et al., Proc. Natl. Acad. Sci. [in press]).
RAS mutated in its effector loop, or in the domain re-
quired for GTP binding, would not interact with
RAF. Binding was to the amino terminus of RAF,
believed to be its regulatory domain. These experi-
ments give further evidence for the hypothesis that
RAF is a downstream effector of RAS and suggest
that RAF is an immediate downstream effector. At
present, we cannot rule out the possibility that the in-
teractions between RAS and RAF are mediated by a
third protein.
We further showed that RAF can form a complex
with MEK, again using the two hybrid system. This
interaction requires only the catalytic domain of
RAF. Moreover, RAS can form a complex with
MEK, but only if RAF is also overexpressed. This
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suggests either that RAF forms a protein bridge be-
tween RAS and MEK or, less likely in our view, that
RAF alters MEK so that it can bind to RAS. It is now
easier to formulate possible hypotheses about how
RAS regulates RAF function: RAS might directly ac-
tivate RAF or RAS might cause RAF to colocalize
with RAS, bringing RAF in proximity to other
regulators or substrates. These comments bear upon
MEK regulation and even MAP kinase regulation by
RAS.
Our results with RAF encouraged us to examine
complex formation between RAS and byr2. byr2
plays a role in S. pombe not unlike the role of RAF in
mammalian cells. byr2 appears to mediate signals
from RAS and appears to activate byrl (Wang et al.,
Mol. Cell. Biol. 11: 3554 [1991]; Neiman et al., Mol.
Biol. Cell 4: 107 [1993]), which is homologous to
MEK. Again, we found that RAS could form a com-
plex with byr2, and again with its amino-terminal,
putative regulatory domain. Although byr2 has an
overall similarity to RAF in that it is a large protein
kinase with a catalytic carboxy-terminal domain, out-
side this domain it has no evident primary sequence
homology with RAF. Moreover, neither RAF nor
byr2 bear any resemblance to the GAP family,
proteins known to interact with RAS. Thus, we think
that either a small and as yet unrecognized primary
sequence motif is responsible for RAS interaction or
interaction with RAS requires a conformational
motif.
Conjugation and Shape
in S. pombe
E. Chang, J. Camonis
While attempting to define genes that might act on
the RAS pathway, we looked for mutations that pro-
duced phenotypes similar to those of rasl- cells.
Several mutants were obtained that were both round
and sterile, and the loci responsible were identified.
These were called scdl and scd2 (for shape and
conjugation deficient). Sequence analysis indicates
that scdl is globally homologous to S. cerevisiae
CDC24 (Miyamoto et al., Gene 54: 125 [1987]),
whereas scd2 is closely related to S. cerevisiae BEM1
(Chenevert et al., Nature 356: 77 [1992]). Moreover,
CDC24 can partially complement loss of scdl func-
tion. CDC24 and BEM1 participate in bud formation
and bud site selection in S. cerevisiae (Bender and
Pringle, Mol. Cell. Biol. 11: 1295 [1991]; Chant et
al., Cell 65: 1213 [1991]). In S. cerevisiae, this pro-
cess involves at least two members of the RAS super-
family: BUD1 (Bender and Pr'ingle, Proc. Natl. Acad.
Sci. 86: 9976 [1989]; Chant and Herskowitz, Cell 65:
1203 [1991]), also known as RSR1, which is closely
related to the RAS proteins, and CDC42, which is a
member of the RHO subfamily. We tested the inter-
relationship of these gene products and have found
that S. pombe rasl (but not S. cerevisiae RAS2) can
suppress defects in S. cerevisiae CDC24, and a mem-
ber of the mammalian RHO subfamily, CDC42Hs
(Shinjo et al., Proc. Natl. Acad. Sci. 87: 9853
[1990]), which can suppress the loss of CDC42 in S.
cerevisiae, can suppress the morphological defects of
rasl- S. pombe. We derive two hypotheses from
these observations. The first is that common
molecular mechanisms can be adapted to different
morphogenic programs (budding in S. cerevisiae,
shape and conjugation in S. pombe). The second is
that rasl in S. pombe may have a role that is
homologous to both S. cerevisiae RAS and S.
cerevisiae BUD1. In other words, whereas S.
cerevisiae has evolved two diverged forms of RAS,
one specialized for regulating morphogenesis (bud-
ding) and one specialized for signal transduction
(through the cAMP-dependent protein kinases), S.
pombe has a single form of RAS capable of regulat-
ing both morphogenesis (cell shape and conjugation)
and signal transduction (the MAP protein kinase cas-
cade).
The Function of CAP and
Related Proteins
K. O'Neill
We previously described the adenylyl-cyclase-
associated protein (CAP) required for RAS-stimulat-
ed adenylyl cyclase activity in S. cerevisiae (Field et
al., Cell 61: 319 [1990]; Gerst et al., Mol. Cell. Biol.
11: 1248 [1991]). The S. pombe homolog, cap, is also
associated with adenylyl cyclase and appears to be
required for its proper regulation (Kawamukai et al.,
Mol. Cell. Biol. 3: 167 [1992]), although the
regulator of adenylyl cyclase in S. pombe does not
appear to be rasl (Fukui et al., Cell 44: 329 [1986];
Nadin-Davis and Nasim, Mol. Cell. Biol. 10: 549
[1990]; Kawamukai et al., Cell Regul. 2: 155 [1991]).
In S. pombe, the gpa2 gene product, a Ga-like
protein, appears to be required for adenylyl cyclase
regulation (Isshiki et al., Genes Dev. 6: 2455 [1992]).
CAP proteins are bifunctional proteins, as we have
described in previous years (Gerst et al., Mol. Cell.
Biol. 11: 1248 [1991]; Kawamukai et al., Ma Cell.
Biol. 3: 167 [1992]). The amino terminus is associa-
ted with adenylyl cyclase and the carboxyl terminus
is associated with morphological functions.
Recently, in collaboration with Makoto Kawamu-
kai, formerly from this lab but now returned to
Shimane University, in Japan, we have succeeded in
cloning a human homolog of CAP by complementa-
tion in S. pombe of the loss of carboxy-terminal cap
function. This gene encodes a protein that is the
homolog of a porcine protein, called ASP-56, isolated
from platelets based on its actin-binding properties
(Gie-selmann and Mann, FEBS Lett. 298: 149
[1992]). In collaboration with Jeff Field, we have
shown that both the human and S. cerevisiae CAP
proteins can bind to S. cerevisiae actin. We previous-
ly noted that loss of carboxy-terminal CAP function
in S. cerevisiae could be suppressed by overexpres-
sion of profilin, an actin- and phospholipid-binding
protein (Vojtek et al., Cell 66: 497 [1991]). This
leads us to postulate that the carboxyl terminus of
CAP and profilin have redundant function. CAP
homologs have now been found in worms and hydra,
and a second human CAP, CAP2, has been found
(collaborations with M. Chalfie, Columbia Univer-
sity, New York, and C. Schaller, University of Ham-
burg, Germany). The carboxy-terminal portion is the
only portion that appears to be so conserved that it
functions in cross species complementation. How-
ever, the amino-terminal primary structure is at least
partially conserved. This raises our hopes that the
amino-terminal domains bind adenylyl cyclase in
other species, and we are hopeful of discovering a
homolog of the yeast form of this enzyme in mam-
mals.
Analysis of the Mechanism of
Tumor-promoting Phorbol
Esters and Protein Kinases C
C. Nicolette
In previous years, we identified a number of human
cDNAs that, when expressed in S. cerevisiae, could
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block the phenotypes induced by activated RAS
(Colicelli et al., Proc. Natl. Acad. Sci. 88: 2913
[1991]). One of these, called JC310, has proven to be
of particular interest because its overexpression in
mammalian cells has a striking phenotype. Analysis
indicates that expression of JC310 blocks the action
of the tumor-promoting phorbol esters. Phorbol esters
activate protein kinases C (PKC), which are thought
to mediate the action of the phorbol esters. In particu-
lar, phorbol esters induce DNA synthesis in quiescent
cells, induce morphological change, induce phos-
phorylation of PKC substrates, induce phosphoryla-
tion of MAP kinase, and induce fos expression (Kik-
kawa and Nishizuka, The Enzymes, Academic Press
[1986]; Ono et al., J. Biol. Chem. 263: 6927 [1988]).
Cells selected for overexpression of JC310 are
resistant to phorbol-ester-induced DNA replication,
fos expression, and morphologic change. However,
such cells do undergo the changes in protein
phosphorylation induced by the phorbol esters. Cells
transiently expressing JC310 and a fos-CAT reporter
construct do not respond to phorbol esters by induc-
tion of CAT (chloramphenicol acetyltransferase). Ex-
pression of JC310 appears to have no effect on the
cellular response to RAS, growth factors that are
mediated through tyrosine kinase receptors, or serum.
We have not yet tested factors that act through G
proteins. JC310 localizes to the nucleus.
These results require some rethinking about
phorbol-ester- and RAS-induced signaling. First, our
results throw into question the cooperative, inter-
dependent relationship between RAS and PKCs (Yu
et al., Cell 52: 63 [1988]; Gauthier-Rouviere et al.,
EMBO J. 9: 171 [1990]). Moreover, JC310 blocks
phorbol esters without apparently blocking the ac-
tivation of PKC, and hence phorbol esters might in-
duce effects through a previously uncharacterized
route. Alternately, JC310 blocks nuclear signaling
from the PKC. The further implication is that nuclear
signaling from phorbol esters proceeds through a
"private line" of communication with the nucleus that
is not shared by serum, RAS, or growth factors acting
via tyrosine kinase receptors. Detailed analysis of the
regulation of the fos promoter are consistent with this
hypothesis (Gilman, Genes Dev. 2: 394 [1988]; Cai
et al., MoL Cell. Biol. 10: 5314 [1990]). Finally, the
failure of cells that overexpress JC310 to respond to
the morphological effects of phorbol esters brings
into question the belief that these rapid effects are
mediated by the purely cytoplasmic effects of activat-
ing PKC.
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Characterization of Mammalian
cAMP Phosphodiesterases
T. Michaeli, G. Bolger
Several years ago, we reported that mammalian genes
encoding cAMP phosphodiesterases (PDE) could be
cloned by selecting from mammalian cDNA libraries
those genetic elements that could block the effects of
activated RAS (RAS2val 19) in S. cerevisiae (Colicelli
et al., Proc. Natl. Acad. Sci. 86: 3599 [1989]). Our
first PDEs were homologous to the Drosophila dunce
gene involved in learning and memory in fruit flies.
We now know that there are four such genes in hu-
mans and that they encode high affinity, cAMP-
specific PDEs that are rolipram-sensitive. Sequence
analysis indicates that they share two regions of con-
served sequence upstream of the catalytic region
(UCR1 and UCR2) and some of the same splice junc-
tions with the Drosophila dunce PDE (G. Bodger et
al., submitted).
We have also identified a new human PDE,
representing a novel family of PDEs, class VII, that
we have called HCP. HCP is a very high affinity (Km
-0.1 tim) cAMP-specific PDE that is insensitive to
both milrinone and rolipram. Its expression is espe-
cially high in skeletal muscle, but we find it is also
expressed in the heart and brain. HCP was cloned by
suppression of the phenotype of a pdel- pde2+ S.
cerevisiae strain. This latter strain is a more sensitive
host strain for screening PDEs than is the RAS2val 19
strain (T. Michaeli et al., J. Biol. Chem., in press.)
Difference Cloning
N. Lisitsyn, N. Lisitsyn, H.-P. Xu
In 1981, it was apparent that gene transfer was
detecting mainly mutant RAS genes in tumor cells
and that an unbiased method was required for the
detection of genetic lesions in tumors. In 1985, we
began in earnest to develop a "difference cloning"
methodology that would enable us to detect the dif-
ferences between two complex genomes. Our early
efforts culminated in a method that could achieve
100-1000-fold enrichment of "difference" sequences
(i.e., "target" found in the "tester" genome, but not
present in the "driver" genome) by reiterated subtrac-
tive methods (Wieland et al., Proc. Natl. Acad. Sci.
87: 2720 [1990]). We also realized that the second-
order kinetics of DNA reannealing could be har-
nessed to achieve even greater enrichment, but we
could not combine the subtractive and kinetic steps.
Hence, we failed to achieve the levels of enrichment
required for the difference analysis of complex
genomes.
In 1991, Nikolai Lisitsyn arrived at Cold Spring
Harbor to continue studies that he had begun on this
problem in Moscow. He brought with him an elegant
technique, based on the polymerase chain reaction
(PCR), to amplify small quantities of homoduplex
DNA in the presence of large quantities of un-
annealed DNA or heteroduplex DNA. While here, we
engineered this technique into a powerful difference
analysis method that utilized subtractive and kinetic
enrichment together in each repetitive step. In the
analysis of complex genomes, we found it was neces-
sary first to sample the genomes, reducing their com-
plexity in a reproducible way. We achieved this by
"whole genome" PCR in which the DNA is cleaved,
ligated to template oligonucleotide linkers, and then
amplified by PCR. Only small fragments amplify
well and hence the resulting "amplicon" has a smaller
overall complexity than the starting material.
Through multiple samplings, much of one genome
can thus be scanned for differences with another
genome. The details of the method, which we call
representational difference analysis (or RDA), were
recently published (Lisitsyn et al., Science 259: 946
[1993]). We demonstrated that RDA could be used to
clone polymorphisms between two individuals and to
detect viral genomes added in single copy to one
genome. The applications of this method, which are
myriad, are discussed here.
First, RDA may be used to search for pathogenic
organisms in infected tissue (tester) that are not pres-
ent in uninfected tissue from the same individual
(driver) or in the pooled uninfected tissue of the
patient's parents. We have demonstrated this method
in reconstruction experiments but have not yet suc-
ceeded in using it to discover new pathogens in dis-
eased tissue. We have found it necessary to extract
high-molecular-weight DNA from the infected tissue,
or else artifacts may arise. Three types of problems
can be anticipated: when the pathogenic organism
does not have a DNA phase, when the infecting
organism has created a host reaction but is no longer
present, and when other foreign organisms are pres-
ent that are not related to the pathogenic process.
Second, RDA may be used for analysis of genetic
lesions in tumors. This may proceed in either of two
ways. When essentially pure tumor cells (un-
contaminated by stroma) can be obtained, DNA can
be extracted and used as driver against normal DNA
as tester. The "target" sequences will represent
restriction enzyme fragment polymorphisms that are
missing in the tumor due to loss of heterozygosity or
sequences that are absent in the tumor due to
homozygous deletion. Such events may mark the loss
of function of a tumor suppressor gene. There are
three problems in applying the method in this man-
ner. First, pairs of pure tumor cell populations and
their normal counterparts are hard to come by. Sec-
ond, the tumor cell source is usually a cell line, and
many genetic changes may have occurred during the
establishment and maintenance of the cell line. Third,
loss of heterozygosity may be so prevalent that
probes for these events will greatly outnumber probes
for the more interesting lesions resulting from
homozygous deletions. We have applied RDA in this
manner in several instances and have consistently
found probes that reflect loss of heterozygosity.
Alternatively, normal DNA can be taken as driver,
with the tumor taken as tester. When applied this
way, RDA yields probes for sequences present in
tumors that are absent in normal DNA. Such se-
quences could arise by chromosomal rearrangements
that fortuitously create small DNA restriction endo-
nuclease fragments containing sequences not present
in amplicons from normal DNA. Thus, this method
has the potential to detect probes for translocations,
deletions, inversions, and insertions. In addition, we
have found that sequences amplified in the tumor cell
can also be detected this way. If viral sequences are
present in tumor cells, they will also be detected.
Rarely, point mutations will create new restriction
fragments that can be cloned. There are several ad-
vantages to applying RDA to tumors in the above-
described manner. Material can be obtained from the
patient, at all stages, by biopsy, and the contamina-
tion by normal stroma will be well tolerated. Lesions
of many sorts should be identifiable and will not be
confounded by loss of heterozygosity. The only dis-
advantage we can anticipate is that some tumor cells
may have so many lesions of biological insignifi-
cance, present as a consequence of errors of DNA
replication or repair, that the significant lesions can-
not be found. In that event, it might be necessary to
examine model animal systems.
Third, RDA can be applied to both inherited genet-
ic disease and sporadic (or spontaneous) genetic dis-
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ease. In the first case, we utilize RDA to find
polymorphic markers linked to the disease. This
method has been successfully tested in model sys-
tems of inherited disease in mice, carried out in col-
laboration with Eric Lander's group at the Massachu-
setts Institute of Technology. The method works be-
cause progeny with the desired phenotypes can be
selected from crosses between polymorphic strains of
animals, and their DNA can be used as tester (or
driver) against DNA from the strain lacking the trait
as driver (or tester). Similar studies with human
families can be undertaken, but we have not yet done
SO.
In the case of sporadic disease, we can anticipate
that genetic rearrangement may be responsible for a
portion of spontaneous lesions. Such a situation is
formally akin to genetic rearrangements in tumor
cells. The affected child's DNA is used as tester, and
pooled parental DNA is used as driver. We expect to
be able to use RDA to isolate probes for genetic rear-
rangements causing a wide variety of diseases, in-
cluding mental retardation, severe developmental
defects, autism, and juvenile schizophrenias. Molecu-
lar approaches to such diseases were previously not
generally available.
Combinatorial Chemical
Libraries
R. Swanson, G. Asouline
The diversity of life is achieved by combinatorial
methods: any codon can follow any codon; any
amino acid the previous one. A small protein of 200
residues has 20200 possible sequences, a number
greater than the number of atoms in the universe.
From this diversity, proteins and nucleic acid se-
quences are selected in the course of evolution.
Something like this, although not as grand in scale,
can now be achieved in the laboratory by synthetic
means. Oligopeptides of great diversity (in the mil-
lions or even in the billions) can be generated, either
chemically or through genetic engineering (Smith,
Science 228: 1315 [1985]; Scott and Smith, Science
249: 386 [1990]; Houghten et al., Nature 354: 84
[1991]). The structure of those few peptides selected
for some characteristic (usually binding to a receptor)
can then be determined. Chemists can generate many
equally diverse libraries of organic molecules, but
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determining the structure of those few compounds
that have desired properties has until now not been
feasible. In collaboration with Clark Still and his col-
leagues at Columbia University, we have solved this
problem.
Details of the method will be submitted for publi-
cation at a later time. In essence, the method entails
making compounds on microsphere beads, each bead
having a high density of a single compound covalent-
ly attached. This method of synthesis has been de-
scribed previously by other investigators in the gener-
ation of vast peptide libraries (Furka et al., Int. J.
Pept. Protein Res. 37: 487 [1991]; Lam et al., Nature
354: 82 [1991]), but whereas the identity of the com-
pounds on a selected bead was previously determined
by microsequencing, a method applicable to oligo-
peptides and oligonucleotides, we perform the
synthesis of the compounds on the beads in such a
way that the chemical identity of the compound on
the bead is readily determined by "reading" the bead.
Using this method, we succeeded in synthesizing a
peptide library of 105 different molecules, selected
beads bearing peptides reactive with a monoclonal
antibody, and correctly decoded the beads so
selected. The method is not restricted to peptides. It is
applicable to the discovery of small organic
molecules that bind to a given target, inhibit a given
enzyme, inhibit the growth of a given microbe, or,
more generally, induce a given response in cells.
Other uses of the methodology will be in the study of
molecular recognition.
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The control of cell proliferation by growth factors
depends on an orderly transfer of information from
the cell surface to the nucleus. Much of the research
into growth control mechanisms in eukaryotic cells
centers on the proteins encoded by the ras proto-
oncogenes. Ras proteins are members of a large su-
perfamily of low-molecular-weight proteins that bind
guanine nucleotides. They are essential for the trans-
duction of diverse extracellular signals that control
cell growth, and abnormal activation of Ras proteins
apparently contributes to the development of several
types of human cancer. Our laboratory has been
studying the mechanisms of signal transduction by
Ras proteins. During the past few years, a number of
cellular proteins involved in the control of the ac-
tivity of Ras proteins have been identified. Our cur-
rent studies are aimed at uncovering how these
proteins interact with Ras proteins to regulate their
activity. The characterization of the intermolecular
interactions required for Ras activity should provide
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insights into the function of Ras proteins in normal
cell proliferation and in oncogenic transformation.
Role of Ras Proteins in Signaling
via the B-cell Antigen Receptor
L. Graziadei
B lymphocytes express antigen receptors in the form
of surface immunoglobulins (sIg). Cross-linking of
these receptors by antigen or anti-immunoglobulin
antibodies (anti-Ig) initially induces receptor cluster-
ing (patching) followed by receptor migration to one
pole of the cell (capping) and then by receptor inter-
nalization. Receptor cross-linking is the seminal
event in the activation of these cells to proliferate and
differentiate. We have previously found that
antibody-mediated cross-linking of slg leads to the
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activation of Ras as indicated by a substantial in-
crease in the proportion of the "active" GTP-bound
form of cellular Ras molecules. This indicated that
Ras can receive signals from cross-linked slg. During
the past year, we have further investigated the nature
of these signals.
Cross-linking of slg is known to activate a number
of signal transduction events, including the metabo-
lism of phosphoinositides that leads to the activation
of protein kinase C (PKC). To determine whether
PKC might regulate Ras activation, we have
employed phorbol myristate acetate (PMA), a
pharmacological activator of PKC. We have found
that treatment of cells with PMA leads to a dramatic
and prolonged activation of Ras. However, inhibition
of PKC activity by pretreatment of cells with the
PKC inhibitor Calphostin had no effect on slg-
mediated Ras activation, indicating that PKC is prob-
ably not a physiological regulator of slg- mediated
Ras activation. Cross-linking of slg has been shown
to activate protein tyrosine kinases (PTK) of the src
family. To examine the role of PTK in slg- mediated
Ras activation, we compared slg- mediated PTK ac-
tivity (as assessed by Western blotting with anti-
phosphotyrosine antibodies) with slg- mediated Ras
activation and found that the two display similar
times of onset. In addition, both Ras activation
PTK stimulation are prolonged when cells are stimu-
lated at 0°C but show rapid down-regulation at 37°C.
This is consistent with the notion that Ras activation
lies downstream from slg- mediated PTK activity. To
further understand the regulation of Ras activation by
the slg receptor, we are currently characterizing the
activities of Ras GTPase activators and guanine
nucleotide exchange factors in untreated and anti-Ig-
stimulated B lymphocytes.
Differential Regulation of
Ras-GAP and Neurofibromin
in B Lymphocytes
M. Boyer [in collaboration with D. Gutmann and F. Collins,
University of Michigan]
The activity of a Ras protein is regulated by the
guanine nucleotide that is bound to the protein. The
GTP-bound state is active, whereas the GDP-bound
state is not. The proportion of Ras in the active state
is believed to be determined principally by two reac-
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tions. An inactive GDP-bound Ras molecule is ac-
tivated by the exchange of a bound GDP molecule for
a GTP molecule. An active GTP-bound Ras molecule
is inactivated by the intrinsic GTPase activity of the
Ras protein. This inactivation reaction is greatly stim-
ulated by Ras-GTPase-activating proteins (GAPs).
To date, two GAPs have been identified: One with a
molecular mass of 120 kD (Ras-GAP) and another
with a molecular mass of 250 kD that is encoded by
the neurofibromatosis type I gene (neurofibromin).
Ras-GAP and neurofibromin are both widely ex-
pressed and have similar biochemical properties in
vitro with respect to activation of Ras GTPase. We
have been interested in determining the biological
significance of the occurrence of these two GAPs.
Immunofluorescence studies performed previously in
our laboratory have demonstrated a spatial and
temporal coincidence between the ligand-induced
migration of slg and Ras in mitogenically stimulated
B lymphocytes. We have employed this relocaliza-
tion event to analyze the involvement of Ras-GAP
and neurofibromin in the Ig-mediated signaling path-
way.
To study the intracellular localization of neuro-
fibromin and Ras-GAP in B lymphocytes, we used
antibodies directed against noncatalytic domain
established the specificity of these
antibodies by immunoblotting analysis as well as by
immunoprecipitation from metabolically labeled B
lymphocytes. By means of double-immunofluores-
cence labeling experiments, we found that neuro-
fibromin accumulates under caps and patches in-
duced by anti-Ig antibodies. In contrast, no change in
the intracellular distribution of Ras-GAP was
detected during the anti-Ig-induced capping. By ex-
amining the kinetics of neurofibromin redistribution,
we found that the movements of neurofibromin and
slg were spatially and temporally coordinated in both
the patching and the capping stages. Neurofibromin
was found to co-cap with a different isotype of slg,
indicating that the redistribution of neurofibromin is a
general feature of signaling by slg. We next exam-
ined the specificity of the neurofibromin redistribu-
tion by analyzing the localization of neurofibromin
during the capping of Con A receptors. Capping of
Con A receptors was not accompanied by the relo-
calization of neurofibromin, suggesting that the
redistribution of neurofibromin is specifically associ-
ated with Ig signaling. These results clearly show that
neurofibromin and Ras-GAP can be differentially
regulated in vivo. Furthermore, together with our
findings that Ras proteins also co-cap with sIg, our
observations are consistent with the possibility that in
B lymphocytes, Ras proteins interact specifically
with neurofibromin to form a signaling complex. We
are currently investigating the mechanisms that may
regulate the assembly of this signaling complex and
its potential functional significance.
The GRB2 Protein: A Component
of the Ras Signaling Pathway
K. Degenhardt, J. Hong, S. Kaplan [in collaboration with
J. Schlessinger, New York University]
The genetic dissection of signal transduction path-
ways in Caenorhabditis elegans has provided new in-
sights into the components of the Ras signaling path-
way. In C. elegans, normal vulval development re-
quires the function of let-23, a tyrosine kinase growth
factor receptor structurally similar to the EGF recep-
tor, and let-60, a Ras homolog. Genetic screening
identified sem-5, which functions downstream from
the let-23 receptor and upstream of the let-60 Ras
homolog. The sem-5 gene encodes a protein that con-
sists entirely of two SH3 domains and one SH2
domain, SH standing for src homology. The mam-
malian homolog of sem-5, GRB2, has been recently
identified in the laboratory of J. Schlessinger by
virtue of its ability to bind to tyrosine phosphorylated
epidermal growth factor (EGF) receptor. We sought
to determine whether GRB2 is a component of the
Ras signaling pathway in mammalian cells. To this
end, purified GRB2 and Ha-Ras proteins were micro-
injected into quiescent cells and their effects on DNA
synthesis were examined. We found that GRB2
stimulated DNA synthesis when microinjected along
with the Ha-Ras protein. In contrast, neither GRB2
nor Ha-Ras alone was ineffective. Moreover, GRB2
proteins containing mutations shown to impair sem-5
functions were unable to induce DNA synthesis when
microinjected with Ha-Ras. These results are con-
sistent with a role for GRB2 in activating Ras.
To further examine the capacity of GRB2 to regu-
late mitogenic signaling by Ras, we analyzed the ef-
fects of constitutive overexpression of GRB2 on
NIH-3T3 cells. NIH-3T3 cells transfected with GRB2
were morphologically indistinguishable from non-
transfected cells. However, when GRB2 was intro-
duced into NIH-3T3 cells overexpressing Ha-Ras, the
transfected cells displayed transformed morphology
that was clearly different from that of the parental
cells. Figure 1 (b-e) shows the morphology of the
parental NIH-3T3 cell line and three GRB2-over-
expressing cell lines. The parental cell line resembled
normal NIH-3T3 cells (Fig. la) in that the cells were
flat, only slightly elongated, and grew as a mono-
layer. In contrast, the GRB2-overexpressing cells
were invariably rounded, refractile, and piled on top
of each other. In addition, the GRB2-over-expressing
cells formed colonies in soft agar, whereas the paren-
tal cell line did not (Fig. if -h). These observations
indicate that GRB2 contributes a positive signal
toward the growth-promoting activity of Ras, thereby
leading to the acquisition of the transformed
phenotype. Studies are under way to determine the
functional position of GRB2 in the Ras signaling
pathway and the mechanisms by which GRB2 con-
tributes to the mitogenic activity of Ras protein.
Regulation of Ras Activity by
Receptor Tyrosine Kinases
N. Gale
A principal intracellular signaling pathway by which
tyrosine kinases regulate cell growth involves the ac-
tivation of Ras by its conversion from the GDP- to
the GTP-bound state. The mechanisms by which this
activation is achieved are unknown. On the basis of
the structural and biochemical properties of GRB2
and the current knowledge of SH2 and SH3 domain
function, a plausible pathway emerges: It is likely
that the SH2 domain of GRB2 interacts with the
tyrosine phosphorylated EGF receptor, whereas the
SH3 domains interact with a Ras regulator. Thus,
GRB2 is thought to function as a molecular adaptor
linking receptor tyrosine kinases to Ras signaling. To
test this hypothesis, we have analyzed the effects of
GRB2 overexpression on the activation of Ras by
EGF. We found that the activation of Ras by EGF is
potentiated in cells overexpressing GRB2 (Fig. 2).
Activation of MAP kinase by EGF, which is depen-
dent on Ras activation, is also potentiated in cells
overexpressing GRB2. These results indicate that
GRB2 overexpression leads to the enhanced activa-
tion of Ras. The activity of Ras is tightly regulated by
two types of proteins: GAPs that act by stimulating
the GTPase activity of Ras and guanine nucleotide
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FIGURE 1 Morphologic transformation induced by constitutive overexpression of GRB2 in NIH-3T3
cells over-
expressing wild-type Ha-ras. Phase-contrast micrographs of normal NIH -3T3 cells (a), NIH-3T3 cells over-
expressing wild-type Ha-ras (b), and NIH-3T3 cell line GRB2 (c, d, and e, respectively). (f, g, h) Micrographs
of soft agar colonies from cell lines shown in c, d, and e, respectively. Expression of GRB2 (i) and ras (I) in
NIH-3T3 cells (lane 1), NIH-3T3 cells (lane 2) overexpressing Ha-ras, and NIH-3T3 cells overexpressing GRB2
(lanes 3-5). Lysates from [35S]methionine-labeled cells were immunoprecipitated with anti-GRB2 serum (i) or
with anti-ras monoclonal antibody Y13-259 (j). For all immunoprecipitations, equal numbers of cpm were com-
pared. Immunoprecipitates were separated on a 12.5% polyacrylamide gel followed by autoradiography at
-70°C. The autoradiogram in panel i was exposed for 16 hr, whereas the autoradiogram in panel j was ex-
posed for 48 hr to show that the levels of endogenous p21ras were identical among the various
cell lines. The
electrophoretic mobility of the transfected wild-type Ha-ras is slower owing to the presence of peptide epitope
at the amino terminus. Migration of molecular size standards is indicated at left in kilodaltons.
exchange factors that act by promoting the exchange
of a bound GDP molecule for a GTP molecule. To
determine the mechanisms by which GRB2 potenti-
ates the EGF-induced activation of Ras, we examined
the effects of GRB2 overexpression on GAP activity
and on the exchange rate of guanine nucleotide on
Ras. These studies revealed that the potentiating ef-
fect of GRB2 overexpression on the EGF-induced ac-
tivation of Ras results from the enhancement of the
rate of guanine nucleotide exchange on Ras. We also
found that GRB2 immunocomplexes contain a
guanine nucleotide exchange factor for Ras. In
response to EGF stimulation, the GRB2 exchange
factor complexes bind to the activated-EGF receptor.
We conclude from these results that GRB2 can con-
trol the activation of Ras signaling by linking recep-
tor tyrosine kinases to a guanine nucleotide exchange
factor for Ras.
Future work will focus on examining the nature of
the interaction between GRB2 and the Ras exchange
factor and how this interaction promotes the activa-
tion of Ras.
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Identification of a Guanine
Nucleotide Exchange
Factor for Ras
S. Kaplan, D. Bar-Sagi [in collaboration with P. Chardin,
CNRS, Valbonne, France]
The regulation of guanine nucleotide exchange on
Ras is a critical aspect of signaling via Ras, as only
the GTP-bound form of Ras is active. Little is known
about the biochemical and biological properties of
guanine nucleotide exchange factors for Ras. The
first exchange factor for Ras protein to be identified
was the CDC25 gene product of Saccharomyces
cerevisiae. Genetic analysis indicated that CDC25
plays an essential role in the activation of Ras
proteins. In Drosophila, the protein encoded by the
son of sevenless gene, sos, contains a domain that
shows significant homology with the catalytic
domain of CDC25. P. Chardin has recently cloned
two human homologs of sos, termed hSosl and
hSos2. hSosl and hSos2 are expressed in a wide
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FIGURE 2 Effect of GRB2 overexpression on EGF-induced Ras activation. The cell lines used for these experiments were
HER14, an NIH-3T3 cell line overexpressing the EGF receptor, and GRB2-HER14, an HER14 cell line overexpressing GRB2.
(a) Time courses of EGF-induced increase in GTP-bound to Ras in HER14 cells (open circle) and in GRB2-HER14 cells (open
box). The p21ras was immunoprecipitated with the ras-specific monoclonal antibody Y13-259 from cells labeled with 32P-
orthophosphate that had been stimulated for the indicated times with 250 ng/ml EGF. Nucleotides were eluted, separated by
thin-layer chromatography, and quantitated using a phosphorimager. The thin-layer chromatogram corresponding to the
quantitative data is shown in the inset. The positions of GDP and GTPstandards are indicated. (b) EGF concentration depen-
dence of the nucleotides bound to Ras in HER14 cells (open bars) and in GRB2-HER14 cells (closed bars). 32P-labeled cells
were incubated with the indicated concentrations of EGF for 2 min. At the end of the incubation, Ras was immunoprecipitated,
and the amounts of nucleotides bound to Ras were quantitated as in a. (c-e) Expression of GRB2, Ras, and EGF receptor in
HER14 cells and in GRB2-HER14 cells. (c) GRB2 was immunoprecipitated using anti-GRB2 serum. (d) Ras was im-
munoprecipitated using anti-p211as serum. (e) Western blot of EGF receptor. Protein (50 rig) from each cell line was elec-
trophoresed on an 8% polyacrylamide gel and transferred to a nitrocellulose sheet. The nitrocellulose sheet was incubated
with anti-EGF receptor sera, washed, and incubated with 1251- labeled protein A. Immunoprecipitations were carried out as
described from lysates of cells labeled with [35S]methionine. lmmunoprecipitates were analyzed on 12.5% polyacrylamide
gels. Migration of molecular size standards is indicated at left in kilodaltons. (Lane 1) HER14 cells; (lane 2) HER14 cells over-
expressing GRB2; (lane C) control immunoprecipitation carried out in HER14 cells by using antibodies that were blocked by
preincubation with an excess of purified antigen. Anti-GRB2 serum was incubated with 5 .tg of purified GRB2 fusion protein
(panel c), and anti-Ras serum was incubated with 5 lig of purified human Ha-ras protein (panel d).
range of tissue types, consistent with a role as posi-
tive regulators of the ubiquitously expressed Ras
genes. We have carried out a set of biochemical ex-
periments aimed at demonstrating that hSos proteins
are in fact guanine nucleotide exchange factors for
Ras. A purified fragment of hSosl corresponding to
the CDC25-related domain was able to induce sig-
nificant stimulation of guanine nucleotide exchange
on recombinant Ras proteins. This activity appeared
to have a rather strict specificity toward Ras, since no
effect could be detected on the rate of guanine
nucleotide exchange on the Ras-related protein RaIA.
Moreover, mammalian cells overexpressing the full-
length hSosl have increased guanine nucleotide ex-
change activity (Fig. 3). These results establish that
hSosl is a guanine nucleotide exchange factor for
Ras.
The identification of the Ras exchange factor
should enable us to obtain a much more complete
picture of how Ras is regulated. One of our immedi-
ate goals will be to find out how the Ras exchange
factor is activated.
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FIGURE 3 Acceleration of exchange of GDP by extracts
prepared from cells overexpressing the full-length hSos1.
(A) Immunoblots of cell lysates prepared from human kidney
293 cells transfected with a control expression vector (lane
1) or with an expression vector encoding the full-length
hSos1 (lane 2). Proteins resolved by SDS-PAGE were elec-
trophoretically transferred to a nitrocellulose strip which was
then probed with anti-hSos1 antibodies. The immunoreac-
tive bands were visualized using the ECL detection system.
(B) Effects of cell extracts on the kinetics of GDP dissocia-
tion. [3H]GDP-bound Ha-ras (5 pmoles) was incubated at
37°C with 500 [1.1 of extracts (6 mg/ml) from human kidney
239 cells (open circles), from human kidney 293 cells over-
expressing the hSos1 protein (closed circles), or with buffer
(open triangles), in the presence of 2 mm unlabeled GTP. At
the indicated times, Ha-ras was immunoprecipitated, and
the amount of [3H]GDP associated with the immunocom-
plexes was determined. Results are plotted as percentages
relative to the values obtained at 0 min. Each datapoint
represents the average of three independent determina-
tions.
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Functional Analysis of SH3
Domains of Signaling Molecules
D. Bar-Sagi
SH2 and SH3 domains are conserved noncatalytic
regions found in a variety of proteins involved in sig-
nal transduction. It is now well established that the
function of SH2 domains is to mediate the interaction
with tyrosine phosphorylated proteins. This interac-
tion is specific inasmuch as different SH2 domains
recognize specifically a short sequence motif flank-
ing the tyrosine phosphorylated residue. Very little is
known about the function of SH3 domains. In view
of our finding that the SH2 and SH3 domain-
containing protein GRB2 appears to be a component
of the Ras signaling pathway, we opted to examine
the biological role of SH3 domains. Our strategy was
to microinject recombinant SH2 and SH3 domains of
signaling molecules into living cells and determine
their subcellular localization. We reasoned that the
functional specificity of different signaling molecules
might be reflected in their differential cellular
localization. The dependence of a specific localiza-
tion pattern of a given signaling molecule on the SH3
domain(s) could then be used as an assay for the
function of these domains. The SH2 and SH3
domain-containing proteins that we chose to use were
PLCy and GRB2. Using immunofluorescence micro-
scopy, we found that a truncated protein composed of
the SH2 and SH3 domains of PLCy was localized to
the actin cytoskeleton. We found the same localiza-
tion pattern when only the SH3 domain of PLCy was
injected, whereas injected protein composed of only
FIGURE 4 Localization of microinjected wild-type and mutant GST-GRB2 proteins by immunofluorescence. Rat em-
bryo fibroblast 52 cells were microinjected with either wild-type GRB2 protein (a) or with mutant GRB2 proteins con-
taining point mutations at the amino-terminal SH3 domain (b) or the carboxy-terminal SH3 domain (c). All proteins
were microinjected at a concentration of 1 mg/ml. Four hours after injection, cells were fixed, permeabilized, and
stained with anti-GST rabbit serum followed by rhodamine-conjugated goat anti-rabbit lg. Magnification, 1240x.
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the SH2 domain of PLC? exhibited diffuse cytoplas-
mic distribution. These results indicate that it is the
SH3 domain that is responsible for the targeting of
PLC? to the actin cytoskeleton. Microinjected GRB2
protein was localized primarily to membrane ruffles
Fig. 4). SH2 loss-of-function mutants of GRB2 ex-
hibited the same localization pattern as the wild-type
protein, whereas SH3 loss-of-function mutants of
GRB2 failed to localize to membrane ruffles. These
results are consistent with the idea that the SH3
domains of GRB2 are responsible for its specific cel-
lular localization. Together, these observations sug-
gest that SH3 domains are responsible for the target-
ing of signaling molecules to specific subcellular
locations. We will be examining this concept specifi-
cally in the context of the linkage between GRB2 and
Ras signaling.
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NUCLEAR SIGNAL TRANSDUCTION
M. Gilman C. Alexandre
R. Attar
L. Berkowitz
D. Grueneberg
J. lafrate A. Ryan
G. Lee H. Sadowski
A. Majid K. Simon
S. Natesan K.-A. Won
Our major focus continues to be the mechanisms by
which extracellular signals are communicated to the
nucleus to control the proliferation and development
of eukaryotic cells. We view this as a two-part prob-
lem. First, we need to understand the simple mechan-
ics of the process. What are the individual molecular
steps by which signals are relayed from the cell sur-
face to nuclear targets? Second, we need to under-
stand where the biological specificity in these signals
is encoded. How do cells know what signal they have
received and respond appropriately?
Our general approach to these questions has re-
volved around studies of the c-fos proto-oncogene.
This gene is rapidly activated at the transcriptional
level by a variety of extracellular stimuli, including
growth and differentiation factors, hormones, and
neurotransmitters. Induction of c-fos transcription oc-
curs within seconds or minutes of exposure to these
signaling molecules and does not require the cell to
synthesize new proteins. Thus, activation of the c-fos
gene is a primary response to the signal transduction
pathways activated by these factors, and our working
hypothesis is that the c-fos gene itself is a physical
target for these signals.
Consequently, our general strategy has been to
identify the sequences that mediate the response of
the c-fos gene to specific signal transduction path-
ways. Using these sequences as reagents, we then
identify and characterize the cellular proteins that in-
teract with them, and we eventually use these
proteins as reagents to identify the next proteins up
the signaling chain. As described below, we have
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made varying degrees of progress working our way
up the different signal transduction pathways that ac-
tivate c-fos transcription. Of particular importance are
recent experiments in which we have been able to
recapitulate at least one such signal transduction
pathway in a cell-free system.
In addition to the mechanics of signal transduction
to the nucleus, we have a strong interest in under-
standing the specificity of this process. How does a
given cell distinguish among different signals that
trigger overlapping signal transduction pathways?
How do different cells manage to respond in unique
ways to the same signal? We know, for example, that
we can generate c-fos promoter derivatives that
respond to only a subset of the signals that normally
activate c-fos transcription, indicating that different
signals use different routes to the nucleus. In some
cases-cAMF', for example -this is due to the use of
completely distinct cis-acting regulatory elements
and trans-acting factors. In other cases, different sig-
nals target distinct nuclear proteins that interact with
a common sequence element. In this way, it is pos-
sible for different signals to target distinct subsets of
genes. A second insight into the specificity of signal-
ing comes from our recent discovery that homeo-
domain proteins may participate in the regulation of
gene transcription by extracellular signals. Since
homeodomain proteins play a role in establishing the
specificity of cell identity in embryonic development,
we suspect that the interaction of these proteins with
the proteins responsible for signal-activated transcrip-
tion may be an important aspect of how the specifi-
city of signaling is achieved. We are pursuing these
studies at structural and functional levels and have
begun a project to test this hypothesis in the context
of Drosophila embryonic development.
Distinct Protein Complexes at the
SRE Mediate Growth Factor
Induction of c-fos Transcription
M. Gilman, R. Graham, H. Sadowski
The serum response element (SRE) is required for the
response of the c-fos gene to at least two distinct sig-
nal transduction pathways, one dependent on protein
kinase C (PKC) and one or more independent of
PKC. In addition, the SRE is target for the rapid
repression of c-fos transcription that follows induc-
tion. Given the complexity of SRE function, it is not
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surprising that the SRE binds several different cel-
lular DNA-binding proteins. One of these proteins,
SRF, appears to be required for all activities of the
SRE. Our working hypothesis is that SRF works by
recruiting an array of distinct proteins to the SRE and
that it is these accessory proteins that carry signaling
information to the SRE. One such accessory protein
is a 62-kD protein termed ternary complex factor
(TCF), recently identified as a member of the ETS
family. TCF specifically recognizes the SRF-SRE
complex, probably contacting both SRF and the SRE.
Mutant SREs that bind SRF but fail to support forma-
tion of the SRF-TCF complex lose response to one of
the two signal transduction pathways that target the
SRE. They fail to respond to the PKC pathway, al-
though they respond at wild-type levels to PKC-
independent signals.
In contrast, we find that the response to PKC-
independent signals requires the cooperation of SRF
with a different protein. This protein, termed SIF,
binds to a sequence 25 by upstream of the SRE, and
in contrast to SRF and TCF, its DNA-binding activity
is induced by growth factors (see below). In the con-
text of a ternary complex mutant that responds only
to PKC-independent signals, we find that this
residual response can be abolished by mutations that
affect the binding of either SRF or SIF, suggesting
that these two proteins cooperate to mediate the
response to these signals. Particularly noteworthy is
the observation that a double mutant that fails to bind
TCF or SIF but still binds SRF loses nearly all
response to signals, strongly suggesting that SRF
alone is not sufficient for response to any signals and
that it functions exclusively via recruitment of
pathway-specific accessory proteins.
Regulation of c-fos Transcription
by Receptor Tyrosine Kinases
H. Sadowski
Signal transduction to the nucleus by growth factor
receptors with protein-tyrosine kinase activity is
complex. The initial event in activation of these types
of receptors is the cross-linking of receptors by
ligand, resulting in the rapid and concerted trans-
phosphorylation of the receptors on multiple tyrosine
residues. Phosphorylation on tyrosine is absolutely
required for receptor signaling. The next step in
receptor signaling is the recruitment of a series of
cytoplasmic and membrane-associated signaling
proteins to the receptor where they may or may not
be phosphorylated on tyrosine. Many of these
proteins associate with phosphotyrosine residues on
the receptor via protein domains termed SH2 (src
homology region-2) domains. Each of these SH2 -
domain- containing proteins is thought to elicit an in-
dependent intracellular signal that is propagated to
downstream targets. Thus, activation of growth factor
receptors elicits a complex array of intracellular sig-
naling events.
Much of our research has focused on how tran-
scription of the c-fos gene is activated by polypeptide
growth factors such as platelet-derived growth factor
(PDGF/c-sis) and epidermal growth factor (EGF),
whose cell surface receptors possess ligand-inducible
tyrosine kinase activity. Growth factor receptor sig-
naling to the c-fos gene involves both PKC-
dependent and -independent pathways. As described
above, PKC-dependent signals act through a ternary
complex composed of SRF and TCF, whereas PKC-
independent signals appear to act through SRF in
conjunction with a different accessory factor, termed
SIF, which binds to a sequence approximately 20 by
upstream of SRF. Unlike SRF and TCF, SIF exists in
a latent form in unstimulated cells that does not bind
DNA. SIF DNA-binding activity is induced within
minutes of exposure of cells growth factors,
without a requirement for protein synthesis. These
observations suggest that SIF is physically modified
in response to growth factor signal transduction. SIF
activity is induced by several growth factors that act
via receptors with intrinsic protein-tyrosine kinase
activity, including PDGF (both the AA and BB
homodimers), EGF, and insulin, depending on the
cell type. It is not induced by PMA, an activator of
protein kinase C (PKC), nor is SIF activation affected
by depletion of PKC, suggesting that SIF activation is
PKC-independent.
Using A431 cells as a model system, we have ex-
amined the mechanism of SIF activation by EGF. Ac-
tivation of SIF by EGF does not involve the well-
characterized signal transduction pathways utilizing
PKC, calcium, or cAMP, but it clearly requires
tyrosine kinase activity as activation is inhibited by
cell-permeable tyrosine kinase inhibitors. SIF activa-
tion is extremely rapid at 37°C, detectable within 20
seconds of EGF addition, peaking within 4 minutes,
and persisting for at least 60 minutes. Three distinct
mobility-shift complexes appear in nuclear extracts,
whereas only the two more rapidly migrating corn-
plexes appear in the cytoplasm. When activations are
performed at 0°C, where internalization of receptors
and nuclear transport of proteins is inhibited, SIF ac-
tivation is still readily apparent within 30 seconds
with apparent accumulation over time of the two
faster-migrating complexes in the cytoplasmic frac-
tion relative to the nuclear fraction. Together, these
data suggest that latent SIF may exist in the
cytoplasm in cells where it is very rapidly activated
by a receptor-proximal event (kinetics just behind
receptor tyrosine phosphorylation), after which the
DNA-binding-competent SIF is then translocated to
the nucleus. UV cross-linking studies with nuclear
extracts identified at least three polypeptides in the
90-94-kD range that were site-specifically cross-
linked and EGF-inducible. Similarly sized [35S]meth-
ionine-labeled polypeptides were detected using site-
specific DNA-affinity precipitations of extracts from
EGF-stimulated cells. Phosphorylation is required for
SIF DNA-binding activity, as treatment of extracts
with nonspecific phosphatase abolishes all three
mobility-shift complexes. Furthermore, at least one
of the complexes requires tyrosine phosphorylation,
as its formation is abolished when DNA-affinity-
purified SIF is treated with a T-cell protein phospho-
tyrosine phosphatase.
Since the activation of SIF by EGF in A431 cells
is quite robust and a receptor-proximal event, we
have used fractions from unstimulated A431 cells to
develop a cell-free assay for SIF activation. In this
assay, we observe time- and ligand-dependent activa-
tion of SIF, with a requirement for detergent-treated
A431 membranes, cytoplasm (from virtually any
cell), ATP, Mg, and Mn. Antibody depletion experi-
ments indicate that activation is absolutely dependent
on the EGF receptor. Activation is blocked by
antibody to phosphotyrosine, by recombinant SH2
domains, and by free phosphotyrosine, indicating that
at least one phosphotyrosine-SH2 domain interaction
is required for SIF activation. We are using this cell-
free signal transduction system to further characterize
the mechanism of SIF activation.
Purification and Characterization
of the SRE-binding Protein p62DBF
S. Natesan
Previous work by Bill Ryan in our laboratory identi-
fied a novel 62-kD SRE-binding protein, termed
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p62DBF, which binds directly to the 5 ' side of the
SRE. Our recent data suggest that p62DBF is antigeni-
cally indistinguishable from the mammalian tran-
scription factor YY1. YY1 is a ubiquitously ex-
pressed zinc finger protein that functions as a tran-
scriptional repressor or activator, depending on its
context. A survey of the mouse c-fos promoter
revealed the presence of three binding sites for this
protein, located in the 310, 255, and 55 regions
of the c-fos promoter. Both recombinant YY1 and
affinity-purified HeLa p62DBF bind to these se-
quences.
Previous data from our laboratory indicated that
p62DBF be a DNA-bending protein. Circular
permutation and phasing analyses clearly show that
both YY1 and p62DBF bend the DNA at all three sites
in the c-fos promoter; at the 310 site within the
SRE, the angle of the bend is 72°. Because DNA
bending may play an important role in transcriptional
regulation by organizing the tertiary structure of
promoter DNA, we have tested the importance of the
YY1-induced bend at 55 in the c-fos promoter.
Mutations in this YY1-binding site increase the basal
rate of c-fos promoter activity by approximately
fivefold, suggesting that this site normally represses
transcription. Surprisingly, however, reversing the
orientation of the YY1 site increases promoter ac-
tivity an additional fivefold, suggesting that in the op-
posite orientation, this site activates transcription. We
believe that this unusual orientation dependence may
reflect bending by YY1. Moreover, these effects were
not observed when the CRE element immediately up-
stream of the YY1-binding site was absent. This ob-
servation suggests that YY1 has no intrinsic activity
at this site, but instead acts to interfere with or facili-
tate-depending on its orientation-the interaction of
CRE-binding proteins with the basal transcription
machinery.
An examination of the interaction of YY1 at the
SRE suggested that YY1 enhances the rate of binding
of SRF to this site. Furthermore, cotransfection of a
YY1 expressor plasmid with a reporter containing a
single SRE leads to the activation of transcription,
suggesting that YY1 may also enhance SRF binding
in vivo. However, we are unable to demonstrate co-
occupancy of the SRE by SRF and YY1. It is pos-
sible that YY1-mediated bending of the SRE lowers
the free energy required for binding of SRF to the
SRE, a process that requires only transient occupancy
of SRE by both proteins. Thus, the function of YY1
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in the context of SRE may be to alter the local DNA
structure to facilitate rapid assembly of SRF and as-
sociated factors on SRE.
Cloning and Characterization of
SRE-ZBP, a Novel SRE-binding
Protein
R. Attar
As described above, the SRE is a target for multiple
signals that activate and repress c-fos transcription.
To understand the complex mechanisms by which the
SRE regulates the c-fos transcription, we have at-
tempted to identify and clone previously unidentified
SRE-binding proteins. We screened a HeLa cell
cDNA expression library for phage-expressing pro-
teins that specifically bound an SRE oligonucleotide.
We isolated a phage that encoded a LacZ fusion
protein that specifically bound this oligonucleotide
but not a mutant site. The fusion protein binds specif-
ically to the SRE in both a Southwestern blot and a
mobility-shift assay. Analysis of the partial DNA se-
quence of this clone revealed that it was a previously
unidentified gene that belongs to the family of zinc-
finger-containing proteins related to the Drosophila
Kriippel gene.
The clone contains seven tandem repeats in the
carboxyl terminus that match the zinc finger con-
sensus for this gene family. This gene is expressed in
a variety of human cell lines at a very low level. Ex-
pression is induced by serum in HeLa cells with
delayed kinetics relative to c-fos. Methylation inter-
ference experiments showed that SRE-ZBP interacts
with the 3 ' side of the SRE. Immunofluorescence as-
says on cells transfected with an SRE-ZBP expres-
sion vector indicate that the protein is localized to the
nucleus.
Before investigating the role of this protein in the
regulation of the c-fos transcription, it was necessary
to isolate the full-length cDNA. We used the RACE
(Rapid Amplification of cDNA Ends) procedure to
extend the existing sequence 208 nucleotides in the
5' direction. To confirm that these new sequences
correspond to the SRE-ZBP gene, we utilized a probe
derived from the 5 ' end of the original cDNA to iso-
lated a 17-kb human genomic fragment carrying the
SRE-ZBP gene. Within this fragment, we found con-
ntiguous sequences corresponding to the RACE
clones and the original cDNA, indicating that the new
cDNA sequence represented the authentic 5 ' end of
the SRE-ZBP mRNA.
Primer-extension experiments suggested that the
mRNA begins 120 by upstream of the putative initia-
tion codon for SRE-ZBP. This ATG codon is in-
frame with the original cDNA; upstream of this ATG,
there are stop codons in all three reading frames. At
positions -31 and -20 of the putative initiation of
transcription are two perfect TATA boxes. Together,
these data suggest that we have located the 5 ' end of
the SRE-ZBP mRNA.
The full-length SRE-ZBP protein expressed in E.
coli runs as a 70-kD protein, in agreement with ear-
lier observations that antibodies raised against recom-
binant SRE-ZBP recognized a 70-kD protein in hu-
man cells. Interestingly, in contrast to amino-
terminally truncated forms of SRE-ZBP, the full-
length protein does not bind to the SRE. This obser-
vation raises the possibility that SRE-SBP contains a
domain that inhibits the DNA-binding activity of the
zinc finger region.
Inactivation of this inhibitory domain may require
covalent modification of the protein or association
with another cellular factor. These issues, together
with ongoing efforts to ascertain the function of SRE-
ZBP in c-fos regulation, will be the focus of our fu-
ture studies.
MADS Box-Homeodomain
Interactions and the Specificity
of Signal Transduction to the
Nucleus
D. Grueneberg
As described earlier, SRF is required for the response
of the c-fos gene to growth factor signals, but it ap-
pears to function by recruiting an array of accessory
proteins with distinct activities. In this regard, SRF
resembles the yeast protein Mcml, both of which are
members of the MADS box family of transcription
factors. Like SRF, Mcml is also involved in the
regulation of genes by extracellular signals, the
mating pheromones, and it functions in cooperation
with accessory proteins. We exploited these similar-
ities to devise a genetic selection in yeast for human
cDNAs encoding proteins that cooperate with Mcml
to activate a cell-type-specific pheromone-responsive
reporter gene. We isolated a cDNA encoding a novel
human homeodomain protein, Phoxl, with a homeo-
domain most closely related to the paired class, ini-
tially identified in Drosophila.
Our initial characterization of Phox1 indicated that
in addition to interacting with Mcm 1 to activate the
yeast reporter gene, Phoxl is also capable of interact-
ing with the human protein SRF. The effect of this in-
teraction in vitro is the enhancement of binding of
SRF to the SRE. This effect is mainly kinetic. Phox1
enhances both the rate of association and the rate of
dissociation of the SRF-SRE complex, acting essen-
tially as an exchange factor to ensure that SRF
reaches equilibrium on the SRE rapidly. This activity
resides within the Phoxl homeodomain and is shared
with other homeodomains of the paired class but not
with more distantly related homeodomains. The en-
hancement activity does not require the DNA-binding
activity of the homeodomain, suggesting that direct
interaction between SRF and the Phoxl homeo-
domain is required.
We have recently devised an assay to study the in-
teraction between Phoxl and SRF in vivo. In HeLa
cells, the homeodomain of Phoxl transcriptionally
activates a reporter gene containing an SRE. Our
results suggest that Phox1 activation of the reporter
requires an interaction with SRF, because a reporter
carrying an SRE mutant that binds Phoxl but not
SRF is not activated by Phox1. Mutational analysis of
Phoxl suggests that activation of the reporter, and
presumably SRF -Phoxl interaction, requires both
DNA binding and direct Phoxl -SRF interactions. In-
terestingly, mutations that affect the DNA-binding
specificity of the homeodomain also affect the ef-
ficiency of complex formation as measured in the
HeLa cell assay. Moreover, different homeodomains
also display different activities in this assay. The re-
lated Drosophila homeodomain protein Paired has
about 40% of the activity of Phox1, whereas the un-
related Drosophila homeodomain protein Deformed
is not active. We speculate that SRF will interact with
different homeodomain proteins on different binding
sites, and we are in the process of identifying such
binding sites. Interactions between homeodomain
proteins and MADS box proteins may account for
how homeodomain proteins function in early devel-
opment to specify transcriptional responses to induc-
tive signals.
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Mutagenesis of the Homeodomain-
SRF Interface
K. Simon
Homeodomain proteins, first characterized in the fruit
fly Drosophila melanogaster, have key regulatory
functions in development. Mutations in their genes
cause changes in cell identity. Homeodomain pro-
teins bind DNA and act as transcription factors, al-
though their specificity of action cannot be predicted
by their DNA-binding activity alone, leading to the
suggestion that homeodomain function requires
cooperation with other proteins. As described above,
we have cloned a novel human homeodomain
protein, Phoxl, that interacts with the yeast MADS
box protein Mcml to restore transcriptional activity
in a reporter gene. Phox I also interacts with the hu-
man MADS box protein SRF to enhance its binding
to the SRE in the c-fos promoter. As in yeast, Phoxl
is also able to activate an SRF-dependent reporter
gene in mammalian cells.
To understand the interaction between Phoxl and
SRF, we have begun to construct and test a series of
Phoxl mutants. Mutations in the DNA recognition
helix of the Phox 1 homeodomain abolish the ability
of Phoxl to cooperate with SRF to activate a reporter
gene, suggesting that DNA-binding activity of the
homeodomain is required for this activity. Moreover,
mutations that affect the DNA-binding specificity of
the homeodomain also influence this activity, sug-
gesting that the primary recognition specificity of the
homeodomain is also important. Initial mutagenesis
suggests that homeodomain residues oriented away
from the DNA are also required for interaction with
SRF, suggesting a role for direct homeodomain-SRF
contact. Thus, we are currently mutagenizing the
Phoxl homeodomain to target residues predicted to
reside on the solvent-exposed surface of the homeo-
domain, where they can potentially make contact
with SRF. We are using three assays to measure
Phoxl-SRF interactions: in vitro DNA binding, a
reporter gene assay in He La cells, and a similar assay
in yeast. Our goal is to identify the key amino acid
side chains in the Phoxl homeodomain that contact
SRF and, having identified those, to identify next the
corresponding contact sites in SRF.
We believe that homeodomain/MADS box protein
interactions could impart specificity of action to
homeodomain proteins in general and that these inter-
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actions are one way in which a developing organism
can initiate cell-type-specific transcriptional activa-
tion that is responsive to external signaling pathways.
Isolation and Characterization of
MADS Box Proteins in Drosophila
A. Ryan, R. Attar
Development of the fruit fly Drosophila melanogas-
ter provides an attractive system to test specific pre-
dictions associated with our studies of SRF-homeo-
domain interactions. Homeodomain proteins were
first discovered in Drosophila, and their functions in
embryonic development are relatively well un-
derstood. Indeed, it is principally from biological
studies of homeodomain function in Drosophila em-
bryos that it has become evident that homeodomain
proteins most likely cooperate with as yet
unidentified protein partners. Our data on SRF-
homeodomain interactions suggest that proteins of
the SRF (or MADS box) family are good candidates
for homeodomain partners. Consequently, we are iso-
lating SRF-related genes from Drosophila.
Members of the MADS box family include SRF
and a family of related human proteins, the yeast
protein Mcml, and a group of plant genes with
homeotic functions in flower development. The
MADS box itself is a moderately conserved block of
about 60 amino acids that forms part of a larger
DNA-binding and protein-dimerization domain. This
domain is also implicated in the interaction of SRF
and Mcml with various accessory proteins, including
proteins of the homeodomain family.
We are using a combination of low-stringency
hybridization and polymerase chain reaction (PCR)
to screen Drosophila genomic and cDNA libraries for
MADS box genes. Candidate genes will be se-
quenced and mapped to polytene chromosomes to
determine if they correspond to any known develop-
mental genes. The expression patterns of the genes
during embryonic development and in the adult fly
will be examined by Northern analysis and in situ
hybridization. The availability of these clones should
allow us to test directly whether these proteins do
function as homeodomain partners during develop-
ment and, additionally, to address the role of SRF-
like proteins in the well-characterized signal trans-
duction pathways active during fly development.
Characterization of MADS Box
Structure and Function in Yeast
C. Alexandre
It is clear that several striking parallels exist between
growth factor signal transduction pathways in animal
cells and the pheromone response pathway in yeast.
These parallels include the use of G proteins and re-
lated protein kinase cascades and the organization of
signal-responsive regulatory elements in target genes.
In particular, cell-type-specific pheromone-respon-
sive genes in yeast are under the control of a
regulatory gene, MCM/, that encodes a protein close-
ly related to SRF; these proteins have overlapping
DNA-binding specificities and participate in similar
types of protein-protein interactions. We are exploit-
ing these similarities in several ways: by producing
human proteins in yeast to study their activities
directly, by producing hybrid proteins derived
primarily from yeast proteins but carrying small
domains from their human counterparts, and, on oc-
casion, by directly studying the yeast proteins in the
hope of learning something that will be relevant to
our understanding of the human proteins.
To study the activity of human proteins produced
in yeast, we have established yeast strains carrying
reporter genes under the control of the human c-fos
SRE. In these strains, we are producing various hu-
man proteins, including SRF, Elk-1 (the ternary com-
plex factor that interacts with SRF), and components
of the MAP kinase cascade. Our goal here is to
reconstitute a functional mammalian signal transduc-
tion pathway in yeast, where simple genetic tools can
be used to study the structure and function of these
proteins. Our use of hybrid proteins is focused princi-
pally on studying the interaction between SRF and
Elk-1, which we believe is analogous to the interac-
tion between the yeast proteins Mcm 1 and al. Inter-
action of SRF and Elk-1 appears to require amino
acids within the dimerization domain of SRF and a
short Elk-1 domain, termed the B box. We find a se-
quence within the al protein that is closely related to
the B box, suggesting that this region of al interacts
with Mcm 1. Indeed, a four-amino-acid insertion
within the B box homology of al inactivates the
protein. Thus, we have constructed two hybrid genes,
an Mcm 1 derivative carrying the dimerization
domain of SRF and an al derivative carrying the B
box of Elk-1. Simple genetic assays can tell us
whether these hybrid proteins can interact produc-
tively in yeast. If so, then we will use these assays to
probe genetically the organization of this protein-
protein interface. We hope to extend this analysis
eventually to include the Phox 1 homeodomain, al-
lowing us to study a putative quaternary complex of
DNA, SRF, Elk-1, and Phox 1, which may be
analogous to the yeast Mcmlial/Stel2 complex.
Control of c-fos Expression
by Calcium in T Cells
G. Lee
Calcium ions function as second messengers in a va-
riety of physiological processes, including prolifera-
tion, muscle contraction, and neuronal signaling. Its
role as an effector is accomplished primarily through
transient fluxes in concentration. Several calcium-
binding proteins are thought to mediate the action of
calcium signals. Rapid changes in cytoplasmic cal-
cium concentration can occur via membrane channels
or by release from internal stores. In many cases,
transient increases in calcium occur in tandem with
activation of PKC, and the combination of these sig-
nals is often synergistic. A clear case of the synergy
of calcium and PKC occurs during the activation of T
cells by antigen. Indeed, treatment of T cells with cal-
cium ionophores and PKC activators can fully mimic
antigen activation, although each treatment alone is
ineffective. This same synergy is also evident at the
level of c-fos expression, suggesting that by under-
standing the synergistic control of c-fos transcription
by calcium and PKC, we may understand in a general
way how these important signal transduction path-
ways interact.
Our studies of c-fos induction in T cells suggest
that synergy arises from two distinct calcium-
mediated effects on c-fos expression. One signal af-
fects promoter function and enhances the initiation of
c-fos transcription in cooperation with PKC acti-
vators. A second signal affects the elongation of c-fos
transcripts, by transiently alleviating a block to
elongation within the first intron of the c-fos gene.
Several lines of evidence support this conclusion.
The major evidence comes from nuclear run-on as-
says that measure the rate of transcription of discrete
portions of the c-fos gene. Treatment of T cells with
the PKC activator PMA results in enhanced transcrip-
tion of the 5 ' end of the c-fos gene, but these tran-
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scripts do not proceed much beyond the end of the
first exon and consequently little mature c-fos mRNA
is made. In the presence of both PMA and a calcium
ionophore, two changes are observed. First, there is
enhanced transcription of the first exon, suggesting
an increase in the rate of transcript initiation at the c-
fos promoter. Second, a much higher fraction of in-
itiated transcripts continue beyond the first exon and
through the entire gene. Thus, through a combination
of enhanced initiation and more efficient elongation
of the primary c-fos transcript, a synergistic effect on
the level of mature c-fos mRNA is observed. These
two effects of calcium are independent of one anoth-
er, because in combination with agents that elevate
intracellular cAMP, the elongation effect is seen, al-
though there is no synergy at the level of initiation.
This observation is confirmed by transfection assays
of the c-fos promoter function in T cells, which
measure only initiation effects and do not recapitulate
the effect of calcium on elongation. We observe that
PMA and calcium cooperatively enhance c-fos
promoter activity, whereas calcium has no effect on
induction of the c-fos promoter by cAMP. Important-
ly, calcium also fails to affect the function of the tran-
scription factor CREB, thought to be a major focus
for calcium action in neuronal cells.
Our current work is focused on the mechanisms
through which calcium cooperates with PKC.
Preliminary data suggest that this cooperation is not
simply due to enhanced activation of PKC in the
presence of elevated calcium, because we see little
enhancement of protein phosphorylation in the
presence of PMA and ionomycin. Transfection of
mutant c-fos promoters suggests that the SRE is re-
quired for the synergistic effect of calcium and PKC
on c-fos promoter activity, but surprisingly, it is not
sufficient. This observation suggests that synergy re-
quires the cooperation of the SRE with an additional
element in the c-fos promoter. Our data clearly rule
out the SIE and CRE elements for this role, and we
are currently focused on an AP1-related site located
immediately adjacent to the SRE.
It will be difficult to establish the mechanism
through which calcium regulates elongation of c-fos
transcripts, because this phenomenon is not faithfully
recapitulated by transiently transfected c-fos genes.
This observation suggests that appropriate regulation
of elongation may require an integrated transcription
unit or the assembly of the gene into chromatin.
Nevertheless, using the nuclear run-on assay, we can
distinguish between two possible models for how
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elongation is modulated. We envision two general
possibilities. First, there may be a discrete block to
transcript elongation that is removed in the presence
of calcium. Second, the c-fos promoter could load a
poorly processive form of RNA polymerase H in the
absence of calcium, and calcium regulates the associ-
ation of an elongation factor that enhances the ef-
ficiency of elongation. By performing nuclear run-on
analysis using a series of small probes that span the
entire c-fos transcription unit, we find that there is a
sharp drop in transcription between the first exon and
first intron and no change in transcription beyond this
point. In the presence of calcium, transcription of all
downstream regions increases coordinately. This ob-
servation argues in favor of a discrete and relatively
complete block, rather than a gradual diminution of
RNA polymerase density, as predicted by the proces-
sivity model.
Linking Growth Factors to Cell Cycle
Control: Transcriptional Regulation
of Cyclin D Genes
K.-A. Won [in collaboration with Yue Xiong and
David Beach, Cold Spring Harbor Laboratory]
How the initial intracellular signaling events trig-
gered by growth factors are linked to the regulatory
machinery that controls cell cycle progression in
mammalian cells is still poorly understood. The
transition from the Go to the G1 phase of the cell
cycle involves quantitative and qualitative changes in
the expression of many genes and their products.
Within minutes after growth factor or serum stimula-
tion and independently of protein synthesis, a set of
genes, termed the immediate-early genes, becomes
transcriptionally active. Yet, not all signals that ac-
tivate the immediate-early genes cause cells to enter
or leave the cell cycle. To understand how cells are
able to discriminate among such signals, we are
studying the regulation of a family of genes whose
expression may be critical to the control of cell cycle
progression: the G1 cyclins.
Yue Xiong and David Beach here at Cold Spring
Harbor Laboratory have cloned a family of human
cyclin genes termed D-type cyclins. One of these
genes, cyclin D1, appears to correspond to the on-
cogene bcl-1, whose chromosomal locus is amplified
or translocated in many tumors. We have examined
the expression of the cyclin Dl and D3 genes in pri-
mary human fibroblasts undergoing the Go/G1 transi-
tion. We find that transcription of these genes is in-
duced by mitogenic growth factors, with increased
mRNA levels appearing 2-4 hours after stimulation
and peak levels appearing just prior to the onset of S
phase. Cyclin D expression is induced by all signals
that are mitogenic for these cultures, consistent with
the idea that cyclin D expression is required for the
G1 /S transition. But the genes are also activated by
signals such as phorbol esters that are not mitogenic
in these cells, suggesting that cyclin D expression is
not sufficient for entering S phase. In addition, induc-
tion of cyclin D gene expression by mitogens is lost
in senescent cells that reside permanently in the Go
stage of the cell cycle. Our data suggest that the role
of cyclin D may not be in the regulation of the G1 /S
transition but rather in the entry into and exit from
the quiescent Go state.
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STRUCTURE, FUNCTION, AND REGULATION OF PROTEIN
TYROSINE PHOSPHATASES
N.K. Tonks S.M. Brady-Kalnay
R.L. Del Vecchio
A.J. Flint
A.J. Garton
P.M. Guida, Jr.
K.R. LaMontagne
C.A. Ostman
The phosphorylation of tyrosyl residues in proteins is
a key component of the control of many fundamental
physiological processes. Our laboratory is particular-
ly interested in the role of tyrosine phosphorylation in
transducing an extracellular signal into an intracel-
lular response, such as proliferation or differentiation.
Most laboratories have focused their studies on the
protein tyrosine kinases. However, phosphorylation is
a reversible, dynamic process in which the net level
of phosphate observed in a target substrate reflects
not only the activity of the kinases that phosphorylate
it, but also the competing action of protein phos-
A.A. Samatar
H. Sun
Q. Yang
phatases that catalyze the dephosphorylation re-
action. We direct our attention to the expanding fam-
ily of protein tyrosine phosphatases (PTPases) that
like the kinases, comprise both transmembrane,
receptor-linked forms and nontransmembrane
cytosolic species (Fig. 1). The structures of the
PTPases indicate important roles in the control of
processes such as cell adhesion, cytoskeletal func-
tion, and the cell cycle. Clearly, their characteriza-
tion will generate a more sophisticated understanding
of the precise physiological roles of tyrosine phos-
phorylation.
113
HP
CD45
HPTP 1
LAR
DPTP 99A
111
HPTP a
HPTPc
Type I Type II Type III Type IV Type V
PTP 1C MEG 2
PTP H1
PEP 1TC-PTP
PTP1B PTP-PEST
VH1
STEP YOP 2b cdc 25A
Extracellular
Intracellular
FIGURE 1 Members of the PTPase family. This figure summarizes work from many groups. The con-
served catalytic domains are shown in black. The PTPs can be categorized as transmembrane,
receptor-like, or nontransmembrane molecules. At the present time, the receptor-like species can be
subdivided into five types based on the structure of their extracellular segments. Type I represents
the CD45 family, multiple isoforms.of which arise from differential splicing of a primary mRNA tran-
script of a single gene; three exons encoding sequences at the extreme amino terminus (horizontal
lines) are differentially expressed. Type II contains immunoglobulin-like (diagonal lines) and tandem
fibronectin-type-111-like repeat domains (stippled); this category includes LAR (leukocyte common
antigen-related), DLAR, DPTP, and HPTP[i. Type III bears multiple fibronectin-type-111-like repeats.
Some type III isoforms such as HPTPI3 have only one internal PTP domain. Type IV isoforms such as
a and E have small glycosylated extracellular segments. Type V possesses an amino-terminal motif
that has homology with carbonic anhydrase. Multiple nontransmembrane forms have also been iden-
tified. Many of the nonreceptor PTPs bear noncatalytic segments that are structurally related to other
well-characterized proteins. The position and relative size of these noncatlytic domains are shown as
boxes containing distinct symbols; noncatalytic regions that have similar sequences are designated
with identical patterns. The noncatalytic segments that have been identified include two SH2 domains
in PTP1C and band 4.1 homology domains in PTPH1, an apparent lipid-binding domain in MEG2, and
segments containing PEST sequences in PEP and PTP-PEST. In TC-PTP and PTP1B, the carboxy-
terminal noncatalytic segments appear to play a role in modulating activity and controlling subcellular
localization. PTP1, STEP, and Yop2b have noncatalytic sequences that are apparently unrelated to
sequences in the databases. The protein from vaccinia virus, VH1, is much smaller than the other
PTPs and presumably encodes only essential sequences within the catalytic domain. VH1 differs from
the other members of the family in that it displays dual specificity, dephosphorylating PSer as well as
PTyr. (Reproduced from Adv. Second Messenger Phosphoprotein Res. 28: [203].)
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The Receptor-like Protein
Tyrosine Phosphatase, PTP[I,
Mediates Cell-Cell Aggregation
S.M. Brady-Kalnay, N.K. Tonks
PTPµ is characterized by the following arrangement
of structural motifs (Gebbink et al., FEBS Lett. 290:
123 [1991]. Its extracellular segment contains one
immunoglobulin (Ig)-like and four fibronectin (FN)-
type- III -like domains and thus displays structural
similarity to members of the Ig superfamily of cell
adhesion molecules that includes NCAM, the neural
cell adhesion molecule. There is a single trans-
membrane domain and a large intracellular segment
containing two PTPase domains preceded by a jux-
tamembrane segment that is 70 residues longer than
the equivalent segment in other receptor-like
PTPases. We have observed that this juxtamembrane
region of PTPli displays homology with the in-
tracellular domain of members of the cadherin family
of cell adhesion molecules. Such homology is unique
among both the receptor-like PTPases and members
of the Ig superfamily.
NCAM mediates homophilic adhesion; i.e.,
NCAM on one cell binds to NCAM on an adjacent
cell. To investigate whether PTPli could also serve in
cell-cell adhesion, we have followed the strategy of
expressing the protein in normally nonadhesive cells
to test whether this induces aggregation. To pursue
this goal, we have generated recombinant baculo-
viruses to express various forms of PTPIA in Sf9 cells.
We have demonstrated that expression of full-length
PT131.1, or mutants bearing an intact extracellular seg-
ment, whether in the presence or absence of the
PTPase domains, induced aggregation (see Fig. 2).
Expression of the catalytic segment of PTPli in Sf9
cells as a soluble protein did not induce aggregation,
suggesting that increased PTPase activity alone was
not sufficient for this response. Furthermore, expres-
sion of a chimeric molecule containing the extra-
cellular and transmembrane domains of the EGF
receptor and the intracellular segment of PTP[i was
similarly ineffective. Thus, overexpression of a non-
specific transmembrane protein was insufficient to
induce aggregation. The degree of aggregation of Sf9
cells induced by PTP[t expression is very similar to
that observed following expression of other well-
characterized adhesion molecules in various model
systems.
The binding reaction has also been reconstituted in
vitro. We have shown that full-length PTPli linked to
fluorescent beads bound specifically to surfaces
coated with the extracellular segment of PTP[I,
purified following expression as a fusion protein in
bacteria. Binding is thus independent of metal ions
and glycosylation. These observations suggest that
PTIIA.-mediated aggregation is induced through
homophilic binding; i.e., the "ligand" for this
receptor-like PTPase is a molecule of the same en-
zyme expressed on an adjacent cell. This view is sup-
ported by the observation that when fluorescently
labeled uninfected cells are mixed with unlabeled
cells expressing full-length PTP[t, labeled cells are
excluded from the aggregates.
As far as we can tell, at least in this system, aggre-
gation, i.e., ligand binding to the extracellular seg-
ment, had no detectable direct effect on the activity
of the intracellular PTPase domains. Nevertheless, if
this holds true for cells in which PTPIA, is normally
expressed, it is possible that such an interaction could
serve a tethering role, controlling the activity of the
PTPase indirectly by restricting its spatial distribution
on the membrane and thus restricting the spectrum of
substrates with which it may interact. The homology
between the juxtamembrane segment of PT1311 and
the intracellular domain of the cadherins may be in-
formative in this regard. The intracellular domain of
the cadherins is the most highly conserved segment
among members of this family (90% identity) and is
essential for adhesion. Through interactions with
molecules called catenins, this domain directs associ-
ation with the actin cytoskeleton. The cadherins are
localized at adherens-type cell junctions. Cell junc-
tions are areas of rapid phosphotyrosine turnover and
locations at which kinases such as src and pp125FAK
are concentrated in normal and transformed cells. In
fact, changes in tyrosine phosphorylation may be in-
volved in controlling the structural integrity of these
junctions. It is possible that the cadherin-related jux-
tamembrane segment of PTP[t may associate with the
cytoskeleton through interaction with a catenin-like
molecule at points of cytoskeleton-membrane associ-
ation such as at intercellular junctions. PTP[1, offers a
unique, potentially direct link between cell-cell adhe-
sion and the triggering of signal transduction path-
ways. The homology of PTPIA, with the cadherins,
NCAM-like molecules, and PTPases predicts an in-
teresting role in cell-cell communication, and con-
tinuing studies of PTP[i should yield important new
insights into the control of signal transduction pro-
cesses.
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FIGURE 2 Aggregation of Sf9 cells following expression of various forms of
PTPµ from recombinant baculoviruses. The picture shows phase-contrast micro-
graphs of infected Sf9 cells after aggregation under low shear conditions for 1
hr. The cells in panel A express a chimeric molecule comprising the extracellular
and transmembrane segments of the EGF receptor fused to the intracellular
PTPase domains of PTP[i. These cells did not form aggregates. The same ob-
servation was made for uninfected Sf9 cells or cells expressing the phosphatase
domains of PTP1.1 as a soluble protein. In contrast, panel B, cells expressing the
full-length form of PTPµ form large aggregates.
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The Growth Factor Inducible
Immediate-Early Gene 3CH134
Encodes a Protein Tyrosine
Phosphatase
H. Sun, N.K. Tonks [in collaboration with C.H. Charles
and L.F. Lau, University of Illinois]
Serum growth factors stimulate cell proliferation
through interactions with their specific cell surface
receptors, activating the intrinsic receptor protein
tyrosine kinases (PTKs). This leads to signal trans-
duction events that include the reversible phosphoryl-
ation of a number of cellular substrates on tyrosyl
residues. Some of these signals are transmitted to the
nucleus, where the activation of a set of immediate-
early genes occurs. These immediate-early genes en-
code a diverse array of regulatory proteins, including
transcription factors and cytokines. Their expression
has been hypothesized to mediate the biological ef-
fects of the stimulatory growth factor.
3CH134 is an immediate-early gene, activated
rapidly and transiently in quiescent fibroblasts treated
with serum growth factors (Charles et al., Oncogene
7: 187 [1992]). 3CH134 is also expressed during
liver regeneration soon after partial hepatectomy, fur-
ther suggesting a link between its expression and the
control of cell growth. Its transcription in fibroblasts
is detected within minutes of growth factor addition,
reaches a peak level by 10-20 minutes, and is
repressed by 1 hour. The 3CH134 mRNA has a very
short half-life and accumulates for only 1-2 hours
during the Go /G1 transition. Likewise, the 3CH134
protein is transiently synthesized and has a half-life
of 40 minutes. Of particular interest is the observa-
tion that the sequence of the 3CH134 protein contains
the motif [I/V]HCXAGXXR[S/T]G that defines the
members of the PTPase family. We have purified a
bacterially expressed form of the 3CH134-encoded
protein and demonstrated that it possesses intrinsic
PTPase activity in vitro.
The identity of the physiological substrates of
3CH134 remains to be established. In light of the
rapid and transient appearance of 3CH134 mRNA
and protein following stimulation of quiescent cells
with serum or growth factors, a role in the regulation
of early steps in signal transduction from growth fac-
tor receptor PTKs is possible. At least two sites of ac-
tion would be consistent with such a role: the recep-
tor PTKs or the downstream serine/threonine kinases
that are themselves regulated by reversible tyrosine
phosphorylation. As an example of the former
category, we assayed PTyr-BIRK, the recombinant
catalytic domain of the insulin receptor, which has
been used as a substrate for PTPases in vitro. No sig-
nificant dephosphorylation by purified 3CH134 was
detected. Candidate substrates in the latter category
include the MAP kinases. A diverse array of
hormones and growth factors elicit a rapid and
transient activation of MAP kinases as an essential
step in their signaling pathways. Maximal activation
of MAP kinases requires phosphorylation of both a
tyrosyl residue and a threonyl residue residue in the
protein; dephosphorylation of either severely at-
tenuates activity. We have demonstrated that 3CH134
dephosphorylates PTyr-p42maPk in vitro 15-fold more
rapidly than PTyr-RCM lysozyme and 200-fold more
rapidly than the phosphorylated synthetic peptide
EDNDYINASL, both of which are standard sub-
strates used in the characterization of members of the
PTPase family. The possibility that, among other
potential physiological substrates, 3CH134 acts on
members of the MAP kinase family in vivo clearly
merits further attention. Much of the study of growth
factor signaling cascades thus far has focused on the
kinases. Our observations regarding 3CH134 point to
a new class of PTPase whose activity is regulated at a
transcriptional level as well as through protein turn-
over, suggesting that 3CH134 may play a role in at-
tenuating the cellular response to stimulated growth
factor receptors. Thus, these signal transduction path-
ways may be fine-tuned at the level of both
phosphorylation and dephosphorylation of key en-
zyme constituents.
A Prokaryotic Protein Tyrosine
Phosphatase
H. Sun, N.K. Tonks [in collaboration with M. Potts
and P.J. Kennelly, Virginia Tech]
Interest in PTPases from bacterial sources has been
piqued by the observation of Guan and Dixon (Ann
Arbor, Michigan) that the YopH gene product, an es-
sential virulence determinant of the pathogenic bac-
terium Yersinia, the causative agent of the Plague or
Black Death, is a member of this enzyme family.
They have gone on to show that the PTPase activity
of the YopH protein is essential for virulence. The
enzyme, which is encoded on a 70-kb megaplasmid,
exerts its effects by dephosphorylating target proteins
in the infected cell.
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Nostoc commune is a heterocystous cyanobacteri-
um, colonies of which grow in depressions formed in
limestone rock in Karst scenery. N. commune has the
ability to fix nitrogen in specialized differentiated
cells termed heterocysts. During differentiation, these
cells undergo structural and biochemical modifica-
tions to provide the reducing environment required
for nitrogen fixation. We have identified a
chromosomally encoded gene, iphP, from N. com-
mune, which contains the [IN]HCXAGXXR[S/T]G
motif that defines members of the PTPase family. We
have expressed the protein in Escherichia coli and
purified it to homogeneity. It displays intrinsic
PTPase activity toward standard substrates used in
assays in vitro (e.g., RCM lysozyme). In addition,
iphP dephosphorylated phosphoseryl residues in
caseine phosphorylated by cAMP-dependent protein
kinase, indicating that it may be regarded as a dual
specificity phosphatase. When cell lysates of N. com-
mune were probed on an immunoblot with an anti-
phosphotyrosine antibody, a protein of 85 kD was
detected. The signal in the immunoblot was com-
peted out by free phosphotyrosine, but not
phosphoserine or phosphothreonine, supporting the
idea that p85 contains phosphotyrosyl residues. Inter-
estingly, this immunoreactive band is detected in
cells grown in the presence of combined nitrogen but
not in the nitrogen-deficient media that induce
heterocyst differentiation.
These data suggest a role for protein tyrosine
phosphorylation and thus, potentially, the PTPase ac-
tivity of iphP in the control of cellular function in this
cyanobacterium. iphP in fact represents the first
PTPase of genuine, unambiguous prokaryotic an-
cestry to be identified. Our observations raise funda-
mental questions as to the origin and function of
tyrosine phosphorylation. Thus, it is possible that
tyrosine phosphorylation may have arisen much ear-
lier in evolution than previously anticipated, i.e., be-
fore the emergence of the eukaryotes as a distinct
group.
Regulation of PTPase Activity
A.J. Flint, K.R. LaMontagne, A.A. Samatar,
P.M. Guida, Jr., N.K. Tonks
The activity of members of the PTPase family may
be regulated at several levels. In the case of the
receptor-like enzymes, there is obviously the poten-
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tial for modulation of activity by ligand binding to
the extracellular segment. In addition, it appears that
many of the members of this family will be respon-
sive to regulation by reversible phosphorylation, in-
tracellular targeting, and association with other
proteins. We are currently studying these matters
with particular emphasis on PTP1B and CD45. This
year, considerable progress has been made in charac-
terizing the phosphorylation of PTP1B in vivo.
(Martijn Gebbink [Netherlands Cancer Institute] has
also contributed to these studies.)
PTP1B is a nontransmembrane PTPase, the first
member of the family to be isolated in homogeneous
form. Its cDNA predicts a protein of 435 amino
acids, of which the carboxy-terminal 114 residues
have been implicated in controlling both the localiza-
tion and function of the enzyme. Neel's group (Beth
Israel Hospital, Boston) has shown that the extreme
carboxy-terminal 35 amino acids, which are of a
highly hydrophobic nature, are both necessary and
sufficient for targeting the enzymes of the cytoplas-
mic face of membranes of the endoplasmic reticulum.
Upon inspection of the sequence of the preceding 80
amino acids, which are predominantly hydrophilic,
we noted several potential sites for phosphorylation
by serine/threonine kinases. We have now confirmed
that in HeLa cells, PTP1B is phosphorylated on seryl
residues in vivo.
We have observed increased phosphorylation of
PTP1B that coincides with the G2/M-phase transition
of the eukaryotic cell cycle. Arrest of cells in mitosis
with nocodazole is associated with a decrease of 30%
in the specific activity of PTP1B in vitro toward sub-
strates such as RCM lysozyme. We have therefore
characterized this process in detail. The phosphoryla-
tion of PTP1B in mitotic cells is accompanied by a
pronounced retardation in its electrophoretic mobil-
ity. We utilized site-directed mutagenesis and poly-
merase chain reaction (PCR) to synthesize templates
in which each seryl residue in the regulatory segment
was individually mutated to alanine. The nocodazole-
induced shift in electrophoretic mobility was then ex-
amined following expression of the various mutants
in 293 cells. Mutation of a single serine, Ser-352, was
sufficient to abolish the mobility shift. In two-
dimensional tryptic maps of 32P-labeled PTP1B from
mitotic cells, two phosphopeptides were resolved.
One of these comigrates with the peptide generated
following phosphorylation of PTP1B on Ser-386 in
vitro by the mitotic protein serine/threonine kinase
p34cdc2:cyclin B. We presume that the second
represents Ser-352. In addition to the changes in
mitosis, stimulation of He La cells with the phorbol
ester TPA also enhances phosphorylation of PTP1B,
predominantly on Ser-378, which is the site labeled
by protein kinase C (PKC) in vitro. Thus, the effect
of TPA is mediated directly by PKC.
In vivo, PTP1B is therefore a point of convergence
for the action of at least three distinct protein
serine/threonine kinases as summarized in Figure 3.
PKC labels Ser-378, which is a major site of
phosphorylation in PTP1B from asynchronously
growing cells. Mitosis is accompanied by a decrease
in the phosphorylation of this site and an increase in
the phosphorylation of two distinct sites, Ser-386,
which is phosphorylated by p34cdc2 in vitro and in
vivo, and Ser-352. The kinase responsible for
phosphorylation of Ser-352 has not yet been identi-
fied. These observations are important because they
illustrate both a novel interplay between serine/
threonine and tyrosine phosphorylation, as well as a
potential novel tier of control of the level of cellular
phosphorylation.
Characterization of Novel
PTPases
R.L. Del Vecchio, A.J. Garton, C.A. Ostman,
Q. Yang, N.K. Tonks
PTPX1 and PTPX10
We have been looking into Xenopus laevis as a model
system in which to investigate how PTPases may
function in cellular signaling. Degenerate primers,
corresponding to conserved residues within the
catalytic domain of PTPases, were used in a PCR-
based protocol to isolate cDNAs representing 14 dis-
tinct phosphatase domains from X. laevis. Two of
these cDNAs, designated X1 and X10, were chosen
for further study and full-length clones were ob-
tained. Full-length X1 encodes a protein of 738
amino acids with a predicted molecular mass of 78
kD (PTPX1); full-length X10 encodes a 652-amino-
acid protein with a predicted molecular mass of 70
kD (PTPX10). Both proteins belong to the non-
transmembrane family of PTPases. PTPX1 and
PTPX10 share segments of 97% identity in both the
carboxy-terminal catalytic domains and the amino-
terminal portions. In addition, PTPX1 contains an 86-
amino -acid insert between the amino- and carboxy-
terminal segments of the protein. PCR analysis of
genomic DNA suggests that these two PTPases are
the products of two separate genes. The amino-
terminal halves of both PTPX1 and PTPX10 are 28%
identical to bovine cellular retinaldehyde-binding
protein and 23% identical to sec14, a yeast
phosphatidylinositol transferase. This similarity may
indicate the potential for regulation of PTPX1 and
PTPX10 by a lipid molecule. Sequence comparison
and Northern blot analysis indicate that PTPX10 is
likely to be the Xenopus homolog of the previously
described human PTPMEG-2. PTPX1, on the other
hand, is a highly related, yet distinct, PTPase.
We have expressed PTPX1 and PTPX10 in Sf9
cells using recombinant baculovirus, and we are cur-
rently analyzing their kinetic properties. Within the
unique insert in PTPX1 are two threonine-proline
motifs that are consensus sites for phosphorylation by
cdc2 and MAPK. The presence of these potential
phosphorylation sites may indicate that although they
are structurally similar, PTPX1 and PTPX10 may be
differentially regulated. PTPX1 can be phosphory-
lated by p42mapk in vitro, and the effects of this
phosphorylation on phosphatase activity are currently
being assessed. Using a polyclonal antibody specific
for PTPX1, we are currently carrying out immuno-
precipitation studies to determine whether the activity
and phosphorylation state of the phosphatase are
altered during the cell cycle.
PTP-PEST
We amplified PTPase-related cDNA from a template
of total RNA isolated from human skeletal muscle.
PTP-PEST was detected by this procedure. Full-
length cDNA clones were isolated from He La cell
cDNA libraries by screening with the PCR fragment.
The cDNA predicts a protein of 780 amino acids
lacking an obvious signal or transmembrane se-
quence, suggesting it is a nonreceptor-type enzyme.
The PTPase domain is in the amino-terminal portion
of the molecule. The carboxy-terminal segment is
rich in proline, glutamic acid/aspartic acid, serine,
and threonine residues, possessing features of PEST
motifs. These motifs are found in proteins with a very
short intracellular half-life, suggesting that PTP-
PEST may turn over rapidly in vivo. Intrinsic activity
has been demonstrated in vitro against a variety of
phosphotyrosine-containing proteins, including the
cytoplasmic PTK domain of the insulin receptor. As
anticipated, the enzyme appears to be specific for
phosphotyrosyl residues. PTP-PEST mRNA is broad-
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FIGURE 3 Schematic depiction of the phosphorylation of PTP1B. PTP1B is drawn
with a globular catalytic domain connected by a hydrophilic spacer of 80 amino
acids to its hydrophobic endoplasmic reticulum (ER) anchoring sequence. The three
major sites of phosphorylation are Ser-352, Ser-378, and Ser-386. Two unidentified
minor phosphopeptide species observed in the two-dimensional maps are
represented by the phosphates on the globular domain. The majority of the
phosphorylation of PTP1B in unsynchronized He La cells occurs on Ser-378. The
phosphorylation state of this site is substantially increased in response to TPA treat-
ment of the cells. However, in cells arrested in mitosis with nocodazole, phosphate
is apparently lost from this site, whereas two new major phosphopeptides are
detected. These sites of phosphorylation correspond to Ser-386, which is the pri-
mary site of p34cdc2 phosphorylation in vitro, and to Ser-352, which is required for
the altered electrophoretic mobility of PTP1B isolated from mitotic cells. The kinase
responsible for the phosphorylation of Ser-352 has not been identified but appears
not to be the p34cdc2:cyclin B complex. (Reproduced from Flint et al., EMBO J.
12(5), in press [1993].)
ly distributed in a variety of cell lines. Stimulation of mRNA levels within 36 hours. The possibility that
rhabdomyosarcoma A204 cells, a transformed muscle PTP-PEST may play a role in signaling responses to
cell line, with insulin led to a fourfold increase in insulin is currently being investigated.
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PTPH3
We have isolated a partial cDNA clone, again from
He La cells, for this receptor-like PTPase. Like
HPTPI3 isolated by Saito and co-workers (Dana Far-
ber Cancer Center, Boston), the intracellular segment
of PTPH3 comprises a single PTPase domain. We
have confirmed that this possesses intrinsic phos-
phatase activity. The clone also encodes a trans-
membrane segment and an incomplete extracellular
domain comprising eight repeated fibronectin type III
motifs (there are 16 such motifs in HPT113). These
motifs appear to be involved in protein:protein inter-
actions and have been observed in a variety of recep-
tors. We are in the process of obtaining full-length
clones and characterizing this enzyme.
PTPH1
This is a nontransmembrane PTPase of 913 residues,
characterized by the presence of an amino-terminal
domain of 320 residues that has homology with the
cytoskeleton-associated proteins: band 4.1, ezrin, and
talin. This domain defines a family of proteins that
are targeted to interfaces between the plasma mem-
brane and the cytoskeleton. For example, band 4.1,
which promotes the association of actin and spectrin
in erythrocytes, interacts through this domain with
the transmembrane protein glycophorin. We propose
that PTPH1 may be similarly restricted in its in-
tracellular localization, and we are currently trying to
identify the proteins with which it may interact.
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CELL BIOLOGY OF THE NUCLEUS
D.L. Spector S. Huang
S.C. Henderson
R. O'Keefe
L.F. Jimenez-Garcia
R. Derby
S. Landon
Studies in our laboratory are focused on the structural
and functional organization of the mammalian cell
nucleus. Our research program evolves around two
specific areas of study: (1) elucidating the organiza-
tion of specific DNA sequences (genes and chromo-
somal regions) in the interphase nucleus and relating
this organization to function and (2) understanding
the organization of factors associated with pre-
mRNA splicing and the RNA substrates with which
these factors interact. The microscopy core facility
has been used extensively during the past year, and
numerous collaborations are under way with the ex-
cellent technical expertise of Robert Derby.
Nonrandom Localization
of DNA Sequences
S.C. Henderson, D.L. Spector
Fluorescence in situ hybridization was used to
determine if DNA sequences occupy specific posi-
tions within human diploid interphase nuclei and if
these positions change during differentiation. In
myoblasts (Fig. la), chromosome-specific a-satellite
DNA sequences appear to be randomly arranged with
respect to each other, although they preferentially
localize to the nuclear periphery or the nucleolar sur-
face. However, we found that as myoblasts become
confluent and begin to differentiate, the nuclei be-
come more elliptical in shape and centromeric se-
quences begin to align in parallel between neighbor-
ing cells. Upon fusion of the cells into a myotube, the
sister nuclei (i.e., nuclei sharing the same cytoplasm,
not necessarily daughter nuclei of a common parent)
align within the myotube and homologous centro-
meres align with the axis of alignment parallel to the
long axis of the myotube (Fig. lb,c). A similar ar-
rangement was observed in sections of human
striated muscle. In addition to a-satellite DNA se-
quences aligning parallel to the long axis of the
myotube, particular a-satellites appeared to occupy
specific positions within each nucleus. In human
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male myotubes hybridized in situ with X-chromo-
some-specific a-satellite DNA, the X centromere
ilocalized at the nuclear periphery and in a similar
quadrant in many of the myotube nuclei (Fig. 1 d,e).
A similar phenomenon was observed for several
other single-copy DNA sequences.
Our finding on the organization of DNA sequences
in the interphase nucleus supports the hypothesis that
as cells terminally differentiate, the organization of
interphase chromatin becomes progressively more
"fixed" in place. However, this restricted order does
not necessarily preclude some chromosomal move-
ment within confined domains of the nucleus upon
differentiation. The hypothesis for the purpose of this
rearrangement is that as cells differentiate, DNA se-
quences to be expressed in the terminal state are
placed in an optimal nuclear environment (i.e., jux-
taposed with specific protein factors and/or other
DNA sequences) in order to enhance (or facilitate)
gene expression. Different nuclear events may re-
quire that the chromatin structure is arranged in dif-
ferent ways such that specific sequences are in
defined places at particular times. Furthermore, vari-
ous tissue types may have specific patterns of organi-
zation of DNA sequences. By identifying patterns of
DNA organization that are characteristic for particu-
lar cell types, we will be able to construct a nuclear
map of the interphase position of genes. These data
may be extremely useful for prenatal diagnosis and/or
biopsy evaluation whereby it may be possible to
identify changes in the three-dimensional spatial
localization of a gene that may later manifest itself in
the development of a pathological condition.
Effect of RNA Polymerase II
Transcription on the
Localization of Splicing Factors
S. Landon, D.L. Spector
Pre-mRNA splicing factors are localized in a speck-
led distribution within mammalian cell nuclei. We
FIGURE 1 Centromeres of homologous chromosomes show
no apparent orientation in isolated myoblasts. (a) Human
male myoblasts were hybridized in situ with a-satellite DNA
probes for chromosome 12. Bar, 10 p.m. In myotubes,
homologous centromeres align parallel to the long axis of
the myotube (b,c). Myotubes formed in vitro by the fusion of
human myoblasts were hybridized in situ with a-satellite
DNA probes for chromosome 1 (b) and chromosome 18 (c).
Bars, 50 p.m. The centromere of the X chromosome oc-
cupies a similar position in sister nuclei of myotubes (d,e).
Human myotubes were hybridized in situ with X-chromo-
some-specific a-satellite DNA. Bars, 10 pm.
have used RNA polymerase II inhibitors to examine
whether the nuclear organization of splicing factors
was dependent on active transcription. In one such
study, cells were incubated in medium containing the
adenosine analog 5,6-dichloro-1-13-o-ribofuranosyl-
benzimidazole (DRB). DRB is known to decrease
pre-mRNA synthesis in He La cells by 70% and to in-
hibit the appearance of mRNA in the cytoplasm by
more than 95% (Sehgal et al., Cell 9: 473 [1976]).
Upon incubation of cells with DRB at a concentration
of 25 µg/m1 for 2 hours, the nuclear speckles round
up and the connections between speckles are lost.
This is similar to the change observed with a-
amanitin treatment under conditions that inhibit RNA
polymerase II. However, unlike a-amanitin, the ef-
fect of DRB on the organization of splicing factors
was found to be reversible within 30 minutes of
removal of the drug. These data demonstrated that the
organization of splicing factors in the cell nucleus is
dependent on RNA polymerase II activity. When
such cells were examined at the electron microscopic
level, a significant decrease in the number of
perichromatin fibrils was observed as compared to
control cells. These data support the idea that the
connections observed between the larger speckles
represent small nuclear ribonucleoproteins (snRNPs)
associated with perichromatin fibrils or sites of nas-
cent transcripts. These findings are in agreement with
previous studies that showed [3H]uridine incorpora-
tion as well as heterogeneous nuclear (hn)RNP and
snRNP antigens to be associated with perichromatin
fibrils (Bachellerie et al., Eur. J. Biochem. 58: 327
[1975]; Fakan et al., J. Cell Biol. 98: 358 [1984]).
Therefore, the organization of splicing factors in the
nucleus is a reflection of the transcriptional activity
of the cell.
Use of Antisense Probes to Examine
RNA Splicing In Vivo
R. O'Keefe, D.L. Spector
To assess the effect of inhibition of pre-mRNA splic-
ing on the organization of splicing factors, antisense
DNA probes were microinjected into living cells.
Oligonucleotide probes of 20 bases (5 ' -CTCCCCT
GCCAGGTAAGTAT-3 ' ), complementary to the
region of U 1 snRNA that base pairs with the 5'
splice site of pre-mRNA and that encompasses se-
quences previously shown to inhibit pre-mRNA
splicing in vitro, were used. When this oligonucleo-
tide probe was microinjected into the cytoplasm of
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He La cells, the oligonucleotide entered the nucleus,
and within 1 hour, changes were observed in the or-
ganization of the speckled pattern. Similar to what
was observed using drugs that inhibit RNA
polymerise II, antisense oligonucleotides targeted to
Ul snRNA caused the speckles to round up, and the
connections between speckles were no longer visible
(Fig. 2A). However, when a control oligonucleotide
that has no complementarity to splice sites or regions
of interaction between snRNAs (5 ' -TCCGGTACC
ACGACG-3 ' ) was microinjected into cells, no
change in the organization of splicing factors was ob-
served (Fig. 2C). Therefore, interfering with the in-
teraction of UI snRNP with the 5' splice site of pre-
mRNAs resulted in a reorganization of splicing fac-
tors. Experiments are under way to determine if in
vivo pre-mRNA splicing was inhibited in these ex-
periments. Microinjected DNA oligonucleotides that
hybridize to RNA sequences have been shown to
stimulate RNase H activity, which results in degrada-
tion of the RNA-DNA hybrid (Akhtar and Juliano,
Trends Cell Biol. 2: 139 [1992]). Upon RNase H
cleavage of the RNA portion of the Ul-oligo comple-
ment, splicing is thought to be inhibited. Splicing fac-
tors then return to storage and/or assembly sites (in-
terchromatin granule clusters) awaiting the initiation
of new pre-mRNA synthesis or synthesis of new
snRNAs and snRNPs. These data suggest that active
pre-mRNA splicing occurs at the perichromatin
fibrils and that factors shuttle between storage and/or
assembly sites (interchromatin granule clusters) and
sites of active transcription (perichromatin fibrils).
FIGURE 2 Microinjected oligonucleotides targeted to inhibit pre-mRNA splicing result in a reorganization of the splicing fac-
tor SC-35. HeLa cells were microinjected with either a specific oligonucleotide targeted to inhibit the interaction of U1 snRNP
with the 5' splice site of pre-mRNA (A,B) or a nonspecific oligonucleotide that should not inhibit splicing (C,D). I m-
munofluorescent labeling with an antibody to the splicing factor SC-35 2 hr after microinjection (A,C) revealed that the
oligonucleotide targeted to disrupt the interaction of U1 snRNP with the 5' splice site (A) resulted in a reorganization of SC-
35, whereas microinjection of the control oligonucleotide (C) had no effect of the localization of SC-35. Oligonucleotides were
coinjected with Texas Red conjugated dextrans (B,D) to mark the cytoplasm of microinjected cells. Bar, 20 µm.
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How Does the Cell's Splicing
Machinery Respond to the
Introduction of Exogeneous
DNA Templates?
L.F. Jimenez-Garcia, D.L. Spector
We have used adenovirus 2 (Ad2) as a model system
to study the spatial and temporal relationship of tran-
scription and pre-mRNA processing in the mam-
malian cell nucleus. The localization of viral RNA
sequences were examined throughout the infection
process and compared to the distribution of several
host-cell factors that are involved in transcription,
pre-mRNA splicing, and packaging RNA transcripts.
Ad2 RNA was first visualized in the cell nucleus as
6-12 dots at 7 hours postinfection. This time coin-
cides with the onset of viral DNA replication and the
switch from the early to the late stage of infection.
These dots were shown to develop, over a 24-hour
time course, into an elaborate series of rings and
large dots that occupy a majority of the nuclear
volume. We have previously reported that at 10-14
hours postinfection, pre-mRNA splicing factors are
shuttled to the sites of Ad2 RNA where they colocal-
ize. We extended these previous studies to determine
if RNA polymerase II and proteins involved in pre-
mRNA packaging are also shuttled to these sites of
Ad2 RNA. In uninfected He La cells, RNA polymer-
ase II is diffusely distributed throughout the nucleo-
plasm (Fig. 3a). However, upon Ad2 infection, RNA
polymerase II is shuttled to new sites of viral RNA,
indicative that these sites represent the sites of active
transcription (Fig. 3b-e). We were next interested in
determining whether proteins involved in packaging
of nascent RNA transcripts would also reorganize
upon Ad2 infection. We evaluated the distribution of
the hnRNP C1 and C2 proteins by using an antibody
that reacts specifically with these proteins (Choi and
Dreyfuss, J. Cell Biol. 99: 1997 119841). In uninfect-
ed cells, the C proteins are diffusely distributed
throughout the nucleoplasm, excluding the nucleolus
(Fig. 4a). Similar to what was observed with SC-35,
snRNPs, and RNA polymerase II, at 10-14 hours
FIGURE 3 Localization of RNA poiymerase II after adenovirus infection.
Upon adenovirus infection, RNA polymerase II is sequestered from its
diffuse nuclear distribution (a) and over the time course of infection
(b-e) localizes at sites of Ad2 RNA, suggesting that these are the sites
of Ad2 transcription.
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FIGURE 4 hnRNP proteins are also shuttled to sites of
adenovirus transcription. In uninfected cells, hnRNP C
proteins localize in a diffuse nuclear distribution (a). Upon
adenovirus infection, the C proteins are shuttled to the sites
of viral RNA (b-e) where they colocalize with RNA
polymerase II, snRNPs, and SC-35.
126
into the infection process, we began to see a
redistribution of C proteins to the sites of Ad2 RNA
localization (Fig. 4b-e). However, the La protein
which is not involved in RNA polymerase II tran-
scription or splicing remained diffusely distributed
throughout the nucleoplasm. Furthermore, in COS-1
cells transiently transfected with a plasmid containing
a portion of the rat tropomyosin gene (Guo et al.,
Genes Dev. 5: 2096 [1991]), a similar shuttling of
splicing factors to sites of new RNA synthesis was
observed (Fig. 5).
Our studies on the localization of pre-mRNA
splicing factors and RNA substrates suggest that the
nucleus is highly organized into macromolecular
domains associated with particular nuclear functions.
At least two potential mechanisms, a scanning mech-
anism or a recruiting mechanism, can be proposed to
account for the transcription-dependent shuttling of
both transcription and pre-mRNA processing factors
upon adenovirus infection. In the scanning mechan-
ism, factors would continuously diffuse throughout
the nucleus in a soluble form or move on components
of a nuclear matrix. When these factors reached a
potential active site, they would dock and transcrip-
tion and processing would occur. Evidence has been
provided that both active sites of transcription, splic-
ing components, pre-mRNA, as well as poly(A)+
RNA, are associated with the nuclear matrix. How-
ever, the continuous movement of factors in living
cells has not yet been demonstrated. In the recruiting
mechanism model, factors would be associated with
specific storage and/or assembly sites in the nucleus.
Prior to or at the initiation of transcription, these fac-
tors would be recruited to the active sites of transcrip-
tion by another factor or chaperon molecule. Evi-
dence to support this model comes from previous
studies which showed that a subpopulation of splic-
ing factors are localized to interchromatin granule
clusters in mammalian cell nuclei. These clusters
contain little labeled RNA after short pulses with
[3H]uridine, suggesting that they may not represent
active sites of transcription. Therefore, in uninfected
cell nuclei, splicing factors are localized to both sites
of active transcription (perichromatin fibrils) and
storage and/or assembly sites (interchromatin granule
clusters). Furthermore, upon introduction of new
transcription sites into the cell nucleus, one observes
a concomitant decrease in the signal intensity of
splicing factors at host-cell speckles with an increase
at new active sites of viral transcription, whereas the
overall level of snRNP proteins remains constant
FIGURE 5 Splicing factors are shuttled to sites of p-tropomyosin transcription. Co localization of p-
tropomyosin RNA (a,c) and SC-35 (b,d) in transiently transfected COS-1 cells. At 24-48 hr posttrans-
fection, p-tropomyosin RNA is localized in numerous fine dots within the nucleoplasm (a). Splicing
factors appear to be localized in smaller and more numerous speckles as compared to cells that
were not transfected (b). At later time points posttransfection, the p-tropomyosin RNA is localized in
fewer nuclear regions which are larger in size (c), and splicing factors are associated with these
regions (arrowheads in c/).
throughout the infection process. These findings
strongly suggest that there are signals generated in
the nucleus that regulate the compartmentalization of
factors to nuclear regions where they will be
functioning. Identification of these signaling mechan-
isms will be key to understanding the integration of a
variety of functional events that occur within the
boundaries of the nuclear envelope.
mRNP Transport
S. Huang, D.L. Spector
We have been interested in how mRNAs travel from
their site of active transcription to the nuclear en-
velope. Several previous studies showing that tran-
scripts localize in a track that extends toward or to
the nuclear envelope (Lawrence et al., Cell 57: 493
[1989], Huang and Spector, Genes Dev. 5: 2288
[1989]) suggest that at least some RNAs may be ac-
tively transported within the cell nucleus. Un-
fortunately, a clean and reliable functional assay to
evaluate mRNP export in mammalian cells is not
available. We have recently used a temperature-
sensitive mutant cell line as a means of studying
RNA transport and potentially identifying factors in-
volved in transport. TsBN2 cells are baby hamster
kidney cells that contain a temperature-sensitive
mutation in the RCC1 gene (Nishimoto et al., Cell
15: 475 [1978]). If G1 cells are placed at the restric-
tive temperature, they arrest in this phase of the cell
cycle. If S-phase cells are shifted to the restrictive
temperature, DNA condensation occurs. However,
mRNA export was also reported to be blocked in this
cell system. We were first interested in determining
how defects in the RCC1 gene would affect the
nuclear organization of pre-mRNA splicing factors
and poly(A)+ RNA. Within 2-4 hours of shifting
Go/G1 cells to the nonpermissive temperature, splic-
ing factors and poly(A)+ RNA reorganized from a
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speckled nuclear distribution to 1-8 round foci within
the cell nuclei. Staining with the DNA fluorochrome
Dapi showed that DNA was not condensed in these
cells, suggesting that the reorganization of splicing
factors is not a result of DNA condensation. We are
examining the possibility that RCC1 is an upstream
regulator whose ultimate effect may result in
maintenance of the speckled nuclear regions to fulfill
the functions of transcription, pre-mRNA splicing,
and mRNP export. In addition, we are evaluating the
level of pre-mRNA splicing in this cell system at the
permissive and restrictive temperatures. Future
studies will address the identification of factors that
may be involved in mRNP transport.
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POSTTRANSLATIONAL MODIFICATIONS AND APOPTOSIS
S.D. Patterson N. Bizios N. Sareen
P. D'Andrea Z. Yu
J. Horwitz
To understand the function of a gene product fully, it
is essential to characterize the endogenous protein to
as great an extent as possible. This includes determin-
ing the posttranslational modifications of the protein
under investigation and whether these modifications
are a dynamic process. Our laboratory is continuing
to pursue this problem both on a "global" scale
through our affiliation with the QUEST Protein Data-
base Center using two-dimensional (2D) gels and at
the level of specific protein molecules using a variety
of techniques including accurate mass determination
by laser desorption-mass spectrometry (LD-MS). In
last year's Annual Report, we described our attempts
to arrest Jurkat T lymphoblasts in a cell-division
cycle-dependent manner with the drug lovastatin. It
was found that these cells were not arrested with
lovastatin (at high concentrations), but they were in-
duced to undergo apoptosis, or programmed cell
death. We have decided to pursue this interesting
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biological phenomenon, specifically in an attempt to
elucidate the putative common signaling pathway
that leads to apoptotic induction in many cell types.
Our experience in protein identification and charac-
terization will assist us to this end.
The highlights of this year have been the demon-
stration of our model systems to achieve enrichment
of cells in different stages of apoptosis for subsequent
characterization and the characterization of proteins
using LD-MS. Apoptosis is characterized by a series
of physiological events that result in cells condensing
their chromatin, exhibiting marked surface "bleb-
bing" and increased buoyant density (due to shrink-
age and exclusion of water), cleaving their DNA into
nucleosome-sized fragments, and finally fragmenta-
tion of the cells into small, membrane-bound apop-
totic bodies. In vivo, these apoptotic cells and bodies
are rapidly taken up by phagocytic cells with no
ensuing inflammation and are disposed of in a man-
ner that does not expose the surrounding tissue to
degradative enzymes. This process is therefore a very
neat way to eliminate unwanted cells. It has been
shown recently that many effective anticancer drugs
work through the induction of apoptosis in the target
cancer cells. A wide variety of agents can induce
apoptosis, but nearly all of them cause the cell to un-
dergo the same process. Therefore, there may be a
common signaling process involved (which in some
cases can be short-circuited). It is our aim to attempt
to elucidate components of this pathway to better un-
derstand the process of apoptotic induction.
The protein chemistry component of the laboratory
has been involved with investigating the utility of
LD-MS to determine accurately the mass of proteins
and their peptide cleavage products, eluted from a
protein-blotting membrane following electrophoresis
(both 1D and 2D gels) and electrotransfer. Accurate
mass analysis is a key component of posttranslational
modification characterization of endogenous proteins
and can also be used for identification. We have
demonstrated the ability to obtain a mass spectrum
from a single protein spot on a preparative 2D gel.
This work is also assisting us with our studies on
apoptosis as it is being used in conjunction with other
protein chemistry methods to identify and character-
ize proteins involved in the induction of apoptosis.
This was an exciting year of change for the 2D Gel
Lab Core Facility both in location and with in-
corporation of new leading edge detection technol-
ogy, which is reported in detail below. Our only staff
change this year was Zailin Yu, who started our cell
culture work. He left for the Fels Institute at Temple
University School of Medicine half way through the
year and was replaced by Peter D'Andrea.
Induction of Apoptosis in
Jurkat T Lymphoblasts
S.D. Patterson, J. Horwitz, P. D'Andrea, Z. Yu
Inhibition of the rate-limiting enzyme of the chol-
esterolgenesis pathway, HMG CoA reductase, in
some cells has been shown to cause a reversible G1
cell cycle phase arrest. We set out to determine
whether the cell line, which we are using in the initial
development of our human 2D gel protein database
(see QUEST Protein Database Center, this section),
could be arrested in a stage of its cell cycle. The aim
of this arrest was to establish a means of synchroniz-
ing the cells for subsequent release and analysis of
stages of the cell cycle. Studies of this drug
demonstrated no obvious G1 cell cycle phase arrest,
but upon flow cytometric analysis of the DNA con-
tent of these cells, a number of cells displaying DNA
content less than Go/G 1 (2n) were observed. Further
microscopic analysis of the cells, as well as separa-
tion of isolated DNA from these cells, confirmed the
suspicion that a portion of the cells were undergoing
apoptosis in response to high concentrations of the
drug. Through the use of Percoll gradients, apoptotic
cells can be separated from nonapoptotic cells be-
cause of their increased buoyant density. We have
conducted labelings of the separated cells (whole-cell
lysates, nuclei-enriched fractions, and their post-
nuclear supernatants) following [35S]methionine and
more recently [32P]orthophosphate labelings.
A somewhat unexpected result of this study is that
the 2D-gel-labeling pattern of the apoptotic cells is
almost indistinguishable from that of untreated cells,
despite their markedly altered morphology. The few
protein differences are being examined further, to-
gether with other biochemical techniques such as
kinase renaturation of ID-gel-separated proteins and
immunoblotting with antisera to known intracellular
signaling molecules. From our studies so far, one of
the few proteins that displays decreased synthesis is
an acidic protein that has a relative mass of 40 kD.
This protein was identified as numatrin (B23) both by
using monospecific antiserum (from Dr. Olson, Uni-
versity of Mississippi Medical Center) and by obtain-
ing the amino acid sequence of the protein.
The sequence data were obtained by separation of
a number of whole-cell lysates by preparative 2D
gels, followed by blotting to nitrocellulose. The
stained, excised nitrocellulose spots were digested
with trypsin. One of the collected peptides was se-
quenced by Dr. R. Kobayashi (see Tumor Viruses
Section) and yielded the sequence MTDQEAIQDL,
confirming the identity of the protein as numatrin
(B23). This protein, which undergoes increased
synthesis upon mitogenic stimulation of lymphocytes
and displays markedly increased concentration in
leukemic cells, is thought to be involved in assembly
of preribosomal particles, intranuclear transport, and
translocation of ribosomal components across the
nuclear envelope. Whether the decreased synthesis of
numatrin (B23) is a result of apoptotic induction or is
an important early feature has not yet been
determined. We are currently using additional agents
to induce apoptosis in these cells.
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"Activation-induced" Apoptosis
in Human T Lymphoblasts
S.D. Patterson [in collaboration with P. Krammer and
M. Peter, Deutsches Krebsforschungszentrum
(DKFZ), Germany]
Apoptosis, or programmed cell death, can be induced
very rapidly (-30 min) in some human cells that pos-
sess the APO-1 surface antigen (the murine homolog
being the Fas antigen). This antigen is recognized by
the anti-APO-1 antibody raised and characterized in
Professor P. Krammer's laboratory at DKFZ. We are
currently collaborating with Professor Krammer and
Dr. Peter to search for alterations in the pattern of
[35S]methionine or [y- 32P]ATP labeling. Dr. Peter
visited our laboratory for a week in August to provide
the first samples for this study and to discuss the
aims.
Cells prelabeled with [35S]methionine and those
labeled during the activation are being analyzed to
search for both posttranslational modifications that
result in altered 2D electrophoretic mobility and new
protein synthesis, respectively. Alterations in phos-
phate labeling are being searched for using [y -32P]-
ATP labeling of cells permeabilized following anti-
APO-1 activation. This study has already revealed
the presence of only a few alterations in phosphate
labeling. We are currently examining the 35S/32P
mixes to determine whether the newly phosphory-
lated proteins can be found in the [35S]methionine-
labeled patterns or whether the proteins are at too low
a level to be detected in the unfractionated post-
nuclear supernatants. The aim of the project is to then
identify the proteins that display altered 2D elec-
trophoretic mobility or altered phosphorylation upon
anti-APO-1 activation-induced apoptosis and to
determine whether any of these components are the
same as those found in our own study on apoptotic
induction.
LD-MS of 2D-gel-separated
Proteins for Identification
and Characterization
S.D. Patterson [in collaboration with B.T. Chait and
W. Zhang, The Rockefeller University, New York]
The initial aim of this research is to determine wheth-
er accurate mass analysis of both intact and frag-
mented proteins is possible following blotting of
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proteins separated by either II) or 21) gel elec-
trophoresis. Using both a commercial 1.1)-MS instru-
ment, the Kompact MALDI III (courtesy of Kratos
Analytical, Ramsey, New Jersey), and one of the
original LD-MS instruments (Professor Brian Chait,
Rockefeller University), we have been examining
whether this approach is feasible. In last year's An-
nual Report, we outlined the characterization of a
new protein-blotting membrane, Immobilon-CD.
This membrane has the advantage that recovery of
proteins from it is both efficient and in a form com-
patible with further sensitive analyses. We have al-
ready established that there are components being
released from the Immobilon-CD membrane that
cause suppression of the LD-MS signal, unless the
membrane is extensively washed with basic organic
solvent, suggesting that the contaminating component
may be residual SDS. Using this technique, we have
been able to produce a spectrum from myoglobin
separated by a 1D gel and blotted to Immobilon-CD.
Following a rapid (2-min) cyanogen bromide (CNBr)
cleavage (a reagent that cleaves after methionine
residues), a spectrum that displays all of the expected
fragments including the partially digested fragments
was observed. The mass of these fragments is very
close to that expected, but there is still more work to
be done to achieve very high mass accuracy.
To test the system we subjected the
nucleolar protein, numatrin (B23) (which was sepa-
rated by preparative 2D gel electrophoresis), to the
same rapid CNBr cleavage. The designation was
made on the basis of its identification by a monospe-
cific antiserum and amino acid sequence analysis (see
above Induction of Apoptosis in Jurkat T Lympho-
blasts). Numatrin (B23) is in relatively high abun-
dance in leukemic cells and displays an acidic iso-
electric point and an aberrant relative molecular mass
of 40 kD (the calculated mass is 32 kD). CNBr prod-
uced a mass spectrum that was consistent with the
protein being numatrin (B23), thereby confirming the
assignment and also demonstrating that this technol-
ogy can be used on proteins separated by 2D gel elec-
trophoresis. Similar results were obtained using the
commercial instrument, the Kompact MALDI III, at
Kratos Analytical, in Ramsey New Jersey; the
smoothed spectrum obtained from a single 2D gel
protein spot of numatrin (B23) is shown in Figure 1.
Development of this technology will allow a rapid
means for identification of proteins separated by 2D
gels, at levels less than that required for sequence
analysis, and most importantly provide data for sub-
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FIGURE 1 A smoothed LD-MS spectrum of a rapid (5-min) CNBr digest of a single protein spot from a preparative 2D gel
obtained using the Kompact MALDI III. Approximately 4% of the material eluted from the excised, cut up, and CNBr-treated
protein spot was applied to the probe. The mass spectrum shows the relative mass region of 2,000-35,000 daltons; no
peaks of mass were observed. their fragment numbers (from partial
cleavages) and charge state (1+ = [M + 1-1]1 +, 2+ = [M + 2FI]2+). Numatrin (B23) has methionine residues at positions 1, 5,
7, 9, 65, 81, 251, and 278. The fragment numbers corresponding to the cleavage products are as follows: 1 = 1 + 2-5 + 6-7
+ 8-9 + 10-65 (the partial cleavage yielding fragment 1-65), 2 = 66-81 (complete cleavage fragment), 3 = 82-251 (complete
cleavage fragment), 4 = 252-278 + 279-294 (the partial cleavage yielding fragment 252-294).
sequent posttranslational modification analysis. This
will also allow us to peptide map more accurately
proteins that have been located in our 2D patterns fol-
lowing in vitro transcription/translation. For example,
within our Jurkat pattern, we have identified the ver-
tebrate actin-related protein, actin-RPV (Lees-Miller
et al., Nature 359: 244 [1992]), in collaboration with
Drs. Lees-Miller and Helfman (see Molecular
Genetics of Eukaryotic Cells Section) using this ap-
proach, but with gel eletrophoretic analysis of the
peptide fragments, not LD-MS. In this case, follow-
ing the translation reaction, the labeled protein pro-
ducts were separated on a 2D gel alone and mixed
with a whole-cell lysate (or appropriate enriched frac-
tion) (Fig. 2). After location of a comigrating protein,
both the in vitro translated protein and the endoge-
nous protein were excised from the gel and subjected
to limited peptide mapping and gel separation to
determine whether the correct protein had been lo-
cated. As the cDNA had been sequenced, the protein
sequence can be deduced and used to assist in con-
firming the peptide map obtained (Fig. 2). However,
the masses obtained by gel electrophoresis are only
approximate, whereas using LD-MS for accurate pep-
tide mapping, and correlating this information with
sequence information, provides valuable information
for scientists interested in characterization of
endogenous proteins.
2D Gel Laboratory
Core Facility
S.D. Patterson, N. Bizios, N. Sareen
There has been a significant change to the operation
of the Cold Spring Harbor Laboratory 2D Gel Lab
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FIGURE 2 Identification of the actin-related vertebrate protein, actin-RPV, gene product in Jurkat cells. Portions of the 2D
gels (pl range of -5.0-6.5, and relative molecular mass of 60-40 kD) are shown in A. (Left panel) In-vitro-translated actin-
RPV (TnT); (middle panel) mixture of the TnT and Jurkat whole-cell lysate (TnT/Whole cell mix); (right panel) Jurkat whole-cell
lysate (Whole cell lysate). Arrowheads in all panels indicate the most basic in-vitro-translated actin-RPV gene product (and
the endogenous protein). The identity of the TnT gene product and the endogenous cellular protein, following excision from
the gel, was then confirmed by 10 NCS (N-chlorosuccinimide, a reagent that cleaves after tryptophan residues) peptide
mapping, shown in B together with the expected cleavage products of the actin-RPV protein shown schematically in C. In C,
M represents the positions of the eight methionine residues, W represents the four tryptophan residues, and the dashed lines
are those peptides that were barely visible in B.
Core Facility this year with the move from our
original location in the McClintock building to
Demerec in early June. Fortunately, there was only
minimal downtime associated with this move and our
thanks go to Buildings and Grounds for helping us in
this regard. The move to a more compact laboratory,
change of our method of detection to storage
phosphor technology, and some operational changes
have allowed improvement of the existing service
through more rapid turnaround of the results. Depen-
dent on the number of samples that are waiting to be
run, many gel images are available within about 1
week of submission. This increase in turnaround is
primarily due to the use of the leading edge imaging
technology, storage phosphor imaging, and the as-
sistance of the QUEST staff in providing software
support for efficient archiving of the image data.
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These images are in digitized form, which is ad-
vantageous for subsequent quantitative analyses.
We ran just over 2100 gels this year; almost 98%
of these were for Cold Spring Harbor Laboratory
staff (and their collaborators), and the remainder
were for external users. In addition, gels were also
run for quality control and testing. This core facility
continues to provide an important service to the
Laboratory scientists, as well as to the general
scientific community.
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QUANTITATIVE REGULATORY BIOLOGY
B.R. Franza G. Mak J. Scheppler
B.-C. Ma Y. Li
M. Neumann H.-R. Tan
A. Calzolari G. Niu
During the time I have been at Cold Spring Harbor
Laboratory, my colleagues and I have demonstrated
our ability to identify and study cellular regulatory
proteins. We have made use of two-dimensional gel
technology in this effort and have demonstrated the
extent to which the computerization of the two-
dimensional gel data is necessary-there are many
regulatory proteins and both the processes that they
control and their own regulation are dynamic. For ex-
ample, the rates of synthesis, posttranslational modi-
fication, and interaction with other cellular proteins
comprise a few of the modalities of regulation of a
particular protein. As cells change their growth
and/or differentiation status, the different protein
states change. We are beginning to learn how to keep
track of sufficient amounts of dynamic information
about these molecular events to describe the mechan-
isms that regulate the expression and function of
regulatory proteins. These studies are expected to
reveal the nature of intermolecular relationships that
determine the growth and differentiation status of the
organism being investigated.
We have studied different classes of cellular
regulatory proteins involved in the growth control of
mammalian cells. Lymphoblasts and hematopoietic
progenitor cells are the normal human tissues we
most commonly use to study the molecular mechan-
isms regulating cell proliferation and differentiation.
To characterize regulatory proteins, we have focused
on three processes. One is the effect expression of
oncogenes has on the entire complement of proteins
present in a particular cell type. The second is the in-
duction of protein alterations when quiescent cells are
stimulated to proliferate. These studies are directed at
determining the molecules involved in conveying sig-
nals to the genome and the earliest responses of the
genome to these signals. The third process is the con-
trol of gene expression at the level of regulation of
transcription of mRNA encoding genes. The Quest II
protein database system is the tool on which we rely
heavily for performing such a comprehensive qualita-
tive and quantitative analysis of regulatory proteins.
The goal, implicit in all of our studies, is to construct
a molecular description of the networks involved in
regulating transcription and other genome responses
to a change in the growth state of the cell. The indi-
viduals listed above work as a group, with those con-
tributing most to a particular project being recognized
by first authorship of published reports (see Publica-
tion list).
In the past year, we have extended the character-
ization of proteins identified to interact with a tran-
scription control element referred to as the x13 site.
Several years ago, we identified a number of cellular
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proteins that were recovered from cells by an affinity
reaction with short, synthetic oligonucleotides con-
taining the 10-base-pair KB motif. We have since
demonstrated that one of those proteins, HIVEN86A,
is the product of the human c-rel gene. We now know
that in addition to Rel, two of the protein clusters we
identified in our original studies are the products of
related genes because they encode regions similar to
a region in Rel. The products of these genes have
been studied extensively by numerous groups and are
referred to as the NF-KB transcription factor. We
have recently shown that the precursor of the p50
subunit of NF-KB, called p105, associates with Rel
and is posttranslationally modified by phosphoryla-
tion.
Rel is also a phosphoprotein. Subsequently, we
demonstrated that Rel and p105 are phosphorylated
on serine, threonine, and tyrosine. The tyrosine
phosphorylation and synthesis of Rel are sensitive to
induced changes in the growth state of cells, includ-
ing lymphoblasts and normal neutrophils. In col-
laboration with Bryan Druker and colleagues at the
Dana Farber Cancer Institute, we have shown that
Rel is one of the most immediately tyrosine-
phosphorylated substrates in a signal transduction
pathway sensitive to the growth factor G-CSF
(granulocyte-colony stimulating factor). G-CSF is
known to result in prolonged survival and enhanced
tumor cell killing by neutrophils. We have shown not
only that Rel is one of the most immediately
modified substrates for G-CSF, but that the event is
specific for G-CSF in that other neutrophil stimula-
tory growth factors do not induce tyrosine phosphor-
ylation of Rel.
We have extended the characterization of other
proteins that interact with the KB site in comparative
analysis of the p50 subunit of NF-KB and Rel. We
have now demonstrated that certain forms of p50,
within the cytoplasm of cells, bind the site in in vitro
affinity precipitation assays (DNAP), that alteration
in nuclear binding activity of p50 is different in dif-
ferent cell types independent of the signal-inducing
event being studied, and that selective forms of Rel
are present in the cytoplasm versus nucleus of cells,
although the forms that associate with the site are
present in both compartments of the cell. The
dynamic nature of response-sensitive changes in
synthesis, modification, and specific DNA interaction
remains incompletely characterized at this point, but
is sufficiently complex to suggest that experiments
that do not replicate the coordinate concentration
fluctuations and differential compartmentalization of
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p50 and Rel that we are measuring as responses to
signals, whether in in vitro biochemical assays or in
"whole cell" assays, are potentially incomplete.
Consistent with our interest in the dynamic
response of regulatory proteins to the cells' transit
through different growth states, we have begun a
more extensive characterization of the kinases and
phosphatases-enzymes that add or remove phos-
phate from specific amino acid components of
proteins. One such study has been conducted in col-
laboration with Nick Tonks (see this section). We
have been able to demonstrate that a specific type of
phosphatase, protein tyrosine phosphatase 1B
(PTP1B), is itself phosphorylated. The phosphoryla-
tion occurs as cells transit the cell division cycle.
Cells also respond to signals induced by an activator
of protein kinase C. In fact, protein kinase C modifies
PTP1B in biochemical assays at the same residue
identified as modified in cells treated with a major
activator of protein kinase C. The task of PTP1B is to
remove phosphate from tyrosine residues in other
proteins, which is why it is referred to as a tyrosine
phosphatase. Interestingly, through our collaboration
with Nick Tonks and a graduate student in his
laboratory, K. Lamontagne, we have demonstrated
that PTP1B is modified by tyrosine phosphorylation.
Using cell lines provided by Bryan Druker, we have
also been able to demonstrate that the expression of
an "activated," oncogenic form of the Abl kinase
results in an apparent increase in tyrosine phosphory-
lation of PTP1B and an increase in the amount of
PTP1B itself. This is demonstrable because the
parental cells not expressing the oncogenic Abl
kinase are used for controlled comparisons of protein
levels and extent of phosphorylation. This is impor-
tant because the mutant, oncogenic form of the Abl
kinase is the result of a translocation and recombina-
tion of a portion of the coding region for another
regulatory protein, Bcr, with a portion of the coding
region for Abl. This Bcr-Abl fusion product is found
in virtually all cases of chronic myelogenous
leukemia and represents the most thoroughly studied
consequence of the chromosomal abnormality re-
ferred to as the Philadelphia chromosome. The
biological significance of the altered regulation of
PTP1B by increased steady-state tyrosine phosphor-
ylation is under investigation.
These highlights of our studies during the past year
indicate, once again, the necessity to resolve the dif-
ferent forms of a particular gene product in order to
discern and quantify the state changes of the protein
coincident with the state changes of cells responding
to different signals and/or traversing the cell division
cycle. The Quest II database of these regulatory
proteins will enable us to monitor and analyze an
otherwise intractably complex system. Such complex
system analysis is fundamental to understanding the
material basis of living organisms.
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During the last few years, our laboratory has focused
on investigating the structure, expression, and func-
tion of the genes encoding the protein components of
the cytoskeleton. These studies have led us to exam-
ine two fundamental problems in molecular and cell
biology: (1) the mechanisms responsible for tissue-
specific and developmentally regulated patterns of
gene expression and (2) the functional significance of
cell-type-specific protein isoform expression. Much
of our efforts have been to understand the regulation
and function of tropomyosin gene expression in mus-
cle and nonmuscle cells. Tropomyosins are major
actin-filament-binding proteins in muscle (skeletal,
smooth, and cardiac) and nonmuscle cells. Actin fila-
ments are involved in a number of fundamental cel-
lular processes including muscle contraction, cell
movement, cell division, and the generation of cell
shape. Of interest to our research is the observation
that different forms of tropomyosin are expressed in
different cell types and tissues. Distinct isoforms are
present in striated muscle (skeletal and cardiac),
smooth muscle, and nonmuscle cells. We now know
that at least 12 different tropomyosin isoforms are ex-
pressed from three separate genes in rat. The a-
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tropomyosin (a-TM) gene encodes nine isoforms, the
13-tropomyosin ((3-TM) gene encodes two isoforms,
and the TM-4 gene encodes a single isoform. We
have been studying the a-TM and [3-TM genes with
particular attention to understanding the mechanisms
responsible for tissue-specific alternative RNA splic-
ing. In addition, we have begun to study alternative
splicing of the clathrin light chain B gene, with an
emphasis on understanding the molecular basis for
neuron-specific splice site selection. We are also in-
terested in determining the function of the various
isoforms of tropomyosin in normal and transformed
fibroblasts, as well as a group of isoforms that are
only expressed in brain. Recently, we identified a
gene in vertebrate cells that encodes a distantly re-
lated member of the actin family and have begun to
study the function of this actin-like protein. Below is
a summary of our studies.
cis-Acting Elements Involved in
Alternative Splicing of the
Rat 13-Tropomyosin Gene
W. Guo, D. Helfman
Alternative RNA splicing is a fundamental process in
eukaryotes that contributes to tissue-specific and de-
velopmentally regulated patterns of gene expression.
We have been using the rat 13-TM gene as a model
system to study the mechanism of alternative splic-
ing. The rat (3-TM gene spans 10 kb with 11 exons
and encodes two distinct isoforms, namely, skeletal
muscle 13-TM and fibroblast TM-1. Exons 1-5,8, and
9 are common to all mRNAs expressed from this
gene. Exons 6 and 11 are used in fibroblasts, as well
as in smooth muscle cells, whereas exons 7 and 10
are used exclusively in skeletal muscle cells. Our pre-
vious studies localized critical elements for regulated
alternative splicing to sequences within exon 7 and
the adjacent upstream intron. We also demonstrated
that these sequences function, in part, to regulate
splice site selection in vivo by interacting with cel-
lular factors that block the use of the skeletal muscle
exon in nonmuscle cells (Guo et al., Genes Dev. 5:
2096 [1991]). This year, we have further character-
ized the cis-acting elements involved in alternative
splice site selection. We have made a chimeric mini-
gene composed of the adenovirus major late tran-
scription unit driven by the cytomegalovirus (CMV)
promoter/enhancer, in which the 13-TM exon 7 and its
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immediate flanking intron regions were inserted be-
tween exons 1 and 3 of the adenovirus early region.
We also cloned into the heterologous minigene three
mutants in the intron upstream of exon 7, termed int-
3, int-5, and d3-5, that were characterized previously
and found to result in the use of exon 7 in nonmuscle
cells. Expression of the wild-type heterologous mini-
gene in nonmuscle cells results in spliced products
containing adenovirus exon 1 spliced to exon 3, and
exon 7 of the TM gene is not used. In contrast,
mutants int-3 and int-5 led to partial use of exon 7, as
shown by the splice product containing adenovirus
exon 1 + (3 -TM exon 7 + adenovirus exon 3. Mutant
d3-5 almost completely activated exon 7 in the
heterologous gene. These results demonstrate that
exon 7 and its immediate flanking intron sequences
are sufficient to regulate the suppression of exon 7 in
nonmuscle cells. To further study the mechanism
responsible for the suppression of exon 7 splicing, we
introduced the wild-type sequences, as well as three
intron mutants into plasmid P2(7/8) that have exons 7
and 8 ligated together, and performed both in vitro
and in vivo assays. Our results indicated that the
blockage of exon 7 in nonmuscle cells is primarily at
its 3' splice site. We then used biotin-labeled RNA
and gel-filtration chromatography to study pre-
splicing complex assembly of exon 7. We studied the
small nuclear ribonucleoprotein (snRNP) composi-
tion and protein components that assemble on wild-
type and mutant constructs during the early stage of
spliceosome assembly. We have found the binding of
Ul and U2 snRNPs are similar for wild-type and
mutant pre-mRNAs. These results suggest that the
factors which block the 3' splice site of exon 7 do
not function by interfering with the binding of Ul
and U2 snRNP particles to the pre-mRNA.
HeLa Cell Nuclear Factors Block
the Skeletal Muscle-type Splicing
of p-Tropomyosin Pre-mRNA
G. Mulligan, D. Helfman
The (3 -TM transcript contains a mutually exclusive
internal cassette, in which exon 7 is spliced into
mRNA in skeletal muscle, and exon 6 is used in all
other tissues. Our studies demonstrate that in non-
muscle cells, exons 6 and 7 do not compete for splice
site recognition, but instead cellular factors block the
use of exon 7. Exon 7 sequences are critical to block-
age, as their mutation can activate splicing in non-
muscle cells. Within the upstream intron, a long
polypyrimidine tract positions the remote branchpoint
associated with splicing of exons 5 to 7, and the in-
tron regulatory element (IRE) located between exon 7
and the upstream polypyrimidine tract is also neces-
sary for nonmuscle blockage of exon 7. Using a mo-
bility shift assay, we purified an IRE-specific binding
activity and found that it is identical to the polypy-
rimidine-tract-binding protein (PTB). Furthermore,
we have shown a direct correlation between reduced
PTB binding and activation of exon 7 (Mulligan et
al., J. Biol. Chem. 267: 25480 [1992]).
Functional analysis of cellular factors involved in
exon 7 blockage has been hampered by the lack of an
extract that uses the skeletal muscle exon to sig-
nificant levels. We have now developed a modifica-
tion in nucleus isolation that allows both He La cell
and 293 cell nuclear extracts to utilize the 3' splice
site of exon 7. This modification alters the distribu-
tion of cellular factors between the nuclear and
cytoplasmic fractions. The stimulation of exon 5 to 7
splicing may be due to the overall increase in splicing
efficiency and/or the reduction of specific blocking
factors. These extracts contain significant levels of
PTB, and addition of more PTB did not reduce exon
7 splicing. Both affinity chromatography and im-
munodepletion with antibodies are being used in
attempts to reduce PTB levels such that possible ef-
fects on exon 7 splicing can be observed. We are also
using this extract as the basis for a complementation
assay to detect factors blocking exon 7 splicing. Ad-
dition of HeLa cell nuclear extract that inefficiently
splices exon 7 indicates the presence of general and
specific inhibitory activities. However, a partially
purified fraction specifically reduces exon 7 use
without inhibiting splicing of controls such as (3-
globin. We are purifying this activity in an effort to
understand both the mechanism and specificity of
exon 7 blockage.
taming exon 5, intron 6, and exon 6 are not normally
spliced in vitro. We have carried out a mutational
analysis to determine which sequences in the pre-
mRNA contribute to the inability of this precursor to
be spliced in vitro. Interestingly, we find that muta-
tions in two regions of the pre-mRNA lead to activa-
tion of the 3' splice site of exon 6, without first join-
ing exon 6 to exon 8. First, introduction of a nine-
nucleotide poly(U) tract upstream of the 3 ' splice site
of exon 6 was sufficient to permit the splicing of
exon 5 to exon 6 with as little as 35 nucleotides of
exon 6. Second, introduction of a consensus 5 ' splice
site in exon 6 leads to splicing of exon 5 to exon 6.
The results obtained with the latter mutation are in
agreement with the exon definition model proposed
by Berget (Mol. Cell. Biol. 10: 84 [1990]). Collec-
tively, our studies demonstrate that three distinct ele-
ments can act independently to activate the use of the
3 ' splice site of exon 6: (1) the sequences contained
within exon 8 (exon-recognition sequences), (2) a
poly(U) tract in intron 5, and (3) the 5 ' splice site of
exon 6. Using biochemical assays, we have deter-
mined that some of these sequence elements interact
with distinct cellular factors for 3' splice site utiliza-
tion. Furthermore, we have also studied how these
elements contribute to alternative splice site selection
using precursors containing the mutually exclusive,
alternatively spliced cassette composed of exons 5-8.
Introduction of the poly(U) tract upstream of exon 6
and changing the 5' splice site of exon 6 to a con-
sensus sequence, either alone or in combination, fa-
cilitated the use of exon 6 in vitro, such that exon 6 is
spliced more efficiently to exon 8. These data dem-
onstrate that intron sequences upstream of an exon
can contribute to the use of the downstream 5' splice
site. These results also demonstrate that in addition to
sequences in and around exon 7 (skeletal muscle-type
splice), multiple cis-elements surrounding exon 6
(fibroblast-type splice) contribute to tissue-specific
alternative splice site selection.
Regulation of Alternative Splice
Site Selection in 13-Tropomyosin
Pre-mRNA
T. Tsukahara, D. Helfman
We have been studying why the splicing of exon 5 to
exon 6 in the 13-TM gene requires that exon 6 first be
joined to the downstream common exon (Helfman et
al., Genes Dev. 2: 1627 [1988]). Pre-mRNAs con-
Molecular Basis for the Ordered
Pathway of Intron Removal in
3-Tropomyosin Pre-mRNA:
Identification of a Novel Activity
Required for Certain 3 Splice Sites
C. Casciato, D. Helfman
We have been studying the internal region of the rat
3 -TM gene that contains mutually exclusive exons 6
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(fibroblast- and smooth muscle-type splice) and 7
(skeletal muscle-type splice). As described in the pre-
vious section, our studies demonstrate that three dis-
tinct elements can act independently to activate the
use of the 3' splice site of exon 6: (1) the sequences
contained within exon 8 (exon-recognition se-
quences), (2) a poly(U) tract in intron 5, and (3) the
5' splice site of exon 6. Using biochemical assays,
we have determined that these sequence elements in-
teract with distinct cellular factors for 3' splice site
utilization. Although HeLa cell nuclear extracts are
able to splice all three types of pre-mRNAs, an S100
fraction plus SR proteins was unable to splice exon 5
to exon 6 using precursors in which exon 6 was
joined to exon 8. Using an in vitro complementation
assay, we have identified a novel factor that is re-
quired for the splicing of exon 5 to exon 6 with this
latter precursor. We have purified this factor ex-
tensively over three chromatographic columns. In ad-
dition, we have identified a putative target site (exon-
recognition element) for the interaction of this ac-
tivity, herein referred to as an exon-recognition factor
(ERF). The properties of the ERF and its target RNA
sequences are under study.
Alternative Splicing of 13-Tropomyosin
Pre-mRNA in a Myogenic Cell System
Y.-C. Wang, D. Helfman
Previous studies in our laboratory on alternative
splicing of p -TM pre-mRNA have indicated that use
of the skeletal muscle-specific exon (exon 7) in non-
muscle cells (HeLa cells) is subject to negative
regulation, due to the presence of an inhibitory ac-
tivity or factor in nonmuscle cells (Guo et al., Genes
Dev. 5: 2096 [1991]). It is possible that skeletal mus-
cle cells simply lack this negative activity, so that
they are capable of incorporating exon 7 in f3-TM
mRNA during pre-mRNA splicing. However, it is
also possible that skeletal muscle cells express a
muscle-specific factor that overcomes the negative
activity, resulting in the use of exon 7. To understand
the molecular basis for muscle-specific splicing of p-
TM pre-mRNA, we are developing an in vitro splic-
ing system from myogenic cells, which will then be
used to study the cellular factors involved in the
regulation of muscle-specific alternative splicing.
The system we are using is derived from BC3H1
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cells, a mouse nonfusing muscle cell line that differ-
entiates in culture and changes from a nonmuscle to a
muscle phenotype. The transition of tropomyosin
isoforms expressed from the 13-TM gene at the
protein and mRNA levels in BC3H1 cells has been
previously characterized during the differentiation
process. The nonfusing muscle feature of BC3H1
cells makes the preparation of nuclear extracts from
these cells easier than that from other skeletal muscle
cells. We have so far successfully made nuclear ex-
tracts from undifferentiated (myoblast-stage) BC3H1
cells that are able to carry out nonmuscle-type splic-
ing of RNA substrates transcribed in vitro from (3-
TM gene fragments. The conditions we have tested
for the splicing reactions show that BC3H1 nuclear
extracts require salt and magnesium concentrations
different from those used in the nonmuscle HeLa cell
system, which is conventionally used in the research
field of RNA splicing. At present, we are working on
the conditions of nuclear extract preparation from dif-
ferentiated (myocyte-stage) BC3H1 cells for a system
that supports muscle-type RNA splicing.
In addition to the in vitro splicing system, we also
use other approaches including UV-cross-linking and
gel-shift assays to investigate nuclear factors that
might show differential binding to 13-TM pre-mRNA
in myoblast versus myocyte nuclear extracts and thus
might mediate splicing. Furthermore,
through the analyses by Western blot assay per-
formed on BC3H1 myoblast and myocyte lysates, we
are studying the protein levels of a variety of factors
that are known to have effects on alternative splicing
in other gene systems.
Regulation of Neuron-specific
Alternative RNA Splicing
S. Stamm, D. Helfman [in collaboration with
Diana Casper, Mount Sinai School of Medicine]
We have determined the gene structure of clathrin
light chain B and the expression pattern of its neuron-
specific exon, termed exon EN (Stamm et al. 1992).
To study the molecular basis for neuron-specific
splice site selection, we are analyzing the regulatory
sequences using minigene constructs that are trans-
fected into primary neuronal cultures from rat mesen-
cephalon and HeLa cells. We constructed a minigene
of exon EN and its flanking exons EIV and EV. This
minigene faithfully reflects the splicing pattern of the
endogenous gene. Deletion analysis of intron se-
quences upstream and downstream from the neuron-
specific exon revealed that the sequences required for
neuron-specific splice site selection are located in the
alternatively spliced exon and its flanking intron se-
quences. We have identified an eight-base-pair motif
that is conserved between the neuron-specific exon
EN in clathrin light chain B and exon 9c in the a-TM
gene (see also Fig. 1). Minigenes containing muta-
tions in this sequence in the clathrin minigene no
longer use the neuron-specific exon in neuronal cul-
tures, indicating that this sequence is involved in
alternative splice site selection. The neuron-specific
exon EN is normally excluded in all cell types other
than neurons. When we were analyzing the sequence
1a 2a 2b 1b
of the splice sites of exon EN, we noticed that both
the 5' and 3' splice sites deviate from the mam-
malian consensus sequence. To address the question
of why EN is excluded, we mutated its 5' and 3'
splice sites to match the consensus 5' and 3' splice
site sequences. All constructs that have at least one
consensus splice site use exon EN in HeLa cells. The
5' splice site seems to be more important for its use
than the 3' splice site. When both splice sites are in
consensus, the exon is changed into a constitutively
spliced exon. Our data suggest that the neuron-
specific exon EN is not used in most cells because its
splice sites are not recognized. On the other hand,
neurons would be expected to express a factor that
binds to the alternatively spliced exon and thereby
promote its use. Using UV cross-linking, we have
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FIGURE 1 Schematic diagram of the rat a-TM gene and nine different isoforms expressed from this gene. Exons are
represented as boxes and introns are represented as lines; they are not drawn to
scale. The gene contains two alternative
promoters that result in expression of two different amino-terminal coding regions (exons 1 a and 1 b), two internal mutually ex-
clusive exon cassettes (exons 2a and 2b and 6a and 6b), and four alternatively spliced 3' exons that encode four different
carboxy-terminal coding regions (exons 9a, 9b, 9c, and 9d). Exons 3-5, 7, and 8 are common to all tropomyosin isoforms and
are black. All other exons are alternatively spliced. The peptide that was used to raise a rabbit polyclonal antibody (anti-
rTM9c) is indicated above exon 9c in the TMBr-1 mRNA.
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identified factors in extracts derived from brain that
bind specifically to sequences contained with the
neuron-specific exon EN. Work is in progress to
characterize these factors.
Since exon 9c of the a-TM gene is used only in
brain and shares sequence identity with exon EN of
the clathrin light chain B gene, we analyzed the de-
velopmental regulation of 9c using an exon-specific
polyclonal antibody (see next section). Exon 9c is ex-
pressed at embryonic day E16 in the rat brain, at the
same day when exon EN of clathrin light chain B is
first expressed, and like exon EN, the expression of
exon 9c is increased in the postnatal brain, reaching
the highest level of expression in the adult brain. We
are now trying to determine whether the regulation of
exons EN and 9c involve common factors.
Brain-specific Tropomyosin
Isoforms TMBr-1 and TMBr-3 Have
Distinct Patterns of Expression
during Development
S. Stamm, J. Lees-Miller, D. Helfman [in collaboration with
Diana Casper, Mount Sinai School of Medicine]
Neurons differ significantly from other cell types in
size and geometry. The morphology of neurons is es-
sential to their function as conductors of information
in a mostly vectorial manner. Their unique size and
shape are reflected in the neuronal cytoskeleton. The
polarity of neurons, related to the directional flow of
information, has been manifested in a unique set of
structural proteins creating this polarity, such as
neurofilaments and microtubules with their associa-
ted proteins that can be preferentially segregated into
axons or dendrites. We previously reported that the
rat a-TM gene expresses at least nine distinct
isoforms (see Fig. 1). Interestingly, the a-TM gene
was found to express a unique set of isoforms in the
rat brain, which were named TMBr-1, TMBr-2, and
TMBr-3, and are 281, 251, and 245 amino acids in
length with apparent molecular weights on SDS-
PAGE of 36,000, 31,000, and 31,000, respectively
(see also Fig. 1). We have generated an isoform-
specific antibody specific for sequences contained
within exon 9c of the a-TM gene and analyzed the
developmental expression and regional distribution of
these proteins in the developing and adult rat brain.
Western blot analysis revealed that the two isoforms
are differentially expressed in development, with
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TMBr-3 appearing in the embryonic brain at 16 days
of gestation, followed by the expression of TMBr-1
at 20 days after birth (Fig. 2). In addition, although
TMBr-3 was detected by Western blot in all brain
regions examined (brainstem, cerebellum, cortex,
hippocampus, midbrain, olfactory bulb, striatum, and
thalamus), TMBr-1 was detected predominantly in
brain areas that derive from the telencephalon
(cortex, hippocampus, olfactory bulb, striatum, and
thalamus). Immunocytochemical studies on mixed
primary cultures made from rat embryonic midbrain
indicate that expression of the brain-specific epitope
is restricted to neurons, and this was confirmed by
the lack of immunoreactivity when immunocyto-
chemistry was performed on glial cultures of the
same origin. The developmental pattern and neuronal
localization of these forms of tropomyosin suggest
that these isoforms have a specialized role in the de-
velopment and plasticity of the nervous system.
At present, the functions of TMBr-1 and TMBr-3
are not known. The different developmental patterns
and regional distributions of these isoforms suggest
that these proteins will have different functions.
Tropomyosins are known to be associated with
filamentous actin in both muscle and nonmuscle cell
types. Actin-based filaments are associated with a va-
riety of neural structures, such as growth cones,
dendritic spines, plasma membranes, axoplasm,
presynaptic termini, and postsynaptic densities. They
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FIGURE 2 Expression of the brain-specific a-TM isoforms
TMBr-1 and TMBr-3 at different developmental stages.
Western blot analysis of equal amounts of protein (15 lAg)
using the rabbit polyclonal antibody, anti-rTM9c, that recog-
nizes sequences encoded in exon 9c of the a-TM gene (see
Fig. 1). Protein was prepared at E8-E12 from whole em-
bryos and from whole brains at 13, 14, 15, 16, and 19 days
of gestation (E13-E19) and 6-30 days after birth (P6-P30)
and adult (3 month).
are thought to play a role in motile processes such as
axoplasmic transport, growth cone movements,
synaptic rearrangements, and vesicle movement.
Work is in progress to further investigate the sub-
cellular localization of these isoforms in neurons and
brain tissue and to determine what proteins associate
with these isoforms.
Functional Differences among
Tropomyosin Isoforms
M. Pittenger, D. Helfman
Although the functions of tropomyosin in muscle tis-
sue have been well studied, the roles of tropomyosin
in nonmuscle cells are not understood. This is partly
due to the large number of isoforms present and to
the difficulty of separating the individual isoforms for
study. We have been interested in elucidating the
role(s) of the individual tropomyosin isoforms in cel-
lular function. Utilizing cDNAs for each of the non-
muscle tropomyosins, we have used a bacterial ex-
pression system (pET system) to purify biochemical
amounts of each tropomyosin for study. Tropomyo-
sin proteins have few modifications and their rela-
tively small size (29-36 kD) and stability make them
ideal proteins for bacterial expression. These full-
length, recombinant tropomyosins are not fusion
proteins and contain only endogenous tropomyosin
sequences. These tropomyosins have proven useful
for in vitro experiments as well as introduction into
cells by microinjection. We have shown in competi-
tion experiments that a 248-amino-acid isoform (TM-
5b) can displace longer 284-amino-acid isoforms
(TM-2 or TM-3) from the actin filament. These
isoforms were each fluorescently labeled and micro-
injected back into cultured fibroblasts in order to as-
certain their subcellular localization (Fig. 3). At the
light microscope level, each was found to incorporate
along microfilaments. Essentially identical sub-
cellular distributions were observed for each isoform
examined. It is worth noting that our experiments to
date have been limited to fixed interphase cells and to
a-TM gene products (TM-2, TM-3, TM-5a, and TM-
5b; Fig. 1). We are in the process of extending these
studies to include TM-1 and TM-4. In addition, we
plan to examine the dynamic distribution of the dif-
ferent isoforms in living cells using video intensifica-
tion microscopy during cell spreading, mitosis, and
cell movement.
Although the bacterial expression system produces
abundant and quite useful vertebrate tropomyosins,
the bacteria do not acetylate the amino terminus, a
modification common in eukaryotic cells. Due to
head-to-tail overlap requirements between certain
tropomyosins that would be adjacent along the actin
filament, this acetylation can possibly effect the as-
sembly of tropomyosins on filaments. To address
such questions, we are using a baculovirus-derived
expression system that will produce acetylated ver
sions of tropomyosins. We have demonstrated that
the TM-1 made in the baculovirus expression system
is acetylated and shows enhanced F-actin binding
compared to the same isoform produced in bacteria.
We have also shown that the association of TM-1
binding to F-actin is greatly enhanced when an addi-
tional tropomyosin (TM-2) is also present. We are
currently investigating the effects of the tropomyosin
isoforms on the association of other microfilament-
binding proteins, in particular, caldesmon, a protein
whose association with microfilaments may be regu-
lated by calcium/calmodulin signals. These studies
will provide important information on the rela-
tionships between tropomyosins and the in vivo orga-
nization of microfilaments.
Partial Reversion of the Transformed
Phenotype by Stable Expression
of Specific Tropomyosin Isoforms
in Transformed Cells
J. Kazzaz, M. Pittenger, D. Helfman
Transformation of cells results in a variety of cellular
changes, including alterations in cell growth, adhe-
siveness, morphology, and organization of the cyto-
skeleton. Morphological and cytoskeletal changes are
perhaps the most readily apparent feature of trans-
formed cells. Although a number of studies have doc-
umented a decrease in the expression of specific
tropomyosin isoforms in transformed cells, it remains
to be determined if the suppression of tropomyosin
synthesis is essential for the establishment and
maintenance of the transformed phenotype. As a
model system, we are using a Kirsten-virus-trans-
formed cell line (ATCC NRK 1569). In contrast to
normal fibroblasts, the Kirsten transformants contain
reduced levels of TM-1 and undetectable levels of
TM-2 and TM-3. These cells have a rounded mor-
phology and are devoid of microfilament bundles.
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FIGURE 3 Localization of TM-3 in fibroblasts. Bacterially produced fibroblast TM-3 was labeled with lis-
samine rhodamine B sulfonyl chloride (LRB) and microinjected into rat fibroblasts (REF52 cells). (A, C,
E) Examples of REF52 cells microinjected with LRB-TM3; (B, D, F) corresponding phase (B) or FITC-
phalloidin-stained fields (D, F). TM-3 is distributed to the edge of the cell and in the edge ruffles (ar-
rowheads). (D) Neighboring uninjected cells labeled with FITC-phalloidin.
We have prepared cDNA expression vectors for
TM-2 and TM-3. Cell lines were established from the
NRK 1569 cells that stably express TM-2 or TM-3.
We have found that increased expression of these
isoforms leads to cell spreading or flattening and
formation of identifiable microfilaments. Other
phenotypes include multinucleation and an increase
in vacuoles and microspikes depending on the
amount of tropomyosin expressed.
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We are currently testing the cellular effects of co-
expressing both TM-2 and TM-3, as well as compar-
ing other characteristics of the transformed
phenotype. Finally, we are introducing TM-1 into a
adenovirus-transformed cell line that expresses no
detectable amount of this isoform. In this way, we
hope to delineate the functional significance of the
altered pattern of tropomyosin synthesis in trans-
formed cells.
A New Tropomyosin Essential
for Cytokinesis in the Fission
Yeast Schizosaccharomyces pombe
D. Helfman [in collaboration with M. Balasubramanian
and S. Hemmingsen, Plant Biotechnology Institute,
National Research Council, Saskatoon,
Saskatchewan, Canada]
Mutations in the Schizosaccharomyces pombe cdc8
gene impair cytokinesis. We have cloned cdc8+ and
found that it encodes a novel tropomyosin. Gene dis-
ruption results in lethal arrest of the cell cycle, but
spore germination, cell growth, DNA replication, and
mitosis are all unaffected. Haploid cdc8 gene dis-
ruptants are rescued by expression of rat fibroblast
TM-2. Immunofluorescence microscopy of wild-type
and cdc8 gene disruptants indicates that cdc8
tropomyosin is present in two distinct cellular distri-
butions: in dispersed patches and during cytokinesis
as a transient medial band. Collectively, these results
indicate that cdc8 tropomyosin has a specialized role,
which, we suggest, is to form part of the F-actin con-
tractile ring at cytokinesis. These results establish the
basis for further genetic studies of cytokinesis and of
contractile protein function in S. pombe.
We have also found that rat fibroblast TM-3 can
also complement the cdc8 disruption in yeast, but two
other fibroblast isoforms (TM-5a and TM-5b) are un-
able to complement the disruption. These results
strongly suggest that the different fibroblast isoforms
will have distinct cellular functions. As described in
the preceding sections, experiments are in progress to
study the role of the different isoforms in cell func-
tion.
A Vertebrate Actin-related Protein Is
a Component of a Multisubunit
Complex Involved in
Microtubule-based Vesicle Motility
J.P. Lees-Miller, D. Helfman [in collaboration
with T.A. Schroer, Department of Biology,
Johns Hopkins University]
Actin is a cytoskeletal protein that is highly con-
served across eukaryotic phyla. Actin filaments, in
association with a family of myosin motor proteins,
are required for cellular motile processes as diverse
as vesicle transport, cell locomotion, and cytokinesis.
Many organisms have several closely related actin
isoforms. In addition to conventional actins, we and
other investigators have found that yeasts (Schizo-
saccharomyces pombe and Saccharomyces cerevisae)
contain actin-related proteins that are essential for
viability. This year, we found that vertebrates also
contain an actin-related protein (herein referred to as
actin-RPV). Actin-RPV is a major component of the
dynactin complex, an activator of dynein-driven
vesicle movement, indicating that unlike conven-
tional actins that work in conjunction with myosin
motors, actin-RPV may be involved in cytoplasmic
movements via a microtubule-based system. Interest-
ing, actin-RPV (also known as centractin) was also
found to be associated with centrosomes, where it
may play a role in regulating microtubule-based
motors required for centrosomal movements (Clark
and Meyer, Nature 359: 246 [1992]).
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QUEST PROTEIN DATABASE CENTER
J.I. Garrels
G.I. Latter
B.R. Franza
S.D. Patterson
T.B. Boutell
J. Chien
P. D'Andrea
J. Horwitz
P.J. Monardo
Z. Yu
The QUEST Protein Database Center has been devel-
oping software and databases for analysis of two-
dimensional (2D) gels. As a National Institutes of
Health Biomedical Research Technology Resource,
we have been preparing our 2D gel analysis software,
now named Quest II, for distribution to the scientific
community as a high-end tool for 2D gel protein
database development. The Quest II software is
aimed at users like ourselves, who wish to build
quantitative databases from the analysis of 100 or
more 2D gels, each containing 1000-2000 protein
spots. The many improvements in the Quest II de-
sign, coupled with ever increasing computer power,
at last promise to make 2D gel analysis nearly as
rapid as 2D gel production. The Quest H system will
be introduced to the user community through a Cold
Spring Harbor Laboratory (CSHL) spring course in
1993.
Our database development work on human cells
has progressed through the work of Scott Patterson
and Robert Franza to identify key proteins and key
protein modifications in lymphocytes. Jim Garrels
has focused his database development work primarily
on yeast, with the current emphasis placed on protein
identification. He and Gerald Latter have made sub-
stantial progress on a new method of spot identifica-
tion based on double-label amino acid analysis.
These reports are presented in detail below.
One staffing change in 1992 was the addition of
Tom Boutell as an applications programmer. He as-
144
sists in the development of the Quest II system. The
2D Gel Laboratory Core Facility continues to be a
key resource for our work (see Posttranslational
Modifications and Apoptosis section in this Annual
Report).
QUEST Software Project
P.J. Monardo, T.B. Boutell, J.I. Garrels, G.I. Latter
The Quest II software for analysis of 2D gels is now
becoming available. We are in a test phase here at
CSHL and are entering 13 test phase outside of the
Laboratory. The software will be furnished to
scientists who attend our first course on "Construc-
tion and Analysis of Two-dimensional Gel Protein
Databases," a CSHL spring 1993 course.
An entirely new tool has been added to the system.
This tool allows users to import their raw data into
the system, to examine and linearize these data, and
to merge multiple raw images, and smooth and detect
them. The scientist can now perform these operations
with no knowledge of computer commands.
Initial testing shows that the new system will
greatly reduce the time to perform analysis of 2D gel
experiments. These results can be stored as part of a
permanent collection of experiments in a 2D gel
protein database. Preliminary results also indicate
that our choice of a client/server architecture for the
Quest II software may allow scientists to view each
others' 2D gel data dynamically over the Internet, the
national network linking major universities and
scientific institutions.
CSHL is now in a position to become a center for
providing 2D gel analysis software to other scientific
institutions interested in constructing 2D gel data-
bases. Our accumulation of experimental results and
baseline data on the human lymphocyte work (see S.
Patterson and B.R. Franza's reports in this section)
will be put into a database that can be used by other
scientists who may not want to repeat these experi-
ments. Scientists can also send samples to the CSHL
2D gel core facility for comparison with other results
in the database or for inclusion into the database. Our
yeast and rat experiments will be converted for use
with the new system. Keith Latham of the Fels In-
stitute, our main p test site, will be putting his mouse
embryo data into the new system.
For other organisms and cell lines, scientists at key
institutions can use our software to acquire and store
2D gel data and linkages between the proteins on 2D
gels and the genes that produced them.
Protein Identification by
Double-label Amino Acid
Analysis
J.I. Garrets, G.I. Latter
2D gel analysis is no longer limited by lack of com-
puter hardware or software. However, it is severely
limited by our lack of knowledge of the identities of
the proteins we detect on 2D gels. We are attempting
to achieve a general solution to this problem by ac-
curate determination of partial amino acid composi-
tions for the proteins resolved in our gels. Through
biosynthetic labeling with two amino acids, one
tagged with 14C and the other with 35S, we can
determine the ratio of the two amino acids for each
spot in the gel. Our computer modeling studies with
yeast protein sequences, as reported last year, indi-
cate that four ratios known to an accuracy of 3%
should be adequate to identify nearly any protein
from the yeast genome.
We have been applying the amino acid ratio meth-
od for both rat and yeast cells. Software has been de-
veloped to align images of double-labeled gels and to
TABLE 1 Reproducibility of 14C/35S Isotopic Measure-
ments for Related Spots
Protein 14C Pro /35S Met 14C Leu /35S Met
HSP73 form 1 0.227 0.192
HSP73 form 2 0.215 0.179
BIP form 1 0.311 0.204
BIP form 2 0.326 0.196
HSP90 form 1 0.109 0.166
HSP90 form 2 0.105 0.131
EF2 form 1 0.148 0.074
EF2 form 2 0.131 0.065
Vinculin form 1 0.130 0.089
Vinculin form 2 0.123 0.088
plot the rate of decay for each pixel in the gel ac-
curately. We can determine through the rate of decay
the ratio of the two amino acids in each pixel of the
image. By averaging data for all the pixels in a spot,
accuracy is substantially increased.
In a pilot experiment in rat cells, on which much
of our prior database work has been based, we
labeled WT2 cells with [14C]proline and [35S]methio-
nine. In exposures taken over a 3-month period, we
were able to determine ratios with an accuracy of 5%.
In Table 1, we list some of the spots known or
strongly suspected to be related by posttranslational
modification. The results show that related spots have
very reproducible 35S/14C ratios. This stage of the
analysis shows us that the ratios are reproducible, and
even one set of isotopic ratios allows us to find the
unknown spot families that are likely to be related by
posttranslational modification. This is especially easy
to see when the spot image is displayed on the com-
puter screen using color to depict the amino acid
ratio.
The second step of our analysis leading to spot
identifications is the conversion of isotopic ratios to
amino acid ratios. We have selected eight protein
spots of known amino acid sequence from the rat pat-
tern, and we have plotted the known amino acid
ratios versus the determined 14C/35S ratios. As shown
in Figure 1, the data for known proteins generate a
linear standard curve that can be used to determine
the amino acid ratios for unknown spots. Approxi-
mately 500 spots from the gel are intense enough for
determinations of the ratio of proline to methionine
using this standard curve. This pilot experiment was
far from optimal in several respects.
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FIGURE 1 Standard curve for proline/methionine ratio
determination in 2D gel spots. The measured 14C/35S ratio
was determined for eight spots of known amino acid com-
position from a gel labeled with [14C]leucine and [35S]-
methionine. When plotted against the known amino acid
ratios, a linear standard curve was obtained. This curve can
be used to obtain the amino acid ratios for unknown spots.
25 3
The overall incorporation of the two isotopes was
not well-balanced, and the phosphorimager scans of
the gel images were made at high sensitivity, which
enhances the noise. Improved experiments have been
conducted in yeast cells. Experiments using leucine
versus methionine and leucine versus cysteine are
now being analyzed. As expected, the ratio deter-
minations have proved to be even more accurate, as
measured by the reproducibility of determination for
the pixels within a spot. Work is now progressing to
identify enough yeast proteins to build the standard
curve and to find optimal labeling conditions in yeast
for linear incorporation of both amino acids.
We thank Dr. Dan Fraenkel of Harvard Medical
School for making laboratory space available to Jim
Garrels to conduct the yeast labeling experiments.
A Human 2D Gel Protein Database:
"Baseline" Experiments and
Posttranslational Modification Sets
S.D. Patterson, P. D'Andrea, J. Horwitz, Z. Yu
The human acute T-cell leukemic line, Jurkat (Clone
E6-1), has been chosen for the initial experiments in
the establishment of a human 2D gel protein data-
base. This cell line is derived from an acute lymph-
oblastic leukemia, is used extensively in studies of
cancer and AIDS, and closely resembles a normal
stage IV peripheral T lymphoblast. A number of ex-
periments considered to be "baseline" for the estab-
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lishment of a more extensive database have been per-
formed on these cells. The experiments include (1) an
extensive protein turnover or time of labeling experi-
ment with six different pulse times and three different
chase periods, (2) three replicate heat-shock experi-
ments, (3) PHA stimulation time course study, and
(4) centrifugal elutriation (for cell cycle analysis).
These experiments are complete, with half of them
being imaged using the old fluorography method, and
half by phosphor autoradiography. Another important
component of the human database will be the inclu-
sion of sets for the identification of proteins carrying
specific posttranslational modifications (Fig. 2). With
one exception (Fig. 20, these have all been per-
formed using metabolic labelings with specific
radioactive labels. The labelings (and labeling times)
for which there are data on both whole-cell lysates
and nucleus-enriched fractions for all listed include:
(1) steady-state phosphorylation (3 hr and 8 hr), (2)
myristylation (3 hr), (3) palmitoylation (3 hr), (4)
prenylation (3 hr and 18 hr), (5) N-linked glycosyla-
tion, mannosylation (3 hr), and (6) 0-linked
glycosylation, labeling following lysis of the cells to
detect carbohydrate chains with terminal N-acetyl-
glucosamine using galactosyltransferase.
The mapping of which proteins in the methionine-
labeled pattern carry these modifications is nearing
completion. All of these radioactive labels, aside
from phosphate, are tritiated. Therefore, these all
have to be imaged for long periods of time using
fluorographed gels (as tritium will not expose
phosphorimaging plates). However, the use of
[35S]methionine/phosphate mixes to identify which
proteins are labeled with 32P has proven to be rapid
using both film and phosphor autoradiography.
To identify members of the small GTP-binding
protein or ras superfamily, the ability of these
proteins to be renatured in situ on a nitrocellulose
blot following 2D electrophoresis has been used to
advantage. [35S]Methionine-labeled cell lysates have
been used to spike "cold" cell lysates for separation
in a micropreparative mode (50 fg total protein). This
allows sufficient protein to be blotted from the 2D gel
to nitrocellulose for subsequent renaturation and in-
cubation with [a-3211GTP. Many, but not all, small
GTP-binding proteins are able to renature sufficiently
to bind the labeled GTP. Approximately 20 proteins
have been found to bind GTP using this method and
through either quenching or not of the 13-emission,
35S-labeled proteins that bind GTP have been lo-
cated.
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FIGURE 2 Composite of 2D gel images of whole-cell lysates (except G, which is from a nucleus enriched frac-
tion) from posttranslational modification sets that form part of the human 2D gel protein database. The labels
are as follows, with the label and labeling period in parentheses: (A) Prenylation ([3H]mevalonate /3 hr); (B)
myristylation ([3H]myristate/3 hr); (C) phosphorylation ([32P]orthophosphate/8 hr); (D) total protein
([35S]methionine/30 min); (E) carboxylmethylation ([3H]methyl-methionine/2 hr); (F) N-linked sugar
([3H]mannose /3 hr); (G) 0- linked sugar (post-lysis, nucleus-enriched, [3H] galactose /galactosyltransferase).
Identification of Proteins in the
Human 2D Gel Protein
Database and the Initial
Link to the REF52 Database
S.D. Patterson, P. D'Andrea, J. Horwitz
In addition to amino acid sequence analysis of
proteins of specific interest ((3-tubulin, during estab-
lishment of our protein chemistry methods, and
numatrin [B23] for our apoptosis studies) and in vitro
transcription/translation of full-length cDNA (see
Posttranslational Modifications and Apoptosis in this
section), we have begun to use enhanced chemilum-
inescence methods to identify proteins of interest in
our 2D gel patterns. We are using the microprepara-
tive system in the CSHL 2D Gel Laboratory Core Fa-
cility to separate 45 fg of cold protein spiked with
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500,000 dpm of radioactively labeled protein, both
from Jurkat cell lysates. The gels are then blotted to
nitrocellulose and probed with antibodies (monospe-
cific for the protein of interest), and the bound
antibodies are visualized using chemiluminescent
detection. Identification of the radioactively labeled
proteins imaged by either film or phosphor
autoradiography is achieved by overlaying with the
chemiluminescent film image. Using commercially
obtained antibodies, we have confirmed the identity
of p42 MAP kinase, PLeyl, and c -raft, and with
antibodies from colleagues, we have identified actin-
RPV (vertebrate actin-related protein, Drs. Lees-
Miller and Helfman, CSHL), numatrin (B23) (Dr. Ol-
son, UMMC, Michigan), PCNA (Mr. Brand and Dr.
Mathews, CSHL), and PTP-1B (Dr. Tonks, CSHL).
We will attempt to identify other signal transduction
molecules of interest to many investigators including
ourselves to increase the usefulness of the human 2D
gel protein database.
Another important aspect of this work is the desire
to link this new database with the model REF52 data-
base. This is being achieved initially through the use
of limited peptide mapping of [35S]methionine-la-
beled protein spots from both Jurkat and WT2 (a
REF52 derivative in the REF52 database) using the
reagent N-chlorosuccinimide, which cleaves after
tryptophan. The fragments generated are separated
using one-demensional gel electrophoresis in a Tris-
tricine buffer system. We have matched 32 proteins
between the Jurkat and WT2 patterns using this
method, including some of the "PCNA-like" set of
proteins identified in the REF52 database.
Human Regulatory
Protein Sets
B.R. Franza [in collaboration with Rodrigo Bravo,
Bristol Myers-Squibb, Jim Roberts, Fred Hutchinson
Cancer Center, and Guilio Draetta, European Molecular
Biology Laboratory]
We have identified cyclin E and D2 in H9 and Jurkat
cells, and cyclin E has been identified in B lymph-
oblasts. We have characterized the cdc2 kinase fam-
ily member, cdk2 in Jurkat cells, and are in the pro-
cess of characterizing cdk3 in the same cells. In
studies of cell cycle regulation, we have identified a
protein tyrosine phosphatase in human lymphoblasts
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and have shown that its phosphorylation state is
altered through the cell cycle.
The characterization of Rel and related cellular
proteins has been extended. We have shown that Rel
and the p50 -NF-KB precursor, p l 05, arc complexed
with each other and that both arc phosphoproteins.
We have also determined the 2D gel position of the
isoforms of p50 NF-KB itself and think we have p65-
NF -KB identified in 2D gel images. We have identi-
fied the location of the inhibitor of NF-KB, IKB (p40)
in 2D gels. Thus, our ability to monitor the behavior
of several classes of regulatory proteins using data-
bases constructed from 2D images of cellular proteins
has been expanded significantly during the past year.
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GENETICS
There was an old man from Bombay
who was asked what he thought of DNA
He said: "Could be worse,
I might have the curse,
of purifying proteins all day."
Genetics is the study of organisms from the perspective of their inherited traits.
From the days of Mendel's genetic crosses with sweet peas in a monastery in
Central Europe, to contemporary studies at Cold Spring Harbor, the underlying
logic of the art of genetics has remained largely unaltered. However, we now use
a battery of methods including gene cloning, whole-genome approaches, two-
hybrid yeast screens, and differential library screens and many more techniques
that enormously expand the power and scope of classical techniques. As in past
years, we continue to use a range of model organisms from yeast to plants. The
most recent revolution, one which will have widespread implications, is the ap-
plication of new methods to the study of human genetics. The time-tested model
organisms such as yeast are still needed, but increasingly human disease and
their genes can be studied directly. The work of the genetics group is described
below.
EUKARYOTIC CELL CYCLE CONTROL
D. Beach S. Allan
M. Caligiuri
D. Casso
T. Connolly
S. Davey
D.J. Demetrick
H. Feilotter
K. Galaktionov
I. Garkavtsev
C. Gawel
G. Hannon
J. Hofmann
J. Hudson
N. Kaplan
D. Lombardi
K. Lundgren
S. Matsumoto
T. Matsumoto
B. Nefsky
During the course of the year, Jim Bischoff left to
take a position with Onyx Pharmaceuticals; Lisa
Molz obtained a Ph.D. and moved to Rusty Williams'
laboratory at the University of California at San Fran-
cisco; Guillaume Cottarell joined Mitotix; Toru
Mizukami returned to Kyowa Hakko Kogyo Co.,
Ltd., Japan; and Catherine Jessus returned to CNRS
in France. We were joined by Greg Hannon, Jim
Hudson, Manuel Serrano, and Sanae Matsumoto.
K. Okamoto
M. Serrano
A. Tesoro
N. Walworth
Y. Xiong
H. Zhang
Cellular Transformation and
Cyclin-CDK Complexes
Y. Xiong, H. Zhang, D. Beach
Following the isolation of the human D-type cyclin
gene family, we have focused our efforts on identify-
ing cyclin-D-associated catalytic subunits and other
cellular proteins that interact with D cyclins. In hu-
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man diploid fibroblasts, we found that cyclin D1 is
complexed with many other cellular proteins. Among
them are protein kinase catalytic subunits cdc2, cdk2,
cdk4 (previously called PSK-J3), and cdk5 (also
called PSSALRE). In addition, polypeptides of 21 kD
and 36 kD were identified in association with cyclin
Dl. We showed that the 36-kD protein is the
proliferating cell nuclear antigen (PCNA). Cyclin D3
also associates with multiple protein kinases, p21,
and PCNA. It was proposed that there exists a
quaternary complex of D cyclin, cdk, PCNA, and p21
and that many combinatorial variations (cyclins D1,
D3, and cdk2, 4, and 5) may assemble in vivo. These
findings link a human putative G1 cyclin that is asso-
ciated with oncogenesis with a well-characterized
DNA replication and repair factor.
Subsequent to the identification of the cyclin-D
quaternary complex, we discovered that PCNA and
p21 are present in all cyclin-cdk complexes that we
have examined as universal elements in normal hu-
man fibroblasts. Upon transformation of diploid
fibroblasts with the DNA tumor virus SV40 or its
transforming tumor antigen (T), the quaternary
cyclin-cdk complexes undergo subunit rearrange-
ments. The cyclin D-p21-cdk-PCNA complexes are
disrupted. In transformed cells, CDK4 totally dis-
sociates from cyclin D and is replaced by p16.
Quaternary complexes containing cyclin A-p21-cdk-
PCNA are rearranged in the transformed cells. A
polypeptide of 19 kD was identified in association
with cyclin A and only appears in the transformed
cells. Both p21 and PCNA are dissociated from
cyclin B1-cdk complexes. The pattern of subunit
rearrangement of cyclin-cdk complexes in SV40-
transformed cells is also shared in those containing
adenovirus and papillomavirus oncoproteins. These
findings provide the first evidence for the alteration
of protein complexes that are involved in cell cycle
control during cellular transformation.
Cell Cycle Genes in Human Neoplasia
D.J. Demetrick, D. Beach
During the past year, our laboratory has attempted to
define the potential role of cell cycle regulatory gene
products in human neoplasia. Genetic alterations of a
variety of cellular genes have been demonstrated to
contribute to human cancer. Some of these genetic
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alterations have been associated with a chromosomal
translocation that either can result in fusion products
with other genes, conferring abnormal protein func-
tion (chronic myelogenous leukemia t[9:22]), or can
result in a change in the regulation of expression of a
tightly regulated gene (Burkitt's lymphoma t[l 1:14]).
Since the expression of many cell cycle genes ap-
pears to be highly controlled, it is possible that altera-
tions in their normal regulation will lead to the ab-
normal cell proliferation present in most human
neoplasia. A cell cycle gene identified by our
laboratory, among others (cyclin D1), has already
been shown to most likely encode the elusive bc1-1
oncogene. Our strategy has been to map the newly
identified human cell cycle regulatory genes cloned
by our laboratory to their chromosomal locations and
to study their expression in tumors and cell lines that
show gross genomic abnormalities involving chromo-
some locations near those genes. This year, the hu-
man cell cycle phosphatase cdc25A was mapped by
our laboratory to chromosomal position 3p21 and
cdc25B was mapped to 20p13 utilizing fluorescence
in situ hybridization techniques and the polymerase
chain reaction. Some histological subtypes of lung
and renal carcinomas show common karyotypic ab-
normalities involving 3p21. The tissue-specific pat-
terns and normal levels of expression of cdc25A and
cdc25B have been determined and their expression in
tumors demonstrating abnormal karyotypes near the
loci of those genes is currently being investigated.
Our laboratory is also currently mapping a variety of
other cell cycle regulatory genes to help determine
whether these genes are involved in the genetic
alterations observed in the cells of some human
tumors.
Rbr-2, an Rb-related Protein,
Interacts with the cdk2 Kinase
G. Hannon, D. Beach
To identify proteins that might play key roles in con-
trolling transit through the G1 and S phases of the
mammalian cell cycle, we sought to isolate previous-
ly unknown proteins that could interact with a known
cell cycle regulatory kinase, cdk2. Toward this goal,
we have used a "two-hybrid" protein interaction
screening procedure. Previously, the discovery of an
interaction between two proteins required not only
substantial information about each potentially inter-
acting member, but also a direct test for their interac-
tion. The two-hybrid system developed by S. Fields
(SUNY, Stony Brook) and colleagues overcomes this
limitation.
We constructed a cDNA library (derived from
He La cell mRNA) that directs the expression of hu-
man proteins as fusions with the yeast GALA tran-
scriptional activation domain. In addition, we con-
structed a vector that directs the expression of the
cdk2 protein kinase as a fusion with the GALA DNA-
binding domain. These were cotransformed into a
yeast strain that carries the his3 and lacZ genes under
the control of GALA-dependent promoters. If an indi-
vidual cDNA directs the synthesis of a fusion protein
that can bind to cdk2, then a competent transcrip-
tional activator is formed, and the his3 and lacZ
genes are expressed. Selection for these gene prod-
ucts can be used to identify such cDNAs, and to date,
three have been isolated by using this procedure.
One cDNA encoded a human homolog of the fis-
sion yeast Sucl protein. Sucl is a protein of unknown
function that is known to tightly bind the fission yeast
cdc2 protein. The human Sucl homolog had been
previously isolated and was known to interact with
cdk2 physically. Thus, the isolation of the human
Sucl homolog provided confirmation that the two-
hybrid screen was capable of identifying proteins that
could interact with cdk2.
A second cDNA encoded a previously unknown
protein with a predicted molecular mass of 24 kD.
This protein showed no homology with any protein
present in the currently available databases, and ex-
periments to ascertain the function of this protein are
currently under way.
The third cDNA encoded a 1082-amino-acid
protein whose sequence showed striking similarity to
a class of proteins, the nuclear "pocket" proteins, of
which the tumor suppressor protein, Rb, is the found-
ing member. The protein encoded by this cDNA has
been termed Rbr-2 (Rb-related) based on this homol-
ogy.
The sequence of Rbr-2 was most similar to the se-
quence of another Rb-related protein known as p107.
Rbr-2 shows approximately 50% amino acid identity
with p107 over the entire length of available p107 se-
quence. Homology with Rb is restricted to the A and
B subdomains, which comprise the "pocket" domain,
and to the "amino-terminal homology region," which
is also shared between Rb and p107.
The pocket domains of Rb and p107 are known to
bind to proteins encoded by DNA tumor viruses:
SV40 T antigen and adenovirus E1A. We have found
that this property is also shared by the pocket domain
of Rbr-2. We are currently investigating the possible
interaction of Rbr-2 with known cell cycle regulatory
proteins. In particular, we are testing whether the in-
teraction between Rbr-2 and cdk2 indicated by the in-
itial yeast screen occurs through a direct physical in-
teraction or, alternatively, through interaction of both
of these proteins with a cyclin. In this regard, p107 is
known to bind cyclin A.
The interaction between Rbr-2 and cdk2 (whether
direct or indirect) provides another example of the
cross-talk between the basic cell cycle regulatory ma-
chinery and the nuclear "pocket" proteins. By binding
to transcription factors, the "pocket" proteins are
thought to regulate the expression of a series of genes
that are critical for cell growth. Thus, interaction be-
tween cdk2 and Rbr-2 may provide a mechanism for
the control of gene expression by cyclin-cdk com-
plexes.
Regulation of p34cdc2 and Cell Cycle
Arrest in Response to DNA Damage
N. Walworth, S. Davey, D. Beach
The regulation of the activity of p34cdc2 in fission
yeast is dependent on both complex formation of
p34cdc2 with the product of cdc13 and phosphoryla-
tion of p34cdc2 on threonine and tyrosine residues.
Tyrosine phosphorylation of p34cdc2 prevents entry
into mitosis and is dependent on the products of the
mikl and weel genes. Simultaneous loss of function
of mikl and weel results in premature advancement
into mitosis leading to cell death. Cold-sensitive al-
leles of cdc2 were found that permit the cell to sur-
vive without functional mikl and weel, but them-
selves lead to a cell division cycle defect at low
temperature. Multicopy expression of cdcl3, a B-
type cyclin that is known to associate with p34cdc2,
suppresses the cold-sensitive growth defect of these
cdc2 alleles. A genomic library prepared from
Schizosaccharomyces pombe DNA has been intro-
duced into two of these cdc2 strains, and high-copy
suppressors have been identified. One of these sup-
pressors encodes a novel protein kinase, chkl. This
kinase is dispensable for vegetative growth; however,
loss of function of chkl causes cells to be sensitive to
both UV radiation and incompletely replicated DNA.
Characterization of chkl suggests that it is required
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for the checkpoint that temporarily arrests the cell
cycle in response to DNA damage; chkl encodes a
checkpoint kinase.
"Checkpoint" is a term used to describe systems
used by the cell to ensure that downstream events do
not take place unless upstream events have been
properly completed. Perhaps the best studied example
is the dependence of mitosis on the completion of
DNA replication. Similarly, cells must ensure that
mitosis is not initiated if DNA has been damaged.
For example, when wild-type cells are exposed to UV
light, they normally arrest the cell cycle in G2 in or-
der to repair the damage. The absence of chkl does
not impair the cell's ability to repair damaged DNA;
rather, the cell fails to recognize that DNA damage
has occurred and attempts to undergo mitosis with
damaged chromosomes. The phenotype of chkl is
similar to that of a subset of mutants that were isolat-
ed because they are sensitive to radiation (rad
mutants). Four of the rad mutants, including radl-1,
are also defective in the checkpoint which signals to
the cell that DNA damage has occurred. Multicopy
expression of chkl partially suppresses the UV
sensitivity of radl-1. Therefore, chkl may provide a
link between the rad-dependent DNA-damage-sens-
ing pathway and cdc2-dependent control of the cell
cycle.
Regulation of the Gi/S Phase
Transition in Fission Yeast
M. Caligiuri, D. Beach
In S. pombe as in other eukaryotic organisms, com-
mitment to the mitotic cell cycle occurs in G1 at
START. Only two genes whose products are required
for the passage through START in fission yeast have
been identified to date. One is cdc2, which is also re-
quired in G2, and the other is cdc10. Strains arrested
in G1 at either the cdc10 or cdc2 restriction points
will conjugate under appropriate nutritional condi-
tions, indicating that cells are not committed to the
mitotic cell cycle until after the execution of p34cdc2
and p85cdcio functions. p85cdcm shares amino acid
sequence similarity with the Swi4 and Swi6 tran-
scription factors from Saccharomyces cerevisiae and
has been shown to be a component of a DNA-binding
complex that recognizes the promoters of the cdc22
and cdtl genes.
We have investigated the role of cdc10 in the
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regulation of the Gi/S-phase transition through the
characterization of the sctl-bl gene, a dominant ex-
tragenic suppressor of a temperature-sensitive cdc10
mutant. The sctl-bl gene suppresses several condi-
tional alleles of cdc10 as well as a cdc10 disruption.
sca+ encodes a protein of 637 residues with 36%
amino acid sequence similarity to p85cdcm. The sctl
polypeptide also shares amino acid sequence simi-
larity with the Swi4 and Swi6 polypeptides which
spans a region containing two 33-amino-acid repeats.
These repeats have been identified in a diverse group
of proteins and have been implicated in providing
dimerization interfaces in heteromeric protein com-
plexes. The similarity between sctl and Swi4 is not
limited to the region containing these repeats; sctl
also shares striking similarity with the DNA-binding
domain of Swi4. Through a comparison of the mutant
sctl-b1 and wild-type sctl + genes, we have identified
a single amino acid substitution that lies in the puta-
tive DNA-binding domain. This mutation renders the
cell independent of the 33-amino-acid repeats and of
cdc10 for the execution of START.
We have shown that the sctl gene product, p72sctl,
binds to the promoters of the cdc22 and cdtl genes in
cdcto Characterization of theassociation with p85
sctl null allele has indicated that sctl is an essential
gene which functions at START. Cells arrested at the
execution point do so as elongated cells that are
capable of conjugation. In fact, cells carrying the sctl
null allele conjugate even when grown on rich media,
a condition that is inhibitory for mating between
wild-type cells. These data suggest that sctl plays a
pivotal role in the life cycle of S. pombe as a tran-
scription factor that acts as a positive regulator of the
mitotic cell cycle and a repressor of its alternative de-
velopmental fate leading to sexual differentiation.
Isolation of Genes Required
for the G1 /S Transition
J.F.X. Hofmann, D Beach
The cdc10 gene product is required for cell cycle
progression at the G1 /S boundary in fission yeast. Its
function is executed immediately before the initiation
of DNA synthesis under a variety of different
physiological conditions. Recent findings suggest
that cdc10 functions as a transcription factor that is
required for the cell-cycle-regulated expression of a
number of genes required for the entry into S phase.
To identify these presumptive target genes, we
prepared protein extracts from S. pombe, and these
extracts were incubated with size-fractionated ge-
nomic yeast DNA. Using specific antibodies directed
against the cdc10 gene product, protein-DNA com-
plexes were immunoprecipitated, and enriched ge-
nomic DNA was amplified by PCR. These hypotheti-
cal promoter sequences were used to screen gene
banks to isolate the respective genes.
Three of the isolated genes have been found to be
periodically expressed in the cell cycle, with a peak
of their steady-state mRNA level in late G1. Se-
quence analysis has established that one of the genes
is identical to cdc22, which has been proposed
recently to be regulated by cdc10. The two other
genes have not been identified previously and have
been termed cdtl and cdt2.
We have shown by DNA footprint analysis that a
protein complex containing the cdc10 gene product
specifically binds to the cdtl promoter, suggesting
that cdc10 is directly involved in the transcriptional
regulation of cdtl. The role of this binding site in the
expression of cdtl is under investigation.
Gene disruption experiments have shown that cdtl
is an essential gene and that it is required for the G1 /S
transition. We have also shown that overexpression
of cdtl from a heterologous promoter in cells that
grow under rate-limiting conditions for the entry into
S phase results in a transient acceleration of this
event. Ectopic expression of cdtl can also comple-
ment a temperature-sensitive mutation of cdc10 at
semipermissive temperature.
These experiments suggest that the cell-cycle-
regulated expression of cdc10 and at least one other
factor is dependent on cdc10 and that their expression
is rate limiting for the G i/S transition. Further genetic
screens are directed toward the identification of addi-
tional genes required for the G i/S transition.
Construction of the Fission
Yeast Physical Map
T. Mizukami, I. Garkavtsev, N. Kaplan, T. Matsumoto
D. Beach [in collaboration with T. Marr, W. Chang, and
D. Lombardi, Cold Spring Harbor Laboratory, and
M. Yanagida, 0. Niwa, and A. Kounosu, Kyoto University]
For the mapping of the fission yeast genome (length
about 14 Mb), a fivefold representative cosmid bank
(1920 clones, primary bank) and phage library were
prepared. At the beginning, four kinds of probes
representing known repetitive sequences (centromer-
ic repeats, 17S and 5S ribosomal repeats, and the
long terminal repeat of transposon elements) were
hybridized to the primary cosmid bank. T3/T7 probes
were prepared from cosmid clones that were not hit
by these probes. Cosmid clones were chosen ran-
domly based on only one criterion-that the clones
had not yet been hit. More than 600 of this type of
hybridization experiment were done. As a result of
our strategy, we were able to assemble clones into
contigs. Simultaneously, contigs were anchored onto
chromosomes. For this purpose, we used three kinds
of physical landmarks: more than 50 markers with
known genetic localization on chromosomes, about
70 new genes that were previously unmapped, and
VI and NotI restriction sites. A complete SfiI restric-
tion map of the S. pombe genome was constructed
previously. Some of the contigs that had no genetic
markers were located by pulse-gel electrophoresis. At
the end of this strategy, the three chromosomes as-
sembled into a total of 60 contigs. In the next step,
real gaps between contigs were filled by probing a
"deeper" cosmid bank (these cosmids were not in-
cluded in the 1920 clones) and phage library. T7/T3
probing from the very end clones is still in process.
We now have 12, 5, and 6 contigs on chromosomes
1, 2, and 3, respectively.
The hybridization mapping strategy is being con-
ducted in parallel with PstI/BamHI restriction map-
ping of the genome. Restriction mapping using six-
base-pair-recognized restriction enzymes enables us
to determine the real physical map of the genome
with good resolution in kilobase units. Approximate-
ly 70% of the cosmids from the primary bank were
digested with PstI, BamHI, and PstI /BamHI. Because
overlap information is available from the hybridiza-
tion mapping, these restriction digests allow assemb-
ly of a unique BamHI /PstI map.
From the analysis of more than 2000 cosmids and
phages, we will be able to designate a unique set of
recombinant clones on one membrane that will
represent sequences for virtually the entire S. pombe
chromosomes. About 450 recombinant clones, which
are termed the "miniset," represent almost all cloned
fragments and split the whole genome into 450 seg-
ments. Each segment has specific chromosomal
localization and can be used for determining specific
locations for any genes or unknown fragments of
DNA on the specific chromosomal sites. The miniset
of clones was chosen for a global systematic genome
sequencing project.
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FIGURE 1 Contig map of the fission yeast contigs are placed to the right of the Noti and Sfil
restriction maps. The position and length of each contig reflect their localization on the
chromosomes. Genetically mapped markers are indicated with bold letters, and new genes that
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cate locations of Sfil and Notl restriction sites.
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An Enhancer-trap/Gene-trap
Mutagenesis System
in Arabidopsis
R. Martienssen, P. Springer, A. Baron, S. Haward
(URP Program), J. Mystowski (Partner for the Future),
T. Volpe, H. Ma, V. Sundaresan [in collaboration
with C. Dean (Cambridge Laboratory) and J. Jones
(Sainsbury Laboratory), John Innes Centre for Plant
Science Research, Norwich, England]
Last year, we reported on the iv itiation of an enhanc-
er-trap/gene-trap system for identifying and disrupt-
ing genes expressed at various stages of plant devel-
opment. On the basis of similar systems in
Drosophila and mouse genetics, we have developed a
transgenic plant system for mobilizing transposable
elements carrying an appropriate reporter gene
around the Arabidopsis genome. This will allow the
identification of target genes both by virtue of their
pattern of expression and by virtue of any mutant
phenotype caused by transposon insertion. We are
using McClintock's Ac /Ds transposon system from
maize, which has been shown to transpose at high
rates in Arabidopsis when suitably modified for its
new host (Bancroft et al., Mol. Gen. Genet. 233: 449
[1992]; Swinburne et al., Plant Cell 4: 583 [1992].
We have constructed two classes of reporter ele-
ments: (1) an enhancer-trap element, which has a
minimal promoter fused to the reporter gene, and (2)
a gene-trap element, which has a multiple splice ac-
ceptor fused to the reporter gene. As described last
year, the 13-glucuronidase (GUS) reporter gene in
these constructs was shown to respond to the
presence of external enhancers and promoters by
transient expression experiments. Several stable
transformants were obtained with each of these con-
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structs, and also with an Ac transposase construct, ob-
tained from J. Jones (Sainsbury Laboratory), which
we modified for use with our selection scheme (de-
scribed below).
When Ds elements excise in Arabidopsis, they fre-
quently fail to reinsert, and when they do, it is typi-
cally close to their original location. Selection
schemes based on transposon excision will therefore
recover many lines that have no transposed elements
or transposed elements that are concentrated in a
small region of the genome. We are using a novel se-
lection scheme that avoids these problems by selec-
ting not for excision, but rather for unlinked
transposition. This will maximize the recovery of in-
dependent randomly distibuted insertions. In our
scheme, both the Ds and Ac constructs carry an ad-
jacent counter-selectable marker gene that encodes
indole-acetic acid hydrolase, an enzyme involved in
auxin biosynthesis. When plants are grown on the
nontoxic auxin precursor a-naphthalene acetamide,
those that have the iaaH gene convert the precursor
into naphthalene acetic acid (NAA), a powerful
auxin. At toxic concentrations, NAA inhibits shoot
growth and causes a proliferation of short roots,
resulting in stunted seedlings. In addition, the Ds ele-
ment carries a positive selectable marker, the nem-
mycin phosphotransferase II gene, that confers
resistance to kanamycin (Kan). Plants heterozygous
for both Ds and Ac are generated by crossing parent
Ac and Ds lines together. Transposition of Ds occurs
in these heterozygotes and results in individual flow-
ers that carry new transposed elements in their germ
line. When these flowers set seed by self-pollination,
the only progeny that arc resistant to both Kan and
NAM are those that carry a Ds element (which con-
fers Kan resistance), but not the Ds donor locus
(which confers NAM sensitivity). These progeny
must carry an unlinked, or loosely linked, transposed
element. Following the practice in Drosophila, they
are referred to as transposants.
During the past year, the transgenic plants that we
generated have been characterized genetically and
molecularly. Five different lines have been estab-
lished that are homozygous for single loci that carry
the Ac transposase gene, driven by a strong promoter.
These Ac lines have been crossed to Ds tester lines
(provided by C. Dean) to confirm that they carry
functional transposase. Eight transgenic "starter"
lines have also been established that are homozygous
for single loci carrying either DsE (the enhancer-trap
FIGURE 1 Selection for unlinked transpositions: F2 progeny from an Arabidopsis plant
heterozygous for both a gene-trap Ds and Ac transposase were germinated on media
containing NAM and Kan. Two seedlings carrying a transposed element are doubly
resistant to NAM and Kan (arrows).
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Ds) or DsG (the gene-trap Ds). The Ac and DsE line
and the Ac and DsG line have been crossed together
in order to generate 10,000 Fl seed. Eventually, all of
these Fl progeny will be grown and self-pollinated to
generate transposants in the F2 generation. Each
transposant line will then be screened for patterns of
reporter gene expression in the F3 generation. In a
pilot study, we have allowed about 200 Fl plants to
self-pollinate. F2 seed from these plants have been
sown on selective media, and the selection conditions
have been optimized to enable large-scale screening
for transposants (Fig. 1). Seven out of 21 enhancer-
trap Fl plants and 88 out of 218 gene-trap Fl plants
gave some F2 progeny that survived double selection
(i.e., transposants). In these families, transposants
comprised between 0.1% and 5% of the progeny.
DNA was isolated from 20 different transposants and
analyzed by Southern blotting and PCR. As expected,
these plants had Ds transposons at novel locations
and did not carry the donor locus or the Ac
transposase gene. A few of the Ac /+ DsG /+ Fl plants
FIGURE 2 A leaf from an Fl plant heterozygous for gene-
trap DsG and Ac transposase. The left half of the leaf com-
prises a sector in which a DsG element has transposed into
a gene expressed in epidermal guard cells, which stain blue
in X-Gluc.
were stained for reporter gene activity, and one was
found to have a large clonal sector comprising two
adjacent leaves, in which the epidermal guard cells
were deeply stained (Fig. 2). Two out of seven
enhancer-trap F2 transposants also expressed the
reporter gene at the seedling stage. One of them dis-
played constitutive expression, whereas the other dis-
played expression restricted to cotyledons and
stipules. These results suggest that both the DsG ele-
ment and the DsE element can transpose into genes
and result in cell-type-specific expression of the
reporter gene.
In the coming year, we hope to generate
1000-2000 transposant lines and screen them for pat-
terns of reporter gene expression. On the basis of our
preliminary screens, we hope to recover several hun-
dred lines that have either a novel pattern of reporter
gene expression or a transposon-linked mutant phe-
notype, or both. Our selection scheme makes generat-
ing large numbers of informative transposant lines
both practical and efficient. It is a significant im-
provement over existing schemes based on selection
for excisions and may prove to be essential when
screens for reporter gene patterns involve embedding
and sectioning plant tissue, or other laborious proce-
dures.
Immunolocalization of the
Hcf106 Membrane Protein in
Maize Chloroplasts
A. Yonetani, A. Baron, R. Martienssen [in collaboration with
R. Derby and D. Spector, Cold Spring Harbor Laboratory,
and L. Dolan, John Innes Institute Norwich, England]
The hcf106 mutant of maize is a nonphotosynthetic
mutant that fails to accumulate chloroplast membrane
protein complexes required for electron transport.
Mutant chloroplast membranes have lost the lateral
morphological heterogeneity associated with wild-
type chloroplast membranes. We have cloned the
hcf106 gene using the Robertson's mutator trans-
posable element as a tag, and last year, we reported
the cDNA sequence of the Hcf106 gene product. It
encodes a 27-kD precursor protein that migrates aber-
rantly as a 35-kD in vitro translation product on SDS-
PAGE. We have raised polyclonal antibodies against
a TrpE::Hcf106 fusion protein and purified them by
affinity to a MalE::Hcf106 fusion protein, both over-
expressed in Escherichia coli. The purified antibodies
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detect a 30-kD mature protein that was localized to
chloroplast membranes by subcellular fractionation
and Western blotting. Although the protein sequence
has no significant homology with known proteins, it
has a putative membrane-spanning domain close to
the amino terminus, and the protein is recovered
quantitatively from chloroplast membranes that have
been sonicated in high salt. This indicates that it is
probably an integral membrane protein, as suggested
by the sequence.
We have attempted to further localize the protein
by immunoelectron microscopy. Preliminary attempts
using the unpurified antibody gave strong labeling in
the chloroplast thylakoid membranes, but they proved
to be difficult to reproduce. Later experiments using
the purified antibody have confirmed at least some of
the earlier results. Maize is a C4 plant and has two
main types of photosynthetic cells in mature leaves:
the mesophyll and bundle-sheath cells. Both cell
types have differentiated chloroplasts, but. only the
mesophyll chloroplasts have large thylakoid "stacks"
that are clearly distinguished from the unstacked
"stromal" lamellae. The Hcf106 protein is found in
both cell types but is enriched in the stacked mem-
branes of mesophyll cell chloroplasts. This location is
consistent with the protein being required for the
formation or the maintenance of these structures:
Chloroplasts from mutant hcf106 leaves lack
thylakoid stacks and form large, uniform whorls of
membranes instead. However, the presence of the
protein in other chloroplast membrane fractions and
in other (nonphotosynthetic) plastid types suggests
that the function of the protein is not limited to these
distinctive membrane domains. We hope to improve
the resolution and sensitivity of these experiments in
the coming year and complete a survey of other
plastid membrane fractions.
Structure of the Hcf106
Locus in Maize
A. Baron, R. Martienssen
We have determined the structure of the Hcf106
locus by partial sequencing of a genomic clone (from
a library provided by G. Johal and S. Briggs). There
are five exons and four introns: The introns are ap-
proximately 0.2, 4.5, 0.5, and 0.4 kb in length,
respectively, and have consensus plant intron donor
and acceptor splice sites. The mature transcript is ap-
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proximately 1.1 kb, so that the entire gene spans
about 6.7 kb. This is the approximate size of a high-
molecular-weight transcript detected by Northern
analysis in some of our total RNA preparations. This
transcript is not detected in RNA from mutant cells
and is severely reduced in polyadenylated mRNA,
suggesting that it is probably a precursor.
Structure and Function of the
lojap Gene in Maize
C.-D. Han, R. Martienssen [in collaboration with
E.H. Coe, USDA-ARS, University of Missouri]
The lojap gene in maize is required for the normal
differentiation of photosynthetic chloroplasts in
certain tissues of the maize plant. Homozygous
mutant iojap plants have a variety of phenotypes
characteristic of different genetic backgrounds. These
phenotypes range from a subtle "grainy" phenotype
to the loss of leaf margins, but typically, iojap plants
have variegated leaves and transmit defective
chloroplasts through a proportion of their female
gametes. The pattern of variegation indicates that
defective chloroplasts are found in groups of cells
that arise around the time of leaf initiation and are
preferentially located at the margins of the leaf. This
has led to the suggestion that these cells are derived
from the LI, or outer layer of the shoot apical
meristem. Periclinal (or out-of-plane) divisions at the
time of leaf initiation are known to lead to similar
patterns of leaf variegation in other monocots in
which it is possible to construct periclinal chimeras.
However, such plants have not been unequivocally
identified in maize.
Last year, we reported the cloning of the lojap
gene, using an allele generated by insertion of a Mul
transposable element. The lojap gene encodes a 229 -
amino -acid open reading frame that has no significant
homology with known genes. Genomic clones have
been isolated from the maize inbred B73 (from a li-
brary provided by G. Johal and S. Briggs). The gene
has four introns of approximately 0.1, 0.3, 0.1, and
9.1 kb, respectively. The reference allele, first de-
scribed by Jenkins in 1924, was found to contain a
Ds-like transposon inserted into the first exon. Exci-
sion of this 1.5-kb transposon leads to revertant
somatic sectors and rare germinal revertant progeny.
Excision is associated with restoration of wild-type
transcript levels and restoration of the putative /j
reading frame. A second transcription unit lies ap-
proximately 2.0 kb upstream of the Iojap gene and
encodes a 2.4-kb transcript transcribed in the same
direction. It has no homology with Iojap and is tran-
scribed in mutant, wild-type, and revertant tissue.
This second transcript encodes a 624-amino-acid
open reading frame that has no homology with
known proteins.
Last summer, we performed a clonal analysis of
Iojap gene function using two different marker genes
required for anthocyanin pigmentation in the leaf.
Anthocyanin pigmentation is restricted to the epider-
mal cells of the leaf blade but is also found in sub-
epidermal cells in the leaf sheath, so that the origin of
sectors that have lost anthocyanin pigmentation can
be traced to one or the other cell layer (McDaniel and
Poethig, Planta 175: 13 [1988]). Seeds heterozygous
for translocations that link either the PI gene (on
chromosome 6L) or the Bz gene (on 9S) with the
Iojap gene (on 7L) were irradiated with varying
doses of y-rays at Brookhaven National Laboratories
last summer; 2000 kernels were planted, and mature
plants were examined for iojap and anthocyanin-less
sectors. Preliminary results suggest that ij sectors al-
ways include the epidermal layer, but these sectors
were only found when the highest doses of y-rays
were used, so very few were obtained. Southern anal-
ysis of ij sectors of the uniform "grainy" phenotype,
as well as analysis of revertant sectors in "grainy"
leaves, suggests that the phenotype may not be fully
cell-autonomous: Revertant sectors that do not pene-
trate the leaf genetically give fully green sub-
epidermal layers, whereas radiation-induced sectors
that do not include all cell layers are fully mutant.
These results support the idea that /j may be required
in cells from only one layer but can influence the
phenotype of their descendants, or their neighbors, in
other layers. Clonal analysis of sectors in homo-
zygous variegated plants, and in situ hybridization of
revertant sectors, will provide a more stringent test of
this hypothesis.
Isolation of Unstable Alleles
of ramosal in Maize
L. Goh (URP Program), A. Baron, R. Martienssen
The maize transposable element Spm (Suppressor-
mutator) is a useful mutagen because of its ability to
generate new derivative alleles at a high frequency.
To obtain new alleles of ij using this transposon, ap-
proximately 55,000 Fl progeny from a cross between
an Spm line and an ij tester were screened at the West
Neck Road cornfield in the summers of 1991 and
1992. The Spm stock (provided by Bob Schmidt,
University of California, San Diego) had a highly ac-
tive Spm element at the opaque2 locus on chromo-
some 7S. The tester stock was multiply marked on
chromosome 7 with o2, glossyl, ramosal, and ij. ra,
gl, and ij are 16, 20, and 36 map units, respectively,
from the o2 locus and are on the long arm of
chromosome 7. Only one ij plant was recovered out
of 55,000 Fl plants, and analysis of linked markers
indicated that this plant was an androgenetic haploid.
However, three independent ramosa plants were
recovered by screening mature plants for highly
branched tassels (see below). Allelism tests con-
firmed that these plants had new alleles at the ral
locus.
The RAMOSA1 gene is a meristem identity gene
required for the determination of branch primordia as
spikelet meristems in maize inflorescences. Maize
flowers are formed via a succession of "switch-
points," resulting in the differentiation of different
types of meristems as they bud from one another:
Floral meristems arise from spikelet meristems,
which arise from spikelet pair meristems, which arise
from branch primordia, which arise from the primary
inflorescence meristems. This is a more complex
situation than that found in plants such as
Antirrhinum and Arabidopsis, where mutation in only
one or two genes can lead to conversion of floral into
inflorescence meristems. In maize, ramosal ears and
tassels have indeterminate branches at the location
normally occupied by spikelet pairs. However,
normal spikelets can develop from these ectopic
branches, so that the plants are fertile.
All three new alleles of ral were unstable and fre-
quently reverted to the wild-type (unbranched) phe-
notype in ear and tassel sectors. An example of a
mutable ear is shown in Figure 3. The origin of the
mutability in each case has not yet been determined,
but germinal reversion from one of these alleles has
been shown to be very high (30-40% of ra-m
gametes). Genetic tests for Spm activity at the locus
are under way, but molecular analysis has failed so
far to reveal any Spm-homologous sequence linked to
the first mutable allele. Another mutable allele of ral
was obtained in a similar screen by Bob Schmidt
(University of California, San Diego), who has kindly
made it available. It differs from our alleles in that
the tassel has a stable mutant phenotype, although
revertant ears are frequently observed. It is not
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FIGURE 3 An ear from a plant heterozygous for ramosal
and a new unstable allele, ral-m. The ear is highly
branched, except for revertant unbranched sectors that
have a normal arrangement of kernels (arrows).
caused by the insertion of an autonomous Spm (R.
Schmidt, pers. comm.).
Establishment of Division Sites
in Plant Development
J. Colasanti, V. Sundaresan [in collaboration with
S. -O. Cho and S. Wick, University of Minnesota]
Since plant cells cannot migrate, it is necessary for
plants to regulate both the timing and direction of cell
division during plant development, i.e., a plant cell
has to know both when to divide and which way to
divide. The details of the process by which the plane
of cell division is regulated are poorly understood at
the molecular level. For example, it is known that the
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choice of the division site is made before mitosis and
is precisely indicated by a
band of microtubules
called the preprophase band (PPB) and that this
choice is imprinted in the cellular memory during
cytokinesis since the PPB
disappears before
metaphase. However, the mechanism of this imprint-
ing is unknown, although it has been proposed that
this is accomplished by F-actin, which is associated
with the PPB in some types of plant cells. Last year,
we reported that the p34cdc2 kinase homolog of high-
er plants colocalized with the PPB band of micro-
tubules that predicts the future division site in
premitotic cells of the maize root tip. This observa-
tion suggested to us that the determination of the
plane of cell division may be mediated by the p34cdc2
kinase. We have now extended on our previous ob-
servations. We find that when the microtubule PPB is
disrupted using the drug oryzalin, p34cdc2 is no
FIGURE 4 Immunofluorescence staining of leaf epidermis
showing a developing stomatal complex. Cells are stained
with tubulin antibody, which reveals the transverse inter-
phase band in the guard mother cell (GMC) and the more
brightly stained preprophase band in the subsidiary mother
cell (SMC) on the left (A), maize p34"Ic2 antibody (B), and
DAPI (C). Magnification, 1600x.
longer associated with the division sites, although it
is able to leave the nucleus. Therefore, it is likely that
the function of the PPB is to direct p34cdc2 to the
division site. Second, we have examined progenitor
cells of the stomatal complex of the leaf epidermis. In
the grasses, the formation of this complex involves
some highly asymmetric cell divisions, and further-
more, F-actin is not associated with the PPB in these
cells (Cho and Wick, J. Cell Sci. 92: 581 [1989]). We
have now shown that the association of p34cdc2 with
the PPB also occurs in the stomatal complex
progenitor cells, both in maize and in rye (Fig. 4). As
in the case of the root tip cells, the association of
p34cdc2 with the PPB seems to occur late in G2/M,
which is consistent with the idea that the PPB forms
first and then directs p34cdc2 to the division site. Our
current model is that the division site is modified by
p34cdc2 by phosphorylation of cortical substrates. In
this model, the phosphorylation of cortical substrates
at the point of contact of the PPB is the mechanism
by which the division site is "imprinted" in the cel-
lular memory, and which is used to direct the expand-
ing cell plate to the division site at telophase.
Cyclins in Higher
Plants
J.-P. Renaudin, J. Colasanti, Z. Yuan, V. Sundaresan
[in collaboration with C. Jessus and H. Rime,
CNRS, France]
The subcellular distribution of p34cdc2 is believed to
be regulated by the associated cyclin, and it is likely
that there may be a specific cyclin required for asso-
ciation of p34cdc2 with the division site. For this rea-
son, we have initiated a study of plant mitotic cyclins,
and we have now isolated clones for seven cyclins
from maize (from a cDNA library constructed by B.
Veit and S. Hake, USDA, Albany), which fall into
four distinct classes numbered type 1 through type 4,
in order of decreasing abundance. We have isolated
full-length or near-full-length clones for one member
of each class and have demonstrated their function-
ality by their ability to induce maturation in oocytes,
by microinjection of sense RNA from each clone. Se-
quence analysis of the clones shows that they all have
homologies with both A and B animal mitotic cyclins
but cannot be classified as clearly A-type or B-type.
However, types 1, 3, and 4 can be termed "B-like"
because they are slightly more homologous to animal
cyclin B, and type 2 can be termed "A-like" because
it is slightly more homologous to animal cyclin A. In
the meantime, the sequences of three other plant
cyclins have been published, one each from soybean,
carrot, and Arabidopsis. Our data show that these
cyclins are prototypes of different classes of cyclins
that are found within a single plant species. The type-
1 and -3 cyclins are homologous to the soybean and
Arabidopsis cyclins, the type-2 cyclin is homologous
to the carrot cyclin, and the type-4 cyclin is in a class
by itself. All four cyclins that we have cloned from
maize are preferentially expressed in proliferating tis-
sues.
The maize cyclins have been mapped to the maize
restriction-fragment-length polymorphism (RFLP)
map by Keith Rufener (ICI Seeds, Iowa). Interesting-
ly, the type-4 cyclin clone maps close to a locus
called polymitotic, which was first identified by
George Beadle in 1930 as a meiotic mutant in which
supernumerary cell divisions occur after the first
meiotic division. We are now investigating whether
the polymitotic mutation may be a mutation in the
type-4 cyclin. We are also generating antibodies to
the different cyclins to study their localization within
dividing cells.
Analysis of Plant
y Tubulins
J. Colasanti, V. Sundaresan
The a and p tubulins comprise the structural subunits
of microtubules. The placement of microtubules
within cells determines cellular architecture, and-their
dynamic movements are essential for many mitotic
functions. Recent studies in animal and fungal cells
have shown that a third class of tubulin, the y
tubulins, has a fundamental role in cytoskeletal orga-
nization. Specifically, y-tubulin protein is localized to
centrosomes and spindle pole bodies in animal cells
and fungal cells, respectively. This suggests that y
tubulin is involved in microtubule nucleation-an es-
sential function for correct chromosome separaiion
and mitosis in general. In plants, cytoskeletal strut
ture is also important for the determination of divi-
sion polarity and morphogenesis. Although the cells
of higher plants lack a defined spindle pole or
centrosomal region found in animal and yeast cells,
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they do possess several unique microtubule-contain-
ing structures. The preprophase band (PPB) is a
dense band of microtubules that forms in the cortex
of the cell before the onset of mitosis and disappears
before the mitiotic spindle is formed. The position of
the PPB within the cell is somehow "imprinted" in
cellular memory, as it predicts where the future wall
will form to divide the daughter cells. It has been
suggested that at least in some plant cells, the PPB is
set up by microtubule nucleation at the cell cortex.
Furthermore, at telophase, the new cell plate is gener-
ated by a different microtubule structure called the
phragmoplast, which has been shown to be associated
with microtubule nucleation. Since y tubulin is found
at centers of microtubule nucleation, in order to iden-
tify the centers of plant microtubule nucleation dur-
ing mitosis, we have initiated experiments to study
the localization of y tubulin in plant cells. We have
taken advantage of the conserved nature of y tubulin
between diverse species to isolate the maize homo-
log. A polymerase chain reaction (PCR) fragment
generated by degenerate primers was used as a probe
to isolate seven partial clones from a maize cDNA li-
brary derived from immature ears (a gift from B. Veit
and S. Hake, USDA). Sequence analysis of these
cDNAs shows that they fall into two distinct types.
Although they are nearly 90% identical at the amino
acid level, one of the clones has a 27-amino-acid
deletion near the middle of the deduced protein.
Southern blot analysis indicates that maize may have
up to four y tubulin genes. Preliminary Northern blot
analysis indicates that the 1.6-kb y-tubulin transcript
is found at higher levels in apical meristem, root tip,
and young leaf tissue than in mature leaf tissue, in-
dicating that there is a correlation between the
proliferative capacity of the tissue and mRNA levels.
At the present time, we are producing polyclonal
antibodies against a portion of the y-tubulin protein,
with the aim of determining the localization of y
tubulin within plant cells by immunofluorescence mi-
croscopy.
Is Mu Element Transposition
Replicative or Conservative?
V. Sundaresan, R. Srinivasan
The Mu elements of maize show high rates of for-
ward transposition but low rates of germinal excision,
suggesting that they may transpose by a replicative
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mechanism. If so, this would make the Mu trans-
poson system unusual, since
all of the other
eukaryotic transposons studied in detail (except the
retrotransposons) appear to transpose by a conserva-
tive or "cut-and-paste" mechanism. In some trans-
P
oson systems (the P elements of Drosophila , and the
T c1 elements of Caenorhabditis elegans), the exci-
sion of the elements is followed by double-strand gap
repair using the element on the homologous
chromosome, so that they appear to generate forward
transpositions without excisions. However, when the
wild-type sequence is present on the homologous
chromosome, the reversion rate is increased by more
than 100-fold, due to gap repair using the wild-type
sequence as a template. We investigated whether a
similar mechanism was operating in Mu element
transposition, i.e., whether Mu element excision was
being masked by double-strand gap repair. If so, we
might expect to see significantly increased rates of
reversion if a gene containing a Mu insertion is
heterozygous with the wild-type gene. We used a line
that contains a Mul element in the Bronzel (Bzl)
gene. This allele (called bzMum9) was linked to
Shrunken (Sh) and waxy (wx) and was made
heterozygous over the wild-type gene Bzl linked to
Sh and wx. We then examined the frequency of
kernels that were purple and carried the Sh and wx
markers in crosses to recessive testers. Since double
crossovers are suppressed by chiasma interference in
this interval, such kernels should arise at low rates
unless there is a high rate of gene conversion using
the wild-type Bzl gene as template following Mu ex-
cision. The cross was Sh bzMum9 wx /sh Bz Wx x sh
bz wx /sh bz wx.
More than 20,000 kernels from this cross were ex-
amined, and purple kernels that were Sh wx arose at a
frequency of about 10-3, which was approximately
the same as the rate of double crossovers in this
region (in control crosses). The germinal reversion
rate of bzMum9 is less than 10-4, but the frequency of
forward transposition in this line is very high (>0.1
new insertions per Mul element per generation), so
that if the forward transposition was due to excision
followed by gap repair using the chromosomal
homolog, we may expect to see a reversion rate of
about 10-1. Thus, we conclude that double-strand gap
repair using the homologous chromosome does not
occur at sufficiently high rates to account for the dis-
crepancy between forward transposition and revers-
ion rates of Mu elements. Instead, our data support a
replicative model for Mu element transposition.
Differential Transcriptional
Regulation by the Maize P Gene
E. Grotewold, T. Peterson [in collaboration with
B. Bowen and B. Drummond, Pioneer Hi-Bred
International, Inc., Johnston, Iowa]
Certain viruses that cause leukemia carry an on-
cogene termed v-myb, which is responsible for the
neoplastic transformation of myelomonocytic hema-
topoietic cells. The v-myb gene is a truncated form of
the cellular c-myb gene, which is required for the
normal proliferation and development of hemato-
poietic cells. Both v-myb and c-myb encode
sequence-specific DNA-binding proteins that activate
transcription. myb-homologous genes have been
identified in a variety of organisms, but their func-
tions in most cases are unknown. We recently dis-
covered that the maize P gene encodes a Myb-
homologous protein (Grotewold et al., Proc. Natl.
Acad. Sci. 88: 4587 [1991]). Because the P gene is
known to regulate the synthesis of flavonoid pig-
ments, we can now examine the function of a Myb-
homologous protein in a well-characterized biosyn-
thetic pathway that is amenable to genetic analysis.
The P gene regulates the expression of three genes
(C2, CHI, and Al) that encode enzymes for phloba-
phene pigment biosynthesis. These three structural
genes are also required for the formation of
anthocyanin pigments but are not sufficient, and
other genes are required including A2, Bzl, and Bz2.
These latter genes are not regulated by P, but by the
maize Myb homologs Cl or PI in conjunction with ei-
ther R or B, which encode basic helix-loop-helix
proteins. Our aim was to determine the mechanism
by which P regulates a subset of the structural genes
for flavonoid biosynthesis, and for this purpose, we
compared the interaction of P with Al (regulated by
P) and Bzl (not regulated by P).
The P gene produces at least two alternatively
spliced transcripts (Grotewold et al., Proc. Natl.
Acad. Sci. 88: 4587 [1991]). We tested each P tran-
script for its ability to activate transcription by using
microprojectile bombardment to introduce P cDNA
clones together with the Al or Bzl target promoters
linked to a luciferase reporter gene into maize cells in
transient transformation assays. The largest cloned P
cDNA (P-cDNA1) efficiently activates the Al
promoter but not the Bzl promoter. We also found
that P does not require R for the trans-activation of
Al, nor does T? alleviate the inability of P to activate
Bzl efficiently. In contrast, C/ requires R for effi-
cient trans-activation of both Al and Bzl. Thus, al-
though P and Cl encode proteins with very similar
Myb-homologous DNA-binding domains, and they
regulate an overlapping set of target genes, P and Cl
may activate transcription through very different me-
chanisms. The smaller P cDNA (P-cDNA2) has no
apparent activating or inhibiting function; this is not
surprising, since P-cDNA2 encodes a protein with a
truncated Myb-homologous domain (Grotewold et al.,
Proc. Natl. Acad. Sci. 88: 4587 [1991]) which would
not be expected to bind DNA.
The P gene could activate transcription of the
flavonoid biosynthetic genes directly (by binding to
the target gene promoters) or indirectly (by first ac-
tivating an intermediate factor which then activates
the flavonoid biosynthetic genes). To test these dif-
ferent models, we examined the DNA-binding ac-
tivity of the protein encoded by P-cDNAl. P-
cDNAl-coding sequences were expressed in Es-
cherichia coli and used for gel-retardation experi-
ments using as a probe the 220-base-pair fragment of
the Al promoter previously shown to confer P in-
ducibility. The results show specific binding of P-
encoded proteins to the Al promoter fragment in
vitro, in the absence of any other maize protein. This
is the first demonstration of a direct interaction be-
tween a plant Myb-homologous protein and a target
supports the idea that P
directly activates the genes for flavonoid biosyn-
thesis.
We determined the binding sites of the P-encoded
protein in the Al promoter by biochemical analyses
of protein-DNA complexes, and we are now testing
the role of these binding sites in Al regulation by P.
The binding sites of P in Al are considerably dif-
ferent from the sequences to which vertebrate Myb
protein binds, as well as from the Bzl promoter se-
quences required for regulation by Cl and R. We fur-
ther characterized P- and Myb-binding sites through
parallel binding selection experiments, and the results
show a clear difference in specificity between P- and
Myb-encoded proteins: P binds preferentially the se-
quence CCT/AACC, and this same sequence motif is
present twice at the P binding site in the Al promoter.
In contrast, Myb binds the sequence c/TAACGG.
These results show for the first time that Myb-
homologous proteins with similar DNA-binding
domains can have very different binding specificities.
Why does P, unlike its homolog Cl, not activate
Bzl in vivo? Gel-retardation assays showed that the
P-encoded protein binds very poorly, if at all, to a
200-bp fragment of the Bzl promoter that is required
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for regulation by Cl and R. This finding is sufficient
to explain the lack of activation of the Bzl gene by P.
To test this hypothesis in vivo, we constructed a
chimeric protein that carries the Myb-homologous
DNA-binding domain of P fused to the transcrip-
tional activation domain of Cl. This P-Cl fusion ac-
tivates Al even in the absence of R but does not effi-
ciently activate Bzl. Thus, no additional protein fac-
tors interacting with the P-encoded protein need be
postulated to explain the differential regulation of the
Al and Bzl promoters. However, it remains possible
that P, like its homolog Cl, interacts with additional
specific factor(s) to activate the target genes Al, C2,
and CHI. Experiments to identify and characterize
such factor(s) are in progress.
ORGAN-SPECIFIC GENE EXPRESSION IN MAIZE:
THE P-wr ALLELE
We have recently shown that the maize P gene en-
codes a Myb-homologous regulator of genes for
flavonoid pigment biosynthesis (Grotewold et al.,
Proc. Natl. Acad. Sci. 88: 4587 [1991]). The P-
regulated pigments are localized to specific floral
organs, including the pericarp (outer layer of the
kernel) and cob glumes (floral bracts subtending the
kernel). Some alleles of P elicit differential pig-
mentation of the pericarp and cob glumes, and these
are identified by a suffix indicating their pattern of
pigmentation in these floral organs (Table 1).
We are interested in determining the mechanism(s)
of organ-specific expression of the P-wr allele.
Northern blot analysis indicates that P-wr transcripts
are present not only in the pigmented cob glumes, but
also in the colorless pericarps. However, P-wr tran-
scripts are not detectable in nonpigmented vegetative
organs such as leaves. Thus, the lack of pigmentation
in pericarp, despite the presence of P-wr transcripts,
is specific to that tissue.
To test whether the pericarp and cob transcripts of
TABLE 1 Differential Pigmentation of the Pericarp and
Cob Glumes of P Alleles
Allele
P-rr
P-rw
P-wr
P-ww
Pericarp
Red
Red
White
(colorless)
White
(colorless)
Cob glumes
Red
White
(colorless)
Red
White
(colorless)
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P-wr can activate transcription of the structural genes
for flavonoid pigment biosynthesis,
Northern blots of
pericarp and cob glume RNAs were hybridized with
probes from the C2 and Al genes, which encode en-
zymes for the first and third committed steps in
flavonoid biosynthesis. The Al probe detected tran-
scripts in both pericarp and cob glumes at 10 DAP
(days after pollination); at 21 DAP, the transcripts
were present in cob glumes but not pericarp. In con-
trast, the C2 gene transcripts were present in both
pericarp and cob glumes at both 10 and 21 DAP. The
C2 transcript level appeared lower in the pericarp of
P-wr when compared to P-rr but higher in the cob
glumes of P-wr compared to P-rr. These preliminary
results suggest that the failure to produce pigment in
the pericarp of P-wr plants is due to the inability of
the P-wr-encoded transcripts to trans-activate the Al
gene (and possibly other genes required for pigment
synthesis). Our current aim is to isolate P-wr cDNAs
from pericarp and cob glumes and compare them to
see whether different transcripts are produced by the
P-wr allele in each organ. We will then use micro-
projectile bombardment to express transiently each
cDNA in pericarp and cob glumes; the results should
indicate whether organ specificity is encoded within
each cDNA or whether it is due to differential
localization of factors that interact with the P-wr-
encoded protein(s).
Ac Transposition Mechanism
Inferred from Twinned
Pericarp Sectors
P. Athma, T. Peterson
The transposable element Ac is a versatile tool for
mutagenizing and cloning genes in maize and other
plants. We used Ac insertional mutagenesis to define
the limits of the P gene genetically (Athma et al.
1992), and we are currently using Ac to generate
mutations at specific sites within the P gene. We are
also analyzing a number of new P alleles resulting
from short-range Ac transpositions to learn more
about the mechanism of Ac transposition. The kernel
pigmentation phenotype conditioned by the maize P
gene is an excellent visual indicator of the effects of
the Ac element on gene expression. The P gene sys-
tem has the additional advantage that one can easily
detect adjacent patches of phenotypically distinct
pericarp known as twinned sectors. Such twinned
10.2. kb 14.5 kb
E
9D201B (P-ovov*)
E
%
B/
E
FIGURE 5 Structures of the P*-9D201B and P*-9D201M alleles derived from a twinned pericarp sec-
tor. The dashed lines indicate the 10.2-kb deletion in P*-90201M.
sectors are formed when a genetic event at the P
locus (such as Ac transposition) generates two non-
identical daughter chromosomes, which are segre-
gated into two adjacent daughter cells. When the
progeny of these cells are included as paired clones
within the pericarp, a twinned sector develops.
Twinned sectors can encompass one or many kernels,
depending on the time during development when the
progenitor twinned cells arise. The alleles that pro-
duce the twinned sector can be recovered from the
progeny of the kernels within each twin. Twinned
sectors are especially valuable because one can ana-
lyze both chromosomal products arising from a single
genetic event and reconstruct the molecular events
leading to twin formation.
One particularly informative twinned sector was
derived from the P-ovov allele, which confers
orange-variegated pericarp and cob glumes. The mul-
tikernel sector had white pericarp twinned with a sec-
tor of pale-orange variegated pericarp. Molecular
analysis indicated that the allele specifying light-
orange variegated pericarp (P*-9D201B) had two Ac
elements in the P locus: one Ac at the original site in
the progenitor P-ovov allele and a second Ac element
at a site 10.2 kb upstream. The allele from the
twinned white sector (P*-9D201M) carried a single
Ac inserted at the breakpoint of a 10.2-kb deletion of
the P locus (Fig. 5). Sequence analysis showed that
the deletion endpoints were precisely at the sites of
Ac insertion (Fig. 6). It is formally possible that the
9D201B: CGTGCCTAGCAGATGGTGAG
10.2 kb CAACTACAAC ACTACAACCCACATGGT
9D201M: CGTGCCTAGCAGATGCTGAG ACTACAACCCACATGGT
FIGURE 6 DNA sequences at the sites of Ac insertion in P*-9D201B and
P*-9D201M alleles. The dashed lines indicate
the deletion in P*-9D201M. The 8-bp target site duplication is underlined.
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FIGURE 7 (A) The P locus during chromosome replication.
Solid bars indicate the Ac element in the P locus. The Ac
transposase makes a double-strand staggered cut at the
target site located ahead of the replication fork. (B)
Chromatid with the donor Ac element associates with the
target site, and the transposase makes a double-strand cut
at one end of the Ac element. (C) The cut end of Ac is
ligated to one free end of the target site. At this point, the Ac
element bridges the target site and the donor site. (D) In a
normal transposition, both DNA strands of the opposite end
of Ac would be cut and ligated into the target site, and then
the ends of the donor site would be ligated together. To
generate the P*-90201B/M twinned sector, only one strand
of Ac is ligated to the target site, and the other strand
remains attached to the donor site. (E,F) Dashed lines with
arrows indicate DNA replication. Replication through the
lower strand generates the P*-9D2018 daughter chromo-
some with two copies of Ac. Replication of the upper strand
releases the acentric fragment derived from the 10.2 kb of
DNA between the Ac donor and target sites (fragment in F).
Template switching to the free end formerly joined to Ac
and continued replication generate the deletion allele
P*9D201M.
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P*-9D201M allele could have been derived from the
P*-9D201B allele by recombination between the two
Ac elements that are in direct orientation. However,
to generate the observed twinned sector, such a
recombination would have had to occur immediately
after the initial transposition that generated the P*-
9D201B allele. In fact, progeny testing of the P*-
9D201B allele indicates that such recombinations are
rare, if they occur at all. Therefore, we propose that
the twinned sector resulted from an aberrant transpo-
sition event as shown in Figure 7 (a similar model
was proposed for transposition of the Antirhinnum
Tam3 element; Robbins et al., EMBO J. 8: 5 [1989]).
The salient features of this Ac transposition model
are that (1) Ac transposes during DNA replication, (2)
there is a physical association of the Ac donor and
target site loci, and (3) the Ac termini are transferred
sequentially from the donor to the target site. This
transposition model fits genetic and molecular data
showing that Ac often transposes during DNA
replication from a replicated donor site to an unrepli-
cated target site. Additionally, the association of
donor and target site loci proposed here can help to
explain the observation that Ac tends to transpose to
nearby sites. Analysis of 11 other twinned sectors
derived from P-ovov have provided further insight
into the mechanism of Ac transposition (P. Athma
and T. Peterson, in prep.).
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ARABIDOPSIS SIGNAL TRANSDUCTION AND
FLOWER DEVELOPMENT
H. Ma C. Flanagan H. Huang
Y. Hu R. Lavi
C. Huang Y. Mizukami
R. Ram
M. Tudor
C. Weiss
Our research continues to emphasize two main areas:
characterization of G-protein function in plant signal
transduction pathways and analysis of a family of
genes involved in flower development and other
functions. Plant cells respond to a variety of external
and internal signals, but little is known about the
molecular mechanisms of the plant signal transduc-
tion pathways involved. To begin to understand plant
signaling processes, we have taken the approach of
studying G proteins, which, in animals and simple
eukaryotes, are known to play important roles in sig-
nal transduction. We have previously isolated an
Arabidopsis gene (GPA1) encoding a G-protein a
subunit (Ma et al., Proc. Natl. Acad. Sci. 87: 3821
[1990]), and we are continuing our characterization
of GPA1. We have recently obtained detailed in-
formation on its expression pattern, providing in-
sights into the possible function of GPA1.
Flower morphogenesis is a complex developmen-
tal process. In recent years, a number of Arabidopsis
floral homeotic genes have been characterized (Coen
and Meyerowitz, Nature 353: 31 [1991]). Mutations
in one of these genes, AGAMOUS (AG), cause
double-flower phenotypes, where the stamens are
converted to extra petals and the ovary is replaced by
a new flower. The AG DNA sequence (Yanofsky et
al., Nature 346: 35 [1990]) indicates that it encodes a
protein with strong similarity to the DNA-binding
domains of transcription factors from humans (SRF)
and yeast (MCM1), suggesting that the AG protein is
a transcription factor (Fig. 1). This domain is also
found in another floral homeotic gene, DEF A from
Antirrhinum majus (Sommer et al., EMBO J. 9: 605
[1990]), and has been referred to as the MADS-box
(Fig. 1) for MCM1-AG-DEFA-SRF (Schwarz-Som-
mer et al., Science 250: 931 [1990]). Additional
MADS-box genes were isolated using AG as a probe,
and designated AGL1 through AGL6 for AG-Like
(Fig. I; Ma et al., Genes Dev. 5: 484 [1991]). We
have been focusing our efforts on AG, AGL1, AGL2,
and AGL3.
The approaches we have taken to study the
MADS-box genes and GPA1 are summarized in the
1990 and 1991 Annual Reports. Two postdoctoral
fellows, H. Huang and C. Weiss, are the major forces
in the work on GPA1. They and two other postdoc-
toral fellows, C. Flanagan and Y. Mizukami, as well
as a technician, Y. Hu, are involved in various studies
on the MADS-box genes. In addition, C. Huang, a
graduate student in the Genetics Program, did a rota-
tion in our laboratory, working with H. Huang on AG
in vivo DNA-binding studies; R. Lavi was a
participant in the "Partners for the Future" program
for talented high school students, and he worked with
C. Weiss; R. Ram was an URP, and she worked on
analysis of wild-type and ag floral RNAs; M. Tudor
was an undergraduate student who performed in vitro
experiments with AG and AGL1 proteins. Here, we
describe our recent progress during the past year in
the area of GPA1 and MADS-box genes, as well as in
a collaborative effort to establish an enhancer/gene
trap transposon system in Arabidopsis thaliana.
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AGL1
AGLS
AGL3
AGL2
AGL4
AGL6
FIGURE 1 Schematic representation of AG and AGL proteins.The
MADS box and the K box are two
regions conserved in all of these proteins, whereas the interbox (I) and the carboxy-terminal
(C) regions
are only conserved between more similar members, as
represented by same type of shaded bars. The
open bars are not conserved. (Modified from Fig. 5A of Ma et al., Genes Dev. 5: 484
[19911.)
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Analysis of GPA1 Expression
Using a Translational Fusion
to a Reporter Gene
H. Huang, H. Ma
Because the developmental stage and localization of
expression may suggest what the function of a partic-
ular gene is, we are interested in characterizing the
temporal and spatial expression pattern of the GPA1
gene. The expression of many G proteins is known to
be regulated; for example, rod and cone transducins
are expressed specifically in rod and cone photo-
receptors, respectively, and the olfactory G protein is
expressed only in the olfactory epithelium. Previous
experiments indicated that GPA1 mRNA is found in
both vegetative and floral organs of Arabidopsis. To
obtain more detailed information about GPAI expres-
sion, we have constructed a translational fusion be-
tween the GPA1 genomic DNA and the bacterial
uidA gene (encoding glucuronidase, or GUS) and in-
troduced it into Arabidopsis plants via Agrobac-
terium-mediated transformation. We have carried out
histochemical analysis of the GPAI -uidA transgenic
plants (Huang et al., submitted [1993b]). Our results
show that GPA1 is expressed at root tips and
cotyledons as early as 32 hours after seed germina-
tion. Later in developing seedlings, GPA1 is ex-
pressed strongly in the shoot apex and in leaf primor-
dium, as well as in root tips and new roots. In fully
expanded cotyledons, rosette leaves, and cauline
leaves, GPAI is more highly expressed in the vas-
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cular system but can also be detected in other cells. In
floral stems of the adult plant, GPAI expression is
localized mainly in the phloem and xylem of the vas-
culature.
In floral buds and mature flowers, carpels exhibit
very strong GUS activity, and sepals and stamens
have weaker but detectable GPA1 expression. Final-
ly, GPA1 is also expressed in developing seeds, but
the expression diminishes gradually to undetectable
levels as the seeds mature. The fact that GPA1 is ex-
pressed in several tissues and at various stages sug-
gests that it may be involved in multiple signaling
processes.
Analysis of the Distribution of
the GPA1 Gene Product
C. Weiss, H. Ma
We have also characterized the distribution of the
GPAI gene product (GPal) more directly using anti-
GPal antibodies (Weiss et al. 1993). Results ob-
tained so far show that the GPal protein is expressed
in all tissues examined with the exception of mature
seeds. It is expressed in roots, cotyledons, rosette
leaves, cauline leaves, floral stems, flowers, seed-
pods, and during all stages of plant development. In-
terestingly, we have found that the level of GPal is
higher in immature organs (i.e., growing leaves)
compared to mature organs (full-size leaves). Im-
munolocalization results indicate that the GPa1
protein is localized predominantly in the vascular tis-
sues of mature organs, especially in the cambium and
phloem. In developing organs, GPa1 is present at a
higher level in the root, leaf, and floral meristems, as
well as in the leaf and floral organ primordia. During
flower development, dividing microspores, but not
mature pollen, show a high level of GPa1 protein.
GPa1 is also present in nectaries, in developing
ovules, and, during fertilization, in the growing pol-
len tube. After fertilization, it is present in developing
embryos as early as the globular stage and in the seed
coat. The results from these studies using antibodies
agree very well with the information obtained using
the reporter gene fusion (see above). Furthermore, the
antibody studies provide detailed information about
the GPa1 distribution during flower development and
early embryo development. The association of the
GPA1 gene product with highly dividing tissues sug-
gests that GPa1 in plants may be involved in cell
division regulation, but further efforts are necessary
to understand G-protein-mediated signal transduction
in plants.
Analysis of AGL3 Function
C. Weiss, H. Ma
Six members of the Arabidopsis MADS-box gene
family were previously identified and designated
AGL1 through AGL6. Among these genes, AGL3 is
unique in that it is not flower-specific; it is also ex-
pressed in vegetative tissues. We have recently isola-
ted and characterized the complete genomic and
cDNA sequences of AGL3 (Huang et al., submitted
[1993a]). To understand the role of AGL3 during
plant development, we analyzed AGL3 expression
using Northern and in situ hybridizations, and the
results show that AGL3 is expressed in rosette leaves,
floral stems, cauline leaves, and seedpods and at
lower levels in flowers, but it is not expressed in
roots. The fact that AGL3 is expressed in a number of
tissues suggests that it has a more general function
than its floral counterparts. To study AGL3 function,
transcriptional fusions between a constitutive promo-
ter and the AGL3- coding region, inserted in either
sense or antisense orientation, were constructed and
introduced into Arabidopsis. Preliminary results indi-
cate that overexpression of the AGL3 gene in the
sense orientation creates a novel phenotype. Com-
pared to wild-type plants, the transgenic plants show
larger and more numerous flowers, as well as short,
abnormal seedpods that contain fewer seeds than
wild-type plants, indicating partial sterility. The
transgenic inflorescence is also flatter than the wild-
type one, suggesting that cell elongation or division
might be affected in the pedicel of these flowers. On
the other hand, transgenic plants carrying an
antisense construct have no morphological defects,
but flower about 2-3 weeks later than wild-type
plants. These results suggest that the AGL3 gene pro-
duct might regulate a great number of target genes,
which may be involved in very different processes of
plant development.
Probing AG and AP2 Interaction
Using Transgenic Arabidopsis
Plants
Y. Mizukami, H. Ma
In ag mutant flowers, reproductive organs (stamens
and carpels) are converted to sterile perianth organs
(petals and sepals), and there is an increase in the
number of floral organs. In contrast, mutations in an-
other floral homeotic gene, AP2, cause the replace-
ment of the perianth organs by the reproductive
organs and the reduction of floral organ number.
Therefore, it has been proposed that AG negatively
regulates AP2 function. We have tested whether AG
inhibits AP2 function by ectopically expressing AG
under the cauliflower mosaic virus (CaMV) 35S
promoter in transgenic Arabidopsis plants. We have
constructed a fusion between the 35S promoter and
the AG cDNA and introduced the fusion into wild-
type Arabidopsis plants. Our results (Mizukami and
Ma 1992) show that many of the transgenic plants
produce ap2-like flowers, which have carpels or car-
pelloid organs in the first whorl. In addition, petals
and stamens are reduced in size and number or are
absent in some transgenic flowers, similar to the ap2
flowers. These results support the hypothesis that AG
negatively influences AP2 function. Using a homolog
of AG from Brassica (BAG1) to transform wild-type
tobacco plants, Yanofsky and colleagues obtained
similar results where ectopic expression of BAG1
leads to ap2-like flowers in the transgenic plants
(Mandel et al. 1992).
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Dissecting AG Functions Using
an Antisense Construct
Y. Mizukami, H. Ma
Genetic evidence indicates that AG is involved in
several aspects of floral morphogenesis: (1) negative
interaction with AP2, (2) organ identity in the inner
two whorls, and (3) determinacy at the center of the
flower. A few mutant alleles of AG have been
reported, and all of them have the same phenotypes.
To begin to dissect these roles, we sought to disrupt
AG function by using antisense RNA, which may
produce different levels of inhibition due to different
levels of antisense RNA. We constructed an AG
antisense fusion to the 35S promoter and introduced
it into wild-type plants. We have observed that trans-
genic plants with the AG antisense construct show a
wide range of phenotypes (Mizukami and Ma, in
prep. [1993]). Some have nearly normal flowers, with
sepals, petals, stamens, and carpels. However, after
more careful inspection, we have found that the ovary
is enlarged compared to wild type, and hand dissec-
tion revealed another flower, as well as seeds, within
the ovary. Furthermore, the inner flower has parts of
a third flower within its ovary. Therefore, in these
transformants, the level of AG activity allows the
morphogenesis of stamens and carpels to produce fer-
tile flowers, but it does not maintain the determinant
growth pattern of a normal flower. It is possible that
different aspects of AG function require different
amounts of AG activity.
Functional Analysis of the AG
Domains in Transgenic Arabidopsis
Y. Mizukami, H. Ma
Comparison of AG and other plant MADS-box gene
products indicates that the AG protein can be divided
into several regions, which may correspond to func-
tional domains. AG function may vary due to differ-
ential interaction with protein factors present at dif-
ferent stages and/or in different cells. The interac-
tions may or may not be mediated by different
domains in the AG protein. We have begun to dissect
the domains required for these functions by express-
ing truncated AG protein in transgenic plants and
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characterizing their effects in transgenic plants. Our
results from transgenic plants with a construct ex-
pressing a truncated AG protein lacking the most
carboxy-terminal domain show that the flowers from
most transgenic plants have an indeterminant pheno-
type (flower within a flower); a smaller subset of
these transgenic plants have abnormal carpel devel-
opment, and still fewer transformants have conver-
sion of stamens to petals, as in ag mutant flowers.
The range of floral phenotypes is similar to that
found in the transformants carrying the AG antisense
construct. Because a large majority of the trans-
formants have the ag-like phenotypes, cosuppression
is not a likely explanation. Rather, we believe that the
truncated AG protein somehow interferes with or in-
hibits the function of the wild-type AG protein. It is
possible that the truncated protein (containing the
MADS-box) can still bind AG target sites. Therefore,
the truncated AG may prevent wild-type AG from
functioning by competing for target sites. We are in
the process of analyzing the effects of other truncated
AG proteins.
AGL1 and AGL2 Are Differentially
Expressed during Flower
Development
C. Flanagan, H. Ma, Y. Hu
We have examined the expression patterns of two of
the MADS-box genes, AGL1 and AGL2, to obtain
clues about their functions. RNA dot-blot hybridiza-
tions showed that AGL1 and AGL2 are both flower-
specific genes (Ma et al., Genes Dev. 5: 484 [1991]).
To characterize the temporal and spatial expression
pattern of AGL1 in more detail, we have used RNA in
situ hybridization analysis with gene-specific ribo-
probes. Our results indicate that AGL1 expression
arises late in flower development (stages 9-10) and is
restricted to the camels. Furthermore, during stages
11 and 12 of flower development (stage 12 is the last
stage before the mature bud opens), AGL1 expression
is concentrated in the developing ovules and in the
regions of the carpel walls where the two carpels fuse
to form the ovary (Fig. 2). Finally, AGL1 is highly
expressed in the nectaries. The AGL1 expression pat-
tern indicates that AGLI is probably involved in the
development of the maturing carpel and of ovules.
We have also performed RNA in situ hybridization
analysis on wild-type floral sections using an AGL2
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FIGURE 2 RNA in situ analysis of the AGL1 gene. (A-C) Bright field; (D-F) dark
field. Flowers of stages 5-8 are shown in A and D, where no AGL1 expression is
detected. At stage 12 (B and E) and stage 13 (C and F), AGL1 is expressed in
the ovules. The floral organs are S, sepal; P, petal; T, stamen; A, anther; F, fila-
ment; C, carpel; and 0, ovule. (Adapted from Fig. 7 of Ma et al., Genes Dev. 5:
484 [19911.)
gene-specific riboprobe. AGL2 expression begins ear-
ly in flower development (at stage 2), before the
onset of AG or AP3 expression but after that of API,
a homeotic gene involved in the transition from in-
florescence to floral meristem. AGL2 expression is
ubiquitous and uniformly high in floral primordia and
floral organ primordia between stages 2 and 7. How-
ever, the expression of AGL2 becomes organ-specific
during later stages of flower development. At stage 8,
AGL2 expression begins to wane in the sepals but
remains high in the other organs. Later, during stages
9-10, AGL2 expression remains high in the carpel,
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petals, and (to some extent) filaments, whereas ex-
pression is reduced in the sepals and anthers. By
stage 12, AGL2 expression is localized primarily to
the ovules. After pollination, the expression of AGL2
remains detectable in the developing seeds, but it
gradually decreases. That AGL2 expression arises
very early in flower development and is expressed in
all parts of the young bud is extremely interesting.
This pattern is different from the expression patterns
of several homeotic genes (e.g., AG and AP3), which
reveal expression in only two of the four floral organ
whorls. Only the AP1 gene is expressed earlier than
AGL2 (at stage 1) and in all cells of floral meristems.
However, in stage-3 and later flowers, AP1, like the
other homeotic genes, is expressed only in two
whorls. Thus, the role of the AGL2 gene product in
flower development is likely to be more general than
that of the homeotic genes AG and AP3, and perhaps
as important in early flower development as AP1,
which is required for converting inflorescence
meristems to floral meristems.
Additional in situ RNA hybridization experiments
with AGL4- and AGL5-specific probes are in prog-
ress. Preliminary results indicate that like AGL1,
AGL5 is expressed only in carpels. Further analysis
will be done with the AGL1, AGL2, AGL4, and AGL5
probes.
Expression of the AGL Genes
in Mutant Flowers
C. Flanagan, H. Ma, Y. Hu
The MADS-box gene family contains homeotic
genes (AG, AP1, AP3), as well as a number of other
flower-specific genes of unknown function (AGLs).
Because the sequence of these genes suggests that
they are all transcription factors, we think it is likely
that they are involved in a regulatory hierarchy con-
trolling flower development. To begin to understand
the functional relationship between the homeotic
genes and the AGLs, we are characterizing the ex-
pression pattern of the AGL genes in the various
homeotic mutant flowers by RNA in situ hybridiza-
tion analysis.
Analysis of the expression pattern of AGL2 in an
ag mutant flower suggests that AGL2 is not regulated
by AG. In ag mutant flowers, anthers and carpels are
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replaced by a second set of petals and another flower,
respectively. AGL2 expression arises very early and
is ubiquitous in young ag buds, as in young wild-type
buds. In later-stage ag flowers, AGL2 expression is
higher in both sets of petals than in the sepals. The
flower primordia of the secondary flower also shows
high AGL2 expression, whereas at later stages of the
secondary flower, AGL2 expression is reduced in the
sepals but remains high in the petals, as in the pri-
mary flower. Thus, AGL2 expression is regulated in a
stage- and organ-specific manner rather than in a
manner specific to the position within the flower (i.e.,
which whorl).
Northern analysis demonstrated that AGL1 and
AGL5 are not expressed in ag mutant flowers (M.
Yanofsky, pers. comm.). Therefore, the interesting
possibility arises that these two AGL genes are target
genes of AG. However, because both of these genes
are only expressed in the carpels, it is also possible
that their lack of expression in ag mutants is more in-
direct, since ag mutants lack carpels. Further analysis
will be required to distinguish between these pos-
sibilities.
In situ RNA hybridization analyses are in progress
to determine the expression patterns of AGL1 and
AGL2 in apl and ap2 mutant flowers.
Characterization of AG Target
Sequences
H. Huang, Y. Mizukami, Y. Hu, H. Ma
The deduced AG amino acid sequence shares sub-
stantial similarity with the DNA-binding domains of
known transcription factors SRF and MCM1, sug-
gesting that AG is also a transcription factor. To test
whether AG is a sequence-specific DNA-binding
protein and to determine the sequence(s) of AG target
sites, we have performed in vitro DNA-binding
studies. To obtain relatively large amounts of AG, we
constructed an Escherichia coli overexpression plas-
mid. After screening pools of random oligonucleo-
tides, it was found that the consensus for SRF-
binding sites is CC(A/T)6GG (Pollock and Triesman,
Nucleic Acids Res. 18: 6197 [1990]). We first tested
the ability of AG to bind one of these sequences,
CCATTAATGG, using a gel mobility shift assay,
and we found AG indeed binds this sequence. As a
control, we performed a parallel binding experiment
with the sequence GGATGCATCC, and the result
was negative. It has been shown that although SRF
and MCM1 can bind to some of each other's natural
target sites, they have different spectra of binding
sites. The consensus for MCM1 is CC(T/C)
(A/T)3NNGG, determined after screening pools of
random oligonucleotides (Wynne and Triesman,
Nucleic Acids Res. 20: 3297119921). To characterize
the spectrum of AG target sites, we screened for AG-
binding sequences among a pool of random
oligonucleotides, essentially as described by Pollock
and Treisman. A pool of random single-stranded
oligonucleotides each having constant ends of 25
bases and a variable center of 26 bases was converted
to double-stranded sequences. The pool of sequences
was subjected to binding with AG, and the DNA-
protein complexes were separated from unbound
DNA using PAGE. The shifted band was cut out and
the bound oligonucleotides were eluted for polymer-
ase chain reaction (PCR) amplification. The PCR
products were then used for a subsequent round of
the AG-binding reaction. After five such rounds, the
PCR products were cloned and analyzed by DNA se-
quencing. From 95 sequences, we find that the AG-
binding site sequences are more similar to the MCM1
than the SRF target sequences, with a consensus of
C93C91(A5 /T33)(A60/T21)(A68/T25)(T59/A29)(T40/
A26)NG78G83. Knowing the AG target sequences, we
hope to find natural AG target genes in Arabidopsis
thaliana.
Toward Establishing an
Enhancer/Gene Trap
Transposon System
in Arabidopsis thaliana
H. Ma, Y. Hu [in collaboration with V. Sundaresan and
R. Martienssen, Cold Spring Harbor Laboratory]
We have continued our experiments to develop an
enhancer/gene trap transposon mutagenesis technol-
ogy, using the maize Ac /Ds transposon system. En-
hancer/gene trap systems have been successfully used
to identify genes with interesting expression patterns
and/or phenotypes in Drosophila and mice. During
the past year, we have worked with Sundar and Rob
to characterize the transgenic lines carrying the Ac
and Ds constructs (for more details on the constructs
and their introduction into plants by Agrobacterium-
mediated transformation, see Plant Genetics in last
year's Annual Reports from V. Sundaresan and R.
Martienssen and from our laboratory). Crosses were
done to test the activity of Ac in our transgenic lines,
the ability of Ds elements to transpose, and the
feasibility of the Nam/Kan double selection scheme
(for a more detailed description, see Plant Genetics in
last year's Annual Report). The homozygous lines
that have been shown to contain active Ac have been
crossed to those carrying either the enhancer-trap or
gene-trap Ds. Several hundreds of Fl seeds have
been planted and F2 seeds have been collected from
them. We will soon select for lines (transposants) that
have inherited a transposed Ds and analyze them for
expression patterns and mutant phenotypes.
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CELL CYCLE CONTROL IN SACCHAROMYCES CEREVISIAE
B. Futcher B. Elliott R. Nash
I. Fitch F. Stincone
M. Linskens G. Tokiwa
L. Littlepage M. Tyers
Our main interest continues to be the regulation of
START in Saccharomyces cerevisae. We are most
interested in the tethering of division to cell growth
and in the generation of the basic cell cycle oscilla-
tion. The G1 cyclin genes CLN1, CLN2, and CLN3
encode unstable proteins that form a central part of
the machine that measures growth and generates os-
cillations.
CLN3 Is an Upstream Activator
of Other Cyclins
M. Tyers, G. Tokiwa, B. Futcher
We have proposed that CLN3 helps to activate CLN1,
CLN2, and other G1 cyclins (Fig. 1). This may occur
by activation of the Swi4 and Swi6 transcription fac-
tors that are part of a positive feedback loop needed
for transcription of CLN1 and CLN2. The "other" G1
cyclins are collectively called "ClnX" in Figure 1. In
the past year, several candidates for the "other" G1
cyclins have been identified. One is HCS26, a cyclin
homolog identified (Ogas et al., Cell 66: 1015
[1991]) as a suppressor of a swi4 mutation. Another
is CLB5, a B-cyclin homolog identified by Epstein
and Cross (Genes Dev. 6: 1695 [1992]) as a suppres-
sor of clnl cln2 cln3 lethality. A third is ORFD, an
HCS26 homolog identified fortuitously during the se-
quencing of another gene. At least two more cyclin
homologs have been identified very recently.
A clnl cln2 cln3 triple mutant arrests in G1 phase.
We predict from the model (Fig. 1) that in a clnl cln2
double mutant, "CLNX" activity should be dependent
on CLN3. We tested this for HCS26, ORFD, and
CLB5. A strain with genotype GAL-CLN3 clnl cln2
was constructed. This strain is alive on galactose me-
dium, because CLN3 is expressed from the GAL
promoter, but is dead on glucose. As shown in Figure
2, this strain expressed HCS26, ORFD, and CLB5
only on galactose medium, where GAL-CLN3 was
on. Thus, the prediction was fulfilled, and the depen-
dence of HCS26, ORFD, and CLB5 expression on
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CLN3 in the clnl cln2 background can explain why
viability depends on CLN3. Interestingly, transcrip-
tion of SWI4 also seems to be dependent on the posi-
tive feedback loop.
Fart and Fus3 Link the Mating
Pheromone Signal Transduction
Pathway to the Clnl, Cln2, and
Cln3 Cdc28 Kinase Complexes
M. Tyers, B. Futcher
Cln 1, Cln2, and Cln3 are found in complexes with
the Cdc28 catalytic subunit, and the complexes have
protein kinase activity. The Cln1 and Cln2 complexes
coprecipitate proteins of 41, 94, and 116 kD, and
these coprecipitated proteins are phosphorylated by
the Cln-Cdc28 kinase complex in vitro. The Cln3-
Cdc28 complex has a coprecipitated substrate of 45
kD. These coprecipitated substrates are candidates for
proteins important in directly mediating START, and
so we have made attempts to identify them.
Pheromone
Cln3
Clnl Cln2 CInX
Start
Th
Swi4, Swi6
FIGURE 1 Model for activation of START. Cln3 activates
Cln 1 Cln2, and other 'downstream" cyclins, which in turn
activate START. Cln3 is weak but constitutive and may ac-
tivate downstream cyclins through the Swi4 and Swi6 tran-
scription factors. The downstream cyclins then participate in
the Swi4,6 positive feedback loop. In the absence of CLN1
and CLN2, CLN3 is essential because it becomes an essen-
tial activator of HCS26, ORFD, CLB5, and perhaps other
cyclins (collectively, CInX). Since CLN3 is not essential in a
wild-type background, there must be CLN3-independent
mechanisms for transcription of CLN1 and CLN2.
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FIGURE 2 CLN3 is required for transcription of HCS26,
ORFD, and CLB5 in a cln1 cln2 strain. A control CLN1 CLN2
CLN3 strain ( "wt") and a clnl cln2 GAL-CLN3 strain (all other
lanes) were grown in galactose medium to induce the GAL
promoter. At zero time, the galactose was removed; 300 min
later, the cells of the experimental strain had arrested at
START, and the HCS26, ORFD, and CLB5 transcripts had
disappeared (despite the fact that START is the point of
maximal transcription of these genes in a wild-type strain).
At 303 min, galactose was added back to the culture. The
resulting burst of GAL-CLN3 expression induced expression
of the other cyclin genes, resulting in passage through
START by about 340 min (by which time, GAL-CLN3 had
been shut off by addition of glucose, which represses the
GAL promoter). None of these genes are galactose-
regulated in a wild-type cell. The actin mRNA is shown as a
loading control.
We have identified the 116-kD substrate as the
Farl protein by three criteria. First, when the Cln-
Cdc28 complexes were immunoprecipitated and p116
was 32P-labeled using the in vitro kinase reaction, the
labeled p116 could be reimmunoprecipitated with an
anti-Farl antibody. Second, when Cln-Cdc28 com-
plexes were immunoprecipitated with an anti-tagged-
Cln antibody, Fan could be detected in the im-
munoprecipitates with the anti-Far1 antibody. Third,
farl deletion mutants had no trace of p116.
Farl is a protein required for cc-factor-induced G1
arrest (Chang and Herskowitz, 1990), and so proba-
bly helps inactivate Cln-Cdc28 complexes. When we
treated cells with a-factor, the amount of Fan associ-
ated with the Clnl and Cln2 complexes increased
tremendously. This increase was noticeable by 5
minutes of treatment. Shortly thereafter, the amount
of Clnl and Cln2 protein decreased sharply, pre-
sumably because of increased turnover, and the Clnl-
and Cln2-dependent kinase activities disappeared. a-
factor also caused Farl to associate with Cln3, al-
though in this case, there was no loss of either Cln3
protein or its associated histone H1 kinase activity.
The a-factor-induced association of Farl with the
three Clns was largely dependent on the FUS3 gene
(e.g., Fig. 3). FUS3 encodes a protein kinase of the
MAP kinase family. M. Peter, A. Gartner, G. Am-
merer and I. Herskowitz (submitted) have recently
shown that Fus3 directly phosphorylates Far1. Thus,
a likely chain of events is that a-factor activates Fus3
kinase, which phosphorylates Farl, which then asso-
ciates with the Cln-Cdc28 complexes, somehow
causing proteolysis and inactivation. This is the first
clearly traced path between a MAP kinase and a cdc2
kinase.
Proteolysis of Cin3 and the
PEST Hypothesis
M. Linskens
THE PEST HYPOTHESIS
The Cln3 protein is very unstable, with a half-life of
2-10 minutes. However, a truncated version of the
protein, Cln3-1, which makes cells small and a-
factor-resistant, is relatively stable. The stabilized,
truncated version lacks the carboxy-terminal third of
Cln3. This third contains regions extremely rich in
proline, serine, and threonine. These have been called
PEST regions and are thought on the basis of their
presence in a variety of unstable proteins to be sig-
nals for proteolysis (the "PEST hypothesis"). Further-
more, the Clnl and C1n2 proteins, which are also un-
stable, also have PEST regions.
To determine whether the PEST regions are im-
portant for the instability of Cln3, we made a set of
+nested deletions from the 3' end of the gene. The
steady-state abundance of the protein and the protein
half-life increase gradually as the PEST regions are
removed (Fig. 4). This result is consistent with the
PEST hypothesis, as well as with other possibilities.
We tried to define the signals for proteolysis more
precisely by adding back artificial sequences to stable
forms of truncated Cln3. Many different short se-
quences destabilized the protein, so we were unable
to discover any specific signal by this method.
THE LIN PHENOTYPE
The 3' CLN3 deletion mutants all ended in unnatural
amino acids. In one of the reading frames, the last
three amino acids were Leu-Ile-Asn-COOH (LIN).
Every one of these LIN alleles behaved as a null al-
lele (none of these alleles are included in Fig. 4).
When the frame of the last few bases of the open
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FIGURE 3 a-factor-induced interaction of Fart with Cln3
depends on FUS3. Various wild-type and mutant cultures
were grown in the absence or presence of a-factor. Cell ex-
tracts were immunoprecipitated with the 12CA5 monoclonal
antibody directed against a triple epitope tag at the carboxy
terminus of Cln3. An in vitro kinase reaction was carried out
with the immunoprecipitated Cln3-Cdc28 complexes, 32P-
labeled ATP, and histone H1. Labeled products were sepa-
rated by SDS-PAGE before autoradiography. The phosphor-
ylated Fart (p116), Cln3, and histone H1 (H1) bands are in-
dicated. The KSS1 gene encodes a protein kinase some-
what homologous to that encoded by FUS3.
Phenotype of some CLN3 C-terminal
deletion-mutants
UNTAGGED Triple-HA
CLN3 TAGGED CLN3
Functional CLN3 Cell amount of protein
(complementation volume protein half-life
of triple cln.) (gm3) (arbit. units) (min.)
44 -2 <2.5
52 -5
-2.5
51 -5
45 10-15
-5
37
35 50-100 -15
33
36 30-50 -10
33 100 -20
35
37
51
54
54
54 0
reading frame was shifted to either of the other two
frames, yielding amino acids other than LIN, the
mutant proteins regained activity. It is as if
carboxy-terminal LIN prevents the protein from
working. This could happen if, for instance, LIN effi-
ciently targeted Cln3 to some inappropriate compart-
ment. There is no known yeast protein ending with
LIN.
Mechanisms of Heat-shock
Resistance
B. Elliott
Although many proteins are induced by heat shocks,
it is not clear how these induced proteins are involved
in heat-shock resistance. In most cases, mutational in-
activation of a heat-shock-induced gene does not
cause cellular heat-shock sensitivity. To find out
about mechanisms of heat-shock resistance, we
looked for mutants that lacked induced heat-shock
resistance. So far, two mutants have been extensively
characterized and the genes have been cloned. Nei-
ther mutant is in the cAMP/Ras pathway, since their
phenotypes are unaffected by a wimp background.
as # 350 400
It *
CLN3-1
500
***
550
I* = (S/T) P
(cdc28)
365
- 352
- - - 345
Acln3
404
394
384
457
447
442
41
478
526
514
phenotype like wt Aaa440-456
phenotype like wt changes of T(444), S(447), S(449) to A or G
FIGURE 4 Effects of PEST deletions on Cln3 protein half-life. The effects of
carboxy-terminal truncations of the Cln3 proteinare shown. High levels of Cln3 cause small cell size. Asterisks show positions of potential sites (TP or SP) for phosphoryla-tion by Cdc28. The effects of different truncations on half-life are loosely correlated with the amount of PEST each trunca-tion removes.
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One gene, COX10, has been previously sequenced.
Our cox10 mutant was partly deficient in stationary-
phase-induced heat-shock resistance and also partly
deficient in heat-shock-induced heat-shock resis-
tance. The COX/0 gene has previously been impli-
cated in assembly of the cytochrome oxidase com-
plex. Although cox10 mutants are therefore petite
(deficient in respiration), other petite mutants are not
deficient in heat-shock resistance. Perhaps the Cox10
protein is a molecular chaperone that helps fold or as-
semble several proteins, not just cytochrome oxidase,
and this is important for induced heat-shock resis-
tance.
The other gene, HSSI (heat-shock-sensitive), has
not been previously sequenced. The hssl mutant was
totally deficient for induced heat-shock resistance.
The gene is somewhat homologous to the CIFI/
FDPI gene of yeast. CIF1IFDP1 is thought to en-
code a subunit of trehalose-6-phosphate synthase, and
cif7 Ifdp1 mutants are heat-shock-sensitive. It may be
that HSSI is also involved in trehalose synthesis. In
yeast, high levels of intracellular trehalose are ex-
tremely well correlated with high levels of heat-shock
resistance. This may mean that trehalose is a primary
cause of heat-shock resistance. Alternatively, it may
mean that regulation of trehalose synthesis is in-
timately linked to regulation of heat-shock resistance.
New mutant alleles of HSS1 along with measure-
ments of trehalose content may distinguish these pos-
sibilities.
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TRANSCRIPTION AND CELL CYCLE REGULATION IN YEAST
K.T. Arndt A. Sutton A. Doseff M. Luke
C. Devlin M.J. Fernandez-Sarabia T. Zhong
C. DiComo F. Lin
We are using the yeast Saccharomyces cerevisiae to
investigate two basic cellular processes: regulation of
transcription by RNA polymerase II and regulation of
commitment for entry into the cell cycle.
Genetic Selection Schemes
for General Transcription Factors
C. Devlin
In the yeast Saccharomyces cerevisiae, three
proteins, BAS I, BAS2, and GCN4, bind to the HIS4
promoter to activate transcription of the HIS4 gene. A
strain containing deletions of BAS1, BAS2, and GCN4
has a His phenotype due to insufficient transcription
of HIS4. An additional protein, RAP1, also binds to
the HIS4 promoter but is not by itself able to activate
transcription of HIS4. At HIS4, RAP1 functions to
phase nucleosomes away from the GCN4-, BAS1-,
and BAS2-binding sites so that these sites are acces-
sible when present within chromatin. Our research
objectives with HIS4 can be divided into two main
areas: One area studies the details of how BAS1,
BAS2, GCN4, and RAPT function for activation of
HIS4 transcription. The second area of research uses
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the HIS4 promoter for genetic selection
schemes to
isolate mutations in genes whose products
function in
transcription. To identify mutations in genes encod-
ing general transcription factors, we isolated His
revertants of a strain containing deletions of BAS1,
BAS2, and GCN4. From these studies, we obtained
the sit/ through sit12 mutations. The sit mutations
cause a strong growth defect and therefore occur in
genes required for normal cellular growth. So far, the
sit mutations have altered either RNA polymerase II
(sitl or sit2), nucleosomes (sit5), and a factor (sit4)
that may regulate a general transcription factor or
chromatin.
We are presently analyzing the sit7 and sit10
mutations for their global transcriptional alterations
and have cloned the corresponding wild-type SIT7
and SIT10 genes.
SIT4 Protein Phosphatase
and Regulation of
G1 Cyclins
M.J. Fernandez-Sarabia, C. Di Como, A. Sutton
The SIT4 gene predicts a protein that is 55% identical
to the mammalian type-2A and 43% identical to the
mammalian type-1 protein phosphatase catalytic sub-
units. However, the SIT4 protein phosphatase is a
unique phosphatase (distinct from the S. cerevisiae
type-1 and type-2A phosphatases) that is required in
late G1 for passage through START. START is a
place in the late G1 phase of the cell cycle where
nutrients and mating signals exert control over entry
into the cell division cycle. Once cells have passed
(or "executed") START, they are committed for DNA
synthesis and cell division.
SIT4 coimmunoprecipitates with two high-molec-
ular-mass proteins, termed p155 and p190. The asso-
ciation of SIT4 with p155 and p190 is cell-cycle-
dependent. In G1 daughter cells, SIT4 is not associat-
ed with p155 and p190. At a time very close to (or at)
START, SIT4 associates in separate complexes with
p155 and p190. SIT4 remains associated with p155
and p190 until about the middle or end of mitosis.
Therefore, SIT4 associates with p155 and p190 very
close to the time that SIT4 executes its function. In
our model, p155 and p190 proteins are regulatory
subunits of SIT4 that target SIT4 to the proper sub-
strates or regulate the substrate specificity of SIT4.
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TRANSCRIPTION OF THE G1 CYCLINS
Because SIT4 is required for the execution of
START, we examined whether other known proteins
required for the execution of START are altered in
sit4 mutants. Known proteins that are required for the
execution of START are the G1 cyclins and the
CDC28 kinase. The G1 cyclins associate with the
CDC28 kinase catalytic subunit. In other organisms,
there is some evidence that cyclins are required for
the kinase activity of cdc2 (equivalent to CDC28 of
budding yeast). In budding yeast, the G1 cyclins fall
into two groups. Group 1 is composed of the SW/4..
dependent G1 cyclins CLN1, CLN2, and HCS26. The
mRNA and protein levels of these G1 cyclins vary
greatly during the cell cycle. In early G1, the mRNA
and protein levels of the group-1 cyclins are very
low. During G1 (especially mid and late G1), the
mRNA levels of the group-1 cyclins increase at a
nearly exponential rate, reaching a maximal level in
late G1, at a time very close to (or at) START. After
START has been executed, the mRNA and protein
levels of the group-1 cyclins rapidly decrease. Tran-
scription of the group-1 G1 cyclin genes requires the
SWI4 transcription factor, which binds to the
promoter of group-1 cyclin genes. G1 cyclin group 2
has only one known member: CLN3. Although CLN3
mRNA levels vary somewhat during the cell cycle,
CLN3 mRNA (and possibly CLN3 protein) is present
throughout the cell cycle. In addition, transcription of
CLN3 is not SWI4- dependent.
Many experiments in our laboratory have shown
that the SIT4 protein phosphatase is required for the
normal accumulation of the SWI4-dependent group-1
cyclin mRNAs (CLN1, CLN2, and HCS26) during
late G1. In contrast, SIT4 is not required for the tran-
scription of CLN3. A model for the role of SIT4 for
the transcription of CLN1, CLN2, and HCS26 is
shown in Figure 1. At some time during late G1, the
levels of CLNI and CLN2 RNAs increase dramatical-
ly. This late G1 increase in the levels of CLN1 and
CLN2 RNAs requires at least one functional CLN
gene (either CLN1, CLN2, or CLN3) and is stimu-
lated by the hyperactive CLN3-1 or CLN3-2 muta-
tion. In addition, the late G1 increase in the levels of
CLN1 and CLN2 RNAs requires the CDC28 kinase.
These results (from the laboratories of F. Cross and
K. Nasmyth) suggested that the CLN genes and
CDC28 jointly function via a positive feedback loop
for stimulating the late G1 accumulation of CLN1 and
CLN2 RNAs. The targets of the CLN1/CDC28,
CLN2/CDC28, and CLN3/CDC28 kinases in this
Signals?
No CLN1
No CLN2
No HCS26
+ An Additional
Function
+ 1- (Essential)
SSD19pathway
/1-;-
CLN3/CDC28
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CLN1 CLN2 and HCS26
CLN1 and CLN2 (HCS26?)
CDC28
Early G1 Late G1
FIGURE 1 Model for SIT4 function in late G1.
feedback loop are not known and are included in the
black box. These substrates could be the
CLN/CDC28 complexes themselves, the SWI4 and
SWI6 transcription factors, and/or some other cur-
rently unknown factor. In Figure 1, the arrow for
SIT4 function points toward SWI4 within the black
box because SIT4 is required for the accumulation of
CLNI , CLN2, and HCS26 RNAs at least partly be-
cause SIT4 is required for the accumulation of SWI4
RNA. In fact, the mechanism giving rise to the in-
crease in SWI4 mRNA levels may be part of the same
positive feedback loop that gives increased transcrip-
tion of CLNI, CLN2, and HCS26 RNAs. The CLN3
pathway and the CLN1, CLN2, HSC26 pathways for
stimulation of CLNI, CLN2, HSC26 transcription
may also function via SWI4.
Since SIT4 is required for SWI4 function, our
model predicts that sit4 mutations should behave like
swi4 mutations (at least for certain functions). A
number of tests of this model have been made, all of
which support the model. One test is the following: A
cell can survive on CLN1 (in the absence of CLN2
and CLN3), on CLN2 (in the absence of CLN1 and
CLN3), or on CLN3 (in the absence of CLNI and
CLN2). However, a cell cannot survive in the ab-
sence of CLN1, CLN2, and CLN3. For this reason,
deletion of SWI4 (gives lower levels of CLN1 and
CLN2 mRNAs) combined with a deletion of CLN3
results in an extremely slow growth rate. Our model
predicts that sit4 mutants should also be more depen-
dent on the function of CLN3, whose transcription
does not depend on SIT4. That sit4 Acln3 cells are al-
most inviable supports the model. Therefore, in this
genetic test (near inviability in combination with
deletion of CLN3), sit4 behaves like swi4 mutants. A
further prediction of the model is that if the CLN2-
coding sequences are transcribed from a promoter
that does not depend on SIT4 (or SWI4), then CLN3
should be dispensable in a sit4 mutant strain. These
experiments show that the requirement of a sit4
mutant for CLN3 is completely eliminated if CLN2 is
expressed from a promoter that is not SIT4 (or SWI4) -
dependent. Moreover, the requirement of a sit4
mutant for CLN3 is completely eliminated if SWI4 -
coding sequences are expressed from a promoter that
is not SIT4- dependent Other tests also suggest that
the requirement for SIT4 in transcription of CLNI,
CLN2, and HCS26 is at least partly via the require-
ment for SIT4 in the expression of SWI4. The me-
chanism that determines when, and the rate at which,
the RNA levels of CLN1, CLN2, and HCS26 (and
SWI4) increase during G1 is central to the cell's deci-
sion to enter the cell division cycle. That SIT4 is re-
quired for this mechanism and that SIT4 associates
with p155 and p190 at a point in late G1 very close to
START suggest that the SIT4 phosphatase is part of
the mechanism that regulates the timing of START.
DESTRUCTION OF THE G1 CYCLINS
After START has been executed, the mRNA and
protein levels of CLNI and CLN2 decrease dramati-
cally. Interestingly, not only is SIT4 required for the
normal expression of CLNI, CLN2, and HCS26, but
it is also required for the normal disappearance of
CLN2 (and possibly CLN1 and HCS26). Normally,
at the nonpermissive temperature, sit4 mutants arrest
in late G1 with very low levels of CLNI and CLN2
(mRNA or protein) and with a In DNA content. This
is because SIT4 is required for the late G1 transcrip-
tion of CLNI and CLN2 and the execution of
START. However, if CLN2 is expressed from a
promoter that is SIT4-independent, then the sit4
mutants arrest with high levels of CLN2 and with a
2n DNA content. Therefore, the requirement for SIT4
for the initiation of DNA synthesis is via the require-
ment for SIT4 for expression of CLN2 (and probably
CLNI).
The CLN2 (expressed from a non-SIT4-dependent
promoter) present in the sit4-arrested cells is hyper-
phosphorylated and has a high associated kinase ac-
tivity. When these sit4-arrested cells are released
from the sit4 block (by returning to the permissive
temperature), the CLN2-associated kinase activity
decreases rapidly, followed very closely by the dis-
appearance of the CLN2 protein. In vitro, the SIT4
PPase not only dephosphorylates CLN2, but also
mediates the destruction of the CLN2 present in
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CLN2 immunoprecipitates (as assayed by Western
analysis of the immunoprecipitates for CLN2). The
SIT4-mediated destruction of CLN2 in vitro requires
the phosphatase activity of SIT4, because addition of
okadaic acid to the reactions prevents the destruction
of CLN2. In addition, the SIT4-mediated destruction
of CLN2 requires that CLN2 have a particular
phosphorylation state. Pretreatment of the CLN2 with
a nonspecific phosphatase removes all of the
phosphates of CLN2 (and CLN2 remains stable after
this treatment). Moreover, subsequent addition of
SIT4 to the fully dephosphorylated CLN2 causes no
destruction of the CLN2.
The results presented above indicate that CLN2 is
probably a direct substrate of SIT4. Presently, we do
not know if the protease that destroys CLN2 comes
from the added SIT4 or if SIT4 activates a protease
that coimmunoprecipitates with CLN2. Our current
studies are designed to identify the phosphoserine or
phosphothreonine residue on CLN2 that SIT4
dephosphorylates and to examine the in vivo con-
sequences (stability, kinase activity, and the effects
on START) of alterations of this residue.
Our results raise the possibility that SIT4 controls
two aspects of CLN2 function. First, SIT4 could
regulate the rate of increase of CLN2 RNA and con-
trol the timing of START. Second, after START has
been executed, SIT4 could regulate the disappearance
of the CLN2/CDC28 kinase via the destruction of
CLN2. The cells may require inactivation of the
CLN2 kinase for normal cell cycle progression and
that this process correspond to a late G1 check point.
Since SIT4/p155 and SIT4/p190 most likely regulate
different processes, future experiments with SIT4
will require reagents so that the specific functions of
SIT4/p155 and SIT4/p190 can be separated and iden-
tified. One form of SIT4 could regulate transcription
of CLN2, and the other form of SIT4 could regulate
destruction of CLN2.
Analysis of the Role of the SSD1
Protein in the Yeast Cell Cycle
A. Sutton
In certain strain backgrounds, deletion of SIT4 is
lethal, and temperature-sensitive sit4 strains arrest in
late G1 at the nonpermissive temperature. However,
in other strain backgrounds, deletion of SIT4 results
in viability, although the strains grow very slowly.
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The viability or inviability of a strain containing a
deletion of SIT4 is due to a single unlinked genetic
locus, termed SSDI. Alleles of SSDI that result in
viability in combination with a deletion of SIT4 are
called SSDI -v alleles; alleles that result in death
when combined with a deletion of SIT4 are called
ssdl-d alleles. Deletion of SSDI by itself results in
only subtle phenotypic effects, but many lines of ge-
netic evidence implicate SSDI in G1 regulation. The
allele of SSDI that suppresses the lethality caused by
deletion of SIT4 has recently been found to also sup-
press phenotypic defects caused by mutations in a
wide variety of pathways. For example, SSD1-v is
able to suppress the lethality of a strain containing
deletions of the CLN1 and CLN2 genes, the heat-
shock sensitivity of strains containing mutations in
the RAS/cAMP pathway, the temperature sensitivity
of strains containing mutations in the protein kinase
C pathway, and the temperature sensitivity of strains
containing mutations in subunits of RNA polymerase
C (III). There is no obvious connection among these
diverse mutations. However, in each pathway, phos-
phorylation and dephosphorylation play key regula-
tory roles. Therefore, the possibility exists that SSD1
functions by interacting with either a phosphatase or
kinase common to all of the above pathways. To ad-
dress this, we have looked for phosphatase and kinase
activities in immunoprecipitates of SSD1. To date,
we have been unable to detect either activity associa-
ted with SSD1. However, such activities may be very
weak, as the levels of SSDI transcript and protein in
the cell are very low.
To help elucidate the cellular role of SSD1, we
recently set up a genetic screen to identify other
genes whose products function in the SSD1 pathway.
In a strain containing ssdl-d, SIT4 is essential. In an
SSD1-v strain, loss of SIT4 function does not cause
lethality. We created a strain in which SIT4- coding
sequences are under the control of the GAL10
promoter (pGAL-SIT4) and which has an SSD1-v al-
lele. When grown on galactose medium, this strain
grows very well because SIT4 is expressed. When
grown on glucose medium, SIT4 is not expressed, but
the strain is viable because of SSD1-v. If either
SSD1-v or any gene required for SSDI -v function is
mutated, then this strain will be alive on galactose but
dead on glucose. We mutagenized the pGAL-SIT4
SSD1-v strain with ethylmethanesulfonate (EMS) and
looked for mutants that are alive on galactose but
dead on glucose. As predicted, we obtained mutations
in SSD1-v. In addition, we obtained an additional
nine mutations that fall into eight complementation
groups (therefore, we have not saturated the genome).
The wild-type genes for these mutations are being
cloned by their ability to rescue the lethality on
glucose. These genes are called PDL1-8 (for
phosphatase-deficient lethality). The pdll mutation
lies in a previously identified gene, CHS1. CHS1 en-
codes a chitin synthase enzyme and is believed to be
required for repair of the cell wall after budding. We
have some evidence from other studies that impli-
cates both SSD1-v and SIT4 in the budding process,
and isolation of CHS1 as a synthetic lethal with SIT4
provides additional support for this. PDL2 and PDL3
have been cloned, and sequence analysis of these
clones as well as the cloning of additional PDL genes
is under way. We hope that the analysis of these
genes will allow us to determine the function of
SSD1. The results from this approach may also pro-
vide insight into the role of the SIT4 phosphatase in
the cell cycle.
A Genetic Search for the SIT4
Regulatory Subunits
A. Doseff
In an otherwise wild-type cell, the SSD1 gene is dis-
pensable. Cells containing a deletion of SSD1 have a
growth rate that is very similar to that of wild-type
cells. However, in cells containing a deletion of
SSD1, the SIT4 gene is essential. Put another way,
Asit4 strains require SSD1-v. Therefore, to obtain
mutations in genes functioning in the SIT4 pathway,
we isolated mutants that require the SSD1-v1 gene for
viability. We are most interested in obtaining the
genes encoding p190 and p155, two proteins that
bind to SIT4.
From a screen of 160,000 colonies resulting from
EMS-mutagenized cells, we obtained about 80
mutants that are inviable or extremely slow growing
in the absence of the SSD1-v1 gene. As expected,
some of these mutants contain a mutation in the SIT4
gene itself and confirm the rationale of our screen.
The non-sit4 mutants were placed into six main com-
plementation groups, termed sapl through sap6.
These sap mutations cause a slow-growth and/or
temperature-sensitive phenotype. SAP1 is a previous-
ly unidentified gene whose protein product has no
homology with proteins in the current database. SAP2
and SAP3 are previously identified genes, termed
SMP3 and SLKI (also known as BCK1), respectively,
that function in the protein kinase C pathway. For
this reason, we are currently examining the rela-
tionship of SIT4 to the protein kinase C pathway. The
sap6 mutations are really mutations in the SAP3 gene
that give rise to intragenic complementation with our
sap3 mutations. The SAP4 and SAPS genes have been
cloned and are under analysis. Hopefully, the analysis
of the sap mutants will provide us with every gene
whose product is required for the SIT4 pathway (or at
least those functions of SIT4 that are essential in the
absence of the SSD1-v gene). The identification of
the genes for p155 and p190 will greatly aid in the
biochemical analysis of SIT4.
Role of Type-2A Protein
Phosphatases in the
S. cerevisiae Cell Cycle
F. Lin
S. cerevisiae has two genes, PPH2a and PPH213, that
encode good homologs (about 80% identity) of the
catalytic subunit of mammalian type-2A protein
phosphatases (PPase). One of our goals is to
determine the role(s) of the S. cerevisiae type-2A
phosphatases in the cell cycle. This analysis is greatly
simplified with strains containing temperature-
sensitive mutations in PPH2a or PPH213. Since we
had a very good temperature-sensitive mutation in
SIT4 (i.e., sit4-102) and since the amino acid residue
altered in the SIT4-102 protein is conserved between
SIT4 and all known type-2A PPases, we prepared
PPH2a and PPH2(3 genes that alter this residue.
Strains containing either the pph2a-102 or pph213-
102 genes as the only source of type-2A PPase are
temperature sensitive for growth. When an asyn-
chronous culture of either strain is shifted to 37°C,
greater than 90% of the cells arrest with a 2n DNA
content. The majority of the cells contain a single
nucleus with a single microtubule-organizing center.
These results suggest that type-2A phosphatases are
required for spindle pole body duplication or separa-
tion but not for DNA synthesis. Since the CDC28
kinase is required for spindle pole body duplication
and progression from the G2 phase into mitosis, we
analyzed whether the activity of the CDC28 kinase is
dependent on the type-2A phosphatase activity.
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These studies show that when the type-2A PPase
mutants are shifted to the nonpermissive temperature,
the histone H1 kinase activity of CDC28 rapidly
(within a few minutes) decreases to very low levels.
The CDC28 kinase seems to be active only when it is
associated with cyclins. For spindly pole body
separation and for entry into mitosis, CDC28 associa-
tes with the B-type cyclins CLB1, CLB2, CLB3, and
CLB4. We have found that a particular phosphory-
lated form of CLB is present in lower amounts in the
absence of type-2A PPase function. These results
raise the possibility that type-2A PPases are required
(directly or indirectly) for the activation of the kinase
activity of the CDC28/CLB2 complex via the
modulation of the phosphorylation state of CLB2.
Our current experiments are aimed at testing this pos-
sibility.
The SIS1 Protein: An Essential
dnaJ Homo log
M. Luke, T. Zhong
The budding yeast SISJ gene encodes the only full-
length dnaJ homolog known to be essential
viability. The Escherichia coli dnaJ protein is a heat-
shock protein required for bacteriophage P1 phage,
and normal host DNA replication. Although it is
believed that the mechanism by which dnaJ functions
is to mediate the dissociation of specific protein/
protein complexes, the precise cellular function pro-
vided by dnaJ is not known.
Like dnaJ, SIS1 is a heat-shock protein. To deter-
mine the essential cellular function provided by SIS1,
we isolated extragenic suppressors of the tempera-
ture-sensitive phenotype resulting from the sis1-85
mutation. These experiments show which mutations
that alter the levels or structure of 60S ribosomal sub-
units suppress the temperature-sensitive phenotype of
sis1-85 strains. These results
led us to determine
whether SIS1 is required for translation. At the non-
permissive temperature, temperature-sensitive sisl-
85 and sis1-86 strains rapidly accumulate high levels
of 80S ribosomes and have decreased levels of poly-
somes. These results indicate that SIS1 is required for
the initiation of translation. At the nonpermissive
temperature, elongation can continue in the absence
of new rounds of initiation (which results in
decreased levels of polysomes). The block in new
rounds of initiation results in the accumulation of
high levels of inactive 80S ribosomes. Additional ex-
periments (effects of cycloheximide, high salt, etc.)
confirm these conclusions. Moreover, mutations that
alter the structure or levels of 60S ribosomal subunits
suppress the temperature-sensitive phenotype of sis/
strains by eliminating the block in translation initia-
tion. That SIS1 is required for the initiation of trans-
lation raises the possibility that SIS1 might associate
with ribosomes. Direct biochemical analysis shows
that SIS1 associates with certain forms of ribosomes.
In summary, these experiments show that the SIS1
heat-shock protein is required for translation, a fun-
damental cellular process. Future experiments will be
directed toward understanding the precise trans-
lational initiation step that requires SIS1.
Parallel experiments show that a fraction of the
SIS1 protein associates in a very large molecular
weight complex with a 40-kD protein (which we term
p40). We have purified p40 (via its association with
SIS1) and have obtained the amino acid sequence of
three different peptides (in collaboration with R.
Kobayashi). The biochemical and molecular analyses
of p40 are in progress.
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INITIATION AND TERMINATION OF TRANSCRIPTION IN
HUMAN sNRNA GENES AND HIV-1
N. Hernandez R.W. Henry
S.M. Lobo
R. Mital
F.C. Pessler
SMALL NUCLEAR RNA GENES
C.L. Sadowski
M. Sheldon
M.L. Sullivan
In eukaryotes, transcription is carried out by three
different RNA polymerases, none of which can
recognize its target promoters directly. Instead,
promoter elements are first recognized by specific
transcription factors that then recruit the correct RNA
polymerase. Because RNA polymerase I, H, and III
promoters are generally very different in structure, it
has long been assumed that RNA polymerase
specificity is achieved through the binding of very
distinct sets of transcription factors. However, the
promoters of human small nuclear RNA (snRNA)
genes are very similar in structure even though some
of them are recognized by RNA polymerase II and
others are recognized by RNA polymerase III. This
suggests that they bind identical transcription factors
and raises the question of how RNA polymerase
specificity is achieved.
The RNA polymerase II U1 and U2 snRNA
promoters and the RNA polymerase III U6 promoter
contain two interchangeable elements: The distal se-
quence element (DSE), which is characterized by the
presence of an octamer motif and functions as an en-
hancer of transcription, and the proximal sequence
element (PSE), which is essential for transcription.
The U6 promoter contains in addition a TATA box
that determines RNA polymerase III specificity.
When the TATA box is mutated, the U6 promoter be-
comes a predominantly RNA polymerase II promot-
er, and when the TATA box is inserted into the U2
promoter, the U2 promoter becomes a predominantly
RNA polymerase III promoter.
The U6 promoter is very different from the gene
internal RNA polymerase III promoters characterized
previously. Thus, the promoters of the 5S genes con-
sist of an internal control element (ICR) and the
promoters of tRNA genes, Alu sequences, and several
viral genes, including the adenovirus-2 VAI and
VAII genes, consist of an A and B box. The factors
required for transcription of the 5S and tRNA-type
RNA polymerase III genes were fractionated more
than 10 years ago over phosphocellulose into three
fractions referred to as the PC-A, PC-B, and PC-C
fractions, which contain TFIIIA, TFIIIB, and TFIIIC,
respectively (see Fig. 1). TFIIIA binds to the ICR of
the 5S genes, and this event allows the subsequent
recruitment of TFIIIC, TFIIIB, and RNA polymerase
III into the initiation complex. tRNA-type genes do
not require TFIIIA for transcription, because TFIIIC
can bind directly to the A and B boxes and recruit
TFIIIB and RNA polymerase III. TFIIIB is thought to
contact RNA polymerase III directly and thus to be
involved in transcription of all RNA polymerase III
genes. What is known about the composition of these
three factors? TFIIIA is a zinc finger protein whose
corresponding cDNA has been cloned. TFIIIB and
TFIIIC have been purified from yeast and human
cells. TFIIIB has been reported to consist of a single
60-kD polypeptide or to contain at least two polypep-
tides of 70 and 90 kD. TFIIIC consists of at least five
polypetides.
In the last year, we have continued our studies of
the transcription factors involved in Ul, U2, and U6
transcription, and we have compared the factors re-
quired for RNA polymerase III transcription of the
U6 gene with those required for transcription of other
RNA polymerase III genes. Specifically, we have ini-
tiated the characterization of the TFIIIB fraction and
the factor that recognizes the Ul, U2, and U6 PSEs.
These studies have revealed that the TATA box bind-
ing protein (TBP), first thought to be involved only in
transcription of TATA-containing RNA polymerase
II mRNA genes, in fact also participates in the initia-
tion complexes of RNA polymerase II snRNA genes
and RNA polymerase HI genes.
HUMAN IMMUNODEFICIENCY VIRUS
Expression from the human immunodeficiency virus
type 1 (HIV-1) is regulated in part by a viral protein
termed Tat. Tat is a strong activator of HIV-1 gene
expression and acts through an RNA target, TAR, en-
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FIGURE 1 Factors required for transcription of different RNA polymerase Ill genes.
The fractionation of the TFIIIA, TFIIIB, and TFIIIC factors on a phosphocellulose
column is indicated. The PC-B, PC-C, and PC-D fractions contain TBP as determined
by immunoblotting.
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coded between positions +18 and +44 downstream
from the transcriptional start site. TAR corresponds
to the upper part of a stable stem-and-loop structure
assumed by the first 59 nucleotides of HIV-1 RNA.
The mechanism by which Tat activates transcription
is controversial. Tat has been reported to enhance ini-
tiation of transcription, elongation of transcription, or
both. The proposal that Tat stimulates transcription
elongation stems in part from the observation that in
the absence of Tat, the HIV-1 promoter synthesizes a
large number of short transcripts, whereas in the
presence of Tat, the number of short transcripts
decreases with a concomitant increase in the number
of full-length transcripts.
We are studying an element, the inducer of short
transcripts or IST, that is located entirely between
positions -5 and +82 relative to the HIV-1 start site.
This element has very unusual properties: It activates
transcription from the HIV-1 promoter and other
promoters very strongly, but the resulting RNAs are
prematurely terminated around position +60. Thus,
IST is responsible for the formation of the short
transcripts observed in the absence of Tat and seems
to direct the formation of transcription complexes
that are unable to elongate efficiently. We have now
localized and characterized more precisely the IST
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element by mutational analysis. Some of these muta-
tions debilitate IST but leave TAR intact. Important-
ly, the constructs carrying these mutations can still be
very efficiently trans-activated by Tat, even though
they do not make any detectable short transcripts.
This indicates that the short transcripts are not re-
quired for Tat trans-activation and therefore that Tat
does not function by allowing elongation of the short
transcripts. Thus, whereas IST activates the forma-
tion of transcription complexes unable to elongate ef-
ficiently, Tat appears to activate the formation of
conventional initiation complexes that are capable of
efficient elongation. In other words, Tat acts at the
level of initiation.
Components of the TFIIIB Fraction
Involved in Transcription of
Different Types of RNA
Polymerase III Genes
S.M. Lobo, M.L. Sullivan, N. Hernandez
We have shown before that as illustrated in Figure 1,
transcription of the U6 gene requires the PC-B, PC-
C, and PC-D fractions. The PC-D fraction is not re-
quired for transcription of 5S or tRNA-type genes. It
is required, however, for transcription of RNA
polymerase II mRNA genes because it contains
TFIID, a complex composed of TBP and associated
proteins that recognizes the TATA box of mRNA
promoters. Like that for basal RNA polymerase II
transcription from mRNA promoters, the PC-D frac-
tion can be replaced by recombinant human TBP for
transcription of the RNA polymerase III U6 gene.
Furthermore, TBP binds to the U6 TATA box but not
to mutated TATA boxes that switch the specificity of
the U6 promoter to RNA polymerase II. This obser-
vation indicates that in the U6 promoter, binding of
TBP to the U6 TATA box determines transcription
by RNA polymerase III.
Figure 1 shows that the TBP is present not only in
the PC-D fraction, but also in the PC-B and PC-C
fractions. In fact, nearly 50% of the cellular TBP
fractionates in the PC-B fraction, whereas a much
smaller amount is found in the PC-C fraction. This
observation raises several questions. Why must the
PC-B and PC-C fractions be supplemented with TBP
for reconstitution of U6 transcription? Is the TBP
present in the PC-B and PC-D fractions modified
such that it is inactive for U6 transcription? And what
are the functions of TBP in the PC-B and PC-C frac-
tions? To address these points, we used a panel of
anti-TBP monoclonal antibodies that we had genera-
ted previously and tested their effect on transcription
from the U6 and VAI gene. We found that, as ex-
pected, addition of anti-TBP antibodies to an extract
inhibits U6 transcription. Interestingly, it also inhibits
transcription from the 58 and VAI genes, suggesting
that TBP is required for transcription of all RNA
polymerase III genes. Transcription of the 5S and
VAI genes requires the PC-B and PC-C fractions,
which both contain TBP (Fig. 1). We determined that
the TBP in the PC-C fraction can be removed by pas-
sage over an anti-TBP column without affecting VAI
transcription. Thus, the TBP required for VAI tran-
scription is provided by the PC-B fraction.
To characterize this fraction better, we fractionated
it by chromatography over Mono-Q and found that
the TFIIIB activity separates into two components,
eluting at 0.38 M (0.38 M- TFIIIB) and 0.48 M (0.48 NA-
TFIIIB) KC1, respectively. Both of these components
are required to reconstitute VAI transcription. We
then showed that the active component of the 0.38 M-
TFIIIB fraction corresponds to a TBP-containing
complex, which cannot be replaced by TBP for tran-
scription of the VAI gene. In sharp contrast, U6 tran-
scription does not require the 0.38 nii-TFIIIB com-
ponent. Together, these results indicate that although
all RNA polymerase III genes use TBP for transcrip-
tion, they differ in the specific form of TBP required.
TATA-containing RNA polymerase III genes such as
the U6 gene use TBP or perhaps the TFIID complex,
whereas TATA-less RNA polymerase III genes such
as the VAI gene require the 0.38 m-TFIIIB complex.
This suggests that at least one of the roles of the
polypetides associated with TBP in the 0.38 tvi-TFIIIB
complex is to anchor TBP to the initiation complex.
These results also reveal that TFIIIB is a complex
factor composed of several subunits. We are now
characterizing further the TBP-associated proteins in
the 0.38 m-TFIIIB complex.
Purification of the 0.48 M- TFIIIB
Activity
R. Mital, N. Hernandez
Unlike 0.38 NA-TFIIIB, which is required for tran-
scription of TATA-less but not TATA-containing
RNA polymerase III genes, the 0.48 m-TFIIIB frac-
tion is required for transcription of all RNA
polymerase III genes. However, this fraction is very
crude, and it is therefore possible that the com-
ponent(s) involved in U6 transcription differs from
those involved in transcription of the VAI gene. To
identify and characterize the active components of
this fraction, we have started their purification.
Factors Involved in Transcription
of the Human U1 and U2
snRNA Genes
C.L. Sadowski, R. W. Henry, S.M. Lobo, N. Hernandez
Unlike RNA polymerase II transcription of mRNA
genes and RNA polymerase III transcription of the
U6 gene, RNA polymerase II transcription of snRNA
genes is difficult to reproduce in vitro, and this has so
far prevented the biochemical characterization of the
factors involved in transcription of these genes. Fol-
lowing a protocol developed by others (Gunderson et
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al., Genes Dev. 4: 2048 [1990]), we have obtained
accurate and efficient initiation of transcription of the
human UI and U2 genes in vitro. Using this system,
we have examined whether RNA polymerase II tran-
scription from the Ul and U2 genes requires TBP.
Since these genes do not have a TATA box in their
promoters, and since the binding of TBP to the U6
TATA box results in RNA polymerase III transcrip-
tion, it is conceivable that Ul and U2 transcription
does not use TBP. However, we find that depletion of
extract with several monoclonal anti-TBP antibodies,
but not with nonspecific monoclonal antibodies, in-
hibits transcription from these genes. Interestingly,
transcription cannot be restored by addition of recom-
binant TBP or by addition of any of the known TBP-
containing complexes, 0.38 M- TFIIIB and TFIID. In-
stead, transcription is restored by addition of frac-
tions enriched in a factor that binds to the PSEs of the
Ul, U2, and U6 promoters. This suggests that this
factor is a TBP-containing complex. Indeed, in an
electrophoretic mobility shift assay with a PSE-
containing probe, addition of anti-TBP monoclonal
antibodies disrupts the PSE-binding factor complex.
These results identify a novel TBP-containing com-
plex that may be involved in transcription of both
RNA polymerase II and RNA polymerase III snRNA
genes. These results also suggest that the U6 initia-
tion complex contains two molecules of TBP, one
bound to the TATA box and the other to the PSE as
part of the PSE binding complex.
Characterization and
Purification of the
PSE-binding Factor
R.W. Henry, C.L. Sadowski, M.L. Sullivan, N. Hernandez
The PSE-binding factor is of great interest to us, be-
cause as described above, it may be involved in RNA
polymerase II and III transcription of snRNA genes.
To establish this point, however, we need to purify
the PSE-binding factor to homogeneity and test the
pure preparation in RNA polymerase II and III func-
tional assays. The pure preparation will also be used
to obtain protein sequence and cDNA clones. We
have purified the PSE-binding factor extensively and
are now scaling up the preparation to obtain enough
material for protein sequencing.
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Characterization of the Inducer
of Short Transcripts
M. Sheldon, F.C.
Pessler, M.L. Sullivan, N. Hernandez
From our previous work, the IST was known to be lo-
cated between positions -5 and +82 relative to the
HIV-1 start site of transcription. Since most of this
region is downstream from the start site of transcrip-
tion, it was possible that IST was, like TAR, an RNA
element. We have now completed the analysis of a
large series of mutations encompassing the region
from +1 to +82. These mutations define IST as a
bipartite element, located at positions -5 to +26 and
+40 to +59. The most important region for activity is
that proximal to the promoter, but the +40 to +59
region is required for maximal activity. The RNA
secondary structure is not important for IST function,
and IST can be inverted without loss of activity,
strongly suggesting that IST is a DNA element.
Some of the mutations we have analyzed debilitate
IST but leave TAR intact. These constructs do not
generate short transcripts and yet they are trans-
activated by Tat. As a result, when transcription is
measured close to the HIV-1 promoter such that both
short and long transcripts are scored, the presence or
absence of the IST element changes the apparent ef-
fect of Tat. With the IST intact, the HIV-1 promoter
produces very few long transcripts and a large
amount of short transcripts in the absence of Tat. In
the presence of Tat, the number of long transcripts in-
creases and the number of short transcripts is reduced
concomitantly. Thus, the total number of transcripts
derived from the HIV-1 promoter is unchanged in the
presence and absence of Tat; only the ratio of these
transcripts (long or short) is changed. Tat therefore
seems to affect transcription elongation. However,
when IST is debilitated, the HIV-1 promoter pro-
duces no short transcripts and still only few long
transcripts in the absence of Tat. In the presence of
Tat, the number of long transcripts is greatly in-
creased. This time, the total number of transcripts is
increased in the presence of Tat, and Tat therefore
seems to affect transcription initiation. These results
provide an explanation for the different effects of Tat
observed by different groups in different systems.
Most likely, IST is very active in systems (for exam-
ple, transfected COS cells) in which Tat has been
reported to act at the level of transcription elongation,
and only slightly or not active in systems in which
Tat has been reported to act at the level of initiation.
Identification of trans-Acting
Factors Involved in 1ST Function
F.C. Pessler, M. Sheldon, M.L. Sullivan, N. Hernandez
In an attempt to identify the factor(s) involved in IST
activity, we have screened fractions derived from
He La cell nuclear extracts for the presence of factors
that bind to probes containing an intact IST but not to
probes containing a debilitated 1ST. We have identi-
fied an activity whose binding to IST and different
1ST mutations correlates well with IST activity. We
are now in the process of characterizing and purify-
ing this activity.
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TELOMERASE AND TELOMERE LENGTH REGULATION
C.W. Greider C. Autexier
A.A. Avilion
K. Collins
L.A. Harrington
L.L. Mantell
K.R. Prowse
S.K. Smith
Accurate chromosome transmission during cell divi-
sion is essential to cell survival. When chromosome
mechanics fail and whole chromosomes or parts of
chromosomes are lost or rearranged, cell death or un-
regulated growth may occur. In contrast to broken
chromosomes which undergo aberrant fusions and
rearrangements, natural chromosome ends containing
telomeres are stable. Telomeres are dynamic struc-
tures, shortening with chromosome replication and
lengthening by the de novo addition of simple
telomeric repeats. Telomere sequences are highly
conserved in eukaryotes, consisting of short G-rich
repeats, for example, TTGGGG in Tetrahymena and
TTAGGG in humans and other mammals. Telomere
G-rich repeats can be synthesized de novo onto
chromosome ends by the enzyme telomerase,
presumably to balance the inability of conventional
DNA polymerises to replicate DNA ends completely.
Telomerase is a ribonucleoprotein enzyme, in which
the RNA component serves as an internal template
for telomeric repeat synthesis. Telomerase, originally
identified in Tetrahymena, has also been isolated
from the ciliates, Euplotes and Oxytricha, as well as
from immortalized human cell lines.
Recent experiments from our laboratory and others
suggest that telomere length and telomerase activity
may play a role in cellular senescence and im-
mortalization. In primary cells, telomere length
shortens with each round of cell division; thus,
telomere length is an excellent biomarker for the
replicative history of cells. Using this biomarker, we
can follow the aging of tissues and primary cell cul-
tures as well as the replicative history and thus the
progression of some forms of cancer.
In the past year, we have greatly expanded our
understanding of telomerase biochemistry. We identi-
fied and characterized a 3 ' to 5 ' nucleolytic cleavage
activity in the Tetrahymena telomerase. This, along
with the finding that short primers are elongated non-
processively, led to a detailed model for telomerase
primer elongation. We have also characterized both
telomere shortening in vitro and tissue-specific devel-
opmental telomere length changes in the mouse Mus
spretus. The results from these studies suggest that
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the mouse is an excellent model organism in which to
pursue the role of telomeres and telomerase in mam-
malian development and cancer. In characterizing the
telomerase activity from mouse cells, we found that
unlike its human counterpart, mouse telomerase is
nonprocessive; it synthesizes only one repeat onto
telomeric primers. Finally, the knowledge that some
telomerase enzymes generate only short products led
to the identification of telomerase in Xenopus oocyte
extracts.
Purification and Reconstitution
of Telomerase
L.A Harrington, K. Collins, C. Autexier
To study the telomerase enzyme mechanism in detail,
our goal is to identify and clone the protein subunits
and reconstitute activity from the purified com-
ponents. To reach this goal, we have focused on iden-
tifying the polypeptide subunits that copurify with
telomerase activity and on reconstituting activity with
synthetic RNAs. Telomerase activity has been
purified using a number of columns, including
phenyl-Sepharose, DEAE, Heparin, Biorex, and
sucrose gradients, to give an overall enrichment of
6000-10,000-fold. The proteins present in the highly
purified fractions were visualized either by silver
staining or by prelabeling the cells with 35S followed
by autoradiography. In the final step of purification
using sucrose gradient sedimentation, we observed a
separation of processive telomerase activity, which
produces long product DNAs, from telomerase ac-
tivity, which produces short addition products; the
more processive enzyme sedimented farther into the
gradient. Northern analysis showed that the telomer-
ase RNA is present in fractions synthesizing both
long and short products, although the peak cosedi-
ments with the short products. We are currently ex-
amining the basis for this distribution of processive
and nonprocessive telomerase activities. Four promi-
nent polypeptides reproducibly copurify with proces-
sive telomerase activity in the sucrose gradients. We
are currently determining which of these polypep-
tides contribute to activity.
To understand the mechanism of telomerase fully,
it will be necessary to reconstitute activity from puri-
fied components. We have used the purified fractions
described above to begin reconstituting activity using
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synthetic RNA transcripts. Protein components were
separated from the telomerase RNA using nuclease
treatment or chromatographic separation of active
telomerase fractions. A T7 transcript of the cloned
RNA component was mixed with the protein frac-
tions and assayed for telomerase activity under a va-
riety of conditions, including different salt, pH, and
MgC12 concentrations. Preliminary results suggest
that some activity may be restored using the synthetic
transcript. We are currently characterizing the ac-
tivity in these reactions.
Primer Cleavage and Nonprocessive
Elongation by Tetrahymena
Telomerase
K. Collins
Our studies of Tetrahymena telomerase biochemistry
led to the identification of two new activities: a 3' -
5 ' nucleolytic cleavage of primer or product DNA
and a nonprocessive mode of elongation. We first
noted a 3' -5' nucleolytic cleavage activity in reac-
tions with 32P-labeled dGTP and dideoxythymidine
triphosphate (ddTTP). Four primers with permuted
telomeric repeat sequences ending in 0-3 dGTP res-
idues, each 18 residues in length, were reacted with
telomerase. The permuted primers d(GGGGTT)3,
d(GGGTTG)3, d(GGTTGG)3, and d(GTTGGG)3
were elongated as expected from the sequence of the
RNA template, except that the primer d(GGGTTG)3
generated an extra labeled product at the size of the
input, 18-residue primer (Fig. 1).
Several lines of evidence suggested that the
primer-sized product of d(GGGTTG)3 was generated
by telomerase and not some unrelated DNA poly-
merase or nuclease activity. First, synthesis of both
primer-sized product and other elongation products
was sensitive to pretreatment of the extract with
RNase. Second, the ratio of primer-sized to longer
products remained constant in telomerase reactions
across a glycerol gradient, indicating that the
cleavage activity cosedimented with telomerase.
Third, the Km of primer activation for synthesis of the
primer-sized product of d(GGGTTG)3 was identical
to the Km of primer activation for the primer +1
nucleotide product of d(GGGGTT)3. This would not
be expected if a small fraction of the added primer
was degraded by a contaminating exonuclease before
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FIGURE 1 Cleavage of the primer d(GGGTTG)3 by
Tetrahymena telomerase. Telomerase reactions were
carried out under standard conditions, and product DNA
was precipitated, separated by PAGE, and subjected to
autoradiography. Primers d(GGGGTT)3 (lanes 1 and 5),
d(GGGTTG)3 (lanes 2 and 6), d(GGTTGG)3 (lanes 3 and 7),
and d(GTTGGG)3 (lanes 4 and 8) were incubated with
telomerase, 32P-labeled dGTP, and ddTTP (lanes 1-4). As a
marker and control for the purity of the input primers, the
same oligonucleotides were reacted with terminal
deoxytransferase and 32P-labeled ddATP (lanes 5-8). The
position of migration of an 18-residue telomeric primer is in-
dicated at the left.
elongation by telomerase. Finally, using primers that
after elongation are only very slowly released by
telomerase, we showed that the cleavage reaction it-
self, separate from nucleotide addition, is sensitive to
RNase treatment. These experiments suggest that
telomerase catalyzes a template position-specific
nucleolytic cleavage reaction. For the primer
d(GGGTTG)3, removal of the 3' deoxyguanosine
was followed by addition of a 32P-labeled dGTP
nucleotide to generate a primer-sized, radioactively
labeled d(GGGTTG)3 product.
The primer specificity of the cleavage reaction
suggested that cleavage occurred if primer or product
sequence aligned with the cytosine residue at the ex-
treme 5' end of the RNA template (3 ' -AACCCC
AAC-5 ' ), the last template position for nucleotide
addition before repositioning of the product 3' end
during processive elongation. We have extensively
characterized the primer requirements for the
cleavage reaction. Cleavage required a complete
telomeric repeat with the permutation d(GGGTTG) at
the primer or product 3' end. Cleavage was not
detected for primers that have the correct 3' end
permutation but lack a complete 3 ' telomeric repeat,
such as (GT)2TTG. When the primer d(GGGTT
G)2GGGTTA was reacted with telomerase, the 3' dA
was removed, and a 32P-labeled dGTP was added in
its place onto the 3' end. This and other experiments
indicated that nucleotides other than deoxyguanosine
could be removed from a primer 3 ' terminus, but
only dGTP was initially added to the cleavage pro-
duct. Finally, cleavage and subsequent nucleotide ad-
dition to the primer d(GGGTTG),,GGGITI'G dem-
onstrated that more than one nucleotide could be
removed by cleavage before elongation.
In addition to the cleavage reaction, we observed a
second, novel property of telomerase: primer length,
sequence, and concentration-dependent processivity.
Previous studies using primers between 12 and 24
nucleotides in length showed that telomerase elonga-
tion is highly processive (Greider, Mol. Cell. Biol.
11: 4572 [1991]). Our more recent studies showed
that at high concentration, primers less than ten
residues in length efficiently stimulated non-
processive synthesis by Tetrahymena telomerase.
Using short primers with different permutations, we
showed that these primers were "filled out" to the end
of the 3' -AACCCCAAC-5 ' RNA template and then
apparently dissociated from telomerase.
The identification of the cleavage reaction and
nonprocessive elongation of short primers provide
evidence for a revised model of telomerase action
(Fig. 2). In this model, two sites are proposed to be
involved in primer binding: the primer 3' end is
bound at the "template site," 3 ' -AACCCCAAC-5 ' ,
whereas the adjacent primer sequence is bound at an
"anchor site" (indicated by a shaded oval in Fig. 2).
Processive synthesis requires that the product DNA
remains bound to telomerase at the anchor site while
dissociating from the template site with each round of
3' -end repositioning. The short primers elongated by
telomerase in a nonprocessive manner may bind only
at the template site, not at the anchor site, and thus be
released from the complex when released from the
template site.
After primer binding, elongation (added nucleo-
tides shown in bold) results in extension of the primer
3' end toward the 5' end of the RNA template.
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FIGURE 2 Model for product synthesis by Tetrahymena telomerase. Two sites are involved in the binding of primer;
the 3' end is bound at the template site, and the adjacent sequence is bound at the anchor site (shaded oval). Sub-
sequent elongation steps, with nucleotides added shown in bold, result in elongation of the primer 3' end toward the
the 5' end of the RNA template. Translocation or repositioning of the product 3' end to the 3' end of the template
occurs after copying of the template sequence. The 3' end of the primer or elongated product bound at the 5' end
of the template sequence can also undergo cleavage. Base-pairing interactions between the template RNA and
primer or product DNA are indicated by dots between base-paired residues.
Repositioning of the product 3' end to the 3' end of
the template site, termed translocation, can occur
after complete or almost complete copying of the
template sequence. Repositioning may occur either
before or after addition of the dGTP encoded by the
most 5 ' template cytosine residue. Instead of
repositioning, the 3' end of primer or product bound
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at the 5' end of the template can also undergo
nucleotide cleavage. The cycle begins again when the
product 3' end reestablishes stable alignment with the
3 ' end of the template. In testing the predictions of
this new model, we will be able to further define the
novel mechanism of DNA synthesis carried out by
the telomerase enzyme.
Mouse Telomere Shortening
In Vitro and In Vivo
K.R. Prowse
Our recent experiments (Counter et al. EMBO J. 11:
1921 [1992]) showed that telomerase activity was not
detectable in cultures of primary human cells when
telomeres were shortening. However, immortalized
clones arising from SV40 T-antigen-transformed pri-
mary cells had both stable telomere length and de-
tectable telomerase activity. This suggests that activa-
tion of telomerase may be essential for the growth of
immortalized human cells. To further explore the role
of telomerase in cellular senescence and immortaliza-
tion, we have extended our studies of telomere length
and telomerase activity to mice.
Primary mouse fibroblast cells have been well
studied and characterized in vitro. A fundamental dif-
ference exists between mouse and human cells in cul-
ture: Human fibroblasts rarely, if ever, spontaneously
immortalize, whereas mouse fibroblasts in culture
spontaneously immortalize at a high frequency.
Studies of telomere length and telomerase activity
during immortalization of both human and mouse
cells may add to our understanding of these dif-
ferences and their implications for cancer.
Mouse telomeres contain the same (TTAGGG)
repeated sequence found in humans, although the
lengths of the terminal restriction fragments in Mus
musculus and Mus domesticus, ranging from 50 to
150 kbp, are significantly longer than in humans.
Therefore, if a decrease in telomere length similar to
that seen in human cells occurred with increasing
replicative age, it would be extremely difficult to
detect in these mice. However, Mus spretus, a wild-
derived mouse species, possess terminal restriction
fragments of only 5 to 15 kbp in length, similar to hu-
mans, and thus any changes in telomere length should
be detectable. For this reason, M. spretus cell cultures
and tissues were used to examine telomere length
changes both in vitro and in vivo.
Primary M. spretus fibroblasts were obtained from
newborn mouse skin and were grown in culture. The
growth kinetics and morphology of the cells were
monitored to determine when the population un-
derwent crisis and spontaneously transformed. At
various times during the cell growth, genomic DNA
was isolated and digested with restriction enzymes,
and telomere length was analyzed by hybridization to
the telomeric oligonucleotide d(TTAGGG)3 (Fig. 3).
In a separate experiment, a Ba131 exonuclease digest-
ion showed that most of the d(TTAGGG)3 hybridiz-
ing bands were truly telomeric. During growth of the
cells in culture, the terminal restriction fragments
decreased in length with increasing mean population
doubling (MPD). After the culture had passed
through crisis, the length of the terminal restriction
fragments remained stable. These results are similar
to what we found using human cells in culture.
The M. spretus fibroblasts were also examined for
telomerase activity both before and after crisis. S100
cell extracts were prepared, fractionated over DEAE
columns, and assayed for telomerase activity. The
results showed that although no telomerase activity
was detected before crisis, telomerase activity was
detected after the culture had undergone crisis and
the cells were immortalized. The lack of detectable
telomerase activity when telomere lengths are
shortening, coupled with the detection of activity
after crisis when telomere lengths are stable, suggests
that telomerase activity is required to maintain
telomere length in transformed cells.
The finding that telomeres shorten during growth
of mouse cells in culture allows us to use the mouse
as a model system to study telomere length during
aging in vivo. We found that telomere lengths in tis-
sues from individual newborns were similar, whereas
telomere lengths from tissues of individual adults dif-
fered. The most striking difference was observed in
the length of testes telomeres. Testes telomere length
was significantly longer in adult mice than in other
tissues. This suggests that a developmentally regu-
lated telomere length increase may occur after birth
in the mouse. To test this hypothesis, we studied both
telomere length and telomerase activity at various
stages of mouse development. At approximately 5
weeks after birth, the length of testes telomeres in-
creased relative to other tissues from the same mouse.
This increase in telomere length coincides with the
appearance of the first mature sperm cells in the male
mouse. Telomerase activity was assayed in testes
from mice 2, 4, 6, 8, 10, 13, and 16 weeks of age. Ac-
tivity was not detected in 2-week-old mice but was
found in those mice 4 weeks and older, which sug-
gested that telomerase activity may be regulated dur-
ing spermatocyte development. To determine
whether telomerase activity came from the germ-line
cells in the testes, testes from mutant W/W(V) mice,
which have a complete lack of primary spermato-
gonia, were assayed for telomerase activity. No ac-
tivity was detected in 9-week-old W/W(V) mice,
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FIGURE 3 Telomere shortening in mouse fibroblasts. Genomic DNA from M. spretus
fibroblasts was isolated at the indicated mean population doubling (MPD), and 2-[tg
samples were digested with Hinfl and separated in a 0.5% agarose gel. The gel was
dried, denatured, neutralized, and hybridized to a 32P-labeled (TTAGGG)3 oligonu-
cleotide. The asterisk indicates the MPD at which the population of cells was in crisis.
The numbers at the left and right indicate the molecular weights of the marker DNA.
whereas normal age-matched siblings did have
telomerase activity.
These studies in mice support and extend our pre-
vious studies on telomere length and telomerase
regulation in human cells during both cellular senes-
cence and immortalization. The observation that
mouse telomere length regulation is similar to that of
humans allows the use of mice to dissect telomere
regulation in vivo. To directly test the role of
telomerase in aging and immortalization, we will
need to alter telomerase and determine the affect on
both cell viability and organismal development. A
thorough characterization of mouse telomere regula-
tion will provide the background for future studies
using transgenic mice with artificially regulated
telomerase.
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Mouse Telomerase Generates Only
Short Addition Products
K.R. Prowse
In the course of our studies on mice, we found that
mouse telomerase has biochemical properties very
different from telomerases characterized from both
ciliates and human cells. Telomerase activity was
identified in extracts from several different mouse
cell lines. Addition of telomeric d(TTAGGG),
repeats was specific to telomeric oligonucleotide
primers and sensitive to pretreatment with RNase A.
In contrast to the hundreds of repeats synthesized by
the human and Tetrahymena telomerase enzymes in
vitro, mouse telomerase synthesized only one or two
d(TTAGGG) repeats onto telomeric primers. The
products observed after elongation of primers with
circularly permuted d(TTAGGG)3 sequences and
after chain termination with ddATP or ddTTP indi-
cated mouse telomerase pauses after the addition of
the first dG residue in the sequence 1TAGGG (Fig.
4). The short length of the products synthesized by
mouse telomerase was not due to a diffusible in-
hibitor in the mouse extract, because the human
telomerase continued to synthesize long products
when mixed with mouse fractions. Primer challenge
experiments showed that the human enzyme
synthesized long d(TTAGGG)n repeats processively
in vitro, whereas the mouse telomerase was much
less processive. The identification of short telomerase
293
3-100
ro3
H
reaction products in mouse extracts suggests that ex-
tracts from other organisms may also generate only
short products. This knowledge may aid in the identi-
fication of telomerase activity in organisms where ac-
tivity has not yet been detected.
Identification of Telomerase
in Xenopus Oocytes
L.L. Mantell
As described above, we found that telomerase ac-
tivity was present in mouse testes extracts. This sup-
FM3A DEAE Active Fraction
ro
0
CD
CD
H
HH
CD
I I If
RNase - + - +
6 -5 -4 -3 -2 -1 -
10 -9-8-
7 -
6 -
5-4-
3 -2-
1 -
32 P-(TTAGGG)
(GTTAGG)3
No
ddN ddA ddT
II
- +
to
0
1 0
H
Ir
- +
to
1-2H
CD
H
CD
1 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18
FIGURE 4 Mouse telomerase synthesizes short products. An FM3A DEAE fraction was assayed for
telomerase activity using different telomeric oligonucleotides as primers. (Lanes 1,2) 293 S100 extract,
(TTAGGG)3; (3-18) FM3A DEAE fraction; (3,4) (TTAGGG)3; (5,6) (GGGTTA)3; (7-12) (GTTAGG)3; (13,14)
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dATP; (lanes 11,12) 0.5 mm ddTTP was used instead of UP. The position of a 32P-labeled (TTAGGG)3 is in-
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ports our model that telomerase activity in germ cells
allows maintenance of telomere length in these cells,
although in some somatic tissues telomeres shorten
with age. To extend our studies of germ-line cells, we
wanted to study telomerase in oocytes. We chose to
analyze oocytes from the frog Xenopus laevis.
Although Xenopus telomeres have not been cloned
and sequenced, in situ hybridization and Southern
blots suggest that Xenopus has the same telomere se-
quences, d(TTAGGG)n, as found in other vertebrates.
Thus, Xenopus telomerase is expected to synthesize
d(TTAGGG)n sequences onto telomeric DNA pri-
mers. Stage VI oocytes were dissected from adult
Xenopus ovaries and treated with progesterone to al-
low maturation. S100 extracts made from these ma-
tured oocytes were fractionated on a DEAE column
and telomerase assays were carried out.
No telomerase activity was detected in S100 ex-
tracts; however, the 0.2 NA NaCl fraction from a
DEAE column contained a product band that closely
resembled that synthesized by mouse telomerase.
Pretreatment of the extract with RNase inhibited
product synthesis. Further experiments showed that
this telomere elongation activity is primer-specific:
Only the telomere sequence primers were elongated.
These properties are consistent with a telomerase ac-
tivity.
Telomerase activities identified in both human and
mouse cell extracts pause at the first G of the
dTTAGGG sequence. To determine whether the se-
quence d(TTAGGG)3 was added to the telomere pri-
mer, different permutations of the primer sequence
were used. Different length products were primed by
each permutation, suggesting that the elongation
products paused at the first G of the sequence
d(TTAGGG), similar to both human and mouse
telomerases. Using dideoxynucleotides to replace the
corresponding deoxynucleotides in the telomerase ac-
tivity assay confirmed that d(TTAGGG)n sequences
were added to telomere primers. Thus, the Xenopus
telomerase activity present in the mature oocytes gen-
erates only short products similar to those synthe-
sized by mouse telomerase. Roth cell cycle and de-
velopmental regulation arc well characterized in
Xenopus. The identification of telomerase in oocytes
provides the opportunity to use Xenopus to explore
telomerase regulation further.
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MOLECULAR CHROMOSOME STUDIES OF
ARABIDOPSIS THALIANA
E.J. Richards T. Kakutani A. Vongs
A. Kelly M. Walsh
We are studying the organization of higher eukary-
otic chromosomes using the flowering plant, Arabi-
dopsis thaliana, as a model system. Our research ap-
plies both genetic and molecular biology approaches.
During the past year, we focused on two projects:
(1) study of telomeric DNA structure and (2) charac-
terization of DNA methylation mutants.
CHARACTERIZATION OF TELOMERIC DNA
FROM A. THALIANA
Telomeres are unusual chromatin domains that cap
the termini of linear eukaryotic chromosomes. The
DNA sequences at the extreme termini are composed
of tandem arrays of short, G-rich repeats. We have
isolated several A. thaliana telomeric DNA clones by
functional complementation in yeast, and our con-
tinuing characterization of these clones has focused
this past year on telomere repeat array (TRA) sub-
structure.
We have determined the primary nucleotide se-
quence of three isolated TRAs, all of which contain
repeats that vary from the canonical A. thaliana
telomere repeat, 5' -T1TAGGG-3 ' . The variant
repeats are clustered in the centromere-proximal
region of the TRA. These variants tend to be uniform
in size and sequence and generally deviate from the
canonical repeat at only one position. At the
centromere-proximal boundary of the TRA, the
variant repeats give way to degenerate repeats that
vary widely in size and sequence. In two of the se-
quenced TRAs, the simple gradient of uniform
(TTTAGGG)->variant-->degenerate repeats--->centro-
mere is replaced by a patchwork of subdomains.
Most striking is the substructure of one TRA from
clone YpAtTS that contains a block of nontelomeric
sequence roughly 100 by in length within the TRA.
We have postulated that the patchwork substructure
arises from unequal crossing over in the TRAs or by
small translocations between TRAs.
Although it is generally assumed that all telomeres
within a cell are the same, we have shown that
telomere repeat variants can be chromosome- and
strain-specific. One of the common telomere repeat
variants we found, TTCAGGG, is present in
Landsberg strains of A. thaliana but is absent in the
common laboratory strain, Columbia. Moreover,
TTCAGGG repeats are only detectable on a subset of
Landsberg telomeres.
The presence of chromosome- and strain-specific
telomere repeats illustrates the fluidity of the genome
at chromosome termini. We hope to study this
fluidity further by following the telomere structural
polymorphisms we have identified.
A. THALIANA DNA HYPOMETHYLATION MUTANTS
In collaboration with Rob Martienssen, our group
isolated A. thaliana DNA methylation mutants to ad-
dress questions concerning the function of eukaryotic
DNA modification using genetic tools. Southern blot
screens were used to identify three independent A.
thaliana mutants with reduced levels of DNA
methylation. During the past year, we have extended
our characterization of these mutants.
Despite a 70% reduction in cytosine methylation
levels caused by the two most severe hypomethyla-
tion mutations, designated ddml-1 and thiml-2,
homozygous mutant plants develop normally and ex-
hibit no striking morphological abnormalities. How-
ever, the mutations are associated with a segregation
distortion phenotype since plants with hypomethyl-
ated genomes are significantly overrepresented in the
progeny resulting from selfing ddml heterozygotes.
We are currently investigating the cause of the
segregation distortion to learn how the plant cell uses
DNA modification.
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STRUCTURE AND COMPUTATION
This section consists of five laboratories interested in computational biology and
the detailed structural properties of proteins. Dr. John Anderson is a macro-
molecular crystallographer studying both the endonuclease and methyltrans-
ferase of the Pvull restriction-modification system. A crystal structure for a com-
plex between the Pvull restriction enzyme complexed with DNA is now close at
hand. Dr. Jeff Kuret's laboratory studies protein kinases including casein kinase 1
and the cAMP-dependent protein kinase. Dr. Tom Marr is a computational
biologist whose laboratory is heavily involved in developing software to aid in the
assembly of genomic mapping and sequencing information as well as its analy-
sis. Dr. Jim Pflugrath is a crystallographer working on the neurotrophic factor
S10013. He also studies the yeast cAMP-dependent protein kinase in collabora-
tion with Dr. Jeff Kuret, and a refined model for this protein has recently been
achieved. Dr. Pflugrath has also been instrumental in developing software to aid
in the collection of X-ray data using area detectors. Dr. Rich Roberts' laboratory
has had a long-standing interest in restriction enzymes and methylases. Most
recently, in collaboration with Drs. Pflugrath and Cheng, the first high-resolution
structure has been obtained for a DNA cytosine methyltransferase. The newest
member of this section is Dr. Xiaodong Cheng, who originally joined Cold Spring
Laboratory as a postdoctoral fellow with Dr. Jim Pflugrath and who has now es-
tablished his own independent laboratory.
During the past year, Dr. R.J. Roberts has moved from Cold Spring Harbor
Laboratory to join New England Bio-Labs, from where he will continue an active
collaboration with Dr. Xiaodong Cheng.
MACROMOLECULAR CRYSTALLOGRAPHY
J.E. Anderson
J.W. Pflugrath
G.K. Balendiran
K. Bilchick
D. Cahill
C.K. Cheung
J.R. Horton
J. Keller
T. Malone
Pvull Endonuclease and DNA
G.K. Balendiran, J. Keller, J.E. Anderson [in collaboration
with I. Schildkraut, New England Bio-Labs, and
R.M. Blumenthal, Medical College of Ohio]
The restriction endonuclease from Proteus vulgaris,
RPvull, recognizes the DNA sequence CAGCTG. In
the presence of magnesium, RPvull cleaves between
the central guanine and cytosine bases. We have
cocrystallized RPvull with the following oligode-
oxynucleotide carrying a Pvull recognition sequence
(underlined):
TGACCAGCTGGTC
CTGGTCGACCAGT
To prevent cleavage of the oligo, EDTA is included
in the crystallization buffer. The crystals are space
group P21.2121 with unit cell dimensions a = 95.1 A,
b = 85.6 A, c = 47.7 A, and diffract to at least 2.6 A
resolution. We have collected native data to 3 A
resolution. To obtain phases to calculate an electron
density map, we have crystallized RPvull with the
following derivative oligos, which have 5-iododeoxy-
uracil or 5-iododeoxycytosine at the indicated posi-
tions:
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TGACCAGCTGGUC
CUGGTCGACCAGT
I
I
TGACCAGCTGGTC
CTGGTCGACCAGT
I
I
TGACCAGCUGGTC
CTGGUCGACCAGT
I
derivative 1
derivative 2
derivative 3
TGACCAGCTGGTC derivative 4
CTGGTCGACCAGT
I
Complexes between RPvull and derivative oligos 1,
2, and 3 crystallize isomorphously and so could pro-
vide phases for the native data. The iodine positions
for derivative 1 were determined, and a single iso-
morphous replacement (SIR) was calculated, but
the map was uninterpretable. Data have been col-
lected for derivatives 2 and 3, and processing is under
way. Once phases are determined, we will calculate a
multiple isomorphous replacement (MIR) electron
density map and begin building a model of the com-
plex. RPvull crystallizes with derivative oligo 4, but
the crystals are not isomorphous.
Pvull Methylase
C.K. Cheung, J. Keller, K. Bilchick, J.E. Anderson
[in collaboration with R.M. Blumenthal, Medical College
of Ohio, and I. Schildkraut, New England Bio-Labs]
We have purified MPvuII, which methylates the N4
atom of the cytosine in the fourth position of the
PvuII recognition sequence. A variety of proteases
cleave MPvull into two to four relatively stable
fragments. The pattern of fragments produced by
protease K depends on the presence or absence of the
essential cofactor S-adenosylmethionine (Ado Met),
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suggesting that Ado Met affects the conformation of
the methylase. Intact M Pvull has so far been
resistant to crystallization. If it continues to be so,
proteolytic fragments of MPvull will be purified,
since they may crystallize more readily.
Stichodactyla helianthus
Cytolysin Ill
J. Keller, J.E. Anderson [in collaboration with W. Kem,
University of Florida College of Medicine]
Cytolysin III (cIII) is a 153-residue protein that is
found in the skin of the Caribbean sea anemone
Stichodactyla helianthus, possibly associated with
nematocysts, the stinging cells of the anemone. It
probably plays both offensive and defensive roles and
appears to function by oligomerizing and forming
pores in cell membranes, leading to osmotic lysis of
target cells. In view of its function as an integral
membrane protein, we were surprised when we were
able to concentrate purified cIII to over 100 mg/ml!
However, it is probably stored at very high con-
centrations in the skin of the anemone before being
released and inserting into target cell membranes, and
this may explain the unusually high aqueous
solubility of cIII. We have obtained small crystals of
cIII under several conditions. One of these includes a
high detergent concentration, which might be ex-
pected of a membrane protein. The crystals are too
small for diffraction analysis, and we are attempting
to increase their size.
Structural Studies of the
Neurotrophic Factor S100(3
D. Cahill, T. Malone, J.W. Pflugrath [in collaboration
with D. Marshak, Cold Spring Harbor Laboratory]
S100(3 is a member of a family of dimeric acidic
Ca++-binding proteins involved in cell differentiation,
cell cycle progression, and calcium signal transduc-
tion. sloop is synthesized and released from
astrocytes in the brain, and its disulfide-linked
dimeric form has neurotrophic activity on cerebral
cortical neurons in vitro. Elevated levels of S10013
protein, mRNA, and specific neurotrophic activity in
autopsy samples of Alzheimer's disease patients sug-
gest the possibility that S10013 contributes to Alzhei-
mer's disease neuropathology. S10013 is homologous
to proteins with EF-hand calcium-binding motifs,
such as calmodulin and intestinal calcium-binding
protein (ICaBP). We are attempting to determine the
crystal structures of S10013 at pH 7 and pH 8 from ex-
isting crystals of S10013 that diffract beyond 1.6 A
resolution. We have grown at least three different
crystal forms of S10013 that may reveal for the first
time conformational differences in a single member
of the Ca++-modulated protein family. The conforma-
tion of the extended amino and carboxyl termini of
S100(3 and the quaternary structure of a S10013
protein will be seen for the first time. The nature of
any change in dimer interaction needed to form inter-
molecular disulfide bonds and how calcium binding
either prevents or enhances any change also will be
unveiled. Finally, the neurotrophic activity of S10013,
its role in the development and maintenance of
neuronal function and in Alzheimer's disease, and its
similarity to many other proteins involved in growth
regulation, cell cycle progression, and cystic fibrosis
suggest the possibility of the development of new
diagnostic and therapeutic agents based on the S10013
structure.
S10013 has significant sequence homology with
ICaBP, whose structure has been refined to high
resolution; thus, we have used molecular replacement
techniques to try to solve for the phases of the pre-
viously collected S10013 native data. We aligned the
92 residues of recombinant rat S100(3 with the 75
residues of ICaBP on the basis of amino acid identity,
surface accessibility, and secondary structure ele-
ments. The following are the main features of the
alignment: (1) Nearly every residue of ICaBP is ei-
ther identical with (28 of 75) or similar to (21 of 75)
its corresponding residue of S10013 unless it is on the
protein surface; (2) S 1 ow has amino- and carboxy-
terminal extensions when compared to ICaBP; (3)
only a single three-residue hydrophilic insertion at
position 45 (a surface loop of ICaBP) is needed for
the alignment; (4) S10013 Cys-68 is aligned with
ICaBP Val-61, which is completely buried in the
calcium-bound form of EF hands; and (5) Cys-84 is
in the carboxy-terminal extension of S10013 and has
no counterpart in ICaBP. This alignment predicts cal-
cium cannot bind to the second EF hand if Cys-68 is
part of a disulfide bond linkage as is expected to oc-
cur in a S100(3 covalent dimer.
The rotation search was done first using the ICaBP
structure, then the ICaBP Ca skeleton with the S10013
sequence-aligned side-chain replacements, then the
separated EF hands of this model individually, and
finally the side-chain model with residues 37-43
deleted. Several resolution ranges were tried with
three different software packages. The rotation func-
tion results were used in translation searches. The
packing of models from the best solutions in the
S10013 unit cell was also checked. Finally, some of
the solutions were subjected to simulated annealing
with restrained least-squares refinement. Refinement
never proceeded to a low enough R-factor to lead us
to believe that any of our molecular replacement
solutions were correct. We are now pursuing isomor-
phous replacement as a method of solving the phase
problem for our S10013 crystals.
Yeast cAMP-dependent
Protein Kinase
J.W. Pflugrath, T. Malone, J. Kuret
Protein kinases are important and conserved com-
ponents of many regulatory pathways because they
can integrate several input signals and coordinate a
response through the phosphorylation of a limited
number of substrate proteins. The three-dimensional
crystal structure of the cAMP-dependent protein
kinase will allow us to define the structural basis of
enzyme/substrate recognition and to assess the im-
plications of this information for the protein kinase
family in general.
We have crystallized the cAMP-dependent protein
kinase catalytic subunit from Saccharornyces cerevis-
iae. The kinase catalytic subunit crystallizes in space
group P6522 with cell dimensions a = b = 61 A, c =
320 A. We have grown crystals as large as 0.6 by 0.6
by 1.5 mm that have diffracted beyond 2.7 A resolu-
tion with synchrotron radiation. Data from native and
pCMBS-soaked crystals were recollected at beamline
X12C of the National Synchrotron Light Source at
Brookhaven National Laboratory. A new version of
the area detector software MADNES, which allows
one to simultaneously display the raw images and
predicted reflections, revealed discrepancies in the in-
dexing of some crystals. When this was corrected, the
R merges for both the native and the derivative data
sets were 8%.
Single isomorphous replacement refinement with
anomalous scattering yielded phases with a figure of
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merit of 0.70, and these were used to calculate an
electron density map that was interpretable. This new
map confirmed our previous preliminary partial se-
quence fit from earlier maps and allowed us to visual-
ly rotate the mouse cAMP-dependent protein kinase
structure (Knighton et al., Science 253: 407 [1991])
onto our density map. It was immediately apparent
that the amino- and carboxy-terminal domains were
oriented differently with respect to each other in the
yeast and the mouse kinase structures. The mouse
structure had been solved with a bound protein kinase
inhibitor peptide, whereas our yeast kinase was an
apo structure without any ligands present in the crys-
tals. After model building and restrained least-
squares refinement, the crystallographic R-factor is
22% for 8210 reflections from 20 to 2.8 A resolution.
The model stereochemistry was restrained throughout
refinement with the final rms deviations from ideality
of 0.015 A for bonds, 2.5° for bond angles, and 0.020
A for planes. Figure 1 shows a diagram of the final
refined model. We are in the process of analyzing the
differences between the unbound protein and the
protein substrate complexes.
FIGURE 1 Topological diagram of the structure of cAMP-
dependent protein kinase catalytic subunit (TPK1A) from S.
cerevisiae. Shown are residues 38 to 318 and residues 334
to 350. Electron density for residues 36-37 and 318-334 is
not seen in the Fourier maps.
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Cell Cycle Protein Regulators
J.R. Horton, J.W. Pflugrath
We have initiated a project to determine the three-
dimensional crystal structures of the major macro-
molecular switches of the cell cycle. These switches
are complexes that contain at least two proteins: a
cdc2-like protein (the catalytic component) and a
cyclin (the regulatory component). These switches
are strongly controlled by other proteins that can turn
them "on" or "off." In the activated "on" state, these
protein complexes have serine/threonine kinase ac-
tivity and phosphorylate other proteins to bring about
the major events of the cell cycle.
Cyclin Dl is a 36-kD protein involved in regulat-
ing some events near the G1 /S transition of the cell
cycle. Overamplification of the cyclin Dl gene has
been linked to the development of several types of
human cancer. An Escherichia coli strain containing
the gene for cyclin D1 has been obtained from Drs.
Xiong and Beach here at Cold Spring Harbor
Laboratory. Unfortunately, although a large amount
of protein is expressed (40-50 mg per liter cell cul-
ture), all of this protein is found in inclusion bodies.
Presently, we are purifying this protein and hope to
crystallize it soon.
Area Detector Software
J.W. Pflugrath [in collaboration E.M. Westbrook,
Argonne National Laboratory]
To elucidate macromolecular structures, crystallog-
raphers must measure thousands of diffracted in-
tensities from numerous crystals. Very often, crystals
are too small, diffract too weakly, have large unit
cells, or are very sensitive to radiation damage, so
that usable data are unobtainable with a conventional
laboratory X-ray source. However, useful data from
such crystals may be measured with a synchrotron
source that offers X-rays 100-1000 times brighter, no
beam divergence, and a tunable wavelength. To max-
imize the usefulness of synchrotron radiation, state-
of-the-art area detectors are being developed with
high count rates, high dynamic range, low noise, fast
readout, and a large area coverage. One such detector
is the 1024 by 1024 pixel charge-coupled device
(CCD) area detector developed at Argonne National
Laboratory and installed at beamline X8C of the Na-
tional Synchrotron Light Source. This beamline and
detector are part of a National Institutes of Health Re-
search Resource that macromolecular crystallog-
raphers can use for crystal structure determinations.
We are responsible for all of the application software
at this resource.
In the past year, we have written, installed, and
tested a set of device handlers for the major hardware
components (the detector, the goniometer, the ion
chamber counters, and the shutter) for the X8C re-
search resource. These are used in a new version of
MADNES, the device-independent area detector soft-
ware developed principally by us. This version
directly controls the detector hardware that simplifies
the user interface, reduces training time, and results
in fewer errors in data collection. Other enhance-
ments to MADNES are visualization tools that dis-
play images either singly or overlayed (contributed
by Phil Evans, MRC) and a graphical user interface
(contributed by John Skinner and Robert Sweet,
BNL). Although MADNES cannot make the crystals
diffract better, it can help to maximize any results ob-
tained with the state-of-the-art CCD detector. This
software has also been exported to several other
laboratories that are designing and building their own
detectors.
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MACROMOLECULAR CRYSTALLOGRAPHY
X. Cheng K. McCloy
Crystal Structure of Hhal DNA
Methyltransferase Complexed with
S-adenosyl-L-methionine
X. Cheng [in collaboration with S. Kumar and R.J. Roberts,
Cold Spring Harbor Laboratory]
The three-dimensional structure of the DNA (cyto-
sine-5)-methyltransferase, M.HhaI, complexed with
S-adenosyl-L-methionine (AdoMet) has been de-
termined at 2.5 A resolution. The molecule comprises
two domains. The large domain consists of a large
a/I3 domain containing most of the conserved se-
quences among all DNA (cytosine-5)-methyltrans-
ferases and is responsible for the binding of cofactor
AdoMet and providing catalytic nucleophile cysteine
81. The small domain of predominantly 13 strands
contains the "variable region" responsible for se-
quence specificity. A cleft between the two domains
is likely to contain the active site of the molecule,
where the binding of AdoMet and DNA can occur in
close proximity to the catalytic center.
DNA methyltransferases are found in many
organisms ranging from bacteriophages to mammals.
They recognize specific DNA sequences and transfer
a methyl group from the cofactor AdoMet to adenine
or cytosine residues. In prokaryotes, DNA methyla-
tion is used by the restriction-modification system to
distinguish between host and foreign DNA. In
eukaryotes, DNA methylation has been implicated in
the control of gene expression, epigenesis, and
genomic imprinting. Recently, the mouse methyl-
transferase was found to be associated with the DNA
replication center in a cell-cycle-dependent manner
and was shown to be essential for embryonic devel-
opment.
MHhal from the bacterium Haemophilus haemol-
yticus methylates the internal cytosine of its recogni-
tion sequence 5' -GCGC-3 ' . It contains 327 amino
acids with a molecular weight of 37,000. The struc-
ture of HhaI methyltransferases complexed with the
methyl donor, AdoMet, was not only the first to be
solved for any DNA methyltransferase, but also the
first for any methyltransferase that utilizes the ubiqui-
tous methyl donor AdoMet. Due to the conserved na-
ture of (cytosine-5)-methyltransferases, the informa-
tion obtained from this structure can be generalized
to the entire family, including the mammalian CpG
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methyltransferase. This structure will assist in
elucidating the mechanisms of the methylation pro-
cess, including substrate binding and activation,
nucleophilic catalysis, and cofactor binding. It will
also aid in understanding DNA binding and sequence
discrimination by catalytic protein.
STRUCTURE DETERMINATION
Crystals of Hhal methyltransferase complexed with
the cofactor Ado Met were monoclinic space group
P21 with two molecules per asymmetric unit and had
unit-cell dimensions of a = 55.3 A, b = 72.7 A, c =
91.0 A, and p = 102.5° (Fig. 1). The structure was
solved with the phases derived from two mercurial
derivatives (Fig. 2). The initial 3 A resolution
MIRAS (multiple isomorphous replacement with
FIGURE 1 Photomicrograph of the crystallized M Hhal-
AdoMet complex grown by the hanging drop vapor diffusion
method at room temperature. The crystal shown has dimen-
sions 0.9 mm x 0.3 mm x 0.3 mm.
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anomalous scattering) map was of sufficient quality
to place a-helixes and (3- strands in recognizable
densities, and a partial, discontinuous polyalanine
model was fitted to the electron density. The two
molecules forming the crystallographic asy mmetric
unit are related by a noncrystallographic twofold axis
of rotation. Two AdoMet molecules were also clearly
identified in the MIRAS map. Phases were further
improved by averaging about the twofold non-
crystallographic axis and solvent flattening. Three
rounds of model building, averaging with the MIRAS
phases, allowed an unambiguous trace of the known
amino acid sequence to the electron density map.
After the initial model building, the twofold averag-
ing was discontinued, and the atomic model was sub-
jected to least-squares refinement with both mono-
mers treated independently. The current model con-
sists of all residues (aa 1:327) and AdoMet for both
monomers. No water molecules or sulfate anions
have been included in the model. The current R-
factor is 0.227 for 20,057 reflections between 8- and
2.5 A resolution.
TOPOLOGICAL OVERVIEW
The structure of MHhal methyltransferase is il-
lustrated schematically in Figure 3. The molecule of
size 40 x 50 is folded two domains, a
large domain (aa 1-193 and aa 304-327) and a small
domain (aa 194-275), with a hinge region (aa
276-303) connecting them. The large domain is a
mixed a/I3 structure consisting of the amino-terminal
two thirds of the protein followed by a crossover con-
nection to an additional helix (aG) from the carboxyl
terminus. There are two 13-a-13 structural elements
and one hairpin element. The twisted six-strand p
sheet contains four adjacent parallel p strands, num-
bered 4, 3, 1, 2, whereas strands 5 and 6 form a p
hairpin next to strand 4. The mixed p sheet is in the
middle and sandwiched by two layers of structures:
helices aC and aD above and aA, aG, and strand 137
underneath. Helix aB runs across the sheet in front of
the sandwich. The small domain consists of seven
strands. The five up-and-down antiparallel strands
(numbers 8, 10, 11, 13, and 14) are arranged in cir-
cular formation like the blades of a propeller. A hinge
region, built up from two helices and one strand (aE-
1315-aF), connects the two domains by forming the
bottom of a cleft. At the surface of the cleft, there is a
cavity embedded in the large domain next to the car-
boxyl end of strand 1 of the 0 sheet. This cavity con-
Oand1
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FIGURE 2 Harker section at v = 1/2. Peaks show pCMBS (p-chloromercuribenzene sulfate) sites in
isomorphous difference Patterson map (left) and anomalous Patterson map (right).
tains the AdoMet binding site and is adjacent to the
least variable PC dipeptide in which the cysteine is
the active site nucleophile.
CONSERVED SEQUENCE MOTIFS AND
SECONDARY STRUCTURE
Comparative analysis of available sequences of
(cytosine-5)-methyltransferases shows the presence
and order of the ten conserved motif sequence blocks
(J. Posfai and R.J. Roberts): six well conserved
motifs and four less conserved motifs. The variable
region, located between conserved motifs VIII and
IX, is responsible for the specificity of DNA recogni-
tion and the choice of the methylation target.
In the MHhaI-AdoMet structure, the first eight
conserved motifs are located in the large domain, and
the variable region folds to form the majority of the
small domain. The last two motifs run back to the
large domains through the hinge region. The con-
served motifs constitute most of the structures that
surround the active site cleft. The six most conserved
motifs form the core structure of the protein (Fig. 3).
This includes the three a helices (aA, aE, and aG),
the four central strands of the R sheet (6-4-3-1) and
associated loop regions, named 1 -1A (between 131 and
aA), 1 -3C (between (33 and aC), 1 -4D (between (34
and aD), and 1 -56 (between 135 and (36), and strand
1314 in the small domain. The four central strands and
the loop regions are part of the active site cleft.
Although the full motifs span 13-strand, a-helices,
and turns, the majority of the highly conserved or in-
variant residues occur in loops immediately adjacent
to ordered secondary structures. Most of these in-
variant residues are clustered around the active site.
In addition, two invariant residues, R272 from strand
1314 in the small domain and E278 from helix aE in
the hinge region, form an ion pair.
ADOMET BINDING POCKET
The presence of bound AdoMet in the crystals clearly
defines the cofactor binding site. AdoMet binds to the
large domain at the surface of the cleft next to the
carboxyl end of the parallel strands of the 13 sheet.
The binding of AdoMet involves the insertion of its
adenosyl moiety into a pocket on the protein surface,
whereas the methionine moiety points toward the
solution. The 131- aA -(32 structural segment that
recognizes AdoMet contains a highly conserved
amino acid sequence F-x-G-x-G among (cytosine-5)-
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FIGURE 3 Ribbon representation showing the structure of M Hhal methyltrans-
ferase complexed with AdoMet. The two structural domains of the molecule are seen
clearly: large domain (aa 1-194, aa 304-327), small domain (aa 195-275), and
hinge region (aa 276-303). The six highly conserved sequence motifs are shaded.
The residues forming the secondary structural elements, N-(131-aA-(32)-aB-(133-aC-
(34)-aD-(135-(36)-137-(138-139-010-13114312-(31 3-1314)-(aE-(315-aF)-aG-C, are 131 (12:17),
aA (23:31), 132 (33:40), aB (43:52), aB' (43:52), 133 (74:78), 133 (83:86), aC
(101:110), 134 (115:120), aD (131:143), 135 (145:154), 136 (165:172), 137 (185:194), 138
(208:211), (39 (215:220), 1310 (225:230), 1311 (239:244), (312 (249:253), 1313
(262:267), 1314 (270:274), aE (276:283), 1315 (289:292), aF (295:303), aG (308:323).
methyltransferases. The glycine-rich region forms a
tight loop between strand (31 and helix aA, which ap-
pears to be crucial in positioning the adenine ring of
AdoMet in its correct conformation in order to have
close contact with the main chain of the protein
framework. Large side chains at these glycine posi-
tions destroyed the general methylation capacity as
shown by a mutational analysis of the SPR methyl-
transferase (Wilke et al., EMBO J. 7: 2601 [19881).
The conserved F18 along with surrounding hydro-
phobic amino acids P80 and L100 forms a hydro-
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phobic platform on one side of the purine and ribose
rings. W41 lies on the other side and its side chain
nitrogen forms a hydrogen bond to N3 of the purine
ring.
Although the sequence motif F-x-G-x-G had long
been suspected of interacting with AdoMet, several
other invariant residues were also involved. Two
acidic residues, E40 and D60, interact directly with
AdoMet. The side chain of E40, which is deeply
buried in the hydrophobic pocket, is roughly per-
pendicular to the plane of the purine ring, with both
side chain carboxyl oxygens pointing to two purine
nitrogens (N1 and N3). The side chain of D60 inter-
acts with the positively charged trivalent sulfur atom,
to which the transferable methyl is attached. N304, in
the bottom of the pocket, forms a hydrogen bond to
N6 of the purine ring. In addition, the backbone
amino nitrogens of residues 41 and 61 form hydrogen
bonds to 02 and 03 of the ribose ring. Most of the
residues interacting with Ado Met are well conserved.
F18, D60, P80, and N304 are absolutely conserved.
E40 has only D variants, and L100 has M and V
variants. W41 is not conserved.
CATALYTIC SITE
Cysteine residue 81, in the PC invariant dipeptide, is
the key catalytic residue of MHhal. From the loop
region outside of strand 3 (1 -3C), C81 lies in the cleft
next to the Ado Met binding pocket. Replacement of
C81 with other amino acids abolishes catalytic ac-
tivity (S. Mi and R.J. Roberts). The corresponding
cysteine residue has recently been identified as the
active nucleophile in MHaeIll (Chen et al., Bio-
chemistry 30: 11018 [1991]).
In close proximity to the sulfur atom of C81, there
is a histidine residue, H127, that is part of the loop
region outside of 13-strand 4 (1 -4D). C81 forms a
strong interaction with the side chain of H127, and
this is probably the reason no mercury derivative was
found to bind at this exposed cysteine in the
substrate-free enzyme. We are not certain about the
significance of this interaction since sequence align-
ment shows that H127 is not conserved. Interestingly,
there are two invariant triplets around this active site:
E119-N120-V121 from the last two residues of 13-
strand 4 and loop 1 -4D, and Q161-R163-R165 from
loop 1 -56. There is a cascade of interactions among
these two triplets, the P80 -C81 region and the T250-
L251 dipeptide in the small domain on the other side
of the cleft.
DNA-BINDING CLEFT
Several observations suggest that the cleft between
the two domains is the DNA-binding site. First, the
presence of Ado Met and the nearby active nucleo-
phile C81 within the cleft identifies this region as the
active site. Second, the amino acids forming the sur-
face of the cleft have a high degree of sequence
homology between (cytosine-5)-methyltransferases,
suggesting an important functional role for the cleft.
Third, positive charges, capable of interacting with
the DNA backbone, are contributed to the surface of
the cleft by both domains. The triplet, Q-R-R, is well-
conserved and lies on the surface of the large domain
facing the cleft. This is a likely candidate for non-
specific interactions with the sugar-phosphate back-
bone. Finally, the cleft itself is about 25-30 A wide
and 15-20 A deep, large enough to accommodate
double-stranded DNA without steric hindrance in a
computer-generated model. The length along the bot-
tom of the cleft, where the Q-R-R is located, is ap-
proximately 40 A, potentially covering about 11 base
pairs. This would correlate well with the 10 base
pairs protected by the enzyme in the footprint experi-
ment (S. Klimasauskas and R.J. Roberts). The length
along the top of the cleft is only about 15 A, which is
the size of the recognition sequence. Thus, the
residues at the bottom of the cleft could serve to
orient the axis of the DNA helix, whereas those at the
top of the cleft could directly interact with specific
nucleotides.
We cannot identify any known DNA-binding
motifs in the structure. In the large domain, a highly
conserved 20-residue subdomain from loop 1 -3C, fol-
lowing the PC dipeptide and connecting to aC, is
quite flexible in the model. The location of this
region suggests that it could close off the cleft and
wrap around the double-stranded DNA after substrate
binding.
Both large and small domains apparently contrib-
ute to the DNA binding if it indeed occurs in the
cleft, although the target specificity of DNA methyla-
tion is known to depend on the variable region, which
constitutes the bulk of the small domain. Within the
variable region, a small subregion, termed the target
recognition domain (TRD), is believed to participate
directly in sequence-specific recognition. Interesting-
ly, the proposed position of the TRD for M.Hhal
(centered around residues T250-L251) places it at
the side of the cleft on the small domain. The
residues of the proposed TRD are located in two
regions in the structure: amino acids 231-240 (the
loop connecting strands 10 and 11 then into strand
11) and amino acids 249-253 (strand 12). These two
regions form the side of the cleft from the small
domain, suggesting that these weakly conserved
amino acids probably provide a "backbone" for DNA
binding together with residues from the large domain.
The specificity of individual target recognition would
then be determined by the amino acids surrounding
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and separating the conserved residues. Discussion of
MHhaI-DNA-AdoMet interaction must await high-
resolution structures of the appropriate protein-DNA
complexes.
Purification, Crystallization, and
Preliminary X-ray Diffraction
Studies of the MHhal-DNA
Complexes
X. Cheng, K. Mc Cloy [in collaboration with
S. Klimasauskas, S. Mi, and R.J. Roberts,
Cold Spring Harbor Laboratory]
Most DNA-binding proteins, such as several restric-
tion enzymes and repressors whose structures have
been solved, are dimers. Because DNA methyltrans-
ferases act as monomers, the structure of MHhal-
DNA complexes will reveal novel properties unique
to monomeric DNA-binding proteins. Crystals have
been obtained for the ternary complex of MHhal,
substrate analog S-adenosylhomocysteine, and a
series of duplex oligonucleotides containing the
recognition sequence GCGC: a blunt-end 12 mer and
11, 13, and 15 mers with one-base overhangs. The
structure determination of the complex with the 13-
mer DNA is currently under way. Crystals are
monoclinic space group C2 and have unit-cell dimen-
sions of a= 173.0 A, b= 99.9 A, c= 122.8 A, and
(3 = 118°. A native data set has been collected and the
structure should be readily determined using mole-
cular replacement, with the refined structure of apo-
methylase as a search model. Concurrently, we are
preparing conventional heavy atom derivatives by
soaking and using iodinated oligonucleotides.
It has been shown that (cytosine-5)-methyl-
transferases form a stable, covalent complex with
DNA containing 5-fluorocytosine. A proposed me-
chanism for MHhal methyltransferase predicts that
this complex is a trapped reaction intermediate during
catalytic methyl transfer, resulting from the formation
of a Michael adduct between a cysteine residue (Cys-
81) and the C-6 position of cytosine. The structure of
this complex will be extremely informative in
elucidating the details of the catalytic mechanism.
Toward this goal, crystallization of a covalent adduct
of 11-mer and 13-mer DNA containing 5-fluorocyti-
dine with MHhal has been successful. We are crys-
tallizing the covalent complexes with different
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lengths of oligonucleotides to obtain crystals with the
highest possible resolution.
Replacement of the conserved cysteine (Cys-81) of
MHhal methyltransfcrase with serine arginine,
histidine, and glycine abolished catalysis (S. Mi and
R.J. Roberts). In addition, the glycine substitution
was cytotoxic to Escherichia coli due to an extremely
high affinity for DNA containing the recognition se-
quence. Purification and crystallization of the two
mutant forms of M-Hhal (C81G and C81S) com-
plexed with DNA have been initiated.
Structural Refinement of
Bacteriophage T7 Lysozyme
X. Cheng [in collaboration with X. Zhang and F.W. Studier,
Brookhaven National Laboratory, and J.W. Pflugrath,
Cold Spring Harbor Laboratory]
Bacteriophage T7 lysozyme is a zinc amidase that
cuts an amide bond on the bacterial cell wall, as well
as being an inhibitor of T7 RNA polymerase. The
crystal structure of a mutant T7 lysozyme (T7L),
which deletes amino acids 2 to 5, has been further
refined at 2.2 A resolution. The initial coordinates for
the T7L model a 2.5 A MIRAS (mul-
tiple isomorphous replacement with anomalous scat-
tering) map (see last year's Annual Report). During
this process, atomic models were used twice to im-
prove the phases by phase combination with the
MIRAS. Coordinates for the non-hydrogen atoms in
T7L were initially refined against 2.5 A native X-ray
data by least-squares refinement, using the program
X-PLOR. One hundred steps of Powell optimization
smoothly reduced the R factor from 0.40 to 0.28 with
no manual intervention, indicating the accuracy of
the initial model. One cycle of simulated annealing
refinement was then carried out, using initial and
final temperatures of 3000K and 350K, respectively,
and reduced the R factor to 0.24. A total of five
rounds of model rebuilding using FRODO and least-
squares refinement was carried out by adjusting the
coordinates and temperature factors of individual
atoms. Adjustments to the model were made from
maps computed with Fourier coefficients (F0-F,) and
(2F0-Fc) and calculated phases. The resolution of the
native data included was extended to 2.2 A. Promi-
nent nonprotein peaks in the (F0-Fe) difference maps
that are close to the protein surface and have rea-
sonable hydrogen bond lengths and angles were inter-
preted as water molecules and incorporated into the
structural model. The occupancies of these waters
were fixed at 1.0, and thus only the temperature fac-
tors and the coordinates were refined. Difference
maps calculated after the fourth round of refinement
revealed both incorrectly positioned solvent mole-
cules and additional water molecules. A revised list
of solvent molecules was then generated and subject
to the final round of refinement. The current model
has the entire sequence built in and 26 well-ordered
bound water molecules and has unbroken backbone
electron density from the amino to the carboxyl
terminus in (2F° -Fo) difference Fourier maps. The R
factor is 0.19 for 6991 reflections with Fo > 2a(F),
and the root mean square deviation from ideal geom-
etry for the 1514 atoms is 0.017 A for bond lengths,
3.3° for bond angles, and 25.6° for the dihedral angle,
all with good stereochemistry for the backbone tor-
sion angles.
aB
FIGURE 4 Side view of the cleft of T7 lysozyme with ribbon diagram. Residues shown include Zn++
ligands and several other amino acids that were the targets of
site-directed mutagenesis. Helix aA,
shown as shaded, appears to participate in both the amidase
and the inhibition functions.
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To identify residues critical for catalysis, the crys-
tal structure was used to guide site-directed mutagen-
esis for several residues located within the cleft
and/or on helix aA (Fig. 4), performed by Zhang and
Studier at Brookhaven National Laboratory. The
mutation at Tyr-46 (to Phe) and seven mutations at
Lys-128 (to Asn, Gln, His, Ile, Met, Thr, or Trp)
abolish amidase activity but have little impact on the
inhibition activity, suggesting a crucial role for these
two residues in catalysis. Helix aA appears to be in-
volved in both functions. Mutants that abolish
amidase activity but only affect inhibition slightly
were obtained for His-36 and Trp-41, both located on
aA and pointing toward the cleft. On the other hand,
mutations that only affect inhibition activity greatly
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were found on two surface residues, Glu-31 and Leu_
42. Since random mutations that reduce the inhibition
activity were also found to be clustered on surface
residues around helix aA and in the amino terminus
(residues 1 to 8), these two nearby regions are likely
to be involved in the interaction with T7 RNA
polymerase.
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A major research effort in this laboratory is directed
at understanding the relationship between structure
and function among the DNA (cytosine-5) methyl-
transferases (m5C-methylases). These enzymes,
which accompany restriction enzymes in bacteria and
are found free in both prokaryotes and eukaryotes,
catalyze the transfer of a methyl group from S-
adenosylmethionine to the 5-position of a cytosine
residue in DNA. They differ as to the specific DNA
sequence they recognize.
We have previously used biochemical, computa-
tional, and molecular biological approaches to study
this class of enzymes. This year has been immensely
productive as a result of a collaboration with Dr. X.
Cheng (Macromolecular Crystallography Section),
which has resulted in a structure at 2.6 A for a com-
plex between the Hhal methylase and its cofactor S-
adenosylmethionine. This has been particularly
gratifying as the Hhal methylase was first discovered
in this laboratory in 1975.
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The Structure of the Hhal
Methylase
S. Kumar [in collaboration with X. Cheng,
Cold Spring Harbor Laboratory]
We are delighted to report that we have solved the
structure of M Hhal bound to its cofactor S-
adenosyl-L-methionine at 2.6 A resolution. This
structure, the first to be solved for any Ado Met-
dependent methyltransferase, confirms the impor-
tance of the ten conserved motifs we had previously
identified by computational methods that are present
in nearly all m5C-methylases. The M Hhal molecule
is folded into two major domains, one small and the
other large, with a deep cleft between them. The core
of the M Hhat structure is dominated by the most
conserved motifs (1, 4, 6, 8, and 10), which cluster
around the cleft and lie within the large domain.
AdoMet and motif 4, the P-C motif that contains the
catalytic nucleophile Cys-81, are situated within the
cleft, suggesting that this region is the active site. The
size of the cleft is sufficient to accommodate DNA
without steric hindrance, and basic residues capable
of phosphate-backbone interactions are found on the
small domain side of the cleft. The variable region
between motifs 8 and 9, which determines the se-
quence specificity of the enzyme, constitutes the ma-
jority of the small domain. Motif 1, suspected to be
part of the Ado Met-binding site on the basis of se-
quence similarity with other Ado Met-dependent
methyltransferases, is shown to be directly involved
in Ado Met interactions. In addition, we find that
motifs 2, 3, and 10 are also involved in binding
Ado Met. Using the knowledge gained from the
MHhal structure, we are proceeding with experi-
ments to delineate the functions of the conserved
motifs, especially their roles in binding Ado Met and
sequence recognition. Further details of the structure
can be found in Dr. X. Cheng's report.
Biochemical and Crystallographic
Analysis of the Ternary
M.Hhal-DNA-AdoHcy Complexes
S. Klimasauskas
MHhal-COFACTOR INTERACTIONS
Recent studies (Kumar et al., Biochemistry 31: 8648
[1992]) indicate that at millimolar concentrations,
MHhal tightly associates with its cofactor, Ado Met,
and can readily be purified to homogeneity and crys-
tallized in the Ado Met-bound form. We have further
investigated several aspects of this binary complex.
First, our data indicate that the complex is reversible.
The addition of urea at concentrations over 2 M leads
to the rapid release of bound Ado Met (several
minutes at room temperature). Dissociation of the
complex is also detectable under nondenaturating
conditions: t112 for the release of [3H]AdoMet during
dialysis of the labeled complex is approximately 2
hours at 25°C and 6.5 hours at 4°C. An estimate of
the binding affinity using equilibrium microdialysis
gives a Kd value of 13 AM (25°C). On the basis of the
above results, we developed a large-scale procedure
for the preparation of MHhaI, free of cofactor.
MHhal-DNA INTERACTIONS
The potential of MHhaI to bind DNA was investi-
gated by gel-mobility-shift analysis. The binding to
the 37-mer oligonucleotide duplex containing a
unique nonmethylated or hemimethylated GCGC site
is fast and quantitative. The interaction is enhanced in
the presence of the cofactor analog, S-adenosyl-L-
homocysteine (AdoHcy). The stoichiometry of the
complex as determined by "titration" analysis is ap-
proximately 1:1. The complex is unstable under
denaturating conditions such as boiling in the
presence of 0.1% SDS or treatment with 4 M urea at
55°C. To determine the length of the DNA region
contacted by the methylase, two synthetic 37-mer
duplexes each containing the unique substrate se-
quence GCGC were footprinted using dimethylsul-
fate in the presence of the methylase and AdoHcy.
The DNA substrates were identical in their sequences
but differed in that their GCGC sites were hemi-
methylated on one strand or the other. The preformed
complexes were briefly exposed to DMS, and, fol-
lowing strand cleavage, guanines protected by the
bound methylase were identified by electrophoresis
and autoradiography. The footprinting experiments
show that interactions between MHizaI and DNA in
the major groove are localized within 10 base pairs,
or approximately 34 A, with the GCGC sequence
residing in the center. This number is in good agree-
ment with an estimated diameter for a monomeric
protein of 327 residues.
CRYSTALLIZATION AND X-RAY DIFFRACTION
OF TERNARY MHhal-DNA-ADOHCY COMPLEXES
This work was done in collaboration with X. Cheng.
A series of synthetic self-complementary oligo-
nucleotides were assayed for their ability to cocrys-
tallize as ternary complexes with MHhal and
AdoHcy. On the basis of our footprinting data, sub-
strates of 11-15 nucleotides were chosen for these
experiments. The oligonucleotides were annealed to
form duplexes and mixed with the methylase and
AdoHcy, and the ternary complexes were isolated by
FPLC on an anion-exchange column. Large-scale
preparations were performed that typically yielded
1-1.5 mg of the purified complexes at concentrations
(10-15 mg/m1) suitable for crystallization. A sparse
matrix screening method was used to search for ini-
tial crystallization conditions by the vapor diffusion
technique in hanging drops. After initial crystals were
observed, the conditions were refined to allow the op-
timal growth of crystals. To confirm that we were ob-
serving co-crystals, direct biochemical analysis was
conducted on the crystals grown from the purified
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complex with the 13-mer duplex DNA. Eleven crys-
tals, previously used to collect diffraction data, were
recovered from capillaries and were subjected to UV-
spectral analysis, colorimetric protein determination,
and urea treatment, followed by HPLC analysis of the
released cofactor. The experimentally determined
molar ratio of DNA:MHhaI:AdoHcy is approxi-
mately 0.87:1:1.2, indicating an equimolar content of
the components in the crystals.
Although all DNA fragments tested yielded crys-
tals large enough for X-ray diffraction studies, there
was significant variation in their diffraction power
and stability. The methylase 15-mer crystals dif-
fracted poorly beyond 10 A resolution. The methy-
lase 11-mer crystals exhibited much stronger diffrac-
tion limited at around 4 A in the synchrotron beam,
but in our hands, they did not grow larger than 0.35
mm. They also had a short life time in mother liquor
as well as in the X-ray beam. Fortunately, the 12-mer
and 13-mer methylase complexes under optimal con-
ditions consistently produced large (0.4 x 0.4 x 1.2
mm) crystals of a diamond morphology that were
stable in their original drops for several weeks. The
diffraction limit varied from crystal to crystal, reach-
ing in many cases 2.5 A in the synchrotron beam.
The 13-mer complex was subjected to further crystal-
lographic analysis.
The crystals of monoclinic space group C2
with unit cell dimensions a = 173.0 A, b = 99.9 A, c
= 122.8 A, and a = 118.0°. The space group identi-
fication is based on the systematic absence of reflec-
tions in precession photographs taken from four dif-
ferent layers of reciprocal space. The calculated
volume of the unit cell is 1.87 x 106 A3.
To our knowledge, this study describes the first
crystals of a specific ternary methylase-DNA-co-
factor complex suitable for X-ray analysis. Isomor-
phous crystals of the complex with synthetic DNA
containing a 5-iodouracil residue replacing one of the
thymines were obtained. We are presently collecting
diffraction data from both native crystals and heavy
atom derivatives. Recently, isomorphous crystals of
the ternary covalent complex with duplex DNA con-
taining 5-fluorocytosine in the methylation target site
have also been produced. This complex represents a
mechanism-based covalently trapped reaction inter-
mediate. Structure determination of these complexes
should provide a detailed picture of substrate binding
including the molecular mechanism of sequence dis-
crimination. Because of the strong conservation of
sequences among methylases, the results will be val-
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uable in designing experiments to probe the func-
tional details of all m5C-methylases.
M.Hhal Mutant Methylases
S. Mi
The family of m5C-methylases shares an overall
common architecture: five highly conserved motifs
about 10 to 20 amino acids long and five moderately
conserved motifs. The P-C motif has universally con-
served proline and cysteine residues and is the en-
zyme catalytic center. The cysteine residue in the P-C
motif is involved in covalent bond formation with the
target cytosine residue during catalysis. It was ob-
served for the EcoRII methylase (MEcoRII, recogni-
tion sequence CCWGG) that replacement of the con-
served cysteine in the P-C motif with serine, valine,
or tryptophan abolished catalysis. A glycine substitu-
tion both abolished catalysis and proved cytotoxic to
Escherichia coli (Wyszynski et al., Nucleic Acids
Res. 20: 319 [1992]). One hypothesis was that the
mutant protein had a very high affinity for its target
DNA, such that binding might interfere with tran-
scription or replication. To investigate this possibility
and to determine whether this cytotoxic phenomenon
can be extended to other m5C-methylases, we have
constructed several MHhaI mutants in the P-C motif
by substitution of the conserved cysteine (Cys-81)
with four different amino acids. Replacement by
arginine, glycine, histidine, and serine all result in
loss of methylase activity. Interestingly, the glycine
mutant is cytotoxic in E. coli.
A series of studies was carried out to establish the
cause of the cytotoxicity of the Gly-81 mutant
methylase. It was found that the glycine mutant
methylase as well as the other three mutants showed
no sensitivity to 5-azacytidine, indicating that the
protein has no enzyme activity. This was confirmed
by the complete sensitivity of plasmid DNAs encod-
ing the mutant methylases to digestion in vitro by the
Hhal restriction endonuclease. Purified Gly-81 mu-
tant protein could only be isolated as a protein-DNA
complex from normal E. coli cells. However, when
the Gly-81 mutant protein was isolated from cells co-
expressing the Sssl methylase (recognition sequence
CG), it was now well-behaved and could be isolated
free of DNA. When subjected to gel-shift competi-
tion assays to assess its DNA-binding properties, the
TABLE 1 Kinetic Constants for the Methyltransferases
Methyltransferase t112 (min) koff x 10-3 (min -1) Kd x 10-9 M
Cys-81 (wt) 11 65 1.25
Arg-81 1.5 481 11
Gly-81 568 1.2 0.45
His-81 0.63 1000 20
Ser-81 69 10 1.69
Gly-81 mutant exhibited a much higher affinity for
its target DNA sequence than the wild-type enzyme.
The koff rate is 50-fold slower and the Kd is 3-fold
smaller than the values for the wild-type protein. The
dissociation rates and the Kd values of the wild-type
and mutants are presented in Table 1.
In summary, replacement of the catalytic cysteine
residue by glycine results in a mutant methylase that
binds DNA extraordinarily tightly. If unchecked, this
tight binding interferes with normal cellular metabo-
lism and causes cytotoxicity in E. coli.
Genetics of Restriction-Modification
S. Kulakauskas
FORMATION OF DIMETHYLCYTOSINE IN VIVO
The EcoRII (or the E. coli dcm methylase) and MvaI
methylases both modify the second cytosine residue
in the CCWGG sequence but differ in the precise
modification introduced. EcoRII produces C5-
methylcytosine, and Mval produces N4-methyl-
cytosine. In vitro, the Mval methylase can modify a
substrate that already carries a methyl group at the C5
position of the target cytosine. The result of this dou-
ble enzymatic methylation is the formation of a novel
modified base, N4,C5-dimethylcytosine (4,5mC)
(Butkus et al., Nucleic Acids Res. 13: 5727 [19851).
We are investigating the formation of 4,5mC in vivo
and its consequences for the growth of E. coli. We
assume that 4,5mC should occur in a dcm strain of
E. coli carrying the MvaII methylase gene on a plas-
mid. We analyzed plasmid DNA in strains expressing
different levels of the Mval methylase and were un-
able to detect 4,5mC, although 5mC and 4mC were
readily detectable (S. Klimasauskas, unpubl.). This
result suggests that 4,5mC residues, if they form, are
effectively removed from DNA.
We tested for the induction of the E. coli SOS sys-
tem after transformation with plasmids carrying the
cloned Mval methylase. Strains containing a fusion
of the 13-galactosidase gene to one of the SOS genes,
dinl, were used. Induction of 13-galactosidase expres-
sion was detectable only after transformation of this
strain with a plasmid carrying an intact MMval
gene. Either a dcm6 mutation in the chromosome or a
point mutation in the MMval gene prevented 13-
galactosidase induction. The SOS response in E. coli
is known to be induced by double-strand breaks in
DNA that may occur because of excision of 4,5mC in
vivo.
We also tested the effect of mutations in the SOS
genes on the viability of dcm cells expressing the
MvaI methylase. A set of strains with various muta-
tions in repair genes were transformed with plasmids
carrying MMval. Strains carrying recBC, recBC
sbcB recF, mutS, or dam mutations show normal
levels of transformation. In contrast, strains carrying
ungl, recA, recD, recJ, mutH, or uvrB mutations ei-
ther fail to produce viable transformants or small
colonies appear after 48 hours incubation. A plasmid
containing an inactivated MMval gene transforms
these strains normally. These results suggest that
synthesis of 4,5mC takes place in vivo, but this un-
usual base is efficiently removed from DNA. This
process of repair is accompanied by induction of the
SOS genes.
SEQUENCE OF THE Hpall RESTRICTION
ENDONUCLEASE GENE
The Hpall restriction-modification system from
Haemophilus parainfluenzae recognizes the DNA se-
quence CCGG. A 10-kb DNA fragment carrying the
active methylase gene had previously been cloned
and the sequence of the methylase gene determined.
However, clones carrying the methylase gene did not
express the cognate restriction endonuclease (Card et
al., Nucleic Acids Res. 18: 1377 [19901). Separately,
a 5-kb fragment of H. parainfluenzae DNA was
cloned that expresses both the Hpall methylase and
restriction endonuclease activities (S. Kulakauskas
and A.A. Lubys, unpubl.). The region was sequenced
and a 1074-bp open reading frame was found
downstream from the methylase gene. It overlapped
the methylase gene by 8 bp. Deletion of the DNA
segment containing this reading frame abolishes
restriction endonu-clease activity, suggesting that it
encodes the Hpall restriction endonuclease.
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Integration Host Factor: A DNA-binding
Protein in Escherichia coli
D. Roberts
Integration host factor (IHF) is a site-specific DNA-
binding protein in E. coli. It was discovered original-
ly because of its essential role in integration of bac-
teriophage k and has since been shown to influence
gene expression, site-specific recombination, and
replication in a variety of bacterial systems. IHF is a
member of a highly conserved family of small basic
proteins in prokaryotes. It has been suggested that
these proteins play a role in DNA structure and orga-
nization analogous to histones in eukaryotes.
We undertook an analysis of IHF with the inten-
tion of mapping the regions of the protein that are
critical for DNA binding, site specificity, and DNA
bending. To do this, mutants of IHF were isolated ei-
ther by random mutagenesis (EMS) or by site-
directed mutagenesis using specific oligonucleotides.
IHF is a heterodimer, and both subunits were muta-
genized. In addition, the two subunits, IHFa and
IHFI3, are highly homologous, and hybrid proteins
were generated by substituting segments of IHFa and
IHFI3. The mutants were analyzed for function in a
variety of assays. They were tested for their ability to
support repression of a Tn/O transposase:lacZ fusion,
replication of the plasmid pSC101, and growth of
several phages (A., A. derivatives, and Mu).
IHFa and IHFI3 are different. Amino acid changes
in the putative DNA-binding arm of IHFa can com-
pletely eliminate IHF activity, whereas identical
changes in IHFI3 have no effect. This result suggests
that IHFa and IHFI3 have different roles in DNA
recognition or binding, with IHFa being much more
important. This is further suggested by the study of
hybrid proteins. IHFI3 is much more tolerant of sub-
stitutions; one third of IHFI3 could be replaced by
IHFa without eliminating IHF activity. In contrast,
IHFa is quite sensitive to substitutions, and most
substitutions, even of 10-20% of the protein,
destroyed IHF activity.
Basic amino acids present in the carboxy-terminal
15% of IHF are important. Loss of only one or two of
these basic residues has little effect on activity. Loss
of three or four greatly reduces IHF function. IHFa
and IHFI3 have little homology in this region except
for the basic amino acids. The two regions are func-
tionally equivalent and either can provide full IHF
activity in hybrid protein.
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Protein Sequence Motifs
J. Posfai, C.-L. Lin
Short stretches of amino acid sequence (motifs) that
correlate with protein function are useful tools to help
in the interpretation of newly determined DNA and
protein sequences. Their presence can often lead to
accurate prediction of the function for hypothetical
products. Our goal is to provide semi-automated
methods for the discovery of such motifs with predic-
tive value and to automate the maintenance of a data-
base of motifs.
Sequences that may share some common function
(e.g., catalyzing the same reaction or binding the
same substrate) are retrieved from DNA and amino
acid sequence databases by routines that are based on
interpretation of database annotations. This initial
step is followed by format conversions and transla-
tions. A combination of automatic and manual prun-
ing eliminates uninformative fragments as well as
duplicate copies of sequences. A clustering algorithm
is used to establish sets of functionally related se-
quences. Conserved regions of these sequence groups
are then determined by alignment, based on algo-
rithms similar to those described by Smith et al.
(Proc. Natl. Acad. Sci. 87: 118 [1990]). Different
representations (consensus patterns, regular expres-
sions, sequence blocks, weight matrices, neural nets)
of conserved sequences are created and considered
initial motifs. These are then used to search the
Swiss-Prot database. If they are found to occur in se-
quences other than those initially used to define them,
the hits are examined for true positives, false posi-
tives, or unknowns. If necessary, the motifs can then
be refined to provide greater predictive value.
A fundamental feature of all our algorithms is that
they look upon sequences as chains of overlapping
amino acid triplets that may span distances of aver-
age secondary structural units. This allows the recog-
nition not just of conserved residues of independent
positions, but also of higher-order conserved patterns
(e.g., amphiphilic helices), as well as interactions be-
tween nonneighboring residues that have remained
stable over evolution. When designing and coding
our programs, high priority is given to innovative
visual presentations of results and to user-friendly in-
terfaces. We are presently integrating the main parts
of our database management utilities and developing
compatible links to other widely used sequence anal-
ysis programs like BLAST, FASTA, and BLOCKS.
REBASE: The Restriction Enzyme
Database
D. Macelis, J. Earle-Hughes, R.J. Roberts
The restriction enzyme database, REBASE, continues
to grow and provide primary information about
restriction enzymes to researchers worldwide. We
have now completed the transition from the
ORACLE data management system to SYBASE.
This has greatly streamlined our operation. The data-
base is distributed in more than 20 different formats
each month, and there has been extensive use of our
anonymous FTP service. During the last year, the
number of known restriction enzymes has grown to
more than 2300, with 186 different specificities
represented.
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PROTEIN KINASE STRUCTURE AND FUNCTION
J. Kuret P. Kearney G. Carmel
A. Sessler B. Leichus
P.C. Wang A. Vancura
Our work focuses on two protein kinases: casein
kinase-1 and the cAMP-dependent protein kinase.
Our progress in applying the techniques of X-ray
crystallography and molecular genetics to the study
of protein kinases is described below.
Casein Kinase-1
P.C. Wang, A. Vancura, B. Leichus
Casein kinase-1 (CK1) is a ubiquitous eukaryotic
protein kinase that phosphorylates acidic substrate
recognition sequences efficiently. Once considered a
single entity, it is now known to consist of subspecies
that together comprise a distinct branch of the eu-
karyotic protein kinase family. Family members iden-
tified to date consist of a highly conserved, approxi-
mately 290-residue amino-terminal catalytic domain,
joined to a carboxy-terminal region that is not con-
served between family members and that varies in
size from 40 to 180 amino acids. Although the full
role of the carboxy-terminal domain is not un-
derstood fully, part of its function is to target the en-
zyme to specific regions of the cell.
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ckil
cki2
cki3
cki4
FIGURE 1 The CK1 family from S. pombe. Shading denotes homologous regions.
This year we isolated the complete catalog of CK1
genes from the yeast Schizosaccharomyces pombe
(Fig. 1). The predicted gene products range in size
from 43 to 52 kD and follow the structural organiza-
tion described above. As in the Saccharomyces
cerevisiae system, two of the isoforms contain a con-
sensus prenylation site at their carboxyl termini
(ckil /2), whereas the other two (cki3/4) contain
glutamine-rich regions.
To examine the biochemical properties of these
enzymes, each was expressed in bacteria, purified to
homogeneity, and characterized enzymologically. A
surprising result was that S. pombe CK1s are dual
specificity kinases (i.e., they phosphorylate tyrosine
as well as serine and threonine residues). Although
each CK1 form can autophosphorylate on tyrosine,
only cki3/4 are capable of trans tyrosine phosphory-
lation to exogenous peptide substrates in vitro. In the
coming year, we plan to investigate the role of
tyrosine phosphorylation in CK1 function.
Subcellular Distribution of
Casein Kinase-1
A. Vancura, A. Sessler
CK1 is implicated in a wide variety of cellular func-
tions. In nuclei, it phosphorylates and inactivates T
antigen (an initiator of DNA replication), as well as
p53, a tumor-suppressor protein. In addition, it binds
and possibly regulates kinesin, a mitotic motor.
Cytoplasmic CK1 is activated in response to growth
factor treatment and is capable of phosphorylating the
cortical cytoskeleton. In addition to its role in normal
cells, CK1 has been implicated in the pathogenesis of
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Alzheimer's disease through the phosphorylation of
protein, the major component of neurofibrillary
tangles.
To identify the individual CK1 isoforms involved
in nuclear or cytoplasmic regulation, we examined
the subcellular localization of each of the CK1
isozymes of S. cerevisiae and S. pombe. We find that
in both of these organisms, the prenylated isoforms
cofractionate with RAS and localize exclusively with
the plasma membrane. Membrane association is
mediated by a pair of carboxy-terminal cysteine
residues that are probable sites of prenylation. These
forms appear to transduce extracellular signals: In the
system, the signal is the osmolarity of the
growth medium. A second pair of CK1 isozymes is
more broadly distributed, being found primarily in
the nucleus and the plasma membrane.
We hypothesize that CK1 functions at two levels.
The plasma membrane forms may act in a classical
kinase cascade mechanism. Here, CK1 probably
receives input from an osmolarity "receptor" or
sensor and dispatches output to intracellular kinases
to coordinate a biological response. Nuclear CK1
may also be a component in a signal transduction
pathway. Yet, the unusual phosphate-directed sub-
strate selectivity of CK1 suggests a second mechan-
ism of regulation we call "transistor amplification"
(in electronics, a transistor amplifies a weak current
by superimposing it on a larger current). A protein
phosphorylated at a single site will become a sub-
strate for CK1. Additional phosphates will improve
CK1-mediated phosphorylation still further, resulting
in the phosphorylation of the substrate to high
stoichiometry. In this analogy, the first phosphoryla-
tion event, which may be catalyzed by a distinct
protein kinase, is the weak current, whereas the mul-
tiple phosphorylation catalyzed by CK1 is the strong
current. The information carried by the first phos-
phorylation event is amplified by the large flux of
phosphate produced by CK1. Transistor amplification
is an efficient mechanism: A typical electronic
transistor produces a 100-fold gain (amplification) in
current. Nuclear CK1 may achieve similar amplifica-
tions without the need of a cascade mechanism.
Casein Kinase-1 Tertiary Structure
G. Carmel, P. Kearney [in collaboration with X. Cheng,
Cold Spring Harbor Laboratory, and R. Sweet,
Brookhaven National Laboratory]
Catalytically, CK1 differs from most other protein
kinases in that its substrate selectivity appears to be
directed toward phosphate groups rather than un-
modified amino acids. Although CK1 can phosphory-
late synthetic peptide substrates containing glutamic
or aspartic acids at position -3 or at position -4 (rela-
tive to the position of a phosphorylatable serine or
threonine residue), substitution of those carboxylic
acid residues with phosphoserine yields a dramatical-
ly superior substrate. How CK1 recognizes phospho-
peptides is unclear and may differ substantially from
the well-characterized between the
cAMP-dependent protein kinase and its inhibitor
protein.
To place CK1 enzymology within a structural
framework, we initiated an effort to determine the
A
crystal structure of a representative member of the
CK1 family. We began with one of the S. pombe
clones described above and engineered it so that it
now encoded only the catalytic domain of the en-
zyme. Next, we produced large amounts of enzyme
through heterologous expression in bacteria and
purified the product to near homogeneity. Finally, the
preparation was concentrated and subjected to crys-
tallization trials, the results of which are shown in
Figure 2. In the absence of substrate, CK1 crystall-
izes as rhombohedral prisms (Fig. 2A) up to 0.3 x 0.3
x 0.3 mm in size that diffract to medium resolution
(3.2 A). By examining the systematic absences of
reflections in our diffraction data, we determined that
the packing of protein molecules in the crystal (i.e.,
the space group) had P212121 symmetry. In the
presence of MgATP, CK1 crystallizes in two dif-
ferent crystal forms. The first form (Fig. 2B) emerged
as natty needles with dimensions 1.0 x 0.1 x 0.1 mm
and that diffract to 2.7 A resolution. Again, assign-
ment to space group P212121 was made on the basis
of systematic absences in our diffraction data. The
second binary form emerged as trigonal prisms with
dimensions 0.8 x 0.5 x 0.5 mm (Fig. 2C) and that dif-
fract to high resolution (-2.0 A). Assignment to
space group P3121 (or its enantiomorph) was made
on the basis of precession photography. Two isomor-
phous heavy atom derivatives of this trigonal crystal
form have been prepared.
Our strategy for the coming year is to use these
derivatives to solve the phase problem (by the classi-
cal method of multiple isomorphous replacement)
FIGURE 2 CK1 crystals. (A) Orthorhombic crystals of unliganded CK1
(maximum dimension is 0.3 mm). (B) Orthorhombic
binary form (maximum dimension is 1 mm). (C) Trigonal binary form (maximum
dimension is 0.6 mm).
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and to deduce the tertiary structures of both enzyme
and ligand. Once a model structure is obtained, the
crystal structures of the needle binary complex and of
the unliganded enzyme will be solved by the
molecular replacement method. Together, the struc-
tures will reveal the location of key residues involved
in nucleotide and protein substrate recognition, as
well as the nature of the conformational changes that
occur upon binding of nucleotide substrate.
The "Open" Conformation of the
cAMP-dependent Protein Kinase
J. Kuret, G. Carmel [in collaboration with J. Pflugrath,
Cold Spring Harbor Laboratory, and R. Sweet,
Brookhaven National Laboratory]
Years ago, using methods similar to those described
above for CK1, we initiated a structural study of
TPK1, the catalytic subunit of the cAMP-dependent
protein kinase (PKA) from S. cerevisiae. Over the
years, we have prepared nearly 0.5 g of purified
protein and have grown more than 1000 single crys-
tals of the unliganded form of TPK1. Eager to com-
plete this project and get out of the cold room, we ob-
tained the coordinates of mammalian PKA and gave
them to our crystallographer. It worked like a charm:
The two structures were so similar that "solving" the
structure of TPK1 appeared trivial.
When the structure of TPK1 is complete, what will
it look like? Well, it will look a lot like the pre-
liminary model illustrated in Figure 3. There, the par-
tially refined catalytic core of TPK1 (2.9 A resolu-
tion) is compared to the highly refined 2.2-A struc-
ture of fully liganded, mammalian PKA. Despite
being separated by over 500 million years of evolu-
tion and having only 50% identity in amino acid se-
quence, the two enzymes appear remarkably similar
in tertiary structure. First, the catalytic core of each
enzyme consists of an 85-residue, amino-terminal
domain (the shaded region in each panel of Fig. 3)
linked to a larger carboxy-terminal 183-residue
domain (illustrated without shading in each panel of
Fig. 3) that contains the peptide-substrate-binding site
(peptide substrate is shown in dark shading). Second,
a phosphorylated threonine residue (Thr-197 in the
mammalian PKA numbering system) is found in
identical positions of the carboxy-terminal domain of
each enzyme.
Assuming the conformational differences between
TPK1 and mammalian PKA result from the absence
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or presence of substrates, what can we learn about the
structural consequences of ligand binding? In its Open
conformation, the ligand-binding surfaces of PKA are
exposed to solvent and are accessible to substrates
(Fig. 3A,C). When substrates bind, the amino -
terminal domain rotates relative to the large domain
along a hinge connecting the two domains, resulting
in closure of the nucleotide-binding loop over the
nucleotide substrate. The movement is a simple rigid
body movement that involves a pivot point located in
the small domain (Fig. 3B,D). The conformation of
the carboxy-terminal domain appears to be un-
affected by ligand binding.
Does the autophosphorylated threonine residue
play a role in substrate binding? In the open con-
formation, phosphothreonine makes hydrogen bonds
to three nearby residues, all of which are located in
the carboxy-terminal domain (the side chains for two
of these, Arg-165 and Lys-189, are shown in Fig. 3A
but omitted in the other panels for clarity). Upon sub-
strate binding, a histidine residue in the small domain
(His-87) moves approximately 7 A to make a new
hydrogen bond with the phosphothreonine, thereby
aligning and stabilizing the ternary complex. The
contribution to stability is modest: Mutation of the
phosphothreonine to an alanine (the side chain of
which is incapable of forming hydrogen bonds)
reduces the apparent second order rate constant for
substrate/enzyme association only threefold.
In the coming year, our preliminary model of
TPK1 will be refined so that it and mammalian PKA
can be compared in detail.
S10013 Is Not a Protein Kinase
J. Kuret, R. Hsu
Robbie Hsu was angry. He had just wasted another
week preparing S10013 from a pile of rat brains that
looked like an Alcino Silva experiment gone horribly
wrong. Worse still, he was unable to reproduce the
notoriously fickle crystallization conditions for the
purified protein. There had to be some way of im-
proving the yield and quality of the protein or the
project would be doomed. Then it hit him. An expres-
sion strain for S10013 would solve the problem. The
strain was constructed and the results were dramatic.
Pure, active protein could be isolated in large
amounts in only 3 days. Better still, the protein crys-
tallized in a form that diffracted to higher resolution
than the original material isolated from animals.
FIGURE 3 Comparison of TPK1 (A,C) and mammalian PKA (B,D) tertiary structures (only the
catalytic cores are illustrated). Panels B/D are related to panels A/C by a 90° rotation around the or-
dinate axis. These images were generated by the program
MOLSCRIPT, written by Per Kraulis.
Progress with S10013 crystallography, which takes
full advantage of our expression strain, is sum-
marized in the Macromolecular Crystallography Sec-
tion.
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Genome Topographer: Computer
Software for Integration and
Elaboration of Comparative
Genomic Data
S. Cozza, E. Cuddihy, J. Sa lit, E.C. Reed,
W. Chang, T. Marr
Significant progress has been made in the ongoing
process of genome-level molecular characterization
of the genomes of human and many model organ-
isms. There are nearly completely ordered YAC and
COSMID contigs of several human chromosomes as
well as the first complete sequence of an entire bud-
ding yeast chromosome (chromosome III, 315 kb).
These are examples of some early remarkable suc-
cesses of the international genome program. A grow-
ing tendency within the genome community is to de-
velop specialized databases centered on specific
organisms (e.g., ACeDB, GDB, Fly Base, Eshericizia
coli). These are very important sources of richly an-
notated (e.g., developmental information, gene dis-
ruption information) collections of genomic informa-
tion, yet each of these databases requires its own
idiosyncratic collection of software and hardware to
be able to view data within the database. This often
presents a significant barrier to using these databases
because it is difficult to learn how to use many dif-
ferent software packages effectively, running on
many different types of computers. Those who study
gene function exploit evolutionary conservation ex-
tensively in their investigations; they are not limited
to studying genes in any one particular organism.
With these facts in mind, our research has explored
the following questions: Can collections of appar-
ently disparate genomic data be organized into what
appears to the user as one computer program/data-
base? Can such a system be developed so that it is
capable of being continuously updated, with regard to
both new understanding concerning existing data and
new data types arising from new technology develop-
ments?
We have developed an advanced prototype of an
object-oriented computer system that uses a largely
organism-independent underlying data model to ac-
complish unification of genomic data, from low-
resolution maps to sequence, across the major
eukaryotic model organisms. The system is highly in-
teractive, using intuitive graphical displays, icons,
pull-down menus, and drag-and-drop paradigms for
user actions, allowing the user to retrieve reference
data, create new data using object-based editors, or
enhance the annotations of existing data, by making
links between independently derived data, for exam-
ple. We are currently extending the system to support
sequence similarity searching (on a network-based,
socket-accessible, nonredundant sequence database
whose structure is optimized for searching), tools to
discover conserved elements in groups of functional-
ly related protein sequences, and tools to find com-
binatorial collections of short conserved elements in
the sequence databanks.
We are working with the Stanford budding yeast
group to construct the first integrated database of the
budding yeast and the fission yeast. These two well-
studied yeasts are as far apart from each other as each
is from the human; detailed comparison of sequences
and genetics of these two organisms will yield much
information on molecular evolution, since it is com-
monly observed that although there are many func-
tional homologs existing between the two yeasts,
many, if not most, of the homologies are not detect-
able at the DNA sequence level by standard sequence
analysis methodologies. The system software is pro-
grammed using the Smalltalk-80 programming lan-
guage and the Gem Stone Object Database Manager
and runs uniformly on the host operating systems of
most popularly used computers, including Macs, PCs,
and Unix machines.
Large-scale Structure
of Genomes
W. Li, M. Zhang, T. Marr
We are interested in how information is organized in
DNA sequences using various mathematical and
statistical analysis. In particular, following up our
recent discovery that correlations far beyond their
neighborhoods exist in some DNA sequences (W. Li,
Int. J. Bifurcation and Chaos 2(1): 137 [1992]; W. Li
and K. Kaneko, Europhysics Letters 17: 655 [1992]).
We are gearing up to study large-scale correlation
structures in completely sequenced chromosomes.
This large-scale organization of the information in a
primary sequence should reflect the overall three-
dimensional structure of the chromosome. On that
aspect, our studies will provide new insight into the
structural organization of chromosomes. We plan to
study the distribution and statistical features of the in-
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itiation sites for replication and transcription in the
sequence of Saccharomyces cerevisiae chromosome
III. It is hoped that this distribution will aid our un-
derstanding of the parallel processes of replication
and transcription.
To study long-range correlations in DNA se-
quences, we performed a statistical analysis of the
entire genomic sequence of yeast chromosome III
(M. Zhang and T. Marr, in press). Many biologists
believe that knowing an adenine at one position
should not change the likelihood of finding another
adenine far apart. It turned out that knowing an
adenine at one position actually increases the
likelihood of finding another adenine even 1000 base
pairs apart.
More specifically, our results showed the follow-
ing. (1) Long-range correlations indeed exist: A like
pair of nucleotides (A-A, C-C, etc.) tends to be posi-
tively correlated and an unlike pair (A-C, G-T, etc.)
tends to be negatively correlated. (2) Global strand
symmetries also exist: The probability of finding
nucleotide x some distance downstream from
nucleotide y is approximately equal to that of finding
Y some distance downstream from X (where X and Y
are complementary to x and y, respectively). These
findings imply that duplication and inversion events
(in roughly equal occurrence) have played a major
role in genome evolution.
Computer Detection of
Protein-coding Regions
W. Li, M. Zhang, T. Marr
One of the more challenging problems in computa-
tional molecular biology is to distinguish noncoding
segments of a DNA sequence from the coding seg-
ments. These "coding measures" usually take into ac-
count certain regularities in the coding region that are
absent in randomly generated sequences (e.g., the ex-
istence of the periodicity of three; the difference of
nucleotide usage in three codon positions). Computer
algorithms for coding-region recognition based on
these coding measures actually distinguish coding
regions from a randomly generated sequence, instead
of distinguishing them from introns.
During our studies of long-range correlations in
DNA sequences, we observed that some introns have
their own regularity when compared with a random
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sequence: They tend to have longer correlation
lengths. The preliminary result was derived from a
small sample set of human DNA sequences. We plan
to carry out a comprehensive study of the correlation
structure in both coding and noncoding regions on a
much larger data set. Specifically, we will calculate
the two distributions of correlation lengths for both
exons and introns (by calculating a correlation
measure called "mutual information" for each dis-
tance; the correlation length is the distance at which
the correlation is more or less zero). The degree of
overlap of these two distributions will provide a con-
clusive answer as to whether the correlation length
can be used as a useful "noncoding measure."
We have been exploring another approach to the
problem of finding coding regions. We began with
the study of exon recognition. We divided the prob-
lem into two subproblems: (1) Given both ends of a
gene (maybe only approximately), how can we locate
all of the introns? (2) Given genomic sequence alone,
how can we find all of the initiation/termination
sites? We took the fission yeast as an initial model;
fission yeast has more introns and less conserved
splicing signals than the budding yeast. The lengths
of introns/exons are usually much shorter than what
is required by many existing software programs.
Based on statistical studies of splicing signals, open
reading frames, 6-mer, and length distributions of in-
tron/exon sequences, an interactive computer pro-
gram was developed.
This program is used routinely on newly se-
quenced genes in David Beach's laboratory. The ear-
ly results from this program are encouraging; for ex-
ample, among 19 introns of 9 new genes, 18 were
predicted correctly and confirmed by the cDNA se-
quences. The one that was missed is a 39-bp in-frame
intron. Without information about promoter/poly(A)
signals, it was surprising to us that all of the predicted
translational initiators and stops also seemed to be
correct, except one where the initiation methionine
codon, ATG, was disrupted by an intron after the
single residue A!
We plan to continue the second subproblem by
making more statistical studies on promoters, poly(A)
signals, codon usage preferences, etc., in order to im-
prove the interactive gene finder tools. To prepare for
large-scale sequencing of the Schizosaccharomyces
pombe chromosome, we plan to automate these tools
and test the success rate against other programs.
Eventually, these tools will be used to analyze other
organisms (fly, mouse, human, etc.).
Collaboration with David Beach's
Laboratory Yielded a 13-kb
Resolution Physical Map
of the 14-Mb Fission Yeast Genome
W.I. Chang, D. Lombardi, T. Marr
In collaboration with the Beach laboratory, we have
completed both the development of a contig assembly
algorithm and its application to the fission yeast S.
pombe genome. More than 1000 sites have been
determined and precisely ordered along the 14-Mb
genome. A gene can now be localized to a 13-kb
region (on average) with a simple hybridization ex-
periment.
Our project is the first successful application of a
nonrandom STS content detection method in map-
ping an entire genome. The novelty of our strategy is
in the use of unique probes made by PCR from both
ends of cosmid clones, selected from the library on
the basis of "sample without replacement;" i.e., only
clones that show no positive hybridization to existing
probes are selected and made into probes for sub-
sequent experiments. Two logical steps are carried
out in tandem: Cosmid clones are assembled into
contigs based on hybridization, and contigs are an-
chored onto chromosomes by integration with genetic
and NotlISfiI restriction maps. We will describe the
assembly process in greater detail.
Because our data are of high quality (7% false
negatives, 2% false positives), the internal con-
sistency of a contig is a powerful indicator of its cor-
rectness. On the other hand, inconsistencies suggest
errors either in the hybridization data or in the puta-
tive ordering of probes. A given probe order gives
rise to a set of inconsistencies that can be scored; a
backtracking program analyzes all possible probe or-
GENOME SEQUENCE ANALYSIS
W.R. McCombie S. Matsumoto
The past two decades have been marked by an explo-
sion in our knowledge of the structure and function of
individual genes. One major factor in these advances
has been the determination of the structure of a num-
ders and finds the one that is most consistent with the
data. Furthermore, any remaining inconsistencies be-
come hypotheses of experimental error, which can be
checked by consulting the original autoradiographs or
running new experiments. Repetitive probes are rare
(library was filtered for known repeats) and are
detected when two self-consistent contigs contain the
same probe. This error checking and the confirmation
of our partial results allow us to proceed at a more
aggressive pace, using a relatively sparse clone li-
brary (1920 cosmid clones representing five times
coverage). The cosmid map was essentially complete
after 1 year (7/91-6/92).
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ber of genes or their respective cDNAs at the level of
their DNA sequence. Individual genes are the basic
components of genetic information, but the most
complex level of genetic organization is the genome
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itself. Recent technical advances now make it feasi-
ble to consider the analysis of the structure and func-
tion of complete eukaryotic genomes at the level of
their DNA sequence. This is the major effort of our
laboratory. Our primary goal is to use the latest ad-
vances in automated DNA sequencing to analyze the
genome of the fission yeast Schizosaccharomyces
pombe. The groups of David Beach and Tom Marr
began the S. pombe genome project by mapping the
S. pombe genome and generating an ordered set of
cosmid clones that comprise most of the genome.
With this outstanding starting point, we will begin
dissecting the S. pombe genome in collaboration with
these groups. Three areas of research will be devel-
oped to accomplish this goal: (1) technology develop-
ment to reduce the cost, increase the speed, and scale
up the process of DNA sequencing; (2) sequencing a
large number of cDNAs from S. pombe; and (3) se-
quencing large regions of the S. pombe genome.
Since coming to the Laboratory in September of
1992, we have begun work on the first two of these
areas.
Sequencing Technology
Development
W.R. McCombie
Theoretically, to sequence large genomes efficiently,
the most desirable strategy is based on a process of
taking sequential sequencing steps with custom
primers known as primer walking. This approach is
not currently used in most large-scale projects be-
cause of the added cost of primers and the added time
required and project management burden caused by
the sequential nature of primer walking. This is op-
posed to the parallel scale up possible with random or
shotgun approaches. Recently, Bill Studier (Brook-
haven National Laboratory) demonstrated that in the
presence of single-stranded binding (SSB) protein,
three adjacent hexamers could prime sequencing
reactions rather than a single 18 mer or longer primer
(Science 258: 1787 [1992]). This advance offers
tremendous potential to improve DNA sequencing ef-
ficiency. The entire set of 4096 hexamers could be
readily synthesized in advance, thus eliminating the
wait required for a new primer to be synthesized after
each step in the sequencing. In addition, the cost
benefits of being able to use multiple aliquots of a
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hexamer to prime many reactions rather than
synthesizing a new 18 mer for each reaction arc very
significant. To make this approach applicable to
large-scale sequencing, I have been collaborating
with Bill Studier to adapt this hexamer-based reaction
to current automated fluorescent DNA sequencers.
This will eliminate the time-consuming, error-prone,
and expensive step of manually reading sequencing
gels and allow computer-readable sequences to be
derived from hexamer-primed reactions. I have been
carrying out experiments to adapt hexamer-primed
reactions to both the Applied Biosystems (ABI) and
Pharmacia DNA sequencers.
Hexamer-primed reactions require an initial exten-
sion of the hexamers at 0°C, followed by termination
of the reactions at 37°C. With the Pharmacia chemis-
try, the most straightforward time to add fluorescent
label to the extension products is during this initial
extension reaction. The low temperature, however,
reduces the incorporation of fluorescein-dATP to un-
detectable levels under the initial conditions at-
tempted. The low temperature greatly reduces the in-
corporation of fluorescein-dUTP as well, but enough
of this label is incorporated to allow detection and ac-
curate sequence determination with control templates
and standard sequencing primers. In addition, initial
results indicate that the presence of single-stranded
DNA-binding protein in the sequencing reactions in-
terferes with fluorescent detection of the sequencing
ladders.
The reactions with the Applied Biosystems instru-
ment use fluorescent dideoxynucleotide analogs for
termination and labeling. It should be possible to do
these termination reactions at 37°C, following a 0°C
extension with standard dNTPs to extend the
hexamers enough to stabilize their binding to the
template. This is potentially an advantage of the ABI
system for hexamer-primed reactions, since the base
analogs do not need to be incorporated at 0. Although
this is not the way the ABI reactions are typically
carried out, I have developed conditions to ac-
complish this. The presence of SSB, however, inter-
feres with detection on the ABI machine as well as
the Pharmacia. I am currently optimizing reactions
primed with hexamers in which the SSB is removed
by phenol extraction. I am also exploring alternate,
less time-consuming ways to remove SSB.
Initial reactions on the Pharmacia gave 60 bases of
sequence using adjacent hexamers, versus 400-500
with standard primers. Under the best conditions de-
veloped thus far, using the ABI machine, hexamer-
TABLE 1 Similarities of S. pombe cDNA Tags to Known Genes
Database identifier Name
SP:RL5_YEAST
SP:UCR9_YEAST
PIR:S16810
SP: RS12RAT
SP:TRXB_ECOLI
SP:ARDLYEAST
GP:MUSADIPCT_1
SP:EF1B_HUMAN
BB:B111730
SP:TRPD_METTH
SP:TPIS_SCHPO
SP:GBLP_HUMAN
GP:YSCRPS28A_1
SP: I LV5_YEAST
SP: RS6_SCHP0
SP:RLD4_SCHP0
60S RIBOSOMAL PROTEIN L5 (YL3). >PIR:S
UBIQUINOL-CYTOCHROME C REDUCTASE SUBUNI
*Ribosomal protein L7a.e - Yeast (Saccha
40S RIBOSOMAL PROTEIN S12. >PIR:R3RT12
THIOREDOXIN REDUCTASE. >PIR:RDECT Thio
ARREST-DEFECTIVE PROTEIN 1. >PIR:TWBYA
Mouse 19.5 kD protein mRNA, complete c
ELONGATION FACTOR 1-BETA (EF-1-BETA)
ribosomal protein S13 [Schizosaccharom
ANTHRANILATE PHOSPHORIBOSYLTRANSFERASE
TRIOSEPHOSPHATE ISOMERASE (TIM). >PIR
GUANINE NUCLEOTIDE-BINDING PROTEIN BETA
ribosomal protein S28 [Saccharomyces c
KETOL-ACID REDUCTOISOMERASE (ACETOHYDRO
40S RIBOSOMAL PROTEIN S6. >PIR:R3ZP6E Ri
60S RIBOSOMAL PROTEIN KD4. >PIR:R5ZPD4
Sequences of cDNAs from S. pombe were used to search protein sequencedatabases using the
Blast server of the National Center for Biotechnology Information at the National Library of Med-
icine. The program used for the search was Blastx, which translates DNA sequences into peptide
sequences and searches protein databases for similarities. Those matches above a cutoff score of
95 are shown in the table above.
primed reactions read 350-450 bases but have sub-
stantially more ambiguities than standard reactions. I
am continuing to optimize these reactions.
S. pombe cDNA Analysis
S. Matsumoto, W.R. McCombie
To aid in the analysis of genomic sequence, it is ex-
tremely useful to have available even partial se-
quences of as many cDNAs from that organism as is
possible. The partial sequencing of cDNAs is also a
rapid and inexpensive way to identify a large number
of genes from an organism. In addition, since we will
also be sequencing large genomic regions of S.
pombe, we will be able to compare the genomic and
cDNA approaches if we also undertake a cDNA-
sequencing project. We have begun to partially se-
quence randomly selected clones from an S. pombe
cDNA library (provided by Gregory Hannon). The
translated sequences were then compared to a series
of protein databases maintained by the National Cen-
ter for Biotechnology Information. These include a
translated version of Gen Bank. An initial analysis of
about 50 of these sequences reveals that 35% of them
are similar to previously known genes from other
species or, in a few cases, genes previously identified
in S. pombe. A list of these genes is shown in Table
1. We are currently working with Diane Lombardi
and Tom Marr to develop a Sybase database for
storage and analysis of these sequences. We are con-
tinuing to sequence cDNAs and to identify new
potential homologs in S. pombe of interesting genes
from other species. Our long-term goal is to sequence
10,000-15,000 genes in this way. This should
represent the majority of genes in S. pombe.

NEUROSCIENCE
This section includes seven laboratories with interests in the development and
function of the brain, with a particular emphasis on the signal transduction pro-
cesses underlying learning and memory. Ron Davis is studying the genes,
molecules, and cells involved in learning in the fruit fly, Drosophila. Grigori
Enikolopov studies the role of nitric oxide, calcium, and other messengers in
gene transcription as related to synaptic plasticity, and in particular, long-term
potentiation. His laboratory recently demonstrated that nitric oxide potentiates the
effect of calcium on transcription of the early immediate gene, fos. This finding
has important implications for signaling processes during learning. Alcino Silva
arrived at Cold Spring Harbor Laboratory in 1992 after making a finding of
enormous importance. Genetically mutant mice deficient in the enzyme cal-
cium/calmodulin kinase II are impaired in learning as well as in long-term
potentiation. This observation is key to understanding the relationship between
calcium-induced phosphorylation, potentiation of transmission at synapses, and
animal learning. The laboratory of Dan Marshak is interested in growth factors
and signaling processes involved in neuronal growth and differentiation. This in-
cludes the growth factor, 510013, a factor with an intriguing relationship to
Alzheimer's disease. Hiro Nawa also studies peptide factors involved in differen-
tiation of neurons. Many diffusible factors determine the neurotransmitter
phenotype of brain neurons. Dr. Nawa's laboratory has provided beautiful evi-
dence that a factor named BDNF is responsible for causing neurons to express
the neurotransmitters, neuropeptide Y and somatostatin. This induction of
neurotransmitter expression is potentially an important method of regulating the
plasticity of synapses and, presumably, learning and memory. Tim Tully's group
uses genetics to probe for genes involved in learning in Drosophila. Their ex-
cellent work has identified a handful of new learning genes. Yi Zhong works at
the heart of neuroscience-studying synaptic plasticity and the excitable
iproperties of neurons. He has uncovered numerous and important alterations in
these properties in neurons from Drosphila learning mutants. The research of the
seven Neuroscience laboratories is detailed below.
NEURONAL GROWTH AND DIFFERENTIATION
D.R. Marshak C. Brecher A. Rossomando
N. Chester M. Vandenberg
L. Pena
This laboratory conducts research on the biochemical
basis of neuronal growth and differentiation. Overall,
the questions that we approach in our research in-
volve the decisions of neuroblasts to cease prolifera-
tion and to subsequently elaborate neuritic processes
prior to terminal differentiation. These questions thus
involve understanding how signal transduction sys-
tems that control cell proliferation in the neuroblast
are altered upon becoming postmitotic as well as
learning which growth factor molecules control these
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switches within cells. Specifically, we are interested
in the action of a growth-stimulating protein, S10013,
that is produced by astrocytes in the brain. The me-
chanism of action of S100(3 is compared to that of
other growth factors, such as those in the family of
neurotrophins or the family of heparin-binding
(fibroblast) growth factors. The involvement of such
neurotrophic factors in degenerative diseases, such as
Alzheimer's disease, has prompted our interest in the
role of such factors in neuropathological processes.
Mechanism of Action
of S10013
L. Pena, D. Marshak [in collaboration with E. Azmitia,
New York University]
During this year, we received a large grant from the
National Institute on Aging to conduct studies on the
mechanism of action of S10013, a polypeptide growth
factor produced by glial cells in the brain. This is a
multisite program grant that brings together anato-
mists, pharmacologists, pathologists, molecular bi-
ologists, and biochemists that work on S10013. Our
laboratory discovered the function of this molecule
several years ago and have more recently discovered
its abnormal levels in Alzheimer's disease. Our work
is central to understanding the potential role of this
factor in the pathology of neurodegenerative disease.
BINDING OF S1000 TO TARGET CELL
MEMBRANES
Binding assays were performed on membranes isolat-
ed from embryonic chick telencephalons and on in-
tact C6 glioma cell cultures. Many of the basic pa-
rameters were systematically investigated in binding
assays using 125I-labeled S10013, including a buffer
system, divalent cation (Mg++ and Ca++) concentra-
tion, incubation times, ligand concentration, and
membrane concentration. In addition, incubations of
radioiodinated S10013 with intact glial cultures were
assayed. Optimal parameters were determined, but no
saturable binding was observed when ligand con-
centration was varied. These data suggest that S10013
does not bind to the target cell membranes in a clas-
sic receptor-ligand manner.
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UPTAKE OF RADIOIODINATED S100(i
Since S10011 does not bind in a saturable manner
to
cell membranes, it is possible that S 100p is taken
up
by cells and is active either within the plasma mem_
brane or in another intracellular compartment. Two
routes of study have been pursued. First, pulse-chase
experiments were designed using 51000 followed by
localization with immunogold labeling and electron
microscopic detection. Such analysis could be profit-
able, but primary cultures of neurons were unable to
withstand the rigorous treatments required for elec-
tron microscopy. Feasibility with other cell types is
being tested. Second, in collaboration with E. Az-
mitia, injection of radioiodinated S10013 into rat
brains was done in the fimbria-fornix tract and in the
Raphe nuclei. In the fimbria, specific uptake has been
observed in granular neurons of the dentate gyms of
the hippocampus. In the Raphe, it appears that uptake
in a subpopulation of serotonergic neurons occurs.
However, no retrograde transport of the ligand was
seen from temporal structures to mid-brain perikarya.
These data suggest that the primary action of sloop
is within neuronal cell bodies proximal to the glial
cells that produce the growth factor.
ROLE OF SEROTONIN
Data from lesion studies in vivo in rats indicated a
role for the neurotransmitter, serotonin, in the release
of S10013 by E. Azmitia and P. Whitaker-Azmitia. In
addition, studies of cultured neurons of the Raphe
nuclei show that S100(3 is a potent neurotrophic fac-
tor for these serotonergic neurons. Unfortunately,
reagents for studying the serotonergic systems were
not available as they are for catecholaminergic and
cholinergic systems. Therefore, we set out to produce
antibodies to two proteins that are critical to these
studies: (1) tryptophan hydroxylase, the mixed func-
tion oxidase that is the rate-limiting step in serotonin
biosynthesis, and (2) serotonin receptor type la,
which has been linked pharmacologically to S10013
induction and cAMP-mediated responses in glia. We
chose to produce these antibodies in rabbits using
antigens based on synthetic peptides that correspond
to particular regions of the molecules. Regions
chosen for antigenic sites are unique to these proteins
and are thought to be located on the proteins' sur-
faces. High-titer antisera were thus prepared and are
excellent tools for immunohistochemical studies as
well as biochemical analysis of proteins.
Distribution of S10013
in Human Brain Diseases
D. Marshak, M. Vandenberg [in collaboration with
W.S.T. Griffin, University of Arkansas, and
P. Whitaker-Azmitia, SUNY Stony Brook]
The proximity of S10013-containing astrocytes to
neuritic, amyloid plaques in the brains of Alz-
heimer's disease (AD) patients suggests a functional
role for S10013 in the pathology of the disease.
Gliosis and elevated S10013 accompanies several
neurodegenerative diseases, and the elucidation of the
role of this growth factor in degeneration is important
to our understanding of the etiology of the diseases.
In addition, basic research in glial-neuronal interac-
tions will help us to learn the fundamental processes
that control brain development and adult function. In
collaboration with W.S.T. Griffin, radioimmunoas-
says for Sloop are being done on a variety of brain
regions from autopsy tissue of AD patients compared
to age-matched controls. Temporal lobe regions that
are clearly affected by amyloid deposition and
degeneration have elevated S10013 in reactive glia. In
a separate study, samples from patients suffering
from AIDS dementia were observed to have in-
creased S10013 but not to as high a level as in AD.
Down's syndrome brain tissue has been analyzed
collaboration with P. Whitaker-Azmitia to analyze
the levels of S10013 in infants. There appears to be
elevation, even in the absence of amyloid deposition.
In another study, patients with a ring chromosome 21
that have some clinical symptoms were shown to
have only two copies of the S10013 gene, unlike full
trisomy 21 patients, who have three copies.
In Alzheimer's disease and Down's syndrome,
severely afflicted brain regions exhibit up to 20-fold
higher protein levels of S10013, and astrocytes sur-
rounding neuritic plaques exhibit higher protein
levels of S10013. A major constituent of the plaques is
13-amyloid protein, which has been reported to have
both neurotrophic and neurotoxic effects in vitro. We
examined the responses of central nervous system
glia to a 13-amyloid peptide. Primary astrocyte cul-
tures, obtained from neonatal rats, and rat C6 glioma
cells were synchronized by serum deprivation and
treated with PA(1-40), a synthetic fragment of 13-
amyloid. A weak mitogenic activity was observed, as
measured by [31-1]thymidine incorporation. Northern
blot analysis revealed increases in S10013 mRNA
within 24 hours, in a dose-dependent manner. Figure
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FIGURE 1 Experiment showing increase in 510013 mRNA in
C6 cells treated with 13- amyloid.
1 shows an experiment that indicates the increase in
S10013 mRNA in C6 cells treated with (3- amyloid.
Nuclear runoff transcription assays showed that
13A(1-40) specificially induced new synthesis of
S100(3 mRNA in cells maintained in serum but
caused a general elevation of several mRNA species
in cells maintained under serum-free conditions. At
the protein level, corresponding increases in S100(3
protein synthesis were observed in response to the
13A(1-40) peptide, measured by immunoprecipitation
of 35S-labeled cellular proteins. The data indicate that
S10013 expression can be influenced directly by (3-
amyloid.
Protein Kinase Modulation
during Neuronal Differentiation
A. Rossomando, L. Pena, D. Marshak [in collaboration with
G. Landreth, Case Western Reserve, Cleveland, Ohio]
We have continued our studies of protein kinase
responses to growth factors in neuronal cells. Two
model systems are currently in use: chicken embryo
neurons stimulated with S10013 and rat pheochromo-
cytoma (PC12) cells stimulated with nerve growth
factor (NGF) or epidermal growth factor (EGF). In
collaboration with Gary Landreth in Cleveland, we
identified a new protein kinase that responds to NGF
and EGF in PC12 cells and that phosphorylates the c-
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fos proto-oncogene product. This is of significance
because it suggests that neuronal responses of in-
creased c-fos expression might be regulated by
phosphorylation of the protein product.
A complete study of p34cdc2 kinase and MAP
kinases in PC12 cells that respond to NGF has been
conducted by A. Rossomando. The rat pheochromo-
cytoma cell line, PC12, undergoes morphological and
biochemical differentiation into sympathetic neurons
in culture under the influence of NGF. The enzyme
p34cdc2 kinase, which is critical to the induction of
mitosis, appears to be down-regulated during NGF-
stimulated differentiation. The previously identified
p46 protein seems to be a form of MAP kinase in
these cells. This protein kinase is known to be stimu-
lated indirectly by growth factor receptor tyrosine
kinases and associated molecules. We are currently
working on the interactions between this family of
kinases and the cell-division-cycle-regulated kinases,
such as p34cdc2 These studies will enable us to work
out pathways of signaling from the surface of the
neuron to the genome.
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MOLECULAR AND CELLULAR BIOLOGY OF LEARNING
R. Davis G. Bolwig
J. Bonacum
J. Cherry
C. Chromey
J. Crittenden
B. Dauwalder
J. DeZazzo
K. Han
S. Hespelt
M. Joyce
A. Nighorn
E. Skoulakis
R. West
K. Wu
Our laboratory continues with its long-term goals of
probing the molecular and cellular biology of learn-
ing. We approach these goals using the techniques of
genetics, molecular biology, biochemistry, behavior,
and anatomy. In general, the techniques of genetics
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and behavior are used to identify genes required for
normal learning/memory, the techniques of molecular
biology and biochemistry are used to clone the re-
quired genes and to characterize the gene products,
and anatomical methods are used to trace the flow of
information in the brain and to understand where the
genes are required to be expressed for normal learn-
ing/memory.
A major and important story contributed by our
laboratory in 1992 was the characterization of the
rutabaga gene of Drosophila. With molecular and be-
havioral techniques, we demonstrated that rutabaga
encodes a calcium/calmodulin-stimulatable adenylyl
cyclase and that this gene is preferentially expressed
in neural centers called mushroom bodies. These
structures are thought to mediate olfactory learning in
insects. Progress on other projects in the laboratory is
described below.
The laboratory expanded in 1992. During the past
year, we have welcomed Jim Bonacum, Marianne
Joyce, Sue Hespelt, Jim DeZazzo, Gert Bolwig, Jill
Crittenden, Kay Han, and visiting scientist Bob West
into our laboratory. We said goodbye to our friend
and colleague, Pyung-Lim Han. Han finished an ex-
cellent thesis on the rutabaga locus and initated post-
doctoral work at the Baylor College of Medicine.
Drosophila Protein Kinase A
E. Skoulakis [in collaboration with D. Kalderon,
Columbia University]
The fly stock, MB581, was isolated in an enhancer-
detector screen to search for mushroom body genes
and was shown to contain a transposable element in
the unique gene for the catalytic subunit (dc0) of
protein kinase A (PKA). In situ hybridization to tis-
sue sections and immmunohistochemical analysis
demonstrated that dc0 is preferentially expressed in
the mushroom bodies. Thus, the preferential expres-
sion of PKA in the mushroom bodies along with the
rutabaga-encoded adenylyl cyclase (AC) and the
dunce-encoded cAMP phosphodiesterase (PDE)
lends strong support for a role of the cAMP cascade
in these neurons to serve learning/memory processes.
Molecular characterization revealed that the
transposon in MB581 was inserted in exon 1, 71 by
downstream from the transcriptional start site of dc0,
thus disrupting the gene. This disruption reduces the
amount of dc0 RNA to barely detectable levels as as-
sayed by in situ hybridization with homozygous
mutant embryos. The insertion produces recessive
lethality and a 35-40% reduction in PKA activity in
heterozygous adults due to the reduction in the level
of the DCO protein. A similar decrease in activity and
a lethal phenotype are exhibited by a different hypo-
morphic allele of this gene (B10) isolated in an
screen by ethylmethanesulfonate (EMS) mutagenesis
(D. Kalderon, unpubl.). The reduction in PKA ac-
tivity in B10 is likely the effect of a missense muta-
tion on the structure of the protein and/or activity of
DCO. Surprisingly, heteroallelic MB581/B10 animals
can be obtained that appear to be normal externally
and normal with respect to brain structure. However,
they exhibit only 20-25% of the PKA activity of con-
trol strains.
The effect of reduced PKA activity on behavior
was investigated by determination of the learning/
memory phenotype of MB581 and B10 heterozygotes
and the MB581/B10 heteroallelic animals using an
olfactory classical conditioning paradigm. Initial
learning of MB581 is slightly reduced compared with
the control strains and B10 heterozygotes. Inter-
estingly, memory assayed 30 minutes or later is
normal. Similarly, B10 heterozygous animals exhibit
a slight dominant effect on learning. Thus, the
35-40% reduction in PKA activity appears to have a
mild effect on learning but is not limiting for
memory. The MB581/B10 heteroallelic animals ex-
hibit a 50% reduction in both initial learning and
memory. This behavioral effect is not due to the in-
ability of the mutants to perceive the stimuli
demonstrated by control experiments in which both
heterozygotes and the heteroallelic animals are in-
distinguishable from the control strains. These results
demonstrate unambiguously that PKA plays a car-
dinal role in learning and memory processes
mediated by the mushroom bodies.
Rutabaga Structure and Expression
P.L. Han [in collaboration with L. Levin and R. Reed,
Johns Hopkins School of Medicine]
Several of the lines identified by enhancer detection
with preferred expression of p-galactosidase in
mushroom bodies were shown to have a P-element
insertion at the cytogenetic position corresponding to
the rutabaga locus, the second best characterized
learning gene of Drosophila. To determine whether
these insertion elements had indeed landed in the
rutabaga locus, the genomic DNA flanking the inser-
tions was isolated and compared to that isolated from
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an adenylyl cyclase (AC) gene thought to be the
rutabaga function. Seven insertions were identified
within 2 kb upstream of the transcription start of the
AC gene. In addition, we were able to show that
several of these insertions were new alleles at the
rutabaga locus behaviorally. By RNA in situ
hybridization with AC probes and immunohisto-
chemistry with anti-AC antibodies, we demonstrated
that the AC RNA is preferentially expressed in
mushroom bodies, that the AC immunoreactivity was
concentrated in mushroom body neuropil, and that
the insertion elements of the new rutabaga alleles
compromised the expression of the AC gene. These
observations add great strength to the idea that
mushroom bodies are neural centers for insect learn-
ing and that the products of known learning mutants
have their effects by altering mushroom body cell
physiology.
Structure and Function of Dunce
Y. Qiu
The dunce locus presented a special challenge in
identifying its transcriptional units and identifying
the biological function of each. The gene extends
over more than 148 kb. This makes dunce the largest
Drosophila locus characterized to date. Transcription
of dunce begins at a minimum of five sites from stan-
dard molecular analysis by primer-extension and S1-
nuclease experiments. Because of the complexity of
the transcriptional units, we initiated a series of ex-
periments to define the biological role of each.
A series of deficiency chromosomes known to
have breakpoints in and around dunce were analyzed
by Southern blot analysis. This allowed for the identi-
fication of deficiencies that remove transcription start
site (tss) 1 and 2, tssl -3, tssl -4, and all known tran-
scription start sites. These flies were assayed for
normal cAMP phosphodiesterase (PDE) activity, the
known product of dunce, for elevated mushroom
body expression of the PDE, for female fertility,
since dunce mutations cause female sterility, and for
learning/memory activity. Surprisingly, removal of
tssl and tss2 has no detectable effect on any of the
phenotypes. tss3 was required for elevated mushroom
body expression but not for female fertility or initial
learning. tss4 contributed to learning and the female
fertility function and tss5 contributed to female fertil-
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ity. The results suggest that the structural complexity
of the gene is needed for serving unique biological
functions.
Cell Adhesion Molecules
and Learning
K. Wu [in collaboration with C. Goodman,
University of California, Berkeley]
Among the enhancer-detector lines, one line named
MB2225 has its P-element insertion site cytogeneti-
cally at 4AB. This is a locus housing the gene for a
Drosophila cell adhesion molecule, fasciclin II (fas
II), which is originally identified as a molecule in-
volved in the early development of the nervous sys-
tem. When tested for their ability to associate an odor
with electric shock, flies from this line showed defec-
tive association and memory at all time points tested
up to 3 hours after training.
To clarify the relationship between fas H and
MB2225, the genomic fragment next to the p-
element insertion site in MB2225 was obtained by
plasmid rescue. Using this fragment for Southern
hybridization and DNA sequence analysis, the inser-
tion site in MB2225 was mapped to the first exon of
the fas II gene at a position between the transcription
start site and the open reading frame. Therefore,
MB2225 was expected to be a fas II mutant. To con-
firm this, protein expression was analyzed by im-
munohistochemistry using antibodies raised against
the transmembrane form of the Fas II protein. In head
sections of wild-type adult flies, the protein is ex-
pressed mainly in the mushroom bodies and the ellip-
soid body of the central complex. This expression is
missing in MB2225. Because of the hypothetical role
for mushroom bodies in learning, Fas II expression in
these structures is consistent with the possibility that
Fas II functions in adult behavior in addition to its
developmental functions.
lightminded, a Putative New
Learning and Memory Mutant
B. Dauwalder, J. Crittenden
Enhancer-detector line 2063 shows preferential ex-
pression of P-galactosidase in the mushroom bodies.
Flies homozygous for the P-element insert are defi-
cient in learning and memory in a classical negatively
reinforced learning paradigm. Initial learning as well
as retention over the 180 minutes tested is lower than
that of wild type. Control experiments confirmed that
mutant flies perceive the stimuli used for condition-
ing (olfactory cues and electrical shock) in a manner
indistinguishable from that of wild type, suggesting a
defect specific for the learning/memory process. An-
other P-element line with an insert only 200 by from
2063 has also been shown to be deficient in learn-
ing/early memory, and this may be allelic to the first.
We have isolated genomic DNA flanking the P-
element insertion site and used it to screen a head-
specific cDNA library. Two classes of transcripts
have been identified. Several head-specific RNAs
were detected by the cDNA probes, some of which
are absent or strongly reduced in the mutant. Future
work will include characterizing these sequences and
their spatial expression pattern.
Mushroom Body Lines
C. Chromey, S. Hespelt
Beginning with the 90 mushroom body stocks that
were previously isolated, approximately 65 have been
tested in an olfactory, classical learning situation to
search for learning/memory deficits. The preliminary
results have been intriguing; several new putative
mutants have been uncovered with differential effects
on the shape of the memory curve. Five distinct
classes of memory curves have been observed to
date: (1) stocks that score lower at all time points
tested, (2) stocks that score low at early time points
but normal at later ones, (3) stocks with normal
scores immediately after training but with a rapid
memory loss, (4) stocks that score lower than normal
at early times but higher than normal at late times,
and (5) stocks with normal scores immediately after
training but with enhanced scores later. These classes
may represent the beginning of the genetic dissection
of different phases of memory.
Mushroom Body Cell Culture
K. Han
The primary goals of this project are to identify the
neurotransmitter receptor(s) coupled to adenylyl
cyclase and to identify the neurotransmitter(s) ex-
pressed by mushroom body cells for communication
with follower neurons. An enhancer-detector line that
expresses P-galactosidase exclusively in mushroom
body cells was used. Third instar larval brains were
dissociated enzymatically and mechanically and
plated; 20,000-50,000 cells are recovered from each
brain. Staining of fixed cells with X-gal after 1 day of
culture or immediately after dissection revealed that
approximately 2% of total cells expressed Es-
cherichia coli ii-galactosidase. This proportion is
comparable with the estimated number of mushroom
body cells in the brain, suggesting no selection for or
against mushroom body cells in culture. The cells
were also identified after hypotonic shock with FDG,
a fluorescent substrate for 13-galactosidase. Thus,
mushroom body cells can be identified among
heterogeneous cultures of brain neurons. The devel-
opment of this procedure will allow the elec-
trophysiological analysis of mushroom body cells as
well as sorting the cells for further biochemical or
cell biological experiments.
Mammalian Homo logs of Dunce
J. Cherry, J. Bonacum
The study of Drosophila has yielded much of our
current understanding of the cellular mechanisms un-
derlying behavior. A number of genes that appear to
be critical for the processes of learning and memory
formation have been identified in this species, includ-
ing the dunce gene, which encodes a cAMP-specific
phosphodiesterase. We are now in a position to ask
whether these genes are structurally and functionally
conserved in other species. We have thus begun to
examine the mammalian homologs of the Drosophila
dunce gene. Four distinct dunce homologs have so far
been reported in mammals; we used polymerase
chain reaction (PCR) to partially clone the mouse
dunce homologs from rat clones obtained from M.
Wigler's laboratory. Antibodies have been generated
to each of the mouse dunce gene products, and we are
now in the process of determining specifically where
in the brain the Dunce proteins occur. Similarly,
antisense RNA probes to brain tissue sections should
indicate where each gene is expressed. Our hope is
that one or more of the mouse dunce genes will be
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found in regions of the brain associated with learning
and memory, such as the hippocampus and cortex.
Ultimately, the question of function of the dunce
genes in mice will be addressed by gene knockouts
using homologous recombination in embryonic stem
cells.
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GENETICS OF LEARNING AND MEMORY IN DROSOPHILA
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S. Boynton
C. Brandes
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Our first full year at Cold Spring Harbor Laboratory
has been a very productive one. Genetic analyses of
genes involved with learning and memory in fruit
flies have moved in iterative fashion from one
phenotypic level to another, yielding important
biological information about several loci. In the last
year, we have continued to characterize our newly
isolated learning/memory genes-latheo and linotte-
at molecular, anatomical, developmental, and behav-
ioral levels of analysis. Work on latheo, in particular,
suggests that this is quite an interesting gene. We
have sequenced our newly isolated temperature-
sensitive allele of pale, revealing a single-amino-acid
substitution in the tyrosine-hydroxylase coding se-
quence. We also have initiated two "reverse genetic"
studies on the RI regulatory subunit of protein kinase
A (PKA) and on Drosophila nitric oxide synthase
(NOS) homologs. Finally, we continue our behav-
ioral analyses of normal and mutant fruit flies. We
have demonstrated additional vertebrate-like proper-
ties of learning and memory, including inhibitory
conditioning, US pre-exposure, and formation of a
bona fide long-term memory (LTM). Initial results
from the latter experiments suggest that LTM does
not form in amnesiac mutants.
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"Forward Genetics" of latheo,
linotte, and pale
T. Tully, S. Boynton, R. Mihalek, C. Jones, D. Wood,
G. Hannon, F. lmrie, K. Han [in collaboration
with Y. Zhong, Cold Spring Harbor Laboratory]
Last year, we summarized the basic behavior-genetic
characterization of latheo, a new gene involved with
associative learning/memory identified while at
Brandeis University. Along with the development of
behavioral control experiments to verify that latheo
mutants sensed, and responded to, odors and electric
shock normally, we also generated lethal alleles of
the gene upon excision of the P-element mutator.
This year, we have looked more closely at the de-
velopmental lethal phase in several genetic variants
of latheo. Lethal latheo mutants hatch, grow through
the larval instars, and pupate normally, but no flies
eclose as adults. This result prompted us to look in-
side third instar larvae just before they pupated. In-
terestingly, we could not find any imaginal discs, and
central brain structures-particularly optic lobes-
appeared to be small. Moreover, we failed to detect
any mitotic activity in the larval central nervous sys-
tem after a 1.5-hour pulse of bromodeoxyuridine,
which labels replicating DNA during cell division.
This overall developmental syndrome is intriguing,
especially since adult brains of flies homozygous for
viable latheo alleles have no obvious structural
defects (Boynton and Tully 1992). Thus, latheo may
be required for normal development of adult struc-
tures. Furthermore, our colleague here at the
laboratory, Dr. Y. Zhong (see his report in this sec-
tion), has discovered a functional defect at the
neuromuscular junction in viable latheo larvae, sug-
gesting that the latheo gene is also required for
normal synaptic function-at least in motor neurons.
We began molecular cloning of latheo by probing
a phage library of genomic DNA fragments from
latheoP1 flies with the labeled P-element sequence
(the latheo P-element was not a newer "plasmid-
rescuable" version). Eleven positives were identified
from a total of 270,000 plaques. We knew from
restriction analysis of latheo genomic DNA that a
Hind!!! digest of the correct phage would yield a
700-bp fragment containing 40 by of P-element DNA
and 660 by of "flanking" genomic DNA. Three of the
11 phage clones yielded such a Hind!!! fragment.
This fragment then was gel-purified and subcloned
into a plasmid. The 700-bp Hind!!! fragment then
was used to probe a phage library containing
genomic DNA from wild-type Canton-S flies. Three
clones were identified; subsequent restriction analysis
characterized 24.2 kb of genomic DNA of the latheo
region. In particular, a 1.9-kb EcoRI-HindIII frag-
ment spanned the P-element insertion site, with 200
by to the left and 1.7 kb to the right. This 1.9-kb
EcoRI fragment was selected for screening cDNA li-
braries. Three partial cDNA clones were identified
from a Canton-S adult head-specific library, with the
largest clone containing a 3.2-kb insert. This larger
cDNA clone and the 1.9-kb EcoRI-HindIII genomic
fragment both identify 3.9-kb and 2.6-kb alternative-
ly spliced messages on a Northern blot containing
poly(A)+ RNA from wild-type Canton-S flies. Impor-
tantly, a 3.6-kb (truncated?) RNA message is present
in latheo RNA, and the amount of 2.6-kb message is
reduced (quantified by overprobing Canton-S and
latheo RNAs with myosin light chain 1; Fig. 1). We
currently are sequencing this putative latheo cDNA.
Molecular cloning of linotte also is proceeding
quickly. The linotte P-element was a newer "iplasmid
rescuable" version, so identifying genomic DNA
flanking the P-element insert was more straightfor-
ward. linotte genomic DNA was cut with SacII,
ligated at low concentration, and transformed into
DH5Alpha E. coli, and clones were selected for
ampicillin resistance. We obtained four colonies.
Restriction analysis of these colonies revealed some
fragments from PlacW and a HindIII-SacII fragment
of "flanking" DNA. We used this fragment to probe a
Canton-S genomic library. Four genomic phage
clones were identified, and subsequent restriction
analysis yielded a 35.8-kb genomic map of the linotte
region. We probed the Canton-S adult head-specific
cDNA library with a 5.7-kb Hind!!! genomic frag-
ment near the P-element insertion site. Four cDNA
clones were isolated, falling into two sets that did not
cross-hybridize. We have shown that the set of
cDNAs farthest away from the P insert corresponds
to a previously cloned gene. We probed a Northern
blot containing poly(A)+ RNA from wild-type and
linotte adults with a 3.0-kb cDNA clone from the
more proximal set. This cDNA hybridized to one 3.5-
kb message in wild-type and mutant flies. When
hybridization intensities were corrected for different
amounts of RNA in each lane (quantified with a
probe for myosin light chain 1), the linotte message
appeared to be sixfold less abundant than normal.
Thus, we presume to have a partial cDNA clone
representing a putative linotte adult message. Addi-
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FIGURE 1 Northern blot analysis of poly(A)+ RNA from wild-
type Canton-S and latheo flies probed with a 1.9-kb EcoRI-
Hind111 genomic fragment spanning the latheo P-element in-
sertion site. This genomic fragment (and a 2.6-kb cDNA
clone from a Canton-S adult head-specific library)
hybridizes in wild-type flies to 3.9- and 2.6-kb messages,
the levels of which are reduced in mutant flies (relative
amounts of RNA in each lane were quantified by overprob-
ing with sequence to myosin light chain 1). An additional
3.6-kb message also is apparent in latheo flies, suggesting
the presence of an aberrant message.
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tional cDNA clones have been identified, and the
entire coding region has been sequenced, revealing
no homologies with known genes. We currently are
attempting phenotypic rescue of linotte's learning
defect with germ-line transformants carrying the
putative linotte+ message.
The linotte P-element is an "enhancer-trap" con-
struct containing a P-galactosidase ((3 -gal) "reporter"
gene behind a weak promoter. Consequently,
endogenous enhancer elements near the P-element
insert can drive expression of the (3 -gal gene. We
have examined frozen tissue sections of linotte adult
brains and whole mounts of linotte third instar central
nervous systems for P-gal activity. The latter show a
distinct and strong pattern of expression primarily in
the lateral hemispheres of the brain lobes. In addition,
two (clusters of) neurons near the anterior end of the
midline and a few neurons scattered throughout the
medial brain hemispheres show some (3 -gal activity.
Little activity is apparent in the ventral ganglia (Fig.
2). Frontal sections of adult heads show P-gal activity
FIGURE 2 Enhancer-driven I3-gal activity in a whole-mount
larval third instar central nervous system of linotte mutants.
Strong expression is seen in the lateral hemispheres of the
brain lobes, primary anatomical sites of developing optic
lobes. Some staining also is apparent in two clusters of
neurons near the anterior end of the midline of, and in a few
other neurons scattered throughout the medial brain hemi-
spheres.
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in the optic lobes, in a cluster of cells anterior and
medial to-but not in-the mushroom body calyces,
in two cells (or clusters) ventral and lateral in the
subesophageal ganglion, and in scattered neurons
throughout the brain. Sagittal sections of fly bodies
revealed no significant (3 -gal activity elsewhere.
The prominent p-gal activity in optic lobes of lar-
vae and adults was surprising to us, since linotte
mutants were identified by disruption of olfactory
learning, which itself does not require optic lobe
function (T. Tully, unpubl.). Thus, we decided to as-
say phototactic behavior in linotte mutants. Again to
our surprise, we discovered that phototactic behavior
was perfectly normal in mutant flies. These results
suggest that the enhancer elements driying expression
of (3 -gal may not regulate the linotte olfactory learn-
ing/memory gene. Instead, the enhancers may regu-
late a different (unknown) gene.
Finally, we have finished sequencing the coding
region of our temperature-sensitive allele of pale, the
structural gene for tyrosine hydroxylase. By compar-
ing this sequence to the sequence from "parental"
nonmutagenized flies, we have identified a single C-
T nucleotide substitution in position one of codon
415, changing an asparginine to a cysteine. Behav-
ioral experiments on pale's mutants unfortunately
have not been as straightforward. Glyoxylic acid
histofluorescence experiments on adult brain
sections have revealed that initial mutant deficits in
catecholamine levels return to normal over several
generations when mutant flies are maintained as
homozygotes. This "accumulation of modifiers"
phenomenon has been observed previously with other
learning/memory mutants and can be controlled by
continuous outcrossing of mutant stocks to wild-type
Canton-S flies. This procedure "equilibrates" genetic
backgrounds. We are in the process of outcrossing
the pale's mutants before proceeding with behavioral
experiments to determine if pale's mutants disrupt ol-
factory learning/memory.
"Reverse Genetics" of
RI and NOS
T. Tully, M. Regulski, M. Del Vecchio [in collaboration
with K. Kaiser, University of Glasgow]
Using a polymerase chain reaction (PCR) primer cor-
responding to the P-element sequence and one cor-
responding to the sequence from the RI regulatory
subunit of protein kinase A (PKA), Dr. K. Kaiser has
"directed" two independent P-element inserts near the
gene, resulting in homozygous viable flies. Northern
blot analysis has revealed larger RNA messages from
both RI mutants, suggesting that the P-element in-
serts are in the coding sequence. We have shown that
homozygotes of each mutant allele (11D4 and 715)
perform abnormally in Pavlovian conditioning exper-
iments (Fig. 3). These performance deficits of the RI
mutants most likely result from disruption of associa-
tive learning per se, since olfactory acuity and shock
reactivity in the mutants are normal (data not shown).
Initial learning levels are low and subsequent
memory decays are normal, suggesting that these RI
mutations affect "learning" rather than "memory." To
our knowledge, this is the first indication in any
species that the RI regulatory subunit of PKA specifi-
cally may be involved with learning.
Nitric oxide (NO) is produced from arginine by
nitric oxide synthase (NOS) and has emerged as an
important messenger molecule involved in a wide va-
riety of physiological processes in different organs
and tissues. Macrophages synthesize NO for their
bacteriocidal and tumoricidal actions. Endothelial
cells of blood vessels send NO as a vasodilating fac-
tor. More recently, NO has been proposed to be a
neuronal (retrograde) messenger during long-term
TIME (hr)
FIGURE 3 Memory retention in wild-type adult flies (control)
and mutants homozygous for a P-element insert in the RI
regulatory subunit of protein kinase A (PKA; 1 1 D4 and 7/5).
A performance deficit is seen immediately after standard
training with a Pavlovian olfactory conditioning procedure.
Subsequent memory decay during the first 3 hr after train-
ing, however, appears normal in mutant flies.
potentiation, a neurophysiological phenomenon
thought to underlie vertebrate learning and memory.
The latter experiments convinced us to look for NOS
homologs in flies, ultimately to mutate such
Drosophila NOS homologs followed by behavioral
analysis.
We used fragments of the rat-brain-specific NOS
cDNA (kindly provided by Dr. S. Snyder) as
heterologous probes to screen Southern blots of
Drosophila genomic DNA. A 1.3-kb Bg111 rat cDNA
fragment includes the FAD- and NADPH-binding
domains, which we thought might be conserved be-
tween rat and fruit fly. At reduced stringency (43%
formamide), this probe hybridized to eight to ten
EcoRI fragments from Canton-S genomic DNA. We
then used the rat cDNA fragment to screen a Canton-
S genomic Sau3A phage library. Fifty of the
strongest hybridization signals from 120,000 plaques
were purified, and DNA was extracted, cut with
EcoRI, electrophoresed, and blotted onto nitrocel-
lulose. These blots were then probed with the 1.3-kb
Bg111 rat cDNA fragment. Genomic fragments that
hybridized with the rat probe were gel-purified and
used to probe the same blots at high stringency. This
approach allowed us to arrange the genomic phage
clones into eight different sets. We also hybridized
our gel-purified Sau3A fragments back to our
Southern blots of EcoRI-cut Canton-S genomic DNA
to verify that our clones still hybridized to the
original fragments.
To date, we have worked most with phage set 1.
The 1.3- and 0.6-kb Bg111 fragments of the rat cDNA
hybridize to a 2.4-kb EcoRI fragment in set 1,
whereas the 0.8-kb Bg111 fragment of the rat cDNA
hybridizes to a 13-kb EcoRI fragment. These results
suggested extensive homology with a rat NOS in this
region of the fly genome. Consequently, we se-
quenced a 720-bp subclone of the 2.4-kb EcoRI frag-
ment, revealing one uninterrupted open reading frame
of 240 (deduced) amino acids. When compared to
NOS proteins over the same region, this 720-bp frag-
ment shows 48% identity to a cow endothelial NOS
protein, 49% identity to a mouse macrophage NOS
protein, and 45% identity to a rat brain NOS protein.
This stretch of the fly protein also contains highly
conserved FAD- and NADPH-binding domains, ar-
ranged in the same order as in other NOSs. A lesser
homology (32% identity) was detected for cyto-
chrome P450 reductase (CPR), a protein also related
to other NOSs. (CPR shares extensive homology with
the carboxy-terminal half of NOSs, most likely des-
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cending from a common ancestor protein.) Thus, the
720-bp Drosophila sequence appears to be more
closely related to other NOSs than to CPR. No other
homologies were identified in protein database
searches.
Given the sequence homology of our 2.4-kb EcoRI
DNA fragment with other NOSs, we wanted to
determine the spatial distribution of RNA for the cor-
responding fly gene. Strand-specific RNA probes
were synthesized and hybridized in situ to frozen
sagittal sections of adult flies. The antisense probe
hybridized to trachea in the brain, to trachea around
the flight muscles, and to a specific region of the gut.
This pattern of expression is consistent with the no-
tion that our 2.4-kb EcoRI fragment is part of a gene
encoding the fly homolog of endothelium-specific
NOS. We continue to characterize the other seven
sets of genomic phage hopefully to identify a brain-
specific NOS homolog.
Behavioral Analyses of Long-term
Memory, Inhibitory Conditioning,
and US Pre-exposure Effects
T. Tully, T. Preat, M. Del Vecchio [in collaboration with
C. Sah ley, Purdue University]
Years ago, we showed that after one "standard" train-
ing cycle of Pavlovian conditioning-in which flies
were shocked in the presence of one odor but not in
the presence of a second odor-memory retention of
conditioned odor responses normally decayed to
about 18% of initial values within 24 hours and to
5% of initial values within 4 days. More recently, we
have automated our training apparatus and, con-
sequently, have been able to demonstrate much
longer-lasting memory after extended training. Ten
training cycles with a deliberate rest interval between
each ("spaced" training) produced memory that
decayed only to 50%, 43%, and 27% of initial values
within 1, 4, or 7 days. Interestingly, ten cycles of
training without a rest interval between each cycle
("massed" training) produced moderate memory
levels (33% of initial levels) within 24 hours but then
decayed to 5% of initial levels within 4 days (as was
the case for one cycle of training). Thus, spaced train-
ing was required to produce long-lasting memory, a
property of memory formation ubiquitously observed
in vertebrates.
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Last year, we mentioned that third instar larvae
could be trained to avoid a shock-paired odor and that
they remembered this odor avoidance through
metamorphosis. In these experiments, we also
showed that such a stable long-term memory (LTM)
was not apparent in amnesiac mutants. This result
prompted us to look this year at LTM in amnesiac
adults after extended training. We have discovered
that spaced training of amnesiac flies produced a
1 -4 -day retention curve similar to that of wild-type
flies after massed training (see above). These results
suggest that amnesiac mutants are not able to form
LTM. Further analyses with additional mutants are
under way.
We continue to demonstrate various properties of
learning and memory that are known to exist in most,
if not all, vertebrates. In the past year, we have shown
that flies become less repelled by an initially aversive
odor if that odor is explicitly unpaired with electric
shock, a phenomenon called inhibitory conditioning.
Under such conditions, flies in essence learn that the
odor is "safe."
We also have demonstrated reduced excitatory
conditioning (which is an increase in avoidance when
a stimulus is paired with shock) to odors after flies
have been exposed to shock alone. In more general
terms, this phenomenon is called the "US pre-
exposure effect." Interestingly, nearly 100 years of
behavioral work never has been able to resolve
whether US pre-exposure effects are due to underly-
ing associative or nonassociative processes. We de-
cided to address the issue genetically, since latheo
mutants show defective associative learning but
normal habituation (nonassociative learning) and
therefore have "genetically dissected" the two pro-
cesses. We discovered that latheo mutants show per-
fectly normal US pre-exposure effects, which favors
the argument that the phenomenon results from
habituation to shock-alone cues. In this manner, we
intend to continue our genetic dissection of learning
and memory with Drosophila mutants.
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REGULATION OF NEUROTRANSMITTER DEVELOPMENT
AND ITS IMPLICATION IN NEURAL PLASTICITY
H. Nawa Y. Bessho
K. Mizuno
M. Waga
Neurons communicate with each other using a large
variety of neurotransmitters and neuropeptides.
Despite this enormous diversity, each functional
neural pathway can be recognized by the particular
set of transmitters, neuropeptides, and receptors
employed. Clearly, this "chemical coding" of path-
ways is critical for controlling neural function and
behavior. The long-term objective of our laboratory
is to define the molecular and cellular mechanisms
that regulate neurotransmitter and neuropeptide
phenotypes in the nervous system. In particular, we
are interested in the physiological consequences of
the regulation. The alteration in neurotransmit-
ter/peptide levels presumably changes the mode of
neurotransmission at each synapse and consequently
modulates neural functions such as cognition and
memory.
We have identified multiple neuronal differentia-
tion factors in heart-cell-conditioned medium (CM),
which control neurotransmitter/peptide expression in
peripheral neurons. One of the factors has turned out
to be identical to the leukemia inhibitory factor (LIF).
It has a wide range of activity to control neurotrans-
mitter/peptide expression not only in sympathetic
neurons, but also in sensory neurons. Another factor
induces only somatostatin expression and a third in-
creases VIP peptide and/or acetylcholine levels.
These observations suggest the possibility that many
distinct, diffusible factors can influence the develop-
ment of the neurotransmitter/peptide phenotype in the
peripheral nervous system. In addition, we recently
found that the heart cell CM also has effects on
neurotransmitter/peptide levels in cultured neurons
prepared from the central nervous system (CNS).
Subsequent biochemical analyses suggested that the
responsible component resembles brain-derived neu-
rotrophic factor (BDNF). BDNF increases and
maintains the expression of putative inhibitory
neuropeptides, neuropeptide Y, and somatostatin in
cerebral cortical neurons.
Our finding demonstrates that as in the peripheral
nervous system, neurotransmitter phenotypes in the
CNS are plastic and can be regulated by many differ-
entiation factors.
Our current efforts have been focused on the three
projects: (1) identification of novel peptidergic differ-
entiation factors, (2) characterization of their biologi-
cal activity and physiological consequences, and (3)
regulatory mechanism of their expression. These
studies will elucidate the mechanism of how such a
complex but highly ordered expression of neurotrans-
mitters/peptides is controlled during development and
how it affects neural plasticity such as learning and
memory processes.
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Characterization of VIP/Acetylcholine-
inducing Activity
H. Nawa
The cholinergic differentiation factor (CDF) in heart
cell CM is known to be identical to LIF. We have
demonstrated that recombinant CDF/LIF alters
dramatically neurotransmitter production as well as
the levels of several neuropeptides (substance P,
somatostatin, and VIP) in cultured rat sympathetic
neurons. These changes are reflected by alteration in
mRNA levels for these protein and peptides. Growth
with 1 nM recombinant CDF/LIF induces mRNA for
the adult form of choline acetyltransferase (ChAT)
mRNA (4 kb) as well as for those peptides. It is
A
NPY
GAD
known that cultured sympathetic neurons contain sig_
nificant basal ChAT enzyme activity. RNA blotting
experiments have shown that the original sympathetic
ganglia do not contain a detectable amount of ChAT
or VIP mRNA, whereas cultured sympathetic neur-
ons grown with rat serum initiate expression of VIP
mRNA and the embryonic form of ChAT mRNA (2.7
kb). After gel-filtration column chromatography, this
activity in serum was recovered in fractions contain..
ing 60-100 kD. This suggests that the responsible
factor is different from the known factors (LIF and
ciliary neurotrophic factor [CNTF]), although further
biochemical characteristics of the factor are un-
known. Similar phenotypical alteration is observed in
vivo: Sympathetic neurons innervating rat footpads
change their neurotransmitter phenotype in response
C
.CONY N F
FIGURE 1 Immunocytochemical analyses of the BDNF effects on NPY- or GAD-
positive neurons. Cortical neurons were grown for 5 days with (C,D) or without (A, B)
BDNF. After treatment with 1 p.m colchicine for 8 hr, neurons were fixed with 4%
paraformaldehyde in 0.15 M phosphate buffer (pH 7.3) and immunostained with rab-
bit anti-NPY antiserum (1:600) (A,C) or sheep anti-GAD antiserum (1:1000) (B,D).
The immunoreactivities were visualized with the biotinylated anti-rabbit IgG or
biotinylated anti-sheep IgG (1:100), followed by the avidin-biotin-peroxidase com-
plex (Vectastain ABC kit) (1:100). The frequency of GAD-positive neurons was 19.4
-± 2.6% in control cultures and 21.6 ± 2.2% in BDNF-containing cultures (n = 3). Bar,
100 Rm.
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to the signals from their targets. These neurons ini-
tially contain catecholamine and neuropeptide Y, but
during postnatal life, they begin to express ChAT and
VIP. Again, neither LIF nor CNTF seems to be
responsible for this in vivo phenomenon. Therefore,
these observations suggest that a novel factor induces
VIP and/or ChAT in sympathetic neurons.
Plastic Regulation of Neuropeptide
Y and Somatostatin Expression
by BDNF
K. Mizuno, Y. Bessho, H. Nawa
The heart cell CM contains a large variety of
neuronal trophic factors including LIF, FGF (fibro-
blast growth factor), IL-1 (interleukin-1), NGF (nerve
growth factor), BDNF, and NT-3 (neurotrophin-3).
Using the heart cell CM as a source of trophic fac-
tors, we are studying its effect on the neurotransmit-
ter/peptide phenotype in cultured cerebral cortical
neurons. These neurons were prepared from the
neocortices of embryonic day-18 rats and received
25% heart cell CM during culture. Among the neuro-
peptides we examined, levels of the putative in-
hibitory neuropeptides, neuropeptide Y (NPY), and
somatostatin were remarkably elevated by addition of
heart cell CM. Further biochemical characterization
of the responsible factor has shown that the activity is
an extremely basic molecule whose size is less than
30 kD, suggesting that it may be one of the
neurotrophins (including NGF, NT-3, and BDNF).
We examined the peptidergic effects of these
neurotrophins. BDNF increases the contents of NPY
and somatostatin as well as their mRNAs without
changing neuronal densities, but the other
neurotrophins exhibited no effect. The level of NPY
mRNA reached a maximum after 5 days addition of
BDNF, but removal of BDNF on day 5 rapidly
returned the level back to a control level. The delayed
addition of BDNF until day 5 still increased the level
of NPY mRNA in the same fashion as above. The
fact that the delay did not alter the induction provides
further evidence that this peptidergic differentiation
activity of BDNF is independent of its trophic ac-
tivity in promoting the neuronal survival reported
previously. These neuropeptides are known to be
colocalized with GABA or its synthetic enzyme GAD
(glutamic acid decarboxylase) in the cerebrum. Im-
munocytochemical analyses have shown that treat-
ment of the neurons with BDNF increased the fre-
quency of NPY-positive neurons from 0.3% to 7.5%
without changing that of GAD-positive neurons (Fig.
1). Moreover, almost all of the NPY-positive neurons
induced by BDNF contain GAD immunoreactivity.
These data suggest that BDNF regulates the neuro-
peptide phenotype of the GABAergic interneurons in
a plastic manner. It is known that excitatory
neurotransmission mediated by glutamic acid en-
hances and maintains BDNF expression. This obser-
vation, in conjunction with our results, suggests that
excitatory neurotransmission might control the in-
hibitory neuropeptide levels in GABAergic neurons
through BDNF.
Regulation of BDNF Expression
in Neurons
Y. Bessho, H. Nawa
In the nervous systems, neuronal activity contributes
to a variety of developmental neural processes such
as synaptic elimination and stabilization, phenotypic
differentiation, etc. We believe that some of these
processes must be mediated by extracellular factors.
We have been studying how neurotransmission regu-
lates the production of neuronal differentiation fac-
tors in the nervous systems. We prepared primary
cultures of cerebellar granule neurons from newborn
rats and examined the influences of glutamatergic
neurotransmission on BDNF expression. Four-hour
exposure of the neurons to the glutamate receptor
agonists, quisqualate, kainate, AMPA, and NMDA
increased levels of BDNF mRNA, although some of
the agonists produced neuronal degeneration. How-
ever, glutamate in combination with antagonists of
the ionotropic glutamate receptors, CNQX, AP-5,
and/or MK-801, still increased levels of BDNF
mRNA. In contrast, the addition of glutamate to the
cultures produced severe neuronal death and failed to
increase the mRNA level. The onset of the increase
in BDNF mRNA by kainate and NMDA significantly
lagged behind that by quisqualate. These results indi-
cate that the nonionotropic glutamate receptor is in-
volved in the induction of BDNF mRNA. Quisqua-
late is known to be a potent agonist of both the
ionotropic AMPA/kainate receptor and the metabo-
tropic glutamate receptor. The specific antagonists of
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the AMPA/kainate receptor, CNQX and DNQX, both
failed to block the increase of BDNF mRNA by
quisqualate. Moreover, the desensitization of the
metabotropic glutamate receptor by phorbol ester
abolished the increase of BDNF mRNA by quisqua-
late. These results suggest that stimulation of the
metabotropic glutamate receptor is the most predomi-
nant component to increase BDNF mRNA in cerebel-
lar granule cell culture. In contrast, NMDA produces
the most drastic effect to increase levels of BDNF
mRNA in cultured cortical neurons, and kainate in-
duces BDNF mRNA most efficiently in cultured hip-
pocampal neurons. All of these observations suggest
that depending on neuronal cell type, the species of
neurotransmitter or its receptor that control BDNF
expression are different.
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GENE TARGETING AND THE BIOLOGY OF
LEARNING AND MEMORY
A.J. Silva R. Burchuladze B. Frenguelli
C.M. Chen K.P. Giese
The key difficulty in the study of learning and
memory is the integration of psychological, anatomi-
cal, and physiological information into a theory un-
restrained by disciplinary boundaries. For example,
physiologists are faced with the Herculean task of
testing the relevance of candidate memory mechan-
isms in the behaving animal, and psychologists strug-
gle to find physiological processes among the dwarf-
ing complexity of the behaving brain! These meth-
odological gaps result in theories of memory mostly
defined within disciplinary boundaries.
Recent developments in mouse embryonic techni-
ques allow the virtual molding of the mouse genome,
and we propose that they will be key to the integra-
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tion of neurobiological information with behavioral
observations. Our laboratory has initiated an in-
terdisciplinary study of mice mutant for genes that
code for key components of hippocampal neural
physiology. For example, with gene targeting, we
have recently deleted the a isoform of the calcium/
calmodulin kinase II (CaMkII) (Fig. 1). Electrophys-
iological studies of these mice revealed an impair-
ment in the ability of the mice to establish a long-
term potentiation of synaptic activity (LTP), a mech-
anism believed to be underlying learning and
memory. Remarkably, other aspects of synaptic
transmission seemed to be unaltered by the absence
of this kinase. Behavioral studies of the mutant mice
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FIGURE 1 The gene-targeting procedure.
also showed a surprising specificity of the affected
behaviors. For example, we found that spatial learn-
ing was severely disrupted, whereas other learning
processes were not. The results demonstrated that this
genetic approach can yield relatively specific func-
tion lesions in the brain, and they were important in
directing our work: First, these results showed that
the approach works, and we have applied it to other
candidate genes. Second, they also demonstrated that
the disruption of aCaMkII interfered with hippo-
campal-dependent learning, providing us with the op-
portunity to determine how this happens. Third, these
results motivated us to look within other analytical
levels, and we have recently found that neural circuits
in the mutants react very differently to low-level
electrical stimulation delivered according to an ex-
perimented paradigm referred to as kindling. Our kin-
dling experiments (in collaboration with Jim Mc-
Namara) uncovered a role for CaMkII in the regula-
tion of the excitability of neural circuits, and they
raised the possibility that this role might underlie the
deficits in LTP and learning found in the aCaMkII
mutant mice.
In the last 4 months of 1992, our laboratory has or-
dered equipment and swelled ranks, and we actually
did get some work done.
Rusudan Burchuladze has set up the Morris water
maze in our behavioral room. The christening of the
pool was done with mice mutant for the neurofibro-
matosis type I (NFl) gene (Fig. 2). In humans, the
mutation of this gene is the second most common
cause for learning disabilities. These cognitive im-
pairments appear to be the most disabilitating con-
sequence of this common genetic disorder. Sur-
prisingly, our studies of both spatial and visual learn-
ing and memory detected no abnormalities in mice
heterozygous for the NFl gene, with the possible ex-
ception that the rate of learning might be slower in
the NFl mutant mice. We must acknowledge the
great support personnel at Cold Spring Harbor
Laboratory. Their thoughtful, and at times inspired,
suggestions have contributed immensely to the
numerous experimentally relevant and time-saving
improvements introduced in our water maze.
Chua Min Chen has developed a targeting vector
that we will use to introduce a substitution of Thr-286
(CGG) for alanine (CAG) in aCaMkII. The vector
design is based on the "hit-and-run" procedure devel-
oped by Alan Bradley (Fig. 3). In our previous
mutants, the complete loss of aCaMkII not only
eliminated the kinase activity of the enzyme, but also
eliminated all other possible functions that such an
abundant component of postsynaptic densities might
have. For example, it is possible that the aCaMkII is
not only a kinase, but also an essential structural
component of spines and even synaptic vesicles.
Thus, the learning impairment could be unrelated to
LTP and be solely due to the potential disruption of
postsynaptic densities. In Thr-286 mutant mice, the
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FIGURE 2 NF1 mutants: The hidden platform task.
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FIGURE 3 The hit-and-run procedure.
structure of the enzyme should be basically un-
disturbed, and all of the Ca/CaM-independent kinase
activity should be eliminated. We are anxious to
determine whether this mutation disturbs LTP and
learning to the same extent as the null mutation.
Karl Peter Giese recently joined our laboratory and
will continue the derivation of mice mutant for the
Thr-286 of aCaMkII. Additionally, he will derive
other mutations in components of hippocampal phys-
iology. Bruno Frenguelli will continue the elec-
trophysiological characterization of our mutant mice.
Next year, we hope to have an exciting account of
our genetic journey through the behavior and physiol-
ogy of learning and memory.
Finally, I must confess that Cold Spring Harbor
Laboratory is much more than what I expected, and I
did expect a lot. Overall, these last 4 months have
been wonderful, and we have been fortunate to put
together a laboratory with an enthusiastic group that
will be able to generate a "learning" mutant and im-
mediately characterize its physiology and behavior.
And thus we forge ahead with the conviction and
naive arrogance that only new but promising ap-
proaches allow.
SIGNAL TRANSDUCTION IN NEURONS
G. Enikolopov N. Peunova
We study how signal transduction and gene expres-
sion in neurons are involved in synaptic plasticity.
Signals that ultimately produce changes in synaptic
plasticity can also elicit modifications of gene ac-
tivity patterns in neurons. Induced changes in gene
activity may underlie both antero- and retrograde
transfer of information and may in turn be required
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for long-term changes in neuronal function. We are
particularly interested in molecular mechanisms that
permit a neuron to integrate coincident signals and to
relay them to other cells. This year, our efforts con-
centrated on the action of nitric oxide, a new type of
cellular messenger. We found that nitric oxide can act
as an amplifier of calcium signals in neuronal cells.
Amplification of Calcium-induced
Gene Transcription by Nitric
Oxide in Neuronal Cells
N. Peunova, G. Enikolopov
Nitric oxide (NO) is a short-lived, highly reactive gas
with free radical properties, which has been identified
as a mediator in vasodilation, an active agent in mac-
rophage cytotoxicity and in neurotoxicity, and a
neurotransmitter in the central and peripheral nervous
systems. Production of NO by neurons is critical for
facilitated synaptic transmission in models of synap-
tic plasticity such as long-term potentiation (LTP)
and long-term depression (LTD), suggesting a role
for NO as a "retrograde messenger" that could com-
plete a hypothetical feedback loop by strengthening
the connection between postsynaptic and presynaptic
cells. We have found that although NO itself has no
evident effect upon transcription, it can synergistic-
ally enhance calcium-mediated signals in neuronal
cells.
A potential problem with the concept of an easily
diffusible messenger is the possibility of nonspecific
activation of many different terminals in the vicinity
of an active synapse, which would contradict the
known specificity of most examples of synaptic
plasticity. One solution to this paradox is restriction
of the effect of NO to cells that are somehow marked
by another event. For example, in the nervous sys-
tem, the response to NO might be limited to recently
active neurons or synapses, thereby coinciding with
transient elevations of calcium levels. In an attempt
to model a situation in which a neuron receives an
NO signal simultaneously with a signal of a different
modality, we exposed neuronal PC12 cells to com-
binations of NO with different inducers of transcrip-
tion and monitored changes in immediate-early gene
transcription. NO was unable to induce transcription
on its own; however, when applied to cells in com-
bination with certain treatments known to induce
immediate-early gene expression, induction of c-fos
expression was greatly enhanced. Importantly, NO
only amplified the action of those agents that act
through calcium ions. The elevated induction of c-fos
mRNA was productive, leading to an increase in
binding activity of the AP-1 transcription factor com-
prising Fos and Jun family proteins. Our experiments
with pulse application of one inducer followed by ad-
dition of the second component indicate that the two
stimuli, NO and calcium, must be present together
within a short time window in order to exert their
synergistic action.
Transfection experiments with c-fos-CAT con-
structs indicate that a short (400 bp) promoter region
of the c-fos gene is sufficient to confer NO/Ca++ in-
ducibility. Using a series of promoter mutation con-
structs and chimeric GAL4-CREB activators (gifts
from Dr. M. Gilman), we have demonstrated that
CRE sequences and the transcriptional activator
CREB are targets for at least one (and, probably, the
major) of the NO/Ca++-induced pathways in the
nucleus.
Ca++ signaling in neurons is mediated by several
serine/threonine-specific protein kinases. To deter-
mine which enzymes are involved in signaling by
NO/Ca++, we have used specific recombinant in-
hibitors of individual protein kinases. These in-
hibitors were constructed based on the autoinhibitory
pseudosubstrate domains of several protein kinases
and were shown to be potent and selective toward
their cognate enzymes. The results of such analysis
suggest that, consistent with the data on promoter
mapping, only the cAMP-dependent protein kinase
(PKA) inhibitor and, to a small degree, Ca++/
calmodulin-dependent protein kinase (CaMK) in-
hibitor blocked the NO/Ca++ response. These results
implicate the PKA-CREB-CRE system as a major
component of the signaling pathway for the transcrip-
tional synergy of NO and Ca++.
The phenomenon of NO-mediated potentiation of
the Ca++ response may have implications beyond
transcriptional regulation. For example, NO could
potentiate the PKA phosphorylation of cytoplasmic
proteins with direct roles in synaptic funtion. The ef-
fect of NO on signaling might be particularly impor-
tant at very low levels of calcium action, at which
this inducer acting alone would have negligible ef-
fect; these very weak signals, which would go un-
noticed by the cell, might be amplified by NO, result-
ing in pronounced physiological changes for the cell.
Since NO diffuses freely and readily leaves and en-
ters cells without need for a secretory system or a
surface receptor, nearby synapses that receive very
weak impulses simultaneously with exposure to NO
might establish facilitated synaptic transmission, a
phenomena that is known for LTP and which may
form the basis for associative memory. NO and Ca++
must act within a very narrow time window for this
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enhancement to occur, suggesting that in the nervous
system, this synergistic effect might be restricted to
the recently active synapses. Amplification of Ca++
action by NO, acting on signaling machinery either-
directly or through reprogramming of gene activity,
might be directly involved in NO-mediated steps in
LTP and similar activity-dependent neuromodulation
phenomena in the brain.
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NEUROBIOLOGY AND NEUROGENETICS OF
SYNAPTIC PLASTICITY
Y. Zhong J. Shan ley
N.J.D. Wright
Z. Xie
The primary focus of our laboratory is on molecular
mechanisms and physiological functions of synaptic
plasticity. Synaptic plasticity is referred to as those
processes that modify the strength of synaptic trans-
a neural activity-dependent manner.
ous processes including facilitation, potentiation, and
depression are exhibited by synaptic plasticity. These
plastic processes have been suggested as a cellular
basis of learning and memory. Thus, it would be ex-
pected that a mutation that causes learning or
memory deficiency may also alter synaptic plasticity.
Therefore, we are taking a major approach to exam-
ine synaptic transmission in Drosophila learning and
memory mutants. The defective synaptic plasticity
identified in these mutants will help not only to frame
whether and how synaptic facilitation, potentiation,
and depression are involved in learning and memory
processes, but also to determine biochemical com-
ponents underlying the disrupted synaptic plasticity.
Synaptic Plasticity in Learning
vs. Memory Mutants
Y. Zhong
About 15 to 20 different lines of learning and
memory mutants have now been isolated and more
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are expected. Some of these mutants are classified as
learning mutants, and they show profound defects in
their initial learning scores, although the decay rate of
this learning appears to be similar to that in normal
flies. In contrast, memory mutants exhibit a sig-
nificantly different decay rate of learning scores after
training.
I have examined short-term potentiation at
neuromuscular junctions of some of these mutants by
the two-electrode voltage-clamp method. Preliminary
results indicated that short-term potentiation was
abolished in memory mutants, including rutabaga
(Fig. 1), turnip, and radish, whereas potentiation was
observable but altered in learning mutants such as
dunce, where it was much shorter (Fig. 1), and in
latheo mutants, where the size was reduced. In addi-
tion to examination of this short-term potentiation, I
will also study facilitation, depression, and a long-
term potentiation in all available mutants in an at-
tempt to determine the differences, if any, in altera-
tion of synaptic plasticity induced by learning muta-
tions vs. memory mutations. Although obtained from
the neuromuscular junctions, these data reflect the
functions of genes important for learning ability in
synaptic transmission, in contrast to those for reten-
tion of learned behavior. In addition, there is also the
possibility of dissecting learning and memory neuro-
biologically.
normal
f ,
potentiated
responses
pre
potentiation
10 nA
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II lilt
FIGURE 1 Short-term potentiation in different genotypes.
Synaptic currents were recorded at the larval neuromus-
cular junctions. Test frequence is 0.5 Hz, tetanic stimulation
is 5 Hz. Normal larvae exhibit potentiation lasting from 2 min
to 15 min, whereas dnc shows less than 10 sec and rut
eliminates this potentiation.
Function of the latheo Peptide
Y. Zhong [in collaboration with T. Tully, Cold
Spring Harbor Laboratory]
The learning mutant latheo has been isolated by Tim
Tully's laboratory. In addition to its phenotype of a
reduced short-term potentiation as mentioned above,
the mutant also exhibited hyperexcitability as indi-
cated in Figure 2. First, its basal level of postsynaptic
currents was increased (comparing the first evoked
response of latheo to that of normal larvae in Fig. 2),
indicating enhanced synaptic transmission. Second, a
normal
lat
10 nA
0.2 s
FIGURE 2 Effect of lat mutation on synaptic transmission.
Excitatory junctional currents were recorded from the body-
wall neuromuscular junctions of third instar larvae at 0.2 mm
Ca concentration. Arrows point to artifacts of electric stimuli.
The lat mutation induces multiple discharges in response to
single nerve stimulus.
single stimulus was able to induce multiple dis-
charges in latheo instead of the single discharge seen
in normal larvae (Fig. 2). This hyperexcitability could
be mimicked by application of K+ channel blockers
to normal larvae, suggesting that the latheo locus
may encode a K+ channel subunit or a modulator of
K+ channels. It is interesting that the modulation of
K+ channels provides an essential molecular mechan-
ism for mediating sensitization and associative learn-
ing in Aplysia and Hermissenda. It may also be im-
portant for induction of long-term potentiation in the
hippocampus.
Membrane Currents in Mushroom
Body Neurons
N.J.D. Wright, Z. Xie, Y. Zhong
The mushroom body is an area in the brain thought to
be important for learning and memory in insects in-
cluding Drosophila. Work in Ron Davis' laboratory
(see this section) has revealed that several genes im-
portant for fly learning and memory such as dunce
and rutabaga are predominately expressed in this
region. They have also isolated several enhancer-
detector lines in which lacZ is expressed exclusively
in the mushroom body. These lines allow us to identi-
fy the mushroom body neurons in culture by fluores-
cent staining of the living cells. Membrane currents
in these stained cells can then be analyzed by the
patch-clamp method. Surprisingly, currents recorded
from these neurons appeared to be very similar (Fig.
3), in sharp contrast to the diverse types of currents
recorded from nonstained neurons. Such uniformity
provides a basis for the genetic analysis of these
membrane currents in neurons that may participate in
learning processes of mutants. In light of the latheo
phenotype as discussed above, and of predominant
expression of a cAMP-specific phosphodiesterase en-
coded by the dunce, an adenylyl cyclase by the
rutabaga locus, a protein kinase A, and a K+ channel
subunit by the Shaker locus in the mushroom body,
we would like to postulate that modulation of K+ cur-
rents by the cAMP cascade is essential for the
physiological functions of the mushroom body
neurons. We are examining the effects of the Shaker
and latheo mutations on K+ currents in identified
neurons and probing their relation to modulation of
the cAMP cascade.
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FIGURE 3 Whole-cell voltage-clamp recordings of mem-
brane currents from the cultured larval CNS neurons. (A-C)
Currents from nonstained neurons; (D) a representative cur-
rent recorded from the stained mushroom-body neuron.
Role of Cell Adhesion Molecules in
Synaptic Plasticity
Y. Zhong, J. Shan ley
The number of cell adhesion molecules is regulated
during induction of long-term facilitation in Aplysia,
and application of antibody against a cell adhesion
molecule blocks the later phase of long-term
potentiation in the hippocampus. Therefore, it is sug-
gested that regulation or modulation of cell adhesion
molecules may lead to the formation of new
synapses, which in turn may enhance synaptic trans-
mission. However, direct evidence is not yet avail-
able to support this hypothesis. The existence of
Drosophila mutants has allowed us to approach this
problem more directly. Immunohistochemical stain-
ing of the neuromuscular preparation of the mutant
fasciculin I (fas 1), which encodes a cell adhesion
molecule, revealed that the numbers of nerve termi-
nal branches and varicosities (corresponding to
synapses) were increased in this null mutant as com-
pared to that in normal nerve terminals (Fig. 4). Con-
versely, the numbers of branches and varicosities
were reduced in flies with an extra copy of the fas I
gene (Dp [fas I]). These results indicate that indeed
the regulation in the number of cell adhesion
molecules may lead to changes in the number of
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synapses formed. however, further electrophysiolog-
ical analysis of these have provided a very intriguing
result. The amplitude of postsynaptic currents was
not accordingly enhanced in fa.s. I mutants, which
showed more synapses as compared to normal flies.
Instead, synaptic currents were enhanced significant-
ly in Dp (fas I). Further examination is under way to
probe the possible mechanisms and significance of
such phenomena.
PUBLICATIONS
Zhong, Y. and C.-F. Wu. 1992. Combinatorial assembly of
the eag polypeptide with K+ channel subunits for
mediating cGMP-dependent modulation of K+ currents
in Drosophila. Soc. Neurosci. 18: 1093.
Zhong, Y., V. Budnik, and C.-F. Wu. 1992. Synaptic
plasticity in Drosophila memory and hyperexcitable
mutants: Role of cAMP cascade. J. Neurosci. 12:
644-651.
In Press, Submitted, and In Preparation
Zhong, Y. 1993. The role of cell adhesion molecule Fasl in
nerve terminal arborization and synaptic transmission
revealed by mutations in Drosophila. (In preparation.)
Zhong, Y. and C.-F. Wu. 1993. Differential modulation of
potassium currents by cAMP and its long-term and
short-term effects: dunce and rutabaga mutants of
Drosophila. J. Neurogenet. (in press).
Zhong, Y. and C.-F. Wu. 1993. Modulation of different K+
currents in Drosophila: A role for a putative subunit in
multimeric K+ channels. J. Neurosci. (in press).
Muscle
fibers
normal
fasl nerve terminalprojection
Dp(fasl)
FIGURE 4 Effects of mutations of the fas I gene on the nerve
terminal arborization. The fas I mutant is a null mutation that
enhances the nerve terminal arborization. The Dp (fas I) fly
has an extra copy of the fas I gene that reduces the num-
bers of branches and varicosities.
CSH LABORATORY JUNIOR FELLOWS
In 1986, Cold Spring Harbor Laboratory began a Junior Fellow program to en-
courage independent research by outstanding young scientists who, during their
graduate studies, displayed exceptional promise of becoming leading scientists
of the future. The purpose of this program is to provide an opportunity for each
Fellow to work independently at the Laboratory for a period of up to 3 years on
projects of their choice. The Fellow is provided with a salary, research support,
and technical assistance so that they can accomplish their goals free from other
distractions. The interaction among research groups at the Laboratory and the
program of courses and meetings on diverse topics in molecular biology contrib-
ute to a research environment that is ideal for innovative science by these Fel-
lows.
Three previous Cold Spring Harbor Fellows, Dr. Adrian Krainer (1987), Dr.
Carol Greider (1988), and Dr. Eric Richards (1989), are currently members of the
scientific staff at the Laboratory. Dr. David Barford is our most recent Fellow, hav-
ing joined us in 1991 from Professor Louise Johnson's laboratory at Oxford. Dr.
Barford is an X-ray crystallographer who has previously worked on glycogen
phosphorylase, but whose present interests lie in the area of protein-mediated
signal transduction. Dr. Barford's current focus is on the serine/threonine-specific
protein phosphatases. Immediately before coming to Cold Spring Harbor, Dr.
Barford spent some time in Dr. P. Cohen's laboratory in Dundee working on
protein phosphatase 2A (PP2A) from rabbit muscle. Dr. Barford hopes to crystall-
ize and solve the structure of this phosphatase.
D. Barford
Structural Studies on Protein
Phosphatases
D. Barford
The aim of my research is to determine the three-
dimensional structure of protein phosphatases using
X-ray crystallography. This information will be use-
ful in describing the overall conformation of the
protein and the mechanism of catalysis and substrate
specificity. This year, progress has been made in
cloning, expressing, purifying, and crystallizing three
protein phosphatases: human protein phosphatase 1
(PP1), human T-cell protein tyrosine phosphatase
(PTPase), and a bacteriophage X, phosphatase. PP1 is
representative of the serine/threonine class of protein
phosphatases, PTPase is a tyrosine-specific protein
phosphatase, and the bacteriophage phosphatase is a
dual specificity phosphatase. The latter phosphatase
shares considerable sequence identity with the
amino-terminal 115 amino acids of PP1 (35% se-
quence identity), hence the finding that it possesses
activity against phosphotyrosine was unexpected.
CLONING, EXPRESSION, PURIFICATION, AND
CRYSTALLIZATION OF PROTEIN
PHOSPHATASES
Human Protein Phosphatase 1 (in collaboration with
Dr. P.T.W. Cohen, Dundee, United Kingdom). The
cDNA encoding human PP1y was cloned into the Es-
cherichia coli expression vector pTactac. E. coli cells
grown at 30°C express appreciable quantities of ac-
tive soluble PP1. The protein is purified to homo-
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FIGURE 1 Portion of the multiple sequence alignment of 45 serine/threonine phosphatases. The family is divided into four classes: PP2B, PP2A, PP1, and PPP/PPT. The
extent of conservation within the family and within subfamilies is indicated by shading. (White letters on black) Invariant residues throughout the family; (white letters on
dark gray) invariant residues within a family; (black letters on light gray) physiochemically related residues within a subfamily; (black letters on white) positions where
there is no sequence conservation. The combined secondary structure predictions for each sequence is shown below the sequence alignment, and the proposed
secondary structure assignment is indicated.
geneity using heparin agarose, mono-Q FPLC, and
gel-filtration chromatography. The purified protein
has been subject to crystallization screening and con-
ditions have been discovered where the protein will
crystallize. The crystals diffract to 2.9 A and are
suitable for structure determination.
Human T-cell Protein Tyrosine Phosphatase (in col-
laboration with Dr. N. Tonks, Cold Spring Harbor
Laboratory). The cDNA encoding the amino-termin-
al 321 amino acid residues of the human T-cell
PTPase has been cloned into the E. coli T7 expres-
sion vector. As much as 10-20 mg of protein can be
purified from 2 liters of bacterial culture using DEAE
Sepharose, mono-S FPLC, and phenyl TSK hydro-
phobic interaction chromatography. The protein crys-
tallizes to form needles of length 1 mm by 0.02 mm
by 0.02 mm. Attempts are being made to improve the
thickness of these crystals to allow crystallographic
data to be collected.
Bacteriophage X ORF221 Protein Phosphatase (in
collaboration with Dr. J.E. Dixon, Michigan Univer-
sity). The cDNA encoding the bacteriophage ORF221
was cloned into the T7 expression vector. Large
quantities of protein are produced that enable kinetic
and structural analyses to be performed. This has
phosphoserine as well as phospho-
tyrosine activities. The protein has been crystallized
and diffracts to better than 4 A with crystal cell
dimensions, a= 80.8 A, b = 193.2 A, c= 53.9 A, 13=
93.3°. Structural studies are in progress.
MULTIPLE SEQUENCE ALIGNMENT OF
SERINE/THREONINE PHOSPHATASES
In addition to efforts to determine the three-dimen-
sional structures of proteins by X-ray crystal-
lography, we have taken advantage of the large num-
ber of cDNA sequences available for the serine/
threonine phosphatase family. A multiple sequence
alignment of a family of related proteins yields in-
formation about the position of invariant residues
(important in catalysis, substrate recognition, regula-
tion, and protein-folding determinants) and the posi-
tions of insertions and deletions (which can only be
tolerated at surface loops and turns). By combining
secondary structure predictions at each position for
all aligned sequences, a more accurate consensus
secondary structure prediction can be obtained. The
pattern of conserved residues also provides clues to
the secondary structure. For example, conserved
hydrophobics at positions i, i+3, i+4, i+7 is sugges-
tive of an a-helix with a hydrophobic surface buried
in the protein core.
In collaboration with Dr. P.T.W. Cohen (Dundee
University) and Dr. Geoff Barton (Oxford Univer-
sity), 45 serine/threonine phosphatase sequences have
been gathered and multiply aligned. The consensus
sequence produced from the alignment matches the
amino-terminal 100 residues of an E. coli diadeno-
sine tetraphosphatase, with conservation of invariant
eukaryotic residues. The similarity among eukaryotic
serine/threonine phosphatases, a bacteriophage phos-
phatase, and an E. coli diadenosine tetraphosphatase
raises interesting questions about the evolutionary
and structural relationships of these proteins. A repre-
sentation of the results is shown in Figure 1.
The study has revealed the positions of invariant
residues, likely to be important in catalysis and has
allowed us to propose a secondary structure predic-
tion. It will be of interest to compare the crystal struc-
ture of a serine/threonine protein phosphatase with
this prediction.
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COLD SPRING HARBOR
MEETINGS

ACADEMIC AFFAIRS
The academic program at Cold Spring Harbor Laboratory includes a wide-
ranging series of postgraduate laboratory and lecture courses, workshops, large
meetings, and a summer research program for undergraduates. The program ex-
tends from a spring session of courses early in April through a fall session of
courses ending early in November. In 1992, 21 courses in molecular genetics
and neurobiology and 14 meetings were held. The academic program continues
to expand, and several new meetings and courses took place this year. Two new
fall courses were held: Monoclonal Antibodies from Combinatorial Libraries
(taught by Carlos Barbas and Dennis Burton) and Molecular-Cell Biology Tech-
niques: Immunocytochemistry and In Situ Hybridization (taught by Paul Hough,
Ken Jacobson, David Spector, and Barbara Trask). The neurobiology courses
were moved from Jones Laboratory to the new Howard Hughes Medical Institute
(HHMI) teaching laboratories on the top floor of the Beckman Neuroscience Cen-
ter. Although many instructors were wary of leaving Jones Laboratory with its fa-
miliar waterfront location, they quickly came to appreciate the state-of-the-art
facilities in the HHMI laboratories.
The courses are supported by a series of grants from public and private
sources. For many years, the summer molecular genetics courses have been
made possible by grants from the National Institutes of Health (NIH) and the Na-
tional Science Foundation (NSF). Grants from the NIH support several of the
newer spring and fall courses, and funds from a grant from the National Institute
of Mental Health cover several neurobiology courses. 1992 represented the first
full year of the Laboratory's renewed education grant from HHMI. This award has
provided stable funding for the neurobiology program as well as support for new
courses, allowing the Laboratory flexibility in initiating courses. The Laboratory
also has an award from the Klingenstein Fund and the Grass Foundation for the
support of the neurobiology program. In addition, the Laboratory courses receive
invaluable aid from many companies (see Educational Activities Section) that
donate supplies and provide large amounts of equipment on loan.
Conferences at the Laboratory have grown to 14 this year, including meetings
that cover new topics and those that are held on a yearly or biannual basis. The
annual Symposium continues to be a highlight of the year. This year's
Symposium, The Cell Surface, was organized by Richard Hynes, Richard Axel,
Corey Goodman, and Bruce Stillman. Several new meetings, e.g., The Cell Cycle
and Gene Therapy, were received very enthusiastically and it was decided to
hold them again in 1994. Although many of the meetings, including the confer-
ences on Genome Mapping and Sequencing and RNA Tumor Viruses, were
oversubscribed, the new and renovated facilities comprising Grace Auditorium,
Blackford Hall, Dolan Hall, and the new cabins made all aspects of the meetings
more pleasant and efficient. The success of the meetings is largely due to the ef-
forts of all of the scientists who serve as organizers and to the enthusiastic partic-
ipation of all of the visiting scientists.
In these times of concern about grants and funding, support for the meetings
program from the Laboratory's Corporate Sponsor Program and from NIH, NSF,
and the Department of Energy was extremely important. In fact, this year, the
Gene Therapy meeting was funded by a most generous grant from the Wellcome
Trust and the Translational Control meeting was supported by funds from ICN
Pharmaceuticals, Inc.
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While graduate students, postdoctoral fellows, and faculty participate in the
courses and meetings, the Undergraduate Research Program (URP) provides an
opportunity for college undergraduates to spend 10 weeks at the Laboratory dur-
ing the summer. The program, headed by Winship Herr, allows students to do re-
search in the laboratories of staff scientists.
That the meetings and courses proceed with such efficiency and good spirit
is due, in large measure, to the skill and hard work of the staff of the Meetings Of-
fice: Barbara Ward, Micki McBride, Diane Tighe, Eileen Paetz, Marge Stellabotte,
Andrea Stephenson, and Nancy Weeks. The audiovisual staff headed by Herb
Parsons manages with great efficiency and good humor the thousands of slides
and projections provided by the scientists at our meetings. The course in-
structors have come to depend on the skills of Cliff Sutkevich and his staff in set-
ting up and maintaining all of the necessary equipment and supplies. It is a
necessity to obtain and manage the many grants that support the academic pro-
gram, and Mary Horton of the Grants Office has ably coordinated these efforts.
The success of the academic program is the result, to a great extent, of the work
and assistance of Laboratory staff from all areas-from scientists who give lec-
tures (and sometimes teach) in the courses, to those in the Purchasing Office
(Sande Chmelev, Pat Hinton, Mary Ellen Fredericksen, and Barbara Zane), to
staff in the Buildings and Grounds Department and Blackford Hall.
Terri G rodzicker
Assistant Director for Academic Affairs
57th COLD SPRING HARBOR SYMPOSIUM
ON QUANTITATIVE BIOLOGY
The Cell Surface
May 27-June 3, 1992
ARRANGED BY
Richard Axel, HHMI, Columbia University
Corey Goodman, University of California, Berkeley
Richard Hynes, Massachusetts Institute of Technology
Bruce Stillman, Cold Spring Harbor Laboratory
321 participants
The biochemical processes that occur at the cell surface have profound effects
on the well-being of single cells and whole organisms. Cell-surface phenomena
are principal areas of study in all disciplines of modern biological research, in-
cluding physiology, development and differentiation, immunology, cancer,
neurobiology, and cell growth and death. Moreover, the molecules that lie on or
immediately subjacent to the cell surface comprise prime targets for alleviation or
treatment of human diseases. Because of the importance of this research, it was
decided to focus the 57th Cold Spring Harbor Symposium on the topic of The
Cell Surface. It was a considerable challenge, however, to attempt to bring to-
gether a diverse group of scientists who study biology at the cell surface. But
there was also comfort in the fact that common molecular themes appear in all
species, from bacteria to humans.
M. Brown
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G. Stiller, B. Stillman, D. Wiley, D. Luke III, H. Horwitz
The very first Symposium organized by Reginald Harris in 1933 was entitled
Surface Phenomena and in the intervening years, many other Symposia have
dealt with many aspects of this broad topic. In 1992, given the breadth of the
program, it was not possible to invite all the major scientists working in this field
and so difficult decisions were necessary. Following an introduction by Jim Wat-
son, the first-night speakers, Christiane NOsslein-Volhard, Dan Koshland, Jr.,
Tony Hunter, and Gerald Edelman provided a fascinating overview and a taste of
what was to come. During the 6 days, 321 participants witnessed a total of 82
oral presentations and 89 posters and the high standard set on the first night was
maintained throughout the meeting. An insightful and wonderful summary was
presented by Mel Simon.
Essential funds to hold such a meeting were provided by the National
Science Foundation, the U.S. Department of Energy, Office of Health and En-
vironmental Research, and the following divisions of the National Institutes of
Health: the National Cancer Institute, the National Institute of Neurological Dis-
H. Lodish, J. Goldstein
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S.-H. Kim, P. Sternberg, H. Bourne
R. Anderson, K. Drickamer M. Simon
orders and Stroke, and the National Institute on Aging. Additional funding came
from our Corporate Sponsors who provide increasingly essential funding: Akzo
Pharma International B.V.; Alafi Capital Company; American Cyanamid Compa-
ny; Amgen Inc.; Applied Biosystems, Inc.; BASF Bioresearch Corporation; Bec-
ton Dickinson and Company; Boehringer Mannheim Corporation; Ciba-Geigy
Corporation/Ciba-Geigy Limited; Diagnostic Products Corporation; The Du Pont
Merck Pharmaceutical Company; Eastman Kodak Company; Genentech, Inc.;
Glaxo; Hoffmann-La Roche Inc.; Johnson & Johnson; Kyowa Hakko Kogyo Co.,
Ltd.; Life Technologies, Inc.; Eli Lilly and Company; Met Path Inc.; Millipore Cor-
poration; Monsanto Company; New England BioLabs, Inc.; Oncogene Science,
Inc.; Pall Corporation; Perkin-Elmer Cetus Instruments; Pfizer Inc.; Recordati;
Sandoz Research Institute; Schering-Plough Corporation; SmithKline Beecham
Pharmaceuticals; Sumitomo Pharmaceuticals Co., Ltd.; Toyobo Co., Ltd.; The
Upjohn Company; The Wellcome Research Laboratories,; Burroughs Wellcome
Co.; and Wyeth-Ayerst Research.
C. Goodman J. Brugge
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M. Mathews, R. Hynes
PROGRAM
Welcoming Remarks: J.D. Watson
Introduction: The Cell Surface
Chairperson: R.O. Hynes, HHMI, Massachusetts Institute of Technology
Receptors
Chairperson: H.R. Bourne, University of California, San Francisco
Regulation at the Cell Surface
Chairperson: A.G. Gilman, University of Texas Southwestern Medical Center, Dallas
Development
Chairperson: C.S. Goodman, HHMI, University of California, Berkeley
Immunology
Chairperson: S. Tonegawa, HHMI, Massachusetts Institute of Technology
Neurobiology
Chairperson: L. M. Reichardt, HHMI, University of California, San Francisco
Morphogenesis and Pattern Formation
Chairperson: J. Kimble, University of Wisconsin, Madison
Cell Adhesion
Chairperson: E. Ruoslahti, La Jolla Cancer Research Foundation
Receptors in the Vascular System
Chairperson: J.S. Brugge, HHMI, University of Pennsylvania, Philadelphia
Dorcas Cummings Lecture
Speaker: M. Brown, University of Texas Southwestern Medical Center, Dallas
Transduction of Signals
Chairperson: J.L. Goldstein, University of Texas Southwestern Medical Center, Dallas
Cell Migration and Axon Guidance
Chairperson: H.R. Horvitz, HHMI, Massachusetts Institute of Technology
Membrane Traffic and Organization
Chairperson: K. Burridge, University of North Carolina, Chapel Hill
Cell-Cell Interactions
Chairperson: M. Takeichi, Kyoto University, Japan
Finale
Chairperson: E.R. Kandel, HHMI, Columbia University, New York
Summary: Melvin Simon, California Institute of Technology, Pasadena
B. Stillman, J. Kimble
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MEETINGS
Molecular Biology of Aging
April 22-April 26, 1992
ARRANGED BY
Caleb Finch, University of Southern California, Los Angeles
Stanley Prusiner, University of California, San Francisco
126 participants
This meeting was intended to interface several communities of researchers of the
general theme of aging, as well as to highlight ongoing advances. Because the
cell biologists and neurobiologists who work on aging, for example, have rarely
attended the same meetings, there were overview lectures at the beginning and
closing of the program. Among the cross-fertilizing themes was the recognition of
the fact that abnormal proteins accumulate during normal aging, as well as in
Alzheimer's disease. The theories of somatic cell genomic damage as a mecha-
nism in aging are finally gaining credibility by demonstrations of loss of telomeric
DNA and by mitochondrial DNA deletions. Although molecular approaches were
represented throughout the presentations, the full powers of recombinant tech-
nology are just beginning to be applied to short-lived invertebrates. A major open
question is the possibility of general molecular mechanisms responsible for aging
changes, despite the manifest species specificity of many diverse pathological
and physiological changes. Enthusiasm was high for further workshops and
symposia in this general area.
This meeting was funded in part by the National Institute on Aging, Division of
the National Institutes of Health.
E. Stadtman, S. Prusiner
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0. Hughes, G. Lithgow
PROGRAM
Overviews
C.E. Finch, University of Southern California
G.M. Martin, University of Washington
Genome Stability
Chairperson: G.M. Martin, University of Washington
DNA Synthesis
Chairperson: V.J. Cristofalo, Medical College of Pennsylvania
Abnormal Proteins and Neurodegenerative Disease
Chairperson: E.R. Stadtman, NHLBI/National Institutes of Health
Neurodegenerative Diseases and Cell Death
Chairperson: M.L. Shelanski, Columbia University
Gene Expression
Chairperson: C.E. Finch, University of Southern California
Genetics of Neurodegeneration and Life Span
Chairperson: T.E. Johnson, University of Colorado
Closing Lectures and General Discussion
Chairpersons: D.L. Price, Johns Hopkins University School of Medicine
S.B. Prusiner, University of California, San Francisco
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Neurobiological Basis of Epilepsy
April 29-May 2, 1992
ARRANGED BY
Charles Gilbert, Rockefeller University
Fred Plum, Cornell University Medical College
Charles Stevens, The Salk Institute
146 participants
This meeting provided an overview of current advances in neurobiology that may
lead to an understanding of mechanisms underlying epilepsy. Given the consid-
erable progress that has been made in elucidating the cellular mechanisms of
neuronal excitability, it is anticipated that these advances will lead to an under-
standing of how seizures might occur in brains of patients with epilepsy. "The
Neurobiological Basis of Epilepsy" meeting brought together clinicians and
neuroscientists working in basic neuronal mechanisms. The clinicians described
the clinical presentation of epilepsy, its neuropathology, and the pharmacology of
anticonvulsants. The description of basic mechanisms included talks on synaptic
mechanisms, neuronal circuits, gene expression and excitability, intracellular
messengers, and development and plasticity. By bringing together molecular,
cellular, systems and clinical approaches, the intention of the meeting was to
apply advances in neuroscience to an understanding of the pathophysiology of
epilepsy and to obtain insights into its treatment.
This meeting was funded by The Esther A. and Joseph Klingenstein Fund,
Inc.
E. Kandel F. Plum
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PROGRAM
The Clinical Picture
Chairperson: F. Plum, Cornell University Medical College
Neuropathology of Epilepsy
Chairperson: F. Plum, Cornell University Medical College
Genetics and Epilepsy
Chairperson: D. Choi, Washington University
Anticonvulsants
Chairperson: C. Stevens, The Salk Institute
Synaptic Mechanisms
Chairperson: C. Stevens, The Salk Institute
Neuronal Circuits
Chairperson: C. Gilbert, Rockefeller University
Gene Expression and Excitability
Chairperson: C. Gilbert, Rockefeller University
Intracellular Messengers
Chairperson: J. McNamara, Duke University/Durham V. A. Medical Center
Development and Plasticity
Chairperson: J. McNamara, Duke University/Durham V. A. Medical Center
Development and Plasticity (continued)
Chairperson: R. Dingledine, University of North Carolina
Summary
Chairperson: E. Kandel, Columbia University
Concert: Violinist: Scott Yoo, accompanied by Max Levinson, piano
R. MacKinnon, James Watson
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Genome Mapping and Sequencing
May 6-May 10, 1992
ARRANGED BY
Richard Myers, University of California, San Francisco
David Porteous, Medical Research Council, Edinburgh, England
Richard Roberts, Cold Spring Harbor Laboratory
441 participants
The fifth Genome Mapping and Sequencing meeting reported on important prog-
ress in many areas over the past year. A recurrent theme was the synergism de-
veloping between genome studies of different organisms, from yeast to humans,
via the nematode, molds, mice, and fruit flies. A major highlight was the im-
pressive progress being made in large-scale genomic sequencing of S.
cerevisiae, C. elegans, and even humans.
We heard how a European 35-center collaboration has just completed the se-
quencing of the entire yeast chromosome Ill. On this basis, the complete se-
quence of this organism seems now a distinct possibility within a few years. The
current effort has revealed a multitude of new genes for genetic and functional
analysis, the scale of the latter problem providing a major stimulus for new and
exciting activity. Profound insights into the eukaryotic transcriptional map are
sure to follow. The USA/UK collaboration to map and sequence C. elegans is al-
ready ahead of their target with 1 Mbp sequenced this year and 3 Mbp promised
for 1993. With only modest improvements in efficiency, the 100-Mbp task could
be completed this decade.
Sequencing the human genome poses altogether new problems of scale and
complexity due to the high level of repeated DNA sequences, but again, the
progress and insights into chromosomal and transcription organization, evolution,
G.-J. Van Ommen, D. Cox, R. Kucherlapati
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and polymorphic variation that have come
from focused efforts to sequence gene
complexes and random contiguous DNA tracts more than justifies the efforts. The
alternative approach of cDNA cloning and sequencing has also made impressive
progress, with several thousand new genes identified in C. elegans, humans, and
mice. Will we need to extend each to full-length sequence for the true function to
be predicted, or understood? Do biological experiments hold the key or can se-
quence comparisons provide at least some of the answers that this wealth of new
data promises? Certainly, improved informatics is an essential complement to
these large-scale genome analyses, and here too, we were provided with graph-
ic evidence for important progress. Potential transcription units can be identified
directly from raw sequences with remarkable confidence. Again, to keep pace
with the demand for faster and longer sequencing capacity, there is clearly room
for technical improvement and a need for further economy. There is still potential
for very significant improvement of conventional technology, but we were also
treated to a possible glimpse of the future, with sequencing by hybridization,
mass spectroscopy, and microchip technology vying to make the quantum tech-
nological breakthrough.
High-density physical and genetic index maps are nearing completion in hu-
mans and mice. We heard too of the exciting progress being made toward com-
plete cloned contig maps of several human chromosomes. The 40 Mbp of
euchromatic Y is essentially cloned and ordered, a task completed in determined
fashion by three pairs of hands in less than 2 years. For the autosome maps,
everyone is looking for help from the remarkable YAC clone resources estab-
lished at CEPH. They estimate that a quarter of the human genome is already in
contigs and that 90% are 5 Mbp or larger. This is just what is needed as a base
resource for positional cloning of disease genes.
The meeting maintained its reputation as the forum for innovative ideas and
enabling strategies, this year featuring novel in situ hybridization techniques,
mutation/polymorphism detection assays, and a variety of methods for introduc-
ing or creating novel restriction cleavage specificities, among others. Several ef-
E. Lander, S. Tingey
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D. Patterson
fective methods for integrating complex genomic sources with cDNAs to isolate
the transcribed components were described, filling an important gap in the posi-
tional cloning strategy for isolating candidate disease genes.
Finally, the warmest reception at the meeting was for Jim Watson, who more
than anyone else has nurtured the Genome Project to the healthy and exciting
state that it currently enjoys and which this meeting aims to reflect. We all look
forward in anticipation to next year's meeting and trust to benefit from Jim Wat-
son's continuing critical enthusiasm and vision for what the future goals must be.
Rich Roberts (with Maynard Olson and Charles Cantor) has coorganized this
meeting from its inception, but after 5 years will bow out, allowing Bob Waterston
to join Rick Myers and David Porteous in the largely pleasant task of organizing
next year's meeting, with further assistance from Eric Green, Ray Geste land, Bar-
bara Trask, Kay Davies, and Rodney Rothstein.
This meeting was funded by the National Center for Human Genome Re-
search, National Institutes of Health.
PROGRAM
Human Maps and Diseases
Chairperson: U. Francke, Stanford University, California
Methods: Cloning and Automation
Chairperson: W. Szybalski, University of Wisconsin, Madison
Sequencing Methodology
Chairperson: R. Geste land, University of Utah, Salt Lake City
Methods: Mapping
Chairperson: B. Trask, Lawrence Livermore National Laboratory
Informatics
Chairperson: R. Myers, University of California, San Francisco
Large-scale Sequence Projects
Chairperson: D. Porteous, MRC, Human Genetics Unit, Edinburgh
Maps of Model Organisms
Chairperson: G. Miklos, Australian National University, Canberra
G. Bernardi, N. Shimizu
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The Cell Cycle
May 13-May 17, 1992
ARRANGED BY
David Beach, Cold Spring Harbor Laboratory
Arnold Levine, Princeton University
Joan Ruderman, Harvard Medical School
338 participants
Scientists from research centers in Europe, the Far East, and the United States
gathered to discuss their latest research concerning control of the cell cycle and
cell proliferation. The program included 74 speakers who discussed such funda-
mental problems as control of mitosis; entry into the cell cycle; the role of anti-
oncogenes and tumor suppressor genes in regulating cell growth; DNA replica-
tion; cell differentiation and cessation of proliferation; role of oncogenes and
growth factors in control of cell proliferation; and chromosome behavior and divi-
sion. The participating leading researchers in these areas of research use a vari-
ety of approaches from genetics to biochemistry to study control of the cell cycle.
A variety of model systems from yeast to humans were discussed, and the meet-
ing provided the opportunity to demonstrate how these different approaches
complement each other. The meeting was one of great intensity and scientific in-
terchange.
Contributions from the Corporate Sponsors provided core support for this
meeting.
PROGRAM
START
Chairperson: A.J. Levine, Princeton University
Networking I
Chairperson: J.V. Ruderman, Harvard Medical School
Networking II
Chairperson: D. Beach, HHMI, Cold Spring Harbor Laboratory
DNA Synthesis
Chairperson: H. Piwnica-Worms, Tufts University
CDC2 Activation
Chairperson: J.L. Campbell, California Institute of Technology
Signaling
Chairperson: B. Futcher, Cold Spring Harbor Laboratory
Checkpoints
Chairperson: L. Breeden, Fred Hutchinson Cancer Research Center
Phosphatases Across the Cycle
Chairperson: P.H. O'Farrell, University of California, San Francisco
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J. Rudderman, D. Beach
RNA Tumor Viruses
May 19-May 24, 1992
ARRANGED BY
Eric Hunter, University of Alabama, Birmingham
Volker Vogt, Cornell University
411 participants
The 1992 RNA Tumor Virus meeting featured papers covering a broad range of
topics in retrovirus biology, including virus-host interactions, virus replication
mechanisms, and viral pathogenesis, the latter including both oncogenesis and
immunosuppression. A strength of the meeting as always was the diversity of
retroviruses included in the various scientific sessions. This allowed the increas-
ing number of presentations on pathogenic human retroviruses to be viewed in
the broad perspective of the retrovirus field as a whole.
This year's meeting was characterized by renewed interest in the processes
of virus assembly, virus entry, and reverse transcription/integration, which togeth-
er comprised more than half the papers presented. The interplay of viral and host
factors in the regulation of retroviral transcription and posttranscriptional pro-
cesses was a major topic of discussions, and the role of "nonessential" genes in
viral pathogenesis was reemphasized.
This was a historical and "final" CSH RNA Virus Meeting, since it was felt by a
majority of the participants that the term RNA Tumor Virus was anachronistic, par-
ticularly when one considers the numbers of papers dealing with nononcogenic
retroviruses and retrotransposons. The 1993 meeting will therefore bear the title
"CSH Retroviruses Meeting."
Contributions from the Corporate Sponsors provided core support for this
meeting.
T. Grodzicker, E. Hunter
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C. Kozak, P. Jolicoeur
PROGRAM
Virus Assembly
Chairpersons: E. Barklis, Oregon Health Sciences University
J. Wills, Penn State University School of Medicine
Encapsidation and Maturation
Chairpersons: C. Carter, State University of New York, Stony Brook
K. Strebel, NIAID, National Institutes of Health
Virus Entry
Chairpersons: J. Cunningham, HHMI and Harvard Medical School
A. Pinter, Public Health Research Institute, New York
Reverse Transcription
Chairpersons: F. Clavel, Institute Pasteur, Paris
S. Hughes, National Cancer Institute-FCRDC, Frederick
Integration and Recombination
Chairpersons: R. Craigie, NIDDK, National Institutes of Health
R. Katz, Fox Chase Cancer Center, Philadelphia
Expression 1: Transcription
Chairpersons: L. Ratner, Washington University School of Medicine
N. Speck, Dartmouth Medical School
Expression 2: Posttranscription
Chairpersons: K. Beemon, Johns Hopkins University
E.-T. Jeang, NIAID, National Institutes of Health
Pathogenesis
Chairpersons: R. Desrosiers, New England Regional Primate Research Center
H. Fan, University of California, Irvine
Retrovirus Potpourri
Chairpersons: J. Elder, Scripps Research Institute
P. Jolicoeur, Clinical Research Institute of Montreal
Expression 3: trans-Activation
Chairpersons: D. Derse, National Cancer Institute-FCRDC, Frederick
B. Felber, National Cancer Institute-FCRDC, Frederick
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A. Pinter, J. Cunningham
D. Derse
Molecular Biology of SV40, Polyoma, and Adenoviruses
August 12-August 16, 1992
ARRANGED BY
Terri Grodzicker, Cold Spring Harbor Laboratory
David Livingston, Dana-Farber Cancer Institute
Carol Prives, Columbia University
234 participants
The small DNA tumor viruses-SV40, polyoma, and adenoviruse-have long
served as model systems to study cellular transcription, replication, and control
of cell growth. Approximately 250 scientists gathered at the 1992 meeting to
present their latest results in about 200 talks and posters.
Much of the emphasis at the meeting concerned the interaction of viral
regulatory proteins (e.g., adenovirus E1A proteins, SV40 T antigen) with cellular
proteins such as p53, the retinoblastoma (RB) gene product, and cyclins, as well
as cell-cycle changes in protein complexes and their state of phosphorylation.
The role of protein modifications and interactions of viral regulatory proteins with
cellular kinases and phosphatases also received attention. Several talks de-
scribed the role of E1A in induction of apoptosis and that of the E1A 19K proteins
in suppression of apoptosis. Much research continues to focus on the purification
and analysis of cellular proteins involved in viral DNA replication and the use of in
vitro systems to dissect the replication process. The study of transcriptional
regulation and the interactions of viral E1A proteins and T antigens(s) with com-
ponents of the transcriptional apparatus using in vitro as well as in vivo systems
was extensively discussed. Talks were also given on RNA splicing, control of
poly(A)-site usage, translational control, cell-cycle-specific protein modifications,
D. Livingston, M. Green
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and the role of different viral proteins in the host's
immune response. The meeting
proved a highly profitable occasion for the discussion of new results emerging
from the study of viral proteins and virus-host cell interactions.
Contributions from the Corporate Sponsors provided core support for this
meeting.
PROGRAM
Oncogenes and Transcriptional Activation
Chairperson: M.R. Green, University of Massachusetts Medical Center, Worcester
Protein Complexes
Chairperson: D. Livingston, Dana-Farber Cancer Institute, Boston, Massachusetts
DNA Replication
Chairperson: B. Stillman, Cold Spring Harbor Laboratory
Transcription: Adenoviruses
Chairperson: A. Berk, University of California, Los Angeles
Transformation
Chairperson: E. Fanning, Universitat Munchen, Germany
Transcription: SV40, Polyoma
Chairperson: C. Cole, Dartmouth Medical School, Hanover, New Hampshire
Posttranscription
Chairperson: J. Mertz, University of Wisconsin, Madison
Host-Virus Interactions
Chairperson: E. White, Rutgers University, Piscataway, New Jersey
M. Botchan, M. Fried, T. Grodzicker
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C. Prives, J. Alwine, B. Stillman
Molecular Genetics of Bacteria and Phages
August 18-August 23, 1992
ARRANGED BY
Susan Gottesman, National Cancer Institute
Peter Model, Rockefeller University
Miriam Susskind, University of Southern California
210 participants
More than 200 people attended the 1992 phage meeting at Cold Spring Harbor
Laboratory, and 169 abstracts were presented in eight platform sessions and two
poster sessions. Thirty six percent of the abstracts were submitted from outside
the United States, and participation in the meeting continues to be an excellent
mix of scientists at a variety of levels in their scientific careers from all over the
world.
As in the past, the meeting emphasized the basic biology of bacterial sys-
tems and responses to environmental change, including interactions between
phage and their hosts. Subject matter presented covered a wide range, including
regulation of gene expression, studies on entry and exit from the cell, replication
and recombination, and protein structure. Course and co-workers extended ear-
lier observations by other investigators on the importance of the RNA polymerase
a subunit in positive activation to a role for this subunit in factor-independent ac-
tivation of rRNA promoters, suggesting changes in both our understanding of
positive activation and the definition of a promoter. Deho and co-workers
reported that the immunity determinant for the P4 bacteriophage is a short RNA,
which appears to act by promoting premature termination of another P4 tran-
J. Watson, J. Roberts, S. Gottesman
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script. Work on the lysis protein of phage 0174 by Schrot and co-workers in
Austria suggests that this protein causes fusion between inner and outer mem-
branes, providing a direct route out of the cell for the phage.
Contributions from the Corporate Sponsors provided core support for this
meeting.
PROGRAM
RNAP-Promoter Interactions
Chairperson: W. McAllister, State University of New York, Brooklyn
Transcription: Promoter Clearance, Elongation, and Termination
Chairperson: R. Weisberg, National Institutes of Health
Repressors and Activators
Chairperson: M. Howe, University of Tennessee
Antisense and Translational Control
Chairperson: A. Poteete, University of Massachusetts
Regulatory Circuits
Chairperson: R. Calendar, University of California, Berkeley
Protein Structure, Chaperonins, and Heat Shock
Chairperson: R. Ebright, Rutgers University
The Outer Limits
Chairperson: M. Russel, Rockefeller University
DNA Replication and Partitioning
Chairperson: M. Yarmolinsky, National Institutes of Health
RNA Processing, Intron Homing, and Recombination
Chairperson: D. Shub, State University of New York, Albany
Genome Analysis and Rearrangement
Chairperson: N. Craig, Johns Hopkins University
H. Bahl, B. Bukau
W. Szybalski, V. Zinkevich
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Mouse Molecular Genetics
August 26-August 30, 1992
ARRANGED BY
Anton Berns, The Netherlands Cancer Institute
Douglas Hanahan, University of California, San Francisco
Robb Krumlauf, MRC National Institute for Medical Research
Andy McMahon, Roche Institute of Molecular Biology
424 participants
The sophisticated approaches currently available to the mouse molecular
geneticist, which allow gene expression to be precisely manipulated in vivo, are
revolutionizing our ability to probe the complex mechanisms involved in generat-
ing a normal adult mouse. The clear spin-off from this work is a better under-
standing of the normal workings of humans, and the development of rational ap-
proaches toward the molecular elucidation and eventual treatment of human dis-
ease. The annual Mouse Molecular Genetics meeting, held this year at Cold
Spring Harbor Laboratory, was a landmark meeting with important advances
reported in the broad fields of developmental biology, immunology, and oncol-
ogy.
At the previous meeting held in Heidelberg in 1991, the organizers hit upon a
meeting format that was successfully adopted at Cold Spring Harbor Laboratory.
Session chairs were invited for each session. In addition, one prominent re-
searcher was invited to give the opening talk in each session. All other speakers
(eight per session) were selected from the list of submitted abstracts. Thus, this
meeting was mainly a forum for the advanced graduate student and postdoctoral
fellow to present their own work, under the guidance of an experienced chairper-
son, an opportunity that is regrettably rare today. So great was the interest in this
A. McMahon, R. Krumlauf, A. Berns, D. Hanahan
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meeting that it was difficult to choose only 64 platform presentations from among
the many excellent abstracts. Fortunately, two well-attended poster sessions al-
lowed the presentation of 150 posters. As usual, Cold Spring Harbor proved to
be an exceptional environment for informal interactions, perhaps the most impor-
tant part of any meeting.
The most remarkable aspect of the meeting was the dramatic realization of
the efficient predictable targeting of mouse genes. No less than 27 talks dealt
with novel mouse mutants generated by targeted mutagenesis in embryo stem
cells, arguably the most important advance in mouse genetics in the last decade.
Although it is hard to select only a few highlights from the many presentations in
which important advances were made using this approach, some of the principal
findings are described below.
Several groups reported the targeting of tumor suppressor genes, in particu-
lar, the retinoblastoma gene, which resulted in a heightened tumor susceptibility.
Surprisingly, targeting of a peptide growth factor, a-inhibin, suggests that this
protein is normally involved in gonadal growth control and thus acts as a tumor
suppressor. Together, these mice offer new ways in which the development of
tumors and the use of therapeutic agents can be explored. Disease models of
cystic fibrosis, hypercholesterolemia, osteoarthritis, and ulcerative colitis were
generated by mutating the cysfic fibrosis transmembrane conductance regulator,
apolipoprotein E, collagen IX, and IL-2 genes, respectively. In the field of im-
munology, an impressive array of proteins associated with antigen presentation
and recognition, including T-cell receptors, MHC class I and II molecules, and
peptide transporters, have been disrupted, in many cases validating current
models, but also generating some unexpected findings. In the area of develop-
mental biology, convincing evidence is finally emerging linking homeobox gene
expression with skeletal patterning along the anterior-posterior axis. Study of
organ development also received a boost from the demonstration that a proto-
oncogene receptor tyrosine kinase, c-ret, is essential for some aspect of the in-
ductive interaction involved in early kidney development.
P. Rowe, E. Fuchs
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I. Kola, A. Dunn
It seems likely that interest in the use of mice as experimental animals will
grow. This will require improved mechanisms for distributing materials, a topic
that led to a lively discussion in a packed auditorium. Clearly, the mouse will
remain in the vanguard of genetic research for the foreseeable future, funding
permitting. We are grateful to Dr. Doug Hanahan who stepped down this year
after many years of organizing this meeting.
This meeting was funded in part by the National Science Foundation, and the
following divisions of the National Institutes of Health: the National Institute of
Child Health and Human Developmnent, the National Cancer Institute, and the
National Heart, Lung and Blood Institute.
PROGRAM
Transcriptional Regulation in Development
Chairperson: S. Tilghman, Princeton University, New Jersey
Pattern Formation in Early Development
Chairperson: J. Rossant, Samuel Lunenfeld Research Institute, Mount Sinai Hospital,
Toronto, Canada
Organ Development and Differentiation
Chairperson: B. Hogan, Vanderbilt University Medical School, Nashville, Tennessee
Hematopoiesis
Chairperson: I. Weissman, Stanford University Medical Center
Mouse Models of Disease
Chairperson: E. Wagner, Institute for Medical Pathology, Vienna, Austria
Mechanisms of Tumorigenesis
Chairperson: H. Varmus, University of California, San Francisco
New Technologies
Chairperson: R. Palmiter, HHMI, University of Washington, Seattle
Signals and Receptors
Chairperson: R. Jaenisch, Whitehead Institute for Biomedical Research, Cambridge,
Massachusetts
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Genetics and Molecular Biology of Breast Cancer
September 2-September 6, 1992
ARRANGED BY
Mary-Claire King, University of California, Berkeley
Marc Lippman, Georgetown University Medical Center
167 participants
In the past year, considerable progress has been made in understanding the
genetics and molecular biology of breast cancer. Genes have been identified
whose alteration, amplification, or loss in tumors is associated with invasion,
progression, or metastasis. A gene has been mapped, and is likely to be cloned
soon, that is responsible for inherited early-onset breast cancer and ovarian can-
cer and that appears also to be altered somatically in breast and ovarian tumors.
The relationships among growth factors and receptors active in normal and
malignant breast tissue have been more precisely defined. The goal of this meet-
ing was to bring together investigators working with genes, with growth factors
and their receptors, and with breast cancer clinically in order to identify how and
when these three avenues of research will converge.
This meeting was funded in part by the U.S. Dept. of Energy and the National
Cancer Institute, National Institutes of Health.
PROGRAM
Welcoming Remarks: J.D. Watson
Plenary Session
Chairperson: J.D. Watson, Cold Spring Harbor Laboratory
Current Clinical Realities, Epidemiology, and Pathology
Chairperson: I.C. Henderson, University of California, San Francisco
Genetics I
Chairperson: M.-C. King, University of California, Berkeley
Genetics II
Chairperson: M.-C. King, University of California, Berkeley
Growth Factors and Their Receptors I
Chairperson: M. Lippman, Georgetown University Medical Center
Growth Factors and Their Receptors II
Chairperson: M. Lippman, Georgetown University MedicalCenter
Invasion and Metastasis
Chairperson: S.A. Aaronson, NCI, National Institutes of Health
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M.-C. King
M. Lippman
I.C. Henderson
Translational Control
September 9-September 13, 1992
ARRANGED BY
Alan Hinnebusch, National Institutes of Health
Michael Mathews, Cold Spring Harbor Laboratory
377 participants
The Translational Control meeting held at Cold Spring Harbor Laboratory this
year exceeded the previous two in the number of participants and abstracts
communicated. As in the past, the research involved many different organisms,
eukaryotic and prokaryotic, and diverse regulatory mechanisms. It is clear that
translational control plays an important role in a variety of biological phenomena,
including responses to nutrient availability, environmental stress, and virus infec-
tion, the control of cell proliferation, and development. Regulation occurs at the
level of mRNA stability, translation initiation, elongation, or termination. A novel
means of regulating initiation was described in bacteria where ribosomes be-
come trapped on the mRNA in nonproductive complexes. In eukaryotes, the 3'
UTR was implicated in various mechanisms affecting mRNA stability or transla-
tional efficiency. Small open reading frames (ORFs) were shown to impede the
flow of scanning ribosomes by a mechanism involving the ORF-encoded pep-
tides. Internal initiation of translation, first identified in picornaviruses, surfaced in
several cellular mRNAs, and there appeared to be considerable diversity in the
RNA elements and trans-acting factors that mediate these specialized initiation
events. Regulation of initiation factor activity by phosphorylation continued to be
the focus of much research, especially for the eIF -2 and eIF -4E that function in
regulating cellular proliferation. The mammalian interferon-induced elF-2a kinase
M. Mathews, A. Hinnebusch
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is targeted by many viruses, and the molecular mechanisms employed by
regulators from adenovirus and vaccinia virus are coming into focus. An elF-2a
kinase from yeast, along with subunits of the GDP-GTP exchange factor for elF-2,
was implicated in gene-specific translational control. Other studies with yeast led
to the identification of new initiation factors not previously detected in mammalian
cell-free translation systems. The rapid progress witnessed at this meeting is
clearly attributable to the powerful combination of genetic, molecular, and
biochemical techniques being applied to the study of translational control in
diverse organisms.
This meeting was funded in its entirety by ICN Biomedicals, Inc.
PROGRAM
Initiation: IREs and IRESs
Chairperson: M. G. Katze, University of Washington
Prokaryotes
Chairperson: D.A. Steege, Duke University Medical Center
Growth Control and Development
Chairperson: C.G. Proud, University of Bristol, United Kingdom
RNA-Protein Interactions and mRNA Stability
Chairperson: J.B. Harford, National Institutes of Health
Elongation and Termination
Chairperson: R. Weiss, University of Utah
Viral Systems
Chairperson: R.J. Schneider, New York University Medical Center
Factors and Mechanism
Chairperson: T.F. Donahue, Indiana University
Concert: Mikhail Yanovitsky, Pianist
Initiation: ORFs and Kinases
Chairperson: R. Rhoads, Louisiana State University Medical Center
J. McCarthy, D. Steege
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T. Donahue, B. Castilho-Valavicius
Modern Approaches to New Vaccines IncludingPrevention of AIDS
September 16-September 20, 1992
ARRANGED BY
Fred Brown, USDA, Plum Island Animal Disease Center
Robert M. Chanock, NIAID, National Institutes of Health
Harold S. Ginsberg, Columbia University College of Physicians & Surgeons
Richard A. Lerner, Research Institute of Scripps Clinic
214 participants
The tenth annual meeting on Modern Approaches to New Vaccines provided an
opportunity for an unusually varied group of basic microbiologists, clinical investi-
gators, epidemiologists, basic immunologists, and pharmaceutical industry
scientists to interact and exchange their latest research observations concerning
ways to improve immunoprophylaxis and extend its reach.
Many new advances were reported. Perhaps the most exciting new method
for active immunoprophylaxis described at the meeting was a simple but effec-
tive form of direct genetic immunization. Several groups reported that direct in-
oculation of cloned DNA into muscle resulted in prolonged expression of the pro-
tective protein antigen encoded by the DNA. Animals immunized in this manner
developed resistance to challenge infection. Also, it was reported that human
antibody Fab fragments with high functional activity could be cloned from a
recombinatorial library with high efficiency. The availability of such antibodies
should provide new opportunities for passive immunotherapy and im-
munoprophylaxis because some of these monoclonal Fabs exhibit extremely high
neutralizing activity for the virus against which the immunoglobulin fragments are
directed.
R. Chanock, H. Ginsberg
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A potential breakthrough in immunization was described for the papil-
lomaviruses, which are associated with a significant proportion of human cancers
worldwide. A high level of papillomavirus neutralizing antibodies was induced for
the first time by immunizing animals with a papillomavirus outer capsid protein
expressed by a recombinant baculovirus. Recent advances in another active
field of research suggests that nonsegmented negative-strand RNA viruses, as
well as segmented double-stranded RNA viruses may soon be amenable to ge-
netic manipulation at the cDNA level. Although rescue of these viruses in an in-
fectious form from their cDNA has not yet been achieved, identification of cis-
acting signals for virus transcription and replication has made it possible to res-
cue synthetic minigenomes from cDNA-encoded RNA transcripts using a helper-
virus-dependent system.
Many issues and developments in experimental immunoprophylaxis of AIDS
were discussed during the course of the meeting. Perhaps most relevant were a
series of presentations that addressed the mechanism responsible for the
resistance to challenge exhibited by monkeys immunized with inactivated simian
immunodeficiency virus (SIV) originally derived from human cell cultures. It now
appears that sterile immunity against cell-free SIV challenge is due in many in-
stances to antibodies directed against human host-cell components associated
with vaccine virus rather than virus-specific immunity. Nonetheless, immunized
monkeys that became infected following challenge with simian-cell-associated
SIV did exhibit resistance to AIDS-like disease under conditions indicating that
the protective effect was virus-specific. Finally, in one circumstance, sterile im-
munity to cell-associated SIV challenge was induced in 50% of monkeys im-
munized with inactivated SIV under conditions in which host-cell antigens did not
appear to play a role. The last two observations offer some hope for the eventual
control of AIDS by immunization.
Contributions from the Corporate Sponsors core support for this
meeting.
E. Norrby, N. Haigwood, S.-L. Hu
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B. Murphy, V. Hirsh, D. McPhee
PROGRAM
Immunology I
Chairperson: D. Burton, Scripps Research Institute, La Jolla
Overview Lecture: Dennis Burton, Scripps Research Institute, La Jolla
AIDS I
Chairperson: N.L. Letvin, Harvard Medical School, New England Regional
Primate Research Center
Virology I
Chairperson: A. Kapikian, NIAID, National Institutes of Health
Immunology, Bacteriology, and Parasitology
Chairperson: F. Brown, USDA, Plum Island Animal Disease Center
AIDS II
Chairperson: E. Norrby, Karolinska Institute, Stockholm
Virology II
Chairperson: P. Collins, NIAID, National Institutes of Health
Aids III
Chairperson: H. Ginsberg, Columbia University College of Physicians & Surgeons
Bacteriology and Parasitology
Chairperson: B.R. Murphy, NIAID, National Institutes of Health
Aids IV
Chairperson: V.M. Hirsch, NIAID, National Institutes of Health
Summary: V.M. Hirsch, NIAID, National Institutes of Health
F. Brown
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Gene Therapy
September 22-September 26, 1992
ARRANGED BY
W. French Anderson, National Institutes of Health, NHLBI
Theodore Friedmann, University of California, San Diego
Richard Mulligan, Massachusetts Institute of Technology
315 participants
The first Cold Spring Harbor meeting devoted to Human Gene Therapy was held
on September 22-26, 1992. Since the initial discussions of the potentials for hu-
man gene therapy in the early 1970s, there has been enormous interest in this
potentially powerful new form of medicine, and impressive technical advances
during the past decade have now indicated that a genetic approach to the cor-
rection of many human ailments will become possible. Within the past several
years, the first experimental gene therapy studies with human patients have been
started with patients suffering both from genetic disorders and from acquired dis-
eases such as cancer, AIDS, Parkinson's disease, Alzheimer's disease, and
many others. Both the basic science aspects and the clinical applications of
these advances were reviewed. This first Cold Spring Harbor meeting is widely
seen as recognition of the importance of this conceptually new approach to
therapy and to indicate broad acceptance of it by the scientific, medical, and
policy communities. The development of human gene therapy is now in an ex-
plosive and productive stage of implementation, and Cold Spring Harbor will
continue to serve as a major avenue for review and catalysis of the field by hold-
ing additional meetings devoted to gene therapy. The second meeting is to be
held in the fall of 1994. This meeting was funded by The Wellcome Trust.
PROGRAM
Hematopoietic Cells
Chairperson: T. Friedmann, University of California, San Diego
Metabolic Disease I
Chairperson: I.M. Verma, Salk Institute, La Jolla, California
Cancer
Chairperson: R.C. Mulligan, Massachusetts Institute of Technology
CNS and Herpes Vectors
Chairperson: F.H. Gage, University of California, San Diego
Public Issues
Chairperson: N.A. Wivel, National Institutes of Health
Animal Models
Chairperson: F.W. Alt, HHMI, Children's Hospital and Harvard
Medical School
Metabolic Disease II
Chairperson: T. Friedmann, University of California, San Diego
Clinical Protocols
Chairperson: W.F. Anderson, National Institutes of Health
Clinical Overview: W.F. Anderson, National Institutes of Health
Gene Therapy for AI Ds
Overview: R.A. Morgan, National Institutes of Health
286
W.F. Anderson, T. Friedmann, R. Mulligan
Learning and Memory
September 30-October 4, 1992
ARRANGED BY
Ron Davis, Cold Spring Harbor Laboratory
Eric Kandel, Columbia University College of Physicians& Surgeons
Larry Squire, University of California, San Diego
104 participants
The 1992 Cold Spring Harbor meeting on Learning and Memory drew together
many major practitioners in the subject area. The scope of the meeting was wide.
It extended from studies typically placed within the field of cognitive psychology,
to developmental aspects of the brain in relation to plasticity, to elec-
trophysiological studies of synapses and synaptic plasticity, to the cellular and
genetic analysis of learning typically dominated by invertebrate preparations,
such as Aplysia and Drosophila. The wide scope provided one of the few op-
portunities for scientists applying molecular approaches to learning/memory to
interact with, and discuss the problem with, those working at the systems level.
With the success of this first meeting, the meeting is now planned to be held
every other year.
Highlights presented at the meeting included the analysis of fear learning and
its mediation by the amygdala, the clarification of the role of the prefrontal cortex
in working memory, and an exhilarating session on long-term potentiation. In ad-
dition, the meeting included two talks on learning in a new experimental system,
C. elegans.
This meeting was funded by the Marie Robertson Memorial Fund.
PROGRAM
Introductory Comments: R. Davis, Cold Spring Harbor Laboratory
Brain Systems and Memory
Chairperson: R.F. Thompson, University of Southern California, Los Angeles
Brain Plasticity, Learning, and Development
Chairperson: L.R. Squire, Veterans Administration Medical Center and
University of California, San Diego
Cellular and Molecular Aspects of Synaptic Plasticity
Chairperson: R. Davis, Cold Spring Harbor Laboratory
Long-term Potentiation
Chairperson: P. Andersen, Institute of Basic Medical Sciences, University of
Oslo, Norway
Cerebellar Learning, and Long-term Depression
Chairperson: R.W. Tsien, Stanford University
Innvertebrate Learning and Plasticity I
Chairperson: R.D. Hawkins, HHMI, Columbia University
Invertebrate Learning and Plasticity II
Chairperson: E.R. Kandel, HHMI, Columbia University College
of Physicians & Surgeons E. Kandel, R. Davis, L. Squire
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EDUCATIONAL
ACTIVITIES

POSTGRADUATE COURSES
The summer program of Postgraduate Courses at Cold Spring Harbor Laboratory
is aimed at meeting the special need for training in interdisciplinary subjects that
are either so new or so specialized that they are not adequately treated by uni-
versities. Our aim is to provide intensive study in the most recent developments
and techniques in these subjects and to prepare students to enter directly into
research in a particular area. To ensure up-to-date coverage of current research
work, we bring together a workshop staff from many laboratories around the
world and supplement this staff with a series of seminar speakers.
Cloning and Analysis of Large DNA Molecules
April 2-April 16
INSTRUCTORS
Birren, Bruce, Ph.D., California Institute of Technology, Pasadena
McCormick, Mary Kay, Ph.D., Los Alamos National Laboratory, New Mexico
Shepherd, Nancy, Ph.D., DuPont Merck Pharmaceutical Co., Wilmington, Delaware
ASSISTANTS
Munk, Chris, Los Alamos National Laboratory, New Mexico
Pfrogner, Beverly, DuPont Merck Pharmaceutical Co., Wilmington, Delaware
Saunders, Liz, Los Alamos National Laboratory, New Mexico
Wrestler, Janet, University of North Carolina, Chapel Hill
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This course covered the theory and practice of manipulating and cloning high-
molecular-weight DNA. Lectures and laboratory work dealt with the use of bac-
teriophage P1 and yeast artificial chromosome (YAC) cloning systems, the isola-
tion and manipulation of high-molecular-weight DNA from mammalian cells for
cloning (including the size-selection of >200-kb DNA fragments), and the analy-
sis of high-molecular-weight DNA by pulsed-field gel (PFG) separation tech-
niques. P1 and YAC recombinant DNA molecules were produced, introduced
into cells (E. coli and yeast, respectively), and reisolated after appropriate clone
selection and colony screening procedures. A variety of size standards for
pulsed-field gel electrophoresis were prepared, and gels were run to compare
the DNA separation capabilities of the common PFG techniques. Students
gained experience with physical mapping of YAC inserts and high-molecular-
weight genomic DNA. Lectures by outside speakers on topics of current interest
supplemented the laboratory work.
PARTICIPANTS
Altenbach, S., Ph.D., USDA, Albany, California
Barbet, A., Ph.D., University of Florida, Gainesville
Campbell, M., B.S., Los Alamos National Laboratory, New
Mexico
Dalrymple, M., Ph.D., Pharmaceutical Proteins Ltd., Edin-
burgh, United Kingdom
Forus, A., M.S., Norwegian Radium Hospital, Oslo
Fults, D., M.D., University of Utah, Salt Lake City
Imai, K., Ph.D., Max Planck Institute, Freiburg, Germany
Kamakura, T., Ph.D., University of California, Davis
Lindemann, G., B.S., University of Kansas Medical Center,
Kansas City
McMillan, T., Ph.D., Institute of Cancer Research, Surrey,
SEMINARS
Gardiner, K., Eleanor Roosevelt Institute. Pulsed-field gel
electrophoresis and mammalian genome organization.
Klapholz, S., Cell Genesys, Inc. YAC cloning and yeast biol-
ogy.
Lai, E., University of North Carolina. Pulsed-field gel elec-
trophoresis.
Shizuya, H., California Institute of Technology. The BAC sys-
tem: Cloning of human DNA in large fragments in E. coll.
United Kingdom
Menancio-Hautea, D., Ph.D., University of Minnesota, St.
Paul
Metcheva, I., Ph.D., Virginia Commonwealth University, Rich-
mond
Saito, H., B.S., University of Wisconsin, Madison
Schorgendorfer, K., Ph.D., Biochemie GmbH, Kufstein,
Austria
Sidenberg, D., Ph.D., Clarke Institute of Psychiatry, Toronto,
Canada
Weitzel, J., M.D., Tufts New England Medical Center, Boston,
Massachusetts
Silverman, G., Harvard Medical School. YAC Characteriza-
tion.
Smoller, D., Washington University. Cloning and character-
ization of a Drosophila P1 library.
Sternberg, N., DuPont Merck Pharmaceutical Co. Cloning
with the P1 vector system.
Szybalski, W., University of Wisconsin. Sequencing without
conventional cloning.
Protein Purification and Characterization
April 2-April 16
INSTRUCTORS
Burgess, Richard, Ph.D., University of Wisconsin, Madison
Guidotti, Guido, Ph.D., Harvard University, Cambridge, Massachusetts
Kadonaga, James, Ph.D., University of California, San Diego
Marshak, Daniel, Ph.D., Cold Spring Harbor Laboratory, New York
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ASSISTANTS
Bankston, Laurie, Harvard University, Cambridge, Massachusetts
Croston, Glenn, University of California, San Diego
Kerrigan, Leslie, University of California, San Diego
Knuth, Mark, Promega Corporation, Madison, Wisconsin
This course was intended for scientists who are not familiar with techniques of
protein isolation and characterization. It was a rigorous program that included
laboratory work all day and a lecture with a discussion session every evening.
Each student became familiar with each of the major techniques in protein
purification by actually performing four separate isolations including (1) a
regulatory protein from muscle tissue; (2) a sequence-specific, DNA-binding
protein, (3) a recombinant protein overexpressed in E. coli; and (4) a membrane-
bound receptor. A variety of bulk fractionation, electrophoretic, and
chromatographic techniques were employed including precipitation by salts, pH,
and ionic polymers; ion exchange, gel filtration, hydrophobic interaction, and
reverse-phase chromatography; lectin affinity, oligonucleotide affinity, and im-
munoaffinity chromatography; polyacrylamide gel electrophoresis, two-
dimensional gel electrophoresis, and electroblotting; and high-performance liq-
uid chromatography. Methods of protein characterization were utilized including
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immunological and biochemical assays, peptide mapping, amino acid analysis,
protein sequencing, and mass spectrometry. Emphasis was placed on strategies
of protein purification and characterization rather
than on automated instrumental
analysis. Guest lecturers discussed protein structure, modifications of proteins,
methodologies for protein purification and characterization, chemical synthesis of
peptides, and applications of protein biochemistry to cell and molecular biology.
PARTICIPANTS
Bardwell, J., Ph.D., Harvard Medical School, Boston, Massa-
chusetts
Bentley, D., Ph.D., ICRF, London, United Kingdom
Borchert, T., Ph.D., EMBL, Heidelberg, Germany
Bracete, A., Ph.D., Medical College of Virginia, Richmond
Brun, Y., Ph.D., Stanford University Medical School, Califor-
nia
Dorsky, D., Ph.D., University of Connecticut, Farmington
Farber, J., M.D., Johns Hopkins University, Baltimore,
Maryland
Klasse, P.J., M.D., Chester Beatty Laboratories, London,
United Kingdom
SEMINARS
Aebersold, R., University of British Columbia. Protein micro-
sequencing.
Burgess, R., University of Wisconsin, Madison. Protein
purification: Basic methods.
Casey, P., Duke University. Alkylation of proteins.
Erickson, B., University of North Carolina. Peptide synthesis.
Garrels, J., Cold Spring Harbor Laboratory. Two-dimensional
gel electrophoresis.
Gierasch, L., University of Texas Southwestern Medical Cen-
ter. Physical methods in protein analysis.
Hart, G., Johns Hopkins University. Glycosylation of
Liebhaber, S., M.D., University of Pennsylvania, Philadelphia
McMahon, M., Ph.D., DNAX Research Institute, Palo Alto,
California
Menard, R., Ph.D., Biotechnology Research Institute,
Montreal, Canada
Roulston, A., B.S., Lady Davis Institute, Montreal, Canada
Royer-Pokora, B., Ph.D., University of Heidelberg, Germany
Saccomano, N., Ph.D., Pfizer Research Inc., Groton, Con-
necticut
Tsai, J.-Y., Ph.D., Princeton University, New Jersey
Vernick, K., Ph.D., Carnegie Institution of Washington, Balti-
more, Maryland
proteins.
Kornberg, A., Stanford University. Why purify enzymes?
Kuret, J., and Tonks, N., Cold Spring Harbor Laboratory.
Phosphorylation of proteins.
Pace, C.N., Texas A&M University. Protein denaturation.
Paterson, Y., University of Pennsylvania. Designing synthetic
antigens.
Rose, G., University of North Carolina. Fundamentals of
protein structure.
Rothman, J., Memorial Sloan Kettering Cancer Center.
Protein trafficking.
Neurobiology of Human Neurological Disease
June 5-June 12
INSTRUCTORS
Choi, Dennis, Ph.D., Washington University School of Medicine
Mobley, William, Ph.D., University of California, San Francisco
This lecture course focused on selected arenas where recent advances in
neuroscience have improved understanding of the pathogenesis of a human
neurological disease. Substantial time was allotted to discussions led by the in-
vited lecturers, so that in-depth delineation of specific approaches, methods, and
results would be possible. An underlying general theme of the course was the ex-
ploration of the highly dynamic interface between basic neuroscience and clini-
cal medicine. What can we learn about certain disease mechanisms by studying
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molecules, cells, and animals, and what must we learn by studying patients?
What experimental and clinical problems hinder the development of novel
therapeutic approaches? Applicants with either neuroscience or clinical back-
grounds were encouraged to apply.
PARTICIPANTS
Abosch, A., Ph.D., University of Pittsburgh, Pennsylvania
Behrens, M., M.D., Centro de Estudios Cientificos, Santiago,
Chile
Carpi, D., B.S., Rutgers University, Piscataway, New Jersey
Delgado-Lezama, R., M.S., Cinvestav, Mexico City, Mexico
De Pasquale, J., B.S., Rogoson Institute, New York, New
York
Eide, F., M.D., University of California, San Francisco
Fields, K., Ph.D., National Institutes of Health, Rockville,
Maryland
Flores, G., Ph.D., Cinvestav, Mexico City, Mexico
Garcia-Hernandez, F., Ph.D., Universidad Nacional
Autonoma, Mexico City, Mexico
Gordon, J., B.A., University of California, San Francisco
Handran, S., B.S., Washington University, St. Louis, Missouri
Hyde, E., Ph.D., University of Pittsburgh, Pennsylvania
Jakeman, L., Ph.D., Syntex Research, Palo Alto, California
Lendon, C., Ph.D., St. Mary's Hospital, London, United King-
dom
Malaspina, D., M.D., New York State Psychiatric Institution,
New York
Massieu, L., M.S., Universidad Nacional Autonoma, Mexico
City, Mexico
Nunez, R., M.D., University of Pittsburgh, Pennsylvania
Oviedo, A., B.A., National Institutes of Health, Bethesda,
Maryland
Sawa, A., M.D., University of Tokyo, Japan
Shafqat, S., B.S., Duke University, Durham, North Carolina
Swirnoff, A., B.S., Washington University, St. Louis, Missouri
Waksman, G., Ph.D., CNRS, Gif-sur-Yvette, France
Waldmann, C., B.S., Aidekman Research Center, Newark,
New Jersey
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SEMINARS
Barchi, R., University of Pennsylvania. Disorders of excitable
membranes.
Chalfie, M., Columbia University. C. elegans neuro-
degenesis.
Choi, D., Washington University School of Medicine. Ex-
citotoxicity and neurodegeneration.
Ciaranello, R., Stanford University. Brain development and
psychiatric disorders.
Ferrendelli, J., Washington University School of Medicine.
Principles of neuropharmacology and development of
novel anticonvulsants.
Fields, H., University of California, San Francisco. New in-
sights into mechanisms and treatment of pain.
Fischbeck, K., University of Pennsylvania. Molecular
genetics of neuromuscular diseases.
Advanced Bacterial Genetics
Johnson, R., Johns Hopkins Hospital. Neurovirology and HIV
encephal.
Landis, D., Case Western Reserve University. Role of glia in
brain injury.
Mazziotta, J., University of California, Los Angeles. PET
neuroimaging, functional anatomy, and neurological dis-
ease.
Mobley, W., University of California, San Francisco
Neurotrophic factors.
Monyer, H., University of Heidelberg. Glutamate receptors in
health and disease.
Prusiner, S., University of California, San Francisco. Prion
diseases of the nervous system.
Selkoe, D., Brigham & Women's Hospital. Alzheimer's dis-
ease.
June 5-June 25
INSTRUCTORS
Maloy, Stanley, Ph.D., University of Illinois, Urbana-Champaign
Stewart, Valley, Ph.D., Cornell University, Ithaca, New York
Taylor, Ronald, Ph.D., University of Tennessee, Memphis
ASSISTANTS
Allen, Scott, University of Illinois, Urbana-Champaign
Goldman, Barry, Cornell University, Ithaca, New York
Kaufman, Melissa, University of Tennessee, Memphis
This laboratory course demonstrated genetic approaches that can be used to an-
alyze biological processes and their regulation, as well as detailed struc-
ture/function relationships of genes. Techniques covered included isolation, char-
acterization, and mapping of mutations; use of transposable genetic elements as
mutagens, linked selectable markers, and portable regions of homology; con-
struction and analysis of operon and gene fusions; use of bacteriophage in ge-
netic analysis; molecular cloning and restriction endonuclease mapping; allele
exchange; Southern blot analysis; polymerase chain reaction; and site-specific
mutagenesis. The course consisted of a series of experiments that employed
these techniques in the genetic analysis of diverse bacterial and bacteriophage
species. Lectures and discussions concentrated on the application ofgenetic
analysis to contemporary questions in bacterial physiology, diversity, and
pathogenesis.
PARTICIPANTS
Cottagnoud, P., Ph.D., Rockefeller University, New York,
New York
Crockford, A., B.S., Imperial College of Science, London,
United Kingdom
Flores, A., B.S., University of Seville, Spain
Frazee, R., B.S., University of Minnesota, Minneapolis
Grandjean, V., M.S., Institut de Genetique et Microbiologie,
Orsay, France
Honeyman, A., Ph.D., Washington University, St. Louis, Mis-
souri
Hsing, W., B.S., University of Massachusetts, Amherst
Kezdy, K., B.A., University of Alabama, Birmingham
SEMINARS
Gross, C., University of Wisconsin. DnaK and 0-70: Global
regulatory strategies in E. coll.
Hughes, K., University of Washington. 1. Using challenge
phage to dissect the protein-DNA interactions that
catalyze flagellar phase variation in S. typhimurium. 2.
Genetic analysis of the regulatory cascade that controls
flagellum biosynthesis in S. typhimurium.
Maloy, S., University of Illinois. The order of magnitude rule
vs. physiological significance: Genetic analysis of nac in
K. aerogenes.
Maurer, R., Case Western Reserve University. 1. Problems
in bacterial DNA replication approached through genetics
Laalami, S., Ph.D., Institut de Biologie Physico-Chimique,
Paris, France
Liao, J., Ph.D., Texas A&M University, College Station
Sanna, M., Ph.D., Sezione Scienze Microbiologiche, Rome,
Italy
Sogaard-Andersen, L., Ph.D., University of Odense, Den-
mark
Tarkowski, T., B.A., University of Oregon, Eugene
Velterop, J., B.S., University of Amsterdam, The Netherlands
Villasenor, A., M.D. Hospital Infantil de Mexico, Mexico City
Waldor, M., Ph.D., Massachusetts General Hospital, Boston
(and biochemistry). 2. What are we doing in here? A foray
into Salmonella pathogenesis.
Ohman, D., University of Tennessee. 1. Genetic analysis in
P. aeruginosa: Activation of genes for capsular polysac-
charide production. 2. Genetics of funny bugs.
Salyers, A., University of Illinois. 1. Conjugal chromosomal
elements in Bacteriodes: Sex without air. 2. Genetics of
truly hilarious bugs.
Stewart, V., Cornell University. Genetic analysis of trans-
membrane signal transduction in E. coll.
Taylor, R., University of Tennessee. Genetics of V. cholerae
virulence.
Molecular Approaches to Ion Channel Expression
and Function
June 5-June 25
INSTRUCTORS
Enyeart, Jack, Ph.D., Ohio State University, Columbus
Goldin, Al, M.D., Ph.D., University of California, Irvine
Papazian, Diane, Ph.D., University of California, Los Angeles
Ruben, Peter, Ph.D., University of Hawaii, Honolulu
297
ASSISTANT
Fleig, Andrea, University of Hawaii, Honolulu
Application of the techniques of molecular biology to neurobiology has provided
novel approaches and a new level of sophistication to the examination of many
neurobiological problems. This intensive laboratory/lecture course was designed
to introduce students to the application of model systems in which to express
cloned neurotransmitter receptors and voltage-gated ion channels. The course
covered the following topics: preparation of RNA transcripts in vitro and micro-
injection in Xenopus oocytes; in vitro mutagenesis of cloned ion channel genes;
characterization of wild-type and mutated channels and receptors expressed in
oocytes, using both two-microelectrode voltage-clamping and patch-clamping
single-channel analysis; transient expression of voltage-gated ion channels in in-
sect cells using baculovirus vectors; characterization of exogenous ion channels
in insect cells using whole-cell patch clamping; and theory and analysis of ion
currents.
PARTICIPANTS
Aggarwal, S., B.S., Harvard Medical School, Boston, Massa-
chusetts
Bouvier, M., M.S., University College London, United King-
dom
Dourado, M., M.S., Florida State University, Tallahassee
Ffrench-Constant, R., Ph.D., University of Wisconsin,
Madison
Hastings, G., Ph.D., National Institute on Alcohol Abuse,
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Rockville, Maryland
Price, C., B.S., University of Alberta, Canada
Ptacek, L., M.D., University of Utah, Salt Lake City
Saugstad, J., Ph.D., Oregon Health Science University, Port-
land
Willoughby, J., M.S., Sandoz Institute of Medical Research,
London, United Kingdom
Xie, J., M.S., Rush Medical College, Chicago, Illinois
Advanced Drosophila Genetics
June 15-June 29
INSTRUCTORS
Ashburner, Michael, Ph.D., University of Cambridge, United Kingdom
Rubin, Gerald, Ph.D., University of California, Berkeley
This intensive seminar course provided an introduction to the theory and practice
of methods used to manipulate the Drosophila genome. It was suitable for gradu-
ate students and researchers with some experience with Drosophila who are in-
terested in expanding their knowledge of the wide range of genetic techniques
now available for use with this organism. Topics covered included chromosome
mechanics, the design and execution of genetic screens, and the use of
transposable elements as genetic tools.
PARTICIPANTS
Anand, A., M.S., Indian Institute of Science, Bangalore
As ling, B., B.S., University of Stockholm, Sweden
Bermann, A., B.S., Max Planck Institute, Tubingen, Germany
Borisy, F., B.S., Johns Hopkins University, Baltimore,
Maryland
Chang, H., B.S., University of California, Berkeley
Crittenden, J., B.S., Cold Spring Harbor Laboratory, New
York
Dixon, L., Ph.D., Penn State University, University Park
Epstein, H., Ph.D., University of California, Davis
Kramer, H., Ph.D., University of California, Los Angeles
Lane, M., M.S., Columbia University, New York, New York
Martin, K., Ph.D., University of California, Los Angeles
Parker, L., Ph.D., Worcester Foundation, Shrewsbury, Mas-
sachusetts
Payre, F., Ph.D., CNRS, Toulouse, France
Prado, A., B.S., Instituto Cajal, Madrid, Spain
Risinger, C., B.S., Uppsala University, Sweden
Rutherford, S., B.A., University of California, San Diego
Schulz, C., B.S., Zoologisches Institut, Munich, Germany
Schweizer, R., M.S., Weizmann Institute, Rehovot, Israel
Serrano-Martinez, N., M.S., Institute Jacques Monod, Paris,
France
Strathmann, M., Ph.D., Lawrence Berkeley Laboratory, Cali-
fornia
Wassarman, D., Ph.D., Yale University, New Haven, Con-
necticut
Welbergen, P., Ph.D., York University, Ontario, Canada
Zamore, P., Ph.D., Harvard University, Cambridge, Massa-
chusetts
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ASSISTANTS
Conlon, Frank, Columbia University, New York, New York
Nichols, Jenny, University of Edinburgh, Scotland
This course was designed for molecular biologists, biochemists, and cell
biologists interested in applying, their expertise to the study of mouse embryonic
development. Lecture and laboratory components of the course emphasized
both the practical aspects of working with mouse embryos and the conceptual
basis of current embryonic research. The following procedures and their potential
applications were described: isolation and culture of germ cells and preimplanta-
tion and postimplantation embryos, embryo transfer, establishment, and genetic
manipulation of embryo-derived stem cell lines, germ layer separation, chimera
formation, nuclear transplantation, microinjection of DNA into eggs, retroviral in-
fection of embryos, microinjection of cell lineage tracers, in situ hybridization, and
immunohistochemistry. Guest lecturers discussed current research in the field.
PARTICIPANTS
Alessandrini, A., Ph.D., Harvard University, Cambridge,
Massachusetts
Bermingham, J., Ph.D., University of California, San Diego
Bettler, B., Ph.D., The Salk Institute, San Diego, California
Bierkamp, C., M.S., University of Koln, Germany
Dymecki, S., Ph.D., Johns Hopkins University, Baltimore,
Maryland
Federoff, H., Ph.D., Albert Einstein College of Medicine,
New York, New York
Liao, X., Ph.D., Brandeis University, Waltham, Massachu-
setts
SEMINARS
Baltimore, D., Rockefeller University. Transcription: NE-K
genes and development.
Beddington, R., Centre for Genome Research. Post-
implantation development.
Bradley, A., Baylor College of Medicine. Homologous
recombination.
Bronner-Fraser, M., University of California, Irvine. Cell
lineages in the neural crest.
Fraser, S., California Institute of Technology. Imaging cell
lineages.
Hastie, N., MRC Human Genetics Unit. Human developmen-
tal mutations and mouse model systems.
Hogan, B., Vanderbilt University. Extraembryonic mem-
branes.
Jackson, I., MRC Human Genetics Unit. Molecular genetics
of mouse coat color: Black, white, brown, and blue mice.
Jessell, T., Columbia University. Establishing symmetry and
pattern in the vertebrate nervous system.
Lovell-Badge, R., MRC National Institute for Medical Re-
search. Sex determination II.
Mann, J., Beckman Research Institute of the City of Hope.
Genetic imprinting in androgenetic and parthenogenetic
ES cells.
McLaren, A., University College London. Germ cells and sex
determination I.
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Lu, Y., Ph.D., Princeton University, New Jersey
Ma, A., M.D., Children's Hospital, Boston, Massachusetts
Reichardt, L., Ph.D., University of California, San Francisco
Shea, M., Ph.D., Roche Institute of Molecular Biology, Nut-
ley, New Jersey
Spicer, D., Ph.D., Harvard Medical School, Boston, Massa-
chusetts
Uchida, N., Ph.D., Stanford University, California
Wassarman, K., Ph.D., Yale University, New Haven, Con-
necticut
McMahon, A., Roche Institute of Molecular Biology. Wnt
genes.
Papaioannou, G., Tufts University. Chimeras/c-Fos.
Parada, L., NCI-FCRDC. Receptor tyrosine kinases: Impor-
tant regulators of vertebrate development.
Rastan, S., MRC Clinical Research Centre. X-inactivation.
Rinchik, G., Oak Ridge National Laboratory. Genetic
resources.
Robertson, L., Columbia University. ES cells: Biology and
uses.
Rossant, J., Mount Sinai Hospital, Toronto. Preimplantation
development.
Solter, D., Max Planck Institute, Freiburg. Genomic imprint-
ing and totipotency.
Soriano, P., Baylor College of Medicine. Cellular oncogenes
in development, etc.
Stewart, C., Roche Institute of Molecular Biology. The mean-
ing of LIF.
Strickland, S., SUNY at Stony Brook. Oocyte maturation.
Waelsch, S., Albert Einstein College of Medicine. History of
mouse genetics.
Wassarman, P., Roche Institute of Molecular Biology. Mam-
malian fertilization.
Wilkinson, D., National Institute for Medical Research. Seg-
mentation in the vertebrate embryo.
SEMINARS
Bezanilla, P., University of California, Los Angeles. Voltage-
dependent gating in ionic channels.
Enyeart, J., Ohio State University. 1. Peptide modulation of a
novel K+ channel in steroid-hormone-secreting cells. 2.
Methods of voltage-clamp data analysis.
Goldin, A., University of California, Irvine. 1. Molecular
aspects of sodium channel inactivation. 2. Electronics of
the voltage and patch clamp. 3. Alternative expression
systems.
Johnson, J., University of Pittsburgh. Modulation of the
NMDA receptor by glycine and by intracellualr mag-
nesium.
MacKinnon, R., Harvard Medical School. Structure/function
studies in voltage-activated potassium channels.
Margiotta, J., Mt. Sinai Medical Center. Regulation of
neuronal acetylcholine receptor function and distribution.
Papazian, D., University of California, Los Angeles. 1.
Molecular biology techniques. 2. Structure and function of
shaker potassium channels. 3. Baculovirus as an expres-
sion system.
Ruben, P., University of Hawaii. 1. Electrophysiology tech-
niques. 2. Structure and function of sodium channels.
Sigworth, F., Yale University. How we spent two years study-
ing one mutation of the potassium channel.
Trimmer, J., SUNY at Stony Brook. Molecular and cellular
mechanisms regulating potassium channels.
White, M., University of Pennsylvania. Insights on the acetyl-
choline receptor.
Molecular Embryology of the Mouse
June 5-June 25
INSTRUCTORS
Lovell-Badge, Robin, Ph.D., National Institute for Medical Research, London, England
Parada, Luis F., Ph.D., Basic Research Program, NCI-FCRDC, Frederick, Maryland
CO-INSTRUCTORS
Mann, Jeff, Beckman Research Institute, Duarte, California
Rastan, Sohaila, Clinical Research Centre, Middlesex, England
Soriano, Phil, Baylor College of Medicine, Houston, Texas
SEMINARS
Ashburner, M., Cambridge University. Basic genetics; spe-
cialized chromosomes; genetic mapping methods.
Cline, T., University of California, Berkeley. Genetic screens
as exemplified by screens for loci affecting sex determ-
ination: Genes and pathways.
Engels, W., University of Wisconsin. Genetics of PM hybrid
dysgenesis and its control: Genetic behavior of P ele-
ments.
Gelbart, W., Harvard University. 1. Hobo mobile element. 2.
Drosophila databases.
Glover, D., Dundee University. Genetic control of cell cycle;
mitosis.
Molecular Cloning of Neural Genes
Hall, J., Brandeis University. Genetics of Drosophila behav-
ior.
Hawley, S., University of California, Davis. Distributive
segregation.
Lehmann, R., Whitehead Institute. Mutagenesis and genetic
screens for maternal effect mutations.
Rubin, G., University of California, Berkeley. Somatic
mosaics: Generation by X-irradiation and FLP/FRT; cell
markers; data interpretation.
Spradling, A., Carnegie Institution. Use of P elements;
heterochromatin.
June 29-July 19
INSTRUCTORS
Boulter, James, Ph.D., Salk Institute, San Diego, California
Chao, Moses, Ph.D., Cornell University, New York, New York
Eberwine, James, Ph.D., University of Pennsylvania, Philadelphia
Nef, Patrick, Ph.D., Salk Institute, San Diego, California
CO-INSTRUCTOR
Inman, Irene, Stanford University, California
ASSISTANTS
Kong, Hae-Young, University of Pennsylvania, Philadelphia
Lai, Cary, Salk Institute, San Diego, California
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This intensive laboratory/lecture course was intended to provide scientists with abasic knowledge of the use of the techniques of molecular biology in examiningquestions of neurobiological significance. Particular emphasis was placed on
using and discussing methods for circumventing the special problems posed in
the study of the nervous system, for example, examination of low abundance
mRNAs in extremely heterogeneous cell populations. The laboratory work in-
cluded mRNA quantitation methods (nuclease protection, etc.), preparation of
hybridization probes, library construction (X. ZAP and 1ST procedure), plaque
screening techniques (probe hybridization, antibody interaction), DNA sequenc-
ing, PCR amplification, RNA amplification, and DNA-mediated gene transfer. A
portion of the laboratory work was devoted to characterization and analysis of
nucleic acids from single live neurons and glia. A major portion of the course was
devoted to in situ hybridization and in situ transcription technologies. The lecture
series, presented by invited speakers, focused on emerging techniques and how
they may be applied to the study of the nervous system.
PARTICIPANTS
Ariano, M., Ph.D., Chicago Medical School, Illinois
Baptista, C., Ph.D., Columbia University, New York, New
York
Cameron-Curry, P., Ph.D., Institut d'Embryologie Cellulaire,
Nogent-sur-Marne, France
Dodson, B., M.D., University of California, San Francisco
Duerr, J., Ph.D., Oklahoma Medical Research Foundation,
Oklahoma City
Fishell, G., Ph.D., Columbia University, New York, New York
Graybiel, A., Ph.D., Massachusetts Institute of Technology,
Cambridge
Ingraham, C., Ph.D., Albany Medical College, New York
SEMINARS
Ballivet, M., University of Geneva. Nicotinic acetylcholine
receptor gene expression.
Blakely, R., Emory University. Expression cloning of
neurotransmitter transporters.
Cepko, C., Harvard Medical School. Cell-type development
in the CNS.
Hatten, M., Columbia University. Control of granule cell
neurogenesis and migration in developing cerebellar
Lerea, L., Ph.D., Duke University, Durham, North Carolina
Malenka, R., Ph.D., University of California, San Francisco
Martone, M., Ph.D., University of California, San Diego
Parfitt, K., Ph.D., Stanford University Medical School, Califor-
nia
Rakhilin, S., Ph.D., University of Chicago, Illinois
Sheen, V., M.S., Children's Hospital, Boston, Massachusetts
Sipe, K., B.A., University of Illinois, Urbana
Wang, Y., Ph.D., Salk Institute, San Diego, California
Wexler, N., Ph.D., Columbia University, New York, New York
Wolszon, L., Ph.D., Columbia University, New York,
New York
cortex.
Heinemann, S., Salk Institute. Glutamate receptors.
Lemke, G., Salk Institute. Molecular genetics of myelination.
Margolis, F., Roche Institute of Molecular Biology. Regula-
tion of olfactory neural gene expression.
Morgan, J., Roche Institute of Molecular Biology. c-fos gene
expression in the CNS.
Molecular and Developmental Biology of Plants
June 29-July 19
INSTRUCTORS
Cashmore, Anthony, Ph.D., University of Pennsylvania, Philadelphia
Klessig, Daniel, Ph.D., Rutgers University, Piscataway, New Jersey
Maliga, Pal, Ph.D., Rutgers University, Piscataway, New Jersey
ASSISTANTS
Tonkyn, John, Rutgers University, Piscataway, New Jersey
Bell, Callum, University of Pennsylvania, Philadelphia
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Dixon, David, USDA, Southern Regional
Research Center, New Orleans, Louisiana
Hennig, Jacek, Rutgers University, Piscataway,
New Jersey
Klimczak, Les, University of Pennsylvania, Philadelphia
Matallana, Emilia, University of Pennsylvania,
Philadelphia
Schindler, Uli, University of Pennsylvania, Philadelphia
Staub, Jeffrey, Rutgers University, Piscataway, New
Jersey
Svab, Zora, Rutgers University, Piscataway,
New Jersey
This course provided an intensive overview of current
topics and techniques in
plant biology, with an emphasis on molecular and
developmental biology and
genetics. It was designed for scientists with experience in molecular techniques
who are working, or wish to work, with plant systems.
The course consisted of a
rigorous lecture series, a hands-on laboratory, and informal discussions. Guest
speakers provided both an in-depth discussion of their work and an overview of
their specialty. The laboratory sessions covered plant development; study of
plasmodesmatal transport by microinjection; transient gene expression assays in
protoplasts; transformation by Agrobacterium and the particle gun; in vitro
reconstitution of protein transport into chloroplasts; in situ detection of RNA and
protein; isolation of transcription factors and their characterization by DNA foot-
printing and methylation interference; modification of protein/DNA interaction by
protein phosphorylation; pulsed-field gel electrophoresis and yeast artificial
chromosomes in the analysis of the Arabidopsis genome.
PARTICIPANTS
Ainscough, J., B.S., Cambridge University, United Kingdom
Ait-Ali, T., M.S., Universite D'Orleans, France
Bellinncampi, D., Ph.D., Universita di Roma 'La Sapienza,'
Italy
Chachulska, A., M.S., Institute of Biochemistry, Warsaw,
Poland
Cruz-Mireles, R., M.S., Universidad Nacional, Cuernavaca,
Mexico
Grossniklaus, U., M.S., University of Basel, Switzerland
Hodgins, R., Ph.D., University of Alberta, Canada
Ise li, B., M.S., Michigan State University, East Lansing
Lund, G., B.S., Istituto Biosintesi Vegeta li, Milan, Italy
Machuka, J., M.S., University of Sussex, United Kingdom
Mollers, C., Ph.D., University of Gottingen, Germany
Quaedvlieg, N., B.S., University of Utrecht, The Netherlands
Sharma, S., Ph.D., DSIR-Grasslands, Palmerston, New
Zealand
Wang, M., Ph.D., Leiden University, The Netherlands
Yi, Y., B.S., Dartmouth College, Hanover, New Hampshire
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SEMINARS
Beachy, R., Scripps Research Institute. Plant RNA viruses:
Molecular biology and applications.
Bisseling, T., Agricultural University, Wageningen, Nether-
lands. Rhizobium-plant symbiotic interactions.
Boynton, J., Duke University. The genetics and molecular
biology of chloroplasts in Chlamydgmonas.
Cashmore, A., University of Pennsylvania. Photoregulated
gene expression.
Dooner, H., DNA Plant Technology Corporation.
Transposable elements in plants.
Ecker, J., University of Pennsylvania. Yeast artificial
chromosomes: A tool for the analysis of hormone path-
ways in A. thaliana.
Jones, A., University of North Carolina. Signal transduction
in plants.
Jorgensen, R., University of California, Davis. Altered gene
expression in plants due to trans-interactions between
homologous genes.
Klessig, D., Rutgers University. Pathogen-plant interactions:
Pathogenesis-related proteins.
Lamppa, G., University of Chicago. Protein targeting in
plants.
Levings, S., North Carolina State University. The molecular
Neurobiology of Drosophila
biology of plant mitochondria: Cytoplasmic male sterility.
Lucas, W., University of California, Davis. Cellular communi-
cation by plasmodesmatal transport.
Maliga, P., Rutgers University. Transgenic plants.
McCarty, D., University of Florida. Seed development: Role
of Vpl in regulation of seed maturation.
McDaniel, C., Rensselaer Polytechnic Institute. Develop-
mental patterns in plants.
Nasrallah, J., Cornell University. Self-incompatibility in
plants.
Nester, E., University of Washington. Agrobacterium biology
and applications.
Quail, P., Plant Gene Expression Center. Phytochrome.
Schroeder, J., University of California, San Diego. Patch-
clamp techniques and the study of ion-channel regulation
in higher plants.
Somerville, C., Michigan State University. Biochemical
genetics in Arabidopsis.
Theologis, A., Plant Gene Expression Center. Antisense
RNA technology: Manipulation of plant hormone levels.
Varner, J., Washington University. The plant cell wall.
Yanofsky, M., University of California, San Diego. Molecular
genetics of flower development.
June 29-July 19
INSTRUCTORS
Hartenstein, Volker, Ph.D., University of California, Los Angeles
Ready, Don, Ph.D., Purdue University, West Lafayette, Indiana
ASSISTANTS
Green, Patricia, University of California, Los Angeles
Wolff, Tanya, Purdue University, West Lafayette, Indiana
This laboratory/lecture course was a series of in-depth discussions with research-
ers active in genetic, physiological, cellular, molecular, and behavioral studies of
Drosophila neurobiology. It was organized around a core of seminars, extensive
informal discussion, and lab work. Lecturers often brought original preparations
for viewing and discussion, and directed lab exercises and experiments-in their
areas of special interest. The course was intended for researchers at all levels
who want to use Drosophila as an experimental system for studying neurobiol-
ogy.The course covered basic electrophysiological techniques, as applied to
mutants with altered ion channels or sensory physiology. In addition, the course
familiarized students with various preparations, including the embryonic nervous
system, imaginal discs, and adult nervous system.
Topics included Shaker and the biophysics and diversity of potassium chan-
nels, the genetics and molecular biology of excitability, the control of
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neurogenesis and neuronal diversity, embryonic and postembryonic develop-
ment of the CNS and PNS, axonal pathfinding, development of the nervous sys-
tem, mesoderm and muscle development, eye and optic lobe development, ol-
faction, learning, and the neural control of flight.
PARTICIPANTS
Engel, J., B.S., University of Iowa, Iowa City
Ferveur, J.-F., Ph.D., Roche Institute of Molecular Biology,
Nutley, New Jersey
Garrity, P., B.A., California Institute of Technology,
Pasadena
Hall, S., B.S., Purdue University, West Lafayette, Indiana
Harshman, K., Ph.D., Sloan Kettering Institute, New York,
New York
SEMINARS
Bieber, A., Purdue University. Axonal pathfinding in the em-
bryonic CNS.
Campos-Ortega, J., Institut Entwicklungsphysiologie.
Neurogenic mutants.
Davis, R., Cold Spring Harbor Laboratory. Molecular basis
of behavior.
Dickinson, M., University of Chicago. Introduction to physiol-
ogy, sensory mechanisms, and aerodynamics of flight.
Doe, C., University of Illinois. CNS II: Neuronal fate.
Ganetzky, B., University of Wisconsin. Genetic dissection of
membrane excitability.
Hartenstein, V., University of California, Los Angeles. 1. Intro-
duction to Drosophila embryogenesis. 2. Early
neurogenesis.
Keshishian, H., Yale University. Neuromuscular develop-
ment.
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Landgraf, M., B.S., University College London, United King-
dom
Seow, K., B.S., National University, Singapore
Silber, J., B.A., Washington University, St. Louis, Missouri
Skeath, J., B.A., University of Wisconsin, Madison
Stewart, B., M.S., University of Toronto, Canada
Urban, J., Ph.D., University of Mainz, Germany
Vinos, J., Ph.D., Universidad Autonoma, Madrid, Spain
Kidokoro, Y., University of California, Lcs Angeles. Synaptic
physiology and receptors.
Lehmann, R., Whitehead Institute. Early pattern formation in
Drosophila.
Ready, D., Purdue University. The morphogenetic furrow.
Strausfeld, N., University of Arizona. Adult CNS structure.
Taghert, P., Washington University. Neuromodulators and
development of the stomatogastric NS.
Tomlinson, A., Columbia University. Eye development in the
third instar.
Tully, T., Cold Spring Harbor Laboratory. Learning/behavior.
Wolff, T., Purdue University. Pupal eye development.
Zagotta, W., Stanford University. Ion channels in Drosophila.
Zuker, C., University of California, San Diego. Signal trans-
duction.
Computational Neuroscience: Vision
July 10-July 24
INSTRUCTORS
Adelson, Edward, Ph.D., Massachusetts Institute of Technology, Cambridge
Heeger, David, Ph.D., NASA - Ames Research Center, Moffett Field, California
Hildreth, Ellen, Ph.D., Wellesley College, Massachusetts
Movshon, J. Anthony, Ph.D., New York University, New York
ASSISTANTS
Chichilinsky, E.J., Stanford University, California
Simoncelli, Eero, Massachusetts Institute of Technology, Cambridge
Computational approaches to neuroscience have produced important advances
in our understanding of neural processing. Prominent successes have come in
areas where strong inputs from neurobiological, behavioral and computational
approaches can interact. Through a combination of lectures and hands-on expe-
rience with a computer laboratory, this intensive course examined several areas,
including feature extraction, motion analysis, binocular stereopsis, color vision,
higher-level visual processing, visual neural networks, and oculomotor function.
The theme was that an understanding of the computational problems, the con-
straints on solutions to these problems, and the range of possible solutions can
help guide research in neuroscience. Students had experience in neurobiological
or computational approaches to visual processing. A strong background in math-
ematics was beneficial.
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PARTICIPANTS
Beall, A., B.A., University of California, Santa Barbara
Boynton, G., M.A., University of California, Santa Barbara
Brady, N., B.A., Cornell University, Ithaca, New York
Braje, W., B.A., University of Minnesota, Minneapolis
Bricolo, E., B.S., Massachusetts Institute of Technology,
Cambridge
Carandini, M., M.S., New York University, New York
Darrell, T., M.S., Massachusetts Institute of Technology,
Cambridge
Econopouly, J., B.S., New York University, New York
Elder, J., B.S., McGill University, Montreal, Canada
Engel, S., B.A., Stanford University, California
Li, A., B.S., University of Rochester, New York
Losada, A., Ph.D., McGill University, Montreal, Canada
SEMINARS
Burt, P., David Sarnoff Research Laboratories. Models of
visual attention and pattern recognition.
De Simone, R., National Institutes of Health. Functional role
of cortical neurons in attention and memory task.
Lisberger, S., University of California, San Francisco. Neural
control and adaptive plasticity of smooth eye movements.
Malik, J., University of California, Berkeley. Computational
models of visual texture processing.
McKee, S., Smith-Kettlewell Institute of Visual Science.
Psychophysics and neurophysiology of stereoscopic vi-
sion.
Marnassian, P., M.S., University of Minnesota, Minneapolis
Pauly, R., B.S., Florida State University, Tallahassee
Pece, A., Ph.D., University of Cambridge, United Kingdom
Pope, A., M.S., University of British Columbia, Vancouver,
Canada
Prut, Y., B.S., Hebrew University, Jerusalem, Israel
Salzman, D., B.A., Stanford University, California
Sheinberg, D., B.A., Brown University, Providence, Rhode Is-
land
Sinha, P., M.S., Massachusetts Institute of Technology, Cam-
bridge
Smallman, H., M.S., University of California, San Diego
Tjan, B., B.S., University of Minnesota, Minneapolis
Young, M., M.S., New York University, New York
Nakayama, K., Harvard University. Psychological studies of
visual attention and memory.
Newsome, W., Stanford University School of Medicine.
Neuronal mechanisms of visual motion perception.
Sejnowski, T., Salk Institute. Models of visual tracking.
Sparks, D., University of Pennsylvania. Superior colliculus
and saccadic eye movements.
Von der Heydt, R., University Hospital Zurich. Neural pro-
cessing of visual pattern and texture.
Wandell, B., Stanford University. Color vision:
Psychophysics, physiology, and models.
Advanced Molecular Cloning and Expression of Eukaryotic Genes
July 21-August 10
INSTRUCTORS
Freedman, Len, Ph.D., Sloan Kettering Institute, New York, New York
Learned, Marc, Ph.D., University of California, Davis
Robbins, Alan, Ph.D., Tularik, Inc., South San Francisco, California
ASSISTANTS
Alroy, Iris, Sloan Kettering Institute, New York, New York
Feeser, Wendi, Dupont Merck Pharmaceutical, Wilmington, Delaware
This course focused on how to manipulate cloned eukaryotic genes to probe
questions on their structure, expression, and function. As a model system, they
examined cis- and trans-acting components involved in the regulation of
eukaryotic gene expression. Students learned the theoretical and practical
aspects of constructing genomic and cDNA libraries. Expression libraries from
various organisms were screened with recognition site probes for specific DNA-
binding proteins. A variety of transfection techniques were used to introduce
cloned DNA molecules that had been manipulated in vitro into eukaryotic cells in
culture. The expression pattern of these transfected DNAs were analyzed by
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nuclease protection and enzymatic assays. Mutants were generated by oligo-
directed and random mutagenesis procedures and characterized by DNA se-
quencing. Techniques and theory for detecting and characterizing the interaction
between regulatory DNA sequences and trans-acting protein factors were pre-
sented. Guest lecturers discussed present problems in eukaryotic molecular biol-
ogy as well as technical approaches to their solutions. Experience with basic
recombinant DNA techniques was a prerequisite for admission to the course.
PARTICIPANTS
Bargonetti, J., Ph.D., Columbia University, New York, New
York
Birken, S., Ph.D., Columbia University, New York, New York
Connor, L., B.S., Baylor College of Medicine, Houston,
Texas
Dietmeier, K., B.S., Institut fOr Physiologische Chemie,
Munich, Germany
Garry, D., Ph.D., University of Minnesota, Minneapolis
Grapin, A., M.S., Institut d'Embryologie du CNRS, Nogent-
sur-Marne, France
Gratzer, S., B.S., University of Graz, Austria
Lorens, J., M.S., University of Bergen, Norway
Malofeeva, L., M.S., Moscow Physical Technical Institute,
SEMINARS
Chandler, V., University of Oregon. The B locus of maize: A
tissue-specific transcriptional activator.
De Lange, T., Rockefeller University. Molecular interactions
at mammalian teleomeres.
Fields, S., SUNY at Stony Brook. A genetic system to detect
protein-protein interactions.
Herr, W., Cold Spring Harbor Laboratory. Promoter-selective
activation by transcription factors that bind to the same
sequence.
Kingston, R., Massachusetts General Hospital. Transcription
factor interactions on nucleosomal templates.
Russia
Powell, A., M.S., Ludwig Institute, London, United Kingdom
Rainwater, R., M.S., University of Alaska, Anchorage
Ross, C., Ph.D., Johns Hopkins Medical School, Baltimore,
Maryland
Shiels, C., B.S., St. Mary's Hospital, London, United King-
dom
Smit, A., Ph.D., Vrije Universiteit, Amsterdam, The Nether-
lands
Suprenant, K., Ph.D., University of Kansas, Lawrence
Zimmermann, R., Ph.D., Max Planck Institute, Bad Nauheim,
Germany
Landy, A., Brown University. Protein-DNA and protein-
protein interactions in the higher-order complexes of X
site-specific recombination.
Rio, D., University of California, Berkeley. Mechanism and
regulation of Drosophila P-element transposition.
Stillman, B., Cold Spring Harbor Laboratory. DNA replication
in human and yeast cells.
Yamamoto, K., University of California, San Francisco. Non-
receptor determinants of transcriptional regulation by
glucocorticoids.
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Imaging Structure and Function in the Nervous System
July 21-August 10
INSTRUCTORS
Katz, Larry, Ph.D., Duke University, Durham, North Carolina
Lewis, Richard, Ph.D., Stanford University, California
ASSISTANTS
Dolmetsch, Richard, Stanford University, California
McFarlane, Matthew, Stanford University, California
Yuste, Rafael, Bell Laboratories, Murray Hill, New Jersey
Recent advances in optical and video microscopy, coupled with the develop-
ment of powerful new fluorescent probes, present unique opportunities for
visualizing the structure and function of individual neurons and neuronal assem-
blies. This intensive laboratory/lecture course provided participants with the
theoretical and practical tools to utilize these emerging technologies. Course
topics included principles of fluorescence and video microscopy; image pro-
cessing techniques; theory and practice of confocal microscopy; and the use of
caged compounds to study intracellular and synaptic signaling. Particular em-
phasis was placed on the use of calcium-sensitive probes (e.g., fura-2, fluo-3) to
monitor cell function in slices and in single cells. Using state-of-the-art equip-
ment, students explored a variety of preparations, including mammalian brain
slices, acutely dissociated neurons, and cultured cells. Applicants had a strong
background in the neurosciences or cell biology.
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PARTICIPANTS
Blum, K., Ph.D., Massachusetts Institute of Technology,
Cambridge
Herrmann, K., Ph.D., University of California, Berkeley
Lachica, E., Ph.D., University of Washington, Seattle
Luo, L., Ph.D., Brandeis University, Waltham, Massachusetts
Miller, K., Ph.D., California Institute of Technology,
Pasadena
Molnar, Z., M.D., Oxford University, United Kingdom
Schweizer, M., B.S., Max Planck Institute, Tubingen,
SEMINARS
Augustine, G., Duke University. Calcium dynamics and
neurotransmission.
Bonhoeffer, T., Max Planck Institute. Optical recording and
electrophysiology in cultured brain slices.
Connor, J., Roche Institute of Molecular Biology. High
spatiotemporal resolution imaging of calcium in brain
slices.
Fraser, S., California Institute of Technology. MRI and fron-
tiers in imaging.
Grinvald, A., Weizmann Institute of Science. Optical imaging
of architecture and function in the living brain.
Inoue, T., Universal Imaging Corporation. Design and imple-
mentation of imaging systems.
Lichtman, J., Washington University. Confocal microscopy
of intact systems.
Yeast Genetics
Germany
Tcheng, T., B.S., University of Illinois, Urbana
Trommald, M., M.D., University of Oslo, Norway
Von Krosigk, M., Ph.D., Yale University, New Haven, Con-
necticut
Wexler, E., B.A., Albert Einstein College of Medicine, New
York, New York
Zipser, B., Ph.D., Michigan State University, East Lansing
Nerbonne, J., Washington University. Principles an applica-
tions of caged compounds.
Ryan, T., Stanford University. Laser scanning confocal micro-
scopy: Factors affecting image quality.
Steinbach, P., ETM Systems. Video image processor
hardware.
Tank, D., Bell Laboratories. Modeling calcium dynamics in
presynaptic terminals: Theory and experiment.
Tsien, R., Stanford University. Calcium oscillations in
sympathetic neurons.
Tsien, R. W., University of California, San Diego. Design and
function of fluorescent indicator dyes for calcium, other
ions, and second messengers.
Wick, R., Hamamatsu Photonic Systems. Low- and high-
sensitivity video cameras.
July 21-August 10
INSTRUCTORS
Kaiser, Chris, Ph.D., Massachusetts Institute of Technology, Cambridge
Michaelis, Susan, Ph.D., Johns Hopkins University, Baltimore, Maryland
Mitchell, Aaron, Ph.D., Columbia University, New York, New York
ASSISTANTS
Roberg, Kevin, Massachusetts Institute of Technology, Cambridge
Sears, Dody, Johns Hopkins University, Baltimore, Maryland
Sia, Rey, Columbia University, New York, New York
The major laboratory techniques used in the genetic analysis of yeast were
studied, including the isolation and characterization of mutants, tetrad analysis,
complementation, and mitotic recombination. Micromanipulation used in tetrad
analysis was carried out by all students. Molecular genetic techniques, including
yeast transformation, gene replacement, analysis of gene fusions, and elec-
trophoretic separation of chromosomes, were applied to the analysis of yeast
DNA. Indirect immunofluorescence experiments were done to identify the
nucleus, microtubules, and other cellular components. Lectures on fundamental
aspects of yeast genetics were presented along with seminars
given by outside
speakers on topics of current interest.
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PARTICIPANTS
Antes, T., B.S., University of California, Davis
Bartholomew, B., Ph.D., Southern Illinois University, Car-
bondale
Csank, C., Ph.D., National Research Council, Montreal, Can-
ada
Edwards, J., M.D., University of California, Torrance
Eshel, D., Ph.D., University of Hawaii, Honolulu
Lee, S., Ph.D., University of California, San Fancisco
Ludewig, G., Ph.D., University of Kentucky, Lexington
Ma la, C., M.S., Max Planck Institute, Martinsried, Germany
Radding, J., Ph.D., Eli Lilly & Co., Indianapolis, Indiana
Raleigh, E., Ph.D., New England Bio-Labs, Beverly, Massa-
SEMINARS
Adams, A., University of Arizona. Genetic analysis of the
yeast actin cytoskeleton.
Boeke, J., Johns Hopkins University. Yeast transposons.
Botstein, D., Stanford University. Molecular anatomy of
yeast.
Carlson, M., Columbia University. Transcriptional control of
glucose-repressed genes.
Fink, G., Whitehead Institute. Dimorphism in yeast: A new
developmental pathway.
Futcher, B., Cold Spring Harbor Laboratory. Control points in
the yeast cell cycle.
Hieter, P., Johns Hopkins University. Centromere function
and chromosome stability.
Hoyt, A., Johns Hopkins University. Mitosis in S. cerevisiae.
Kaiser, C., Massachusetts Institute of Technology. Protein
secretion in yeast.
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chusetts
Schwarz, E., Ph.D., Institut fOr Physiologisch Chemie,
Munich, Germany
Sherman, M., Ph.D., Harvard Medical School, Boston, Mas-
sachusetts
Shimizu, M., Ph.D., Tokyo College of Pharmacy, Japan
Siebel, C., B.A., Whitehead Institute, Cambridge, Massachu-
setts
Smith, M., B.A., Columbia University, New York, New York
Zacharewski, T., Ph.D., University of Western Ontario,
London, Canada
Michaelis, S., Johns Hopkins University. The novel a-factor
processing and secretion pathway.
Mitchell, A., Columbia University. Control of meiotic gene
expression.
Petes, T., University of North Carolina. Homologous and
nonhomologous recombination in yeast.
Rose, M., Princeton University. Nuclear fusion in yeast.
Sherman, F., University of Rochester. Transformation with
synthetic oligonucleotides: Mechanisms and applications.
Sprague, G., University of California, Berkeley. Signal trans-
duction in the mating response pathway.
Wig ler, M., Cold Spring Harbor Laboratory. Functions of
RAS and adenyl-cyclase-associated proteins.
Winston, F., Harvard Medical School. Regulators of Ty ele-
ment transcription.
Molecular Neurobiology: Brain Development and Function
July 28-August 10
INSTRUCTORS
McKay, Ronald, Ph.D., Massachusetts Institute of Technology, Cambridge
Patrick, James, Ph.D., Baylor College of Medicine, Houston, Texas
Schwarz, Thomas, Ph.D., Stanford University, California
This lecture course presented both basic concepts and currently exciting re-
search problems in molecular neurobiology. It focused on approaches and meth-
ods now used to study the development and function of the nervous system.
Topics covered included gene expression, receptor structure and function, ion-
channel cloning, second-messenger systems, learning, sensory transduction, be-
havioral genetics, neural induction, cell lineage, immortal cell lines, cell adhesion,
oncogenes, and neurite outgrowth. The course provided the opportunity to dis-
cuss this rapidly expanding research area with invited lecturers. Individuals from
a wide variety of backgrounds (graduate students to faculty) were encouraged to
apply.
PARTICIPANTS
Agoston, D., M.D., National Institutes of Health, Bethesda,
Maryland
Basta, D., Ph.D., Duke University, Durham, North Carolina
Bito, H., M.D., University of Tokyo, Japan
Cheyette, B., B.A., University of California, Los Angeles
Gale, H., M.S., Harvard University, Cambridge, Massachu-
setts
Gorman, M., B.A., Stanford University, California
Hay-Schmidt, A., Ph.D., University of Copenhagen, Den-
mark
Hoban, C., Ph.D., Massachusetts Institute of Technology,
Cambridge
Jacobson, M., Ph.D., University College London
Jakowec, M., Ph.D., Yale University, New Haven, Con-
necticut
Jungbluth, S., B.S., Max Planck Institute, Martinsried,
Germany
Kaiser, K., Ph.D., University of Glasgow, United Kingdom
Lardelli, M., Ph.D., Karolinska Institute, Stockholm, Sweden
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LoPresti, P., M.D., SUNY at Stony Brook, New York
Maher, F., Ph.D., National Institutes of Health, Bethesda,
Maryland
Maury, K., M.S., University of Geneva, Switzerland
Noda, M., Ph.D., Cancer Institute, Tokyo, Japan
Pan, D., B.S., University of California, Los Angeles
Schmucker, D., B.S., Max Planck Institute, Gottingen,
Germany
Shifman, M., Ph.D., Mt. Sinai School of Medicine, New York,
SEMINARS
Albright, T., Salk Institute. Functional diversity in the primate
visual system: How we see motion, color, and form.
Bargmann, C., University of California, San Francisco. Genet-
ic basis of chemosensation in C. elegans.
Byrne, J., University of Texas, Houston. Analysis of simple
neural networks in Aplysia.
Campbell, K., University of Iowa. Dystrophin and its associ-
ated proteins.
Cline, H., University of Iowa. Activity-dependent events in the
development of the topographic retinotectal projection.
Crews, S., University of California, Los Angeles. Drosophila
CNS development.
Harris, K., Childrens Hospital, Boston. Synaptic integration.
Hatten, M., Columbia University. Cerebellar development.
Jahn, R., Yale University. Neurotransmitter release mecha-
nism.
Jay, D., Harvard University. Laser inactivation of proteins
during neural development.
Joyner, A., Mt. Sinai Hospital. Genetic approaches to neural
development.
New York
Stapleton, G., B.S., Edinburgh University, United Kingdom
Van der Putten, H., Ph.D., Ciba-Geigy Research, Basel,
Switzerland
Van Eekelen, J., Ph.D., University of Leiden, The Netherlands
Vandaele, S., Ph.D., University of Montreal, Canada
Yamada, G., Ph.D., Max Planck Institute, Gottingen,
Germany
Julius, D., University of California, San Francisco. Serotonin.
Katz, L., Duke University. Development of neuronal connec-
tions in cortex.
McConnell, S., Stanford University. Determination of neuronal
identities in the developing cerebral cortex.
McKay, R., Massachusetts Institute of Technology.
Transplanting neuronal cells into the mammalian CNS.
Patrick, J., Baylor College of Medicine. Ligand gated ion
channels.
Reed, R., Johns Hopkins University. Olfactory receptors.
Rutishauser, U., Case Western Reserve University. Regula-
tion of cell interactions during neural development.
Schuman, E., Stanford University. Nitric oxide, intercellular
signaling, and long-term potentiation.
Schwarz, T., Stanford University. Voltage-gated ion channels.
Simon, M., University of California, Berkeley. Signaling
neuronal fate in the Drosophila eye.
Yancopoulos, G., Regeneron Pharmaceuticals. Neurotrophic
factors.
Analysis and Genetic Manipulation of Yeast Artificial
Chromosomes
October 8-October 21
INSTRUCTORS
Carle, Georges, Ph.D., Universite de Nice, France
Green, Eric, M.D., Ph.D., Washington University, St. Louis, Missouri
Rothstein, Rodney, Ph.D., Columbia University, New York, New York
ASSISTANTS
Canard, Bruno, Universite de Nice, France
Sunjevaric, Ivana, Columbia University, New York, New York
Tidwell, Rose, Washington University, St. Louis, Missouri
Cloning in yeast artificial chromosomes (YACs) is rapidly being applied to a wide
variety of molecular genetic problems. This course provided basic scientific ex-
pertise in current techniques for the analysis and manipulation of YACs. In gener-
al, a blend of theoretical and practical information was provided, with the goal to
establish a strong foundation for applying YAC cloning to a diversity of scientific
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problems. Topics included standard yeast genetic techniques (such as the
propagation and storage of cells, tetrad dissection, colony hybridization, and
DNA transformation); YAC library screening using both PCR- and genetic-based
strategies; characterizing YAC inserts by pulsed-field gel electrophoresis and
PCR; manipulating YAC clones by recombination-mediated disruption, targeted
and YAC-YAC recombination; and techniques for introducing YACs
into mammalian cells. Participants learned through hands-on experience, in-
formal discussions, and lectures given by prominent experts designed to com-
plement the experimental activities.
PARTICIPANTS
Avraham, K., Ph.D., National Cancer Institute, Frederick,
Maryland
Borbye, L., M.S., Risoe National Lab, Roskilde, Denmark
Cook, G., Ph.D., Medical Research Council, Cambridge,
England
Derry, J., Ph.D., Stanford University, California
Eyers, M., Ph.D., ICI Seeds, Berkshire, England
Ghazal, P., Ph.D., Scripps Research Institute, La Jolla, Cali-
fornia
Hayashi, Y., Ph.D., ICRF, London, England
Heikoop, J., Ph.D., Leiden University, The Netherlands
SEMINARS
Bentley, D., Guy's Hospital, London. Isolation and utilization
of YACs: Mapping human chromosomes X and 22.
Burke, D., University of Michigan. Development and uses of
a mouse genomic YAC library.
Friedman, J., Rockefeller University. Genetic and physical
mapping of mouse obesity genes.
Hieter, P., Johns Hopkins University. Modification of YACs
Ji, H., Ph.D., University of Wisconsin, Madison
Myklebost, 0., Ph.D., Institute for Cancer Research, Oslo,
Norway
Rosier, M-F., B.S., CNRS, Villejuif, France
Shepel, L., Ph.D., University of Wisconsin, Madison
Sornson, M., B.A., University of California, San Diego
Thiesen, H.-J., Ph.D., Basel Institute for Immunology, Swit
zerland
Thomas, W., Ph.D., Genentech, Inc., South San Francisco,
California
Wright, T., B.S., St. Mary's Hospital, London, England
using homologous recombination-based techniques.
Silverman, G., Children's Hospital, Boston. Expression of
genes within YACs after their genetic transfer to mam-
malian hosts.
Vollrath, D., Whitehead Institute. Chromosome cartography:
A high-resolution physical map of the human Y
chromosome.
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Macromolecular Crystallography
October 9-October 22
INSTRUCTORS
Furey, William, Ph.D., V.A. Medical Center, Pittsburgh, Pennsylvania
Gilliland, Gary, Ph.D., Center for Advanced Research in
Biotechnology, Rockville, Maryland
McPherson, Alexander, Ph.D., University of California, Riverside
Pflugrath, James, Ph.D., Cold Spring Harbor Laboratory, New York
ASSISTANT
Dyda, Frederick, V.A. Medical Center, Pittsburgh, Pennsylvania
Crystallography and X-ray diffraction yield a wealth of structural information un-
obtainable through other methods. This intensive laboratory/computational
course focused on the major techniques used to determine the three-dimensional
structures of macromolecules. It was designed for scientists with a working
knowledge of protein structure and function, but who are new to macromolecular
crystallography. Topics covered included protein purification, crystallization,
crystal characterization, data collection, data reduction, anomalous dispersion,
phase determination, molecular replacement and averaging, electron density in-
terpretation, structure refinement, molecular graphics, and molecular dynamics.
Participants learned through extensive hands-on experiments, informal discus-
sions, and lectures on current applications of these and related procedures given
by outside speakers.
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PARTICIPANTS
Almog, 0., M.S., Hebrew University, Jerusalem, Israel
Darst, S., Ph.D., Stanford University, California
Edwards, A., Ph.D., McMaster University, Hamilton, Canada
Gajiwala, K., M.S., Texas A&M University, College Station
Hassell, A., M.S., Glaxo Research Institute, Research Tri-
angle Park, North Carolina
Heikinheimo, P., M.S., University of Turku, Finland
Huber, A., B.S., California Institute of Technology, Pasadena
Jin, L., B.S., Boston University, Massachusetts
Li, T., Ph.D., Johns Hopkins University, Baltimore, Maryland
SEMINARS
Brunger, A., Yale University. The accuracy of X-ray crystal
and solution NMR structures.
Clore, G. M., National Institutes of Health. Determination of
high-resolution structures of larger proteins by 3D and 4D
NMR.
Fitzgerald, P., Merck Sharp & Dohme Research Labora-
tories. HIV-protease: A target for structure-based drug de-
sign.
Furey, W., V.A. Medical Center. Structure determination of
pyruvate decarboxylase.
Gilliland, G., Center for Advanced Research in Biotechnol-
ogy. 1. The crystal structure of a gluthathione S-
ransferase from a Mu gene class. 2. Crystal structure
determinations and analysis of subtilisin BPN mutants
for studying thermal stability.
Holden, H., University of Wisconsin, Madison. The three-
dimensional structure of myosin subfragment-1.
Kjeldgaard, M., Aarhus University. The structure of elonga-
Olkowski, J., B.S., Eli Lilly & Company, Indianapolis, Indiana
Roca, A., B.S., University of Wisconsin, Madison
Thomas, L., M.S., SUNY at Buffalo, New York
Vanderhoff-Hanaver, P., Ph.D., University of Tennessee,
Oak Ridge
Weisgraber, K., Ph.D., Gladstone Institute, San Francisco,
California
Wilce, M., Ph.D., St. Vincent's Institute, Melbourne, Australia
Zhang, W., M.S., Albert Einstein College of Medicine, New
York, New York
tion factor Tu-GDP.
Kuriyan, J., Rockefeller University. A sliding clamp and a
clamping switch: X-ray structures of DNA polymerase pro-
cessing factor and the SH2 domain.
McPherson, A., University of California, Riverside. The struc-
ture of satellite tobacco mosaic virus.
Otwinowski, Z., Yale University. Data reduction and profile
fitting.
Ramakrishnan, V., Brookhaven National Laboratory. The
MAD method to determine protein structure: Application
to histone H5.
Sweet, R., Brookhaven National Laboratory. Laue diffraction
as a probe for in-crystal dynamics: The example of
guanido-benzoyl trypsin.
Tronrud, D., University of Oregon. Macromolecular refine-
ment.
Wilson, I., Scripps Research Institute. Immune recognition of
peptide antigens.
Advanced In Situ Hybridization and Immunocytochemistry
October 9-October 22
INSTRUCTORS
Hough, Paul, Ph.D., Brookhaven National Laboratory, Upton, New York
Jacobson, Ken, Ph.D., University of North Carolina, Chapel Hill
Spector, David, Ph.D., Cold Spring Harbor Laboratory, New York
Trask, Barbara, Ph.D., University of Washington School of Medicine, Seattle
ASSISTANTS
Derby, Robert, Cold Spring Harbor Laboratory, New York
Lipfert, Jennifer, University of North Carolina, Chapel Hill
This course focused on specialized techniques and concepts in microscopy re-
lated to localizing nucleic acid sequences and proteins in cells and preparing
isolated nucleic acids for microscopic examination. The course was designed for
the molecular biologist who is in need of microscopic cell biological approaches
and for the cell biologist who is not familiar with the practical application of the
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advanced techniques presented in the course. The course emphasized the use
of the latest techniques and methods in epifluorescence microscopy, confocal
laser scanning microscopy, and electron microscopy to localize nucleic acids
and proteins in mammalian cells. Among the methods presented were prepara-
tion of tagged nucleic acid probes, fixation methods, detection of multiple nucleic
acids in a single cell, chromosome spreads, use of a variety of reporter
molecules and nonantibody fluorescent tags, direct and indirect antibody label-
ing, and detection of multiple proteins in a single cell. In addition, electron micro-
scopic techniques to observe isolated nucleic acids and proteins were present-
ed. For each technique, several experimental protocols were presented allowing
the students to assess the relative merits of each and to relate them to their own
research. The students were encouraged to bring specific probes to the course
which could be used in addition to those provided by the instructors. The
laboratory portion of the course was supplemented by invited lecturers who gave
up-to-the-minute reports on current research using the techniques being present-
ed in the course.
PARTICIPANTS
Bridge, J., M.D., University of Nebraska, Omaha
Chen, C., M.S., Columbia University, New York, New York
Chu, M.-L., Ph.D., Thomas Jefferson University, Philadel-
phia, Pennsylvania
Eccles, M., Ph.D., University of Otago, Dunedin, New
Zealand
Fan, F., B.S., University of Southern California, Los Angeles
Kaech, S., Ph.D., National Institutes of Health, Bethesda,
Maryland
Lakoski, J., Ph.D., University of Texas, Galveston
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McDonough, K., Ph.D., Albert Einstein College of Medicine,
New York, New York
McKinnon, D., Ph.D., SUNY at Stony Brook, New York
Pauletti, G., Ph.D., University of California, Los Angeles
Rosen, B., Ph.D., University of Edinburgh, United Kingdom
Shinowara, N., Ph.D., Winthrop University Hospital, Mineola,
New York
So lc, C., Ph.D., Massachusetts General Hospital, Boston
Tuor, U., Ph.D., Hospital for Sick Children, Toronto, Canada
White, M., Ph.D., University of Oxford, United Kingdom
SEMINARS
Brinkley, W., Baylor College of Medicine. Ultrastructural or-
ganization of the kinetochore.
Hansma, P., University of California, Santa Barbara. Imaging
of biological samples with the atomic force microscope.
Hough, P., Brookhaven National Laboratory. 1. Image pro-
duction in the electron miocroscope. 2. Analysis of macro-
molecular complexes by STEM.
Jacobson, K., University of North Carolina. 1. Basic intro-
duction to light microscopy. 2. Fluorescence microscopy.
Murray, J., University of Pennsylvania. Use of confocal micro-
scopy and deconvolution techniques.
Singer, R., University of Massachusetts. Cytoplasmic organi-
zation of mRNA.
Spector, D., Cold Spring Harbor Laboratory. 1. Im-
munocytochemistry. 2. An integrated microscopic ap-
proach to examining nuclear organization.
Trask, B., University of Washington School of Medicine.
Mapping chromosomes and interphase nuclei by in situ
hybridization.
Waggoner, A., Carnegie Mellon University. Development of
fluorochromes and filters for fluorescence microscopy.
Ward, D., Yale University. 3D cytogenetics and cell biology.
Essential Computational Genomics for Biologists
October 26-November 4
INSTRUCTORS
Branscomb, Elbert, Ph.D., Lawrence Livermore Laboratory, California
Goodman, Nat, Ph.D., Massachusetts Institute of Technology
Marr, Tom, Ph.D., Cold Spring Harbor Laboratory, New York
Myers, Gene, Ph.D., University of Arizona
This course was intended primarily for molecular biologists and geneticists who
are mounting large-scale projects that require informatics components. No prior
experience with the use of computers or mathematics was assumed. Lectures
and computer work delved deeply into both the theoretical issues and practical
approaches to a number of important computational problems in genomic analy-
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sis. The course included an overview of informatics systems
analysis and design
principles. Topics included such basics as
database design and data modeling
to more complex analytical methods. Technical
issues relating to the analysis of
raw data such as image analysis, sequence assembly, physical mapping,
genetic-linkage analysis, and data integration were
covered. Students were intro-
duced to, and gained hands-on experience with, a variety of software tools used
in computer systems design and.data acquisition and analysis running on
Macintosh computers. It was intended that students gain sufficient knowledge
and experience from this course to enable them to initiate active collaborations
with computational scientists at their home institutions.
PARTICIPANTS
Caporale, L., Ph.D., Merck & Co., Inc., Rahway, New Jersey
Darvasi, A., M.S., Hebrew University, Jerusalem, Israel
Davies, P., Institut Pasteur, Paris, France
Glamann, J., M.D., State Seruminstitute, Copenhagen, Den-
mark
Gnirke, A., Ph.D., University of Washington, Seattle
Kanyion, P., Ph.D., Justus-Liebig University, Giessen,
Germany
Lagunez-Otero, J., Ph.D., Weizmann Institute, Rehovot,
Israel
Meisler, M., Ph.D., University of Michigan, Ann Arbor
Reiner, 0., Ph.D., Baylor College of Medicine, Houston,
Texas
Ringwald, M., Ph.D., Max Planck Institute, Freiburg, Germany
Sabour, M., Ph.D., Agriculture Canada, Ottawa
Schmitt, K., M.S., University of Southern California, Los
Angeles
Williams, C., Ph.D., Weyerhaeuser Research, New Bern,
North Carolina
Molecular Genetics, Cell Biology, and Cell Cycle
Yeast
October 27-November 9
INSTRUCTORS
Chappell, Tom, Ph.D., Duke University, Durham, North Carolina
Fantes, Peter, Ph.D., University of Edinburgh, Scotland
McLeod, Maureen, Ph.D., State University of New York, Brooklyn
ASSISTANTS
Ayscough, Kathryn, ICRF, London, England
Devoti, James, State University of New York, Brooklyn
Wu, Shaw-Yun, State University of New York, Brooklyn
Recent advances in cell cycle research, largely due to studies on the fission
yeast Schizosaccharomyces pombe, have prompted much interest in this
organism. Although cell cycle studies continue to flourish, S. pombe is in-
creasingly being chosen as a model organism for investigations into other
aspects of cell biology and genetics using the powerful molecular and genetical
techniques available. The content of the course reflected all these areas of inter-
est and provided participants with the skills necessary to pursue their own inves-
tigations. Topics covered included mutagenesis and analysis of mutants, trans-
formation and gene transplacement techniques, isolation of nuclei, preparation of
nuclear DNA, plasmid recovery from yeast into bacteria, cell cycle methods,
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cytology, and immunological techniques. In addition to hands-on experience,
participants had the opportunity to learn through informal group discussions and
formal lectures given by prominent S. pombe researchers drawn from the ex-
panding international community.
PARTICIPANTS
Albright, C., Ph.D., Whitehead Institute, Cambridge, Massa-
chusetts
Bachhawat, A., Ph.D., Carnegie Mellon University,
Pittsburgh, Pennsylvania
Belenguer, P., Ph.D., University Paul Sabatier, Toulouse,
France
Brun, C., Ph.D., Roswell Park Cancer Institute, Buffalo, New
York
Dhillon, N., Ph.D., Salk Institute, La Jolla, California
Gul M-P., Ph.D., Lab de Biologie du CNRS, Toulouse,
France
Hoffmann, L., M.S., University of Copenhagen, Denmark
SEMINARS
Caligiuri, M., Cold Spring Harbor Laboratory. The role of
Cdc10 in the cell cycle.
Chappell, T., Duke University. Golgi-localizing proteins.
Davey, J., University of Birmingham. Sex appeal and
endocytosis in S. pombe.
Fantes, P., University of Edinburgh. Cell cycle control in fis-
sion yeast.
Futcher, B., Cold Spring Harbor Laboratory. Cell cycle
clocks in S. cerevisiae.
Gould, K., Vanderbilt University. Cell cycle regulation of the
cdc2 protein kinase.
Hoffman, C., Boston College. Glucose repression and signal
Lum, P., M.S., University of Washington, Seattle
Miller, P., B.S., University of Vermont, Burlington
Moussy, G., M.S., CNRS, Villejuif, France
Rasmussen, C., Ph.D., University of Alberta, Canada
Romano, P., Ph.D., National Institutes of Health, Bethesda,
Maryland
Saltsman, K., B.A., Massachusetts General Hospital, Boston
Smith, A., Ph.D., Whitehead Institute, Cambridge, Massa-
chusetts
Smythe, C., Ph.D., University of Dundee, Scotland
Su, J.-Y., Ph.D., University of Colorado, Denver
transduction in S. pombe.
Klar, A., NCI Frederick Cancer Facility. Decisions cells make
during mating-type switching of fission yeast.
McLeod, M., SUNY at Brooklyn. Protein kinases that regu-
late meiosis.
Subramani, S., University of California, San Diego. Role of S.
pombe rad genes in DNA repair, recombination and cell-
cycle checkpoints.
Wig ler, M., Cold Spring Harbor Laboratory. Studies of RAS in
yeast.
Young, P., Queen's University. Na, pH, and the cell cycle.
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Monoclonal Antibodies from Combinatorial Libraries
October 27-November 9
INSTRUCTORS
Barbas, Carlos, Ph.D., Scripps Research Institute
Burton, Dennis, Ph.D., Scripps Research Institute
ASSISTANTS
Cababa, Doug, Scripps Research Institute
Pilkington, Glenn, Scripps Research Institute
Recent advances in the generation and selection of antibodies from com-
binatorial libraries allow for the rapid production of antibodies from immune and
nonimmune sources. This laboratory/lecture course focused on the construction
of combinatorial antibody libraries expressed on the surface of phage and selec-
tion of desired antibodies from pre-existing libraries by panning. Students
learned the theoretical and practical aspects of constructing combinatorial librar-
ies from immune and nonimmune sources as well as the construction of synthetic
antibody libraries. Production, purification, and characterization of Fab fragments
expressed in E. coli were also covered. Students were encouraged to select
antibodies against an antigen of their interest from the pre-existing libraries. The
lecture series, presented by a number of invited speakers, focused on the biol-
ogy of filamentous phage and the utility of surface expression libraries, expres-
sion of antibodies in E. co/i and mammalian cells, antibody structure and func-
tion, antibody diversity, catalytic antibodies, and recent results on the use of
antibodies in therapy.
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PARTICIPANTS
Abate, M., M.S., Dartmouth Medical School, Lebanon, New
Hampshire
Bjorling, E., B.S., Karolinska Institute, Stockholm, Sweden
Bodeus, M., Ph.D., INSEAM, Paris, France
Deutscher, S., Ph.D., University of Missouri, Columbia
Godenir, N., M.S., University of Cape Town, South Africa
Greenspan, N., Ph.D., Case Western Reserve University,
Cleveland, Ohio
Herlyn, D., D.V.M., The Wistar Institute, Philadelphia,
Pennsylvania
Logan, J., Ph.D., EPG Laboratories, Manhasset, New York
SEMINARS
Barbas, C., Scripps Research Institute. Antibodies from
combinatorial libraries.
Burton, D., Scripps Research Institute. 1. Antibody structure
and function. 2. Human antibodies from combinatorial li-
braries.
Dimmock, N., University of Warwick. Antibody neutralization
of animal viruses.
Glennie, M., University of Southampton. Antibodies in hu-
man therapy.
Hilvert, D., Scripps Research Institute. Catalytic antibodies.
Ou, S., M.S., California Institute of Technology, Pasadena
Shepard, A., Ph.D., Alkermes Inc., Boston, Massachusetts
Shiba, K., Ph.D., Cancer Institute, Tokyo, Japan
Takkinen, K., Ph.D., VTT Laboratory, Espoo, Finland
Tit low, C., Ph.D., Massachusetts General Hospital, Boston
Torrance, L., Ph.D., Scottish Crop Research Institute,
Dundee
Tse, W., Ph.D., Stanford University, California
Williams, D., Ph.D., Kennedy Institute, London, United King-
dom
Matthews, D., Genentech, Inc. Optimization of binding and
catalysis by phage display technology.
Model, P., Rockefeller University. Filamentous phages.
Sanz, I., University of Texas. Generation of antibody diver-
sity.
Scott, J., University of Missouri. Discovering peptide ligands
using epitope libraries.
Wilson, I., Scripps Research Institute. Antibody-antigen in-
teraction at the molecular level.
Molecular Markers for Plant Breeding
November 11-November 22
INSTRUCTORS
Burr, Ben, Ph.D., Brookhaven National Laboratory, Upton, New York
Helentjaris, Tim, Ph.D., University of Arizona, Tucson
Tingey, Scott, Ph.D., DuPont Experimental Station, Wilmington, Delaware
ASSISTANTS
Jung, Mark, DuPont Experimental Station, Wilmington, Delaware
Hanafey, Mike, DuPont Experimental Station, Wilmington, Delaware
Matz, Eileen, Brookhaven National Laboratory, Upton, New York
McCreery, Tom, University of Arizona, Tucson
This course was designed to train scientists in the use of molecular markers in
plant breeding. It was taught through both a theoretical and practical approach
to the subject, including lectures and extensive laboratory work. Participants
learned a variety of techniques that can be used to approach problems such as
single gene introgression, analysis of genetic diversity, gene mapping, and
quantitative trait analysis. These techniques included DNA preparation, non-
radioisotopic Southern analysis, PCR, RAPDs, and DNA sequencing. The course
included training in computational analysis of both RFLP and RAPD data and
taught methods from a variety of plant and animal systems with an emphasis on
potential future strategies. Course participants were expected to have knowledge
of, but not necessarily practical experience with, the basic principles of
molecular biology and genetics.
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PARTICIPANTS
Andrade, E., B.S., Max Planck Institute, Koln, Germany
Chang, Y.-F., M.S., CIBA-GEIGY Corp., Research
Triangle
Park, North Carolina
Cheah, S.-C., Ph.D., Palm Oil Research Institute, Lumpar,
Malaysia
Chomet, P., Ph.D., Deka lb Plant Genetics, Mystic, Con-
necticut
Doerge, R., M.S., North Carolina State University, Raleigh
Farish, G., M.S., University of North Dakota, Grand Forks
Grattapaglia, D., B.S., North Carolina State University,
Raleigh
SEMINARS
Beckman, J., Centre d'Etude du Polymorphisme Humain,
Paris. Molecular mapping in mammals.
Burr, B., Brookhaven National Laboratory. Use of molecular
markers for plant genetics.
Ecker, J., University of Pennsylvania. Map based cloning;
creating anchored physical maps.
Lander, E., Whitehead Institute. Use of molecular markers
for genome analysis.
Michelmore, R., University of California, Davis. Future ap
Hubbard, L., B.A., USDA-ARS, Albany, California
Messenguer, R., Ph.D., IRTA Cabrils, Barcelona, Spain
Morgante, M., Ph.D., University of Udine, Italy
Murigneux, A., M.S., BIOCEM, Aubierre, France
Nair, S., Ph.D., International Centre for Genetic
Engineering, Delhi, India
Rameau, C., Ph.D., INRA, Versailles, France
Schneerman, M., M.S., Illinois State University, Bloomington
Van Deynze, A., M.S., University of Guelph, Canada
plications of molecular markers.
Rafalski, A., DuPont Experimental Station. 1. Polymorphism
detection techniques. 2. Automation technology.
Romero-Severson, J., Agrigenetics. The measurement of
linkage in heredity.
Sederoff, R., North Carolina State University. Application of
molecular markers to perennials.
Smith, S., Pioneer Hi-Bred International. Use of molecular
markers in germ plasm analysis.
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SEMINARS
Cold Spring Harbor Seminars were initiated to provide a semiformal avenue for
communication between the various research groups at the Laboratory. They are
particularly useful for research personnel who have joined the Laboratory during
the summer. The seminars also afford a necessary opportunity for the graduate
students and postgraduate staff to develop their skills in defending, organizing,
and presenting their research.
1992
January
Sergei Sokol, Harvard University, Cambridge Massachu-
setts. Growth factors and the body plant formation in
Xenopus early development.
Karen Fien, Cold Spring Harbor Laboratory. Identification of
RFC from Saccharomyces cerevisiae: A component of the
leading-strand DNA replication complex.
Melanie Cobb, University of Texas, South Western Medical
Center. Regulation of MAP kinases by insulin and EGF.
Grigori Enikolopov, Cold Spring Harbor Laboratory. Recom-
binant inhibitors of protein kinases: New tools for studying
signal transduction.
Will Phares, Cold Spring Harbor Laboratory. HIV-1 LTR se-
quences amplified from peripheral blood cells of infected
individuals contain a °hot spot" for sequence duplication.
February
Tom Steitz, Yale University, New Haven, Connecticut. Com-
parison of the structures of HIV reverse transcriptase
Klenow fragment: Implications for function.
Elizabeth Moran, Cold Spring Harbor Laboratory.
Adenovirus E1A oncogene intervention in cell growth con-
trol pathways.
Paul Schimmel, Massachusetts Institute of Technology,
Cambridge. Enzymatic recognition of RNA minihelices
and decoding genetic information.
Ian Fitch, Cold Spring Harbor Laboratory. Cloning and char-
acterization of four B-type cyclin genes, CLB1-CLB4,
from Saccharomyces cerevisiae.
Janet Rossant, Mt. Sinai. Anterior/posterior patterning in the
postimplementation mouse embryo.
Jacek Skowronski, Cold Spring Harbor Laboratory. Altered
T-cell activation and development in transgenic mice ex-
pressing the HIV-1 nef gene.
Elizabeth Ullu, Yale University, New Haven, Connecticut.
RNA processing reactions in African trypanosomes.
Adrian Krainer, Cold Spring Harbor Laboratory. Regulation
of pre-mRNA splice site selection by antagonistic factors.
March
Matt Thomas, Washington University, St. Louis, Missouri.
Protein tyrosine phosphatases and T-cell activation.
Jim Pflugrath, Cold Spring Harbor Laboratory. T7 lysozyme:
An amidohydrolase that inhibits T7 RNA polymerase.
Michael Sinensky, Eleanor Roosevelt Institute, Denver,
Colorado. Prenylated proteins of the mammalian nuclear
lamina.
Steve Bell, Cold Spring Harbor Laboratory. ATP-dependent
recognition of S. cerevisiae origins of DNA replication.
Susan Amara, Vollum Institute. Molecular diversity of
neurotransmitter transporters.
Mark Pittenger, Cold Spring Harbor Laboratory. Cellular and
molecular aspects of tropomyosin diversity.
April
Jeff Hall, Brandeis University, Waltham, Massachusetts.
How a gene keeps time: Molecular neurobiology of period
in Drosophila.
Dorre Grueneberg, Cold Spring Harbor Laboratory. Interac-
tion of a novel human homeodomain protein with SRF
(serum response factor).
Dan Littman, Howard Hughes Medical Institute. CD4 and
CD8 in T-cell development and activation.
George Mulligan, Cold Spring Harbor Laboratory. RNA-
binding proteins in the regulation of f3-tropomyosin
alternative splicing.
Jack Dixon, University of Michigan, Ann Arbor. Structure,
function, and catalysis of protein tyrosine phosphatases.
Sui Huang, Cold Spring Harbor Laboratory. Nuclear organi-
zation of pre-mRNA splicing factors and their substrates.
May
Susan Lobo, Cold Spring Harbor Laboratory. snRNA gene
transcription by RNA polymerases II and III.
Lea Harrington, Cold Spring Harbor Laboratory. Purification
and characterization of Tetrahymena telomerase.
Erich Grotewold, Cold Spring Harbor Laboratory. Transcrip-
tion regulation by a maize Myb homolog: The P gene.
June
Ricardo Attar, Cold Spring Harbor Laboratory. Expression
cloning of a novel zinc finger protein that binds to the c-
fos serum response element.
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October
Nikolai Lisitsyn, Cold Spring Harbor Laboratory.
Genomic
difference analysis: A representational approach.
James Darnell, Rockefeller University,
New York, New York.
IFN activation of genes: Signal transduction by protein-
protein interaction.
Dan Kalderon, Columbia University, New York, New
York.
Genetic investigation of A-kinase function in Drosophila.
Yue Xiong, Cold Spring Harbor Laboratory. Human D-type
cyclins associate with multiple protein kinases and PCNA.
David Levin, Johns Hopkins University, Baltimore, Maryland.
Role of the protein kinase C/MAP kinase pathway in yeast.
Simon Green, Cold Spring Harbor Laboratory. A novel RNA-
binding motif in the double-stranded RNA-activated
protein kinase, DAI.
November
Jiminez Garcia, Cold Spring Harbor Laboratory. Spatial or-
ganization of transcription and pre-mRNA splicing in
adenovirus-infected cells.
Jo Messing, Waksman Institute. Methionine overproduction
and a new somatic mutation in maize.
Andrew Flint, Cold Spring Harbor Laboratory. The non-
transmembrane protein tyrosine phosphatase PTB1B is a
target for three different serine/threonine kinases in vivo.
December
Wen-Hwa Lee, University of Texas Health Science Center.
What's new with RB?
Danny Reinberg, Robert Wood Johnson Medical School at
Rutgers University, New Brunswick, New Jersey. Regula-
tion of initiation of transcription by polymerase II.
Peter Yaciuk, Cold Spring Harbor Laboratory. Characteriza-
tion of the E1A-associated 300-kilodalton host cell protein
and its associated cell growth regulating activity.
Eckard Wimmer, State University of New York, Stony Brook.
CAP-independent translation and cell-free, de novo
synthesis of poliovirus.
UNDERGRADUATE RESEARCH
An important aspect of the summer program at the Laboratory is the participation
of college undergraduate students in active research projects under the supervi-
sion of full-time laboratory staff members. The program was initiated in 1959.
Since that year, 378 students have completed the course, and many have gone
on to creative careers in biological science.
The objectives of the program are to provide (1) a greater understanding of
the fundamental principles of biology; (2) an increased awareness of major prob-
lem areas under investigation; (3) a better understanding of the physical and in-
tellectual tools for modern research and the pertinence of this information to fu-
ture training; and (4) a personal acquaintance with research, research workers,
and centers for study.
The following students, selected from more than 160 applicants, took part in
the program, which was supported by Baring Brothers & Co., Ltd., Bio-Rad
Laboratories, Burroughs Wellcome Fund, Theodore N. Danforth, The Garfield In-
ternship, Hanson Industries, Imperial Chemical Industries, Libby Internship, Na-
tional Science Foundation, Robert H.P. Olney Memorial Cancer Fund, Philips
Petroleum Foundation., Inc., William Shakespeare Internship, and Frederica von
Stade Internship.
Kenneth Bilchick, Dartmouth College
Advisor: John Anderson
Sponsor: National Science Foundation
Purification, crystallization, and structure determination
of MPvull methylase protein.
Chad Brecher, Brown University
Advisor: Dan Marshak
Sponsor: Burroughs Wellcome Fund
Examination of the mechanism of action of S100p and
determination of the interaction of S100p and p-amyloid
(1-40) in the C6 rat glioma cell line and newborn rat
astrocytes.
Daniel Cahill, Yale University
Advisor: Jim Pflugrath
Sponsor: Burroughs Wellcome Fund
Structure determination of sloop.
Howard Y. Chang, Harvard University
Advisor: Gil Morris
Sponsor: Robert H.P. Olney Memorial Cancer Fund
Mechanism of trans-activation of the human PCNA
promoter by the 243-amino-acid E1A protein.
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Victor Wee-Teck Chua, Cambridge University
Advisor: Adrian Krainer
Sponsor: Bio-Rad Laboratories
In vivo functional analysis of the general splicing factors SF2
and hnRNP Al.
Leena Gandhi, University of Utah
Advisor: Arne Stenlund
Sponsor: Burroughs Wellcome Fund
Analysis of the interaction between El and E2 in coopera-
tive binding of the BPV origin of replication.
Keow Lin (Lindee) Goh, California Institute of
Technology
Advisor: Robert Martienssen
Sponsor: Philips Petroleum Foundation, Inc.
Molecular cloning and characterization of the ramosal
mutant of maize.
Sam Haward, Cambridge University
Advisor: Venkatesan Sundaresan
Sponsor: Baring Brothers & Co., Ltd.
Devising and testing a screening system for selecting for
transposable element insertions into Arabidopsis plants.
Gilbert L. Henry, University of Califorinia at
Santa Barbara
Advisor: Winship Herr
Sponsor: National Science Foundation
Transcriptional activation domains.
JoAnn Hong, Yale University
Advisor: Dafna Bar-Sagi
Sponsor: Frederica von Stade Fund
The effect of GRB2 overexpression in NIH-3T3 fibroblast
cells containing moderately high levels of wild-type p21
RAS.
Fraser R. lmrie, University of Glasgow
Advisor: Tim Tully
Sponsor: Hanson Industries
Molecular cloning of linotte, a new learning and memory
gene in Drosophila melanogaster.
Ingrid Kelly, University of Cambridge
Advisor: Tom Peterson/Erich Grotewold
Sponsor: Anonymous
Purification of antibodies to the P gene in maize.
Laurie Littlepage, University of North Texas
Advisor: Bruce Futcher
Sponsor: National Science Foundation
Suppressing the lethality of WHI3 overexpression in S.
cerevisiae.
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Rachna J. Ram, University of California, Berkeley
Advisor: Hong Ma
Sponsor: Burroughs Wellcome Fund
Differential hybridization screening for floral organ-specific
cDNAs in Arabidopsis thaliana.
Rustam Rea, Oxford University
Advisor: Nick Tonks/Andrew Flint
Sponsor: Libby Internship
Investigation of the phosphorylation of two cytosolic protein
tyrosine phosphastases.
Adam Todd Ross, University of Michigan
Advisor: B. Robert Franza
Sponsor: The Garfield Internship
Initial characterization of human I-KB and other
Rel-associated proteins.
Anjanette Searfoss, Juniata College
Advisor: Kim Arndt
Sponsor: National Science Foundation
Cloning of SAP-4, a SIT4-associated protein.
Anna Sessler, Allegheny College
Advisor: Jeff Kuret
Sponsor: National Science Foundation
Cellular localization of the protein kinase CKI-1 in
Saccharomyces cerevisiae.
Wenying Shou, Pomona College
Advisor: Tom Marr
Sponsor: William Shakespeare Internship
Dispersed pattern recognition in a group of proteins.
Rebecca Smith, Bard College
Advisor: Bruce Stillman
Sponsor: National Science Foundation
Elucidation of ORC binding to S. cerevisiae ARS1 through
high-resolution footprinting.
Michael J. Walsh, Tuskegee University
Advisor: Eric Richards
Sponsor: National Science Foundation
Study of variant telomere repeats in Arabidopsis thaliana.
Jennifer Whangbo, University of North Carolina,
Chapel Hill
Advisor: Ron Davis
Sponsor: National Science Foundation
An approach to studying the molecular basis of behavior in
mammals through the use of promoter trap mice.
Lucie L.-N. Yang, University of Maryland
Advisor: David M. Helfman
Sponsor: Cold Spring Harbor Laboratory
Identification of a cellular factor blocking splicing of a
skeletal-muscle-specific exon in nonmuscle cells.
NATURE STUDY PROGRAM
The Nature Study Program gives elementary and secondary school students the
opportunity to acquire a greater knowledge and understanding of their environ-
ment. Through a series of specialized field courses, younger students can
engage in introductory programs such as Nature Bugs and Nature Detectives I
and II, and older students can enroll in more advanced programs such as Marine
Biology and Nature Photography.
During the summer of 1992, a total of 420 students participated in 29 courses
within the program; 17 of these courses were filled to capacity. The classes were
held outdoors, weather permitting, at the Uplands Farm Preserve, the head-
quarters of the Long Island Chapter of the Nature Conservancy. The Laboratory
has equipped and maintains classroom and laboratory facilities as well as a
darkroom at Uplands Farm. This facility is used as a base for the students' ex-
ploration of the local environment. Field classes are held on Laboratory grounds,
St. John's Preserve, Fire Island National Seashore, Caumsett State Park, the Cold
Spring Harbor Fish Hatchery and Aquarium, as well as other local preserves and
sanctuaries.
In addition to the three 2-week sessions, the Adventure Education course
meets on two Saturdays for trips. The students go on a 10-mile bicycle hike to
Sagamore Hill and a 12-mile canoe trip on the Nissequogue River.
PROGRAM DIRECTOR
William M. Payoski, M.A., Adjunct Professor, Nassau Community College
REGISTRAR
Catherine Schratwieser, M.A., Dowling College
INSTRUCTORS
Kimberly Hamilton, B.S., Colgate University
Michael Manfredonia, Teaching Candidate, Marist College
Linda Payoski, B.A., Science Teacher, Uniondale High School
Marjorie Pizza, B.A., Science Teacher, Bayville School District
Donna Stokes, Teaching Candidate
Sarah Whiteside, Photography Undergraduate
COURSES
Nature Bugs
Nature Detectives I and II
Advanced Nature Study
Ecology Explorers
Frogs, Flippers, and Fins
Pebble Pups
Rock Hounds
Bird Study
Freshwater Life
Seashore Life
Marine Biology
Nature Photography
Adventure Education
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The Laboratory would like to acknowledge
the generosity of the following com-
panies who loaned equipment and reagents
to the various courses:
Amersham Corp.
Applied Biosystems, Inc.
AT-Biochem
Axon Instruments
Beckman Instruments, Inc., Fullerton Division
Beckman Instruments, Inc., Spinco Division
Bio 101, Inc.
Biometra
Bio-Rad Laboratories
Bio-Rad, Microscience Division
Boehringer Mannheim Biochemicals
Brinkmann Instruments, Inc.
CBS Scientific
Clontech Laboratories, Inc.
Dagan Corp.
Denton Vacuum
Diagnostic Products Corp.
Drummond Scientific Corp.
Eastman Kodak Co.
Electron Microscopy Sciences
Eppendorf Inc.
ETM Systems
FMC Corporation
Fuji Medical Systems
General Valve Corporation
GIBCO
Grass Instrument Co.
Hampton Research
Hoefer Scientific Instruments
International Biotechnologies, Inc. (IBI)
ICN Pharmaceuticals, Inc.
Integrated Separation Systems
IntelliGenetics, Inc.
Kramer Scientific
Micro Video Instruments
Millipore Corp.
Mitsubishi Electronics America, Inc.
MJ Research, Inc.
New England Biolabs, Inc.
Newport
Nikon Inc.
Nissei Sangyo America, LTD
Omega Optical
Organon Technika-Cappel
Perkin Elmer Cetus
Polysciences
Promega Corp.
Q-Life Systems
Qiagen Inc.
Robbins Scientific Corp.
SAS Institute
Savant Instruments, Inc.
Schleicher & Schuell, Inc.
Stratagene
Sutter Instrument Co.
Tektronix
United States Biochemical Corp.
Vector Laboratories, Inc.
Warner
World Precision Instruments
Carl Zeiss, Inc.
BANBURY
CENTER

BANBURY CENTER
DIRECTOR'S REPORT
1992 marked the 15th anniversary of the opening of the Banbury Center, donated
to Cold Spring Harbor Laboratory in 1975 by Mr. Charles S. Robertson. What had
been the garage for the Robertson estate was converted into the conference
room during 1976, and Francis Crick was the inaugural speaker at the dedication
that took place on June 14, 1977. Jim Watson, in his annual report for that year,
wrote of the new building that we believe (it) to be the most striking conference
center now available to biologists." His confidence has been fully justified by the
enthusiasm of researchers for our meetings and the high esteem in which the
Banbury program is held by biologists throughout the world. The reputation of the
Center has spread beyond academia into the worlds of biotechnology and
science policy, sometimes with unexpected consequences. Our 15th year was
celebrated with 16 meetings attended by more than 500 visitors.
Banbury Conference Center
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Robertson House provides housing and dining accommodations at Banbury Center
Sloan Foundation Workshops
A description of the year's events must begin with a special tribute to the Alfred
P. Sloan Foundation for the support it has provided to the Banbury Center pro-
gram. This support goes back to the very beginning of the program with a grant
that, together with a similar grant from the Esther A. and Joseph Klingenstein
Fund, provided the bedrock for the first two years of the Center's existence. Vic-
tor McElheny, the Center's first director, then persuaded the Sloan Foundation
that science education of influential groups was essential for a civilized society
and thus began the series of "public information workshops" for science journal-
ists and congressional staff. These workshops provided an opportunity for the
participants to spend 2 days with leading scientists and learn in depth about
matters of biology that had important public policy implications. This series
proved to be a tremendous success, and two of these workshops have been
held every year since 1980. The workshops have been very influential because
the participants are opinion leaders, ideally placed to transmit what they learned
at Banbury.
The two workshops in 1992 exemplified the quality and the importance of
these small meetings. The Commercialization of Biology meeting dealt with the
vexing question of the degree to which research in molecular biology and
genetics is being compromised by the rush to exploit the findings. Speakers
came from industry, the National Institutes of Health, academia, and the Patents
& Trademarks Office. It was at this meeting that the changes in licensing for the
polymerase chain reaction were first made public. Later in the spring, there was
a meeting on Occupational and Environmental Health. III health related to the
workplace places enormous economic strain on the nation and personal cost on
those individuals affected. Improvements in occupational health should be a
major target for any administration concerned with reducing health care costs,
and this meeting introduced the science journalists and congressional staff to
leading workers in the field.
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The Alfred P. Sloan Foundation decided, regretfully, that all good things must
come to an end. The Foundation will not extend funding for the program beyond
1992, although there will be one more workshop in 1993. So at the same time that
we thank the Foundation for its insight and forward thinking in supporting these
workshops, we are actively looking for future long-term support for the program.
New Technical Developments in Molecular Biology
The first of the meetings funded by the Corporate Sponsors Program dealt with a
topic of great general interest and of special interest to biotechnology and
pharmaceutical companies, namely, producing protein molecules with desired
characteristics. "Rational" design strategies have not been very effective because
the huge number of possible variants of a protein precludes systematic testing of
all forms, and our lack of knowledge of the relationships between protein function
and structure hinder prediction of which variants to select for testing. The Phage
Display meeting discussed a new strategy that involves cloning the gene for the
protein to be modified into bacteriophage so that the protein is displayed on the
surface of the virus. The gene is randomly mutated, and phage bearing a variant
protein with characteristics closer to those desired are selected from the
enormous population of phage that can be grown in bacteria. The first papers on
this technique appeared during 1991, and this was almost certainly the first
meeting to discuss these new developments. The meeting set a new Banbury
Center record for biotechnology participation with no fewer than 31 of the 45
participants coming from companies!
Molecular Biology
The other meetings funded by the Corporate Sponsor program were all con-
cerned with molecular biology and the ways it has illuminated our understanding
of the biology of organisms.
An intriguing biological problem with important medical implications concerns
the mechanisms by which some viruses, having infected cells, become dormant.
How is it that the DNA of these viruses remains in the infected cells, although the
cells continue to function normally? Equally intriguing and important are the
mechanisms by which this DNA later becomes activated. Molecular Mechan-
isms of Viral Latent Infections reviewed these topics in relation to the herpes-
viruses, Epstein-Barr virus, and, of course, human immunodeficiency virus and
other RNA viruses.
One way that viral infections might be controlled is by using oligonucleotides
that hybridize to and shut down viral genes. This "antisense" strategy has been
under intensive development for a number of years, but some new developments
led us to hold the meeting Oligonucleotide Manipulation of Gene Expression:
Its Therapeutic Potential. These developments include the synthesis of
oligonucleotides that are more stable when they are in cells and that make more
stable combinations with DNA and RNA; further information on the ways in which
oligonucleotides enter cells that may in turn lead to improved methods of
delivery; and new data on the formation of triple helices.
The meeting Mechanisms of Neuronal Survival: The Action of
Neurotrophic Factors dealt with the fascinating topic of growth factors that
af-
fect nerve cell growth and survival. Sessions discussed not only the factors
them-
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selves, but also their receptors; regulation of their activities in vivo; their role in
development; and the mechanisms by which nerve cells are killed. There is clear-
ly great potential for developing therapies to induce or promote nerve regenera-
tion following nerve damage.
The Wellcome Trust/Cold Spring Harbor Laboratory Meeting
The Wellcome Trust is the principal non-Government source of funding for
biomedical research in the United Kingdom and has recently begun to hold
meetings. Constructing Organisms was a joint meeting of The Wellcome Trust
and the Laboratory, the Trust providing funds to cover the costs of the large con-
tingent of European scientists who attended. The meeting brought together re-
searchers working on a veritable zoo of creatures, including fruit flies, mice, ze-
bra fish, nematode worms, sea urchins, toads, leeches, and weeds! Participants
examined the extent to which Nature employs common developmental strategies
in building organisms. We hope that this may be the first of other joint meetings.
Human Molecular Genetics
In something of a departure compared with recent years, there was but one
meeting dealing directly with human genetics. However, the meeting, entitled
DNA Repeats and Human Gene Mutations, was extremely timely, providing an
opportunity to bring together scientists working on three different inherited dis-
orders. The molecular defects in these disorders-Fragile X syndrome (the most
common form of inherited mental retardation); myotonic dystrophy (a muscle dis-
order); and Kennedy's disease (a nerve problem)-had been discovered only in
the year preceding the meeting and have been found to be similar. The muta-
tions arise because of the instability of a portion of the DNA in the genes for each
disorder. The gene in an affected individual is larger than in an unaffected per-
son, and it continues to enlarge as it is passed on to the next generation. In addi-
tion to scientists investigating these disorders, the meeting was attended by
scientists who have been working on genome instability in other organisms such
as bacteria and yeast in the hope that common themes would be discernible.
Baring Brothers/Cold Spring Harbor Laboratory Meeting
The seventh of these annual meetings, funded initially by Shearson Lehman and
more recently by Baring Brothers of London, was held in October 1992. These
meetings comprise what has become one of our longest-lived series, so it was
appropriate that the 1992 meeting was on Aging. The range of topics covered
was broad, from the social and economic consequences of our aging population,
through basic mechanisms of aging, to Alzheimer's disease. Once again, a
group of world-class scientists discussed their latest research, and it was espe-
cially pleasing to have Carol Greider present her research on telomere shorten-
ing in aging cells. The executives were leaders in the worlds of biotechnology
business and, investment, and it is clear that this meeting has become a
prestigious event.
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Databases for Forensic DNA Fingerprinting
We held a meeting at Banbury Center in 1988 on DNA and Forensic Science that
examined the new techniques of DNA "fingerprinting" that were just then being
taken up in the United States. Although many of the issues raised at that meeting
are resolved only partially, implementation of DNA typing has proceeded apace.
One problem of tremendous practical consequence concerns the development
of databases for storing DNA-typing information, in particular allowing for future
technical developments and ensuring the security of such databases. Agencies
in New York State are proceeding cautiously and carefully, and this meeting DNA
Forensic Fingerprinting was held to explore the requirements of these agen-
cies. In addition, representatives of the U.S. Federal Bureau of Investigation and
the law enforcement agencies of Florida, Minnesota, and Virginia described their
systems. The meeting ended with a discussion of a pilot project to develop a
database for New York State.
Human Genome and Genetic Analysis Workshops
Banbury Center and the DNA Learning Center held the second and third in the
current series of these workshops sponsored by the Department of Energy in
1992. The format followed that established with the first workshop, namely, lec-
tures on the basics of genetics, talks by invited speakers at the Banbury Center,
and practical laboratories at the DNA Learning Center. The presentations by the
invited speakers were uniformly excellent and the participants welcomed the op-
portunity to spend time informally with scientists, genetic counselors, and
bioethicists, subjecting them to merciless questioning. An example of the
topicality of these workshops has been the presentation of talks on gene therapy
by Dr. Kenneth Culver. The first gene therapy treatments were begun in Septem-
ber 1990 on children with a disorder called adenosine deaminase deficiency. We
were delighted to welcome one of these children and her family to the workshop
in February.
Science Policy Meetings
Banbury Center's role as a meeting place to discuss science policy began some
5 years ago with an influential meeting on scientific misconduct. This year, two
fascinating meetings dealt with issues that affect the financing of scientific re-
search. The first meeting, with the rather prosaic title Indirect Costs and the In-
dependent Research Institute, was anything but dull. Indirect costs are those
expenses relating to the operating costs of an institution that are charged to a
grant, in addition to the direct costs of doing the research. Indirect costs can be
substantial, and the ire of the Oversight and Investigations Subcommittee of the
House Committee on Energy and Commerce was aroused when it appeared that
some universities were charging inappropriate items to indirect costs.
As a con-
sequence, indirect cost rates for universities came under close scrutiny and
revised rates are still being negotiated. Independent research institutions like
Cold Spring Harbor Laboratory are governed by a separate set of rules, but it
seems clear that these rules are also likely to be revised with potentially
catastrophic financial consequences for the independent research institutes.
So
we decided to hold this meeting to review the current state of
indirect cost
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charges and to assess what changes were in store and what their consequences
might be.
The second policy meeting discussed a topic of immense importance, name-
ly, research in the neurosciences, including basic research in neurobiology and
neurology. President Bush issued a proclamation declaring the 1990s the
Decade of the Brain. However, relatively little seems to have come from this initia-
tive and there seems to be an absence of leadership and coordination in exploit-
ing this proclamation. The Charles A. Dana Foundation is developing a strong in-
terest in medical neuroscience, and the Foundation provided funding for a meet-
ing entitled Funding for the Decade of the Brain. The meeting brought together
the leading players from the National Institutes of Health, the various Founda-
tions, concerned with neuroscience, and some of the leading neuroscientists to
determine what could be done. Many such meetings end on a high note, but their
impact dissipates once the participants have dispersed; there is every reason to
believe that this will not be the fate of this meeting. With the Dana Foundation
playing the role of midwife, the meeting will give birth to a movement that will
make the first decade of the 21st century (if not the 1990s) the Decade of the
Brain.
Charles A. Dana Foundation and Manic-Depressive Illness
An event of great significance for the Laboratory and for the Banbury Center was
the award of a grant from the Charles A. Dana Foundation for a program to pro-
mote research on manic-depressive illness. This program encompasses work at
the Johns Hopkins Medical School, Stanford University Medical School, and Cold
Spring Harbor Laboratory. Our part of the program, to be based at Banbury, will
involve establishing a database that includes information on all aspects of manic-
depressive illness and can be accessed by all research workers; this will be de-
veloped in collaboration with Tom Marr's group. In addition, we will develop a
meetings and courses program as well as a public information program. This
work will be a natural extension of Banbury's work on human genetics and
science education. We expect that a program director will be appointed in the
spring of 1993 and that the program will begin in earnest during the summer.
Other Meetings
As in previous years, we have made Banbury Center available to other groups.
The Lloyd Harbor Seminar Series provides an opportunity to learn something of
what goes on in the institutions that have their homes in Lloyd Harbor Village, as
well as providing a venue to hear the interesting experiences of our neighbors.
The Boards of a number of local community groups held their annual meetings
here, including the Lloyd Harbor Historical Society, the Lloyd Harbor Conserva-
tion Board Society, and Huntington Hospital. In addition, the Cold Spring Harbor
School District held a meeting here and the faculty of West Side school came for
a pre-school conference.
Funding
The Corporate Sponsors Program continues to be the foundation on which the
Banbury Center meetings program is built; six of our meetings in 1992 were
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funded by this Program: Phage Display: Engineering and Selecting Proteins;
Molecular Mechanisms of Viral Latent Infections; Oligonucleotide Manipula-
tion of Gene Expression: Its Therapeutic Potential; Control of HIV Gene Ex-
pression; Superantigens and Antigenic Presentation; and Mechanisms of
Neuronal Survival: The Action of Neurotrophic Factors. In addition, a number
of other companies contributed to meetings during the year. For example,
Repligen Corporation, Hoffmann-La Roche, and Merck Research Laboratories
contributed to the Control of HIV Gene Expression meeting. Repligen Corpora-
tion together with Abbott Laboratories contributed to the Constructing
Organisms meeting. However, private foundations continue to be major sup-
porters of our program. I have already discussed the extraordinary support that
the Alfred P. Sloan Foundation has provided during the past 14 years. The impor-
tance of such long-term support to an institution such as the Banbury Center can-
not be overemphasized.
We continue to search for a replacement. There was not time in 1992 to hold
a meeting funded by the William Stamps Farish Fund, but the first meeting of
1993 will be on the Polygenic Basis of Cancer. Here again, the 3-year support
of this foundation helps provide stability for our program. The Wellcome Trust
joined with us in holding the Constructing Organisms meeting, and the Charles
A. Dana Foundation supported what we hope and expect will turn out to be a his-
toric meeting: Funding for the Decade of the Brain.
Acknowledgments
1992 was an exceptionally busy year for the Center, especially during the fall
when we had ten meetings and were also planning and organizing the spring
1993 meetings. Bea To liver and Ellie Sidorenko in the Banbury Center office
dealt with the huge influx of participants and coped with the flood of queries,
phone calls, and faxes that accompanies every meeting. Katya Davey, hostess at
Robertson House, looked after the participants with her customary panache.
Looking Forward to 1993
To begin by looking back, 1992 marked the end of my fifth year at the Banbury
Center, and in that period, we have held 75 meetings with some 2500
participants. One of the great pleasures and virtues of the Banbury Center is that
the topics of the meetings range so widely and that the participants are equally
varied in their interests and backgrounds. Meetings and participants are unified
in their commitment to excellence and all of these factors make Banbury Center a
unique facility. As usual, the 1993 program is still being developed at this time,
but it will provide the same variety of interests and live up to those same stan-
dards, with meetings on cancer, gene therapy, neurobiology, cell death, Lyme
disease, and science policy. We will begin a new relationship with Helix Partners,
which will fund meetings on the science underlying important biotechnological
advances, and there will be the new developments on manic-depressive illness
just described. One final acknowledgment is necessary. The work of the Banbury
Center would not be possible without the support of Jim Watson and the
entire
Laboratory. My thanks, and those of everyone who comes to Banbury Center, go
to all who work on the other side of the Harbor.
Jan A. Witkowski
339

MEETINGS
Congressional/Science Journalists Workshop on the
Commercialization of Biology
January 24-January 26
FUNDED BY
Alfred P. Sloan Foundation
ARRANGED BY
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1
C. van Horn, U.S. Patent and Trademarks Office, Arlington,
Virginia: Mechanics of obtaining a patent.
R. Merges, Boston University Law School, Massachusetts:
Comparative studies of patenting in biology and other
sciences.
J. Barton, Stanford University Law School, California: Spe-
cial issues in biotechnology patenting.
G. Rathmann, ICOS, Bothell, Washington: Intellectual prop-
erty and the development of biotechnology.
SESSION 2
M. Bloom, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory: Isolation of DNA.
D. Botstein, R. Merges, R. Charrow
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SESSION 3
D. Botstein, Department of Genetics, Stanford University
School of Medicine, California: Materials and data shar-
ing between scientists: The effects of commercialization.
R. Adler, Office of Technology Transfer, National Institutes of
Health, Bethesda, Maryland: NIH's responsibilities and
role in developing scientific discoveries.
A.L. Beaudet, Howard Hughes Medical Institute, Baylor Col-
lege of Medicine, Houston, Texas: Impact of commercial
considerations on the use of DNA-based 'diagnosis of ge-
netic diseases.
SESSION 4
L.L. Nelsen, Technology Licensing Office, Massachusetts
Institute of Technology, Cambridge: Why and how do
academic institutions exploit the intellectual property of
their scientists?
H. Edgar, Columbia University School of Law, New York,
New York: Conflicts of interest in the exploitation of in-
tellectual property.
R.P. Charrow, Crowell & Moring, Washington, D.C.: Sum-
mary of issues.
Phage Display
K. Hudson
April 4-April 7
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
G. Smith, University of Missouri, Columbia
M. Zoller, Genentech, Inc., South San Francisco, California
SESSION 1
P. Model, The Rockefeller University, New York, New York:
Filamentous phage assembly.
SESSION 2: Peptides on Phage
W.J. Dower, Affymax Research Institute, Palo Alto, California:
Small peptides that mimic conformation-dependent
epitopes: Isolation from phage display libraries.
G. Cesareni, University of Tor Vergata, Rome, Italy: Peptide
libraries presented by the major coat protein of filamentous
phages.
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G. Smith, University of Missouri, Columbia: Filamentous fu-
sion and phage.
J. Scott, The Scripps Research Institute, La Jolla, California:
Performance of a hexapeptide epitope library.
R.A. Houghten, Torrey Pines Institute for Molecular Studies,
San Diego, California: The use of synthetic peptide
combinatorial libraries for drug discovery and basic re-
search.
SESSION 3: Methods and Alternative Displays
J.A. Wells, Genentech, Inc., South San Francisco, California:
Applications of phage display technology for high-affinity
and receptor selective hormone analogs.
W. Mandecki, Abbott Laboratories, Abbott Park, Illinois:
Strategies for evolving novel proteins.
J.A. Sorge, Stratagene, La Jolla, California: k13ZAP:
Filamentous surface expression with the efficiency of k
SESSION 4: Antibodies on Phage
C.F. Barbas, The Scripps Research Institute, La Jolla, Cali-
fornia: Combinatorial antibody libraries on the surface of
phage: Opportunities in therapy and antibody engineer-
ing.
D. Burton, The Scripps Research Institute, La Jolla, Califor-
nia: Phage surface antibody libraries to select anti-viral
antibodies.
D.J. Chiswell, Cambridge Antibody Technology Limited,
SESSION 5: Other Proteins on Phage
M. Zoller, Genentech, Inc., South San Francisco, California:
Phage display and mutagenesis of human tumor necrosis
factor.
C.S. Craik, University of California, San Francisco: Trypsin
phage: Display of a proteolytic enzyme.
C. Hession, Biogen, Cambridge, Massachusetts: Phage dis-
play of VCAM-1 domains: Epitope mapping of VCAM-1
antibodies.
SESSION 6: Peptides on Phage
R. Cortese, IRBM, Rome, Italy: Construction of epitope li-
braries.
V.A. Petrenko, Research and Technology Institute, Berdsk,
Russia: Inserting foreign peptides into the major coat
protein of bacteriophage M13.
R. Hoess, The Du Pont Merck Pharmaceutical Company,
Wilmington, Delaware: Using constrained peptide librar-
packaging.
W. Szybalski, McArdle Laboratory for Cancer Research,
University of Wisconsin, Madison: Phage X vectors.
M. Uhlen, Royal Institute of Technology, Stockholm,
Sweden: Display of recombinant proteins on the surface of
gram-positive bacteria.
United Kingdom: Phage display of functional protein
domains: Isolation and improvement of antibodies.
L.J. Garrard, Genentech, Inc., South San Francisco, Califor-
nia: Generation of and selection from Fab phage display
libraries.
M. Little, German Cancer Research Center, Heidelberg,
Germany: Surface expression of antibodies on phagemid
particles.
R.C. Ladner, Protein Engineering Corp., Cambridge, Massa-
chusetts: Engineering neutrophil elastase inhibitors.
H. Lowman, Genentech, Inc., South San Francisco, Califor-
nia: Selection of variants of human growth hormones from
random libraries using monovalent phage display.
J. Winter, Sandoz Crop Protection, Palo Alto, California: A
model system for surrogate receptor evaluation.
ies for epitope mapping and receptor binding.
R.N. Perham, University of Cambridge, United Kingdom: Dis-
play of foreign peptides on the surface of engineered bac-
teriophage fd: Immunological and other properties.
B. Malcolm, Chiron Corporation, Emeryville, California:
Simplified construction and assessment of peptide libraries
in bacteriophage.
/".
M. Zoller, G. Smith, Guest, R. Houghten
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Workshop on Human Genetics and Genome Analysis
February 23-February 26
FUNDED BY
Office of Health and Environmental Research, U.S. Department of Energy
ARRANGED BY
M. Bloom, DNA Learning Center, Cold Spring Harbor Laboratory, New York
D. Mick los, DNA Learning Center, Cold Spring Harbor Laboratory, New York
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Mendelian view of the gene.
J.A. Witkowski, Banbury Center, Cold Spring Harbor
Laboratory, New York: Modern view of the gene.
T.H. Murray, Case Western Reserve University School of
Medicine, Cleveland, Ohio: Ethical implications of human
molecular genetics.
SESSION 2
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory: DNA restriction en-
zymes and restriction mapping.
D. Erickson, M. Bloom
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SESSION 3
M. Bloom, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Cloning genes.
J.A. Witkowski, Banbury Center, Cold Spring Harbor
Laboratory, New York: Human molecular genetics and in-
herited disorders.
SESSION 4
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory: Transformation of E.
coif with plasmid DNA.
M. Bloom, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory: Human DNA finger-
printing by polymerase chain reaction.
SESSION 5
E. Fearon, Johns Hopkins University School of Medicine,
Baltimore, Maryland: Analyzing the molecular genetics of
cancer.
D. Micklos, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory results: Transformation
of E. co/i with plasmid DNA.
M. Bloom, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory results: DNA finger-
printing by polymerase chain reaction.
SESSION 6
K. Culver, National Institutes of Health, Bethesda, Maryland:
The first human gene therapy trials.
J.D. Watson, National Center for Human Genome Research,
Bethesda, Maryland; Cold Spring Harbor Laboratory, New K. Culver, D. Micklos, S. Cutshall
York: The Human Genome Project.
Congressional/Science Journalists Workshop
on Occupational and Environmental Health
April 10-April 12
FUNDED BY
Alfred P. Sloan Foundation
ARRANGED BY
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1
P. Landrigan, Mt. Sinai Medical School, New York, New
York: How serious is the problem and what are the eco-
nomic consequences?
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N.A. Ashford, Center for Technology, Policy and Industrial
Development, Massachusetts Institute of Technology,
Cambridge: Legal and regulatory issues in environmental
and occupational health.
B.D. Goldstein, Environmental and Occupational Health
Sciences Institute, Piscataway, New Jersey: Physicians:
Environmental and occupational health.
SESSION 2
M. Bloom, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory: DNA experiment.
SESSION 3
K. Rest, Occupational Health Program, University of Massa-
chusetts Medical Center, Amherst: Ethical aspects of oc-
cupational and environmental health.
F.W. Mirer, International Union, United Automobile Workers,
Detroit, Michigan: A practical approach to preventing oc-
cupational injury and illness.
D.P. Rall, Washington, D.C.: What can be done? The
responsibilities and activities of federal agencies.
G. Ellis, J. Witkowski
D. Liskowski, R. Borchelt, D. Vogt
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Indirect Costs and the Independent Research Institute
April 30-May 1
ARRANGED BY
J.D. Watson, Cold Spring Harbor Laboratory, New York
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1: Indirect Costs At Research Institutions
Chairperson: M.F. Singer, Carnegie Institution of Washington, D.C.
M.F. Singer, Carnegie Institution of Washington, D.C.: Intro-
ductory remarks
W. Keen, Cold Spring Harbor Laboratory, New York: Sum-
mary and review of questionnaire.
SESSION 2: Audits
Chairperson: F.J. McKay, Fox Chase Cancer Center, Philadelphia, Pennsylvania
J. O'Neill, KPMG Peat Marwick, Washington, D.C.: Audits of
indirect costs at universities.
R.D. Leedy, Fox Chase Cancer Center, Philadelphia,
Pennsylvania, and L.A. Keinath, The Wistar Institute, Phila-
delphia, Pennsylvania: Audits of indirect costs at research
institutions.
SESSION 3: Perspectives on Washington
Chairperson: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
M.F. Singer, Carnegie Institution of Washington, D.C.: A
view from the NIH Subcommittee on Indirect Costs.
J. Pratt, The Whitehead Institute, Cambridge, Massachu-
setts: Congressional players and legislative activities.
SESSION 4: Future Strategies and General Discussion
Chairperson: G.M. Browne, Cold Spring Harbor Laboratory, New York
G. Schiff, James N. Gamble Institute of Medical Research,
Cincinnati, Ohio: Role of AIRI.
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Molecular Mechanisms of Viral Latent Infections
July 6-July 9
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
B. Roizman, University of Chicago, Illinois
SESSION 1: Herpesviruses I
Chairperson: B. Roizman, University of Chicago, Illinois
B. Roizman, University of Chicago, Illinois: Introduction.
E. Kieff, Harvard Medical School, Boston, Massachusetts:
EBV latency.
G.I. Miller, Jr., Yale University School of Medicine, New
Haven, Connecticut: Mechanism of the ZEBRA protein in
the switch between latency and lytic replication of EBV.
SESSION 2: Herpesviruses II
P. Lai, Tampa Bay Research Institute, St. Petersburg, Flor-
ida: Cellular proteins that bind to on -p sequence of EBV
genome.
E.S. Mocarski, Stanford University School of Medicine, Cali-
fornia: CMV latency.
Chairperson: E. Kieff, Harvard Medical School, Boston, Massachusetts
N. Frenkel, Tel Aviv University, Ramat Aviv, Israel: Latency
and reactivation of human herpesviruses 6 and 7: In vivo
and in culture.
A.Y. Sears, University of Chicago, Illinois: Function of host-
specific origins of viral DNA replication in HSV latency.
J.G. Stevens, University of California, Los Angeles: HSV ge-
netic expression during establishment, maintenance, and
reactivation from latent infection.
J. Hay, State University of New York, Buffalo, School of Medi-
cine: Expression of varicella zoster virus genes in neural
tissues.
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SESSION 3: Papillomaviruses
Chairperson: H.S. Ginsberg, Columbia University College of Physicians & Surgeons, New
York, New York
H. zur Hausen, Deutsches Krebsforschungszentrum, Heidel-
berg, Germany: Host cell control of papillomavirus genome
persistence.
S. Vande Pol, National Cancer Institute, Bethesda,
Maryland: The bovine papillomaviruses constitutive en-
SESSION 4: RNA Viruses I
hancer is essential for transformation, DNA replication, and
the maintenance of latency.
L. Laimins, University of Chicago, Illinois: Regulation of
human papillomavirus life cycle differentiating epithe-
lium.
Chairperson: I.S.Y. Chen, University of California, Los Angeles, School of Medicine
I.S.Y. Chen, University of California, Los Angeles, School of
Medicine: Incomplete reverse transcription as a mecha-
nism for HIV-1 low-level persistence in T cells.
SESSION 5: RNA Viruses II
B.R. Cullen, Howard Hughes Medical Institute, Duke Univer-
sity Medical Center, Durham, North Carolina: Role of REV
in lentiviral latency.
Chairperson: I.S.Y. Chen, University of California, Los Angeles, School of Medicine
W. Greene, University of California, San Francisco:
Molecular analysis of HIV-1 'latency': Role of cellular tran-
scription factors in viral activation.
A.T. Haase, University of Minnesota, Minneapolis: New ex-
SESSION 6: Other RNA Viruses
perimental tools for the analysis of viral latency.
M. Stevenson, University of Nebraska Medical Center,
Omaha: Preintegration events influencing HIV-1 la-
tency.
Chairperson: R.M. Chanock, National Institute of Allergy and Infectious Diseases,
Bethesda, Maryland
J.C. de la Torre, The Scripps Research Institute, La Jolla,
California: Disturbances in host's differentiated functions
caused by a noncytolytic virus.
M.L. Nibert, Harvard Medical School, Boston, Massachu-
setts: Persistent infections of murine L cells with mam-
malian reoviruses: Coevolution of cells and viruses during
maintenance of persistent infection involves a specific
early step in the infectious cycle.
SESSION 7: AAV; Adenoviruses
Chairperson: K.I. Berns, Cornell University Medical College, New York, New York
Surgeons, New York, New York: 'How adenoviruses per-
sist.'
W.S.M. Wold, St. Louis University Medical Center, Missouri:
Adenovirus proteins that counteract CTL and
TNF/macrophage-mediated immunosurveillance.
K.I. Berns, Cornell University Medical College, New York,
New York: Integration and rescue of AAV from the in-
tegrated site.
R.J. Samulski, University of Pittsburgh, Pennsylvania: AAV
latent infection.
H.S. Ginsberg, Columbia University College of Physicians &
Oligonucleotide Manipulation of Gene Expression:
Its Therapeutic Potential
October 13-October 16
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
M. Matteucci, Gilead Sciences, Inc., Foster City, California
SESSION 1: Mechanistic, Tissue Culture, and In Vivo Antisense Results I
Chairperson: M. Matteucci, Gilead Sciences, Inc., Foster City, California
L. Neckers, National Cancer Institute, Bethesda, Maryland: In
vivo continuous intrathecal infusion of oligonucleotides:
Pharmacokinetics and efficacy.
G. Zon, Applied Biosystems, Inc., Foster City, California:
Recent investigations of antisense phosphorothioate
oligodeoxynucleotides.
Y.-C. Cheng, Yale University School of Medicine, New
Haven, Connecticut: Cellular and molecular pharmacol-
ogy of phosphorothioate oligodeoxynucleotides.
C. Stein, Columbia University College of Physicians &
Surgeons, New York, New York: Pathways of
oligonucleotide internalization in hematopoietic cell lines.
R.W. Wagner, Gilead Sciences, Inc., Foster City, California:
Understanding hurdles in oligonucleotide antisense devel-
opment.
B. Lebleu, Universite Montpellier II, Montpellier Cedex,
France: Cell targeting, transmembrane passage, and in-
tracellular distribution of antisense oligonucleotides.
SESSION 2: Mechanistic, Tissue Culture, and In Vivo Antisense Results II
Chairperson: P.S. Miller, The Johns Hopkins University School of Hygiene and Public
Health, Baltimore, Maryland
S. Agrawal, Hybridon, Inc. Worcester, Massachusetts:
Oligonucleotide phosphorothioates as antiviral agents.
R. Juliano, University of North Carolina School of Medicine,
Chapel Hill: Cellular uptake and intracellular distribution of
chemically modified oligonucleotides.
L. Arnold, Genta Inc., San Diego, California: Development of
antisense therapeutic agents.
D.J. Chin, Agouron Institute, La Jolla, California: Hybrid
complexes in living cells studied by fluorescence energy
SESSION 3: New Structural Modifications of Oligonucleotides I
Chairperson: M.H. Caruthers, University of Colorado, Boulder
P.S. Miller, The Johns Hopkins University School of Hygiene
and Public Health, Baltimore, Maryland: Interaction of base
analogs with dsDNA.
C.K. Mirabelli, ISIS Pharmaceuticals, Carlsbad, California:
Pharmacokinetics of chemically modified oligonucleotides:
Impact on therapeutic uses.
J.A. Walder, University of Iowa, Iowa City: Synthesis and
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transfer.
J.-J. Toulme, Universite de Bordeaux II, Bordeaux Cedex,
France: Efficiency and selectivity of RNase-H-mediated in-
hibition of translation and reverse transcription by
antisense oligonucleotides.
A.M. Krieg, University of Iowa, Iowa City: Effects of
oligonucleotide modification on cell binding, uptake, and
antisense efficacy.
therapeutic applications of new achiral oligonucleotide
analogs.
G. Trainor, The Du Pont Merck Pharmaceutical Company,
Wilmington, Delaware: Oligonucleotide analogs with sul-
famate and sulfamid internucleotide linkages.
H.E. Moser, Ciba-Geigy AG, Basel, Switzerland: Carbocyclic
oligonucleotides: Synthesis and properties.
C. Mirabelli, E. Saison-Behmoaras
SESSION 4: New Structural Modifications of Oligonucleotides II
Chairperson: J.A. Welder, University of Iowa, Iowa City
P.E. Nielsen, The Panum Institute, Copenhagen, Denmark:
Sequence-specific DNA recognition by peptide nucleic
acid chimera.
L.E. Babiss, Glaxo, Inc., Research Triangle Park, North
Carolina: Antisense and antigenic potentials of peptide
nucleic acid oligomers.
M.H. Caruthers, University of Colorado, Boulder: Synthesis,
biochemistry, and biological applications of new
SESSION 5: Triple Helix Results
Chairperson: H.E. Moser, Ciba-Geigy AG, Basel, Switzerland
M. Matteucci, Gilead Sciences, Inc., Foster City, California:
Phosphodiester analogs of oligonucleotides.
M.E. Hogan, Baylor College of Medicine, The Woodlands,
Texas: Triplex forming oligonucleotides.
J. Klysik, Texas A&M University, Houston: DNA triplexes.
L.-S. Kan, The Johns Hopkins University School of Hygiene
and Public Health, Baltimore, Maryland: How to increase
polynucleotide analogs.
J.H. van Boom, State University Leiden, The Netherlands: A
study directed toward the preparation and hybridization
potential of DNA fragments containing internucleosidic
methylene acetal bonds at predetermined positions.
E. Saison-Behmoaras, INSERM/CRS, Paris, France: Selec-
tive inhibition of mutation Ha-ras expression by antisense
oligonucleotides.
the stability of triplex formation.
S.F. Singleton, California Institute of Technology, Pasadena:
An analysis of the energetics of triple helix formation using
quantitative affinity cleavage titration.
D.J. Patel, Columbia University College of Physicians &
Surgeons, New York, New York: Solution structure of Y-RY
and R-RY DNA triplexes.
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DNA Repeats and Human Gene Mutations
October 18-October 21 
FUNDED BY
U.S. Department of Energy
ARRANGED BY
M. Radman, Institut Jacques Monod, Paris, France
S.T. Warren, Howard Hughes Medical Institute, Emory University School of Medicine, 
Atlanta, Georgia
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1: Human Genome: Fragile X
Chairperson: M. Radman, Institut Jacques Monod, Paris, France
disorders caused by dynamic mutation.
J. -L. Mandel, LGME/CNRS, INSERM U184, Strasbourg, 
France: Phenomenology of mutation and methylation in 
fragile-X syndrome.
K. E. Davies, John Radcliffe Hospital, Oxford, United King- 
dom: Methylation, fragile sites, and instability.
S.L. Sherman, Emory University, Atlanta, Georgia: Population 
dynamics of the fragile-X mutation.
D.L. Nelson, Baylor College of Medicine, Houston, Texas: 
Structure of the CGG repeats in FMR-1.
R.l. Richards, Adelaide Children's Hospital, North Adelaide, 
South Australia: Trinucleotide repeats in human genes: In- 
elusion by chance or necessity—Common properties of
SESSION 2: Myotonic Dystrophy
Chairperson: S.T. Warren, Emory University School of Medicine, Atlanta, Georgia
K. Johnson, Charing Cross and Westminster Medical School, 
London, United Kingdom: Characterization of the CTG 
repeat in myotonic dystrophy patients.
D. Shaw, University of Wales College of Medicine, Cardiff: 
Myotonic dystrophy—Analysis of the mutation and specula- 
tions on nature of gene product.
SESSION 3: Spinal Bulbar Muscular Atrophy
Chairperson: S.T. Warren, Emory University School of Medicine, Atlanta, Georgia
K.H. Fischbeck, University of Pennsylvania Medical School, J.-L. Mandel, LGME/CNRS, INSERM U184, Strasbourg, 
Philadelphia: The molecular genetics of X-linked spinal and France: Instability in SBMA. 
bulbar muscular atrophy.
SESSION 4: Other Sequences
Chairperson: D.L. Nelson, Baylor College of Medicine, Houston, Texas
M. Schalling, Massachusetts Institute of Technology, Cam- 
bridge: Detection of novel expanded repeats and expres 
sion of repeat containing genes.
S.T. Warren, Emory University School of Medicine, Atlanta, 
Georgia: Repeat sequences in other genes.
R. M. Cawthon, University of Utah Medical Center, Salt Lake 
City: Mutations in two tumor suppressor genes: 
Neurofibromatosis 1 and adenomatous polyposis coli.
S. S. Sommer, Mayo Clinic/Foundation, Rochester, Min- 
nesota: The underlying pattern of spontaneous human 
germ-line mutation: Lessons from the factor IX gene.
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SESSION 5: Data from Other Genomes
Chairperson: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
T.D. Petes, University of North Carolina, Chapel Hill: Genetic
control of the stability of simple repetitive yeast DNA se-
quences.
J. Armour, University of Leicester, United Kingdom: Repeat
unit turnover at human minisatellite loci.
M. Radman, Institut Jacques Monod, Paris, France:
Homologous DNA interactions in the evolution of gene and
chromosome structure.
M.A. Resnick, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina:
Genome stability: The interaction between recombination,
repair, and cell signaling.
SESSION 6: Generation of Sequence Polymorphisms
R.D. Wells, Texas A&M University, Houston: Unusual DNA
structures and repeat sequences.
R.R. Sinden, Texas A&M University, Houston: The impact of
DNA secondary structure on mutations and preferential
mutagenesis of leading and lagging strands.
M.S. Fox, Massachusetts Institute of Technology, Cam-
bridge: Mismatch repair and mutation avoidance in E.
coli.
R.M. Liskay, Yale University School of Medicine, New Haven,
Connecticut: Multiple homologs of a DNA mismatch repair
gene (MutL) in mammals and yeast.
Chairperson: K.E. Davies, John Radcliffe Hospital, Oxford, United Kingdom
E.U. Selker, University of Oregon, Eugene: Inactivation of
duplicated genes in fungi.
G. Faugeron, University of Paris-South, Orsay, France:
Cytosine methylation and gene silencing triggered by DNA
repeats.
P. Kourilsky, INSERM U277, Paris, France: The extensive
SESSION 7: Recombination in Mammalian Genes
polymorphism of the major transplantation antigens and
its possible relationship with the CpG content of MHC
genes.
T.P. Yang, University of Florida College of Medicine, Gaines-
ville: High-resolution methylation analysis of the FMR-1
repeat by genomic sequencing.
Chairperson: K.E. Davies, John Radcliffe Hospital, Oxford, United Kingdom
R.S. Kucherlapati, Albert Einstein College of Medicine,
Bronx, New York: Manipulating the mammalian genome
through homologous recombination.
H. Eisen, Fred Hutchinson Cancer Research Center, Seattle,
Washington: Use of pseudogenes and recombination in
the generation of diversity and ordered gene expression.
J.-C. Weill, Institut Necker, Paris, France: Molecular mech-
anisms involved in the generation of antibody diversity
(gene conversion, somatic mutation).
K. Davies
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Control of HIV Gene Expression
October 24-October 27
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program, Repligen
Corporation, Merck Research Laboratories, and Hoffmann-La Roche Inc.
ARRANGED BY
B.R. Cullen, Howard Hughes Medical Institute, Duke University Medical Center, Durham,
North Carolina
R. Franza, Cold Spring Harbor Laboratory, New York
F. Wong-Staal, University of California, San Diego, School of Medicine, La Jolla
SESSION 1: Infection and Integration
Chairperson: R. Franza, Cold Spring Harbor Laboratory, New York
J.P. Moore, The Aaron Diamond AIDS Research Center, New
York University School of Medicine, New York: Envelope
glycoprotein of HIV-1: Roles of HIV-1 entry into CD4+ cells
and neutralization thereof.
D.R. Littman, University of California, San Francisco: Role of
CD4 in HIV entry and pathogenesis.
H.E. Varmus, University of California, San Francisco, School
of Medicine: Retroviral integration.
SESSION 2: Cellular Factors
M. Stevenson, University of Nebraska Medical Center,
Omaha: Nuclear import of HIV-1 preintegration complexes:
Cell cycle dependence.
M.A. Martin, National Institute of Allergy and Infectious Dis-
eases, Bethesda, Maryland: Cell-to-cell virus spread.
M. Emerman, Fred Hutchinson Cancer Research Center,
Seattle, Washington: HIV infection of nondividing cells.
Chairperson: H.E. Varmus, University of California, San Francisco, School of Medicine
R. Franza, Cold Spring Harbor Laboratory, New York: Differ-
ential expression of KB-binding protein and their cellular
associates.
A.S. Baldwin, University of North Carolina, Chapel Hill: Con-
trol of NF-KB activity.
P.A. Baeuerle, Genzentrum de LMU, Martinsried, Germany:
Oxidative stress and the activation of NF-KB and HIV.
G.J. Nabel, Howard Hughes Medical Institute, University of
Michigan Medical Center, Ann Arbor, Michigan: Role of
NF-KB in HIV transcriptional initiation and virus replication.
SESSION 3: Tat and Rev I
W.C. Greene, Howard Hughes Medical Institute, Gladstone
Institute of Virology and Immunology, San Francisco,
California: NF-KB and the regulation of HIV-1 gene ex-
pression.
R.G. Roeder, The Rockefeller University, New York, New
York: Role of cellular factors in basal and Tat-induced HIV
transcription.
N. Hernandez, Cold Spring Harbor Laboratory, New York:
Formation of short transcripts in the HIV-1 LTR.
Chairperson: F. Wong-Staal, University of California, San Diego, School of Medicine,
La Jolla
B.R. Cullen, Howard Hughes Medical Institute, Duke Univer-
sity Medical Center, Durham, North Carolina: Recent in-
sights into HIV-Rev function.
R. Gaynor, University of Texas Southwestern Medical School,
Dallas: HIV DNA and RNA binding proteins.
K.A. Jones, The Salk Institute, La Jolla, California: HIV-1 tran-
scription: Tat, TAR, and cellular factors.
B.M. Peter lin, Howard Hughes Medical Institute, University
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of California, San Francisco: Tat and transcriptional
regulation of HIV.
M.F. Laspia, Cold Spring Harbor Laboratory, New York:
Trans-activation of transcription by Tat.
J. Karn, MRC Laboratory of Molecular Biology, Cambridge,
United Kingdom: Tat and rev: Chemistry of RNA binding
and biological properties in vivo and in vitro.
D. Littman, B. Cullen
SESSION 4: Tat and Rev II
Chairperson: B.R. Cullen, Howard Hughes Medical Institute, Duke University Medical
Center, Durham, North Carolina
F. Wong-Staal, University of California, San Diego, School of
Medicine, La Jolla: Role of NFRRE in HIV replication and
latency.
M. Zapp, University of Massachusetts Medical Center, Wor-
cester: Mechanisms of Tat and Rev action.
A. Frankel, Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts: Structural determinants of Tat
and Rev RNA recognition.
T.G. Parslow, University of California, San Francisco: REV
and REX.
J. Hauber, Sandoz Research Institute, Vienna, Austria: Func-
tional analysis of the HIV-1 Rev trans-activator.
G.N. Pavlakis, National Cancer Institute-Frederick Cancer
Research and Development Center, Frederick, Maryland:
Rev protein counteracts inhibitory/instability sequences
throughout the HIV-1 genome.
SESSION 5: Other Aspects
Chairperson: M.A. Martin, National Institute of Allergy and Infectious Diseases,
Bethesda,
Maryland.
R.C. Desrosiers, Harvard Medical School, Southborough,
Massachusetts: The importance of 'nonessential' genes for
AIDS pathogenesis.
J. Skowronski, Cold Spring Harbor Laboratory, New York:
HIV-1 nef gene and T-cell activation.
H. Goettlinger, Dana-Farber Cancer Institute, Cambridge,
Massachusetts: New insights regarding the function of the
R. Desrosiers, J. Skowronski
HIV-1 regulatory protein vpu.
M.H. Malim, Howard Hughes Medical Institute,
University of
Pennsylvania School of Medicine, Philadelphia: Inhibition
of HIV-1 replication using transdominant
mutants of the
viral Rev trans-activator.
E. Gilboa, Sloan-Kettering Institute,
New York, New York: In-
tracellular immunization against HIV using RNA
decoys.
K. Roeder, N. Hernandez
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Baring Brothers/Cold Spring Harbor Laboratory Executive
Conference on Aging
October 30-November 1
ARRANGED BY
J.D. Watson, Cold Spring Harbor Laboratory, New York
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New
York
SESSION 1
J.D. Watson, Cold Spring Harbor Laboratory, New York: In-
troductory remarks.
R.N. Butler, The Mt. Sinai Medical Center, New York, New
York: The longevity revolution.
SESSION 2
G.M. Martin, University of Washington School of Medicine,
Seattle: Implications of evolutionary theory for human
aging.
B.N. Ames, University of California, Berkeley: Mechanisms
of aging: Oxidation.
SESSION 3
D. Mick los and M. Bloom, DNA Learning Center, Cold
Spring Harbor Laboratory, New York: Laboratory: DNA fin-
gerprinting by PCR.
SESSION 4
S.B. Prusiner, University of California, San Francisco, School
of Medicine: Prions and neurodegenerative diseases.
D.L. Price, The Johns Hopkins University School of Medi-
cine, Baltimore, Maryland: Neurotrophic factors and aging
of the central nervous system.
C. Greider, Cold Spring Harbor Laboratory, New York: Excit-
ing developments in aging research at Cold Spring Har-
bor.
SESSION 5
D.J. Selkoe, Harvard Medical School, Brigham and
Women's Hospital, Boston, Massachusetts: Amyloid
protein and the molecular mechanism of Alzheimer's dis-
ease.
A.D. Roses, Duke University. Medical Center, Durham, North
Carolina: Alzheimer's disease: Unraveling the genetics.
D. Mick los and M. Bloom, DNA Learning Center, Cold
Spring Harbor Laboratory, New York: DNA fingerprinting
results.
D.E. Redmond, Jr., Yale University School of Medicine, New
Haven, Connecticut: Fetal tissue transplantation and
Parkinson's disease.
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B. Ames, S. Prusiner, G. Martin
Funding for the Decade of the Brain
November 4-November 6
FUNDED BY
Charles A. Dana Foundation
ARRANGED BY
W.M. Cowan, Howard Hughes Medical Institute, Bethesda, Maryland
K.R. Jamison, Washington, D.C.
F. Plum, Cornell University Medical College, New York, New York
J.D. Watson, Cold Spring Harbor Laboratory, New York
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1: The Decade of the Brain: Impact on Research
Discussion Leader: H. Pardes, New York State Psychiatric Institute, New York
Review of the genesis, intent, and funding of the Proclama-
tion on the Decade of the Brain.
L.L. Judd, University of California, San Diego, School of
Medicine, La Jolla
How the National Institutes of Health have been able to
respond.
M. Goldstein, National Institute of Neurological Diseases
and Stroke, Bethesda, Maryland
Impact on the academic community.
R.C. Collins, University of California, Los Angeles
J.B. Martin, University of California, San Francisco, School of
Medicine
S.J. Ryan, University of Southern California Medical School,
Los Angeles
Barchas, University of California, Los Angeles, School
of Medicine
W. M. Cowan, A. Aguayo, J. Watson
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SESSION 2: The Decade of the Brain: Who
Needs to be Persuaded of Its Importance?
Discussion Leader: G.M. McKhann, Johns Hopkins
University, Baltimore, Maryland
(A) Are there useful models for the Battle for the Brain?
The war on cancer
J.D. Watson, Cold Spring Harbor Laboratory, New York
The Human Genome Project
R. Cook-Deegan, National Academy of Sciences, Washing-
ton, D.C.
Alzheimer's disease
N.G. Cavarocchi, CR Associates, Washington, D.C.
The scientific community; Congress; the media; advocacy groups
K.R. Jamison, Washington, D.C.
Reaching out to influential members of business and media
D. Mahoney, The Charles A. Dana Foundation, New York,
New York
(B) Strategies for arousing the public's interest and enthusiasm
The fascination of knowing how thenormal mind works
G.M. McKhann, Johns Hopkins University, Baltimore,
Maryland
Targeting diseases
D.J. Selkoe, Harvard Medical School, Brigham and
Women's Hospital, Boston, Massachusetts
E..M. Shooter, Stanford University School of Medicine, Cali-
fornia
Economic arguments
R.J. Wyatt, National Institute of Mental Health Neuroscience
Center at St. Elizabeth's, Washington, D.C.
SESSION 3: How to Reach Specific Groups?
Discussion Leader: R.M. Rose, The John D. & Catherine T. MacArthur Foundation,
Chicago, Illinois
Advocacy groups and the scientific community
H. Pardes, New York State Psychiatric Institute, New York
Foundations
M. Goldstein, B. Metheny
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R.M. Rose, The John D. & Catherine T. MacArthur Founda-
tion, Chicago, Illinois
D. Mahoney, The Charles A. Dana Foundation, New York,
New York
Congress: Who are the key figures?
F.K. Goodwin, National Institute of Mental Health, Rockville,
Maryland
B. Metheny, South Dartmouth, Massachusetts
SESSION 4: Determination of Specific Goals
Discussion Leader: F. Plum, Cornell University Medical College, New York, New York
General Discussion:
Setting goals that have a high priority in terms of their inherent interest and importance and
that have the potential for exciting public support for the whole of the Decade of the Brain
program. This discussion emphasized (a) topics where funding would make a significant
difference; (b) why a major effort should be made to achieve these goals; (c) how to
ensure that the commitment to these goals is maintained; and (d) how to ensure that the
progress made is used to further the aims of the project.
SESSION 5: Consolidation of Goals
Discussion Leader: W.M. Cowan, Howard Hughes Medical Institute, Bethesda, Maryland
General Discussion
HOW CAN THe efforts and results of the present meeting be
used best?
What should be done by federal institutes, academic asso-
ciations, and foundations to further the aims of the
Decade of the Brain?
Can these efforts be coordinated?
What are the political dimensions?
What political strategies need to be pursued (lobbying?)?
R. Rose, R. Cook-Deegan
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Superantigens and Antigenic Presentation
November 8-November 11
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
B.T. Huber, Tufts University School of Medicine, Boston, Massachusetts
E. Palmer, National Jewish Center, Denver, Colorado
SESSION 1: Bacterial SAG/MHC/TCR Interaction
Chairperson: R.J. Hodes, National Cancer Institute, Bethesda, Maryland
J.W. Kappler, Howard Hughes Medical Institute, National
Jewish Center, Denver, Colorado: Structural featuresof su-
perantigens.
S. Swaminathan, VA Medical Center, Pittsburgh, Pennsyl-
vania: The crystal structure of staphylococcal enterotoxin
B.
J.D. Fraser, University of Auckland School of Medicine, New
Zealand: Structural studies of staphylococcal enterotoxins
A and E. Functional domains involved in TcR and MHC
SESSION 2: T-cell Interaction with SAG
binding.
D.R. Karp, University of Texas Southwestern Medical Cen-
ter, Dallas: Distinct binding sites on HLA-DR for invariant
chain and staphylococcal enterotoxins.
R.S. Geha, Children's Hospital, Boston, Massachusetts: Sig-
nal transduction via la (MHC class II) molecules.
N.S. Braunstein, Columbia University College of Physicians &
Surgeons, New York, New York: T-cell recognition of MHC
molecules.
Chairperson: E. Palmer, National Jewish Center, Denver, Colorado
S.R. Webb, The Scripps Research Institute, La Jolla, Califor-
nia: Mls antigens: Immunity and tolerance.
R. Abe, Naval Medical Research Institute, Bethesda,
Maryland: Role of superantigens in T-cell receptor-
mediated signaling and T cell repertoire selection.
D. Woodland, St. Jude Children's Research Hospital,
Memphis, Tennessee: MHC-restricted recognition of su-
perantigens.
M. Blackman, St. Jude Children's Research Hospital,
Memphis, Tennessee: Role of the TCR a chain in recogni--
tion of superantigens.
E. Simpson, Clinical Research Centre, Harrow, Middlesex,
United Kingdom: Effect of endogenous superantigens on T
cell repertoire selection of transgenic mice.
K. Tomonari, Clinical Research Centre, Harrow, Middlesex,
United Kingdom: V13 repertoire and viral superantigens.
Discussion: R.J. Hodes, National Cancer Institute, Bethesda,
Maryland and J. Sprent, The Scripps Research Institute, La
Jolla, California
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SESSION 3: Retroviral Biology
Chairperson: H. Diggelmann, Swiss Institute for Experimental Cancer Research,
Epalinges, Switzerland
S.R. Ross, University of Illinois College of Medicine, Chica-
go: Endogenous superantigen expression protects mice
against MMTV infection.
H. Acha-Orbea, Ludwig Institute for Cancer Research,
Lausanne, Switzerland: Infectious minor lymphocyte
stimulating antigens.
H.C. Morse, National Institute of Allergy and Infectious Dis-
eases, Bethesda, Maryland: Murine AIDS: Possible role of
an MLV superantigen in pathogenesis.
SESSION 4: Control of MMTV Expression
Chairperson: A. Korman, Institut Pasteur, Paris, France
G.J. Thorbecke, New York University Medical Center, New
York: MTV- encoded superantigen expression in B
lymphoma cells in SJL mice as a stimulus for 'reverse im-
munosurveillance.'
J.S. Butel, Baylor College of Medicine, Houston, Texas:
Characterization of the MMTV LTR ORF gene product.
P. Jolicoeur, Clinical Research Institute of Montreal,
Quebec, Canada: Is Pr65 GAG protein of the murine AIDS
virus a superantigen?
B. T. Huber, Tufts University School of Medicine, Boston,
Massachusetts: Biology of MTV-7 SAG expression.
P.-A. Cazenave, Institut Pasteur, Paris, France: Polymor-
phism of TCR V13 regions and clonal deletions in wild
mouse populations.
R.B. Corley, Duke University Medical Center, Durham, North
Carolina: Regulation of MMTV genes and gene products in
cells of the B lineage.
W.H. Gunzburg, Institute of Molecular Virology, Neuherberg,
Germany: MMTV-encoded naf and superantigen ac-
tivities: Different functions of the same gene?
SESSION 5: Viral Superantigens in Humans
Chairperson: J. Sprent, The Scripps Research Institute, La Jolla, California
D.N. Posnett, Cornell University Medical College, New York,
New York: Is HIV-1 associated with a superantigen?
R.-P. Sekaly, Clinical Research Institute of Montreal,
Quebec, Canada: Structure-function interaction of bacterial
and viral superantigens with human T cells.
D. Primi, Conbiotec-Laboratory of Biotechnology, Brescia,
Italy: Role of superantigens in human infections.
M. Lafon, Institut Pasteur, Paris, France: Evidence for a viral
superantigen in humans: The rabies virus nucleocapsid.
B.L. Kotzin, National Jewish Center, Denver, Colorado: Su-
perantigens in human autoimmune diseases.
P. Marrack, Howard Hughes Medical Institute, National
Jewish Center, Denver, Colorado: Control of VP bearing
cells in man.
E. Palmer, E. Simpson
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Constructing Organisms
November 13-November 16
FUNDED BY
The Wellcome Trust, Repligen CorporatiOn and Abbott Laboratories
ARRANGED BY
M. Bate, University of Cambridge, United Kingdom
A. Martinez-Arias, University of Cambridge, United Kingdom
SESSION 1: Gene Expression and Allocation of Cell Fates in Early Embryos
E.H. Davidson, California Institute of Technology, Pasadena:
Cell interaction and gene expression in the initial specifica-
tion of lineage founder cells in the sea urchin embryo.
M. Fuller, Stanford University School of Medicine, California:
Control of cell division and subcellular morphogenesis
during spermatogenesis.
E. Wieschaus, Princeton University, New Jersey: Mor-
phogenetic movements during gastrulation in Drosophila.
H. Jaeckle, Max-Planck-Institute of Biophysical Chemistry,
Gottingen, Germany: Positional information: Complex inter-
actions of transcriptional activators and repressors in
Drosophila.
SESSION 2: Patterning the Nervous System
M. Bate, University of Cambridge, United Kingdom: Intro-
duction.
T.M. Jessell, Howard Hughes Medical Institute, Columbia
University, New York, New York: Signals that control
neural cell pattern in vertebrates.
J.A. Campos-Ortega, University of Cologne, Germany:
Mechanisms of early neurogenesis.
Y.-N. Jan, Howard Hughes Medical Institute, University of
T. Doniach, University of California, San Francisco: Induc-
tion of anteroposterior neural pattern in Xenopus.
S. Cohen, Howard Hughes Medical Institute, Baylor College
of Medicine, Houston, Texas: Allocation of the imaginal
disc primordia in the Drosophila embryo.
G. Jurgens, University of Munich, Germany: Early events
in apical-basal pattern formation in the Arabidopsis em-
bryo.
N. Hopkins, Massachusetts Institute of Technology, Cam-
bridge: Genetic approaches to early vertebrate develop-
ment using zebrafish.
California, San Francisco: Mechanisms shared by neural
development, sex determination, and oogenesis
in Drosophila.
C.Q. Doe, University of Illinois, Urbana: The role of wing-
less/wrt-1 in Drosophila neural precursor formation and
specification.
A. McMahon, Roche Institute of Molecular Biology, Nutley,
New Jersey: Cell signalling in CNS development.
E. Macagno, N. Hopkins, K. Howard
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E. Wieschaus
M.J. Stern, Yale University, New Haven, Connecticut: Con-
served signaling systems controlling cell migration and cell
fate determination in C. elegans.
E. Macagno, Columbia University, New York, New York:
Factors affecting the assembly of the nervous system of
the leech: Neuron-neuron and neuron-target interactions.
M.C. Raff, University College London, United Kingdom:
SESSION 3: Cell Behavior during Development
K. Howard, Roche Institute of Molecular Biology, Nutley,
New Jersey: Introduction.
V. Hartenstein, University of California, Los Angeles: Em-
bryonic development of the Drosophila head.
J.W. Fristrom, University of California, Berkeley: Functional
requirements for changes in cell shape.
Control of a neural cell death and survival.
D. Ready, Purdue University, West Lafayette, Indiana: The
cytoskeleton in Drosophila eye development.
I.A. Meinertzhagen, Dalhousie University, Halifax, Nova
Scotia: Dendritic retraction, sprouting, and reactive synap-
togenesis: Evidence for growth factors in the lamina of
Drosophila?
H. Skaer, University of Cambridge, United Kingdom: Cell in-
teractions in Malpighian tubule development during
Drosophila embryogenesis.
M. Ashburner, University of Cambridge, United Kingdom:
Concluding remarks.
M. Raff, T. Jessell
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Mechanisms of Neuronal Survival: The Action of
Neurotrophic Factors
November 19-November 22
FUNDED BY
Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY
M. Furth, Regeneron Pharmaceuticals, Inc., Tarrytown, New York
R. McKay, Massachusetts Institute of Technology, Cambridge
SESSION 1: Themes and Variations-Neurotrophins, CNTF, and Beyond
Chairperson: M. Furth, Regeneron Pharmaceuticals, Inc., Tarrytown, New York
M. Furth, Regeneron Pharmaceuticals, Inc., Tarrytown, New rytown, New York: The receptors and signaling pathways
York: Introductory remarks. that neurotrophic factors use to keep neurons alive.
L.A. Greene, Columbia University College of Physicians & S. Landis, Case Western Reserve University, Cleveland,
Surgeons, New York, New York: Neurotrophins and sur- Ohio: Regulation of neurotransmitter phenotypes by
vival of cell bodies and axons. neurokines.
G.D. Yancopoulos, Regeneron Pharmaceuticals, Inc., Tar-
SESSION 2: Neurotrophins and Their Receptors
Chairperson: G.D. Yancopoulos, Regeneron Pharmaceuticals, Inc., Tarrytown, New York
B. Hampstead, Cornell University Medical College, New responses of trk family members to neurotrophins.
York, New York: Functions of NGF receptors. C. Ibanez, Karolinska Institute, Stockholm, Sweden:
M. Barbacid, Bristol-Myers Squibb Pharmaceutical Re- Structure-function relationships of neurotrophins and their
search Institute, Princeton, New Jersey: The trk family of receptors.
neurotrophin receptors. P. Barker, Stanford University School of Medicine, California:
D.R. Kaplan, National Cancer Institute-Frederick Cancer Re- Tissue specific alternative splicing generates two isoforms
search and Development Center, Maryland: Neuronal sig- of the trkA receptor
nal transduction by trk receptors. A. Rosenthal, Genentech, Inc., South San Francisco, Califor-
D. Soppet, National Cancer Institute-Frederick Cancer Re- nia: NT-5, and beyond?
search and Development Center, Maryland: Differential
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SESSION 3: Actions and Regulation of Neurotrophic Factors In Vivo
Chairperson: M.E. Hatten, Columbia University College of Physicians & Surgeons, New
York, New York
R.M. Lindsay, Regeneron Pharmaceuticals, Inc., Tarrytown
New York: Neurotrophic factors from culture to the clinic.
K. Nikolics, Genentech, Inc. South San Francisco, Califor-
nia: Developmental regulation of neurotrophin receptors.
H. Persson, Karolinska Institute, Stockholm, Sweden:
Regulation of neurotrophins and their receptors.
F. Hefti, University of Southern California, Los Angeles:
Physiological role and neuroprotective actions of
neurotrophins in the adult brain.
C. Gall, University of California, Irvine: Regulation of
neurotrophin expression: Evidence for cellular specificity
in the response properties of forebrain neurons.
F.H. Gage, University of California, San Diego, La Jolla: Cell
survival and regeneration in the adult brain.
L. Williams, The Upjohn Company, Kalamazoo, Michigan: Ef-
fects of NGF on cholinergic transmission in the young and
aged rat.
SESSION 4: Interactions of Neuronal Precursors and Neurotrophic Factors
Chairperson: S. Landis, Case Western Reserve University, Cleveland, Ohio
D.J. Anderson, Howard Hughes Medical Institute, California
Institute of Technology, Pasadena: Acquisition of NGF-
responsiveness and NGF-dependence by embryonic
sympathetic neurons.
S. Weiss, University of Calgary, Alberta, Canada: Growth fac-
tor regulation of CNS stem cells and progeny in vitro.
M.E. Hatten, Columbia University College of Physicians &
Surgeons, New York, New York: Control of cerebella
granule cell neurogenesis and differentiation.
D. Lindholm, Max-Planck-Institute for Psychiatry, Munich,
Germany: Neurotrophins in rat cerebellum: Action and
regulation.
R. McKay, Massachusetts Institute of Technology, Cam-
bridge: Neurotrophin responses in CNS precursor cells.
SESSION 5: Signal Transduction Mechanisms
Chairperson: M. Barbacid, Bristol-Myers Squibb Pharmaceutical Research Institute,
Princeton, New Jersey
M.E. Greenberg, Harvard Medical School, Boston, Massa-
chusetts: Neurotrophin regulation of gene expression dur-
ing cell growth and differentiation.
H. Nawa, Cold Spring Harbor Laboratory, New York:
Regulation of neuropeptide expression by BDNF.
T. Pawson, Mt. Sinai Hospital, Toronto, Ontario, Canada:
SH2 and SH3 domains in signal transduction.
J. Schlessinger, New York University Medical Center, New
York: Signal transduction by receptors that regulate
tyrosine phosphorylation.
S. Green, University of Iowa, Iowa City: Convergence and
specificity in intracellular signaling in PC12 cells.
M. E. Hatten, M. Greenberg
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SESSION 6: Mechanisms of Neuronal Death
Chairperson: R. McKay, Massachusetts Institute of
Technology, Cambridge
D. Hockenbery, Fred Hutchinson Cancer Research
Center,
Seattle, Washington: Regulation of cell death and
the ac-
tion of bd-2.
S. Estus, Washington University Medical School, St.
Louis,
Missouri: Studies of gene expression in neurons undergo-
ing programmed cell death.
E.W. Rubel, University of Washington, Seattle: Afferent
regulation of neuronal life and death: Plasticity of cytoplas-
mic organelles.
M.A. Bothwell, University of Washington, Seattle: Ribosome
structural changes: An early event in neuronal cell death.
R. McKay, Massachusetts Institute of Technology, Cam-
bridge: Concluding remarks.
Workshop on Human Genetics and Genome Analysis
December 6-December 9
FUNDED BY
Office of Health and Environmental Research, U.S. Department of Energy
ARRANGED BY
M. Bloom, DNA Learning Center, Cold Spring Harbor Laboratory, New York
D. Mick los, DNA Learning Center, Cold Spring Harbor Laboratory, New York
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Mendelian view of the gene.
J.A. Witkowski, Banbury Center, Cold Spring Harbor
Laboratory, New York: Modern view of the gene.
N. Press, University of California, Los Angeles, Medical Cen-
ter: Population screening for genetic diseases.
J. Botkin, P. Ward
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SESSION 2
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory: Using restriction en-
zymes and constructing chromosome maps.
SESSION 3
M. Bloom, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Cloning genes.
J.A. Witkowski, Banbury Center, Cold Spring Harbor
Laboratory, New York: DNA diagnosis of human genetic
diseases.
P. Ward, Baylor College of Medicine, Houston, Texas:
Counseling for human genetic diseases.
SESSION 4
M. Bloom, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory: Human DNA finger-
printing by polymerase chain reaction.
D. Mick los, DNA Learning Center, Cold Spring Harbor
Laboratory, New York: Laboratory: Inserting DNA into
bacteria and making gene libraries.
SESSION 5
D. Mick los and M. Bloom, DNA Learning Center, Cold
Spring Harbor Laboratory, New York: Laboratory Results:
Inserting DNA into bacteria and human DNA fingerprint-
ing.
K. Culver, National Institutes of Health, Bethesda, Maryland:
The first human gene therapy trials.
SESSION 6
R. Davis, Cold Spring Harbor Laboratory, New York: Search-
ing for the genetic basis of learning and memory.
J. Forehand, V. Logan, M. Bloom 367
DNA Forensic Fingerprinting
December 13-December 15
FUNDED IN PART BY
New York State Division of Criminal Justice Services
ARRANGED BY
J. Ballantyne, Suffolk County Crime Laboratory, Hauppauge,
New York
T. Marr, Cold Spring Harbor Laboratory, New York
P.F. Palmedo, Long Island Research Institute, Setauket, New York
SESSION 1: Overview of Policies and Strategies
Chairperson: V. Crispino, Suffolk County Crime Laboratory, Hauppauge, New York
J.W. Hicks, Federal Bureau of Investigation Laboratory,
Washington, D.C.: Federal and national systems.
R. Girgenti, New York State Division of Criminal Justice Ser-
vices, Albany: New York State.
SESSION 2: Review of Current Systems
Chairperson: V. Crispino, Suffolk County Crime Laboratory, Hauppauge, New York
J.R. Brown, Federal Bureau of Investigation Laboratory,
Washington, D.C.: The FBI system.
J.D. Ban, Virginia Division of Forensic Sciences, Richmond,
Virginia: The State of Virginia.
D. Coffman, Florida Department of Law Enforcement, Tal-
lahassee: The State of Florida.
F.C. Dolejsi, Minnesota Department of Public Safety, St.
Paul: The State of Minnesota.
J. Hicks, P.F. Palmedo
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SESSION 3: Review of New York State Laboratories
Chairperson: R. Girgenti, New York State Division of Criminal Justice Services, Albany
R. Horn, New York State Police Crime Laboratory, Albany
B. Duceman, New York State Police Crime Laboratory, Al-
bany
J. Ballantyne, Suffolk County Crime Laboratory, Hauppauge,
New York
J.P. Simich, Erie County Central Police Services, Buffalo,
New York
S. Wan lass, Nassau County Police Department, Mineola,
New York
L. Duffy, Westchester County Department of Laboratories
and Research, Valhalla, New York
SESSION 4: Developments in Computer Databases
Chairperson: K.L. Monson, FBI Academy, Quantico, Virginia
T.G. Marr, Cold Spring Harbor Laboratory, New York: New
database technologies.
M. Cinkosky, Los Alamos National Laboratory, New Mexico:
Ten year's experience with running an international
genetics database.
S.T. Smith, Los Alamos National Laboratory, New Mexico:
Comments on computer security.
SESSION 5: Presentation and Discussion of Pilot Project
Discussion Leader: T.G. Marr, Cold Spring Harbor Laboratory, New York
T. Marr, K. Monson
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During his tenure as founding director of the National Center for Human Genome
Research, Laboratory Director James Watson called for at least 3% of genome
research funds to be devoted to examining the ethical, legal, and social implica-
tions of genetics research. This was a bold and unprecedented step to tie
biological research directly to its social effects. Dr. Watson's sensitivity to the so-
cial issues of genetics was heightened by his knowledge of its history. Indeed,
the New York metropolitan area provides an especially good vantage point from
which to examine the striking parallel between the rapid advance of molecular
genetics and its applications to human disease in the last several decades of the
20th century, and the explosive birth of modern genetics and its applications to
eugenics during the first several decades of the century.
The era of modern genetics began in 1900 with the rediscovery of Mendel's
laws, which had laid dormant in an obscure European journal since 1865. Re-
searchers who were then trying to recreate evolutionary processes under con-
trolled conditions-the so-called experimental evolutionists-were quick to adopt
Mendelian genetics as a tool for analyzing inheritance in their laboratory plants
and animals. From such a background came Thomas Hunt Morgan, whose group
at Columbia University was largely responsible for elaborating the mechanisms of
Mendelian inheritance, and Charles Davenport, director of the Station for Experi-
mental Evolution at Cold Spring Harbor (the forerunner of the current Laboratory)
from 1904 to 1924. Davenport and other early practitioners of genetics also had
backgrounds in plant and animal breeding. Thus, the Station for Experimental
Evolution resembled an experimental farm, complete with cornfields, hen houses,
and grazing sheep.
The Station for
Experimental Evolution
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genetics
to human inheritance. Davenport helped usher in the study of human
tics with a 1907 publication in the journal Science explaining the inheritance
of blue and brown eye color, and he later published papers on epilepsy, Hunting-
ton's chorea, albinism, and neurofibromatosis. Mendelian analysis of human
characteristics merged easily with the growing eugenics movement, founded in
Europe in the late 1800s, which Davenport aptly described as "the science of hu-
man improvement through better breeding." in 1910, Davenport obtained
sponsorship from the widow of E.H. Harriman (the railroad robber baron) to es-
tablish a Eugenics Record Office at Cold Spring Harbor. Until its disbandment in
1940, the Eugenics Record Office was the epicenter of the American eugenics
movement, training eugenics field workers to collect pedigree data and amass-
ing 750,000 genetic records. The institution also provided advice "concerning the
eugenical fitness of proposed marriages"; eugenic family histories were fash-
ionable among families who could afford the cost. By 1920, Eugenics exhibitions
and "Fitter Families Contests," appraising the genetic quality of human families,
were found alongside livestock and produce competitions at state fairs.
The eugenicists were not content merely to chart human inheritance or hag-
gle over whose families were fittest, they began to develop very definite ideas
about what constituted the right genetic stuff. Equipped with "scientific" studies
purporting to show the Mendelian inheritance of socially unacceptable traits such
as nomadism, feeblemindedness, violent temper, lack of moral control, and shift-
lessness, they began to force through restrictive and coercive eugenics legisla-
tion. Eugenicists' "data" on the genetic inferiority of Jews, blacks, Asians, and
southern and eastern European immigrants provided the "scientific" basis for the
Johnson Immigration Restriction Act of 1924, which effectively closed the flood-
gate on the waves of early 20th century immigrants who arrived primarily at Ellis
Island, New York, and from whom a majority of Americans living today are de-
scended. By 1931, 30 American states had laws allowing the involuntary steriliza-
tion of sex offenders and habitual criminals, as well as the insane and mentally
retarded. Historians now believe these mandates were also used as an excuse to
sterilize individuals on the basis of race and socioeconomic status. Germany
passed its first law for the compulsory sterilization of "hereditary defectives" in
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1933; children of mixed race were sterilized beginning in 1937; euthanasia of
children with birth defects commenced in 1938; and "special actions" to ex-
terminate Jews, Gypsies, and other "undesirable elements" began in 1941.
It is easy to dismiss the eugenics movement as pure quackery that could
never again be foisted upon society. However, eugenics was branded only in
retrospect. In its time, the eugenics movement was respectfully regarded as
bona fide science and drew into its circle a number of eminent scientists,
philanthropists, and institutions. The recent "ethnic cleansings" in Cambodia and
the former Yugoslav Republics illustrate the ever-present potential for abuse of
personal freedom in a social climate that values racial purity.
The Social Consequences of Genetic Screening
Perhaps the most immediate social challenge presented by the Human Genome
Project will come from the rapid growth of mass genetic screening to detect
asymptomatic individuals at risk of developing a disease or of passing a disease
gene on to offspring. DNA-based tests are now available for approximately 40
genetic diseases, but the current expense of such tests limits screening primarily
to individual families with known risk factors. As technology becomes less ex-
pensive, population genetic screening should become as commonplace as
cholesterol screening is today. Nobel laureate Walter Gilbert, who discovered a
key method for sequencing genes, predicts that routine screening will be avail-
able for as many as 50 genetic conditions by the year 2000 and for several thou-
sand diseases by 2010.
Retrospective studies of the first mass-screening programs of the
1970s-notably for Tay-Sachs disease and sickle cell anemia, as well as con-
temporary programs for screening neural tube defects and X-linked dis-
orders-confirm several dangers to be faced as genetic screening becomes
widely available:
Acceptance of genetic screening correlates with increased income and
formal education.
Understanding and retention of genetics information presented by medical
professionals correlates with increased income and formal education.
Families with greater increased income and formal education are less will-
ing to accept the risk of bearing a disabled child.
Misunderstanding and misinformation about carrier status can stigmatize
asymptomatic carriers as being at increased risk for medical problems and
subject them to employment and insurance discrimination, as well as
psychological distress.
Many women who receive a positive screening result indicating the possi-
bility of a serious genetic defect in their unborn fetus show little under-
standing of the testing process, the seriousness of the situation, or
their
options. These women regard the discovery of an unexpected
genetic de-
fect as a medical emergency, whose resolution should be decided by
their
doctor, rather than as a potential ethical dilemma for themselves.
These results are consistent with National Science
Foundation studies con-
ducted over the last three decades, showing that scientific literacy
and attention
to scientific information correlate with increased income and formal education.
In
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conglom erate, the data suggest that a clin ic or docto r’s o ffice is not the proper 
context for a first exposure to genetic testing and that pub lic  education 
cam paigns and counseling primarily affect those individuals w ith some pre- 
exposure to genetics concepts. Poorer and less educated ind ividuals are more 
likely to forego genetic testing or cede decisions about genetic testing to their 
doctors. This suggests a frightening scenario in which poorer and less educated 
fam ilies face an increasing burden of genetic disease, driv ing them further into 
disadvantage.
Funding from the Ethical, Legal, and Social Issues Program of the Human 
Genome Project is currently focused on informed patient consent to genetic test- 
ing and protection of private genetic records. Many argue that these issues have, 
in fact, already been thoroughly examined in sim ilar contexts of general m edi- 
cine. However, relatively little funding has been devoted to the problem  of build- 
ing a genetically literate public that understands elements of personal genetic 
health and partic ipates effectively in policy issues of genetic information. Even 
the most informed of our great private foundations involved in education and so- 
cial policy still regard genetics as an essentially scientific problem . They have yet 
to internalize the looming social im pacts—both hopeful and d istressing—of genet- 
ic m edicine at the close of the 20th century.
Extending our Expertise to Minority and Disadvantaged Settings
If we accept the prem ise that m inority populations stand the greatest risk of 
being excluded from the benefits and harmed by the m isuse of genetic technol- 
ogy, then genetic literacy issues are especially relevant to the metropolitan New 
York area, an historical melting pot of minority, racial, and ethnic groups. 
Minorities com pose 64% of 1.3 million precollege students enrolled in pub lic  
schools in New York City, Nassau County, and Suffolk County. Many of these 
children are ill-prepared by home experiences when they enter elem entary 
school and are at elevated risk of educational failure. Stigm atized as slow 
learners, at-risk students are often given remedial exercises that do little to devel- 
op problem-solving skills or to p lace learning in the context of their own interests 
and experiences. Thus, they fall further and further behind throughout elementary 
and secondary school. This vicious cycle appears to a ffect science interest and 
aptitude disproportionately; the percentage of minorities receiving undergraduate 
and graduate degrees in scientific d iscip lines is far below  their representation in 
the general population.
We believe that genetics is an especially appropria te  vehicle to reconnect mi- 
nority/disadvantaged students with science. As a paradigm  of "whole learning," 
genetics offers an almost unparalleled opportunity to integrate concepts across 
discip lines and to relate technology to an ind iv idual’s life and culture. Genetics 
issues entail d iscussions of personal autonomy, allocation of pub lic  resources, 
and equity for women, minorities, and the disabled. Em phasizing sensitivity to mi- 
nority and disabled issues of genetics is consistent with the ob jectives of the 
Americans with Disabilities Act and New York C ity ’s so-called "rainbow cur- 
riculum." The DNA Learning Center’s (DNALC) m inority/d isadvantaged outreach 
is an interdisciplinary m icro-application of the princip les em bodied in the Ac- 
celerated Schools Project of Stanford University and the Center for Educational 
Innovation of the Manhattan Institute. These and other projects have "rescued" ur- 
ban schools from the downward spiral into academ ic failure by em phasizing aca- 
dem ic acceleration, teacher innovation, and com m unity involvement.
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With DNA summer camp
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disadvantaged students
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his younger sister.
The recruitment of minority educator Robert Willis, in July, allowed us to ini-
tiate a measured, substantive response to the problems of minority/disadvan-
taged genetics education. With support from the William Randolph Hearst Foun-
dation and the Barker Welfare Foundation, three Fun With DNA summer camps
were held in August serving 54 minority and disadvantaged students from ten
Long Island schools. Contributions from Long Island businesses allowed us to
provide scholarships for 155 students to attend laboratory field trips to the
Bio2000 Laboratory during the academic year.
Advance planning was completed on an Intensive Enrichment Program,
which will become our major vehicle to provide in-school and supplemental
resources to support the science literacy needs and career aspirations of minori-
ty and disadvantaged students in the New York metropolitan area. The object is
to use genetics as a focal point for accelerated science instruction extending
from upper elementary through high school. Five Resource Clusters of
elementary and middle schools will be built around hub high schools in Harlem,
Brooklyn, Queens, the Bronx, and mid-Long Island. Each of the five hub high
schools will maintain basic equipment sets needed for genetics laboratories to
be shared with elementary and middle schools in their Resource Cluster. Special-
ized equipment will be available on loan from the DNALC for advanced experi-
ments and student research projects. Faculty will receive training during the sum-
mer through the DNALC's established workshops. Modeling of teaching
strategies by DNALC staff and easy availability of technical support will
lead In-
tensive Enrichment teachers into independent instruction.
Wealthy school districts of Long Island have been the proving ground and ini-
tial beneficiaries of the DNALC's curricula and teacher training.
Thus, we also en-
vision a "Robin Hood" aspect to the Intensive Enrichment program
through which
these wealthy school systems can work together with resource-poor
school sys-
tems to promote excellence in science education. A number of Long
Island
school districts with well-established genetics instruction have agreed to be part-
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mentoring, and cooperative student projects. Previously trained faculty in the
partner districts will be linked in a resource group with Intensive Enrichment fac-
ulty to stimulate innovation, curriculum coordination, and resource sharing across
grade levels.
We also want to help establish the Intensive Enrichment schools as "com-
munity science centers" to provide continuing genetics education to parents and
community members. By stimulating collaboration between teachers, parents,
community service groups, genetics researchers, genetic counselors, and genet-
ic disease foundations/support groups, we hope to develop community infra-
structures to support diffusion of public health messages. We intend to rotate to
each Resource Cluster our mobile mini-exhibit on genetics-the Genetic Video
Arcade. The arrival of the exhibit will create a significant "event" around which to
organize a rich program of in-school field trips and seminars, student
laboratories, and a community genetics fair. Analogous to a student science fair,
the community genetics fair would include a number of public events, including
seminars, panel discussions, dramatic presentations, debates, mock trials, stu-
dent laboratory demonstrations, and research projects.
An Educational Imperative
Modern constructivist and cognitive models of learning assert that individuals
build knowledge by integrating new information into a pre-existing network of as-
sociations. According to these models, decisions about personal and social im-
pacts of genetics must be tied to pre-existing knowledge and value systems de-
veloped during childhood and adolescence. This line of reasoning leads to the
inescapable conclusion that the precollege school system must be responsible
for ensuring that all school children receive sufficient pre-exposure to genetics to
empower their future decision-making. This conclusion has been echoed at least
twice in the last two decades in the strong recommendations of a 1975 National
Academy of Sciences panel and a 1983 Presidential Commission:
It is essential to begin the study of human biology, including genetics and
probability, in primary school, continuing with a more health-related program
in secondary school.... Sufficient knowledge of genetics, probability, and
medicine leading to appropriate perceptions of susceptibility to and serious-
ness of.genetic disease and of carrier status cannot be acquired as a con-
sequence of incidental, accidental, or haphazard learning.
Efforts to develop genetics curricula [at all levels] and to work with educators
to incorporate appropriate materials into the classroom...should be furthered.
The knowledge imparted is not only important in itself but also promotes
values of personal autonomy and informed public participation.
There is growing awareness among educators that a basic understanding of
genetics, disease risk, and health choices is an essential element of cultural liter-
acy-as important in the education of a developing child as is a basic under-
standing of hygiene and nutrition. Systematic genetics education should begin in
elementary school with principles of human variability, inheritance, and disease
risk; progress in middle school to more formal aspects of Mendelian analysis,
modern gene manipulation, and genetic testing; and culminate in high school
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with elements of gene regulation and signal transduction. This effort would fulfill
three important objectives, which essentially parallel student development:
To inculcate basic tenets of genetic literacy that are essential for all
students as they assume management of personal and family health care
as adults.
To help prepare college-bound students for their future roles as opinion
leaders in government, industry, education, medicine, and law.
To maintain and broaden the interest of the approximately 15% of
science-interested students who are intent on biology or health-related
majors, and to stimulate this interest in other motivated students.
Teacher Training and Evidence of Success
The social imperative of the Human Genome Project demands the development
of teaching resources capable of bringing science education into the gene age.
However, the majority of precollege teachers in the United States have been out
of college for 10-20 years, precisely the period of explosion in genetic biology.
The majority of all 10th to 12th grade science teachers have completed a
Master's degree, generally needed for salary advancement and tenure, so fewer
are returning to college for continuing education. At the same time, evidence
suggests that most teachers rely heavily on textbooks, which tend to emphasize
the formal aspects of Mendelian inheritance using plant and animal examples.
With these problems in mind-and in advance of the Human Genome Pro-
ject-the first major precollege training programs in molecular genetics were
initiated in 1985, notably here and at Georgetown University. Our analysis of a
genetics education database developed by the National Academy of Sciences
indicates that there are now approximately 30 major, ongoing training programs
for precollege teachers in genetics/biotechnology that are administered through
academic institutions in the United States. The majority of these programs focus
on molecular genetic techniques, are targeted at the high school level, and are
clustered in the urban east, California, and several midwestern states. Most train-
ing programs include the "core" techniques of transformation (putting DNA into
bacteria), restriction (cutting DNA with enzymes), and ligation (recombining
DNA). Student laboratories on these core techniques were not taught prior to
1985, and gearing up for them entails significant teacher investment in supplies,
equipment, and time.
The rapid adoption of these relatively sophisticated laboratories in molecular
genetics at the advanced high school level provides a clear example of the
dramatic effects of teacher training, especially when coupled with a national
mandate for innovative instruction. Follow-up surveys of 443 faculty trained by
DNALC staff in 1987-1988 showed that significant numbers had implemented
laboratories on transformation (35%), restriction (25%), and ligation (18%) during
the school year following their workshop experience. The notion that
hands-on
experience in molecular genetics is essential for college-bound
students was
legitimized in 1989, when the Educational Testing Service recommended
two of
the core DNA manipulation laboratories for students who take the
nationally ad-
ministered Advanced Placement Biology curriculum. Following
this mandate,
Implementation of the core laboratories rose
substantially for 242 teachers
trained in 1989-1990: 51% for transformation, 42% for restriction,
and 27% for
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ligation. Extrapolating these rates to the estimated 3,500 American teachers
trained thus far suggests that there are approximately 100,000 precollege stu-
dent exposures to core DNA manipulation laboratories annually, and $2 million
are spent on needed equipment, supplies, and reagents.
Analysis of our database also suggests that several hundred American high
schools now include substantial laboratory-based units or elective courses in
molecular genetics. Laboratory genetics units are typically incorporated into ex-
isting electives, such as anatomy, physiology, biology 11_, honors biology, and re-
search. In collaboration with Fred Gil lam, we completed a survey of 190 college
students taken the molecular genetics course he has offered Sachem
High School since 1987. The data strongly suggest that genetics electives, like
that offered at Sachem, influence science-interested students to choose college
majors in biology and health-related disciplines and to consider careers in these
fields. The data also suggest that genetics courses preferentially support young
women's aspirations for careers in the biological sciences.
Moving Genetics Education into the Elementary Schools
Despite evidence of success of introducing modern genetics at the advanced
high school level, we and others have come to regard the elementary schools as
the first front in the battle for genetic literacy. Here, student and teacher
enthusiasm, flexible scheduling, and lack of standardized curricula greatly
simplify instructional change. Elementary teachers, who work with the same class
of children all day, have an unparalleled opportunity to use genetics as the hub
of a rich learning network that links skills and concepts across the disciplines of
reading, writing, math, and science. This is consistent with a recommendation of
the National Research Council's 1990 study of American biology education that
"science stories" be integrated into elementary language arts. Early genetics edu-
cation should focus on human development, variability, and health. Sensitive
dialogue on social and ethical issues may be especially important to elementary
children, who are in the process of forming fundamental attitudes. Genetics also
offers ideal subject matter to explore elements of probability included in the na-
tional math standards for students, including collecting and analyzing data,
drawing samples, and comparing predicted versus experimental ratios.
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The DNALC's initial forays into elementary genetics education date to 1989
when we piloted the Fun With DNA summer camp. With funding from the William
Randolph Hearst Foundation, in 1991 we expanded the summer program to six
camps and initiated an academic-year program of laboratory field trips for
elementary and middle school students. This year, we began a major new initia-
tive, Genetics as a Model for Whole Learning in Elementary Science. Six local
school districts-Commack, Great Neck, Half Hollow Hills, Locust Valley,
Plainedge, and Roslyn-each pledged $10,000 over two years to support the sys-
tematic introduction of genetics modules in their elementary and middle school
classes. The object is to train classroom teachers, usually with backgrounds in
reading and language arts, to use genetics as a means to link science with the
more familiar disciplines of math, geography, and the humanities. Under the pro-
gram, each district receives 100 hours of consultation with DNALC Education
Manager Jane Conigliaro. The program's first year involved 27 faculty and 1,000
students at 15 elementary and middle schools.
In the small school districts of Long Island, we are thus beginning to see
working models of science education for the gene age, incorporating hands-on
learning about genetics at several stages during child and adolescent develop-
ment. Typically composed of only two or three elementary schools, one middle
school, and one high school, these districts present ideal situations in which to
introduce coordinated and system-wide instructional innovation. This is exactly
what we envisioned in 1985, when we began our educational efforts on Long
Island.
Another Busy Year of Laboratories, Lectures, and Workshops
The Bio2000 Laboratory was kept very busy during the academic year, with 3300
precollege students participating in laboratory field trips. During a typical week,
we now offer five high school laboratories in the mornings and three middle
school laboratories in the afternoons. Teachers choose from a "menu" of
laboratories, designed to complement science courses typically offered at local
schools:
Variability and Inheritance
Corn Genetics and Mendelian Inheritance
Cells, Chromosomes, and Mutations
DNA Structure and Recombination
Bacterial Transformation
DNA Restriction Analysis
Human DNA Fingerprinting
Grade Level Time
5-8 1.5 hours
5-8 1.5 hours
5-8 1.5 hours
5-8 1.5 hours
9-12 2 hours
9-12 3 hours
11-12 2 hours
The Great Moments in DNA Science Lecture Series, held in the spring, con-
tinued as a popular element of our annual calendar of events,
drawing the at-
tendance of 1,000 students and teachers. Included in the
audience were many
regulars"-faculty who have attended each year since the inception of the lecture
series in 1985. This year's lectures aptly illustrated molecular approaches to
basic biological problems, as well as applications in health and law:
"The First Human Gene Therapy Trials," Kenneth Culver, National
Institutes of Health.
"Using DNA in Criminal Investigations," Robert Shaler, New York
City
Medical Examiner's Office.
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The Molecular Basis of Learning and Memory," Ronald Davis, Cold
Spring Harbor Laboratory.
"Human Immunodeficiency Virus Variability," Winship Herr, Cold Spring
Harbor Laboratory.
Summer has traditionally been our busiest time, and the summer of 1992 was
no exception. With support from the National Science Foundation, the Depart-
ment of Education, and the Howard Hughes Medical Institute, a total of 18 train-
ing workshops were conducted for elementary through college faculty. Margaret
Henderson assisted lead middle school teachers trained in previous summers to
conduct "second-round" workshops for 80 additional faculty in New York and
Maryland. The popular DNA Science Workshop-taught by David Mick los and
now in its eighth year of operation-reached 155 high school teachers at work-
shops held in Arkansas, Kentucky, Maryland, Nevada, and Puerto Rico. Mark
Bloom presented his Advanced DNA Science Workshop to 100 college faculty at
workshops in New York, Washington, D.C., Illinois, and Puerto Rico. Student
workshops are becoming an increasingly large component of our summer ac-
tivities. The DNALC was site for six Fun With DNA summer camps attended by
128 5th and 6th graders, including three workshops especially designated for
minority and disadvantaged students. Research-oriented high school students
(19) from local school districts outnumbered teachers at the DNA Science Work-
shop held at the DNALC.
With funding from the Department of Energy's program on the Ethical, Legal,
and Social Issues of Human Genome Research, we continued to hold workshops
for opinion leaders and public policy makers. Each of two workshops held in
1992 drew together an eclectic group of administrators and communicators from
federal and state governments, genetic support groups, foundations, associa-
tions, the mass media, the legal community, and the ethics community-all of
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whom desire to deepen their insight into human genetics. Most participants come
to the workshop with rather extensive "book knowledge" on genetics, but with
only fragmentary understanding of the technology upon which modern genetic
analysis is based. Thus, the workshop aims to deepen insight into the research
process and to fill in gaps in participants' understanding. Jointly administered
with our friend Jan Witkowski, the 3-day workshop combines high-level seminars
at his Banbury Center with hands-on laboratories at the DNALC that illustrate ele-
ments of chromosome mapping, gene library construction, and human DNA
polymorphisms. Seminars provided experts' views of the progress and problems
of genetics research:
"The Human Genome Project," James Watson, Cold Spring Harbor
Laboratory.
"Population Screening for Genetic Diseases," Nancy Press, UCLA
Medical Center.
"Counseling for Human Genetics Diseases," Patricia Ward, Baylor
College of Medicine.
"Ethical Implications of Human Molecular Genetics," Thomas
Murra
Case Western Reserve University School of Medicine.
"Analyzing the Molecular Genetics of Cancer," Eric Fearon,
Johns
,
Hopkins University School of Medicine.
"Searching for the Genetic Basis of Learning and
Memory," Ronald
Davis, Cold Spring Harbor Laboratory.
"The First Human Gene Therapy Trials," Kenneth Culver,
National
Institutes of Health.
y,
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Initiating a Major Capital Development Program
The Laboratory's Board of Trustees has endorsed a $3.5 million capital develop-
ment program to create the physical resources for the DNALC to take on an ex-
panded role as a prototype "Human Genome Education Center." The three-phase
program is expected to be completed in 1994:
Phase I: Purchase of the DNALC property from Cold Spring Harbor Central
Schbol District at the conclusion of its lease/option on December 31, 1992.
Phase II (January-June, 1993): Redevelopment of the existing property,
including renovation of a 104-seat auditorium, renovation of galleries, in-
stallation of new exhibits, installation of a computer multimedia laboratory,
installation of fire sprinklers, and improvement of visitor parking and handi-
cap access.
Phase III (Fall 1993-Fall 1994): Construction of a 3,500-square-foot
Bio Media addition to the south side of the building, including a second
teaching laboratory, library, and an atrium/lunchroom. The term BioMedia
engenders our goal to explore ways to link experimental, computer, and
audiovisual resources to encourage understanding of biological concepts.
The new and redev'eloped facilities will allow students to move
between biochemical experiments, microscope observations, and parallel
computer experiences that illustrate molecular events.
The capital program is based on an architectural design by Centerbrook As-
sociates, who have been responsible for architectural design at the Laboratory
for more than a decade. In November, the Suffolk County Industrial Development
Agency approved a tax-exempt municipal bond for the purchase and redevelop-
ment of the facility. Approval to proceed with the capital program was based
upon receipt of lead grants in 1991 from the Stone Foundation ($250,000) and
the Weezie Foundation ($100,000), and in 1992 from Cablevision Systems Corpo-
ration ($250,000) and the E.S. Webster Foundation ($50,000). We were also very
pleased to receive from Beckman Instruments gifts of an L8-70M ultracentrifuge
and GS-6 tabletop centrifuge.
International Collaborations
We were happy for an opportunity to aid long-time friend Marcel lo Siniscalco in
his efforts to bring into operation a new genetics institute on the Sardinian coast:
the Porto Conte Research and Training Laboratories. In the context of recent
revelations in Italy of millions of dollars misspent for bogus public works projects,
the Porto Conte Laboratory is one of only a very few successful projects to bring
technological development to the poorer regions of Italy. Sardinia is an almost
ideal site for a laboratory on human genetics. The Sardinian people represent es-
sentially a closed gene pool, derived from a distinctive prehistoric culture and cut
off from major immigration for centuries.
Marcel lo also has received seed money from the Italian Ministry of University,
Scientific, and Technological Research, to develop a plan for an education cen-
ter adjacent to the research laboratories. To help publicize this educational mis-
sion, we were subcontracted to develop a prototype Genetic Video Arcade for
display in Sardinia. Susan Lauter collaborated with Paola Me lis to translate four
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interactive computer presentations into Italian and to mail 1,000 pounds of com-
puters and display modules to Sardinia. Four computer modules and a wide-
screen video projector were installed in the Museo Nazionale Sanna in Sassari.
The Genetic Video Arcade's frank modernism-in design and content-contrasted
with a contemporaneous exhibit of Columbian documents and the museum's
noteworthy collections of bronze-age artifacts. The arcade was visited by 7,000
students during the Italian national "Week of Scientific Culture," April 8-16, which
included lectures by Italian Nobel laureate Luigi Cavalli-Sforza and Sir Walter
Bodmer, director of the Imperial Cancer Research Fund. Response in Sassari
was so favorable that the Genetic Video Arcade was set up in Genoa as part of
the Columbian 500th anniversary celebrations in June.
We initiated a new collaboration with the municipality of Svalov, a small
agrarian community in Skania Province of southern Sweden. Only a brief ferry
ride away from Copenhagen, Skania has a long history in agricultural genetics.
The horse-breeding station at Flyinge has functioned continuously since the 12th
century and has been responsible for developing the Swedish "warm-blood,"
which is in great demand for high-level equestrian sports. The company Svalof
AB was established in 1886 to develop grain, forage, vegetable, and oil seeds for
use by farmers throughout Sweden. Thus, it is not surprising that the municipality
of Svalov is now developing plans for a science education center to focus on ag-
ricultural genetics.
After visiting the DNALC in January, the Svalov planners decided that
the
DNALC was a useful model for the science center they envision in Southern
Sweden. Four elementary and high school teachers from Svalov were trained to
perform hands-on genetics laboratories during summer workshops at the
DNALC. To help publicize the proposed science center,
David Mick los was in-
vited to participate in "Gene Vision," an exhibit on agricultural genetics
and ac-
companying interpretive activities during several weeks in October.
The exhibit
included Swedish translations of two computer presentations from our
Genetic
Video Arcade; seminar speakers included Swedish scientist Ulf Pettersson,
who
did postdoctoral research at Cold Spring Harbor Laboratory in 1971 in
hands -on
exhibit received 1500 visitors, and 1200 persons (aged 9-65) participated 
s  laboratories on DNA restriction, bacterial transformation,
DNA struc-
ture, and Mendelian genetics.
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Marcel lo Siniscalco of
Sardinia, Italy views one
of the computer
presentations of the
Genetic Video Arcade
displayed at the Museo
Nazionale in Sassari
(right).
In early summer, Margaret Henderson left the DNALC to accept a position as
Head of Library Services at the main Laboratory campus. As Education Manager,
Margaret fit in easily with the rest of our small staff and proved herself as a gifted
instructor and untiring organizer. We were happy that Margaret was able to find
within the Laboratory a position that so well utilizes her graduate training in library
science, but we miss her team spirit and even disposition.
The loss of Margaret from our staff was eased by our success in recruiting
Robert Willis, who joined the DNALC staff in July. As Special Programs Manager,
Robert is responsible for developing and administering programs targeted for mi-
nority and economically disadvantaged students in the New York metropolitan
area. A native of Tallahassee, Florida, Robert received his undergraduate degree
in biology from Florida State University. Prior to joining the DNALC, he taught
biology, general science, chemistry, and math at Ballou Senior High School in
Washington, D.C. He has also taught English as a Second Language to non-
English speaking adults and served as an extension math and science teacher.
In recent years, Robert received teacher fellowships from the American Society
for Biochemistry and Molecular Biology, the Cafritz Foundation, and the Founda-
tion for Advanced Education in the Sciences. As part of his fellowship research,
he conducted a study of biotechnology curricula and developed plans to in-
tegrate biotechnology into the curriculum of the Washington, DC public schools;
he intends to continue this work while at Cold Spring Harbor.
We were also thankful for the opportunity to work with Twana Adams, another
gifted and energetic minority educator. An instructor at the Bronx Comprehensive
Night High School, Twana assisted with the minority Fun With DNA camps and
organized a very successful training workshop that drew minority educators from
throughout the New York metropolitan area. We anticipate that Twana will play a
key role in organizing our new Intensive Enrichment program, acting as our agent
in her hometown Harlem, as well as in the Bronx.
The laboratory-intensive nature of the Fun With DNA summer camps requires
increased supervision for 5th and 6th grade participants. Assisting Jane Con-
igliaro with laboratory instruction at the 1992 camps were Diane Jedlicka, of the
Roslyn OMNI Gifted Program, and Adele Nicefero, of the Hicksville Academic En-
richment Program. We owe a special debt of gratitude to these lead educators,
and their students, for bringing genetics education into the elementary class-
room. They were among the very first to use the DNALC as a resource for
Twana Adams (above, at
right) and Robert Willis
(below, second from right)
oversee Fun With DNA
students.
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DNA Learning Center Staff. (Top) Robert Willis, Mark Bloom, Sandy Ordway,
Mark Staudinger, David Holtman. (Bottom) Jane Conigliaro, David Mick los,
Susan Lauter, Ken Bassett.
gifted/talented instruction and provided the impetus for the initial development of
the Fun With DNA camp. Student aides Tara Marathe, of Northport High School,
and Lina Hwang, of SUNY, Stony Brook, provided campers an additional
measure of personal attention.
Student interns from neighboring school districts worked behind the scenes
to prepare reagents used in student field trips during the academic year and for
teacher training workshops during the summer. After ably assisting Mark Bloom
with an intense 8-week schedule of college faculty workshops in the summer,
Amy Phillips joined the sophomore class at SUNY, Geneseo, to continue her
major in biochemistry. Following Amy's departure, Mark Staudinger, of Cold
Spring Harbor High School, filled her position as senior intern. Mark assisted with
4 weeks of summer faculty workshops and assumed responsibility for overseeing
several new sophomore interns: Ken Bassett, of Massapequa High School;
Andrea Conigliaro, of St. Anthony's High School; and Michael Conigliaro, ofCold
Spring Harbor High School. Cold Spring Harbor senior David Holtman continued
to focus primarily on computer applications, assisting Sue Lauter with the devel-
opment of multimedia educational programs. We were also fortunate to take on
Paul Kwitkin, a senior at Commack High School with background in DNA re-
search at SUNY, Buffalo. Claudio Siniscalco, of Westminster School in London,
returned for his second summer, assisting at several faculty workshops and de-
veloping multimedia programs.
David Mick los participated in important studies being carried out by two
branches of the National Academy of Sciences. He is an appointed member of a
National Research Council committee that is assembling a report on effective
methods of in-service training for precollege biology teachers. He prepared a
background paper that was used as a basis for educational recommendations
proposed by an Institute of Medicine committee on genetic
testing. Mark Bloom
began consulting for Ralph Appelbaum Associates, Inc. on the design of
biotechnology exhibits for the new National Science and
Technology Museum in
Taiwan, due to open in 1993.
Publications
Bloom, NA., G. Freyer, and D. Mick los. Laboratory DNA science:
An introduction to recom-
binant DNA technology and methods of genome
analysis. (In press.)
Micklos, D. Genetic Testing: An educational imperative to our
schools. In Proceedingsof
the Committee on Assessing Genetic Risks, Institute of Medicine. (In
press.)
Micklos, D. Genetics Education in American Schools: A
View From Cold Spring Harbor
Laboratory. Journal of the Swedish Seed Association
102 (4): December 1992.
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Sites of Major 3- to 10-Day Workshops 1985-1992
ALABAMA University of Alabama, Tuscaloosa
1987,1988,1989,1990
ARIZONA Tuba City High School 1988
ARKANSAS Henderson State University, Arkadelphia 1992
CALIFORNIA University of California, Davis 1986
University of California, San Francisco 1991
CONNECTICUT Choate Rosemary Hall, Wallingford 1987
FLORIDA North Miami Beach Senior High School 1991
University of Western Florida, Pensacola 1991
Armwood Senior High School, Tampa 1991
GEORGIA Fernbank, Inc., Atlanta 1989
Morehouse College, Atlanta 1991
HAWAII Kamehameha Secondary School, Honolulu 1990
ILLINOIS Argonne National Laboratory, Chicago 1986, 1987
University of Chicago 1992
INDIANA Butler University, Indianapolis 1987
IOWA Drake University, Des Moines 1987
KENTUCKY Murray State University 1988
University of Kentucky, Bowling Green 1992
Western Kentucky University 1992
LOUISIANA Jefferson Parish Public Schools, Harvey 1990
MANITOBA Red River Community College, Winnipeg 1989
MARYLAND Annapolis Senior High School 1989
McDonogh School, Baltimore 1988
Montgomery County Public Schools 1990,1991,1992
St. John's College, Annapolis 1991
MASSACHUSETTS Beverly High School 1986
Dover-Sherborn High School, Dover 1989
Randolph High School 1988
Winsor School, Boston 1987
MICHIGAN Athens High School, Troy 1989
MISSISSIPPI Mississippi School for Math & Science, Columbus 1990,1991
MISSOURI Washington University, St. Louis 1989
NEW HAMPSHIRE St. Paul's School, Concord 1986,1987
NEVADA University of Nevada, Reno 1992
NEW YORK Albany High School 1987
Bronx High School of Science 1987
Cold Spring Harbor High School 1985,1987
DeWitt Middle School, Ithaca 1991
DNA Learning Center 1988(3),1989(2),1990(2),
1991, 1992
DNA Learning Center 1990, 1992
DNA Learning Center 1990,1991,1992
Fostertown School, Newburgh 1991
Huntington High School 1986
Irvington High School 1986
Junior High School 263, Brooklyn 1991
Lindenhurst Junior High School 1991
Key: High School Workshops, College Workshops, and Middle School Workshops
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Orchard Park School, Orchard Park 1991
Plainview-Old Bethpage Middle School, Plainview 1991
State University of New York, Purchase 1989
State University of New York, Stony Brook 1987,1988,1989,1990
Titusville Middle School, Poughkeepsie 1991
Wheatley School, Old Westbury 1985
NORTH CAROLINA North Carolina School of Science, Durham 1987
OHIO Case Western Reserve University, Cleveland 1990
Cleveland Clinic 1987
North Westerville High School 1990
PENNSYLVANIA Duquesne University, Pittsburgh 1988
Germantown Academy, Fort Washington 1988
PUERTO RICO University of Puerto Rico, Mayaguez 1992
University of Puerto Rico, Mayaguez 1992
SOUTH CAROLINA Medical University of South Carolina, Charleston 1988
University of South Carolina, Columbia 1988
TEXAS J.J. Pearce High School, Richardson 1990
Langham Creek High School, Houston 1991
Taft High School, San Antonio 1991
VERMONT University of Vermont, Burlington 1989
VIRGINIA Jefferson School of Science, Alexandria 1987
Mathematics and Science Center, Richmond 1990
WASHINGTON, DC Howard University 1992
WEST VIRGINIA Bethany College 1989
WISCONSIN Marquette University, Milwaukee 1986,1987
University of Wisconsin, Madison 1988,1989
1991WYOMING University of Wyoming, Laramie
1992 Workshops, Meetings, and Collaborations
January 7-8
January 14
January 16
January 18-19
January 25
January 25-26
February 2-3
February 3-March 3
February 5
February 8-9
February 15-16
February 21-23
February 23-26
February 25
February 29-March 1
March 11
March 15-21
March 17
March 25
March 26
March 26-28
March 30-April 11
April 1-8
April 11
April 11
April 15
April 21-24
April 29
May 6
May 6-7
May 7
May 27-29
May 25-June 5
June 6-7
June 8-12
June 22-July 3
June 22-26
June 23-25
June 24-26
Site visit by Svalovs Kommun Delegation (Sweden)
Student Workshop, A. Philip Randolph High School, Harlem, New York
Grant review, William Patterson College, Wayne, New Jersey
National Science Foundation High School Faculty Workshop, Miami, Florida
Congressional Aides Workshop
National Science Foundation High School Faculty Workshop, Tampa, Florida
National Research Council Committee Meeting, Washington, DC
Site visit by Paola Melis of Porto Conte Research and Training
Laboratories, Sardinia, Italy
Site visit by Jackie Grennon Brooks of SUNY, Stony Brook
National Science Foundation Middle School Faculty Workshop, Annapolis,
Maryland
National Science Foundation College Faculty Workshop, San Francisco, California
Seminar, Coalition for Education in the Life Sciences Meeting, Racine, Wisconsin
Department of Energy Opinion Leaders Workshop
Great Moments in DNA Science Student Lecture
National Science Foundation College Faculty Workshop
Great Moments in DNA Science Student Lecture
National Research Council Committee Meeting, Irvine, California
Great Moments in DNA Science Student Lecture
Middle School Faculty Workshop
Great Moments in DNA Science Student Lecture
Workshop, National Association of Biology Teachers Meeting, Boston,
Massachusetts
"Week of Scientific Culture" Exhibit, Sardinia, Italy
Site visit by Kerry and Bev Clarke, Australia
Cold Spring Harbor Laboratory Association Workshop
Congressional Aides Workshop
Corporate Advisory Board Meeting and Reception
Consultation, Carolina Biological Supply Company, Burlington, North Carolina
Lecture for Kiwanis of Long Island, Northport
Grant review, William Patterson College, Wayne, New Jersey
National Science Foundation Middle School Faculty Workshop, Howard County,
Maryland
Lecture, Suffolk County Organization for Promotion of Education
Multi-Media Expo, New York
National Science Foundation College Faculty Workshop, University of Puerto Rico,
Mayaguez
Middle School Faculty Workshop
National Science Foundation High School Faculty Workshop, University of Puerto
Rico, Mayaguez
Department of Education College Faculty Workshop, Howard University,
Washington, DC
Howard Hughes Medical Institute High School Faculty Workshop,
Montgomery County, Maryland
National Science Foundation Middle School Faculty Workshop, Baltimore County,
Maryland
National Science Foundation Middle School Faculty Workshop, Frederick County,
Maryland
June LJ-JUly
June 29-July 3
June 29-July 3
July 6-12
July 9-10
July 13
July 13-17
July 13-19
July 20-24
July 21-23
July 27-August 7
August 3-7
August 3-7
August 10-14
August 10-21
August 11-13
August 11-13
August 17-21
August 18-20
August 24-28
September 4
September 25-27
October 12-16
October 16-18
October 28-Nov 1
October 31
November 1
November 3
November 7-8
November 14
November 14-15
November 14-15
November 19
November 21-22
December 5-8
National Science Foundation High School Faculty Workshop, Henderson State
University, Arkadelphia, Arkansas
Fun With DNA Student Summer Camp
Site visit by Fred Gil lam, Sachem High School
Fun With DNA Student Summer Camp
High School Faculty Workshop, University of Central Arkansas, Conway
Grant review, New York Hall of Science, Queens
National Science Foundation High School Workshop, University of Western
Kentucky, Bowling Green
Fun With DNA Student Summer Camp
National Science Foundation High School Faculty Workshop, University of
Kentucky, Lexington
National Science Foundation Middle School Faculty Workshop, Anne
Arundel County, Maryland
National Science Foundation College Faculty Workshop, Cold Spring Harbor
National Science Foundation High School Faculty Workshop, University of
Nevada, Reno
Fun With DNA Minority Student Summer Camp
Fun With DNA Minority Student Summer Camp
Department of Education College Faculty Workshop, University of Chicago
National Research Council Committee Meeting, Woods Hole,
Massachusetts
National Science Foundation Middle School Workshop, Anne Arundel County,
Maryland
Fun With DNA Minority Student Summer Camp
National Science Foundation Middle School Faculty Workshop, Cecil County,
Maryland
High School Student/Faculty Workshop
National Science Foundation Middle School Faculty Workshop, Ithaca, New York
Winding Your Way Through DNA Conference, San Francisco, California
"Gene Vision" Exhibit, Svalov, Sweden
Department of Education Meeting, Washington, DC
Site visit by Cindy Kelleher, University of California, San Francisco
Baring Brothers Workshop
Corporate Advisory Board Presentation and Dinner
Student Workshop, Valley Stream High School
National Science Foundation High School Faculty Workshop,
University of
Kentucky, Lexington
Lecture, Long Island Museum Association Meeting
National Science Foundation High School Faculty
Workshop, Western Kentucky
University, Bowling Green
Middle School Minority Faculty Workshop
Workshop, National Association of Science
Teachers Meeting, New York
National Science Foundation Faculty
Workshop, Henderson State University,
Arkadelphia, Arkansas
Department of Energy Opinion Leaders Workshop
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1992 PUBLICATIONS
General Books
The Cell Cycle
Symposia on Quantitative Biology 56
DNA on Trial: Genetic Identification and Criminal Justice
P.R. Billings (ed.)
The Dynamic Genome: Barbara McClintock's Ideas
in the Century of Genetics
N. Fedoroff and D. Botstein (eds.)
Phage and the Origins of Molecular Biology, expanded
edition
J. Cairns, G.S. Stent, and J.D. Watson (eds.)
The Power of Bacterial Genetics: A Literature-based Course
J. Beckwith and T.J. Silhavy
A Short Course in Bacterial Genetics: A Laboratory Manual
and Handbook for Escherichia coli and Related Bacteria
J.H. Miller
Vaccines 92: Modern Approaches to New Vaccines
Including Prevention of AIDS
F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner
(eds.)
CSHL Monograph Series
Transcriptional Regulation
S.L. McKnight and K.R. Yamamoto
Current Communications in Cell and Molecular
Biology Series
Vol. 5: Molecular Biology of Free Radical Scavenging
Systems
J.G. Scandalios (ed.)
Vol. 6: Lyme Disease: Molecular and Immunologic
Approaches
S.E. Schutzer (ed.)
Cancer Surveys Series
Vol. 12: Tumour Suppressor Genes, the Cell Cycle
and Cancer
A.J. Levine (ed.)
Vol 13: A New Look at Tumour Immunology
A.J. McMichael and W.F. Bodmer (eds.)
Vol. 14: Growth Regulation by Nuclear Hormone
Receptors
M.G. Parker (ed.)
Vol. 15: Oncogenes in the Development
of Leukaemia
O.N. Witte (ed.)
Genome Analysis Series
Vol. 4: Strategies for Physical Mapping
K. Davies and S. Tilghman (eds.)
Journals
Genes & Development (Volume 6, numbers 1-13)
PCR Methods and Applications (Volume 1, numbers
3 and 4; Volume 2, numbers 1 and 2)
Other
CSHL Annual Report 1991
Banbury Annual Report 1991
DNA Learning Center Annual Report
Administration and Financial Annual Report
Abstract/program books for 14 CSHL meetings
COLD SIRING HARBOR LABORATORY PRESS
1992 was a year of unqualified success for Cold Spring Harbor Laboratory Press.
Its financial goals were met, with a total income of over $3.7 million, up by over
20% from 1991. The surplus before deduction of allocated Laboratory overhead
exceeded $0.51 million, a satisfying result after the loss incurred in 1991. We are
still predominantly a book publisher, and book sales contributed more than 60%
of our revenues. Journal revenues are increasing annually and for the first time
exceeded $1.0 million.
Book Publishing
Within our book program, the most successful titles continue to be our laboratory
manuals, monograph series, and the annual Symposium volume. Outstanding
additions to each of these categories were made in 1992.
Jeffrey Miller completed his masterly A Short Course in Bacterial Genetics.
The book combines a manual of techniques refined by constant use in the au-
thor's laboratory with a handbook of reference data on Escherichia coli and its
relatives, organisms with a central place in current biotechnology. The book was
eagerly awaited in the genetics community, and we expect it to have the wide
appeal and long life span of Miller's Experiments in Molecular Genetics, the first
of Cold Spring Harbor's laboratory manuals, which was published 20 years ago
and is still in print.
The recently revived series of monographs, which began in the early 1970s,
continued this year in its classic tradition with a magnificent volume entitled Tran-
scriptional Regulation, edited by Steven McKnight and Keith Yamamoto. Con-
scious of the past achievements and undaunted by an enormous and in-
tellectually demanding field, the editors recruited contributions from more than 50
of the leading investigators and worked tirelessly to mold the chapters into a
coherent whole. The resultant two-volume set will stand for years at the center of
the field's literature.
This year's Symposium volume also maintained a tradition of excellence,
focusing on the cell cycle. The book captured the excitement of an area of re-
search in rapid advance, as a growing understanding of the biochemistry of cell
division complements awareness of the genetic basis of tumor development in
humans.
In total, 15 new book titles were published in 1992. The complete list appears
on the opposite page. Each had something special to offer. The Power of Bac-
terial Genetics for example, provided a novel approach to teaching un-
dergraduates through close analysis of primary research papers, based on the
experience of Tom Silhavy at Princeton and Jon Beckwith at Harvard. In DNA on
Trial, Paul Billings collected a series of essays on the controversial
use of DNA
typing in criminal justice, to create a book unlike any other currently available.
In its limited space, this report cannot adequately describe all the new
book
titles in 1992. One, however, must be singled out because of the
respect, affec-
tion, and secrecy with which it was prepared. The Dynamic
Genome was born
out of a desire, first expressed by James Watson, to surprise Barbara McClintock
on her 90th birthday with a book about the science she had
influenced so much.
From the beginning, it was clear that producing something Barbara
herself would
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like would be no easy task. To edit it, we turned to Nina Fedoroff and David Bot-
stein, two of her long-time friends and colleagues, whom we knew would assem-
ble the book with taste and care. The 30 invited contributions combined thought-
ful analysis of transposable elements in a variety of species with some history,
some personal reminiscence, and a discreet amount of eulogy. Published in a
striking dust jacket, the book has been widely reviewed and warmly praised. Best
of all, it satisfied its subject's own exacting standards. With Barbara McClintock's
death in September, the book is now a monument to the legacy of one of the
century's great scientists.
In this respect, The Dynamic Genome resembles the classic work Phage and
the Origins of Molecular Biology, published by Cold Spring Harbor in 1966 as a
festschrift for Max Delbruck. Hailed as an important document in the history of
biology and a formative influence on many of today's leading scientists, the book
went out of print in the early 1980s. The editors John Cairns, Gunther Stent, and
James Watson agreed with our view that a new generation of molecular biologists
deserved a fresh introduction to the book. Cairns wrote a charming memento of
Delbruck to preface the new edition, which also included a major review of the
original book (and its rejoinder) and Stent's 1982 obituary of DelbrOck. The
popularity of the reissue has reassured us that despite the overwhelming stream
of new research results, molecular biologists remain curious about the roots of
their discipline.
The editorial work, design, and production of the new 1992 titles were un-
dertaken with their customary skill and dedication by Managing Editor Nancy
Ford and the staff of her department in Urey Cottage. The year's list of new titles
was the largest and most complex yet produced by the Press. All but three books
were typeset in-house. In the past few years, the book publishing staff have be-
come fewer but have produced more pages. This efficiency has benefited us
financially, and the staff's commitment to the highest standards has assured our
books' continuing quality and reputation.
Among the backlist titles, the manuals Molecular Cloning and Antibodies con-
tinued to sell strongly, maintaining their dominant position in the technical litera-
ture of molecular biology. Sales of the second edition of Molecular Cloning now
exceed the first. The continued success of two 1991 titles, Apoptosis and Origins
of Human Cancer, was also notable. Both occupy a unique place in the literature
of their fields, the first as the only current review of an emergent topic and the
second as a comprehensive overview of an enormous and vital area of research.
We continued to distribute large numbers of the remarkable books on biology
by Fran Balkwill and Mic Rolph, which originate with Harper Collins U.K. The au-
thor/illustrator team achieved strong sales with their latest Work DNA Is Here To
Stay, about the structure of DNA and protein synthesis. Their writing is classified
as "children's literature," but it clearly also appeals to adults without a science
background who are intrigued by the increasingly public discussion of genetic
research. We are delighted with this extension of our publishing activities into
more general education and plan to build on this promising beginning.
Marketing Activities
The activities of the Marketing Department were essential to the success of our
publishing program in 1992. Conducted practically single-handedly by Ingrid
Benirschke, they centered on three subject areas: genetics, cancer biology, and
neuroscience. With the creative input of our designer Jim Suddaby, eye-catching
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catalogs for each subject were created and mailed to selected customer lists.
These were reinforced by three issues of our newsletter Notebook and by
advertisements in prominent journals that promoted new titles and best-selling
backlist books. In the fall, a handsome catalog was widely circulated, containing
the complete list of CSHL Press books and journals. The resultant sales response
was excellent. Mailings were also done to test reduced-price offers of older titles
from our backlist and a special, gift-oriented selection of general interest books
and other items. Both experiments were judged successful and encouraged us
to pursue these potential new revenue streams.
In addition to its customary reliance on direct mail, the Press exhibited at the
annual meeting of six national societies of biological research. These promotional
appearances, where our books and journals are available for scrutiny and pur-
chase, are an invaluable and encouraging opportunity to meet and learn from
customers in the field.
An ancillary but increasingly important aspect of our marketing activities is
the campus bookstore in the Grace Auditorium. Managed by Connie Hallaran, it
provides Laboratory staff and meetings attendees with the opportunity to browse
among our books and journals and an eclectic selection of science publications
from other sources. In 1992, the bookstore's activities expanded, as in the pre-
vious year. More books and a greater range of items for visitors were stocked.
Despite the small space available, sales increased substantially, encouraging the
view that with a greater floor area, the bookstore would have considerable finan-
cial potential.
Journal Publishing
Genes & Development ended the year with a consolidated reputation as one of
the elite journals in biology. Demand to publish in the journal is growing consider-
ably, and the number of manuscripts submitted rose by more than 13%. In addi-
tion, the scope of work available to the journal became broader. The editors, Terri
Grodzicker and Nick Hastie, with the help of the advisory board, continued to
apply stringent standards of assessment, accepting about 35% of papers of-
fered. The quality of the published work is remarkably high. Although there was
only a modest increase in the number of editorial pages published in 1992, the
pressure on space in the journal is growing. This is a consequence of the jour-
nal's ever-increasing visibility, and discussion is in progress about strategies for
dealing with it in 1993 and beyond.
The circulation of Genes & Development rose by 4% overall, with increases
among both individuals and institutions. The journal has subscribers in over 40
countries, predominantly the United States, Japan, and Western Europe, and cir-
culation increased in each of these markets. The circulation
growth, the journal's
reputation for editorial excellence, and the caliber of its subscribers offer
useful
advertising opportunities for product manufacturers. Revenue
from this source,
however, although considerable, was less than in 1991, owing to economic
recession in the commercial sector and growing competition
for advertising dol-
lars among scientific journals. New strategies in the approach to potential
ad-
vertisers are being planned, with the aim of reversing this trend.
The journal's financial performance overall was excellent and met budget
projections. Total revenue increased, assisted by circulation growth
and a 7-10%
increase in subscription prices. Costs were well-controlled
and the surplus rose.
For CSHL Press, and its minor partner in the journal, the Genetical
Society of
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tion analysis for 1991 by tne
showed that the "impact factor for Genes & Development had increased striking-
ly during 1991 and was again the highest of any monthly journal in biology. By
this measure, Genes & Development was confirmed as the top journal in genetics
and developmental biology.
After the spectacularly successful launch of our new quarterly PCR Methods
and Applications with two issues in 1991, we were eager to see what would hap-
pen to the manuscript submission rate and subscription and advertising sales in
the subsequent calendar year. To our great satisfaction, the momentum con-
tinued in all three areas. Seventy original papers and six commissioned reviews
were published. With the essential help of the associate editors Richard Myers,
Eric Green, Richard Gibbs, and David Bentley, editor Judy Cuddihy published
papers of a high standard, declining more than half the manuscripts offered for
publication. A complimentary review in Nature confirmed that the journal was
meeting a widespread need for reliable information about the immensely power-
ful, but technically challenging, polymerase chain reaction. This was underlined
by the strong rate of subscription renewal after the first volume in June. We were
also gratified by an increase in the number of sponsored subscriptions for
Volume 2 purchased by the Perkin-Elmer Corporation. Its support, and the sub-
stantial advertising sales solicited by Nancy Kuhle, combined with subscription
growth in over 20 countries, created a strong cash flow that enabled the journal,
remarkably, to achieve a surplus after only six issues.
The staff of the journal department responded willingly to the challenges pre-
sented by more manuscript submissions and larger issues. Led by Managing
Editor Judy Cuddihy, they demonstrated an exacting level of care and attention
to detail and ensured that all the 1992 issues of both journals appeared on
schedule and error-free. They also succeeded in keeping the interval between
submission and publication of a manuscript to a minimum. We welcomed Valerie
Nicolette to the staff as production editor; she has proved to be a quick and ef-
fective study in her first publishing job after graduating from college.
Order Fulfillment and Dispatch
Underpinning any publishing program are vital support services without which
editorial and marketing activities would be fruitless. The staff responsible for
sales processing, dispatch, and customer service form the front line of communi-
cation with purchasers. For many members of the scientific community, this is the
sole contact with the Laboratory and its Press. Guy Keyes, the new head of the
department, and his colleagues worked hard to improve its efficiency of opera-
tion. In 1992, the number of book orders processed and journal subscriptions ful-
filled increased substantially, with no increase in staff. More direct mail was dis-
patched. In addition, the potential of the sales management computer system
was exploited more fully, for detailed marketing results, sales data, and customer
category analysis.
Financial Management
Further essential support became available in March with the appointment of
Nancy Hodson to the new position of Finance Coordinator. With a strong back-
ground in finance and accounting, and considerable computer skills, Nancy
398
quickly impressed us with her quiet efficiency and competence. By the year's
end, she had overhauled our accounting and reporting systems, improving staff
awareness of financial trends and permitting quicker, more accurate forecasting.
With the assistance of financial management software, the flow of information
within and from the Press dramatically improved. Controls on spending were
tightened, thanks to continuous monitoring of results and budgets. These im-
provements helped us to achieve our financial targets and gave us the con-
fidence to predict further growth next year.
New Publishing Projects
1992 was forecast as a time of consolidation in which cost-effectiveness could be
improved, our book list expanded, and our journal program made securely
profitable. These goals were achieved. At the same time, it was necessary to
plan for the future, since few publishing projects of any merit can be completed
in less than 2 years and many require even longer. During the year, more than 30
new projects of different types were begun, with planned completion dates in
1993-1995. These projects will be described fully in future reports. They include
videotapes, which we have found to have a useful place in the communication of
science, and potential electronic publications, a medium with extremely interest-
ing prospects. New journal possibilities are also being explored.
But most of these new projects are books. There is no doubt that cash
restraints among both libraries and individual investigators have harmed sales of
science books, and there is an added tendency among some investigators to be-
lieve that the speed of advance in knowledge makes many books out of date as
soon as they are printed. However, our market intelligence convinces us
that the
kind of books Cold Spring Harbor does especially well will continue to be
impor-
tant, even as additional information sources become available. By harnessing
new technology and by careful cost control, we have maintained our
books' qual-
ity at reduced cost, giving them the best chance of financial viability.
A major review of the Press program late in the year gave us
a reason to ex-
amine the financial history of book publishing at Cold Spring Harbor,
from the ex-
pansion initiated by James Watson in 1970 to the end of 1991.
The income from
book sales in this period was close to $25.5 million. After deduction
of direct ex-
penses, over $5.0 million has been made available to the
Laboratory to support
overhead and running costs. We are proud of this financial
success. We are
equally aware of the part played by all our publications, both
books and journals,
in enhancing the Laboratory's worldwide reputation as a place
of scientific ex-
cellence. With our current plans for growth and development,
we intend both
kinds of contributions to continue.
John R. Inglis
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FINANCIAL
STATEMENTS

LIABILITIES AND FUND BALANCES
Operating Funds
Endowment &
Similar Funds
Land,
Building, &
Equipment Funds
Total All FundsUnrestricted
RestrictedUndesignated Designated 1992 1991
Liabilities:
Accounts payable and accrued expenses $1,751,327 - 115,873 - 415,638 2,282,838 3,555,228
Notes payable - - - - 1,227,037 1,227,037 910,127
Bonds payable - - - - 20,000,000 20,000,000 20,000,000
Deferred revenue 1,156,836 - 2,402,284 - - 3,559,120 3,845,730
Total liabilities 2,908,163 - 2,518,157 - 21,642,675 27,068,995 28,311,085
Fund balances:
Unrestricted-undesignated 3,652,272 - - - - 3,652,272 1,937,391
Unrestricted-designated
- 1,350,000 - - - 1,350,000 750,000
Endowment and similar funds
- - - 29,276,357 - 29,276,357 20,881,513
Land, buildings, and equipment:
Expended
- - - - 31,209,369 31,209,369 31,352,674
Unexpended-Donor restricted
- - - - 291,723 291,723 1,079,986
Unexpended-Board authorized
- - - - 2,079,639 2,079,639 1,457,746
Total fund balances 3,652,272 1,350,000 - 29,276,357 33,580,731 67,859,360 57,459,310
Total liabilities and fund balances $6,560,435 1,350,000 2,518,157 29,276,357 55,223,406 94,928,355 85,770,395
STATEMENT OF SUPPORT, REVENUE AND EXPENSES, 
AND CHANGES IN FUND BALANCES 
Year ended December 31,1992 
with comparative amounts for 1991
Operating Funds Land,
Unrestricted Endowment & Building, & Total A ll Funds
Undesignated Designated Restricted Similar Funds Equipment Funds 1992 1991
Support and revenue: 
Public support $1,869,338 7,633,686 7,302,098 551,885 17,357,007 13,116,508
Government grant awards - - 8,680,512 - - 8,680,512 7,982,835
Indirect cost allowances 8,508,920 - - - ־ 8,508,920 7,280,352
10,378,258 - 16,314,198 7,302,098 551,885 34,546,439 28,379,695
Other revenue: 
Program fees 1,332,830 1,332,830 1,329,875
Rental income 298,104 - - - - 298,104 278,840
Publications 3,709,326 - - - - 3,709,326 3,078,938
Dining services 1,464,949 - - - - 464,949, י | 1,439,224
Rooms and apartments 1,320,424 - - - - 1,320,424 1,239,585
Distribution from Robertson Funds 475,000 - 1,085,000 - - 1,560,000 1,350,000
Investment income 139,666 - - 1,966,523 9,847 2,116,036 1,973,581
Royalty & licensing 291,841 - - - - 291,841 318,029
Miscellaneous 198,054 - - - - 198,054 92,042
Total other revenue 9,230,194 - 1,085,000 1,966,523 9,847 12,291,564 11,100,114
Total support and revenue 19,608,452 - 17,399,198 9,268,621 561,732 46,838,003 39,479,809
Expenses: 
Program services: 
Research 12,985,969 12,985,969 13,026,253
Summer programs 939,106 - 3,814,480 - - 4,753,586 2,994,584
Publications 3,547,638 - - _ - 3,547,638 3,488,100
Banbury Center conferences 201,740 - 249,261 - 451,001: 447,044
DNA Education Center programs 12,054 - 485,667 - - 497,721 379,804
Total program services 4,700,538 - 17,535,377 - - 22,235,915 20,335,785
Supporting services: 
Direct research support 1,290,609 1,290,609 903,032
Library 468,569 - _ _ - 468,569 433,496
Operation and maintenance of plant 4,575,804 - _ _ - 4,575,804 4,221,594
General and administrative 3,101,996 - - 114,029 _ 3,216,025 3,081,287
Dining services 1,604,098 - - - - 1,604,098 1,322,422
Interest - - - - 689,118 689,118 934,105
Total supporting services 11,041,076 - - 114,029 689,118 11,844,223 10,895,936
404
Depreciation
Total expenses
Excess (deficiency) of support and
2,357,815 2,357,815 1,898,421
15,741,614 17,535,377 114,029 3,046,933 36,437,953 33,130,142
revenue over expenses before designation $3,866,838 (136,179) 9,154,592 (2,485,201) 10,400,050 6,349,667
Designation:
Funds designated for research
program (600,000) 600,000 -
Excess (deficiency) of support and
revenue over expenses and designation 3,266,838 600,000 (136,179) 9,154,592 (2,485,201) 10,400,050 6,349,667
Other changes in fund balances:
Capital expenditures (2,134,865) - (532,705) - 2,667,570 - -
Transfer to restricted funds (150,000) - 668,884 (518,884) - - -
Transfer to endowment funds (379,208) - - 871,252 (492,044) - -
Transfer to unrestricted funds 1,112,116 - - (1,112,116) - - -
Net increase in fund balances 1,714,881 600,000 - 8,394,844 (309,675) 10,400,050 6,349,667
Fund balances at beginning of year 1,937,391 750,000 20,881,513 33,890,406 57,459,310 51,109,643
Fund balances at end of year $3,652,272 1,350,000 33,580,731 67,859,360 57,459,310
Copies of our complete, audited financial statements, certified by the independent auditing firm
of KPMG, Peat, Marwick & Co., are available upon request from the Comptroller, Cold Spring
Harbor Laboratory.
SOURCES OF REVENUE
YEAR ENDED DECEMBER 31, 1992
Federal Grants 35.6 %
Endowments and Similar Funds 7.5 %
Auxiliary Activities 17.4 %
Foundation and Private
Contributions and Grants 32.9 %
Interest and Miscellaneous 1.4 %
Corporate Contributions and Grants 5.2 %
COMPARATIVE OPERATING HISTORY
1988-1992
(Dollars in Thousands)
1988 1989 1990 1991 1992
Income:
Main Lab:
Grants & contracts 10,799 13,062 13,535 15,172 16,800
Indirect cost reimbursement 5,707 6,412 6,558 7,170 8,388
Other 3,205 4,034 3,976 5,056 5,520
Ao
CSH Press
Banbury Center
1,641
976
4,450
1,012
4,223
1,120
3,079
1,090
3,709
1,104
DNA Learning Center 660 622 585 744 822
Total income 22,988 29,592 29,997 32,311 36,343
Expenses:
Main Lab:
Grants & contracts 10,799 13,062 13,535 15,172 16,800
Operation & maintenance of plant 3,010 3,412 3,759 3,904 4,241
General & administrative 2,102 2,377 2,414 2,468 2,634
Other 3,049 3,165 2,973 3,375 4,141
CSH Press 1,719 3,934 3,708 3,488 3,548
Banbury Center 910 1,038 1,125 1,063 1,070
DNA Learning Center 590 635 615 752 843
Total expenses 22,179 27,623 28,129 30,222 33,277
Excess before depreciation and designation of funds 809 1,969 1,868 2,089 3,066
Depreciation (1,286) (1,399) (1,485) (1,898) (2,358)
Designation of funds (1) - (400) (250) (100) (600)
Net operating excess (deficit) $ (477) 170 133 91 108
The above amounts are presented on a combined basis for all funds for which Cold Spring Harbor Laboratory prepares operating budgets.
(1) Funds designated to underwrite future direct and indirect expenses of the neuroscience and other research programs.
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FINANCIAL SUPPORT OF THE LABORATORY
Cold Spring Harbor Laboratory, Banbury Center, and the DNA Learning Center receive a substan-
tial portion of their funding through grants from the Federal Government and through grants, capital
gifts, and annual contributions from private foundations, corporations, and individuals. The follow-
ing section summarizes funding that occurred during 1992.
GRANTS January 1, 1992-December 31, 1992
COLD SPRING HARBOR LABORATORY
Grantor
FEDERAL GRANTS
NATIONAL INSTITUTES OF HEALTH
Program Projects
Research Support
Program/Principal Investigator Duration of Grant Total Award
Cancer Research Center, Dr. Mathews
Cancer Center Support, Dr. Stillman
Oncogene Program Project, Dr. Wigler
Dr. Anderson
Dr. Arndt
Dr. Arndt
Dr. Bar-Sagi
Dr. Beach
Dr. Beach
Dr. Beach
Dr. Beach
Dr. Davis
Dr. Davis
Dr. Franza
Dr. Franza
Dr. Futcher
Dr. Futcher
Dr. Garrels
Dr. Gilman
Dr. Greider
Dr. Greider
Dr. Helfman
Dr. Hernandez
Dr. Hernandez
Dr. Herr
Dr. Krainer
Dr. Kuret
Dr. Kuret
Dr. Marr
Dr. Martienssen
Dr. Mathews
Dr. Moran
Dr. Moran
Dr. Peterson
Dr. Richards
Dr. Roberts
Dr. Roberts
Dr. Roberts
Dr. Spector
Dr. Stillman
Dr. Stillman
Dr. Tonks
Dr. Tully
Dr. Wigler
1/92- 12/96
8/90- 7/95
3/88- 2/93
4/90- 3/93
4/88- 3/93
1/91- 12/94
7/91- 6/96
12/84- 1/93
9/86- 8/94
7/88- 6/93
8/90- 7/93
9/91- 8/95
7/92- 6/96
9/85- 11/94
10/91- 8/94
4/88- 3/93
1/91- 12/94
1/85- 12/94
9/92- 8/97
12/89- 11/94
8/91- 7/96
9/85- 3/94
7/92- 6/96
9/91- 8/96
3/92- 2/96
7/89- 6/94
7/89- 6/94
5/91- 4/95
8/91- 7/94
8/92- 7/94
2/92- 1/97
8/91- 6/96
8/91- 5/95
4/88- 3/93
7/90- 6/92
7/88- 6/93
9/88- 8/92
4/91- 3/94
4/90- 3/95
7/83- 5/96
7/91- 6/95
8/91- 5/96
9/91- 1/93
7/92- 6/99
8/90- 7/93
$17,939,397*
11,982,730
4,869,923
176,000
1,288,964
773,411
1,280,538
1,481,482
3,032,957
1,488,740
1,287,507
847,368
1,101,137*
1,497,483
487,949
1,115,434
604,467
6,818,544
1,722,797*
1,130,019
1,465,240
2,109,264
1,441,344 *
1,141,822
854,936*
1,298,402
1,312,808
760,241
1,122,933
245,421 *
1,396,361 *
1,299,986
1,122,557
704,475
340,932
1,598,876
681,311
652,140
1,441,475
2,672,015
763,393
1,631,345
126,301
13,298,000 *
640,923
" New Grants Awarded in 1992 409
Program/Principal Investigator Duration of Grant Total Award
Grantor
Equipment Support Dr. Marshak
6/92- 6/93 187,000*
Fellowships Dr. BallesterDr. Brill
2/89- 1/92
8/89- 7/92
63,966
46,667
Dr. Connolly 1/90- 1/93 69,000
Dr. Del Vecchio 12/91- 11/93 22,700
Dr. Grueneberg 10/90- 9/93 69,000
Dr. Jones 10/91- 9/94 85,800
Dr. Otto 9/90- 8/92 67,720
Dr. Regulski 8/91- 6/92 49,658
Dr. Prowse 9/92- 8/94 55,500*
Dr. Skoulakis 9/92- 8/94 48,300 *
Dr. Szymanski 11/90- 11/92 49,000
Dr. Kwang-Ai Won 5/92- 4/95 81,200*
Dr. Hwei-Gene Wang 8/92- 7/93 55,500*
Dr. Zhang 9/92- 8/97 416,558 *
Training Support Institutional, Dr. Grodzicker
7/78- 4/94 2,364,146
Course Support Advanced Bacterial Genetics,
Dr. Grodzicker 5/80- 4/93 559,540
Cancer Research Center
Workshops, Dr. Grodzicker 1/83- 3/92 1,010,057
Neurobiology Short-term Training,
Dr. Hockfield 5/82- 4/96 1,300,588
CSHL Analysis Large DNA Molecules,
Dr. Grodzicker 1991- 1996 475,538
Essential Computational Genomics for
Molecular Biologists, Dr. Marr 1991- 1996 132,619
Advanced In Situ Hybridization
and Immunocytochemistry, Dr. Spector 1992- 1997 228,841 *
Meeting Support Genome Mapping and Sequencing Conference 1990- 1993 78,040
57th Symposium: The Cell Surface 1992 19,000 *
Molecular Biology of Aging 1992 24,525 *
Genetics and Molecular Biology of Breast Cancer 1992 11,000 *
Mouse Molecular Genetics 1992 10,250 *
RNA Processing 1992 2,000 *
NATIONAL SCIENCE FOUNDATION
Research Support Dr. Anderson 9/90- 8/93 315,000
Dr. Ma 5/91- 4/93 399,000
Dr. Ma 8/91- 7/94 360,000
Dr. Martienssen 7/89- 6/92 305,000
Dr. Peterson 11/91- 4/93 207,212
Dr. Roberts 2/90- 2/93 210,000
Dr. Sundaresan 12/92- 11/95 140,000 *
Fellowship Support Dr. Pena 6/92- 5/95 4,600 *
Training Support Undergraduate Research Program,
Dr. Herr 6/91- 5/94 150,000
Course Support Plant Molecular Biology,
Dr. Grodzicker 8/86- 8/93 160,929
Meeting Support RNA Processing Meeting 4/91- 3/94 30,000
57th Symposium: The Cell Surface 5/92- 4/93 6,667 *
Mouse Molecular Genetics 3/92- 8/93 10,144*
* New Grants Awarded in 1992
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Grantor Program/Principal Investigator Duration of Grant Total Award
DEPARTMENT OF ENERGY
Research Support
Meeting Support
OFFICE OF NAVAL RESEARCH
Course Support
U.S. DEPARTMENT OF AGRICULTURE
Research Support
Course Support
NONFEDERAL GRANTS
Research Support
Allied Signal
American Cancer Society
American Heart Association
Amersham International plc
American Foundation for
AIDS Research
Arab Republic of Egypt
Argonne National
Laboratories
Sara Chait Foundation
Council for Tobacco
Research
Garfield Foundation
Greenwall Foundation
Geron Corporation
Irving A. Hansen Memorial
Foundation
Hitachi Foundation
Hechler Private
Investments
Howard Hughes Medical
Institute
Human Frontier Science
Program
ICOS Corporation
Dr. Marr
Dr. Martienssen
Dr. Peterson
57th Symposium: The Cell Surface
Genetics and Molecular Biology of Breast Cancer
Training in Computational
Neuroscience at CSHL, Dr. Hockfield
Dr. Sundaresan
Dr. Ma
Dr. Martienssen
Support of a Workshop on Molecular
Markers for Plant Breeding, Dr. Sundaresan
Dr. Greider
Dr. Gilman
Dr. Gilman, Institutional
Dr. Spector
Dr. Sutton
Dr. Wigler, Professorship
Dr. Wigler
Dr. Helfman
Dr. Krainer
Dr. Laspia
Dr. Mathews
Dr. Marshak
Dr. Pflugrath
Dr. Pflugrath
Dr. Marshak
Dr. Greider
Dr. Helfman
Dr. Spector
AIDS Research
Dr. Marshak
Dr. Greider
Dr. Tonks
Dr. Nawa
Dr. Enikolopov
Neurobiology Support
Dr. Futcher
Dr. Davis
Dr. Futcher
Dr. Tonks
7/91- 2/94
8/91- 8/93
5/92- 5/95
1992
1992
6/92- 5/93
8/91 -8/94
9/92- 9/94
9/91 -8/93
10/92- 9/93
11/92- 10/93
7/91 -5/94
7/90- 6/92
7/91- 6/92
1/92 -12/93
1986- 2012
4/92 -3/93
7/91 -6/96
11/86- 10/92
12/91- 11/93
10/91 -9/93
11/91- 10/94
2/91 -8/93
1/92- 12/92
12/91- 11/96
7/92- 6/93
7/91- 6/93
7/92- 6/93
12/91- 5/93
7/92- 6/93
8/92- 8/95
7/92 -6/94
3/92- 2/94
12/91 -5/92
1987- 1992
6/92- 5/96
5/92- 4/95
7/92- 6/94
4/92- 3/94
814,022
144,000
291,000*
15,000*
10,150 *
32,815*
221,000
138,000*
128,000
35,015*
100,000*
300,000
100,000
50,000
190,000*
1,333,333
10,000*
175,000
827,925
120,000
120,000
48,907*
192,232
100,000*
125,000
52,000*
160,000
80,000 *
200,000
70,439*
225,000*
20,000'
10,000*
27,812
1,000,000
183,986*
147,935*
126,995*
227,842'
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Grantor
Program/Principal Investigator Duration of Grant Total Award
ICI Seeds
Johnson & Johnson
Esther and Joseph A.
Dr. Martienssen/Dr. Richards
Dr. Skowronski
Dr. Nawa
1/92- 12/94
5/92- 4/95
7/92- 6/95
41,676 *
270,000 *
100,000*
Klingenstein Fund, Inc.
Lucille P. Markey Neurobiology Support
7/90- 6/96
Charitable Trust Neuroscience
2,000,000
Building Fund 2,000,000
Mathers Charitable Foundation Dr. Davis
8/91- 7/94 1,028,000
Mellam Family Foundation Dr. Franza
12/88- 11/95 350,000
Richard Meltzer Fund
for Cancer Research
Dr. Stillman 3/90- 2/92 50,000
(World Business Council)
John Merck Fund Dr. Tully
9/91- 5/94 180,000
Massachusetts Institute of Dr. Marr
11/91- 7/92 49,006
Technology (Subcontract)
Muscular Dystrophy Dr. Helfman
1/91- 12/93 126,100
Association
National Down's Syndrome Dr. Marshak 7/90- 6/92 50,000
Society
NYU Consortium with NIH Dr. Marshak 5/92- 4/97 886,546 *
Oncogene Science, Inc. Monoclonal Agreement 6/92- 5/95 300,000 *
Oxnard Foundation Dr. Gilman
2/91- 1/94 150,000
Pew Memorial Trust Dr. Greider 7/90- 6/94 200,000
Dr. Krainer 7/92- 6/96 200,000 *
Dr. Tonks 7/91- 6/95 200,000
Pioneer Hi-Bred Dr. Peterson 8/91- 7/94 150,000
International Inc.
Rita Allen Foundation Dr. Hernandez 10/89- 9/94 150,000
Samuel Freeman Charitable
Trust
Freeman Laboratory
of Cancer Cell Biology
7/89- 6/94 1,000,000
Equipment Support
Florence Gould Neuroscience Equipment 7/91- 6/94 300,000
Foundation
Fellowships
American Cancer Society Dr. Caligiuri 1/91- 12/93 69,000
Dr. Flanagan 7/92- 6/95 78,000 *
Dr. Hinkley 9/92- 8/95 72,000 *
Dr. Mi Sha Jung 8/92- 7/94 54,000 *
Dr. Lundgren 1/92- 12/92 28,000 *
Dr. Nefsky 7/90- 6/93 69,000
American Foundation for Dr. Scheppler 7/91- 6/94 112,000
AIDS Research
American Heart Association Dr. Kazzaz 1/92- 12/93 60,000 *
Cancer Research Institute Dr. Flint 1/92- 12/95 87,000 *
Cancer Research Fund of the Dr. Hannon 1/92- 12/94 84,000 *
Damon Runyon-Walter Winchell Dr. Hardy 9/92- 8/95 84,000 *
Foundation Dr. Horton 9/92- 8/95 84,000 *
Dr. V. Jung 5/92- 4/95 84,000 *
Dr. Ruppert 8/91- 7/94 84,000
Dr. Sun 5/92- 4/95 84,000 *
Dr. Walworth 9/90- 8/93 84,000
Ford Foundation
Dr. Wilson
Dr. Pena
1/91- 12/93
9/91- 5/92
69,000
30,000
* New Grants Awarded in 1992
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Grantor Program/Principal Investigator
Government of Canada
Joyce Green Family
Foundation
Helen Hay Whitney
Foundation
Human Frontier
Science Program
Irvington Institute
for Medical Research
The Leukemia Society
of America
CSHL Association
Life Science Research
Foundation
Muscular Dystrophy
Association
Andrew Seligson
Memorial Fellowships
Training Support
Anonymous
Baring Brothers & Co., Ltd.
Bio-Rad Laboratories
Bliss Fund
Burroughs Wellcome
Foundation
Theodore Danforth
Grass Foundation
ICI
Phillips Petroleum Co.
Robert H.P. Olney
Memorial Fund
Hansen White Foundation
Course Support
Howard Hughes Medical
Institute
Esther and Joseph A.
Klingenstein Fund, Inc.
Meeting Support
Boehringer Mannheim Co.
Clontech Laboratories
Council for Tobacco
Research
ICN Biomedicals
Esther and Joseph A.
Klingenstein Fund, Inc.
March of Dimes
Miles, Inc.
Wellcome Trust
* New Grants Awarded in 1992
Dr. Demetrick
Dr. Sun
Dr. Bell
Dr. Alexandre
Dr. Clarke
Dr. Mayeda
Dr. Tansey
Dr. Giordano
Dr. Das
Dr. Bischoff
Fellowships
Dr. D. Roberts
Dr. Collins
Dr. Kaufman
Dr. Tsukahara
Cancer Research
Fellowships
Summer Undergraduate Program
Summer Undergraduate Program
Summer Undergraduate Program
Summer Undergraduate Program
Summer Undergraduate Program
Summer Undergraduate Program
Neurobiology Scholarship Support
Summer Undergraduate Program
Summer Undergraduate Program
Undergraduate Research Program
Summer Undergraduate Program
Postgraduate Courses
Advanced Neurobiology Courses
Regulation of Liver Gene
Expression and Disease
Regulation of Liver Gene
Expression and Disease
Cytoskeleton Cell Function
Translational Control Meeting
Epilepsy Meeting
Cytoskeleton Cell Function
Regulation of Liver Gene
Expression and Disease
Gene Therapy Meeting
Duration of Grant Total Award
413
11/91- 10/93
12/91- 2/92
7/91- 6/94
1/92- 12/93
7/91- 6/93
7/91- 6/93
9/92- 9/94
7/90- 6/92
7/89- 6/92
7/91- 6/94
4/92- 3/93
9/89- 8/92
6/92- 5/95
7/92- 6/95
7/91- 6/92
9/90- 5/93
1992
1990- 1992
1992
1992
1991- 1993
1992
1980- 1992
1992
1992
1991
1991- 1995
3/91- 2/94
1992
1992
1992
1992- 1993
1992- 1993
1992- 1993
1992
1992
6,137
5,000
75,000
84,560 *
76,000
77,000
68,216 *
4,000
76,140
76,140
125,000 *
90,000
105,000 *
105,000 *
25,000
145,000
18,750 *
75,233
1,000*
4,000 *
49,200
2,000 *
201,030
7,441 *
1,000*
5,000*
6,400 *
1,000,000
180,000
250
300*
1,000*
20,000 *
96,537 *
4,000*
1,000*
43,175 *
DNA LEARNING CENTER
Program/Principal Investigator Duration of Grant Total Award
Grantor
FEDERAL GRANTS
NATIONAL SCIENCE FOUNDATION High School Faculty Enhancement 1990 -1993 489,036
Middle School Faculty Enhancement 1990 -1993 252,614
College Faculty Enhancement 1991 -1993 264,467
U.S. DEPARTMENT OF EDUCATION College Faculty Enhancement 1991-1993 170,033
NONFEDERAL GRANTS
Cablevision Systems Corporation Capital Support
1992 250,000 *
Stone Foundation Program Support
1991 -1994 250,000
Howard Hughes Medical Institute High School Faculty Enhancement 1990 -1993 46,500
Henderson State University High School Faculty Enhancement
1992 2,472 *
University of Kentucky, Lexington High School Faculty Enhancement 1992 2,240 *
University of Nevada, Reno High School Faculty Enhancement 1992 2,835 *
Abell Foundation Minority and Special Programs 1992 2,100 *
Barker Welfare Foundation Minority and Special Programs 1992 5,000 *
Brinkmann Instruments Minority and Special Programs 1992 1,000
Corporate Advisory Board Minority and Special Programs 1992 14,500 *
Harweb Foundation Minority and Special Programs 1992 2,000 *
Laurie Landeau Minority and Special Programs 1992 4,000
Life Technologies Minority and Special Programs 1992 500
SUNY at Stony Brook Minority and Special Programs 1992 10,000 *
Edwin S. Webster Foundation Minority and Special Programs 1992 15,000
Italian Ministry of Research Exhibit Support 1992 45,450
The Weezie Foundation Exhibit Support 1991 -1992 100,000
New York State Legislature Middle School Program 1992 50,000 *
William Randolph Hearst Foundation Middle School Program 1991 -1994 100,000
Commack Union Free School District Whole Learning Program 1992 5,000*
Half Hollow Hills Central School District Whole Learning Program 1992 5,000 *
Locust Valley Central School District Whole Learning Program 1992 5,000*
Plainedge Union Free School District Whole Learning Pogram 1992 5,000 *
Commack Union Free School District Curriculum Study 1992 500
East Williston Union Free School District Curriculum Study 1992 500
Elwood Union Free School District Curriculum Study 1992 2,000 *
Garden City Union Free School District Curriculum Study 1992 500
Great Neck Public Schools Curriculum Study 1992 500
Half Hollow Hills Central School District Curriculum Study 1992 500
Harborfields Central School District Curriculum Study 1992 500
Herricks Union Free School District Curriculum Study 1992 500
Island Trees Union Free School District Curriculum Study 1992 500
Jericho Union Free School District Curriculum Study 1992 500
Kings Park Central School District Curriculum Study 1992 500
Lawrence Union Free School District Curriculum Study 1992 500
Lindenhurst Union Free School District Curriculum Study 1992 500
Locust Valley Central School District Curriculum Study 1992 500
Manhasset Union Free School District Curriculum Study 1992 500
Massapequa Union Free School District Curriculum Study 1992 1,500
* New Grants Awarded in 1992
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Grantor Program/Principal Investigator Duration of Grant Total Award
Northport-East Northport Union Free
School District
North Shore Central School District
Oyster Bay-East Norwich
Central School District
Plainview-Old Bethpage
Central School District
Plainedge Union Free School District
Port ledge School
Port Washington Union Free
School District
Roslyn Public Schools
Sachem Central School District
at Holbrook
South Huntington Union Free
School District
Syosset Central School District
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
Curriculum Study
1992
1992
1992
1992
1992
1992
1992
1992
1992
1992
1992
500
500
500
500
500
500
500
500
500
500
500
BANBURY CENTER
Grantor Program/Principal Investigator
Duration of Grant Total Award
FEDERAL GRANTS
DEPARTMENT OF ENERGY
NONFEDERAL SUPPORT
Meeting Support
Abbott Laboratories
Abbott Laboratories
Allen & Hanburys
(Glaxo, Inc.)
The Charles A. Dana
Foundation
Dr. Amy and James Elster
Research Fund
Hoffmann-La Roche Inc.
Pfizer Inc.
Merck Research Laboratories
RepliGen Corporation
RepliGen Corporation
Sandoz Corporation
Alfred P. Sloan
Foundation
The Wellcome Trust
The William Stamps
Farish Fund
Human Genetics and Genome Analysis:
Practical Workshop for Public Policy
Makers and Opinion Leaders
DNA Repeats and Human Gene Mutations
Constructing Organisms
Lyme Disease Symposium
Lyme Disease Symposium
Decade of the Brain
Marfan Meeting
Control of HIV Expression
Lyme Disease Symposium
Control of HIV Expression
Constructing Organisms
Control of HIV Expression
Marfan Meeting
Journalists and Congressional
Workshops
Contructing Organisms
Meetings on Complex
Genetic Diseases
3/91 -3/93
9/92 -9/93
1992
1993
1993
1992
1991
1992
1993
1992
1992
1992
1991
1990 -1992
1992
1991-1993
128,059
15,000 *
1,000*
5,000 *
10,000 *
27,200 *
2,000 *
2,000 *
10,000 *
4,000*
5,000*
5,000*
2,500 *
150,000
19,579 *
150,000
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CORPORATE SPONSOR PROGRAM
Restricted
The Corporate Sponsor Program provides support
for the meetings held in both
Grace Auditorium and Banbury Center. It is generally agreed that the
Laboratory's meetings program is second to none in the world both in the topics
selected for discussion and in the quality of the meetings themselves. That we
are able to maintain such an excellent series is due in large measure to the
stability provided by the continuing generosity of the companies who are mem-
bers of the Program. In 1992, the number of members increased from 32 to no
fewer than 38; these companies are listed below.
In acknowledgment of our members' contributions, we waive all on-site fees
for eight representatives of each company at our meetings. Three of these
scientists may attend meetings at the Banbury Center, where attendance is
otherwise only by invitation of the organizers. Furthermore, Corporate Sponsors
receive gratis copies of all publications of the Cold Spring Harbor Laboratory
Press. These include the journal Genes & Development, which has ranked first
among cell and developmental biology journals for two consecutive years, and
PCR, which received an enthusiastic review iri Nature. These benefits add up to a
package that accounts for a substantial part of the membership fee.
In addition, our Sponsors are acknowledged in all relevant publications, ab-
stract booklets, and other materials published by Cold Spring Harbor Laboratory
Press. We list the Corporate Sponsors' names on the meeting poster and in 1992,
we included a specially designed poster in the package given to the more than
6000 scientists who attended our meetings. We and all those scientists thank our
Corporate Sponsors for their commitment to scientific excellence.
Total Annual Contributions $732,875
Akzo Pharma International B.V.
Alafi Capital Company
American Cyanamid Company
Amgen Inc.
Applied Biosystems, Inc.
Armstrong Pharmaceuticals Inc.
BASF Bioresearch Corporation
Becton Dickinson and Company
Boehringer Mannheim Corporation
Ciba-Geigy Corporation/Ciba-
Geigy Limited
Diagnostic Products Corporation
The Du Pont Merck
Pharmaceutical Company
Eastman Kodak Company
Genentech, Inc.
Glaxo
Hoffmann-La Roche Inc.
Johnson & Johnson
Kyowa Hakko Kogyo Co., Ltd.
Life Technologies, Inc.
Eli Lilly and Company
Met Path Inc.
Millipore Corporation
Monsanto Company
New England BioLabs, Inc.
Oncogene Science, Inc.
Pall Corporation
Perkin-Elmer Cetus Instruments
Pfizer Inc.
Recordati
Sandoz Research Institute
Schering-Plough Corporation
SmithKline Beecham
Pharmaceuticals
Sumitomo Pharmaceuticals Co., Ltd.
Takeda Chemical Industries, Ltd.
Toyobo Co., Ltd.
The Upjohn Company
The Wellcome Research Laboratories,
Burroughs Wellcome Co.
Wyeth-Ayerst Research
CAPITAL GIFTS
Second Century Campaign
January 1, 1986-December 31, 1992
As part of the Laboratory's Centennial celebration in 1990, the public phase of a
major fund-raising campaign-the Second Century Campaign-was organized,
with a goal of raising a total of $44 million in support of construction, endowment,
and program projects of the Laboratory. At the end of 1992, the Campaign had
raised $51,092,883, including $1,538,100 of net interest. The very important net
effect of this Campaign has been to expand the Laboratory's capacity to pursue
science and to strenghten its financial structure.
Unrestricted Contributions
The Achelis Foundation
Alumni Cabin Contributors
Mr. Amyas Ames
Anonymous (7)
Mr. S. Reed Anthony
Mrs. Edward H. Auchincloss
George F. Baker Trust
Mr. and Mrs. Benjamin H. Balkind
Banbury Fund #1
Banbury Fund #2
Mr. Edmund Bartlett The Baxter Foundation
Mr. and Mrs. Sherburn M. Becker
Arnold and Mabel Beckman Foundation
Mrs. Patricia Bell-Thomson
Mr. Rodney B. Berens
Mr. and Mrs. Nicholas Biddle, Jr.
Mrs. Dorothy Bird
The Cornelius N. Bliss Memorial Fund
The Bodman Foundation
Boehringer Mannheim
Mr. and Mrs. Allen L. Boorstein
Booth Ferris Foundation
Dr. Jonathan Borkum
Dr. Herbert Boyer
Mr. and Mrs. William Braden
Mrs. Leonie T. Brigham
The Brinkmann Foundation
Bristol-Myers Squibb Company
Holly Brooks
Mr. and Mrs. G. Morgan Browne
Mary Livingston Griggs and Mary Griggs
Burke Foundation
Burroughs Wellcome Co.
Cablevision
Mr. and Mrs. Samuel Callaway
Mr. and Mrs. John Campbell
Mr. and Mrs. Ward Campbell
Mr. and Mrs. Peter Cannell
Mrs. Jean Cattier
Chemical Bank
Dr. Eleanor Chernick
Ciba-Geigy Corporation
Mr. and Mrs. David C. Clark
Dr. Bayard Clarkson
Mr. and Mrs. John Cleary
Mrs. C. Payson Coleman
Mr. and Mrs. Miner D. Crary, Jr.
Mr. and Mrs. Arthur Crocker
Charles E. Culpeper Foundation
Mr. Robert L. Cummings
Mr. and Mrs. Roderick H. Cushman
Mr. A. Neville Cutting
Mr. and Mrs. George W. Cutting, Jr.
Mr. Theodore N. Danforth
Mr. and Mrs. Norris Darrell, Jr.
Ms. Katya Davey
Michael David-Weill Foundation
Mrs. Rosamond Arthur Dean
Ira W. De Camp Foundation
Mr. and Mrs. Raymond deClairville
Mr. Charles Delafield
Mr. and Mrs. Donald Deming
Mrs. Jamie Tilghman Deming
Mrs. Carolyn C. Dilworth
Dolan Family Foundation
Russell and Janet Doubleday Fund
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Mr. and Mrs. Joseph P. Downer
Dr. and Mrs. Lester Dubnick
E.I. DuPont
Mr. and Mrs. James Eisenman
Mrs. Duncan Elder
Mr. Martin Elias
Mr. and Mrs. William Everdell Ill
The William Stamps Farish Fund
Mr. and Mrs. Harold L. Fates
Samuel Freeman Charitable Trust
Mr. and Mrs. Jack B. Friedman
Mr. and Mrs. Jack N. Friedman
The Fort Hill Foundation
Dr. Barry Michael Gaines
Mr. and Mrs. Clarence Galston
Mr. and Mrs. Robert B. Gardner
Mr. and Mrs. Robert B. Gardner, Jr.
George Garfield
Dr. and Mrs. H. Bentley Glass
BF Goodrich Company
Florence J. Gould Foundation
Oliver and Lorraine Grace
Mr. Maurice Green
Mr. and Mrs. Edward Greenberg
Mr. C. Groel, Jr.
Mr. and Mrs. Gordon S. Hargraves
Mr. and Mrs. Henry U. Harris, Jr.
The Harris Trust
Mr. and Mrs. Sinclair Hatch
Lita Annenberg Hazen
Dr. and Mrs. Alfred D. Hershey
The Hoffmann-LaRoche Foundation
Howard Hughes Medical Institute
Mrs. Julie Hunnewell
The Hyde and Watson Foundation
Mr. and Mrs. Robert Dean Jay
Mr. and Mrs. Morris I. Karpen
W.M. Keck Foundation
Mr. and Mrs. Albert Key
Dr. and Mrs. Alan M. Kisner
Esther A. and Joseph Klingenstein Fund, Inc.
Mr. and Mrs. Townsend J. Knight
Dr. Barbara B. Knowles
Mr. and Mrs. Abraham Krasnoff
The Kresge Foundation
Mr. and Mrs. Mort Kunst ler
Mr. and Mrs. Edward M. Lamont
Estate of Charles Henry Leach II
Mrs. John H. Leib
George and Mary Lindsay
Mr. and Mrs. George N. Lindsay, Jr.
Litchfield Charitable Trust
Mr. Angus C. Littlejohn
Mr. and Mrs. John Livingston
Long Island Biological Association
Mr. and Mrs. David L. Luke Ill
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Ms. Martha Makanna
Dr. Thomas Maniatis
Marion Merrell Dow Inc.
Lucille P. Markey Charitable Trust
The Marks Family Foundation
Mr. and Mrs. Robert R. Maxfield
Mr. and Mrs. Edward McCann II
James S. McDonnell Foundation
Mr. and Mrs. Warren J. McEntee
Miss Diana Mcllvaine
Mr. and Mrs. Robert M. McLane
The Merck Company Foundation
Mr. and Mrs. Robert G. Merrill
Mr. and Mrs. Clarence Michalis
Mr. O.B. Miller
Mr. William H. Miller
Mr. and Mrs. William R. Miller
Milliken Foundation
Leo Model Foundation
Elinor White Montgomery
J.P. Morgan and Co. Incorporated
Mr. and Mrs. Grinnell Morris
Dr. and Mrs. Larry Nathanson
National Institutes of Health
National Science Foundation
New England Biological Laboratories
New York State
Nichols Foundation
Mr. and Mrs. Adams H. Nickerson
North Country Garden Club
Mr. and Mrs. Charles Noyes
Mr. and Mrs. George O'Neill
Mr. and Mrs. William H. Osborn, Jr.
Dr. and Mrs. David B. Pall
Pall Corporation
Mr. Edward L. Palmer
Mr. William Parsons, Sr.
Pew Charitable Trusts
Pfizer Inc.
Mr. Sterling Pile, Jr.
Pioneer Hi-Bred International
Mrs. Francis T.P. Plimpton
Mr. and Mrs. Martin Pollak
Mrs. Margaret S. Pomeroy
Mr. and Mrs. F. Thomas Powers
Mrs. H. Irving Pratt
Mr. and Mrs. Richardson Pratt, Jr.
William and Maude Pritchard Charitable Trust
Dr. Mark Ptashne
Mr. Edward Pulling
Mr. and Mrs. Thomas Pulling
Mr. James T. Pyle
Mrs. Eleanor Raynolds
Mrs. Curtis S. Read
Sara D. Redmond
Mr. and Mrs. John R. Reese
Mr. Jon Rehnberg
Rhone-Poulenc Rorer Inc.
Dr. Frederic Richards
Fannie E. Rippel Foundation
Mr. Arthur M. Rogers, Jr.
Mrs. Quentin Roosevelt
Mr. and Mrs. J. Wright Rumbough, Jr.
Mr. and Mrs. Thomas A. Saunders III
Dr. and Mrs. David Salten
Schering-Plough Foundation
Mrs. John M. Schiff
The Schiff Foundation
Dr. Carl J. Schmidlapp II
Mrs. Franz Schneider
Mr. and Mrs. Frederick E. Seymour
Mr. and Mrs. Paul Sheeline
Mrs. Edward M. Shepard
Mr. Richard Slade
Mr. and Mrs. H. Turner Slocum
Mrs. Alexandra White Smith
SmithKline Beecham
Mr. and Mrs. Peter Solbert
Dr. George F. Sprague, Jr.
Seth Sprague Educational and Charitable
Trust
Starr Foundation
The Stebbins Fund
Mr. Byam K. Stevens, Jr.
Net Interest Earned 12/31/92
Total
Drs. Carol and Sidney Strickland
Stone Foundation, Inc.
Mr. and Mrs. David S. Taylor
Mr. and Mrs. Seth A. Thayer
Mr. and Mrs. Gilbert Tilles
Mrs. Robert Tilney, Jr.
Mr. and Mrs. George Toumanoff
The Upjohn Company
Dr. and Mrs. Robert N. Van Son
Frederica von Stade
Mr. and Mrs. Philip R. von Stade
Mr. and Mrs. Colton Wagner
Mrs. Bayard Walker
Margo Geer Walker
Mrs. George G. Walker
Mr. and Mrs. Douglas A. Warner III
Dr. Jonathan Warner
Dr. and Mrs. James D. Watson
Mr. and Mrs. Bradford G. Weekes III
Weezie Foundation
John L. Weinberg Foundation
Westvaco Corporation
Mr. and Mrs. Taggart Whipple
Mr. and Mrs. A. Morris Williams
Mrs. Henry A. Wilmerding
Mrs. John C. Wilmerding
Mr. and Mrs. Robert Winthrop
Mr. and Mrs. Sigi Ziering
1,538,100
$51,092,883
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SECOND CENTURY CAMPAIGN COMMITTEES
David L. Luke Ill, Chairman
Steering Committee
Oliver R. Grace, Co-chairman*
George W. Cutting, Jr., Co-chairman
Mrs. Sinclair Hatch, Co-chairman
Townsend J. Knight, Co-chairman
Taggart Whipple, Co-chairman"
Leadership Gifts Committee
Oliver R. Grace, Chairman*
G. Morgan Browne
Bayard D. Clarkson, M.D.
David L. Luke Ill
James D. Watson, Ph.D.
Taggart Whipple*
Major Gifts Committee
Mrs. Sinclair Hatch, Chairman
Amyas Ames
Mrs. Harry A. Brooks
Robert L. Cummings
William Everdell
Mrs. Henry U. Harris, Jr.
Abraham Krasnoff
Laurie Landeau, V.M.D.
Dr. Cynthia MacKay
Mrs. George G. Montgomery, Jr.*
H. Turner Slocum
Colton Wagner
Special Gifts Committee
George W. Cutting, Jr., Co-chairman
William H. Miller, Co-chairman
Mrs. Philip R. von Stade, Co-chairman
Mrs. Edward Greenberg, Co-chairman
Edmund Bartlett
David C. Clark
*deceased 1992
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H. Gray Colgrove*
Arthur M. Crocker
Lawrence L. Davis
Mrs. Donald L. Deming
Joseph P. Downer
Charles J. Hubbard
Gordon Lamb
Edward Pulling*
John R. Reese
J. Wright Rumbough, Jr.
Mrs. James F. Stebbins
Corporate Committee
David L. Luke Ill, Chairman
G. Morgan Browne
Peter B. Cannel]
Robert E. Cawthorn
William R. Miller
David B. Pall, Ph.D.
Douglas E. Rogers
James D. Watson, Ph.D.
Henry Wendt
Sigi Ziering, Ph.D.
Foundation Gifts Committee
Taggart Whipple, Chairman*
Mrs. C. Payson Coleman
Robert Ebert, Ph.D.
James W. Fordyce
John Klingenstein
Clarence F. Michalis
William E. Murray
Planned Gifts Committee
Townsend J. Knight, Chairman
Maureen Augusciak
John Cleary
William J. Kramer
William Parsons, Sr.
Colton Wagner
ANNUAL CONTRIBUTIONS
Summary of Annual Contributions
Unrestricted Annual Contributions
CSHLA Major Gifts $347,279
CSHLA Memberships 63,691
Memorials 25,570
$436,540
Restricted Annual Contributions $94,723
Corporate Advisory Board-DNA Learning Center $29,100
Undergraduate Research Program $128,404
Total Annual Contributions $688,767
Annual unrestricted contributions are donations from members of the Cold Spring
Harbor Laboratory Association. In 1992, these totaled $436,540 from 896 mem-
bers.
Major Gifts ($1,000-$10,000) accounted for $347,279 of this total from 173
members. Major givers (Associates, Patrons, Benefactors) participate in a pro-
gram of research briefings, guest lectures, and "hands-on" laboratory workshops
and are invited to the annual Associates cocktail party. Membership in the Cold
Spring Harbor Laboratory Association, which sponsors a program of lectures and
other activities at the Laboratory, requires an annual contribution of $50 or more.
For the past 5 years, the Association has provided funds for postdoctoral fel-
lows who work under the guidance of senior laboratory scientists. The 1992 fel-
lowship recipients were Judy Wang, Anthony Rossamando, Gert Bolwig, and
Keiko Mizuno. The Annual Fund provides also New Investigator Start-up Funding
to new staff members for purchase of equipment or supplies. This year's
recipients were Yi Zhong and Alcino Silva.
In addition to the Annual Fund of the Cold Spring Harbor Laboratory Associa-
tion, the Laboratory received $94,723 of restricted annual contributions and
$128,404 for support of the Undergraduate Research Program from a variety of
corporate and individual sources. The Annual Fund of the DNA Learning Center,
which is sponsored by the Corporate Advisory Board, raised $29,100 in 1992;
Douglas B. Fox is Chairman of the Corporate Advisory Board. Total annual contri-
butions for 1992 were $688,767.
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COLD SPRING HARBOR LABORATORY
ASSOCIATION
Officers
George W. Cutting, President
Mrs. Henry U. Harris, Jr., Vice President
Mrs. E. Maxwell Geddes, Secretary
Byam K. Stevens, Jr., Treasurer
G. Morgan Browne, Asst. Secretary/Treasurer
Directors
Mrs. Allen L. Boorstein Mrs. Edward Greenberg
Mrs. Harry A. Brooks Mrs. Henry U. Harris, Jr.
David C. Clark Mrs. Sinclair Hatch
John P. Cleary Alan M. Kisner, M.D.
George W. Cutting Gordon E. Lamb
Mrs. Donald L. Deming Mrs. James L. Large
Joseph P. Downer Mrs. George N. Lindsay
Mrs. Duncan Elder Edward F. McCann II
Mrs. E. Maxwell Geddes, Jr. Mrs. Walter C. Meier
John Grace Mrs. Vincent Nesi
PRESIDENT'S REPORT
Arthur M. Rogers, Jr.
Douglas E. Rogers
Phillip M. Satow
Mrs. Thomas A. Saunders Ill
Mrs. Peter G. Schiff
James L. Spingarn
Byam K. Stevens, Jr.
Mrs. Philip R. von Stade
James D. Watson, Ph.D.
1992 was an active year for the Cold Spring Harbor Laboratory Association,
measured in terms of number of events sponsored for the community and the an-
nual giving support provided for the Laboratory.
Annual Giving swelled to $531,263, a new record. There were 173 Associates
(donors of $1000 or more), including 33 Patrons (donors of $3000 to $9999), and
10 Benefactors (donors of $10,000 or more). There were 72 Friends (donors of
$300 to $999), 525 Family Members (contributors of $50 to $299), and another 60
contributors of lesser amounts.
The Association Directors, Laboratory Administration, and, most importantly,
the scientists themselves thank all of the donors for their support. Contributions of
all sizes played important roles in achieving the success of our annual giving ef-
fort.
Another source of Annual Fund support has been Memorial Contributions
(see Memorial Contributors at end of section). In 1992, gifts were made in
memory of
Cathy S. Bird
Leonie Brigham
Donald Caldarelli
Wilfred P. Cohen
Loretta Coyne
Oliver R. Grace
Maxine Harrison
Alvin Hayim
Betty Hktkterfurth
Gladys Houghton
Daniel J. Mahoney
Barbara McClintock
Gladys H. McGrath
Elinor Montgomery
Helen O'Gorman
Diana Peters
Anthony Rizza
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Marjorie R. Rose
Mrs. Charles Shapiro
Stanley Share
Jesse Skaggs Ill
Hildegarde R. Slocum
Bruce Stark
Frank Urf
Taggart Whipple
Dorothy Zehner
Calendar of Events
1992 began with our Annual Meeting on January 12th. Drs. Ron Davis and Tim
Tully, who use fruit flies to study learning and memory, gave a talk on neuro-
science and their particular research efforts. Gert Bo !wig, a young Ph.D. in Ron
Davis' laboratory, was the recipient of a 1992 Association Fellowship award.
On January 25th, Peter Orth returned to give a piano recital, again to a full
house. His exciting playing dazzled the crowd of members and friends. March
27th was the evening we had a dinner at the Piping Rock Club, involving several
members of the scientific staff, which resulted in a wonderful informal discussion
about science.
In April, we held a DNA workshop for Major Givers at the DNA Learning Cen-
ter. These events give our members a real idea of what basic research is like,
particularly since they can see first hand that some experiments fail while others
succeed. This year, workshops will be made available to Friends, as well as As-
sociates, Patrons, and Benefactors.
Barbara Conolly, a leading ornithologist, led a nature walk along the shoreline
and through our campus grounds for Major Givers on May 2nd. Her expert eyes
helped us to identify many birds and trees that we were not aware existed on the
Laboratory grounds. The following afternoon, the Laboratory sponsored an
enthusiastically received violin recital by Scott Yoo for visiting scientists and As-
sociation members.
On May 31st, Dr. Michael Brown became the third consecutive Nobel prize
winner to address the Dorcas Cummings Memorial Lectures. He had excellent
slides and spoke so clearly that most of us came away with a much better under-
standing about the process of exchange of information from one cell to another.
Following the lecture, many of the scientists, who were attending the Laboratory's
Symposium on the Cell Surface, went to 19 dinner parties hosted by community
members of the Association. They were joined by members of our scientific staff,
as well as friends of the hosts. The hosts and hostesses were
Mr. and Mrs. Loren Berry
Mr. and Mrs. G. Morgan Browne
Mr. and Mrs. John Cleary
Mr. and Mrs. Donald L. Deming
Mr. and Mrs. Joseph P. Downer
Mr. and Mrs. E. Maxwell Geddes, Jr.
Mr. and Mrs. John Grace
Mr. and Mrs. Gordon S. Hargraves
Mrs. Sinclair Hatch
Dr. and Mrs. Alan Kisner
Mr. and Mrs. James L. Large
Mr. and Mrs. David L. Luke Ill
Dr. and Mrs. Walter Meier
Dr. and Mrs. Larry Nathanson
Mr. and Mrs. Vincent Nesi
Mr. and Mrs. Walter H. Page
Mrs. Francis T. P. Plimpton
Mr. and Mrs. Peter G. Schiff
Mr. and Mrs. James L. Spingarn
Mr. and Mrs. John C. Stevenson
Mr. and Mrs. Martin Travis
Mr. and Mrs. Niklaus Versch
September got off to an auspicious start. Drs. Mary Claire King and Mark
Lippman conducted a panel discussion on breast cancer the day before they
led
a Banbury conference on this topic for scientists from around the country. It
seemed appropriate to bring our membership up to date as well on recent prog-
ress. Since their panel discussion was scheduled for a Tuesday evening
and a
good attendance was sought, an order was sent out to your President in Alaska
to provide a dinner featuring native Alaskan treats. He was able to catch
enough
halibut to feed all the attendees in the newly expanded Blackford Hall. One
might
say that the membership "rose to the bait" as Grace Auditorium was
filled! The
progress on breast cancer is exciting, with Laboratory scientists playing
impor-
tant roles. Every effort will be taken to keep the community up to date on
the
progress of this research effort.
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The Sutherlands address
the Association.
The annual cocktail party was held on October 8th, following the dedication of
the Racker Reading Room in Blackford Hall. In attendance were Laboratory
Trustees, Association Directors, and Alumni from the 1940s and 1950s, as well as
many of our scientific staff.
October 18th was another exciting day in the Association's calendar of
events. Dr. Michael Novacek, Director of Science for the American Museum of
Natural History, spoke to the membership on his recent expeditions to the Gobi
Dessert in search of dinosaur fossils.
On November 7th, a panel discussion on Alzheimer's disease organized by
Dr. Daniel Marshak was jointly sponsored by the Harvard Club of Long Island
and the Association. Finally, on November 5th, we were very fortunate to have Dr.
Thomas Sutherland and his wife address our members. Dr. Sutherland came at
Dr. Watson's invitation. He is the former director of the Biology Department at the
American University of Beirut and was a hostage for more than 5 years. The
strength of these two extraordinary people was apparent from the start and the
evening was certainly one of the highlights of the year.
In summation, the programs in 1992 for members and our scientific staff were
highly diversified and surely touched upon the varied interests of all.
As I step down as Association President after 7 years, I do so with confidence
that the Association will continue to support the young scientists and offer an in-
formative program for its membership. The Board of Directors has done an ex-
traordinary job of building the level of support to where it stands today. Every
Director has been an active participant in our effort, and each has contributed to
the 1992 Annual Fund. The aggregate contribution from Directors has now
reached $60,000!
The Annual Fund has become a very important part of the Laboratory's fund-
ing of science programs and, although it reached well over $500,000 in 1992 for
the first time, we must seek higher levels to meet the Laboratory's needs. Our
most effective Development Department staff and Association Directors depend
on the members themselves to build Annual Fund support to ensure that science
at Cold Spring Harbor maintains its excellence through the continued infusion of
highly qualified young scientists.
George W. Cutting, President
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Members of the Cold Spring Harbor Laboratory
Association
BENEFACTORS*
Mr. Jeffrey Braverman
Mrs. John L. Davenport
Mr. Robert B. Gardner, Jr.
Mr. & Mrs. Robert R. Maxfield
Dr. & Mrs. Walter C. Meier
Mr. & Mrs. William R. Miller
Mr. & Mrs. Alan Seligson
Mr. & Mrs. Douglas A. Warner III
PATRONS **
Mr. & Mrs. Sherburn M. Becker
Mr. & Mrs. Cornelius N. Bliss III
Mr. & Mrs. Harry A. Brooks
Mr. & Mrs. G. Morgan Browne
Mr. & Mrs. Peter B. Cannell
Mr. William H. Grover
*Mr. & Mrs. John P. Cleary
Mr. Ronald M. Craigmyle, Jr.
Mr. & Mrs. Arthur M. Crocker
Mrs. Oliver R. Grace
The Joyce Green Family Foundation
Mr. & Mrs. John W.B. Hadley
Mrs. Sinclair Hatch
Dr. Laurie Landeau
Mr. & Mrs. James M. Large
Mr. & Mrs. George N. Lindsay
Mr. & Mrs. David L. Luke III
Mr. & Mrs. Robert G. Merrill
Mr. Donald A. Pels
Mr. & Mrs. John J. Phelan, Jr.
Mrs. H. Irving Pratt
Mrs. Curtis S. Read
Mr. Eric Ridder
Mr. & Mrs. Peter G. Schiff
Mr. & Mrs. T.M. Shogren
Mr. & Mrs. James L. Spingarn
Mr. & Mrs. Peter Tilles
Mrs. Ernest T. Turner
ASSOCIATES+
Mr. & Mrs. David L. Banker
Mrs. William N. Bannard
Mr. & Mrs. Edmund Bartlett
Mr. & Mrs. Rodney B. Berens
Mr. & Mrs. Loren C. Berry
Mr. & Mrs. Allen L. Boorstein
Mr. & Mrs. Lester E. Brion, Jr.
Mrs. Mary Griggs Burke
Mrs. Carol Caldarelli
Mr. & Mrs. John P. Campbell
Mr. & Mrs. Vincent Carosella
Mrs. Jean Cattier
Mr. & Mrs. David C. Clark
Dr. & Mrs. Bayard D. Clarkson
Mrs. Robert L. Clarkson, Jr.
Mr. James W. Cleary
Mr. & Mrs. Gregory S. Coleman
Mr. & Mrs. John H. Coleman
Mrs. John K. Colgate, Sr.
Dr. & Mrs. Paul Cushman, Jr.
Mr. & Mrs. Roderick H. Cushman
Mr. & Mrs. George W. Cutting, Jr.
Mr. Theodore N. Danforth
Mr. & Mrs. Norris Darrell, Jr.
Michael Davidson Memorial Fund
Mr. & Mrs. Murat H. Davidson, Jr.
Mr. & Mrs. William Tucker Dean
Mr. Charles B. Delafield
Mr. & Mrs. Donald L. Deming
Mr. & Mrs. Joseph P. Downer
Mr. & Mrs. Mark A. Doyle
Dr. & Mrs. Lester Dubnick
Mr. & Mrs. William T. Dunn, Jr.
Mr. & Mrs. James A. Eisenman
Mr. & Mrs. Duncan Elder
Mr. & Mrs. William Everdell
Mr. William Ewing, Jr.
Mr. Stephen C. Eyre
Mr. John R. Fell
Dr. Orrie M. Friedman
Dr. Barry Michael Gaines
Mr. & Mrs. Clarence E. Galston
Mr. & Mrs. Charles S. Gay
Mr. & Mrs. Robert A. Gay
Mr. & Mrs. E. Maxwell Geddes, Jr.
Mr. & Mrs. Edward H. Gerry
Mr. & Mrs. Thomas S.T. Gimbel
Mr. & Mrs. Lionel M. Goldberg
Mr. & Mrs. John R. Grace
Mr. & Mrs. Edward Greenberg
Rev. Linda Peyton Hancock
Mr. & Mrs. Gordon S. Hargraves
Mr. & Mrs. Henry U. Harris, Jr.
Mrs. Dorothy H. Hirshon
Mr. & Mrs. Waldo Hutchins III
Mr. Frederic B. Ingraham
Mrs. Gilbert W. Kahn
Mr. Richard Kandel
Mr. & Mrs. Albert Key
Mrs. Francis S. Kinney
Dr. & Mrs. Alan M. Kisner
Mr. & Mrs. John Klingenstein
Mr. & Mrs. Townsend J. Knight
Mr. & Mrs. Gordon E. Lamb
Mr. & Mrs. Edward M. Lamont
Dr. Robert V. Lewis
Mr. & Mrs. Robert V. Lindsay
Mrs. V.S. Littauer
Mr. & Mrs. John H. Livingston
Mr. & Mrs. Edwin Marks
Mr. & Mrs. William L. Matheson
Mr. & Mrs. Gerald M. Mayer, Jr.
Miss Diana Mcllvaine
Mr. George S. Meyer
Mr. & Mrs. Clarence F. Michalis
Dr. & Mrs. Peter Model
Mr. George G. Montgomery, Jr.
Mr. & Mrs. F. Warren Moore
Mr. & Mrs. Grinnell Morris
Mr. & Mrs. Charles E. Murcott
Mr. & Mrs. Stephen V. Murphy
Mr. & Mrs. Francis W. Murray III
Mr. & Mrs. William J. Nammack
Mr. & Mrs. Vincent Nesi
Mr. & Mrs. Albert Nickerson
Mrs. Ann L. Nolte
Nordemann Foundation, Inc.
Norwood Foundation, Inc.
Mr. & Mrs. Charles P. Noyes
Mr. & Mrs. Bernard Nussdorf
Mr. & Mrs. George D. O'Neill
Mr. & Mrs. Arthur W. Page, Jr.
Mr. & Mrs. Walter H. Page
Mr. & Mrs. Edward L. Palmer
Mr. & Mrs. Nicholas R. Parks
Mr. & Mrs. William Parsons, Jr.
Mr. & Mrs. Nicholas B. Paumgarten
Mr. & Mrs. Howard Phipps, Jr
Mrs. Francis T.P. Plimpton
Mr. & Mrs. A.J. Powers
Mr. & Mrs. F. Thomas Powers, Jr.
Mr. & Mrs. Richardson Pratt, Jr.
Mrs. Sherman Pratt
Mrs. Seena H. Purdy
Ms. Augusta Reese
Ms. Victoria Reese
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Mr. & Mrs. John R. Reese
Mrs. Willis L.M. Reese
Mr. & Mrs. William S. Robertson
Mr. & Mrs. Arthur M. Rogers, Jr.
Mr. & Mrs. Douglas E. Rogers
Mr. Robert Sabin
Mr. & Mrs. Phillip M. Satow
Mr. & Mrs. Thomas A. Saunders' Ill
Mrs. John Schiff
Mr. & Mrs. Owen T. Smith
Mr. & Mrs. Peter Solbert
Mrs. H.G. Spencer
Mr. & Mrs. James F. Stebbins
Mr. & Mrs. Henry R. Stern, Jr.
Mr. & Mrs. Byam K. Stevens, Jr.
Mr. & Mrs. Robert L. Strong
Mrs. Jane S. Sykes
Mr. & Mrs. Daniel G. Tenney, Jr.
Mr. & Mrs. Stanley S. Trotman
Mrs. Martin Victor
Mr. & Mrs. Philip R. von Stade
Mrs. Margo G. Walker
Dr. & Mrs. James D. Watson
Mr. & Mrs. Bradford Weekes III
Mrs. Taggart Whipple
Mr. Gerald I. White
Mr. & Mrs. Robert Winthrop
FRIENDS ++
Mr. Warren S. Adams II
Mrs. Jules Aubry
Mr. & Mrs. Henry D. Babcock Jr.
Mr. R. Baron
Dr. & Mrs. Paul Berg
Dr. Gunther Blobel
Ms. Jane S. Block
Drs. Thomas Broker & Louise Chow
Mr. Harry A. Brooks
Mr. & Mrs. Thomas Calabrese, Jr.
Mr. & Mrs. Gilbert W. Chapman, Jr.
Dr. Eleanor Chernick
Mrs. Thomas H. Choate
Mrs. C. Payson Coleman
Mr. & Mrs. Emilio G. Collado
Mr. & Mrs. William Comfort
Mr. & Mrs. Charles Craig
CSHL Arts & Crafts Participants
Mr. & Mrs. Lawrence L. Davis
Mr. & Mrs. Daniel P. Davison
Mr. & Mrs. David Deming
Mr. Don Durgin
Mr. & Mrs. Joseph Gerrity
Dr. & Mrs. Roger G. Gerry
Mr. & Mrs. Morris W. Get ler
Mr. & Mrs. Peter Guida Jr.
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Dr. Matthew N. Harris
Mrs. Horace Havemeyer, Jr.
Mr. & Mrs. Harold W. Hawkey
Dr. & Mrs. Alfred D. Hershey
Dr. & Mrs. Lawrence Horn
Mrs. Joan M. Hutchins
Mrs. Ruth Bennett Jordan
Dr. & Mrs. Ralph Landau
Mr. Rolf A. Lange
Mr. & Mrs. Henry Luce III
Mr. Robert L. Marcus
Mr. & Mrs. William H. Mathers
Mr. & Mrs. James A. McCurdy II
Mr. J. McGuire
Mr. & Mrs. James D. Mooney, Jr.
Mrs. William S. Niven
Mr. & Mrs. James J. Pirtle, Jr.
Mr. Henry Platt
Mr. & Mrs. Frank Polk
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Cold Spring Harbor Laboratory is a nonprofit research and educational institution
chartered by the University of the State of New York. Significantly less than half
(37.1%) of our annual support is derived from Federal grants and contracts, and
thus we rely heavily on support from the private sector: foundations, corporations,
and individuals. Contributions from the private sector are tax exempt under the
provisions of Section 501(c)(3) of the Internal Revenue Code. In addition, the
Laboratory has been designated a "public charity" and therefore may receive
funds resulting from the termination of "private foundations."
METHODS OF CONTRIBUTING TO COLD SPRING HARBOR LABORATORY
Gifts of money can be made directly to Cold Spring Harbor Laboratory.
Securities: You can generally deduct the full amount of the gift on your income tax return,
and, of course, you need pay no capital gains tax on the stock's appreciation.
We recommend any of the following methods:
(1) Have your broker sell the stock and remit the proceeds to Cold Spring Harbor
Laboratory.
(2) Deliver the stock certificates to your broker with instructions to open an account for
Cold Spring Harbor Laboratory and hold the securities in that account pending in-
structions from Cold Spring Harbor Laboratory.
(3) Send the unendorsed stock certificates directly to the Laboratory: Comptroller, Cold
Spring Harbor Laboratory, One Bungtown Road, Post Office Box 100, Cold Spring
Harbor, New York 11724. In a separate envelope, send an executed stock power.
Pooled Income Funds: Combine gifts from a number of donors in a pool for attractive in-
vestment and tax purposes.
Appreciated real estate or personal property: Sizable tax benefits can result from such
donations; the Laboratory can use some in its program and can sell others.
Life insurance and charitable remainder trusts can be structured to suit the donor's
specific desires as to extent, timing, and tax needs.
Bequests: Most wills probably need to be updated. Designating Cold Spring Harbor Labo-
ratory as beneficiary ensures that a bequest will be utilized as specified for continuing
good.
Conversion of private foundation to "public" status on termination: This may be done
by creating a separate fund within Cold Spring Harbor Laboratory whereby the assets of
the private foundation are accounted for as a separate fund and used for the purposes
specified by the donor. Alternatively, the private foundation can be established as a sup-
porting organization of Cold Spring Harbor Laboratory.
For additional information, please contact the Director of Development, Cold Spring Harbor
Laboratory, One Bungtown Road, Post Office Box 100, Cold Spring Harbor, NY 11724, or
call 516-367-8840.
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Institute Employees
Support Staff
Susan Allan
Craig Gawel
Judy Smith
Adrienne Tesoro
Visiting Scientists
Roussoudan Bourtchouladze
Douglas Demetrick
Grigori Enikolopov
Konstantin Galactionov
Igor Garkavtsev
Saulius Klimasauskas
Nicholas Muzyczka*
Natalya Peunova
Frederick Schachat+
Kikuo Sen
Huan-Ran Tan
Robert West+
Support Staff
Art
Michael Ockler
James Duffy
Philip Renna
Laboratory
Liliana Vigovsky-Attar
Technical Programming
Thomas Boutell
Lisa Catapano
Steven Cozza
Elisabeth Cuddihy
Diane Lombardi
Patrick Monardo
Edwin (Corp) Reed
Jacqueline Salit
Secretarial
Sadie Arana
Cherylene Behrendt
Patricia Bird
Carol Marcincuk
Karen Otto
Jane Reader
Madeline Wisnewski
*Funding provided by Howard Hughes Institute
On sabbatical at CSHL
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Graduate Students
Ariel Avilion
Maureen Barr
Celeste Casciato
David Casso
Nicholas Chester
Michele Cleary
Jill Crittenden
Kurt Degenhardt
Charles Di Como
Benhao Dong
Andrea Doseff
Beth Elliott
Karen Fien
Richard Freiman
Nicholas Gale
Kimberly Gavin
Linda Graziadei
Wei Guo
Lea Harrington
Jiann-Shiun Lai
Kenneth La Montagne
Gary Lee
Yuliang (Frank) Ma
York Marahrens
Robert Mihalek
George Mulligan
Robert Nash
Charles Nicolette
Alan Nighorn
Raymond O'Keefe
Kathy O'Neill
Frank Pessler
Hai Rao
Ann Ryan
Cynthia Sadowski
Ahmed Samatar
Michael Sheldon
Kenneth Simon
Deborah Taylor
William Thomann
George Tokiwa
Kwok-Hang Wu
Tao Zhong
Research Assistants
Rolf Kluttig
Laboratory Technicians
Gigi Asouline
Deborah Aufiero
Nick Bizios
Lynn Borzillo
Francoise Chadrin
Chuan-Min Chen
Lekha Das
Patricia Burfeind
Peter D'Andrea
Maria Del Vecchio
Robert Derby
Margaret Falkowski
Peter Guida
Gretchen Hannon
Susan Hespelt
Jill Horwitz
Yi Hu
Marianne Joyce
Nancy Kaplan
Susan Kaplan
Paul Kearney
James Keller
Diane Kozak
Shelley Landon
Natalia Lisitsyn
Arshad Majid
Gilda Mak
Thomas Malone
Lisa Manche
Sanae Matsumoto
Karen Mc Cloy
Robert McGuirk
Ronnie Packer
Nora Poppito
Peter Recksiek
Michael Riggs
Simone Salghetti
Neena Sareen
Jason Shan ley
Stacy Shlachtman
Tiina Sedman
Caroline Skoulakis
Stephanie Kaplan Smith
Frances Stincone
Maureen Sullivan
Spencer Teplin
Mark Vandenberg
Miho Waga
Patricia Wendel
Regina Whitaker
Jeanne Wiggins
Douglas Wood
Zhuang Yuan
Research Associates
Carmelita Bautista
Georgia Binns
Linda Rodgers
Media Makers/
Laboratory Aides
Esteban Araya
Graceann Bartilucci
James Beresford
June Blanchford
Jack Brodsky
Rodney Chisum
Martha Daddario
Janice Douglas
Salvador Henriquez
Brigitte Hofmann
Bei Cong Ma
Vincent Meschan
Gang Niu
Peter Recksiek
Margaret Wallace
Processing Center
Fred Stellabotte
Jim Bense
Elizabeth O'Connor
Bobbie Peters
David Ruderman
Environmental Health
and Safety
Arthur Brings
Safety
Christopher Hubert
Randal Jones
John Pisciotta
Donald Rose, Sr.
Marlene Rubino
Harris Research Support Facility
Lisa Bianco
Charlene De Poto
Halina Swidzinski
Richard Swidzinski
Security
Robert Gensel
Frank Carberry
Donald Rose, Jr.
CSHL Press
Acquisition
Phyllis Chen
Advertising
Nancy Kuhle
Editorial/Production Books
Nancy Ford
Patricia Barker
Dorothy Brown
Mary Cozza
Mary Liz Dickerson
Joan Ebert
Elaine Gaveglia
Annette Kirk
Lee Martin
Elizabeth Ritcey
Inez Sialiano
Marie Sullivan
Pauline Tanenholz
Editorial/Production Journals
Judy Cuddihy
Nadine Dumser
Lori Hearfield
Doris Lawrence
Valerie Nicolette
Fulfillment/Distribution
Guy Keyes
Kathleen Cirone
Ann Felten
Jacqueline Matura
Penny Sheppard
Barbara Terry
Finance
Nancy Hodson
Marketing
Ingrid Benirschke
Connie Hallaran
James Suddaby
Library/Public Affairs
Susan Cooper
Laura Hyman
Library
Margaret Henderson
Clare Bunce
Leigh Johnson
Kelly Kasso
Wanda Stolen
Public Affairs
Margot Bennett
Edward Campodonico
Nathaniel Comfort
Lisa Gentry
Herb Parsons
Accounting
Julie Belfiore
Sharon Bense
Jennifer Blovsky
Guy Cozza
Karen Fabian
Mary Ellen Goldstein
Patricia Maroney
Alison McDermott
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Carlos Mendez
Mary Ann Miceli
Robert Pace
Catherine Schratwieser
Patricia Urena
Barbara Wang
Grants
Susan Schultz
Mary Horton
Patricia Kurfess
Mary Markiewicz
Dee McKeon
Jean Schwind
Personnel
Cheryl Sinclair
Carolyn Catarella
Jan Eisenman
Kim Gronachan
Barbara Purcell
Merilyn Simkins
Food Service
James Hope
Dwayne Blackman
Francis Bowdren
Todd Brummer
Donna Corbett
Michael Corral
Joan Doxey
Donna Dykeman
Julie Ehrlich
Alec Firestone
Katherine Hamas
Renee Le Strange
Thomas McDermott
Francis Mcllvaine
Teresa Purcell
Mauricio Rodriguez
William Suescun
Joanne Tansey
Cesar Vera
Leslie Wenzel
Meetings
Barbara Ward
Michela McBride
Eileen Paetz
Margaret Stellabotte
Andrea Stephenson
Diane Tighe
Nancy Weeks
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Purchasing
Sandra Chmelev
Bruce Fahlbusch
Maryellen Fredriksen
Patricia Hinton
Susan Rose
Mary Smith
Barbara Zane
Central Administration
Maureen Berejka
Roberta Sa lant
Delia Costello
Development
Gordon Hargraves
Claire Fairman
Gisela Jennings
Debra Mullen
Joan Pesek
Banbury Center
Katya Davey
Eleanor Sidorenko
Beatrice Toliver
DNA Learning Center
Mark Bloom
Jane Conigliaro
Susan Lauter
Sandra Ordway
Robert Willis
Buildings and Grounds
Jack Richards
Peter Stahl
Administration
Leslie Allen
Margaret Chellis
Charles Schneider
Carpentry and Painting
Michael Demers
Jeffrey Goldblum
John Meyer
Joseph Pirnak
Peter Rohde
Frank Russo
Peter Schwind
Harry Wozniak
Equipment and Repair/
Machine Shop
Gus Dulis
George Newell
Danielle Strano
Cliff Sutkevich
Custodial
Stephen Gay
David Gomez
Daniel Jusino
Morgan Kelly
Pino Kos
George Leedham
Aldo Leo
Peter Prianti
Ronald Romani
Jaroslaw Swidzinski
Steven Tang
Mario Testani
Jorge Valdes
Curtis Williams
Yew Teo
Electrical and Mechanical
Maintenance
Russell Allen
Richard Gallagher
Steven Guy
Louis Jagoda
John Kopyta
Stanley Miecnikowski
Grounds
Robert Arena
Vincent Carey
Joseph Ellis
Edward Haab
William Kearney
Christopher McEvoy
Daniel Miller
Andrew Sauer
Eric Schlitter
Stanley Schwarz
Darius Slodkowski
Hans Trede
Christopher Williams
Housekeeping
Rita Abrams
Elizabeth Bolt
Catherine Burke
Carol Caldarelli
Patricia Carroll
Dessie Carter
Mary Genova
Susanne McPherson
Dora Merlino
Claudia Schmid
Danuta Slodkowska
Dorothy Youngs
Plumbing
Lane Smith
Keith Spooner
Shipping and Receiving
Christopher Oravitz
James Sabin
Randy Wilfong
Uplands
Timothy Mulligan
Scientific Staff Departures
During 1992
Genetics Research Unit
Carnegie Institution of Washington
Barbara McClintock (deceased)
Research Staff Maria Sarabia
Eric Richards Seth Stern
Paul Szymanski
Staff Associates Toshifumi Tsukahara
James Lees-Miller Kanna Visvanathan
Tamar Michaeli Kwang-Ai Won
William Phares II-Je Yu
Postdoctoral Fellows
Glenn Bauer
Steven Brill
Chiu Kwong Cheung
Guillaume Cottarel
Anindya Dutta
Antonio Giordano
Xavier Grana-Amat
Geeta Joshi-Tope
Chitra Kannabiran
Mark Kessler
Saulius Kulakauskas
Sanjay Kumar
Sushma Ogram
Gary Otto
Yasuji Rikitake
Denise Roberts
Visiting Scientists
Anna Calzolari
Catherine Jessus
Tetsuji Kakutani
Toru Mizukami
Janos Posfai
Jean Pierre Renaudin
Mart Ustav
Zuo-Peng Xie
Graduate Students
Rajeev Aurora
Laura Berkowitz
Fred Bunz
Lisa Molz
Yuhong Qiu




